

AUTHOR INDEX*

Volume 50

A

- Aakvaag, A., 7806
 Aardema, M. J., 3722
 Aaronson, R. A., 5199
 Abbate, M., 4771
 Abbott, P., 2303
 Abbruzzese, J. L., 4572, 6823
 Abe, K., 3257
 Abe, M., 480
 Abeloff, M. D., 4595
 Abemayor, E., 722
 Abita, J.-P., 2203
 Abrams, K., 3562
 Abrams, M. J., 6971
 Abromson-Leeman, S. R., 5643s
 Ackermann, R., 4504
 Adachi, K., 2296
 Adamo, S., 3377
 Adams, D. B., 4595
 Adams, D. J., 3663
 Adams, E. G., 2485
 Adams, G. P., 1014s
 Adamson, P. C., 4464
 Adelstein, D., 7206
 Adelstein, S. J., 5199
 Adi, S., 4233
 Adlakha, A., 7557
 Adolph, S., 4146
 Agarwal, C., 5947
 Aglietta, M., 5065
 Agostini, C., 1768
 Aguanno, S., 3377
 Ahlert, T., 5962
 Ahn, D. K., 5773
 Aicher, K. P., 7376
 Airolidi, L., 6870
 Aisaka, K., 2455
 Akagi, M., 3952
 Akakura, K., 4979
 Akao, Y., 4856
 Akazawa, K., 3043
 Akedo, H., 2018
 Åkerlin, G., 3422
 Åkerman, K. E. O., 3422
 Åkerström, G., 748
 Akiyama, F., 7184
 Akiyama, S.-i., 3055
 Akiyama, S. K., 1601, 4485
 Akiyama, Y., 2885
 Akiyoshi, T., 7212
 Akman, S. A., 1397
 Al-Achi, A., 3339
 Aladib, W., 7650
 Alaoui-Jamali, M. A., 1810
 Alavi, A., 958s
 Al-Baker, S., 4254
 Albanes, D., 3610
 Albeida, S. M., 6757
 Albert, J. L., 3306
 Alberti, D. B., 2667
 Albertini, R. J., 6302
 Albino, A. P., 4190, 6410
 Alcaín, F. J., 5887
 Alderton, P., 5136
 Alejandro, M., 1470
 Alena, F., 3743
 Alexander, J., 2363

- Alfieri, A. A., 7252
 Ali, S. A., 783s
 Ali-Osman, F., 6976
 Alitalo, K., 2379
 Alken, P. M., 3670
 Allalunis-Turner, J., 278
 Allavena, P., 7318
 Allegra, C. J., 3574, 5834, 7279
 Allen, L. E., 1897
 Allen, P. B. R., 278
 Allison, D. C., 710
 Almoguera, C., 1279
 Alterman, R. L., 2524
 Altorki, N., 6410
 Altschuler, E., 7116
 Alvarez, E., 5269
 Alvarez, O., 1897
 Alvarez, R., 7301
 Alvarez, V. L., 857s, 985s
 Alvord, W. G., 2979
 Amadori, D., 2943, 7811
 Amakawa, R., 2423
 Ames, M. M., 206, 3905, 6525
 Amin, S. G., 2613
 Amlot, P., 2929
 Amox, D. G., 1022s
 Ananthaswamy, H. N., 637,
 1544, 3159
 Anderson, F. A., 3646
 Anderson, C. W., 7754
 Anderson, K. M., 3610
 Anderson, L. M., 4239, 4366
 Anderson, M., 4818
 Anderson, M. W., 266, 1591,
 3772, 4619
 Anderson, P. M., 1853
 Anderson, S. K., 1243
 Anderson-Berg, W. T., 4221
 Andersson, T., 3413
 Ando, D. T., 7042
 Andoh, T., 7198
 Andre, J., 3786
 Andreassen, P., 6827
 Andreeff, M., 2049, 7535
 Andreesen, R., 7450
 Andrew, S. M., 4423, 5225
 Andrews, A. F., 7942
 Ang, V. T. Y., 7882
 Angelin, B., 483
 Ångström, T., 2027
 Aninipot, R., 828s
 Anker, G., 5851
 Anna, C. H., 4619
 Antaky, T., 1337
 Antholine, W. E., 4468
 Anton, A. R., 1658
 Antunez, A. R., 1620
 Anumula, K. R., 6787
 Aoki, T., 596, 2429
 Aoyama, T., 2060
 Apelgren, L. D., 3540
 Apfel, R., 6981
 Apodaca, G., 2322
 Appelbaum, F. R., 1017s
 Applegate, K. G., 7153
 Applegate, L. A., 637
 Aprille, J. R., 7876
 Aquilina, G., 4248

- Ara, G., 7876
 Araki, K., 3106
 Arancia, G., 5119
 Arbuck, S. G., 6854
 Arcesi, R. J., 5392
 Archer, G. E., 1822, 1954
 Archer, L. T., 2215
 Archer, M. C., 6955
 Archibald, L. H., 4098
 Arentsen-Honders, M. W., 6515
 Arii, S., 7601
 Aristoff, P. A., 2485
 Arita, M., 3055
 Ariyoshi, K., 3167
 Arkesteyn, G. J. A., 6515
 Arlett, C. F., 7511
 Armitage, J. O., 4845
 Armstrong, L. W., 6176
 Arneheim, N., 1279
 Arnold, A., 1216
 Arnold, J. T., 2068
 Aronyk, K. N., 278
 Arps, H., 6100
 Arrick, B. A., 299
 Asano, S., 5102
 Asch, B. B., 2404
 Asch, H. L., 2404
 Ashihara, T., 7008
 Ashkenazi-Kimmel, T., 3073
 Ashley, S. W., 6529
 Ashworth, L. K., 4951
 Aslo, A., 7950
 Assaraf, Y. G., 4946
 Aston, D. A., 5773
 Aten, J. A., 2803
 Atherholz, T. B., 1189
 Atsmon, J., 1879
 Augenlicht, L. H., 1596
 Aukenman, S. L., 5876, 7376
 Ausserer, B., 1576
 Avdalovic, N. M., 1495
 Averett, D. R., 1817
 Avery, T. L., 2625
 Avramis, V. I., 7226
 Awa, A. A., 4050
 Awwad, M., 2228
 Azuma, C., 488
 Azuma, I., 345, 3631
 Azuma, M., 7062

B

- Baan, R. A., 7887
 Baas, F., 5392
 Baba, M., 2095, 4931, 5308
 Baba, M., 7358
 Baccarani, M., 4291
 Bachmann, M., 5636s
 Back, T. T., 7926
 Bader, C., 1195
 Badger, B., 7179
 Badger, C. C., 783s, 1017s, 5421
 Badiner, G. J., 2485
 Baer-Dubowska, W., 3048
 Bagheri, K., 1795
 Bagli, D. J., 2518
 Bagnati, R., 6870
 Baguley, B. C., 503, 6966

- Bahri, S., 4190
 Baidoo, K. E., 799s
 Bailey, F. C., 318, 664
 Bailey, H., 5475
 Bailey, N. M., 558
 Bailly, C., 385
 Baiocchi, G., 5801
 Bair, K. W., 3663, 7494
 Baird, J., 2296
 Baisch, H., 6389
 Bajardi, F., 6663
 Bajorin, D. F., 7490
 Bakanauskas, V. J., 97
 Baker, A. L., 1790
 Baker, J. B., 5039
 Baker, M. A., 5003
 Baker, M. S., 4676
 Baker, N., 2221
 Baker, R. M., 3921
 Baker, S. J., 7717
 Bakshi, S., 7973
 Balaschak, M., 653
 Balch, C. M., 5263, 7153
 Baldew, G. S., 7031
 Baldwin, R. W., 2936
 Bales, W. D., 2215
 Balinska, M., 3979
 Balis, F. M., 4464, 7915
 Balkwill, F. R., 4436
 Ball, E. D., 7216
 Ball, R. W., 2493, 4918
 Ballance, C., 828s, 2823
 Ballard-Barbash, R., 2152, 3610
 Ballon, D., 7252
 Bally, M. B., 575
 Balslev, I., 1257
 Baltzer, L., 1151
 Bambara, R. A., 5340
 Ban, S., 4050
 Band, V., 7351
 Banda, M. J., 2322
 Bander, N. H., 4190, 5531
 Bandieramonte, G., 4561
 Bando, T., 6396
 Bang, Y.-J., 2773
 Bani, M. R., 4771
 Bania, C., 147
 Banks, G., 5778
 Bannerji, R., 7820
 Baranczuk, R. J., 7799
 Baranowska-Kortylewicz, J.,
 5199
 Barbara, L., 1156
 Barbat, A., 6334
 Barbet, J., 3445
 Barcellos-Hoff, M. H., 3551
 Barlozzari, T., 2518
 Barnes, W., 3709, 4670
 Baron, A. E., 6502
 Barra, S., 6502
 Barranco, S. C., 3614
 Barrett, A., 1043s
 Barrett-Connor, E., 169, 6571
 Barriga, F., 5406
 Barrow, B. J., 1911
 Barreco, J. R., 4639
 Bartels, C. J., 3921
 Bartels, P. H., 147

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Barth, R. F., 1061, 4338
 Barthel, G., 5127
 Bartholomew, R., 3638
 Bartles, J. R., 669
 Bartoszek, A., 7789
 Bartram, C. R., 5464
 Bartsch, H., 3002
 Barzilai, M., 1764
 Baserga, R., 6769
 Bass, R. A., 2215
 Bast, M., 4845
 Bast, R. C., Jr., 3231, 4087
 Bastié, M. J., 5829
 Basu, H. S., 3137
 Batist, G., 1941
 Battaglio, S., 6478
 Battalora, M. S. J., 5675s
 Battista, P., 6107, 6987
 Bauer, B. L., 7442
 Bauer, L., 7206
 Baum, C. L., 3915
 Baurnal, R., 288
 Baumgartner, K. J., 6811
 Baxter, J. R., 4239, 6192
 Baxter, L. T., 4478
 Bayard, F., 5845
 Baylink, D. J., 6902
 Bazill, G. W., 7505
 Beardmore, C., 6919
 Beasley, E. G., 3614
 Beaton, D., 2449
 Beatty, B. G., 840s, 846s, 922s,
 989s, 1008s, 1029s
 Beatty, C., 7399
 Beatty, J. D., 840s, 846s, 922s,
 989s, 1008s, 1029s
 Beauvillain, J. C., 385
 Beavis, A. J., 20, 4741, 6062
 Beck, D., 7530
 Beck, W. T., 1132
 Becker, C. E., 5049
 Becker, F. F., 2337, 6235
 Becker, K. L., 1960
 Beckman, W. C., Jr., 735
 Becton, D. L., 5204
 Bedwell, J., 4533
 Beebe, G. W., 4050
 Beehler, B. C., 3921
 Beerman, T. A., 6154
 Begg, A. C., 3556
 Beggs, J. D., 7789
 Begleiter, A., 2872
 Behl, C., 6981
 Behmel, A., 4160
 Belinka, B. A., Jr., 857s
 Belinsky, S. A., 3772
 Belinson, J. L., 6302
 Bell, D. R., 2953
 Bell, P. B., 2215
 Bell, W., 3087
 Bellanger, J., 438
 Belli, J. A., 2191
 Beman, J., 7343
 Bement, W. J., 5219
 Benabid, A. L., 1566
 Ben-Baruch, N., 1220
 Bender, L. I., 7081
 Bender, M. A., 4050
 Benedetto, C., 6663
 Benedict, W. F., 7085
 Benhamou, E., 6203
 Benjamin, J. C., 4105
 Benjamin, R. S., 904s
 Benjamin, T. L., 5643s
 Bennett, G., 4584
 Bennett, J. A., 415
 Bennett, J. M., 2212
 Bennett, R. A. O., 7525
 Bennett, R. C., 7708
 Benzinger, M. J., 1580
 Berchuck, A., 4087
 Berdel, W. E., 2203, 3025
 Berebbi, M., 5892
 Berek, J. S., 6959, 7364
 Berends, F., 7887
 Berens, M. E., 2322
 Berenson, J., 7364
 Bergen Henegouwen, J. B., 1905
 Berger, H. J., 958s
 Berger, N. A., 2713
 Bergeron, R. J., 3137
 Berghard, A., 1626
 Berling, B., 6534
 Bernacki, R. J., 4401
 Bernard, D. J., 3301, 6620
 Bernard, L. D., 5618s
 Bernhard, E. J., 3872
 Bernier, J. L., 385
 Bernstein, I. D., 783s, 1017s,
 5421
 Bernstein, L., 3605
 Berston, E. D., 728
 Bertoncello, I., 4199
 Besa, E. C., 5240, 6876
 Best, A. J., 5112
 Best, K. L., 142
 Bester, A. J., 4911
 Bettaille, B., 7333
 Beuscart, R., 6931
 Beuzeboc, P., 438
 Bevacqua, S. J., 4121
 Bezwoda, W. R., 5387
 Bharathan, S., 5250, 6800
 Bhat, P. V., 5731
 Bhatia, K. G., 38, 5406
 Bhattacharya, B., 2105
 Bhuyan, B. K., 2485
 Bianchi, A. B., 4441
 Bianchi, M. S., 2379
 Bianchi, N. O., 2379
 Biasco, G., 1156, 7937
 Biasi, G., 5703s
 Bibbo, M., 147
 Bickerstaff, T., 4355
 Biddle, W. C., 2991, 7973
 Bidoli, E., 6502
 Biedermann, K. A., 7835
 Biernat, L., 4900, 5876
 Bignami, M., 4248
 Bigner, D. D., 58, 284, 1251,
 1803, 1822, 1954, 2347,
 2455, 2987, 4105, 6039, 8017
 Bigner, S. H., 1954, 2347, 2987,
 6039, 8017
 Bignon, Y.-J., 6620
 Bigotti, A., 1271
 Bijvoet, O. L. M., 3589
 Billings, P. C., 580
 Binder, K. A., 328
 Birckbichler, P. J., 7830
 Birnbaum, L. S., 7190
 Birse, R., 1216
 Birt, D. F., 499
 Bischoff, F. Z., 7979
 Bishop, J. A., 5212
 Bissett, D. L., 1580
 Biswas, R., 2234
 Bitter-Suermann, D., 1102
 Bjelfman, C., 6908
 Bjelke, E., 6836
 Bjerkvig, R., 6039
 Bjerner, L., 2027
 Björk, O., 7781
 Bjorn, M. J., 288, 5992
 Black, J., 1929
 Black, P. M., 5199
 Blair, A., 6585
 Blair, D. G., 5671s
 Blamey, R. W., 3545
 Blanck, A., 2679
 Blaney, S. M., 7915
 Blangy, D., 5892
 Bläenstein, P., 7435
 Blay, J.-Y., 2371
 Blazejewski, N., 794s
 Bleakley, P., 4676
 Bleyer, W. A., 4464
 Blick, M., 2724
 Blieck, J., 3279
 Bligh, H. F. J., 7789
 Bliss, D. P., Jr., 2773
 Bloch, A., 1346
 Bloedow, D. C., 5954, 7068
 Blot, W. J., 3804, 6836
 Blottière, H. M., 1051s
 Blume, A., 7932
 Blumenthal, R. D., 964s, 1003s
 Boarman, D., 3574, 5834
 Boccadoro, M., 6478
 Boccoli, G., 5795
 Bock, E., 1102
 Bock, K. W., 3569
 Bock, S., 3934
 Bodammer, J. E., 6744
 Boder, G. B., 4417
 Bogdahn, U., 6981
 Bogden, A. E., 2646, 4360
 Bohm, S., 1626
 Bohman, R., 5358
 Boice, J. D., Jr., 2741
 Bokhari, F., 1031s
 Bolanowska, W. E., 1726
 Bolognesi, A., 4291
 Bolt, M. J. G., 3915
 Bona, C. A., 6034
 Bonewald, L. F., 2673
 Bonfanti, M., 6870
 Bonfil, R. D., 7159
 Bonnem, E., 606
 Bonnetere, J., 6931
 Bonney, G., 5406
 Bonnichon, P., 438
 Bontadini, A., 4291
 Boobis, A. R., 7992
 Boone, C. W., 2
 Boosfeld, E., 1403
 Bor, A. M.-S., 5987
 Boraschi, D., 4771
 Borch, R. F., 6218
 Borchardt, R. T., 3838
 Borchers, A. H., 1786
 Borden, E. C., 26, 1071, 4588
 Bordin, G. M., 6095
 Borg, A., 4332
 Borkenhagen, K., 1658
 Borowitz, M. J., 6015
 Borst, P., 1779
 Borysko, K. Z., 4891
 Bosl, G. J., 5904
 Bosland, M. C., 691, 700, 1092
 Bossen, E. H., 2455
 Bouché, M., 3377
 Boucher, Y., 4478
 Bouhana, K., 2322
 Bouillard, B., 3786
 Boukamp, P., 2840, 7666
 Bourget, L., 432
 Bousquet, P. F., 1431
 Boussiatis, V. A., 2759
 Bove, K., 2786
 Bovens, J., 3934
 Bowden, G. T., 4061
 Bowlin, T. L., 4510, 5460
 Boyd, J. A., 3394
 Boyer, B., 129
 Boyer, C. M., 3231
 Boyer, J. C., 2593
 Boyett, J., 7206
 Boyle, P., 4497, 6274
 Bozzi, A., 5119
 Braakman, R., 2604
 Brack-Werner, R., 5636s
 Bradley, E. C., 2009, 6708
 Bradley, M. O., 5245
 Brajtburg, J., 3274
 Brambilla, C., 1566
 Brambilla, E., 1566
 Branda, R. F., 6302
 Brasch, R. C., 7376
 Brasel, J. A., 2765
 Brash, D. E., 5369
 Brasitus, T. A., 3915
 Braslawsky, G. R., 6600, 6608
 Brattain, M. G., 7579
 Braun, J., 7042, 7050
 Braun, L., 4809, 7023, 7324
 Braunschweiger, P. G., 4709
 Brechbiel, M. W., 4221
 Breit, S., 4411
 Breitman, T. R., 6268
 Brendler, C. B., 6668
 Brenes, M., 7815
 Brennan, M. F., 5488
 Brent, T. P., 58
 Brentani, M. M., 1479
 Brentani, R. R., 1479
 Brenz, R., 6075
 Bresalier, R. S., 1299, 6371
 Brésil, H., 5426
 Breslow, N. E., 3212
 Bresnick, E., 499
 Bretton, P. R., 7912
 Briand, P., 1257
 Briggs, J. A., 1183
 Briggs, R. C., 1183
 Briggs, S. L., 3540
 Brill, A. B., 1031s, 7272
 Brillanti, S., 1156
 Brinton, L. A., 3657, 4670, 7815
 Bristol, G., 5631s
 Brockhausen, I., 5003
 Brockschmidt, J. K., 7174
 Broder, S., 3470
 Brodeur, G. M., 2987
 Brodt, P., 1948
 Broitman, S. A., 632
 Brombacher, F., 6534
 Bröndum-Nielsen, K., 7781
 Brooke, J., 7793
 Brooks, S. C., 6075
 Brothman, A. R., 3795
 Browman, G. P., 1216
 Brown, B. A., 835s, 852s
 Brown, B. W., 4349
 Brown, C., 5520
 Brown, E. J., 3843

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Brown, J. M., 7745
 Brown, L. M., 6585
 Brown, M. B., 941s
 Brown, P. D., 5431, 6184
 Brown, R., 6841
 Brown, R. R., 4588
 Brown, S., 1017s
 Brown, T. D., 7494
 Brownstein, B. H., 4111
 Broxmeyer, H. E., 5027
 Broxterman, H. J., 5392
 Brubaker, P. G., 993s
 Bruce, W. R., 6955
 Bruchelt, G., 2177
 Bruchovsky, N., 2275
 Brucker, A., 6894
 Brüderlein, S., 7232
 Brueggemeier, R. W., 3652
 Bruggemann, E. P., 1748
 Brugger, W., 7448
 Bruggink, J., 2667
 Brugières, L., 6203
 Brunette, E. N., 375
 Brunetti, A., 7858
 Brunetti, I., 4026
 Brunning, R. D., 4984
 Bryan, G. T., 1071
 Bryant, L. D., 1658
 Bryant, M., 5088
 Bryant, M. S., 181
 Brylawski, B. P., 2593
 Bryngelsson, C., 4619
 Bucana, C. D., 3619, 7775
 Bucci, L., 2139
 Buchegger, F., 6534
 Bucher, K. D., 7942
 Buchmann, A., 5464
 Buchsbaum, D. J., 993s
 Buck, C. A., 6757
 Buckley, J. D., 7129
 Buckley, M. J., 794s
 Budd, G. T., 7206
 Buddenbaum, W. E., 2577
 Buist, J., 3416
 Buitenen, F. v., 5767
 Bukowski, R., 2363, 7206
 Bulcavage, L., 2119
 Bulian, P., 1768
 Bull, R. L., 6379, 7926
 Bullerdiek, J., 3095
 Bullock, B. C., 7675
 Bumol, T. F., 3540, 7632
 Bungo, M., 2549, 4698, 5919
 Bunin, G. R., 2608, 7129
 Bunn, P. A., Jr., 5954, 7068
 Banni, M., 3979
 Burak, E. S., 4366
 Burger, K. A., 909s
 Burger, P. C., 2987
 Burgess, A. W., 606
 Burgess, W. M., 3367
 Burke, A., 5756
 Burmeister, L. F., 6585
 Burns, F. J., 3073
 Burón, M. I., 5887
 Burrows, F., 84
 Bursch, W., 5127
 Burstein, D. E., 7393
 Burstein, N. A., 6848
 Burton, P., 1608
 Burton, G. V., 4951
 Busch, H., 2704, 4830
 Busch, R. K., 2704
 Bush, T. L., 3859
- Bushe, H., 7272
 Bushmeyer, S. M., 26
 Bustin, M., 2022
 Bustos, A., 7301
 Bustuabad, O. D., 7159
 Butler, J., 2003
 Bütler, T. M., 6323
 Buys, S. S., 4704
 Byar, A. A., 958s
 Byers, M. G., 6146
 Byrd, B. L., 4546
 Byrne, T. N., 6636
 Byrnes, R. W., 5275
- Center, M. S., 1426
 Ceriani, R. L., 5925
 Cerny, R. L., 3005
 Cerutti, P. A., 2840
 Chabot, M. C., 7174
 Chafouleas, J. G., 6554
 Chaganti, R. S. K., 6330, 6410, 6417
 Chakraborty, R., 6330
 Challine, D., 6203
 Chambon, P., 333, 3832
 Chamness, G. C., 3317, 3974
 Champagne, J., 7226
 Chan, C. K., 4664
 Chan, D., 7116
 Chan, P.-K., 5987
 Chan, W.-S., 4533
 Chandar, N., 7575
 Chaney, S. G., 4539, 6497
 Chang, A. E., 4371
 Chang, L.-C., 5107
 Chang, M.-J., 5682s
 Chang, S. K., 2075
 Chang, Y. S., 6278
 Chang-Claude, J. C., 2268
 Chang-Liu, C.-M., 339, 3963
 Chapekar, M. S., 3600
 Chaplin, D. J., 7428
 Chapman, P. B., 1503, 7488
 Chapman, P. H., 2499
 Chapot, B., 245
 Chapuis, Y., 438
 Char, D. H., 5773
 Charboneau, J. W., 5969
 Charpin, C., 7333
 Chase, D., 459
 Chassagne, J., 3301, 6620
 Chastre, E., 6716
 Chatterjee, M., 2818
 Chatterjee, S., 2713
 Chaudhuri, L., 5008
 Chauffert, B., 6626
 Chauvin, C., 1566
 Chavez, J., 2673
 Capizzi, R. L., 7174
 Caporaso, N. E., 1857, 3002
 Capps, D., 4900
 Cardinali, M., 8010
 Carew, J. A., 580
 Carlini, P., 5795
 Carlson, D. A., 3331
 Carlson, K., 1634
 Carmella, S. G., 5438, 5453
 Carpen, M., 552
 Carpenter, R. N., 2963
 Carr, B. I., 6222
 Carrano, A. V., 4951
 Carrasquillo, J. A., 820s
 Carrel, S., 1822
 Carrière, D., 5558
 Carroll, J., 5643s
 Carroll, R. G., 932s
 Carter, B. S., 6830
 Carvalho, A. P., 2753
 Case, D. C., Jr., 6833
 Casellas, P., 2909
 Castagna, M., 2081
 Castellazzi, M., 3754
 Castelli, M., 6023
 Castello, M. A., 4929
 Castleden, W. M., 6649
 Castonguay, A., 1810, 3435
 Catalona, W. J., 3843
 Cate, C. C., 5312
 Cavaliere, R., 1271
 Cavallari, A., 7420
 Cavanaugh, P. G., 515
 Cayco, R., 1216
 Ceccherelli, G., 1988
 Cechner, R. L., 7569
- Chiodino, C., 5351
 Chiron, M., 5558
 Chisari, F. V., 3400, 3805
 Chitambar, C. R., 1484, 4468, 6466
 Chlebowksi, R. T., 2119
 Cho-Chung, Y. S., 7093
 Choi, H. G., 7579
 Chojnowski, G. M., 4199
 Chollet, P., 3301, 5898, 6620
 Chopra, H., 7686
 Chou, B. J., 6592
 Chou, M. Y., 5107
 Chou, P., 6023
 Chou, R. H., 3199
 Chou, T.-C., 5618s
 Chou, Y.-M., 6222
 Chouaib, S., 2371
 Choudhury, S., 6636
 Chrestan, C. M., 4067
 Christensen, M. L., 4951
 Christian, B. J., 4779
 Christison, W. H., 6344
 Christoforov, B., 438
 Christopherson, R. I., 7793
 Chrouzos, G. P., 5488
 Chu, E., 5834
 Chu, F.-F., 1397
 Chu, T. M., 1107, 3013
 Chung, A., 1658, 3036
 Chung, F.-L., 2613, 6817
 Chung, S. I., 8010
 Chung, S. m., 658
 Chung, T. D. Y., 2901
 Churchill, J. R., 3199
 Churchill, P., 5858
 Chyou, P.-H., 7501
 Cipriani, A., 1768
 Clafin, G., 6848
 Clapp, D. W., 1701
 Clark, G. M., 3317, 4332
 Clark, J. C., 5481
 Clark, J. H., 1470
 Clark, J. W., 185, 2979, 7343
 Clarke, B. V., 3284, 4595
 Clarke, C. L., 6430
 Clarke-Pearson, D. L., 4087
 Clausen, H., 1375, 1608
 Clauss, M. A., 3487
 Clausse, N., 3754
 Claustrat, B., 4081
 Clay, M. E., 1620
 Cleary, E. G., 2164
 Cleary, K. R., 3331
 Clemens, M. J., 7221
 Clementi, F., 3892
 Clendeninn, N. J., 4464
 Clendenon, N. R., 4338
 Clifford, C., 5710
 Clynes, M., 3390
 Cmarik, J. L., 2747
 Coakham, H. P., 4105
 Coccio, M. G., 5291
 Co Chien, H. T., 6836
 Cochran, A. J., 3585
 Coda, M., 3002
 Coderre, J. A., 138
 Coffey, R. J., 261
 Cohen, A., 2891
 Cohen, A. M., 862s, 877s
 Cohen, C., 7351
 Cohen, J. A., 421
 Cohen, J. S., 544, 552, 6565, 6936

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Cohen, P., 7343
 Cohen, P. S., 6055
 Cohen, S. A., 1834
 Cohen, S. M., 3005
 Coit, D. G., 7488
 Colapinto, E. V., 1822, 4105
 Colasante, A., 6107, 6987
 Colcher, D., 820s, 4872
 Coldham, N. G., 193
 Coldman, A. J., 2275
 Coleman, C. N., 5055
 Collavo, D., 5703s
 Collazos, T., 4731, 4737
 Colley, M., 6344
 Collins, A. R. S., 2356
 Collins, J., 1031s
 Collins, J. L., 4923
 Collins, J. M., 3905, 6652
 Collins, V. P., 483, 5863
 Colly, L. P., 6515
 Colombatti, M., 1385
 Colombo, N., 7318
 Colp, P., 3737
 Colvin, O. M., 284, 1954, 2455
 Combaret, V., 2371
 Comora, S., 2949
 Comstock, G. W., 3859
 Comstock, K. E., 6848
 Conlon, K., 2979, 7343
 Connally, R., 2363
 Conney, A. H., 4741
 Connolly, D. T., 1774
 Connolly, J., 7351
 Connolly, J. M., 7139
 Connors, K. M., 6095
 Constantinidis, I., 4709
 Constantinou, A., 2618
 Conti, J., 4441
 Conway, E., 7830
 Cook, C. A., 7553, 7557
 Cook, M. G., 3176
 Cooke, D. B., 735
 Coombes, R. C., 1381, 7882
 Coon, W., 941s
 Cooper, A. J. L., 4839
 Cooper, B. N., 1997
 Cooper, H. L., 2105
 Cooper, K., 3231
 Cooper, M. J., 3694, 6055
 Cope, D. A., 1803
 Corbett, T. H., 4900, 5876
 Corbitt, R. H., 5997
 Cordeiro-Stone, M., 2593
 Cordon-Cardo, C., 6417, 7488
 Cornelisse, C. J., 4003
 Corpet, D. E., 6955
 Corradini, P., 6478
 Correa, E., 1645, 1960, 3435
 Correa, P., 2268, 4731, 4737
 Correll, L., 2356
 Cory, J. G., 4552
 Cosgrove, M. M., 1279
 Cossman, J., 5406
 Costa, P., 4315
 Costantini, R. M., 6107, 6987
 Cote, P. J., 7843
 Coughlin, D. J., 857s
 Coulombe, R. A., Jr., 2493, 4918
 Cova, L., 2156
 Covey, J. M., 648
 Cowan, K. H., 1220
 Cowburn, D., 7252
 Cox, P., 955s
 Coy, D. H., 2646, 4360
- Cramer, P., 7159
 Crawford, E. K., 4578
 Creekmore, S., 2979, 7343
 Cremer, G. A., 438
 Crépin, M., 3754
 Crespi, M., 2268
 Crews, J. R., 3231
 Crippa, M. P., 2022
 Crist, W., 7371
 Croce, C. M., 4856, 5240, 6171,
 6478, 6565, 7399
 Cronauer, M. V., 7037
 Cronin, K., 7820
 Crook, J. E., 4546
 Crook, T. R., 4067
 Cross, B. A., 6229
 Crowley, N. J., 492
 Crowther, P. J., 4199
 Crum, E., 7343
 Cuadrado, C., 1608
 Cuddy, D. P., 2658
 Cuello, C., 4731, 4737
 Cui, M.-Y., 3429
 Cullen, J. M., 4072
 Cullen, K. J., 48
 Cullinan, E. B., 6154
 Cullis, P. R., 575
 Culp, L. A., 2808, 4388
 Cumber, A. J., 7517
 Cunha, G. R., 4747
 Cunliffe, W. J., 5790
 Curcio, C. G., 6107
 Curia, M. C., 6987
 Curtis, R. E., 2741
 Cuttitta, F., 6068
 Czajkowski, C. A., 3262
 Czermak, B., 1576
 Cziepluch, C., 7232
- D
- D'Agnano, I., 7420
 Dagnino, L., 6549
 Dahiya, R., 1299
 Dal Cin, P., 7902
 Daling, J. R., 3212
 Dalton, B. A., 3383
 Daly, P. F., 552
 Daly, R. J., 5868
 Dam, A., 3416
 Damiani, D., 4291
 d'Amico, F., 3113
 Damjanovich, L., 6757
 Dan, M. E., 4900
 Danenberg, K., 1757
 Danenbergs, P. V., 1757
 Daniel, J. C., 7895
 Daniel, M. T., 5692s
 Daniels, B., 7820
 Daniels, L. M., 717
 Danks, J. A., 7708
 Dantes, L., 7488
 Darbon, J. M., 5845
 Darbre, P. D., 5868
 Darling, G., 4008
 Darnowski, J. W., 4026
 D'Arpa, P., 6919
 Darrow, T. L., 492
 Darzynkiewicz, Z., 5746, 7912
 Das, P. K., 5112
 Da Silva, C., 2081
 da Silva-Neto, J. B., 1479
 Dastugue, B., 6620
 Daues, A., 6600
- D'Avanzo, B., 4497, 5231, 6274
 Davenport, J., 1381
 Davenport, R., 941s
 Davidson, N. E., 2251
 Davies, D. S., 7992
 Davies, K. A. A., 563
 Davis, B. B., 4650
 Davis, C. A., 6636
 Davis, G. E., 1113
 Davis, G. F., 4510
 Davis, R. G., 7754
 Davis, W. L., 6423
 Davison, A., 2198
 Dawe, C. J., 5643s
 Dawe, S. C., 5679s
 Daxenbichler, G., 7037
 Day, B. W., 4611
 Day, R., 3681
 Day, R. S., III, 278
 Day-Lollini, P., 4935
 Daylong, A., 4355
 Dear, T. N., 1667
 Dearborn, C. B., 835s
 De Artxabala, X., 509
 Deb, G., 4929
 DeBernardi, M., 5406
 DeBrujin, E. A., 5790
 Debs, R. J., 375
 Decarli, A., 4497
 Decker, J., 6285
 DeCosse, J. J., 381, 8023
 Dedrick, R. L., 7382
 Deen, D. F., 2719, 2769, 3137,
 3551
 Degawa, M., 2729
 de Goeij, J. J. M., 7031
 de Graaf, S. S. N., 3493
 DeHerdt, S. V., 7632
 DeJager, R. L., 1055s
 Dejana, E., 4771
 de Jong, B., 3416
 de Jong, S., 304
 de Kraker, J., 3279
 de Kuiper, P. E., 3509
 Delaage, M., 3445
 de Laat, S. W., 7770
 de la Chapelle, A., 2379
 De la Concha, E. G., 7301
 Del Bino, G., 5746
 Del Bufalo, D., 5119
 De Lena, M., 2958
 Delgado, G., 4670
 Dell'Arciprete, L., 1385
 Delmon-Moingeon, L. I., 2198
 del Rosario, R. B., 804s
 de Luise, M., 2953
 Demaille, A., 6931
 Demant, E. J. F., 3311
 Demers, L., 7179
 Demetrick, D. J., 4557
 Demignot, S., 2936
 D'Emilia, J. C., 2518
 Demura, H., 4915
 DeNardo, G. L., 1014s
 DeNardo, S. J., 789s, 1014s
 den Engelse, L., 3556
 den Holder, F., 6238
 Denis, K. A., 7042
 Denner, L. A., 6430
 Denning, M. F., 2239
 Dennis, J. W., 1867
 Den Otter, W., 6689
 de Palazzo, I. G., 7123
 De Palo, G., 4501
- de Pijk, D., 3509
 Deroussent, A., 6203
 Deryck, R., 299
 DeSantes, K., 1243
 Deschner, E. E., 381
 DeSisto, W. C., 5199
 de Smidt, P. C., 7476
 De Stefani, E., 426
 Detchon, P., 6649
 de-Thé, G., 5692s
 de Tribolet, N., 6683
 Devereux, D., 6158
 Devilee, P., 3279
 Devitt, M. L., 7252
 de Vries, E. G. E., 304
 Dewhurst, M. W., 1803, 2075
 Dexter, D. L., 2524
 Dexter, T. M., 7503
 Dezube, B. J., 6806
 Dezzutti, C. S., 5687s
 Dhesi, J. K., 5022
 Diasio, R. B., 197
 Dick, F., 6585
 Dickson, R. B., 4446
 Diddens, H., 6793
 Dieckmann, B. S., 6471
 Diehl, V., 84, 2929, 6944
 Diener, E., 1538
 Dienhart, D. G., 5954, 7068
 Dietel, M., 2470, 6100
 Dietrich, S. E., 5587
 Di Febo, G., 1156
 DiGiovanni, J., 3048
 Diglio, C. A., 7684
 Dijkhuizen, T., 3416
 Dijkman, R., 3556
 Dillberger, J. E., 5587
 Dilliman, R. O., 4154
 Dimaggio, J. J., 1151, 7488
 Di Muccio, A., 4248
 D'Inca, M., 1988
 D'Incan, M., 6620
 Ding, L., 1538
 Ding, V. D-H., 256
 Dinota, A., 4291
 Dion, A. S., 880s, 927s
 DiPaolo, J. A., 1316, 3709
 Dippold, W. G., 7666
 Director, E. P., 5072
 Dirksen, T. J. M., 700
 Diserens, A-C., 6683
 Divgi, C., 862s, 877s
 Dixon, W. T., 4557
 Djakiew, D., 1966
 Do, T., 840s, 846s
 Doak, K. W., 2599
 Dobler, K. D., 278
 Dodge, R., 4087
 Dodin, G., 7966
 Doe, W. F., 4676
 Doerr, R. J., 1834
 Dogliotti, E., 4248
 Dohi, K., 4050, 7660
 Doi, O., 444
 Doig, R. G., 5095
 Dokidos, A., 6062
 Dollbaum, C., 2943
 Dominici, C., 4929
 Donaldson, E. S., 7799
 Donehower, R. C., 710, 3284,
 4595
 Donelli, A., 1988, 5825
 Donfrancesco, A., 4929
 Donner, D. B., 2654

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Donohue, J. H., 6508
 Donovan, C., 1701
 Dooley, M., 3390
 Dopfer, R., 2177
 Doppler, W., 7037
 Dorf, M. E., 5643s
 Dorighi, J. A., 6302
 Doroshow, J. H., 1397
 Dorsk, B. M., 6833
 Doskas, C., 5731
 Dosse Pasqualini, C., 7159
 Dotzlaw, H., 4204
 Douglas, A., 7591
 Douglass, E. C., 2781, 2987
 Douillard, J.-Y., 873s
 Douillard, J. Y., 1051s
 Dowsett, M., 1381
 Doyle, G. A., 4619
 Drake, F. H., 2901
 Drenkard, D., 6981
 Drieu, K., 5892
 Dritschilo, A., 38, 5653s
 Drozynski, C. A., 835s
 Drucker, D. J., 2631
 D'Souza, T., 1216
 Du, D.-L., 4038
 Dubeau, L., 1897
 Dubensky, T. W., 5643s
 Dudley, J. P., 5911
 Dudouet, B., 438
 Duffie, G. P., 2973
 Duffy, M. J., 6827
 Duh, Q.-Y., 1299
 Dumanski, J. P., 5863
 Dumenco, L. L., 1701
 Duncan, L. W., 6545
 Duniec, Z. M., 4650
 Dunitz, J., 1279
 Dunsford, H. A., 3400, 3439
 Dupon, J. W., 7376
 Dupont, J., 7966
 Durbec, P. L., 6364
 Durivage, H. J., 6636
 Durkacz, B. W., 1992
 Dürsi, M., 7324
 Dusre, L., 648
 Dussaulx, E., 6334
 Du Toit, R., 4911
 Duvander, A., 6358
 Düzgünçü, N., 375
 Dvorak, H. F., 1774
 Dykes, D. J., 3239
 Dytch, H., 147
 Dzielendziak, A., 2003
- E**
- Earhart, R. H., 5475
 Earley, K., 5088
 Eary, J. F., 783s, 1017s
 East, M., 941s
 Eastmond, D. A., 393
 Eaton, D. L., 615
 Eberlein, T. J., 1138, 2587
 Ebert, E. C., 6158
 Ebert, T., 5531
 Eckelman, W. C., 780s
 Eckert, K., 642
 Eckert, R. L., 5947
 Economou, J. S., 2949
 Eda, H., 2290, 4528
 Eddy, R. L., 6146
 Eder, J. P., 6806
 Edinger, M., 2363
- Edson, M. A., 6600, 6608
 Edwards, J. A., 974s
 Edwards, M. L., 5460
 Egner, P. A., 2251
 Egorin, M. J., 4044, 4322
 Ehrlich, K. C., 6865
 Ehrlich, M., 6865
 Eibl, B., 7037
 Eibl, H., 3025
 Eid, P., 3533
 El, C., 3087
 Einhorn, S., 7781
 Eisert, D. R., 5296
 Ejima, D., 2885
 Eker, A. P. M., 1905
 Eklind, K., 6817
 El Alami, N., 1810
 Elberg, S., 3274
 Elder, D. E., 6757
 Eldor, A., 4787
 Elias, A. D., 1170
 Elias, D. J., 4154
 Eling, T. E., 4650
 Elion, G. B., 284
 Eliot, H. M., 648
 Elkind, M. M., 2577
 Ellenbogen, R., 1459
 Elling, F., 4880
 Elliott, W. L., 3239
 Ellis, M., 4572
 Ellison, M. D., 4377
 Emami, S., 6716
 Emanuel, B. S., 7129
 Emond, H., 129
 Emond, G., 1031s
 Emond, J. Y., 3556
 Endlich, B., 97, 4515
 Endo, S., 740
 Endo, T., 1079
 Endo, Y., 2538
 Endoh, K., 240
 Engberg, B., 108
 Engert, A., 84, 2929, 6944
 Engler, H., 7488
 English, H. F., 3748
 Enomoto, M., 4131
 Enomoto, T., 6139
 Entwistle, M. L., 1237
 Epenetus, A. A., 159, 563
 Epstein, A. L., 1650
 Epstein, J. I., 6830
 Epstein, L. B., 3146
 Erexson, G. L., 4635, 5088
 Erfle, V., 4146, 5636s
 Erickson, L. C., 62
 Eriksson, B., 3413
 Eriksson, L. C., 3569
 Erroi, A., 7318
 Ertürk, E., 1071
 Ervin, T. J., 6833
 Eskild, W., 1528
 Essner, R., 2949
 Esteban, J. M., 989s
 Estève, J., 426
 Esworthy, R. S., 1397
 Ethier, S. P., 5351
 Eto, S., 4344
 Eto, Y., 3182
 Ettenson, D., 288
 Ettinger, D. S., 3284, 4595
 Ettinger, L. J., 7226
 Evans, P. C., 503
 Evans, R., 5039
 Evans, S., 4272
- Evans, W. E., 4267, 6854
 Evarts, R. P., 3439
 Evelhoch, J. L., 363
 Everard, M. J., 2511
 Everett, G. D., 6585
 Everett, M. L., 6015
 Everson, R. B., 4951
 Ezaki, H., 4050
- F**
- Fabricant, M., 632
 Facchinetti, A., 5703s
 Faff, O., 5636s
 Fagnani, R., 3638
 Fair, W. R., 7912
 Fairchild, R. G., 138, 1061, 4860
 Falconi, R., 6107
 Falcone, A., 4026
 Falette, N. S., 3974
 Fallavollita, L., 1948
 Faller, D. V., 601
 Falletta, J. M., 3212
 Faltynek, C. R., 26
 Fan, D., 3619, 7775
 Fan, X., 2081
 Fand, I., 138, 885s
 Fanelli, R., 6870
 Fang, M.-Z., 2139
 Fanin, R., 4291
 Fantini, J., 5164
 Faris, R. A., 4755, 4809
 Farrell, D., 3390
 Farzad, Z., 3585
 Faucher, C., 5845
 Fauque, J., 3832
 Faustino, P. J., 544
 Fausto, N., 1464, 3805, 4809,
 7023
 Favre, S., 7530
 Favrot, M. C., 2371
 Fayos, B. E., 669
 Fazely, F., 5618s
 Feder, J., 1774
 Fefer, A., 1160
 Feindel, W., 3062
 Feingo'd, K. R., 4233
 Feinstein, A. R., 4664
 Fekete, I., 1251
 Felber, M., 3073
 Felix, J., 8023
 Fell, H. P., 2449
 Felsher, D. W., 7042, 7050
 Fendly, B. M., 1550
 Fennelly, J. J., 6827
 Fenton, B. M., 1681
 Ferguson, R. J., 7942
 Fernandez, L. A., 3737
 Fernö, M., 4332
 Fernsten, P. D., 4656, 4872,
 4885
 Ferone, R., 3207
 Ferrari, S., 1988, 5825
 Ferrario, A., 539, 3985
 Ferris, D. K., 6379
 Ferrone, S., 1271, 1559
 Feruglio, C., 1768
 Festoff, B. W., 5039
 Feuerstein, B. G., 3137
 Fey, M. F., 1355
 Fibach, E., 5003
 Fichtinger-Schepman, A. M.,
 7887
 Fidler, I. J., 3619, 6130, 7775
- Fiers, W., 4233, 5537
 Figarella-Branger, D. F., 6364
 Figg, C. G., 1102
 Filaccio, M. D., 5263
 Filic-DeRicco, S., 4839
 Finan, J., 4856
 Finch, J., 4061
 Finch, R. A., 2625
 Fine, N., 1764
 Fine, R., 1220
 Fingar, V. H., 2599
 Finger, L. R., 5240
 Finke, J. H., 1176, 2363
 Finklestein, J., 7226
 Finlay, P., 3545
 Finstad, C. L., 5531
 Finston, R., 4935
 Fireman, B. H., 7547
 Fireman, Z., 1764
 Firestone, G. L., 6010
 Fisch, P., 2683
 Fischer, J., 642
 Fischer, P. H., 2667
 Fisher, D., 1017s
 Fisher, P. B., 7420
 Fittler, F., 5008
 Fitzgerald, D. J., 7750, 7786
 Fitzgerald, K. A., 6600
 Fix, D. V., 1790
 Flandrin, G., 5692s
 Flannery, J. T., 2741
 Flavell, D. J., 3131
 Fleming, R. A., 6854
 Fletcher, J. A., 4092
 Fletcher, S., 7591
 Flickinger, K. S., 4388
 Fligiel, S. E. G., 7684
 Floot, B. G. J., 3556
 Flotte, T. J., 4167
 Flubacher, M. M., 3199
 Foekens, J. A., 2604, 3832
 Fogler, W. E., 6379
 Foiles, P. G., 5438
 Foley, J. F., 3772
 Fon'k, Y., 3301, 6620
 Fondy, C., 1431
 Fondy, T. P., 1431
 Fong, D., 6278
 Fontana, J. A., 1977, 1997
 Fontanelli, R., 5291
 Fontham, E., 4731, 4737
 Foo, D. Y., 2840
 Foon, K. A., 2991, 7973
 Forbes, M. E., 1411
 Ford, C. P., 7466
 Ford, H., Jr., 1220
 Ford, H. T., 1381
 Ford, J. M., 1748
 Fornace, A. J., Jr., 2356, 7908
 Forrest, G., 1397
 Forrester, J. A., 7517
 Forrester, K., 1279
 Forrow, S. M., 1936
 Forsslund, G., 4281
 Foshag, L. J., 5358
 Foss, O. P., 2341
 Foulke, R. S., 6264
 Fourcade, A., 4698
 Fournie, J. W., 5978
 Fox, M. E., 5813
 Fox, M. H., 6176
 Fox, R. M., 606
 Fox, T. R., 4014
 Fradet, Y., 293, 432

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Fraker, D. L., 2261, 3928, 4008
 Fram, R. J., 72
 Franceschi, S., 4497, 5231, 6274, 6502
 Francis, G. E., 3453
 Francis, K., 4254
 Franco, E. L. F., 1479
 Frankfurt, O. S., 4453
 Franklin, W. A., 6344
 Franks, C. R., 2371
 Franzén, L., 2027
 Frati, L., 6987
 Fraumeni, J. F., Jr., 2311, 3804
 Frazier, D. E., 5687s
 Freedman, L. S., 5710
 Freeman, C. S., 3453
 Freeman, D. H., Jr., 7550
 Freeman, G. L., 7494
 Freeman, K., 1620
 Freeman, M. L., 1879, 5296
 Frei, K., 3322
 Freitag, C. M., 1726
 French, D., 6987
 French, F. S., 735
 Frenkel, K., 7562
 Frese, G., 6793
 Freudenheim, J. L., 3295
 Freund, R., 5643s
 Friedlander, N. J., 6571
 Friedman, B., 533
 Friedman, E., 261, 2245
 Friedman, G. D., 7549
 Friedman, H. S., 284, 1251, 1803, 1822, 1954, 2347, 2455, 2987, 8017
 Friis, R. R., 6323
 Fritz, P., 2191
 Fritzberg, A. R., 7973
 Frizzera, G., 2698
 Frödin, J.-E., 4866
 Frohlich, M., 6291
 Frost, P., 4572
 Frøysa, A., 1528
 Frucht, H., 2773
 Fu, Y., 227
 Fuchs, D., 2863
 Fuchs, H. E., 1954
 Fuchs, H. J., 375
 Fuhrer, J. P., 7695
 Fujii, N., 5841
 Fujii, S., 5345
 Fujikawa, S., 358
 Fujiki, H., 533, 3521, 4974, 7085
 Fujimoto, I., 444
 Fujimoto, K., 4528
 Fujioka, K., 7003
 Fujita, T., 4522
 Fujiwara, T., 7003
 Fujiwara, Y., 2549, 5919
 Fukuda, S., 345
 Fukuda, Y., 2917, 5497
 Fukuahara, S., 2423
 Fukui, I., 2848
 Fukunaga, Y., 5574
 Fukushima, S., 4195
 Fukushima, T., 5697s
 Fuller, G. N., 1954, 4105
 Fulton, D., 278
 Fults, D., 5784
 Funa, K., 748
 Fung, P. Y. S., 4308
 Fuqua, S. A. W., 3974, 4332
 Furcht, L. T., 273, 3781, 7610
 Furmanski, P., 3805, 4709, 5682s, 5954, 7557
 Furr, B. J. A., 568
 Furumoto, N., 7852
 Furusawa, H., 4139
 Furuta, T., 1715
 Furuta, Y., 4473
 Furuya, Y., 4979
 Furuya-Suguri, H., 3521
 Fusenig, N. E., 2840, 7666
 Fusetani, N., 3521
 Futami, H., 7926
 Futscher, B. W., 62
 G
 Gabius, H.-J., 3322
 Gabizon, A., 6371
 Gabrielson, E. W., 1890
 Gaczynski, M., 1183
 Gadski, R. A., 7632
 Gaffney, D. K., 7765
 Gaida, F.-J., 2128
 Gailani, D., 2895
 Gajic, D., 2631
 Galazka, A., 7318
 Galivan, J., 3979
 Gallagher, G. T., 5107
 Galli, A., 6870
 Gallinger, S., 2476
 Gallion, H. H., 7799
 Gamma Sosa, M. A., 5618s
 Gambacorti-Passerini, C., 5551
 Gamliel, H., 4111
 Gams, R., 6833
 Gan, L., 2385
 Gan, L.-S., 4611
 Gandhi, V., 3675
 Gan-Elepano, M., 2221
 Ganis, B., 1929
 Gansbacher, B., 7820
 Gansow, O. A., 4221
 Ganther, H. E., 1206
 Gao, N.-H., 7695
 Gardner, H. S., 5671s
 Garg, P. K., 3514
 Gariboldi, P., 6870
 Garland, C., 169
 Garlick, P. J., 1125
 Garofalo, A., 4771
 Garrido, M. A., 4227
 Garrigues, H. J., 2183
 Garrigues, U., 2183
 Garte, S. J., 3073
 Gatenby, R. A., 7997
 Gates, J. A., 6636
 Gause, B., 5406
 Gautherot, E., 3445
 Gauthier, J., 293
 Gavrilovic, J., 129
 Gawron, L. S., 6154
 Gayle, M., 2449
 Gazdar, A. F., 120, 421, 2773, 3067, 5481, 5488, 6068
 Gazer, J.-C., 1381
 Gazzera, S., 1566
 Gebhardt, R., 4407
 Geiges, M., 1421
 Geissler, F., 1243
 Gekeler, V., 6793
 Gelbard, A. S., 4839
 Gelboin, H. V., 2060
 Gelfand, E. W., 5727
 Geller, N. L., 5904
 Gelmann, E. P., 67
 Gemmill, R. M., 7902
 Genne, P., 6626
 George, S. L., 3231
 Gera, J. F., 7364
 Gérard, B., 1231
 Gerber, M., 6833
 Gerbracht, U., 3701
 Gercel-Taylor, C., 7123
 Gerhard, D. S., 6529
 Gerin, J. L., 7843
 German, G. S., 318, 6002
 German, J., 3141
 Gerritsen van der Hoop, R., 2437
 Gersdorf, E., 1576
 Gerson, S. L., 1701
 Gerwin, B. I., 2022
 Gescher, A., 2203
 Gespach, C., 6716
 Gessain, A., 5692s
 Gessner, T., 3921
 Ghanta, V. K., 4295
 Ghezzi, P., 4771
 Ghidini, G., 7937
 Ghilchik, M. W., 193
 Ghiringhelli, B., 6663
 Ghose, T., 3737
 Giaccia, A., 2356
 Giacomini, P., 7420
 Giannimarioli, A. M., 4248
 Giannella, G., 5795
 Giardiello, F. M., 6486
 Giavazzi, R., 4771
 Gibbons, G. R., 6497
 Giblin, J. R., 2322
 Gibson, D. P., 3722
 Gibson, N. W., 7293, 7481, 7553, 7557
 Gibson, R., 6585
 Gibson, S. L., 7236
 Gierke, L. W., 527
 Gil, J., 7301
 Gilboa, E., 7820
 Gil-del-Real, M. T., 6520
 Gildersleeve, D. L., 4891
 Gill, R. D., 3048
 Gilles, F. E., 587
 Gillespie, A., 4464
 Gillette, E. L., 54, 6176
 Gillette, S. M., 54
 Gillis, S., 1160
 Gilman, S. C., 6423
 Gilmour, S. K., 2088, 4741
 Gilvarry, U., 3390
 Gimenez, I. B., 2505
 Gimenez-Conti, I. B., 4441
 Gingras, M. C., 4061
 Ginsberg, G. L., 1189
 Giovannella, B. C., 7979
 Girod, C., 4081
 Gispens, W. H., 2437
 Gissmann, L., 3730
 Gizzi, G., 1156
 Gjerset, R., 10
 Glass, J. D., 138
 Glatfelter, A. A., 993s
 Glatstein, E., 7735
 Glazer, R. I., 2022
 Glenn, S. D., 7068
 Glickson, J. D., 4709
 Glogowski, J., 3002
 Glonk, T., 527
 Gloudemans, T., 6689
 Glurich, I., 686
 Gnatt, A., 1983
 Gobbi, M., 4291
 Godden, J., 4692
 Godeneche, D., 5898
 Godwin, T., 8023
 Goebel, R., 1576
 Goffman, T. E., 7735
 Goffney, W. H., 459
 Gokhman, I., 2554
 Gold, D. V., 828s, 6405
 Goldberg, H., 6876
 Goldberg, L. H., 637
 Goldenberg, D. M., 778s, 794s, 828s, 866s, 869s, 880s, 885s, 909s, 964s, 1003s, 1039s, 1055s, 1330, 2330, 2823, 6405
 Goldenberg, H., 909s, 2823
 Goldenberg, S. L., 2275
 Goldfarb, A. N., 4984
 Goldfarb, S., 113, 6779
 Goldfine, I. D., 7858
 Goldhaber, M. K., 4600
 Goldman, I. S., 8023
 Goldman, L. R., 5049
 Goldman, M., 2056
 Goldman, M. B., 2283
 Goldrosen, M. H., 1834, 2991, 7973
 Goldsmith, L. A., 1201
 Goldstein, M. B., 1853
 Golomb, H. M., 4111
 Gombar, C. T., 1144, 4366
 Gomer, C. J., 539, 3985, 5365
 Gomez, A. P., 6278
 Gomi, M., 1873
 Gong, D., 1538
 Gonzales, D., 3754
 Gonzalez, F. J., 2060
 Gonzalez-Crussi, F., 6023
 Good, R. A., 2582
 Goode, N. T., 1510, 1828
 Gooderham, N. J., 7992
 Goodluck, L. A., 5153
 Goodridge, R. J., 7793
 Goodrow, T., 4818
 Goppelt-Struebe, M., 323
 Gordon, D. F., 6208
 Gordon, G. B., 3859
 Gordon, S. G., 6229
 Gordon, W. A., 4338
 Goris, M. L., 4935
 Gorodetskaya, N., 1701
 Gorschboth, C. M., 4008
 Gorski, J., 7920
 Gottardis, M. M., 3189
 Gottesman, M. M., 1748
 Gotwals, B., 2786
 Gould, M. N., 4286
 Goulette, F. A., 4026
 Gout, O., 5692s
 Gouyette, A., 6203
 Goyette, M., 4809
 Grabowski, D., 7206
 Graf, L. H., Jr., 1559
 Graham, B. S., 5943
 Graham, M. L., II, 6208
 Graham, S., 3295
 Gralnick, H., 4485
 Grandier, D., 7781
 Grandi, M., 4291
 Grandjean, H., 5558
 Granetzny, A., 642

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX TO VOLUME 50*

- Grant, B. W., 6302
 Grant, G., 7979
 Granzow, C., 403
 Grattan, J. A., 6600
 Grauffel, C., 5077
 Graves, T., 5790
 Gray, J. D., 3585
 Grebenau, R., 794s
 Greco, C., 5119
 Greco, W. R., 5318
 Green, M., 7815
 Green, M. D., 606, 5095, 5136
 Green, M. R., 1022s
 Greenberg, A. H., 4061
 Greenberg, P. D., 1160, 5421, 6256
 Greenberg, P. L., 6471
 Greene, D. G., 7174
 Greene, G. L., 3974
 Greene, M. I., 421, 5184
 Greene, R. F., 6652
 Greenfield, R. S., 6600, 6608
 Gregor, A., 1000s
 Gregory, R. R., 1470
 Greiner, J. W., 820s, 6248
 Greiter, E., 7037
 Grem, J. L., 2667, 7279
 Gresser, I., 3533
 Grever, M. R., 6483
 Gridley, D. S., 3124
 Gridley, G., 6836
 Grier, H., 1459
 Grierson, H. L., 4845
 Grieshaber, C. K., 4038
 Griffin, T. W., 1031s, 6696, 7272
 Griffith, O. W., 1251, 2455
 Grimm, E. A., 3331, 3526
 Grindey, G. B., 318, 664, 3910, 4417
 Grist, S. A., 4584
 Griswold, D. P., Jr., 3239
 Grochow, L. B., 3284, 4595
 Groeneveld, E., 5143
 Groffen, J., 3429
 Groot, K., 3716
 Grootuis, D. R., 1251
 Groscurth, P., 980s
 Gross, J., 5136
 Gross, J. L., 2524
 Gross, L., 8034
 Gross, N., 7532
 Gross, S. S., 2455
 Grossberg, S., 4588
 Grosse, R., 642
 Grosso, M. I., 5551
 Grove, J. S., 627, 7084
 Groves, E., 6379
 Gruaz-Guyon, A., 3445
 Gruffman, S., 3212
 Grunert, F., 6534
 Grunewald, R., 6823
 Grunfeld, C., 4233
 Gruppuso, P. A., 1464, 7324
 Grusy, E., 7926
 Gu, J.-r., 7695
 Gu, T.-g., 7695
 Guadagni, F., 6248
 Guengerich, F. P., 2036, 2747
 Guigou, M., 328
 Guilbault, D. M., 993s
 Guillen, J. G., 3595
 Gum, J. R., 1085
 Gundel, R. M., 2351
 Guo, X.-J., 5164
 Guo, Y.-S., 6772
 Guo, Z., 6817
 Gupta, K. P., 7775
 Gupta, N., 958s
 Gupta, R., 5088
 Gurfel, D., 4111
 Gustafsson, J.-Å., 2679
 Gutowski, M. C., 1790
 Guterman, J. U., 3154, 5801
 Guzelian, P. S., 5219
 Guzman, R. C., 6010
 Gyekko, M. R., 4957
- H
 Ha, Y. L., 1097
 Haag, J. D., 4286
 Haas, M., 10
 Hachiya, T., 5515
 Hacker, M. P., 2351, 7863
 Hackett, A. J., 2943
 Hada, T., 1079, 3408
 Hadley, C. G., 6311
 Haenszel, W., 4731, 4737
 Hagan, M. S., 3638
 Hageman, P. C., 5143
 Hagemeister, F. B., 558
 Hagiwara, M., 5515
 Hahn, G. M., 7867
 Hahnel, E., 1800
 Hahnel, R., 1800
 Hainaut, P., 3754
 Haines, I., 1151
 Hainsworth, J. D., 3910
 Hait, W. N., 1165, 1748, 6636
 Hajdu, J., 3025
 Hajto, T., 3322
 Hakoda, M., 1738
 Hakomori, S.-i., 1375, 3245
 Haldar, S., 6565, 7399
 Haley, L. L., 6146
 Halila, H., 2375
 Hall, J., 5426
 Hall, T. C., 909s
 Halley, M. C., 4552
 Halpern, S. E., 1022s
 Halsey, H. K., 1596
 Hamada, H., 3167
 Hamada, J.-i., 358
 Hamamoto, Y., 5287
 Hamazaki, S., 5574
 Hamby, C. V., 1559
 Hameister, H., 4146
 Hamilton, M., 3910
 Hamilton, S., 7715
 Hamman, R. F., 3657
 Hammond, D., 7226
 Hammond, G. D., 3212, 6525, 7129
 Hamou, M.-F., 6683
 Hampton, B., 48
 Hampton, L. L., 3600, 7460, 7466
 Han, T., 2991
 Hand, P. H., 820s
 Handa, S., 1284
 Handa, S., 3257
 Hande, K. R., 3910
 Handgrettinger, R., 2177, 6793
 Hank, J. A., 2683, 5234
 Hankin, J. H., 7499
 Hanlon, M. H., 3207
 Hann, I. M., 1000s
 Hanna, D. E., 993s
 Hanna, N., 2636
 Hanna, N. B., 2625
 Hansen, H. H., 3311
 Hansen, H. J., 794s, 828s, 909s, 964s, 2823
 Hansen, L. A., 5740
 Hanson, R. W., 1701
 Hansson, V., 1528
 Hantel, A., 3284, 4595
 Hara, H., 32
 Hara, H., 3106
 Haran-Ghera, N., 2554
 Harel, W., 6311
 Harker, W. G., 5931
 Harlow, B. L., 4702
 Harmenberg, U., 6358
 Harper, B. L., 6192
 Harper, S. J., 4724
 Harrington, G. W., 4366
 Harris, A. L., 1992, 2818, 4692
 Harris, B. E., 197
 Harris, C. C., 1857, 1890, 5369, 6580, 7085
 Harris, M., 3579
 Harrison, C. L., 3514
 Harrison, S. D., Jr., 3239
 Harsanyi, M. C., 7793
 Hart, C. E., 6344
 Hart, G. W., 7261
 Hart, I. R., 1510, 1828, 4533, 5537
 Hartinger, J., 3470
 Hartley, J. A., 1732, 1936
 Hartmann, F., 6944
 Hartmann, L. C., 2979
 Hartmann, O., 6203
 Hartzler, J. L., 5997
 Harvey, R. G., 4239
 Harvey, S., 2245
 Harwood, S. J., 932s
 Hasan, T., 4167
 Hasday, J. D., 4578
 Hasegawa, R., 4195
 Hasegawa, S., 7601
 Hashida, M., 1640
 Hashimoto, Y., 2729
 Hass, R., 323
 Hata, K., 3681
 Hatanaka, T., 2135
 Hatfield, J. S., 7684
 Hattori, Y., 7758
 Haugen, S. A., 5219
 Haugh, L. D., 6302
 Haughey, B. P., 3295
 Hauler, J. A., 985s
 Hausen, A., 2863
 Hauser, G. J., 3503
 Havlin, K. A., 7494
 Hawkins, W. E., 5675s
 Hay, F. G., 6545
 Hayakawa, K., 5263
 Hayashi, C., 3257
 Hayashi, H., 2538
 Hayashi, I., 3691
 Hayashi, K., 3345
 Hayashi, N., 4747
 Hayashi, Y., 4032
 Hayashi, Y., 7826
 Hayes, D. F., 1170, 6738
 Hayes, D. M., 6833
 Hayes, R. B., 2311
 Hayman, J. A., 7708
 Hays, E. F., 5631s
- Hazelton, B. J., 6002
 He, R., 6268
 Headington, J., 941s
 Hébert, C. D., 7190
 Hecht, S. S., 5438, 5446, 5453
 Hecht, T. T., 4227
 Hedborg, F., 6908
 Hedley, A., 1381
 Hedrick, E., 6379
 Hee, S. Q., 3351
 Heerdt, B. G., 1596
 Hefta, L. J. F., 2397
 Hegedus, L., 7915
 Hehlmann, R., 5636s
 Heiblum, R., 4685
 Heidel, S. M., 2239
 Heideman, R. L., 7915
 Heike, Y., 3167
 Heikkilä, J., 3422
 Heilbronn, R., 5756
 Hein, D. W., 7942
 Heine, U. I., 1324, 5567
 Heisterkamp, N., 3429
 Heitmeyer, D. A., 1580
 Heitz, P. U., 5969
 Hekman, A., 5767
 Heldin, C.-H., 748
 Hellinger, N., 3878
 Hellström, I., 2183, 2449
 Hellström, K. E., 2183, 2449
 Helman, L. J., 6055
 Helsel, W. E., 3610
 Nelson, L., 4929
 Helzlsouer, K. J., 3859
 Hemingway, L., 6708
 Hemstreet, G. P., III, 2009, 2215, 6708
 Henderson, B. E., 7413
 Henderson, G. B., 1709
 Henderson, K. W., 5671s
 Henderson, M. A., 7708
 Hendrich, S., 472
 Hendrix, M. J. C., 4121
 Hénichart, J. P., 385
 Henner, W. D., 6848
 Hennings, H., 653, 4794
 Henriksson, R., 2027
 Henry, E., 7912
 Henry, H. L., 6857
 Henry, R. V., 7517
 Henry, W. M., 6146
 Hensel, C. H., 3067
 Henslee, J. G., 2773
 Hentosh, P., 2356
 Heo, D. S., 3113, 3681
 Herberman, R. B., 3113, 3681
 Herblin, W. F., 2524
 Hergl, A., 328
 Herlyn, D., 2296
 Herlyn, M., 2296, 6757
 Herman, C., 6023
 Herman, T. S., 2734, 3339, 3826, 5055, 6971
 Herold, M., 2979
 Herring, S. J., 6902
 Hersh, E. M., 2009
 Hertel, L. W., 4417
 Herzog, P. J., 4718
 Heur, Y.-H., 1144
 Heyting, C., 3279
 Hiatt, R. A., 4600, 5049
 Hickman, J. A., 2203, 3327
 Hicks, J. W., 1085
 Hickson, I. D., 4692, 7789

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Hidaka, H., 621, 5515
 Hietala, O. A., 2088, 4741
 Higashi, Y., 2848
 Higashino, K., 1079, 3408
 Higginbotham-Ford, E., 909s
 Higgins, J. R., 5628s
 Higuchi, C. M., 1160
 Hilditch, T. E., 1000s
 Hilf, R., 7236
 Hilgers, J., 3754, 3848
 Hill, L. R., 922s
 Hill, M., 3036
 Hill, R. P., 5031
 Hillebrand, G. G., 1580
 Hiller, A., 2943
 Hilliard, C., 7591
 Hilton, J., 2455
 Hilz, H., 2470
 Himeno, T., 4941
 Hincks, J. R., 7553, 7559
 Hindenburg, A., 5003
 Hinds, M., 7116
 Hinrichsen, L. I., 7569
 Hinson, N. A., 7632
 Hinton, D. E., 5504
 Hioki, K., 2418
 Hirai, Y., 5751
 Hiraiwa, N., 2917, 5497
 Hiramoto, N. S., 4295
 Hiramoto, R. N., 4295
 Hirano, K., 3408
 Hirano, T., 2885
 Hiraoka, T., 4050
 Hird, V., 563
 Hirohashi, S., 1075
 Hirose, T., 5060
 Hirschowitz, L., 4154
 Hiti, A. L., 44
 Hixson, D. C., 4755, 4809
 Hnatowich, D. J., 7272
 Ho, J.-T., 2719
 Hoban, P. R., 4692
 Hoehn, H., 5204, 6981
 Hoeijmakers, J. H. J., 1905
 Hoekman, K., 3589
 Hooper, B. J., 4510
 Hoey, B. M., 2003
 Hoffman, R. M., 6095
 Hoffman, T., 873s, 1049s
 Hoffmann, D., 1795, 5446
 Hofland, L. J., 6238
 Höfler, H., 4160
 Hofmann, G. A., 2901
 Hofmann, R., 3934
 Hofslie, E., 3997
 Holcenberg, J. S., 7226
 Holdaway, I. M., 5883
 Holden, S. A., 2734, 3339
 Holland, S. L., 1650
 Hollander, M. C., 7908
 Hollanders, V. M. H., 1092
 Hollingsworth, M. A., 2997,
 6015
 Holloway, E. C., 4546
 Holly, E. A., 5773
 Holman, B. L., 2198
 Holmes, E. H., 4702
 Holroyde, C. P., 2088
 Hong, C. I., 4401
 Hong, W. K., 2505, 4441
 Hong, X., 4072
 Hongyo, T., 2135
 Honn, K. V., 6278, 7684
 Hoon, D. S. B., 5358
 Hooper, N. K., 5049
 Hoover, D. M., 142
 Hoover, R. N., 1857
 Horai, T., 2018
 Horii, S., 3257
 Horichi, N., 4698
 Horii, I., 2290
 Horii, M., 2423
 Horio, T., 4522
 Horisberger, M., 4588
 Hornback, N. B., 5027
 Hornung, R. L., 1742, 7926
 Horowitz, J. A., 909s, 1039s
 Horsman, M. R., 7430
 Horta, B. L., 7112
 Horton, S. A., 1686
 Horvath, P. J., 3295
 Horwitz, K. B., 6208
 Hoskin, D. W., 2476
 Hoskins, J., 7632
 Hostanska, K., 3322
 Hotta, H., 2296
 Hotta, T., 8028
 Houghton, A. N., 1503, 7488
 Houghton, J. A., 318, 664, 2781,
 3493, 3940, 6002
 Houghton, P. J., 252, 318, 664,
 2781, 3493, 3940, 6002
 Healdsworth, J., 6417
 Housman, D., 5392
 Houston, L. L., 3231
 Howbert, J. J., 664
 Howe, G. R., 5017
 Howell, B. A., 5301
 Howell, S. B., 7535
 Howes, A., 6455, 6461
 Hozumi, M., 1346
 Hrubec, Z., 3804
 Hsia, C.-C., 3439
 Hsieh, C.-L., 3067
 Hsieh, J.-T., 2239
 Hsieh, L.-L., 1675
 Hsing, A. W., 6836
 Hsu, P.-L., 350
 Hsu, S.-M., 350, 2929
 Hu, X. F., 2953
 Huang, A. T., 4429
 Huang, M.-T., 4741
 Huang, T. H., 6222
 Huang, W., 4522
 Hubbell, J., 7494
 Huber, B. E., 1521
 Huber, C., 2979
 Huber, W., 3701
 Huberman, E., 2618
 Huberty, J., 6371
 Hudson, M. A., 3843
 Hudson, M. M., 3154
 Hudziak, R. M., 1550
 Huebner, K., 6478
 Huff, J., 6592
 Huff, L. Y., 5687s
 Huggett, A. C., 3367, 3600,
 7458, 7468
 Huggett, R. J., 5978
 Hughes, E. N., 3872
 Huhn, R. D., 3087
 Hui, S.-W., 4401
 Hull, W. E., 5790
 Humphrey, L. E., 7579
 Humphrey, P. A., 6039, 8017
 Humphrey, R. M., 4355
 Hunt, B., 4572
 Hunter, K. J., 2769
 Hunter, N., 4473
 Huot, A. E., 2351, 7863
 Huper, G., 2303, 6701
 Hupf, H., 1022s
 Huppi, K., 5406
 Hurst, R. E., 2215
 Hurteau, T., 3851
 Husain, I., 6497
 Hussnäter, R., 4504
 Hustedt, C., 5414
 Hutchins, G. M., 3694
 Hutter, R. V. P., 880s
 Huyser-Wierenga, D., 278
 Hwang, J., 5649s
 Hwong, C.-L., 5649s
 Hyams, D. M., 989s
 Hynes, N. E., 7037
- I
- Ichii, M., 4931, 5308
 Ichikawa, A., 8028
 Ichikawa, T., 4979
 Ichikawa, T., 6349, 6668
 Ichimaru, M., 6171
 Ido, M., 6554
 Iga, H., 7852
 Igleshart, J. D., 2303, 6701
 Iguchi, H., 3691
 Iida, F., 5515
 Iida, M., 5345
 Iishi, H., 2095, 4931, 5308
 Iizuka, M., 3345
 Iizuka, R., 754
 Ikeda, I., 1284
 Ikeda, S., 6171
 Ikegaki, N., 6316
 Ikebara, S., 2582
 Ikeuchi, T., 7166
 Ilett, K. F., 6649
 Ilgen, C., 2128
 Iliakis, G., 6575
 Iliopoulos, D., 2296
 Imai, S., 3848
 Imai, Y., 7585
 Imaida, K., 2868
 Imam, A., 1650
 Imamura, F., 2018
 Imamura, K., 7101
 Imamura, S., 5526
 Iman, D. S., 1890
 Imanishi, H., 1079, 3408
 Imanishi, J., 658, 7008
 Imoto, H., 1640
 Imura, H., 2917, 5497
 Inaba, K., 2582
 Inaba, M., 2582
 Inada, H., 310
 Inagaki, H., 3172
 Infante, D., 2245
 Ingolic, E., 4160
 Ingram, D. M., 6649
 Inokuchi, J.-i., 6731
 Inoue, H., 7701, 7955
 Inoue, I., 7826
 Inoue, M., 6139
 Inoue, N., 3119
 Inoue, S., 1693
 Inoue, T., 515
 Inskeep, P. B., 2747
 loachim, H. L., 5612s
 Ip, C., 1206
 Irimura, T., 3331
 Irino, S., 2549
- Isaacs, J. T., 1449, 3748, 6349,
 6668
 Isaacs, W. B., 6830
 Isacchi, G., 5795
 Isbrücker, L., 7770
 Ishibashi, T., 480
 Ishida, T., 7077
 Ishii, K., 1284
 Ishii, K., 5526
 Ishikawa, M., 2538
 Ishikawa, T., 2290, 4528
 Ishikawa, T., 3226
 Ishitsuka, H., 2290, 4528
 Ishizaki, K., 7950
 Ishizuka, I., 2917
 Isobe, M., 4300
 Isobe, M., 6171
 Isoe, T., 6925
 Isoye, S. T., 669
 Israel, M. A., 3694, 6055
 Issandou, M., 5845
 Itahashi, K., 2641
 Itai, S., 7603
 Itakura, K., 6222
 Itkonen, O., 2375
 Ito, A., 7660
 Ito, H., 8002
 Ito, M., 6034
 Ito, M., 8002
 Ito, N., 3270
 Ito, S., 3743
 Ito, T., 1031s
 Ito, T., 6915
 Ito, T., 7955
 Ito, Y., 6559
 Ito, Y., 7198
 Itoh, K., 5263
 Itoyama, T., 6171
 Ivanyi, D., 5143
 Iwahara, Y., 7680
 Iwama, T., 7166
 Iwasaki, K., 2429
 Iwasaki, K.-i., 596
 Iwasaki, S., 4277
- J
- Jackman, A. L., 5212, 7542
 Jackson, L., 3910
 Jacob, L., 438
 Jacobson, H. I., 415
 Jacoby, L. B., 6783
 Jacquet, C., 2156
 Jacrot, M., 1566
 Jadaud, P., 3493, 3940
 Jaffrézou, J.-P., 5558
 Jahnsen, T., 1528
 Jain, R. K., 814s, 3487, 4478
 Jakesz, R., 7057
 Jakse, G., 3934
 Jalava, A. M., 3422
 Jambrosic, J., 2296
 James, V. H. T., 193
 Jani-Sait, S., 7902
 Jansen, G., 7544
 Jansen, J. W. G., 5464
 Jardillier, J.-C., 1231
 Jarolim, L., 4061
 Jaroszewski, J. W., 6936
 Jaspers, N. G. J., 1905
 Jassim, A. D., 2064
 Jatlow, A. D., 958s
 Jayaraj, A., 7206

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Jeannesson, P., 1231
 Jefferson, S., 4199
 Jeggo, P., 5778
 Jégou, B., 1308
 Jeney, A., 4552
 Jenkins, J. S., 7882
 Jennemann, R., 7444
 Jensen, D. E., 1440
 Jensen, E. M., 4704
 Jensen, J. C., 3928, 4008
 Jensen, P. B., 3311
 Jensen, P. J., 2296
 Jensen, P. S., 3311
 Jensen, R. T., 2773
 Jensen, S. M., 6068
 Jerry, L. M., 4557
 Jessup, J. M., 7715
 Jhanwar, S. C., 6410
 Ji, H., 6430
 Jiang, Y.-Z., 245
 Jimbo, M., 6731
 Jimbow, K., 3743
 Jimenez, J. J., 227
 Jindal, H. K., 7754
 Joel, D. D., 138
 Joenje, H., 5392
 Johansson, I., 6908
 Johns, T. G., 4718
 Johnson, B. E., 2773, 3067,
 5406
 Johnson, C. S., 4709, 5682s,
 7557
 Johnson, D. A., 1790
 Johnson, D. K., 7272
 Johnson, J. T., 3113
 Johnson, J. W., 941s
 Johnson, R. K., 2901
 Johnson, S. L., 370
 Johnstone, B., 1216
 Johnstone, R. W., 4423, 5225
 Jolivet, A., 2390
 Joly-Pharaboz, M-O., 3786,
 4081
 Jones, A. G., 2198
 Jones, A. L., 794s
 Jones, C. A., 339
 Jones, C. J., 3657
 Jones, C. S., 1726
 Jones, D., 5806
 Jones, J., 3199
 Jones, L. M., 4891
 Jones, P. A., 44, 1897, 7081,
 7413
 Jones, P. L., 852s
 Jones, P. L., 2215
 Jones, P. S., 339
 Jones, R., 5077
 Jones, R. F., 5351, 6075
 Jones, S., 4670
 Jones, S. M., 2734
 Jones, W. B., 6330
 Jongasma, A. P. M., 2803, 5392
 Jordaan, A. M., 4911
 Jordan, V. C., 3189, 4177, 7285
 Joseph, D. R., 735
 Joshi, P. A., 1960, 3435
 Joyal, J. L., 7876
 Juhlin, C., 748
 Juliusson, G., 2212
 Jung, R., 4794
 Jung, S.-E., 1138
 Jung, W., 84
 Jung, W.-H., 1459
 Junghans, R. P., 1495
- Jurlina, J. L., 503
 Juster, R., 7376
- K
- Kaba, D. S., 1544, 3159
 Kablitz, C., 4704
 Kadlubar, F., 3002
 Kadematsu, K., 3043
 Kaemmerlen, P., 2371
 Kagami, Y., 8028
 Kagan, J., 5240, 6171
 Kagan, M., 5438
 Kagan, S. S., 5438, 5453
 Kahl, S. B., 4860
 Kahle, L. L., 2152, 2311
 Kahn, M., 2449
 Kaighn, M. E., 1890
 Kaila, S., 2759
 Kairemo, K. J. A., 937s, 949s
 Kakegawa, T., 3952
 Kakita, T., 2423
 Kaled-Ezra, J., 4860
 Kalifa, C., 6203
 Kalman, T. I., 1726
 Kalmus, J., 15
 Kalofonos, H., 159
 Kamata, T., 509
 Kamataki, T., 2641
 Kamatani, N., 1738
 Kameda, T., 8002
 Kamel, A., 4087
 Kameya, A., 6559
 Kameyama, K.-z., 3167
 Kami, T., 2481
 Kamiura, S., 488
 Kamiya, Y., 103, 4915
 Kan, N., 6199
 Kanani, A., 5003
 Kanayama, Y., 5345
 Kane, A. B., 5153
 Kaneda, N., 1715, 1721
 Kaneko, S., 7077
 Kaneko, T., 6600, 6608
 Kaneko, Y., 2698
 Kaneko, Y., 3101
 Kangwanpong, D., 7232
 Kannagi, R., 2917, 5497, 7601
 Kannan, R., 2221
 Kannel, W. B., 3610
 Kano, T., 6559
 Kanoh, M., 2708
 Kantarjian, H., 5801, 6823
 Kanzawa, F., 5919
 Kao, C., 4779
 Kao, M-S., 4923
 Kaplan, O., 544, 6936
 Kaplinsky, C., 2794
 Karasuno, T., 5345
 Kardos, G., 6793
 Karmali, R. A., 381
 Karan, P., 1532
 Karvelas, J., 4204
 Kasahara, K., 2549, 4698, 5919
 Kasakura, S., 596
 Kasid, A., 5072
 Kasimos, J. N., 527
 Kasliwal, R., 5954, 7068
 Kasper, C. B., 7789
 Kassis, A. I., 5199
 Kasumi, F., 7184
 Kaszkin, M., 7932
 Katagiri, S., 1873
 Kataoka, K., 1693
- Kataoka, T., 2290
 Kataoka, T., 7703, 7955
 Kataoka, Y., 2481
 Katar, R. S., 4885
 Katic, N. E., 3652
 Kato, G. J., 6430
 Kato, I., 2423
 Kato, I., 6559
 Kato, S., 6915
 Kato, Y., 3521
 Kato, Y., 7701
 Katsanis, E., 1853
 Katzenellenbogen, B. S., 3947
 Kaufman, D. G., 3394
 Kaufmann, W. K., 2593
 Kaul, H. K., 1516
 Kavanagh, J. J., 2724
 Kavanagh, R. L., 4267
 Kawada, S.-z., 5841
 Kawamura, K., 5697s
 Kawasaki, C., 7455
 Kawashima, K., 7198
 Kawata, S., 3270
 Kay, R. G., 5883
 Kazakoff, K., 1634
 Keating, M. J., 6823
 Kedar, I., 2979
 Keefer, L. K., 1144
 Keenan, E. J., 6848
 Keilhauer, G., 3670
 Keist, R., 1421
 Keith, B. R., 3207
 Keith, D., Jr., 3947
 Keith, W. N., 6841
 Keller, R., 1421
 Keller-McGandy, C., 580
 Kelley, J. A., 1220, 7915
 Kelley, M. A., 958s
 Kelloff, G. J., 2, 2068, 2562
 Kelly, R. C., 2485
 Kelly, R. H., 7134
 Kelsen, D. P., 6410, 6417
 Kelsey, K. T., 1585
 Kelsten, M. L., 97
 Kempenaar, J., 3589
 Kenady, D. E., 7799
 Kennedy, A. R., 580
 Kennedy, D. W., 4485
 Kennedy, K. A., 1786
 Kennel, S. J., 6107
 Kennett, R. H., 6316
 Kenney, S., 1324, 5567
 Kensler, T. W., 2251
 Kent, M. L., 5679s
 Kerckaert, G. A., 3722
 Kern, D. E., 1160, 6256
 Kern, D. H., 459
 Kern, J. A., 421, 5184
 Kernan, W. J., 6461
 Kerns, B. J., 4087, 6701
 Kerr, L. A., 6508
 Kerr, J. A., 4718
 Kerster, M. G. D., 6515
 Kestell, P., 503
 Ketterer, B., 2747
 Kettman, J. R., 1917
 Khadekar, V. S., 3826
 Khaw, K.-T., 169, 6571
 Khokhar, A. R., 4254
 Khuon, S., 669
 Kido, Y., 2113
 Kiguchi, K., 754
 Kiguchi, K., 2618
 Kihara, K., 2848
- Kikuchi, H., 596, 2429
 Kikuchi, J., 310
 Kikuchi, R., 7166
 Killander, D., 4332
 Kim, H. S., 5328
 Kim, J. H., 7252
 Kim, J.-P., 2773
 Kim, S. G., 5333
 Kim, S. N., 2692
 Kim, T.-Y., 5263
 Kim, Y. S., 1085, 1299
 Kimler, B., 5039
 Kimmel, M., 7912
 Kimmig, A., 2177, 6793
 Kimura, H., 509
 Kimura, T., 345
 Kimura, T., 488
 Kimura, T., 4522
 King, L., 3249
 Kinkade, J. M., Jr., 222
 Kinney, R., 4087
 Kinoshita, A., 4131
 Kinsella, T. J., 4962
 Kinuta, M., 2135
 Kinzel, V., 7932
 Kinzler, K. W., 7902
 Kirkwood, K. L., 5399
 Kirlin, W. G., 7942
 Kise, Y., 2418
 Kishimoto, S., 3866, 5060
 Kishimoto, T., 2885
 Kissin, M. W., 7708
 Kitada, M., 2641
 Kitson, J., 7123
 Kittrell, F. S., 1470
 Kiue, A., 310, 5819
 Kiyosue, T., 3055
 Klarnet, J. P., 5421, 6256
 Klasa, R. J., 4906
 Klein, J. L., 974s, 1011s
 Klein, K. M., 880s
 Kleinerman, E. S., 3154
 Kligerman, A. D., 4635, 5088
 Klijn, J. G. M., 3832
 Kline, I., 2088
 Kline, K., 4764
 Kline, L. E., 4154
 Kline, T. F., 6787
 Klingel, R., 7668
 Klöppel, G., 6389
 Klotz, J. B., 6520
 Knick, V. C., 3663
 Knödgen, B., 5077
 Knöflach, A., 1576
 Knoppel, E., 3429
 Knowles, R. D., 3154
 Knox, S. J., 4935
 Knudson, A. G., 6765
 Kobata, A., 1079
 Kobayashi, H., 358
 Kobayashi, K., 480
 Kobayashi, N., 5287
 Kobayashi, S., 6559
 Cobb, S. M., 7257
 Koch, J., 5618s
 Koch, K., 1867
 Kochervar, J., 2968
 Kochi, M., 3119
 Kochibe, N., 1079
 Kodama, S., 760
 Koduru, P. R. K., 6330
 Koefller, H. P., 1346, 2031,
 6857, 7950
 Koeller, J. M., 7494

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Koenig, K. L., 7562
 Koeppen, H. K., 3851
 Koga, M., 3866, 4849, 5060
 Koganty, R. R., 4308
 Kohda, K., 6192
 Köhler, L., 323
 Kohn, E. C., 5937
 Kohn, K., 310, 3043, 5819
 Koike, M., 7166
 Koivunen, E., 2375
 Kolbinger, F., 6534
 Kole, K. L., 4957
 Kolitz, J. E., 2009
 Komada, F., 621
 Komada, H., 2418
 Kondo, S., 6222
 Kondo, Y., 7852
 Kondoh, S., 596
 Kong, S., 4906
 Konishi, H., 2698
 Konishi, Y., 766
 Kono, A., 3691
 Konrad, M. W., 2009, 6708
 Koper, J. W., 2604, 6238
 Kopher, K. A., 974s
 Kopp, R., 6490
 Kopp, W. C., 185, 2979
 Koprowski, H., 1051s, 2296
 Korbut, T. T., 3826
 Korc, M., 299
 Korelitz, B. I., 3627
 Korf, B. R., 1459
 Kornblith, A. B., 7252
 Kornblith, P. L., 2524
 Kortright, K., 7068
 Kosaka, T., 509
 Kosaka, T., 2577
 Kosano, H., 3172
 Koscielnak, E., 2177
 Koshizaka, T., 7826
 Kosir, M. A., 4388
 Koskelo, E.-K., 592
 Kössig, J., 3670
 Kostiala, A. A. I., 5668s
 Kostron, H., 1576
 Kotler, M., 4787
 Kouhara, H., 5060
 Koutcher, J. A., 7252
 Kovach, J. S., 206
 Kovar, J., 5727
 Kowal-Vern, A., 6023
 Koyama, K., 658, 7008
 Koyama, M., 488
 Kozlowski, P., 686
 Kozuru, M., 3106
 Kraft, A., 5520
 Krag, D. N., 459, 2385
 Kralio, M. D., 6525, 7226
 Kramer, D. L., 3838
 Kramer, R. H., 728
 Krauer, K. G., 6028
 Kraupp-Grasl, B., 3701
 Kraus, M. H., 6701
 Krause, S., 7448
 Krauss, R. S., 677
 Kreger, B. E., 3610
 Kremers, P., 7343
 Kretschmar, C., 1459
 Krett, N. L., 6208
 Krieg, R. J., 4377
 Krishnan, R., 2164
 Kristiansen, J. J., 5773
 Kristjansen, P. E. G., 4880
 Kristofik, M. P., 7134
 Kroener, J. F., 4154
 Krohn, K. A., 783s, 1017s
 Kroin, J. S., 4417
 Krontiris, T. G., 1857
 Ku, S., 5801
 Kubonishi, I., 7682
 Kudo, S., 5751
 Kufe, D. W., 1170, 6738, 7101
 Kugai, N., 3172
 Kuhlein, E., 5558
 Kuhlmann, E. T., 7550
 Kuhn, J. G., 7494
 Kuhns, W., 5003
 Kuijten, R. R., 2608
 Kuipers-Dijkshoorn, N. J., 4003
 Kulesa, V., 7351
 Kulesz-Martin, M., 686
 Kuma, S-i., 2582
 Kumada, M., 240
 Kumar, N., 4709
 Kumar, S. P., 5761
 Kung, A. L., 7307
 Kunicka, J., 7488
 Kunugi, K. A., 4962
 Kunz, A., 794s
 Kunz, W., 7015
 Kuo, J. F., 3025
 Kuper, C. F., 1092
 Kurata, K., 1284
 Kurata, Y., 1873
 Kuratsu, J-i., 3119
 Kurabayashi, K., 5526
 Kurihara, M., 2481
 Kurimura, T., 6915
 Kurita, Y., 2773, 5481
 Kurman, R. J., 4670
 Kurokawa, K., 3101
 Kuroki, M., 4872
 Kuroki, T., 7405
 Kurosawa, Y., 3167
 Kurzrock, R., 5801
 Kusaba, I., 1863
 Kusuvara, M., 3257
 Kutlaca, A., 4584
 Kuttesch, J., 3910
 Kuwano, H., 7212
 Kuwano, M., 310, 3043, 5819
 Kvols, L. K., 5969
 Kyriacou, N., 1449, 3748, 6349
 Kyrtopoulos, S. A., 2759
- L
- Laborda, J., 873s
 Lackides, G. A., 3146
 LaCreta, F. P., 3562
 Lacroix, A., 5731
 Ladanyi, M., 6410, 6417
 Laerum, O.-D., 328, 6039
 Lafolie, P., 108
 Lafreniere, R., 1658
 Lagace, L., 6554
 Lage, H., 6100
 Lage, J. M., 4092
 LaGreca, S. D., 2613
 Laguzza, B. C., 1790, 7632
 Lahooti, H., 7806
 Lai, L. C., 193
 Lambert, V., 2156
 Lamberts, S. W. J., 2604, 6238
 Lamela, R. A., 1585
 Lamki, L. M., 904s
 Lampidis, T. J., 4698
 Lampkin, B., 2786, 7950
 Lampson, L. A., 5199
 Lan, M. S., 2997
 Lancaster, W. D., 4670
 Landkamer, G. J., 4991
 Lando, M., 722
 Landolfi, N. F., 1495
 Landolph, J. R., 7835
 Lane, B., 6995
 Lange, B., 7371
 Langevin, A.-M., 7494
 Langstein, H. N., 3928
 Langston, B. C., 6701
 Lanks, K. W., 4776
 Lannom, L., 4670
 Lantz, T. K., 5399
 Lapis, K., 3716, 4552
 Larcombe McDowell, J. B., 363
 Larjava, H., 1601
 Larocca, D., 5925
 LaRocca, R. V., 2773, 5488
 Larson, R. G., 2704
 Larson, S. M., 820s, 892s
 LaRue, S. M., 6176
 LaSala, P. A., 2524
 Laskin, D. L., 20, 6062
 Laskin, J. D., 20, 4741, 6062
 Lasky, L. C., 3249
 Lasky, S. R., 3087
 Laster, B. H., 4860
 Laster, W. R., Jr., 3239
 Latham, P. S., 4578
 Lau, D. H. M., 4056
 Laudonio, N., 5119
 Laurén, D. J., 5504
 Laurensse, E. J., 4644
 Laurent, G., 5558
 Laursen, I., 1257
 Lautersztain, J., 4254
 Laval, F., 5898
 Laval Univ. Urology Group, 432
 La Vecchia, C., 4497, 5231,
 6274, 6502
 Laven, D. L., 932s
 Law, E., 3390
 Lawrence, D. D., 6146
 Lawson, D., 2275
 Lazebny, C. M., 3327
 Lea, J. S., 2003
 Lea, O. A., 7806
 Leander, K. R., 5245
 Lear, J. L., 5954, 7068
 LeBlanc, G. A., 5720
 LeBoeuf, R. A., 3722
 Le Doussal, J.-M., 3445
 Ledwith, B. J., 5245
 Lee, C. L. Y., 3737
 Lee, D., 4572
 Lee, E. Y.-H. P., 3067
 Lee, H., 4239
 Lee, H.-Y., 6430
 Lee, J. H., 2724
 Lee, J. S., 2505
 Lee, K. N., 7830
 Lee, M.-S., 2868, 4300
 Lee, R. E., 909s, 1039s, 2823
 Lee, S. H. S., 3737
 Lee, S. J., 1151
 Lee, W., 7695
 Lee, W.-H., 3067
 Lee, Y.-C. C., 4546
 Levert, A.-K., 4866
 Legha, S. S., 904s
 Lehman, H. F., 3657
 Lehman, J. M., 4776
 Lehnert, T., 381
 Lehtovirta, P., 937s
 Lei, M., 288
 Leib-Mösch, C., 5636s
 Leichner, P. K., 1011s
 Leister, I., 7232
 Leith, M. K., 2872
 Lemire, J., 6203
 Lemmon, M. J., 7745
 Lenoir, G. M., 4448
 Leonard, A. S., 1853
 Leonard, R. C. F., 6545
 Leonard-Vidal, F. J., 2587
 Leong, S. P. L., 7902
 Leopold, W. R., 3239, 4900
 LePage, D. J., 4360
 Lepera, P., 4501
 Lerma, E., 147
 Lerner, L. J., 4177
 Le Roy, M., 7333
 Leser, H.-G., 7448
 Leslie, D. S., 3231
 Leslie, K. K., 6208
 Lessmann, V., 323
 Lester, B. R., 1237
 Lesti, G., 6987
 Lesuffleur, T., 6334
 Lvade, T., 5558
 Lever, S. Z., 799s
 Levi, R., 2455
 Levine, M. N., 1216
 Levine, P. H., 3186
 Levine, R. S., 3657
 Levitt, M. L., 120
 Levy, A. T., 5431, 6184
 Levy, N. B., 1014s
 Lévy, P., 6716
 Levy, R., 1017s, 4935
 Levy, S. B., 7895
 Lewine, M. A., 5399
 Lewis, G. P., 5537
 Lewis, I., 1176
 Ley, R. D., 637
 Li, B.-L., 5328
 Li, D., 3991, 7577
 Li, G. C., 4515
 Li, J.-Y., 174, 6882
 Li, L. H., 2485
 Li, Y.-T., 5497
 Lian, J. B., 1183
 Liang, J. C., 370, 558
 Liang, P., 5574
 Liang, Q. S., 2268
 Lichtenstein, A., 7364
 Lidor, Y., 3231
 Liebert, M., 941s
 Lieman-Hurwitz, J., 1983
 Lien, E. A., 5851
 Lien, K., 3124
 Lieschke, G. J., 606
 Liewendahl, K., 937s
 Liggitt, D., 375
 Lillemark, J., 108
 Lilley, E. R., 284
 Lilly, M., 5520
 Lim, I. K., 1701
 Lin, J.-C., 7108
 Lin, J.-R., 1732
 Lin, K.-H., 3600
 Lin, K. M., 1107
 Lin, T.-h., 3013
 Lin, W.-c., 2808
 Lin, X., 669
 Lincke, C. R., 1779

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Lindahl, R., 5858
 Lindemeyer, R. G., 7985
 Lindgren, C. G., 1160
 Lindgren, P. G., 3413
 Lindhe, B., 2679
 Ling, C. C., 97, 4515
 Link, E. M., 2963
 Link, M., 7371
 Link, T. A., 5008
 Linkhart, T. A., 6902
 Linnane, A. W., 4718
 Linnoila, R. I., 5481, 6068
 Linsenmeyer, M. E., 4199
 Liotta, L. A., 4121, 5431, 6184
 Lipari, M. T., 1550
 Lipkin, M., 1596, 2651
 Lippman, M. E., 48, 2943, 4446, 7402
 Lips, C. J. M., 6689
 Lipski, K. M., 1431
 Lisafeld, B., 686
 Lissoni, A., 7318
 Littbrand, B., 2027
 Litwack, G., 7985
 Litwicki, D. J., 152
 Litwin, S., 2088
 Litz, C. E., 4984
 Liu, C., 6882
 Liu, C.-M., 1361, 1368
 Liu, F. J., 4349
 Liu, J., 7488
 Liu, L., 1810
 Liu, L. F., 5919, 6919, 7962
 Liu, N. H., 3614
 Liu, X-Y., 5328
 Livingston, P. O., 1403
 Lizzio, E. F., 873s
 Lock, R. B., 3761, 3767
 Loeb, L. A., 6894
 Loeffler, C. M., 1853
 LoGerfo, P., 3595
 Lohman, P. H. M., 1905
 Löhre, G. W., 7448
 Lombardi, B., 7575
 Lonberg, M., 1503
 Lonergan, J. A., 1857
 Longenecker, B. M., 4308, 4801
 Longley, C., 5954
 Longnecker, D. S., 7552
 Longo, D. L., 185, 2979, 6379, 7343
 Lönn, S., 3141
 Lönn, U., 3141
 Lønning, P. E., 5851
 Loo de Lao, S., 7815
 Look, A. T., 2781, 2987
 Lopes, A. D., 6423
 Lopes, M. C. F., 2753
 Lopez, D. M., 227
 Lopez-Berestein, G., 4254
 López-Larraza, D., 2379
 Loprinzi, C. L., 3905
 Lorico, A., 6723
 Lordin-Rosa, B., 1608
 LoRusso, P. M., 4900, 5876
 Lorusso, V., 2958
 Los, G., 7031
 Losman, M. J., 1055s
 Lotan, D., 4121
 Lotan, R., 2505, 3453, 4121
 Lotze, M. T., 5072
 Loucy, K. J., 1431
 Loughrey, H., 575
 Louvard, D., 438
 Lowe, M. E., 3956
 Lowe, S. R., 3124
 Lowenthal, D. A., 1151
 Löwik, C. W. G. M., 3589
 Lown, J. W., 1732, 1936
 Lowry, L., 3351
 Lozano, Y., 2973
 Lu, J., 370
 Lu, J., 2316
 Lu, L., 5027
 Lu, L.-W. B., 2146, 4239, 6192
 Lu, R.-F., 5017
 Lubahn, D. B., 735
 Lubin, J. H., 174
 Lucas, V. S., 7494
 Ludueña, R. F., 4277
 Ludwig, A., 2470
 Ludwig, R., 4411
 Luikart, S. D., 3781
 Lund, B., 4626
 Lundberg, J. H., 6466
 Lund-Johansen, M., 6039
 Luo, Y., 32
 Luqmani, Y. A., 7882
 Lusk, E., 6876
 Lyman, S., 5275
 Lynch, J., 7179
 Lynch, J. H., 1966
 Lynch, V., 3390
 Lyon, R. C., 544
 Lyon-Caen, O., 5692s
 Lyons, J., 5464
 Lyons, S. D., 7793
 Lyttle, C. R., 3306
 Lyver, A., 2056
- M
- Mabuchi, S., 7242
 Macaulay, V. M., 2511
 MacDonald, M. J., 7203
 Mace, K. F., 1742
 Macfarlane, D. E., 2895
 MacGregor, J. T., 5049
 Maciak, R. S., 7632
 Macias-Kiger, D., 4254
 Mack, T. M., 2569
 Mackay, A. R., 5997
 Mackay, I. R., 4718
 Mackay, R. L., 1440
 Mackensen, D. G., 3124
 MacLean, G. D., 4801
 MacLean, K. K., 3614
 MacLean, M., 2449
 MacLeod, M. C., 4355
 MacIure, M., 181
 Macpherson, P., 1532
 Madej, M., 4308
 Madelmont, J.-C., 5898
 Madrid-Marina, V., 2891
 Madsen, M. W., 1257
 Maeda, H., 1571, 3897
 Maeda, M., 4941
 Maeda, Y., 7166
 Maehara, Y., 3952
 Mafune, K.-i., 3888, 6291
 Magagnotti, C., 6870
 Magdelenat, H., 438
 Magee, P. N., 4366
 Maggi, A., 5291
 Maggioni, D., 7318
 Magrath, I. T., 5406
 Mahadevan, V., 5537
 Maher, D., 606
 Maher, V. M., 4014, 5587
 Maier, H., 1576
 Maimonides, P., 6738
 Mairs, R., 1000s
 Major, P. P., 880s, 927s
 Mak, J. Y., 4515
 Maley, F., 3979
 Maley, G. F., 3979
 Malik, S. T. A., 5537
 Mallette, S., 941s
 Malley, K., 4670
 Mallin, K., 3657
 Malone, W. E., 2
 Maloney, T. M., 6075
 Malof, F., 2283
 Malspeis, L., 6483
 Maltoni, M., 7811
 Maluish, A. E., 185
 Mamarella, S., 6987
 Manam, S., 5245
 Mancino, V., 1559
 Mandjes, I., 3279
 Mane, S. M., 3627
 Maneckjee, R., 2234
 Maneval, D. C., 3493
 Manfai, M., 6626
 Manfredini, R., 1988, 5825
 Mangeat, P. H., 6045
 Manger, R., 5992
 Mangia, A., 2958
 Mangioni, C., 7318
 Maniglia, C. A., 3781
 Mann, D. L., 1857
 Mann, V. M., 7815
 Mannens, M., 3279
 Mannervik, B., 6848
 Manni, A., 7179
 Manning, D. L., 4098
 Mansell, P. W. A., 2009
 Manthey, C. L., 4991
 Mantovani, A., 4771, 7318
 Mao, B.-L., 174
 Mapstone, D. E., 3199
 Marcelli, M., 5382
 Marchesini, R., 4501
 Marcocci, L., 5119
 Marcon, L., 185
 Mardirossian, G., 7272
 Margulies, I. M. K., 5431, 6184
 Marian, B., 2245
 Mariano, M. T., 7371
 Marion, P. L., 4072
 Mark, J., 8017
 Markaverich, B. M., 1470
 Markowitz, A. B., 3154
 Markowitz, M., 4619
 Markowitz, S., 7715
 Marks, A., 288
 Marks, J. R., 6701
 Marks, P., 4087
 Markstein, E., 1403
 Markus, G., 2245
 Markus, I., 164
 Maronpot, R. R., 266, 472, 3772, 4818
 Marozio, L., 6663
 Marquardt, D., 1426
 Marquardt, H., 6540
 Marques, L. A., 1479
 Marquis, D. M., 1212
 Marsden, E. R., 3439
 Marshall, G. M., 3078
 Marshall, J. F., 4533
 Marshall, J. R., 3295
 Marshall, M. H., 6264
 Marshall, R. J., 5883
 Martelly, I., 2081
 Martel-Planche, G., 5426
 Marth, C., 7037
 Martin, B. M., 1113
 Martin, D. A., 7023
 Martin, F., 6626
 Martin, G., 2929
 Martin, M., 3445
 Martin, P. J., 1017s
 Martin, P.-M., 5892
 Martin, R., 6981
 Martin, S. E., 1279
 Martin, T. J., 2953, 7708
 Martinez-Maza, O., 6959, 7364
 Martinez-Vazquez, H., 2891
 Marton, L. J., 2719, 2769, 3137, 3551
 Martuza, R. L., 6783
 Maru, M., 6915
 Maruguchi, Y., 5526
 Maruyama, K., 5697s
 Maruyama, Y., 7585
 Marvaldi, J., 5164
 Masciarelli, M., 1768
 Masciulli, R., 5795
 Maseki, N., 2698
 Mason, D., 575
 Mason, B. H., 5883
 Mason, T. J., 6520
 Masquelier, M., 108
 Massad, L. S., 4923
 Massaro, A. F., 1138, 2587
 Masters, A., 1800
 Masters, J. R. W., 7511
 Mastroberardino, G., 5795
 Masuda, H., 1863
 Masurel, D., 252
 Matherly, L. H., 3262
 Matsubara, Y., 7601
 Matsuda, H., 1863
 Matsuda, Y., 3270
 Matsuguchi, T., 7457
 Matsumoto, K., 2316, 3866, 5060, 6179
 Matsumoto, M., 596
 Matsumoto, M., 1284
 Matsuo, K.-i., 5819
 Matsuoka, H., 2113, 7212
 Matsuoka, J., 7003
 Matsushima, R., 4974
 Matsuura, A., 6559
 Matsuura, H., 1608
 Matsuya, T., 4139
 Matsuyama, F., 2423
 Matsuyama, T., 5287
 Matsuzawa, Y., 3270
 Matta, K. L., 5003
 Mattano, S. S., 4566
 Mattern, M. R., 2636, 2901
 Mattes, M. J., 880s, 927s
 Matthews, W., 4272
 Mauldin, S. K., 6497
 Maunoury, M. T., 438
 Maurizis, J.-C., 3301
 Mavelli, I., 5119
 May, C., 3036
 May, J., 7517
 Mayall, B., 2943
 Mayer, L. D., 575
 Mayes, J., 7116
 Mazzocchi, M., 5703s

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- McBride, W. H., 2949, 3585
 McCaffrey, J., 6811
 McCarthy, J. B., 3781, 7610
 McCartney, A. J., 1800
 McClelland, R. A., 3545
 McCormick, J. J., 4014, 5587
 McCormick, K., 5414
 McCrone, S., 1426
 McCully, C., 7915
 McCune, C. S., 1212
 McDonald, J. W., 5369
 McDougall, C. J., 8023
 McDougall, S., 5631s
 McEntire, K. D., 4755
 McGovren, J. P., 5475
 McGrath, C. M., 6075
 McGrath, K., 606
 McGregor, J. R., 5931
 McGuire, J. J., 1726
 McGuire, M. H., 152
 McGuire, W. B., 4595
 McGuire, W. L., 3317, 3974,
 4332
 McGuire, W. P., 3284
 McIntosh, J. K., 2463, 3503
 McIsaac, A. M., 3331
 McKean, D. J., 6508
 McKean, J. D. S., 278
 McKeever, P., 4957
 McKenna, W. G., 97, 6575
 McKenney, B. K., 142
 McKenzie, I. F. C., 89, 4423,
 5225, 6028
 McKenzie, S., 4087
 McKerrow, J. H., 2322
 McKnight, J., 7343
 McLachlan, J. A., 7675
 McLaughlin, J. K., 3804, 6836
 McManus, M. E., 3367
 McMichael, A. J., 3176
 McMillan, T. J., 1392
 McNeal, J. E., 3795
 McNurlan, M. A., 1125
 McPhaul, M. J., 5382
 McPhillips, J. B., 169
 McTiernan, R., 7257
 McVie, J. G., 7031
 Mead, J. E., 1464, 7023
 Meadows, A. T., 2608, 7129
 Meager, A., 5537
 Meares, C. F., 789s
 Mecucci, C., 2212
 Medina, D., 1470
 Medline, A., 6955
 Medoff, G., 3274
 Mee, P. J., 6841
 Meerpohl, H.-G., 7448
 Mehrotra, R., 2156
 Meiers, W., 7318
 Meisner, L. F., 4779
 Meistrich, M. L., 370
 Melamed, M. R., 7912
 Melder, D. C., 4458
 Melfi, C. J. M., 5767
 Melikian, A. A., 1795
 Mellitt, R. J., 152
 Melloni, E., 4501
 Mellsted, H. T., 4866, 6358
 Melnick, R. L., 6592
 Meltzer, S. J., 3627
 Melville, S., 1125
 Mendonca, M. S., 2123
 Menear, J. H., 266
 Mennel, H.-D., 7442
 Mennie, R. J., 3694
 Menon, K. M. J., 3019
 Menrad, A., 2177
 Menter, D. G., 3331
 Mercatello, A., 2371
 Merchant, B., 922s, 989s
 Merchant, R. E., 4377
 Merchant, T. E., 527
 Meredith, M. J., 1879, 2747,
 5296
 Merrill, A. H., Jr., 222
 Merritt, W. D., 202
 Mertelsmann, R., 2009
 Mertz, R. J., 7203
 Messina, M., 5710
 Messing, E. M., 2530
 Mette, S. A., 6757
 Metzgar, R. S., 2997, 6015,
 7246
 Metzger, L., 6575
 Meyer, D. J., 2747
 Meyer, K., 5387
 Meyer, W. H., 2781
 Meyers, S. L., 5911
 Meyer zum Büschenthal, K.-H.,
 7666
 Mezu, A. B., 1977, 1997
 Micca, P. L., 138
 Michael, D. M., 4794
 Michalides, R. J. A. M., 1102
 Michel, F.-B., 4382
 Michelassi, F., 147
 Michieli, M., 4291
 Mickisch, G. H., 3670
 Mico, B. A., 1144
 Midorikawa, O., 5574
 Midorikawa, Y., 6243
 Miglioli, M., 1156
 Mihaly, G., 5095
 Mihsara, Y., 3119
 Mihich, E., 7402
 Miki, H., 1324
 Miki, Y., 7166
 Mikumo, R., 7324
 Milas, L., 4473
 Milgrom, E., 2390
 Millar, J. L., 2511
 Millar, W. T., 1043s
 Miller, A. M., 7257
 Miller, C. W., 7950
 Miller, D. C., 7393
 Miller, E. M., 4962
 Miller, G. J., 7068
 Miller, L. A., 6208
 Miller, L. S., 7942
 Miller, R., 7343
 Miller, R. A., 1017s, 1022s,
 4935
 Miller, R. A., 6592
 Miller, R. C., 4050
 Miller, S. R., 3859
 Miller, T., 4204
 Millot, J.-M., 6626
 Mills, G. B., 3036
 Mills, S. L., 1014s
 Minamiyama, Y., 5574
 Minato, K., 5919
 Minke, J. M. H. M., 4003
 Minkin, S., 6955
 Mirabelli, C. K., 2636, 2901
 Miranda, D., 1977, 1997
 Mira-y-Lopez, R., 78
 Mirzadeh, S., 4221
 Misdorp, W., 4003
 Mise, K., 6199
 Miser, J., 4464
 Misiorowski, R. L., 4121
 Mison, A. P., 1008s
 Misra, H., 7272
 Mitchell, B. S., 4566
 Mitchell, J. B., 4272, 7735
 Mitchell, M. S., 6311
 Mitrius, J. C., 4209
 Mitsudomi, T., 2113, 7077
 Miura, K., 3167
 Miura, S.-i., 2729
 Mivechi, N. F., 2044, 2877
 Miwa, K., 509
 Miyachi, H., 2044
 Miyachi, Y., 5526
 Miyagi, T., 7680
 Miyakawa, M., 400
 Miyaki, M., 7166
 Miyakoshi, J., 278
 Miyamoto, S., 6010
 Miyamoto, Y., 1571
 Miyasaka, Y., 2885
 Miyatake, S.-i., 596, 2429
 Miyauchi, M., 1693
 Miyazaki, I., 509
 Miyazaki, K., 4522, 7758
 Miyoshi, I., 7680
 Mizejewski, G. J., 415
 Mizoguchi, T., 3055
 Mizuno, K., 5751
 Mizuno, M., 7826
 Mizushima, Y., 1847, 2099
 Mochizuki, S., 5697s
 Modali, R. V., 1857
 Modest, E. J., 4458
 Modica-Napolitano, J. S., 7876
 Mody, D. R., 6632
 Moertel, C. G., 206, 3905, 5969
 Mohan, S., 6902
 Mohri, M., 7101
 Moi, M. K., 789s
 Mokyr, M. B., 7639
 Molina, A., 4946
 Molinari, R., 5551
 Molinaro, M., 3377
 Molinolo, A., 1291
 Moll, R., 7666
 Moll, U. M., 6162, 6995
 Moloney, W. C., 2741
 Momosaki, K., 6731
 Momose, H., 7062
 Mondovi, B., 5119
 Monestier, M., 1055s
 Monet, J.-D., 1195
 Monson, R. R., 2283
 Montag, A. G., 147, 6344
 Montcourier, P., 6045
 Monteiro-Riviere, N. A., 5740
 Montesano, R., 245, 2156, 5426
 Montesoro, E., 5795
 Moody, C. E., 5250, 6800
 Mooi, W. J., 5143
 Moolenaar, C. E. C. K., 1102
 Mooradian, D. L., 273
 Moore, A. L., 6302
 Moore, G. W., 6486
 Moore, J., 6876
 Moore, J. P., 1510, 1828
 Moore, M. A. S., 4216
 Moore, R. E., 7632
 Moorer-van Delft, C. M., 1924,
 2437
 Mor, O., 2794
 Morais, R., 6675
 Moran, P., 7068
 Moran, R. G., 5212
 Moran, T. M., 6034
 Morantz, R. A., 5039
 Moreau, J.-P., 2646, 4360
 Morelli, S., 5065
 Moret, M., 6870
 Morgan, A. C., Jr., 5992, 6311,
 6379, 7973
 Mori, M., 7212
 Mori, M., 7662
 Mori, N., 4344
 Moriarty, J., 5250, 6800
 Moriarty, M., 3390
 Morikage, T., 1847, 2099
 Moriki, T., 3106
 Morioka, S., 4139
 Morishima, Y., 7198, 7701,
 7955
 Morishita, Y., 7198, 7701, 7955
 Morisset, M., 6045
 Moriwaki, K., 1873
 Morley, A. A., 4584
 Morotomi, M., 3595
 Morris, C., 3429
 Morris, I. D., 568
 Morris, R. J., 3048
 Morrison, R. S., 2524
 Morrissey, M. A., 932s
 Morse, M. A., 2613, 6817
 Morstyn, G., 606, 5095
 Morton, B. A., 922s, 1008s
 Morton, C. C., 4092
 Morton, D. L., 3585, 5358
 Moseley, J. M., 7708
 Moseley, M. E., 7376
 Moseley, R. P., 4105
 Moser, A., 4233
 Moses, H. L., 2203
 Moses, K., 1992
 Moskal, J. R., 2524
 Mossie, K., 5628s
 Motta-Hennessy, C., 2330
 Moulinoux, J.-P., 5077
 Moustacchi, E., 2443, 3289
 Moy, B. C., 2485
 Muchmore, A., 6285
 Mueller, B. M., 5234
 Mueller, E. A., 3646
 Mueller-Klieser, W., 1681
 Muensch, S. P., 3262
 Muhlbauer, L. H., 1954
 Muindi, J., 1151
 Muir, C. S., 6441
 Mukai, H., 240
 Mukai, M., 2018
 Mulder, K. M., 7581
 Mulder, N. H., 304
 Mulé, J. J., 2463
 Mullaney, S., 5618s
 Mullen, J. B. M., 2476
 Mullenix, P. J., 6455, 6461
 Muller, E. J., 1102
 Müller, K., 2470
 Müller, L. J., 1924, 2437
 Müller, W., 323
 Müller-Hermelink, H. K., 5192
 Müller-Holzner, E., 7037
 Mullick, A., 333
 Mullin, J. M., 2172
 Mullin, R. J., 3207
 Mullins, R. E., 5790
 Mulshine, J. L., 5481

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Mulvihill, J. J., 4050
 Munakata, T., 3897
 Mundy, G. R., 2673
 Munekata, E., 240
 Muñoz, N., 426, 2268, 7112
 Munson, G. P., 5045
 Münz, P. A., 3569
 Murakami, H., 103
 Murant, R. S., 7236
 Muraro, R., 6987
 Murata, J., 3631
 Muratani, K., 1079, 3408
 Murchelano, R. A., 6744
 Murphy, C. S., 7285
 Murphy, J. R., 7068
 Murphy, L. C., 4204
 Murphy, M. J., Jr., 4038, 7695
 Murphy, R. F., 7915
 Murphy, S. E., 4685, 5446
 Murr, C., 1576
 Murray, J. L., 904s
 Murray, T., 1000s
 Murthy, S., 7206
 Murti, K. G., 664, 6002
 Muschel, R. J., 97, 3872, 5581, 6575
 Musgrove, E. A., 4849
 Mutch, D. G., 4923
 Myers, C. E., 552, 5488
 Myers, T. W., 5340
 Myoga, A., 1284
- N
 Nabi, I. R., 409
 Nadal, J. C., 4644
 Nagai, K.-i., 2917
 Nagamatsu, A., 6731
 Nagamine, S., 6396
 Nagasaki, T., 8028
 Nagasaki, K., 3257
 Nagase, H., 6158, 6995
 Nagase, T., 3270
 Nagashima, K., 2641
 Nagata, H., 1715
 Nagata, K., 4344
 Nagata, K., 7585
 Nagata, N., 3172
 Nagata, S., 5102
 Nagata, Y., 480
 Nagaochi, O., 2423
 Nagorney, D. M., 5969
 Nagura, H., 400
 Naito, M., 7660
 Nakagawa, K., 2549, 5919
 Nakagawa, M., 2418
 Nakagawara, A., 3043, 7242
 Nakai, H., 6146
 Nakaizumi, A., 2095, 4931, 5308
 Nakajima, H., 2135
 Nakajima, K., 6915
 Nakajima, M., 3631, 4121
 Nakamura, H., 7242
 Nakamura, Y., 3257
 Nakamura, Y., 7166, 7184
 Nakanishi, M., 6199
 Nakano, H., 5841
 Nakao, H., 2698
 Nakao, H., 5345
 Nakatsukasa, H., 3439
 Nakayama, E., 480
 Nakayama, H., 8002
 Nakayama, J., 1284
 Nakayama, T., 3101
- Nakayasu, M., 4974
 Nakazato, H., 2397
 Namba, Y., 596
 Nance, S., 1375
 Nandi, S., 6010
 Nanus, D. M., 4190
 Naoe, T., 480
 Nap, M., 3832
 Napier, M. A., 1550
 Nara, N., 7587
 Narasimhan, J., 4468
 Narayan, S., 6772
 Narisawa, S., 754
 Narod, S. A., 4448
 Nasioulas, G., 403
 Nass, C. C., 2608
 Natale, R. B., 941s
 Natali, P. G., 1271, 7420
 Navas, P., 5887
 Navon, G., 544
 Nayersina, R., 2949
 Nayini, J., 2562
 Naylor, M. S., 4436
 Naylor, S., 4611
 Naylor, S. L., 3067
 Neave, L. M., 5883
 Neckers, L. M., 6316
 Neda, H., 4941
 Needleman, S. W., 3627
 Neequayi, J., 5406
 Negri, E., 4497, 5231, 6274, 6502
 Negrier, S., 2371
 Negrini, B. P., 4670
 Nehme, C. L., 669
 Neijt, J. P., 4626
 Nelpl, W. B., 783s, 1017s
 Nelson, B., 4588
 Nelson, D. L., 185
 Nelson, G., 5088
 Nelson, J. A., 4328
 Nelson, K., 7799
 Nelson, K. K., 6278, 7684
 Nemoto, N., 3226
 Néri, C., 5892
 Nesnow, S., 5088
 Nettesheim, P., 740
 Neubauer, B. L., 142
 Neumaier, M., 2128
 Neumann, M., 6793
 Neumeister, B., 7057
 Newberne, P., 580
 Newbold, J. E., 4072
 Newbold, R. R., 7677
 Newell, D. R., 7517, 7542
 Newkirk, C., 3627
 Newman, E. S., 794s, 828s
 Newman, M. A., 3351
 Newman, R. A., 1732, 4349
 Newmark, H. L., 2651
 Newton, P., 3605
 Nexø, E., 642
 Ng, S.-f., 464
 Ngoi, S. S., 8023
 Nguyen, T. T., 4611
 Nicholls, G. P., 6520
 Nichols, P. W., 44, 7081
 Nichols, W. W., 5245
 Nicholson, D., 3545
 Nicholson, R. I., 3545
 Nicolson, G. L., 515, 2203
 Nicotra, M. R., 1271
 Niederhuber, J. T., 941s
 Nielsen, K. V., 1257
- Niendorf, A., 6100
 Niethammer, D., 2177, 6793
 Nieling, L. M., 2667
 Nieuwint, A. W. M., 5392
 Nieves, E., 4839
 Niho, Y., 7455
 Niitsu, Y., 4941
 Nilsson, K., 2027
 Nims, R. W., 1144
 Ning, S., 7867
 Nishida, Y., 4131
 Nishiguchi, I., 4473
 Nishi, K., 3866
 Nishikata, J., 7601
 Nishikawa, A., 5345
 Nishikawa, K., 1732
 Nishikawa, M., 621
 Nishikawa, R., 3848
 Nishiki, M., 4050
 Nishioka, K., 1738
 Nishioka, K., 2505
 Nishioka, T., 596
 Nishiura, T., 5345
 Nishiyama, M., 4698
 Nishiyama, M., 6291
 Nishizawa, Y., 3866
 Nishizawa, Y., 3866, 6179
 Nisselbaum, J., 5904
 Nissen-Meyer, J., 3997
 Nisticò, P., 7422
 Niwa, M., 2481
 Niwa, T., 8028
 Nizze, A. S., 5358
 Nobunaga, T., 488
 Nocentini, S., 2443
 Nocera, M. A., 6405
 Noe, D. A., 3284, 4595
 Nöhammer, G., 6663
 Nolta, J., 1455
 Nomura, A. M. Y., 627, 7084, 7499
 Nomura, T., 2135
 Nonomura, N., 2316, 6179
 Nordan, R. P., 7786
 Nordberg, J. E., 421, 5184
 Nordin, M., 5863, 6908
 Norman, A. W., 6857
 Norris, M. D., 3078
 North, R. J., 2228
 Norton, J. A., 2261, 3928, 4008
 Norton, T. R., 5301
 Nose, Y., 3043
 Noska, M. A., 1822
 Notohara, K., 2698
 Noujaim, A. A., 4801
 Novak, J. M., 4704
 Novak, R. F., 5333
 Novak-Hofer, I., 7437
 Nowell, P. C., 421, 4856, 6876
 Nozawa, S., 754
 Nudelman, E., 1375
 Nylen, E., 1960
 Nylen, U., 3141
- O
 Oakes, W. J., 2347
 Obayashi, H., 4630
 Öberg, K., 748, 3413
 Oberyszyn, T. M., 6062
 O'Brian, C. A., 3619, 7775
 O'Brian, M. T., 5911
 O'Brien, P. E., 2411
 O'Brien, P. J., 1516
- O'Brien, T. G., 2088, 4741
 Ochoa, A. C., 1853
 Ochs, J., 4267
 O'Connell, M. J., 206
 O'Connell, S. M., 20, 6062
 O'Conner-Tressel, M., 840s, 846s
 O'Connor, B. M., 5212
 O'Connor, M., 606
 O'Connor, R., 5192
 Oda, S., 4344
 Oda, T., 1571
 Oda, Y., 596, 2429
 O'Donnell, D., 1337
 O'Donnell, K., 2088
 Oegema, T. R., Jr., 3781
 Oettgen, H. F., 1403, 7488
 Offerhaus, G. J. A., 6486
 Offermann, M. K., 601
 Ogata, E., 3182
 Ogata, H., 2582
 Ogawa, K., 4195
 Odgen, J., 1226
 Ogolla, F., 7942
 O'Grady, L. F., 1014s
 Ogura, H., 5102
 Ogura, M., 7701, 7955
 O'Hara, C., 6738
 Ohe, Y., 2549
 Ohgaki, K., 6199
 Oh-hara, T., 6925, 7962
 O'Higgins, N., 6827
 Ohkouchi, K., 1640
 Ohmura, E., 103, 4915
 Ohnishi, H., 1107
 Ohnishi, K., 8028
 Ohno, H., 2423
 Ohno, T., 345
 Ohta, K., 2641
 Ohto, M., 1121
 Ohtsuji, E., 7008
 Ohtsuki, Y., 7680
 Ohue, Y., 240
 Ohyama, K., 4557
 Ohyashiki, J. H., 7680
 Ohyashiki, K., 7680
 Oie, H. K., 120, 5481, 5488
 Oikawa, S., 2397
 Oishi, K., 3025
 Okabe, T., 1671, 3863
 Okada, M., 103, 4915
 Okada, S., 5574
 Okamoto, M., 7166
 Okamoto, T., 4941
 Okamura, S., 7455
 Okano, A., 2885
 Okano, T., 1693
 Okayasu, T., 1361
 O'Keefe, S. J. D., 1226
 Okino, T., 6199
 Oksenberg, D., 6471
 Okubo, Y., 5497
 Okumoto, M., 3848
 Okumura, M., 310
 Okunieff, P., 15
 Old, L. J., 1403, 5531
 Oldham, R. K., 1686
 Olech, L. J., 6600
 Oleinick, N. L., 1620
 Oliff, L., 5790
 Olinski, R., 1183
 Olsen, R. A., 4458
 Olsen, R. G., 5687s
 Olshan, A. F., 3212

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Olt, G., 4087
 Olumi, A. F., 7081
 Omata, M., 1121
 Omiecienski, C. J., 4315
 Onoda, J. M., 6278
 Onoda, N., 103, 4915
 Onoda, T., 7003
 Oosterhuis, J. W., 3416
 Ooyama, S., 509
 Orazi, A., 5551
 Order, S. E., 974s, 1011s
 O'Riordan, M. A., 1911
 Orita, K., 7003
 Orloff, M., 1645
 Ørntoft, T. F., 1375
 Ortaldo, J. R., 5328
 Oseroff, A. R., 5369
 Oseroff, A. R., 7876
 Oshima, H., 2848
 Oshimura, M., 740
 Osinaga, E., 7333
 Ossowski, L., 78
 Ostchega, Y., 2256
 Ostella, F., 794s, 828s
 O'Sullivan, C., 6827
 Ota, D. M., 3331
 Ottenlinger, C., 2177
 Otto, U., 6389
 Overgaard, J., 7428
 Overstreet, R. M., 5675s
 Ow, K. T., 4098
 Owen, A. M., 193
 Owen, R. D., 6430
 Owens, N. E., 222
 Owen-Schaub, L. B., 3526
 Oyama, F., 1075
 Oyasu, R., 7062
 Ozaki, S., 4630
 Ozanne, B. W., 1917
 Ozawa, K., 5102
 Ozkaynak, M. F., 1455
 Ozols, R. F., 2256
 Ozturk, M., 6291
- P**
- Pacheco, D. Y., 7555
 Padarathsingh, M., 3805
 Paganelli, G. M., 1156
 Page, J. D., 6497
 Page, R. L., 2075
 Pähliman, S., 6908
 Pai, L. H., 7750
 Paietta, E., 2049
 Palella, T. D., 4566
 Palevsky, H. I., 958s
 Palladino, G., 5438
 Palmer, A. E., 4366
 Palomino, A., 5446
 Palumbo, A. P., 6478
 Palumbo, G. J., 1917
 Pan, H.-O., 4131
 Panasci, L. C., 3062
 Pancino, G., 7333
 Pancok, J., 2991, 7973
 Pandey, J. P., 3186
 Pandiella, A., 3892
 Panella, T. J., 4429
 Pangalos, G. A., 2759
 Panozzo, M., 4968, 5703s
 Pap, S. A., 1170
 Papa, V., 7858
 Papadopoulou, D., 3289
 Papadopoulos, E., 3562
- Papageorge, A., 67
 Papahadjopoulos, D., 6371
 Papanicolaou, V., 748
 Papas, T. S., 5671s
 Papathanasiou, M. A., 7908
 Papenhausen, P., 2049
 Paradis, W. M., 393
 Paradiso, A., 2958
 Paraskeva, C., 4724, 7715
 Pardee, A. B., 6806
 Parent, M., 6675
 Pariza, M. W., 1097
 Park, H. S., 5318
 Park, H.-Y., 7145
 Park, J.-G., 2773, 3681
 Park, J. H., 5653s
 Parker, B. A., 1022s
 Parker, W. B., 4891
 Parkinson, D. R., 5263
 Parkman, R., 1455
 Parmiani, G., 5551
 Parmiter, A., 2296
 Parnell, G. D., 7517
 Parpia, B., 6882
 Parris, C. N., 7513
 Parry, D. M., 4050
 Pash, J. M., 2022
 Pass, H. I., 4272
 Passaniti, A., 7261
 Pastan, I., 1748, 7750, 7786
 Patel, A. M., 3795
 Patel, D., 2853
 Patel, H. R. H., 5112
 Patel, K. V., 235
 Paterson, A. R. P., 6549
 Pathak, S., 7979
 Pati, U. K., 6430
 Patterson, M. K., Jr., 7830
 Patterson, R. M., 266
 Patton, J. R., 375
 Paukovits, W. R., 328
 Pauley, R. J., 6075
 Paulien, S., 7902
 Pauls, E. A., 1890
 Paulsen, L. A., 1431
 Paulus, W., 2177
 Pavelka, K., 4092
 Pavlik, E. J., 7799
 Pawlin, G., 2794
 Pawlita, M., 3095
 Pawlyk, D. A., 1039s, 2330, 2823
 Paxton, J. W., 503, 2692
 Paxton, R. J., 840s, 846s, 922s, 1029s, 2128
 Peace, D. J., 5421
 Pearce, W., 6608
 Pearson, J. W., 6379
 Peccatori, F., 7318
 Pedersen, E. J., 4880
 Pedersen, J. Z., 5119
 Pedone, C. A., 5784
 Peehl, D. M., 3795
 Pegg, A. E., 6119
 Pegram, C. N., 58
 Pekny, K. W., 4656
 Pedersen, E. J., 2554
 Peled, A., 2554
 Pellarin, M., 2769, 3137
 Pellegata, N. S., 7811
 Pelletier, H., 6626
 Pellicer, A., 3805
 Pellis, N. R., 7153
 Pence, J. C., 5177
 Pendergrass, T. W., 6525
- Penta, J. S., 4464
 Peraino, C., 1675
 Perantoni, A. O., 6139
 Perchellet, E. M., 5806
 Perchellet, J.-P., 5806
 Perdue, J., 48
 Perez, P., 4227
 Perez-Soler, R., 4254, 4260
 Peries, J., 5692s
 Perkel, V. S., 6902
 Pero, R. W., 4619
 Perry, R. R., 4272
 Perucco, M., 1279
 Pesando, J. M., 3245
 Peschle, C., 5795
 Pestka, S., 5328
 Peter, S., 4504
 Petering, D. H., 5275
 Peters, B., 5049
 Peters, G. J., 4644
 Petersen, O. W., 1257
 Peterson, C. O., 108, 483
 Peterson, J. A., 5925
 Peterson, V. A., 5399
 Peterson, W. D., Jr., 6075
 Petrkova, A., 7129
 Petrella, E., 3124
 Petrides, P. E., 3934
 Petruk, K., 278
 Pettengill, O. S., 5312
 Pettersson, B., 108
 Pettit, G. R., 3422, 4794, 5520
 Petzold, G. L., 2485
 Petzold, S. J., 2713
 Peyrat, J. P., 6931
 Pfaff, M., 5192
 Pfau, W., 5464
 Pfeiffer, L. M., 2654, 4190
 Pfeiffer, M. R., 2734, 3826
 Pfeiffer, A., 6490
 Pfister, D. G., 4664
 Pfragner, R., 4160
 Freudenthal, M., 84, 2929, 6944
 Philip, R., 375
 Philip, T., 2371
 Phitakpraiwan, P., 6663
 Piacibello, W., 5065
 Piao, Y.-F., 1671
 Picard, J., 6716
 Pichon, M.-F., 2390
 Pickett, C. B., 256
 Piepmeyer, J., 6636
 Pierce, G. B., 1346
 Pierceall, W. E., 3159
 Pierson, J., 4845
 Pierson, N. R., 1165
 Pietersz, G. A., 4423, 5225, 6028
 Piffanelli, A., 5291
 Pike, M. C., 7413
 Pileggi, D., 4929
 Pilieri, A., 6478
 Pilieri, S., 4291
 Pillay, M., 955s
 Pillwein, K., 1576
 Pilon, J., 2088
 Pimm, M. V., 2936
 Pinedo, H. M., 4644
 Pink, J. J., 7285
 Pinon, F., 438
 Pinsky, C. M., 909s
 Pitot, H. C., 472
- Piwnica-Worms, D., 2198
 Plager, C. E., 904s
 Plagne, R., 3301, 6620
 Planting, A., 955s
 Platsoucas, C. D., 4328
 Pleshkewych, A., 1929
 Plunkett, W., 3675, 6823
 Pohl, C., 6944
 Poiner, A., 7793
 Pointereau-Bellanger, A., 438
 Poirier, M. C., 2256
 Polin, L., 4900, 5876
 Pollack, I. F., 7134
 Pollard, R. B., 3897, 4032
 Polyzos, A., 717
 Pompon, D., 6949
 Ponder, B. A. J., 4448, 7992
 Ponec, M., 3589
 Ponstingl, H., 403
 Pontes, E., 2363
 Ponz de Leon, M., 1156, 7937
 Poole, D. J., 4872
 Poon, M.-C., 1658
 Poore, G. A., 4417
 Poot, M., 5204, 6981
 Popenoe, E. A., 4860
 Popescu, N. C., 1316
 Poplack, D. G., 4464, 7226, 7915
 Popp, J., 2455
 Porfirio, B., 3289
 Porsch-Hällström, I., 2679
 Porter, B., 1017s
 Porter, C. W., 1929, 3838, 6146
 Posner, M. R., 3087
 Potter, J. D., 3176
 Pouillard, P., 438
 Pour, P. M., 1634
 Pourbohloul, S. C., 5682s
 Povey, A. C., 6580
 Povirk, L. F., 7525
 Powell, C. B., 4923
 Powell, J. B., 2455
 Powers, B. E., 54, 6176
 Powis, G., 2203, 4458
 Pradayrol, L., 5829
 Prahalada, S., 5245
 Prasad, G. L., 2105
 Prasad, S. C., 38
 Prasad, V., 4277
 Preisinger, A. C., 7715
 Press, O. W., 783s, 1017s, 1243
 Preston, D. F., 7799
 Preston-Martin, S., 7415
 Pretlow, T. G., II, 2808
 Pretlow, T. P., 1911, 2808
 Preusch, P. C., 7293, 7481
 Previdere, C., 7811
 Price, D. C., 6371
 Price, J. E., 717, 3159
 Price, P., 1392
 Pribe, T., 4328
 Pribe, W., 4260
 Priest, D. G., 3979
 Priestly, A., 1532
 Princler, G. L., 26
 Prinsen, I., 6689
 Prinsen, M. K., 691, 700
 Prody, C. A., 1983
 Proietti, E., 3533
 Prud'homme, J.-F., 2390
 Prus, K. L., 1817
 Psiakis, J. T., 3262
 Pugh, T. D., 113, 6779

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Pujol, H., 4382
 Pujol, J-L., 4382
 Pulaski, K., 6783
 Purchio, A. F., 273
 Puri, R. K., 5543
 Purohit, A., 193
 Purtilo, D. T., 4845
 Purvis, J., 7494
 Putz, B., 3701
 Pyle, J. M., 7639
 Pylypiw, H. M., Jr., 4366
- Q
- Qian, X-d., 1132
 Qiao, Y-l., 174
 Quarmby, V. E., 735
 Quart, A. M., 5438
 Quart, E., 5438
 Quattrochi, L. C., 3367
 Quax, P. H. A., 1488
 Queen, C., 1495
 Quesenberry, C. P., 4600
 Qui, S. L., 2651
 Quigley, J. P., 6162
 Quinn, L. M., 1003s
 Quistorff, B., 4880
- R
- Raber, M. N., 4254
 Racevskis, J., 2049
 Radal, M., 4382
 Radford, D. M., 6146, 6529
 Radin, A. I., 6641
 Radin, N. S., 6731
 Radinsky, R., 4388
 Radparvar, S., 2625
 Raedsch, R., 2268
 Raffel, C., 587
 Rahman, A., 6002
 Rajagopalan, S., 648
 Railings, M., 606
 Ramakrishnan, S., 3231
 Raman, R., 3737
 Ramjee, G., 1226
 Ramos, D. M., 728
 Ramos, E. O., 7112
 Ramos, F., 6620
 Ramsawak, R. D., 5531
 Ramsdell, H. S., 615
 Ramsey, P. S., 6508
 Randall, M. S., 7134
 Randerath, K., 3991, 7575
 Ranzani, G. N., 7811
 Rao, A., 4764
 Rao, J. S., 5039
 Rao, J-Y., 174
 Rao, J. Y., 2215
 Rao, M. S., 669
 Rao, P. H., 6410
 Rao, V. N., 5013
 Rapp, M., 5898
 Rappa, G., 6723
 Raska, K., Jr., 5328
 Raso, V., 6696
 Raspagliesi, F., 5291
 Rastad, J., 748
 Ratliff, T. L., 3843
 Raubertas, R. F., 7236
 Raubitschek, A., 820s, 7735
 Rauth, A. M., 1516
 Ravikumar, T. S., 3888
 Rawls, J. A., 7815
 Rawls, W. E., 7815
- Rayman, P., 2363
 Raz, A., 409, 4121
 Rea, D. W., 857s
 Read, L. D., 3947
 Reading, C. C., 5969
 Reaman, G., 7226
 Reaman, G. H., 202
 Recht, L. D., 6696
 Reddy, B. S., 2562, 5761
 Reddy, E. S. P., 5013
 Reddy, J. K., 669
 Redlich, C. A., 4315
 Redman, B. G., 5876
 Redpath, J. L., 2123
 Ree, A. H., 1528
 Reed, E., 2256
 Reed, J. C., 6565, 7399
 Reed, M. J., 193
 Reese, C. C., 7858
 Reeves, W. C., 7815
 Reger, G., 4349
 Rehfeldt, W., 323
 Rei, Y. G., 2268
 Reibnegger, G., 2863
 Reichard, G. A., 2088
 Reichlin, S., 1237
 Reichman, M. E., 2311
 Reid, J. M., 6525
 Reilly, D., 6827
 Reilly, T. M., 2524
 Reimer, K. A., 2455
 Reiner, A., 7057
 Reiner, G., 7057
 Reiners, J. J., Jr., 6062
 Reisfeld, R. A., 4656, 5234,
 6311
 Reiss, M., 6641
 Remick, S. C., 2667
 Ren, J., 358
 Ren, S., 1403
 Rennie, P. S., 2275
 Renwick, A., 6976
 Resau, J. H., 1857, 3627
 Resch, K., 323
 Rescigno, A., 7272
 Reshef, R., 1764
 Resnick-Roguel, N., 4787
 Reszka, K., 1936
 Reubi, J. C., 5969
 Revankar, G. R., 2625
 Retet, B., 2443
 Reynolds, J. C., 820s
 Reynolds, K., 89
 Reynolds, R. K., 3019
 Reynolds, S. H., 266, 1591, 4818
 Reznik, G. K., 1645
 Reznikoff, C. A., 4779
 Rhee, M. S., 3979
 Rhim, J. S., 563s
 Rhim, S-H., 7050
 Ricchio, M. E., 3189
 Rice, J. M., 132^a, 4366, 5567,
 6139
 Richards, C. A., 1521
 Richards, J., 7932
 Richardson, P. M., 6430
 Richardson, R. L., 206, 3905
 Richel, D. J., 6515
 Richter, K. Y., 783s
 Ridell, S. R., 1160
 Ries, L. G., 2741
 Riethorst, A., 2803, 5392
 Rifkin, D. B., 7393
 Rifkin, J., 261
- Rigas, B., 8023
 Riggs, A. D., 2128
 Riggs, C. W., 1324, 5567, 6379
 Rigotti, J., 2562
 Rijksen, G., 4020, 4604, 7542
 Rinehart, J. J., 6483
 Ring, D. B., 3231
 Ringer, D. P., 5301
 Rinzel, S. M., 4417
 Rio, B., 5692s
 Rio, M-C., 3832
 Ritchev, J. K., 3843
 Ritter, G., 1403
 Ritter, M. A., 563
 Ritter, R. A., III, 152
 Rittmann-Grauer, L., 7632
 Rivera, G. K., 4267
 Riviere, J. E., 2075
 Rivoire, M., 862s, 877s
 Rivoltini, L., 5551
 Roach, M. C., 4277
 Robb, J. A., 4154, 6095
 Robbins, G., 7101
 Robbins, P. F., 6248
 Robert, J., 432
 Roberts, A. I., 6158
 Roberts, D. D., 5937
 Roberts, J. A., 3019
 Roberts, J. D., 6302
 Roberts, J. R., 710
 Roberts, L. J., II, 1879
 Robertson, F. M., 4741, 6062
 Robertson, I. G. C., 503
 Robertson, J. F. R., 3545
 Robertson, M. L., 393
 Robertson, N. M., 7985
 Robichaud, N., 72
 Robine, S., 438
 Robins, R. K., 2625, 5269
 Robinson, J., 568
 Robinson, R., 421
 Robinson, R. A., 5184
 Robinson, R. R., 5234
 Robinson, V. A., 4794
 Robison, L. L., 3212
 Robson, C. N., 2818, 4692, 7789
 Rochefort, H., 6045
 Rockwell, R. W., 1299
 Rodden, A., 7442
 Roder, J. C., 2476
 Rodman, J. H., 3493, 4267
 Rodriguez, C., 7101
 Rodriguez, E., 6410
 Rodriguez-Aguilera, J. C., 5887
 Roebuck, B. D., 6811
 Rofstad, E. K., 1681
 Roger, H., 6620
 Rogers, R. A., 2075
 Rohan, T. E., 3176
 Röhrdanz, E., 3569
 Rojanapo, W., 6663
 Romagna, F., 4619
 Romano, G., 1271
 Ronai, Z. A., 5374
 Roncucci, L., 7937
 Roodman, S. T., 152
 Roop, D. R., 4441
 Roos, E., 3509
 Roossien, F. F., 3509
 Rordorf, C., 3322
 Rosbe, K. W., 6971
 Rose, D. P., 7139
 Rosen, C. F., 2631
 Rosen, N., 48
- Rosenau, W., 7376
 Rosenberg, C. D., 1559
 Rosenberg, M. C., 284
 Rosenberg, S. A., 2463, 3503,
 5072, 5543
 Rosenberger, A. L., 4510, 5460
 Rosenblum, M. L., 2322
 Rosenspire, K. C., 4839
 Rosenstraus, M. J., 6423
 Rosenthal, L., 927s
 Roseto, A., 7333
 Rosini, S., 6987
 Rosinski, K. B., 6162
 Rosner, M. C., 4111
 Rosner, M. R., 533
 Rosolen, A., 6316
 Ross, A. H., 2296
 Ross, D., 7293, 7481
 Ross, D. D., 2658
 Ross, J., 5088
 Ross, K. L., 1231, 4056
 Ross, R. K., 3605, 7413
 Ross, W. E., 3761, 3767
 Rossi, E., 5825
 Rossi, J. J., 2877
 Rostaing-Capaillo, O., 2909
 Rotenberg, S. A., 677
 Roth, J. A., 3526
 Roth, J. S., 1675
 Roubin, R., 5164
 Roubos, E. W., 1924, 2437
 Rougon, G. N., 5164, 6364
 Rouleau, G. A., 5863
 Rouleau, G. A., 6783
 Rousset, S., 2443
 Rowinsky, E. K., 710, 3284,
 4595
 Rowley, D. A., 3851
 Rowley, J. D., 3816
 Rowlinson, G., 159
 Roy, S. J., 5761
 Royston, I., 1022s
 Roza, L., 1905
 Rozemuller, E., 4020
 Rozen, P., 1764
 Rozengurt, E., 3968
 Rozhin, J., 6278
 Rubin, A. L., 2832, 5171
 Rubin, H., 5171
 Rubin, J., 3905
 Rubinstein, A., 2587
 Rubio, C. A., 6358
 Rucker, N., 5365
 Rudling, M. J., 483
 Rudolph, G., 2177
 Ruegg, C. L., 4221
 Ruehl, W., 4935
 Ruggieri, E. M., 5795
 Ruggiero, R. A., 7159
 Ruit, M. v. d., 3589
 Ruiz, B., 4731, 4737
 Ruiz de Morales, J. G., 7301
 Rumberger, B. G., 4639
 Rund, J., 1226
 Runkel, S., 4473
 Ruprecht, R. M., 5618s
 Rusckowski, M., 7272
 Russell, C. A., 1726
 Russell, E. K., 6068
 Russell, S. M., 4423, 5225, 6028
 Russo, A., 4272
 Russo, G., 6171
 Russo, J., 6075, 6087
 Rustan, T. D., 7942

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Rustum, Y. M., 4401, 5318, 6154
 Rutherford, M., 6295
 Rutka, J. T., 2322
 Rutteman, G. R., 4003
 Ruzicka, F. J., 26
 Rygaard, K., 5312
- S
 Saal, F., 5692s
 Saarinen, U. M., 592
 Sabatini, M., 2673
 Sabatino, R. D., 5340
 Sabbioni, G., 245
 Sacchi, A., 6107
 Sacchi, M., 3113
 Sacchi, S., 1988
 Sacco, R., 6987
 Sack, T. L., 1085
 Sadamori, N., 6171
 Safe, S., 3579
 Sagawa, T., 2708
 Sager, R., 7351
 Saggiorno, D., 4968
 Sahali, Y., 4611
 Sahin, U., 6944
 Sahuet, A., 6045
 Saito, N., 2549, 4698, 5919
 Saiki, I., 3631
 Saito, H., 7198, 7701, 7955, 8028
 Saji, F., 488
 Saka, M., 4139
 Sakagami, K., 7003
 Sakaguchi, A. Y., 3067
 Sakai, K., 4371
 Sakamoto, G., 7184
 Sakamoto, K.-i., 2099
 Sakayori, M., 754
 Sakoda, R., 3055
 Sakuma, T., 754
 Sakurai, J., 3226
 Sakurai, M., 2698
 Sakurai, Y., 1693
 Salazar, G., 6045
 Salehi, Z., 5653s
 Salimi, A. R., 6696
 Salk, D. F., 904s
 Salmon, R. J., 438
 Salomon, D. S., 2105
 Samiowski, W. E., 5931
 Samuel, J., 4801
 Sanavio, F., 5065
 Sandberg, A. A., 3106, 7902
 Sanders, B. G., 4764
 Sanders, M. E., 3132
 Sanderson, B. J. S., 6848
 Sandler, D., 552
 Sands, H., 809s, 835s, 852s, 1031s
 Sano, K., 7242
 Sano, T., 310
 Santoro, O., 4501
 Saragoni, A., 7811
 Sardina, E. E., 2582
 Sarhan, S., 5077
 Sarkar, A., 2719
 Sartorelli, A. C., 6723
 Sasaki, H., 4032
 Sasaki, Y., 2549, 4698
 Sasso, N. L., 1039s
 Sato, B., 2316, 3866, 5060, 6179
 Sato, J., 7226
- Sato, K., 472
 Sato, M., 6396, 7648, 7852
 Sato, N., 4979
 Sato, R., 4979
 Sato, S., 3167
 Sato, S.-i., 310, 3043, 5819
 Sato, T., 7184
 Sato, Y., 7393
 Satoh, K., 6199
 Satterlee, W., 3910
 Sattler, G. L., 472
 Satyawaroop, P. G., 3189
 Saunders, P. P., 5269
 Sausville, E. A., 5257, 5406
 Sauvezie, B., 3301
 Savage, H. E., 4349
 Savolainen, T. A., 3383
 Savouret, J.-F., 2390
 Sawamura, Y., 6683
 Sawey, M. J., 3073
 Sayers, T. J., 5414
 Sailors, R. L., III, 2987
 Scalmati, A., 7937
 Scanlon, K. J., 2044
 Scarpellini, D. G., 766
 Scemama, J. L., 5829
 Schacter, B., 7750
 Schaefer, C., 1681
 Schäfer, G., 2470
 Schally, A. V., 1841, 3716
 Schantz, S. P., 4349
 Schatz, B., 5892
 Schatzkin, A., 174, 2152, 2311, 3610
 Schauenstein, E., 6663
 Schauuller, H. M., 3435
 Schechtman, K. B., 3274
 Scheffel, U., 799s
 Scheffer, G. L., 5392
 Scheibenbogen, C., 7448
 Scheinberg, D. A., 962s
 Schell, K., 2683
 Schellenberg, K., 3614
 Schemper, M., 7057
 Scher, B. M., 3878
 Scher, W., 3878
 Scherf, H. R., 5464
 Schibig, L., 1375
 Schiele, J., 4935
 Schiffman, M. H., 3610, 4670
 Schilbach-Stueckle, K., 2177
 Schiller, J. H., 26, 4588
 Schimke, R. T., 4946, 7307
 Schirrmacher, V., 5962
 Schisselbauer, J. C., 3562
 Schlag, P., 5790, 7232
 Schlageter, K. E., 1251
 Schlick, E., 3670
 Schlom, J., 820s, 1291, 4872, 4885, 6248
 Schmalbach, T. K., 6218
 Schmeiser, H. H., 5464
 Schmelter, R. F., 7068
 Schmidberger, H., 3249
 Schmidt, D., 2177
 Schmitt, D., 4032
 Schmutz, C., 6540
 Schneider, W. P., 1495
 Schoenberg, J. B., 6520
 Schoeny, R., 3351
 Schol, D. J., 1102
 Schold, S. C., Jr., 1954
 Scholz, M., 4167
 Scholz, W., 7015
- Schoof, D. D., 1138, 2587
 Schornagel, J. H., 7542
 Schow, D., 1853
 Schreiber, H., 3851
 Schrenk, D., 3569
 Schreve, H., 2397
 Schrey, M. P., 235
 Schrier, P. I., 3556
 Schroff, R. W., 904s
 Schroy, P., 261
 Schubiger, P. A., 7435
 Schuchter, K., 1576
 Schütze, K., 7015
 Schuller, H. M., 120, 1645, 1960
 Schulthe-Hermann, R., 328, 3701, 5127
 Schultz, K. R., 5421
 Schultz, R. M., 7621
 Schulz, P., 5008
 Schuman, L. M., 6585, 6836
 Schumann, A. M., 4014
 Schunior, A., 6455, 6461
 Schuster, J. M., 1954
 Schuurhuis, G. J., 1779
 Schwab, G., 7786
 Schwab, M., 4411, 7232
 Schwaller, M.-A., 7966
 Schwartzmann, G., 4644
 Schwartz, B., 5328
 Schwartz, D. A., 5184
 Schwartz, E. L., 3473, 5735
 Schwartz, M. R., 6632
 Schwartz, S. M., 1886
 Schwarz, M., 7015
 Schweigerer, L., 4411
 Seckinger, D., 4453
 See, W. A., 2499
 Seeger, R. C., 6055
 Seewald, M. J., 4458
 Seftor, E. A., 4121
 Seftor, E. B., 4121
 Segal, D. M., 4227, 6508
 Seguin, P., 3832
 Sehested, M., 3311
 Sehgal, I., 4458
 Seid, C., 3619
 Seidenfeld, J., 521
 Seigler, H. F., 492
 Seiler, N., 5077
 Seki, M., 7166
 Sekiguchi, K., 1075
 Sekiguchi, K., 1284
 Sekiya, T., 3345
 Selby, J. V., 4600
 Seligman, P. A., 5727, 6295, 7068
 Selker, R. G., 7134
 Sell, S., 3400, 3811
 Selleck, C. M., 1138
 Selleri, L., 1988
 Sem, D., 5275
 Semenzato, G., 1768
 Sen, P., 558
 Sender, L., 3429
 Sendo, F., 6243
 Senger, D. R., 1774
 Seno, T., 5497
 Sensintaffar, J. L., 6959
 Senter, P., 6944
 Seo, H., 7826
 Seon, B. K., 32
 Seppälä, M., 937s
 Serraino, D., 6502
 Serres, M., 5426
- Setlow, R. B., 4050
 Seto, K., 3055
 Seva, C., 5829
 Severino, A., 5065
 Severson, R. K., 627, 7084
 Sezaki, H., 1640
 Shackleton, C. H., 5488
 Shaeffer, J., 3614
 Shah, E. M., 4578
 Shaikh, N. A., 193
 Shalet, S. M., 568
 Shalinsky, D. R., 7537
 Shanken, L. J., 904s
 Shapiro, D. N., 6002
 Sharkey, R. M., 794s, 828s, 866s, 869s, 885s, 909s, 964s, 1003s, 1039s, 1055s, 1330, 2330, 2823
 Sharma, P. L., 5618s
 Sharoni, Y., 5257
 Shasha, S. M., 1764
 Shau, H., 6311
 Shaw, A., 6285
 Shaw, S., 3132
 Shea, C. R., 4167
 Shea, L. C. C., 1757
 Shea, T. C., 6848
 Shearin-Jones, P., 3963
 Sheffels, P. R., 1144
 Shellito, J. E., 375
 Shen, H.-S. L., 4595
 Shen, R.-N., 5027
 Shen, Y.-M., 3193
 Shen, Z.-S., 2031
 Sheprl, L. A., 7920
 Shepherd, J., 1941
 Sheppard, B. C., 2261, 3928
 Sher, E., 3892
 Sherblom, A. P., 5250, 6800
 Sheridan, W. P., 606, 5095
 Sherman, G. J., 4072
 Sherman, M. L., 7101
 Sherwood, M. E., 4167
 Sherwood, S. W., 4946, 7307
 Shestowsky, W., 1948
 Sheytne, J. D., 6358
 Shibai, H., 3182
 Shibata, D., 1279
 Shibuya, M. L., 2577
 Shidnia, H., 5027
 Shields, P. G., 6580
 Shigematsu, K., 2481
 Shih, W. J., 7799
 Shiku, H., 480
 Shiloh, Y., 2794
 Shimada, T., 2036
 Shimazaki, J., 4979
 Shimazu, H., 3952
 Shimeno, H., 6731
 Shimizu, S., 6171
 Shimizu, T., 2538
 Shimizu, T., 5751
 Shimosato, Y., 1075
 Shin, D. M., 2505, 4441
 Shinkai, K., 2018
 Shiozaki, S., 7003
 Shirabe, K., 2113
 Shirai, T., 2156, 4195
 Shiraishi, M., 3345
 Shiraishi, Y., 3106
 Shirakawa, S., 621
 Shirasuna, K., 4139
 Shiroeda, O., 658
 Shiurba, R. A., 6010

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Shively, J. E., 922s, 1029s, 2128, 2397
 Shively, L., 2128
 Shizume, K., 103, 4915
 Shkolnik, T., 1764
 Shojo, M., 3025
 Shores, R., 653
 Short, S. A., 1521
 Shorter, N. A., 5177
 Shows, T. B., 6146
 Shrivastav, S., 820s
 Shu, S., 4371
 Shudo, N., 3055
 Shulkin, B. L., 941s
 Siccardi, A. G., 899s
 Siciliano, M. J., 7979
 Sidell, N., 722
 Sidik, K., 1613
 Sidky, Y. A., 1071
 Siebecker, D. A., 7272
 Sieber, F., 7765
 Siegall, C. B., 7786
 Siegel, D., 7293, 7483
 Siegel, J. A., 1039s, 2330
 Sies, H., 4504
 Sigaux, F., 5692s
 Sigurdson, E. R., 862s, 877s
 Sigurdsson, H., 4332
 Siimes, M. A., 592
 Siiteri, P. K., 7858
 Sikic, B. I., 4056
 Sikora, L. K. J., 4557
 Silber, R., 3562
 Silver, H. K. B., 4906
 Silverlight, J. J., 7882
 Simone, G., 2958
 Simoni, J. L., 1022s
 Simonson, R. B., 985s
 Simony, J., 4382
 Simpson, J. F., 1291, 4872
 Sinclair, J. F., 5219
 Sinclair, P. R., 5219
 Singer, B., 2853
 Singh, A., 193
 Singh, P., 6772
 Singhal, A. K., 1375
 Sinha, B. K., 648
 Sinkeldam, E. J., 1092
 Sinni, B. J., 932s
 Sirak, A. A., 20
 Sironi, M., 7318
 Sirotnak, F. M., 4639
 Sitrin, M. D., 3915
 Sitrin, R. G., 4957
 Sivam, G., 5992, 6379
 Sivolapenko, G. B., 563
 Skalski, V., 3062
 Skelly, C. M., 6800
 Skierski, J. S., 5746
 Skinner, D. G., 44, 7081
 Skinner, M. A., 2303
 Skinner, S. A., 2411
 Skipper, P. L., 181, 3002, 4611
 Skubitz, A. P. N., 7612
 Slade, L., 5931
 Sladek, N. E., 4991
 Slaga, T. J., 2505, 4441
 Slamon, D. J., 3947, 4446, 7950
 Slapak, C. A., 7895
 Slater, R. M., 3279
 Slater, T. F., 6663
 Slavc, I., 1459
 Sleeper, A. M., 1011s
 Slingluff, C. L., Jr., 492
- Sloane, B. F., 6278
 Slørdal, L., 4216
 Slyuser, M., 451
 Sly, W. S., 48
 Smart, R. C., 5740
 Smardon, M. J., 1613
 Smiley, S., 677
 Smit, J. J. M., 1779
 Smith, A., 980s
 Smith, D. F., 5049
 Smith, D. M., 3146
 Smith, G. J., 164, 3383
 Smith, H. S., 2943
 Smith, I. E., 2511
 Smith, J. W., II, 2979, 7343
 Smith, L., 3383
 Smith, M. T., 393
 Smith, P. A., 5049
 Smith, P. J., 5813
 Smith, R. A., 3005
 Smith, T., 5911
 Smith, T. J., 6817
 Smith, V., 1800
 Smithgall, T. E., 2022
 Smulson, M. E., 38, 5406
 Snock, K. V., 2172
 Snow, S., 2979
 Snyder, J. S., 3154
 Snyder, S. W., 4044, 4322
 Snyderman, C. H., 3113
 Sobel, M. E., 4121
 Sobol, M. M., 5095
 Sobue, T., 444
 Söderhäll, S., 7781
 Soffer, D., 4787
 Solheim, E., 5851
 Soloway, A. H., 1061
 Solvason, H. B., 4295
 Somerville, R. L., 5658s
 Sommers, C. L., 67
 Sondel, P. M., 2683, 5234
 Song, C. W., 7108
 Song, R., 197
 Sonobe, H., 7680
 Sonoda, T., 2316
 Soong, S.-j., 197, 4295
 Soper, J. T., 4087
 Soprano, D., 3193
 Soprano, K. J., 3193
 Sørensen, B. S., 3311
 Sorenson, G. D., 5312
 Soreq, H., 1983
 Sosman, J. A., 2683
 Sosula, L., 3078
 Soued, M., 4233
 Souhami, R. L., 1936, 4067
 Soukup, S., 2786
 Soule, H. D., 6075, 6087
 Souliotis, V. L., 2759
 Souteyrand, P., 6620
 Southby, J., 7710
 Spang-Thomsen, M., 4880, 5312
 Sparnins, V. L., 2064
 Spencer, S. R., 7871
 Spicer, J. A., 7799
 Spindler, C. D., 5269
 Spit, B. J., 700
 Spitalny, G. L., 6600, 7750
 Spitzer, G., 5801
 Spona, J., 7057
 Sprague, W. S., 521
 Spratt, T. E., 5453
 Spriggs, D. R., 7101
 Sproll, M., 2177
- Squadrelli-Saraceno, M., 5551
 Squire, R. A., 6668
 Sreekanthaiah, C., 7902
 Srkalovic, G., 1841, 3716
 Staal, G. E. J., 4604
 Stacchini, A., 5065
 Stahel, R. A., 980s
 Stallcup, W. B., 1403
 Stamp, D., 6955
 Stamp, G. W. H., 4436
 Stanbridge, E. J., 2840
 Stanek, J., 1929
 Stanley, E. R., 2049
 Stanley, J., 1176
 Starling, J. J., 7634
 Staroselsky, A. N., 7775
 Starr, R. J., 1022s
 Stathopoulos, E., 1650
 St. Clair, W. H., 580
 Steele, G. D., Jr., 2518, 3888, 6291
 Steele, J. G., 3383
 Steele, V. E., 2068
 Stein, C., 6565
 Stein, C. A., 5488
 Stein, D. E., 6976
 Stein, G. S., 1183
 Stein, H., 84
 Stein, R., 866s, 869s, 1330
 Stein, R. C., 1381
 Steinberg, G. D., 6668
 Steinberg, S. M., 2256
 Steis, R. G., 185, 2979, 7343
 Stellato, T. A., 1911
 Stemericick, D., 5460
 Stemhagen, A., 6520
 Stemmermann, G. N., 627, 7084, 7499
 Stenman, U.-H., 2375
 Stephen, R. L., 4704
 Stephens, J. K., 6344
 Stephens, R., 6405
 Stephenson, C., 1532
 Steplewski, Z., 993s, 1051s, 4546
 Stettler-Stevenson, W. G., 4121, 5431, 6184
 Stevens, S., 7272
 Stevens, V. L., 222
 Stevens, Y.-W., 1151
 Stevenson, H. C., 185, 7343
 Stewart, B. W., 3078
 Stewart, C. F., 6854
 Stewart, J. A., 6302
 Stewart, J. S. W., 563
 Stewart, M., 7343
 Stewart, R. M., 6757
 Stickney, D. R., 3124
 Stillwagon, G. B., 1011s
 Stirpe, F., 4291
 Stoehr, M., 1031s
 Stockhammer, G., 1576
 Stöhr, M., 403
 Stoler, M. H., 3709
 Stolley, P. D., 3657
 Stolwijk, J. A. M., 4003
 Stoner, G. D., 1591
 Storer, B., 4588
 Storer, R. D., 5245
 Storkson, J., 1097
 Storm, F. K., 459
 Stoter, G., 955s
 Stout, D. L., 2337
 Stovroff, M. C., 5072
- Straka, E. J., 544
 Strand, M., 962s, 4221
 Strandstrom, H. V., 5628s
 Stratford, I. J., 4692
 Strauss, A. W., 3956
 Strauss, B. P., 1709
 Strauss, B. S., 2853
 Strauss, P. G., 4146
 Straw, J. A., 1786
 Straw, R. C., 6176
 Streeter, A. J., 1144
 Strickler, J. G., 4984
 Strnad, J., 7632
 Strobl, J. S., 5399
 Strohmeyer, T., 4504
 Stromberg, P. C., 5687s
 Strong, L. C., 7979
 Stroud, M. R., 1375
 Stroup, G. B., 6787
 Sturm, S. A., 4146
 Subasinghe, C., 6565
 Subiza, J. L., 7301
 Sudilovsky, O., 7569
 Suedhoff, T., 7830
 Sueyoshi, N., 3119
 Sufrin, J. R., 3838
 Sugamura, K., 2683
 Suganuma, M., 3521, 4974
 Sugarbaker, E. V., 4453
 Sugarbaker, P. H., 5790
 Sugimachi, K., 2113, 3952, 7077, 7212
 Sugimoto, Y., 4698, 5919, 6657, 6925, 7962
 Sugimura, H., 1857
 Sugimura, K., 345
 Sugimura, T., 3521, 4974
 Suginoshita, T., 4630
 Sugita, K., 7826
 Sugiura, K., 2582
 Sugiyama, K., 509
 Suguri, H., 4974
 Sullivan, A. S., 4277
 Sumi, Y., 400
 Sumiyoshi, H., 5084
 Summerhayes, I. C., 2518
 Sun, C., 2123
 Sun, T. T. H., 4546
 Sunderland, M., 4267
 Sundstrom, S. A., 3306
 Sung, C., 7382
 Sunkara, P. S., 4510
 Supakar, P. C., 6865
 Surbone, A., 1220
 Suresh, M. R., 4801
 Surfus, J., 5234
 Sussenbach, J. S., 6689
 Sutherland, D. R., 5003
 Sutherland, R. L., 4849
 Sutherland, R. M., 1681
 Suzaki, A., 3257
 Suzuki, C., 2885
 Suzuki, F., 3897, 4032
 Suzuki, F., 4131
 Suzuki, K., 760
 Suzuki, K., 6995
 Suzuki, K.-i., 310
 Suzuki, N., 4979
 Suzuki, T., 444
 Suzuki, T., 7585
 Suzuki, Y., 1361, 1368
 Svensen, R., 4533
 Swain, S., 2943
 Swanson, N. A., 941s

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Swayne, L. C., 909s
 Sweetman, B. J., 1879
 Swisselton, K., 7351
 Szabados, E., 7793
 Szczyluk, C., 7371
 Szende, B., 3716
 Sznoł, M., 2979, 7343
- T
 Tada, M., 1121
 Tadano-Aritomi, K., 2917
 Taetle, R., 6295
 Tagliafico, E., 1988, 5825
 Taguchi, T., 2290
 Tahara, E., 8002
 Tainsky, M. A., 7979
 Tait, L., 6087
 Takada, Y., 7003
 Takagi, K., 6222
 Takahashi, J., 596
 Takahashi, M., 4277
 Takahashi, N., 7601
 Takahashi, T., 4698
 Takai, Y., 7242
 Takaishi, K., 3270
 Takaki, S.-i., 3119
 Takaku, F., 5102
 Takaku, H., 4522
 Takakura, Y., 1640
 Takamatsu, M., 1284
 Takano, H., 3043, 5819
 Takaoka, K., 7601
 Takatani, O., 3172
 Takatsuki, F., 2885
 Takeichi, N., 358
 Takeichi, N., 7660
 Takesue, B. Y., 7641
 Taki, T., 1284
 Takigawa, M., 4131
 Takuwa, N., 240
 Takuwa, Y., 240
 Talalay, P., 7871
 Talamini, R., 6502
 Talaska, G., 3002
 Talavera, F., 3019
 Talpaz, M., 5801
 Tamai, K., 5515
 Tamura, R. N., 142
 Tamura, S., 3270
 Tan, C., 5904
 Tan, M-T., 5269
 Tanabe, S., 2423
 Tanaka, A., 2316, 6179
 Tanaka, H., 6615
 Tanaka, K., 7166
 Tanaka, M., 5497
 Tanaka, O., 7601
 Tanaka, S., 3172
 Tanaka, T., 1863
 Tanaka, T., 2290, 4528
 Tanaka, T., 7242
 Tanaka, Y., 2290, 4528
 Tanaka, Y., 4344
 Tandon, A. K., 3317, 4332
 Taneda, M., 2641
 Tang, X-L., 89
 Tani, K., 5102
 Tanigami, A., 7184
 Taniguchi, H., 2095, 4931, 5308
 Taniguchi, N., 2538, 5345
 Tanimoto, M., 7198
 Tanizawa, O., 488, 6139
 Tannenbaum, S. R., 181, 3002,
 4611, 4731, 4737
 Tapiero, H., 4698
 Tarassoff, P., 6823
 Tarbell, N. J., 6455, 6461
 Tardif, M., 432
 Tarkington, M. A., 1966
 Tarone, R. E., 3186
 Tarui, S., 3270, 5345
 Tasaka, F., 6192
 Tassi, C., 4291
 Tassinari, M. S., 6455, 6461
 Tateishi, M., 7077
 Tateishi, R., 444
 Tatro, J. B., 1237
 Tatsuta, M., 2095, 4931, 5308
 Taub, J. V., 5658s
 Taub, R. N., 5003
 Tayek, J. A., 2119, 2765
 Taylor, A. H., 7882
 Taylor, B. J., 202
 Taylor, C. R., 1650
 Taylor, D. D., 7997
 Taylor, G. A., 5212
 Taylor, J. D., 7684
 Taylor, J. E., 2646, 4360
 Taylor, K., 5801
 Taylor, P. R., 174, 2152, 2311
 Tazawa, A., 3226
 Tazzari, P. L., 84, 4291
 Tchabo, J-G., 4670
 Teale, J. D., 2511
 Tecce, R., 7420
 Teh, J. G., 5225
 Teh, S. J., 5504
 Teicher, B. A., 2734, 3339,
 3826, 5055, 6971
 Temple, C. G., Jr., 3239
 Templeton, M. A., 7488
 Templeton, N. S., 5431
 Templin, J., 5275
 Temponi, M., 1271
 Tennant, B. C., 7843
 Tennant, R. W., 2857
 Tepper, M., 7750
 Teppo, A.-M., 592
 Terakawa, N., 6139
 Teramura, Y., 6199
 Terheggen, P. M. A. B., 3556
 ter Riet, P. M., 6515
 Terry, V. H., 993s
 Tersmette, A. C., 6486
 Tersmette, K. W. F., 6486
 Terzakis, J. A., 3627
 Testa, U., 5795
 Teuchmann, S., 426
 Tew, K. D., 3562
 Thacher, S. M., 120, 2505
 Theilen, G. H., 5628s
 Theon, A. P., 2385
 Thiele, C. J., 6055
 Thielmann, H. W., 6894
 Thierry, A., 5898
 Thiery, J. P., 129
 Thomas, E. D., 1017s
 Thomas, G. A., 5784
 Thomas, M., 1195
 Thomas, P. E., 6817
 Thomas, R. V., 1220
 Thompson, D., 5735
 Thompson, E. B., 1337, 1873
 Thompson, J. A., 1160
 Thompson, J. A., 2397, 6534
 Thompson, J. S., 5668s
 Thompson, M. G., 3327
 Thompson, N. L., 4755
 Thomsen, L. L., 6966
 Thor, A., 1291
 Thorgeirsson, S. S., 1521, 3439,
 3600, 7458, 7466
 Thorgeirsson, U. P., 5997
 Thorpe, P., 84, 2929
 Thorsen, T., 7806
 Thrall, D. E., 2075
 Thraves, P. J., 38, 5653s
 Thurlow, S. M., 5682s
 Thurneyssen, O., 5558
 Thurnham, D. I., 2268
 Tilgen, W., 7666
 Till, G. K., 4539
 Tilley, W. D., 5382
 Timmermann-Trosiener, I., 5127
 Timms, R. M., 4154
 Tisdale, M. J., 5022
 Titani, K., 1075
 Titus, J. A., 4227
 Tjandra, J. J., 89
 Tjuljandin, S. A., 5095
 To, M., 2275
 Tobe, T., 6199, 7601
 Tobias, V., 3078
 Toda, K-I., 5526
 Todd, G. C., 4417
 Toftgård, R., 1626
 Toguchida, J., 7950
 Tohda, S., 7585
 Tökés, Z. A., 1231
 Tokiwa, T., 6615
 Tokugawa, Y., 488
 Tokumo, K., 2562, 5761
 Tokura, S., 3631
 Tom, C., 5931
 Tomatis, L., 2156
 Tombes, M. B., 2667
 Tominaga, S., 6559
 Tomita, M., 3952
 Tomiyama, J., 7585
 Tomiyama, Y., 5345
 Tommasi, S., 2958
 Tompkins, C., 5520
 Tondini, C., 1170
 Toner, G. C., 5904
 Tonomura, A., 7166
 Torelli, G., 1988, 5825
 Torelli, U., 1988, 5825
 Torloni, H., 1479
 Torney, L., 5184
 Torok-Storb, B., 5992
 Toscano, W. A., Jr., 1585
 Towatari, M., 7198, 7701, 7955
 Townsend, C. M., Jr., 3614,
 6772
 Townsend, L. B., 4891
 Toyama, K., 7680
 Toyokuni, S., 5574
 Toyoshima, K., 7085
 Trask, D., 7351
 Travis, E. L., 2139
 Travis, W. D., 2463, 3503, 5543
 Trayner, I. D., 7221
 Treisman, J., 1160
 Trentesaux, C., 1231
 Trentin, L., 1768
 Trepel, J. B., 2773, 5257
 Trépo, C., 2156
 Treuner, J., 2177
 Triche, T. J., 5488
 Trickett, A., 3078
 Tridente, G., 1385
 Trinidad, A., 7942
 Triozzi, P. L., 6483
 Tritton, T. R., 2203
 Trivedi, D., 2713
 Troll, W., 7562
 Trott, P. A., 2511
 Trotta, P. P., 6264
 Trouillas, J., 4081
 Trowbridge, I. S., 6295
 Trujillo, J. M., 3218
 Trujillo, Y. P., 6023
 Trump, B. F., 1857
 Trump, D. L., 2667
 Trushin, N., 4685
 Tsai, C. C., 152
 Tsai, D., 909s
 Tsai, Y. C., 44, 7081
 Tsao, M-S., 1941
 Tsay, C., 7950
 Tschada, R. K., 3670
 Tsichlis, P. N., 6478
 Tsuchiyama, H., 2481
 Tsuji, Y., 4941
 Tsujimoto, Y., 4856
 Tsujino, T., 8002
 Tsujioka, K., 5526
 Tsukahara, S., 6925, 7962
 Tsukamoto, A., 3101
 Tsunamoto, K., 4411
 Tsuruo, T., 3167, 6657, 6925,
 7962
 Tsuruo, T., 4291
 Tsushima, T., 103, 4915
 Tsuyuoka, K., 5497
 Tubbs, R. R., 1176, 2363
 Tucker, G. C., 129
 Tucker, J. D., 4951
 Tukey, R. H., 3367
 Tura, S., 4291
 Turc-Carel, C., 7902
 Turner, D. R., 4584
 Turner, J., 6023
 Turner, J. N., 7494
 Turner-Smith, L. M., 1216
 Turusov, V., 2156
 Tutsch, K. D., 2667
 Tuttle, R. L., 3663, 7494
 Tutton, P. J. M., 2411, 4718
 Tye, L., 499
 Tymms, M. J., 4718
 Tytgat, G. N. J., 6486
 Tzeng, J-J., 4338
 Tzung, S-p., 1834
 U
 Uchida, S., 7003
 Uchimura, S., 3897
 Uchino, R., 8010
 Udagawa, T., 2290
 Udagawa, Y., 754
 Ueffing, M., 677
 Uehara, H., 2095, 5308
 Ueland, P. M., 5851
 Uemura, M., 754
 Uemura, S., 3119
 Uemura, Y., 621
 Ueo, H., 2113, 7212
 Uhlund, W., 4935
 Ulchaker, J., 1176
 Ullrich, A., 1550
 Ultee, M. E., 857s, 985s
 Umbreit, J. N., 6095
 Umeda, M., 4522, 7758

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Umenishi, F., 7758
 Upton, A. C., 6765
 Urba, W. J., 185, 2979, 7343
 Uribe, L., 3429
 Urmacher, C., 7488
 Urrea, R., 5925
 Ursule, E., 4382
 Urtasun, R. C., 278
 Ushio, Y., 3119
 Uskokovic, M. R., 1183, 6857
 Usuba, O., 6034
 Usuda, N., 5515
 Utaaker, E., 7806
 Utsgui, T., 2636
 Utsumi, H., 2577
 Utsumi, S., 2708
 Utsunomiya, J., 7166
 Uveges, A. J., 6423
 UWagawa, S., 4195
- V
 Vagg, R., 828s
 Vaickus, L., 2991
 Vaira, A. M., 5065
 Valdayo, M. J., 4227
 Valdez, B. C., 2704
 Valdivieso, M., 5876
 Vale, M. G. P., 2753
 Valleria, D. A., 3249
 Valteau-Couanet, D., 6203
 Valtieri, M., 7371
 Valverius, E. M., 2105
 van Beek, M. E. A. B., 370
 Van Beneden, R. J., 5671s
 van Berkel, T. J. C., 7474
 van Berlo, R. J., 3416
 Vance, E., 3284
 Van den Abeele, A. D., 2198, 5199
 Vandebroucke, J. P., 6486
 van den Eijnden, D. H., 5003
 van der Blieck, A. M., 1779
 van der Burg, B., 7770
 VanderElst, I., 1867
 van der Heijden, M. C. M., 4604
 Vanderheyden, J.-L., 7973
 VanDerMeid, K. R., 7236
 van der Valk, M. A., 7031
 van der Velde-Koerts, T., 1779
 van der Velde-Visser, S. D., 7887
 van der Vijgh, W. J. F., 4644
 van Deurs, B., 1257
 Van De Water, L., 1774
 van Dijk-Knijnenburg, H. C. M., 7887
 Van Doornewaard, G., 5143
 van Groenigen, M., 5392
 van Groenigen, C. J., 4644
 van Haelst-Pisani, C., 3905
 van Helden, P. D., 4911
 van Heugten, H. G., 4020
 van Houwelingen, H. C., 4626
 van Koetsveld, P. M., 6238
 van Leeuwen, R. T. J., 1488
 Van Lier, S. F., 6585
 Van Meir, E., 6683
 van Nagell, J. R., Jr., 7799
 Van Noorden, C. J. F., 5112
 van Oosterom, A. T., 7887
 Van Pelt, C. S., 515
 van Putten, W. L. J., 3832
 van Selm-Miltenburg, A. J. P., 7770
- Van Unnik, J. A. M., 6689
 Van Veld, P. A., 5978
 Van Wyk, J. J., 2511
 van Zoelen, E. J. J., 7770
 van Zwieten, M. J., 5245
 Varani, J., 4957
 Varga, D., 2823
 Varma, M., 1470
 Varma, R. S., 1470
 Varnes, M. E., 1620
 Vasallo, A., 426
 Vasquez, K. M., 2625
 Vassal, G., 6203
 Vassos, A. B., 1022s
 Vatten, L. J., 2341
 Vaughan, L. A., 3921
 Vaughan, M., 1929
 Vaupel, P., 15
 Vawter, G. F., 1459
 Vaysse, N., 5829
 Vazquez-Padua, M. A., 4962
 Vedder, D. M., 1092
 Vegeto, E., 5291
 Veitch, B. A. J., 4718
 Velez de la Calle, J. F., 1308
 Venturelli, D., 7371
 Venturo, I., 6107
 Venzon, D., 3928
 Verdonck, L. F., 4020
 Vergidis, R., 1538
 Verheijen, J. H., 1488
 Verity, M. A., 722
 Verma, A. K., 2239
 Vermeulen, N. P. E., 7031
 Vermeulen, W., 1905
 Veronesi, M. E., 3367
 Verspaget, H. W., 1488
 Vertosick, F. T., Jr., 7134
 Verweij, J., 955s
 Vescio, R. A., 6095
 Veyre, A., 5898
 Viallet, J., 5257
 Victor, T., 4911
 Victora, C. G., 426, 7112
 Vieira, W., 5658s
 Vielh, P., 1608
 Vignaux, F., 3533
 Vigneri, R., 7858
 Vile, G. F., 2307
 Villalba, J. M., 5887
 Vindeløv, L., 3311
 Vineis, P., 3002
 Viñuela, J. E., 7301
 Vio, A., 7811
 Visani, G., 4291
 Vishwanatha, J. K., 7754
 Vogel, S. M., 4209
 Vogelbein, W. K., 5978
 Vogelstein, B., 2347, 7715, 7902, 8017
 Vogler, W. R., 3025
 Vollmer, R., 2303
 Vollmers, H. P., 5192
 Volpe, D. A., 4038
 Volpi, A., 2943
 Vonderhaar, B. K., 2234
 von Eschenbach, A. C., 5263
 Von Hoff, D. D., 6264, 7496
 von Kleist, S., 6534
 von Knebel Doeberitz, M., 3730
 von Wronski, M., 58
 Voss, S. D., 2683
 Vredenburgh, J. J., 7216
 Vuist, W. M. J., 5767
- W
 Waber, D. P., 6461
 Wacholder, S., 6836
 Wachter, H., 2863
 Wada, Y., 345
 Wadler, S., 2056, 3473, 5735
 Waggoner, S., 3709
 Wagner, T. E., 1701
 Wahl, R. L., 804s, 941s
 Wahrendorf, J., 2268
 Waibel, R., 980s
 Wainer, I. W., 252, 3493, 3940
 Wainscoat, J. S., 1355
 Wakamiy, N., 6915
 Waldburger, K., 7364
 Waldmann, T. A., 1495
 Waldren, C. A., 2356
 Walenta, S., 1681
 Wali, R. K., 3915
 Walker, C., 740
 Walker, K. A., 1000s
 Walker, K. J., 3545
 Walker, L. E., 4154, 4656
 Walker, M. C., 7511
 Walker, W. W., 5675s
 Walkup, G., 5925
 Walloch, J., 6023
 Walport, M., 563
 Walser, V., 4160
 Walsh, T. D., 1151
 Walton, M. I., 4692
 Wands, J. R., 6291
 Wanek, P. M., 974s, 1008s
 Wang, C.-H., 5649s
 Wang, C.-J., 5470
 Wang, C. Y., 2868
 Wang, D.-Q., 6915
 Wang, J. H., 7571
 Wang, L. D., 2651
 Wang, M.-Y., 2146, 6192
 Wang, P., 7527
 Wang, T., 927s
 Wang, Y., 227
 Wang, Y., 1591
 Wang, Z. F., 869s
 Wang-Wuu, S., 2786
 Ward, D., 6708
 Ward, J. A., 568
 Ward, P. L., 3851
 Ward, T. H., 2003
 Ware, J., 6358
 Wargin, W., 7494
 Wargovich, M. J., 2505, 5084
 Warman, B., 1701
 Warner, T. F., 7203
 Warrell, R. P., Jr., 1151
 Warren, D. J., 4216
 Warren, S. D., 783s
 Waser, B., 5969
 Washburn, L. C., 4546
 Waskerwitz, M., 3212
 Wassermann, K., 1732
 Wasson, J. C., 2987
 Watanabe, H., 409
 Watanabe, H., 7660
 Watanabe, K., 4344
 Watanabe, M., 760
 Watanabe, M., 3245
 Watanabe, M., 5515
 Watanabe, M., 6657
 Watanabe, N., 4941
 Watanabe, P. G., 4014
 Watanabe, T., 4630
- Watatani, K., 4139
 Watkins, P. J., 3663
 Watson, D. M., 5095
 Watson, G., 227
 Watson, J. M., 6959
 Wattenberg, L. W., 2064
 Waud, W. R., 3239
 Wawrzynszak, E. J., 7519
 Waxman, D. J., 464, 5720, 6449
 Waxman, S., 3453, 3878
 Webber, B. L., 2781
 Webster, W. B., 932s
 Wedrychowski, A., 1183
 Weernink, P. A. O., 4604
 Wehr, C. M., 5049
 Wehrle, J. P., 4709
 Wei, H., 499
 Wei, L. L., 6208
 Weick, J., 7206
 Weidner, U., 4504
 Weilbach, F. X., 6981
 Weil-Hillman, G., 2683
 Weinberg, K. I., 587
 Weinberg, V., 5735
 Weiner, D. B., 421, 5184
 Weiner, L. M., 7123
 Weinstein, I. B., 677, 1675, 3595, 5374
 Weinstein, W. M., 3627
 Weintraub, B., 3614
 Weir, B., 278
 Weisberg, T. F., 6641
 Weisenburger, D. D., 4845
 Weiss, D., 7042
 Weiss, G. R., 7494
 Weiss, M. C., 97
 Weiss, N. S., 1886, 4702
 Weith, A., 7232
 Wells, C. K., 4664
 Wells, R. J., 4464
 Wells, S. A., Jr., 6529
 Welt, S., 862s, 877s
 Wen, P. Y. C., 5199
 Wenzel, A., 4411
 Werbel, L. M., 4900
 Werner, E. R., 2863
 Werner, T., 5636s
 Werner-Felmayer, G., 2863
 Wersto, R., 5735
 Wessels, B. W., 970s, 974s
 West, C. R., 4401
 Westendorf, J., 6540
 Westera, G., 980s
 Westerhof, G. R., 7542
 Westerveld, A., 3279
 Weston, A., 1857, 6580
 Wetherall, N. T., 5943
 Wetzel, M., 5801
 Whang-Peng, J., 5649s
 Wharam, M. D., 974s
 Wharton, J. T., 2724
 Wheelock, E. F., 1361, 1368
 Wheldon, T. E., 1000s
 Whitacre, C. M., 7571
 Whitaker, R., 4087
 White, C. M., 3772
 White, D. L., 7376
 White, L., 3078
 White, R., 5784, 7166
 White, S., 6295
 Whitehead, R. H., 5225
 Whitehead, R. P., 6708
 Whitesell, L., 6316
 Whiteside, T. L., 3113, 3681

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- Whitfield, L. R., 2692
 Whitman, M. M., 3193
 Whitsett, J. A., 5481
 Wiegandt, H., 7442
 Wieman, T. J., 2599
 Wiemann, M., 3087
 Wiencke, J. K., 1585
 Wierenga, W., 1071
 Wiernik, P. H., 2049, 2056
 Wiessler, M., 5464
 Wietharn, B. E., 4322
 Wilander, E., 3413
 Wilcox, H. B., 6520
 Wilczak, C. A., 7871
 Wild, C. P., 245, 2156, 5426
 Wilding, G., 67
 Wildrick, D. M., 2724
 Wilkinson, B. P., 2068
 Wilkinson, G., 3295
 Willemse, R., 6515
 Williams, A. C., 4724
 Williams, B., 4199
 Williams, C. J., 927s
 Williams, J. A., 974s
 Williams, L. E., 922s, 1029s
 Williams, L. G., 3493, 3940
 Williams, M. G., 5475
 Williams, R. D., 2499
 Williams, T. E., 4464
 Williams, W. V., 421
 Williams, Z., 44
 Williamson, D. S., 3005
 Williamson, P., 4626
 Willmore, E., 1992
 Willson, J. K. V., 2667
 Willson, J. K. V., 7715
 Wilmer, J. L., 4635
 Wilson, B. S., 941s
 Wilson, B. S., 3124
 Wilson, C. M., 5382
 Wilson, D. M., 5587
 Wilson, D. W., 2493, 4918
 Wilson, E. M., 735
 Wilson, J. M., 72
 Wilson, V. L., 6580
 Wiltrot, R. H., 1742, 5414,
 6379, 7926
 Wiltrot, T. A., 5414
 Winawer, S., 261, 2245
 Winblad, G., 3141
 Wingard, D. L., 169
 Winget, M., 1550
 Wingfield, P., 6285
 Winkelhake, J. L., 7376
 Winkler, D. F., 4227
 Winslow, M. S., 1580
 Winterbourne, C. C., 2307
 Winton, D. J., 7992
 Winton, E. F., 222
 Wirth, P. J., 7466
 Wishnok, J. S., 4611
 Withrow, S. J., 54, 6176
 Witschi, H.-P., 1960
 Witt, B. C., 318
 Witt, P. L., 4588, 6248
 Witteveen, E. O., 4020
 Wittliff, J. L., 1841
 Woda, B. A., 72
 Woessner, R. D., 2901
 Wolburg, H., 2177
 Wolf, C. R., 7789
 Wolf, J., 3095
 Wölfe, D., 6540
 Woll, P. J., 3968
- Wolman, S. R., 6075
 Woloschak, G. E., 339, 3963,
 5045
 Wong, A. H. C., 2476
 Wong, A. J., 8017
 Wong, D. T. W., 5107
 Wong, G., 7488
 Wong, J. H., 459
 Wong, J. M., 3888
 Wong, J. Y. C., 1029s
 Wong, S., 5365
 Wong, V., 3585
 Wong, Y. C., 4747
 Wong, Y.-H. H., 4650
 Wood, P. K., 3627
 Wood, W. M., 6208
 Wood, W. R., 4121
 Woodcock, D. M., 4199
 Woodrow, G. C., 4676
 Woods, W. G., 7129
 Woodworth, C. D., 3709
 Wooldridge, L., 4845
 Wooldridge, T. N., 4845
 Workman, P., 2203, 4692
 Worland, P. J., 7458
 Worley, J. F., III, 5399
 Worlock, A. J., 7246
 Worrell, N. R., 7517
 Wotring, L. L., 4891
 Wozniak, A. J., 4900
 Wright, C., 7179
 Wright, D. H., 3131
 Wright, J. A., 4061
 Wright, M. A., 2973
 Wu, B., 5027
 Wu, J. K., 3032
 Wu, K., 6865
 Wu, S.-H., 4111
 Wu, S.-Q., 4779
 Wunderlich, D., 4872
 Wunderlich, J. R., 4227
 Wu-Williams, A. H., 2569
 Wykle, R. L., 7174
 Wyrick, S., 4539
 Wyrobek, A. J., 4951
 Wysocki, S. J., 1800
- X
- Xia, L., 7695
 Xie, S., 1538
 Xing, P.-X., 89
 Xu, D., 7575
 Xu, D.-D., 5017
 Xu, J., 152
 Xu, Y.-h., 472
 Xuan, X-Z., 174
- Y
- Yadav, M., 3186
 Yager, J. W., 393
 Yagi, K., 7826
 Yaginuma, Y., 2538
 Yagiri, Y., 2698
 Yagita, M., 3331
 Yajima, M., 754
 Yaldae, S., 1151
 Yalowich, J., 4267
 Yamada, H., 2868
 Yamada, K. M., 1601, 4485
 Yamada, N., 1693
 Yamada, S. S., 4485
 Yamada, Y., 5574
 Yamada, Y., 6171
- Yamadori, I., 1324, 5567
 Yamaguchi, A., 509
 Yamaguchi, K., 3257
 Yamaguchi, N., 658, 7008
 Yamaguchi, Y., 7358
 Yamakawa, H., 7358
 Yamakawa, K., 7184
 Yamamori, S., 6171
 Yamamoto, K., 1284
 Yamamoto, M., 2418
 Yamamoto, N., 5287
 Yamamura, M., 2418
 Yamamura, Y., 7008
 Yamamuro, T., 7950
 Yamanaka, A., 7166
 Yamane, M., 4050
 Yamanishi, H., 2316, 6179
 Yamasaki, S., 6199
 Yamasaki, T., 596, 2429
 Yamashita, J., 4522
 Yamashita, K., 240
 Yamashita, T., 3182
 Yamashita, T., 6243
 Yamashita, U., 4344
 Yamashita, Y., 5841
 Yamashita, Y., 7585
 Yamauchi, D., 922s
 Yamauchi, N., 4941
 Yamauchi, T., 2708
 Yanagawa, T., 6396, 7852
 Yanai, N., 7501
 Yang, C. S., 1144, 2651, 6817
 Yang, D., 5587
 Yang, G. R., 2651
 Yang, L-Y., 3218
 Yang, S. C., 3526
 Yang, S. S., 5658s
 Yannelli, J., 1686
 Yano, B. L., 4014
 Yano, K., 2113
 Yano, S., 1847, 2099
 Yao, A., 5171
 Yao, S.-X., 174
 Yarosh, D. B., 7908
 Yasui, H., 3533
 Yasui, T., 6179
 Yasui, W., 8002
 Yasukawa, K., 3863
 Yasumitsu, H., 7758
 Yasumoto, S., 3521
 Yasumuzu, R., 2582
 Yasutomo, Y., 3172
 Ye, J. N., 7697
 Yee, D., 48
 Yeger, H., 2794
 Yelton, D. E., 2449
 Yen, A., 1411
 Yeoh, G. C. T., 7593
 Yi, X.-Y., 7610
 Yim, S. O., 7979
 Yin, S., 4087
 Yokokura, T., 1715, 1721
 Yokota, S., 32
 Yokoyama, K., 6222
 Yokoyama, M., 1693
 Yonemura, Y., 509
 Yonezawa, T., 5345
 Yoo, J. H., 5653s
 Yoshida, H., 6396, 7648, 7852
 Yoshida, J., 7826
 Yoshida, K., 480
 Yoshida, K., 862s, 877s
 Yoshida, K., 8002
 Yoshida, M. C., 3345
- Yoshii, Y., 6559
 Yoshimura, A., 3055
 Yoshioka, H., 4139
 Yoshizawa, S., 3521, 4974
 You, M., 1591
 Youle, R. J., 7382
 Young, C. L., 252
 Young, C. W., 1151
 Young, D., 503
 Young, D. C., 6483
 Young, G., 4349
 Young, H. A., 1742
 Young, M. E., 2973
 Young, M. R. I., 2973
 Young, R. C., 2256
 Young, S. D., 5031
 Youngkin, T., 6095
 Youngleib, G. L., 6162
 Yousefi, S., 1867
 Yow, H., 3888
 Yu, A., 10
 Yu, B., 7458
 Yu, H., 7623
 Yu, L., 1538
 Yu, M. C., 2569
 Yu, R. K., 1403
 Yu, S-Z., 5017
 Yu, Y. H., 3231
 Yuan, L. A., 5049
 Yum, K. Y., 2088
 Yum, S., 6565
 Yun, J., 1701
 Yung, B. Y.-M., 5987
 Yura, Y., 6396, 7852
 Yuspa, S. H., 653, 2256, 4794
- Z
- Zabrenetzky, V. S., 5937
 Zacharewski, T., 3579
 Zagzag, D., 7393
 Zajchowski, D., 7351
 Zakut, H., 1983
 Zalcberg, J. R., 2953
 Zalutsky, M. R., 1803, 1822,
 3514, 4105, 7246
 Zambello, R., 1768
 Zamir, R., 1983
 Zang, E., 2562
 Zangara, L. M., 932s
 Zanovello, P., 5703s
 Zarama, G., 4731, 4737
 Zardi, L., 4388
 Zavala, D., 4731, 4737
 Zbar, B., 2543
 Zeilstra-Ryalls, J. H., 5658s
 Zeimet, A. G., 7037
 Zeltzer, P., 2987
 Zengel, A. E., 6455
 Zenser, T. V., 4650
 Zetterberg, A., 4281, 7307
 Zhang, K., 5658s
 Zhang, L., 669
 Zhang, N., 3036
 Zhang, R., 4286
 Zhang, R. D., 717
 Zhang, W.-W., 5858
 Zhang, X.-Y., 6865
 Zhang, Y., 2191
 Zhao, Q., 7610
 Zhao, X.-X., 5328
 Zheng, B., 3025
 Zheng, Z.-S., 1201
 Zhong, Q., 7579

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

AUTHOR INDEX

- | | | | |
|------------------------|----------------------------|--------------------------------|------------------------------|
| Zhong, Z., 7564 | Zijl, R., 1924 | Zipf, T. F., 7116 | Zukowski, K., 2868 |
| Zhou, D., 6949 | Zijlstra, J. G., 304 | Zivkovic-Gilgenbach, Z., 1484, | Zunino, F., 4501 |
| Zhou, J-Y., 2031, 6857 | Zijno, A., 4248 | 4468 | Zupi, G., 5119, 6107 |
| Zhou-Li, F., 3786 | Zimmerman, D. L., 3540 | Zoli, W., 2943 | zur Hausen, H., 3095, 3730, |
| Ziegler, G. H., 6278 | Zimmerman, T. P., 1817 | Zuber, M., 2587 | 5756 |
| Ziegler, R. G., 2311 | Zimmermann, W., 6534 | Zucker, S., 6995 | Zweibaum, A., 6334 |
| Ziemiecki, A., 6323 | Zinkewich-Péotti, K., 6675 | Zugmaier, G., 552 | Zwelling, L. A., 1732, 3619, |
| Zier, K., 7820 | Zinn, S., 5834 | Zukiwski, A. A., 904s | 7116 |

* For title of article and coauthors, see listing in Volume Table of Contents beginning on page i at the end of this index issue.

C

Index to Volume 50

Subject Index

- A**
- Abelson virus**
-infected murine pre-B-cells
multistage progression, tumorigenic state, 1917
- Abrin A chain**
pharmacokinetics of immunotoxins, 7519
- Accessory cells**
Lyt-2⁺ T-cell proliferative response
syngeneic tumor, absence of L3T4⁺ T-cells, 6256
- N-Acetoxy-2-acetylaminofluorene**
oxidative stress-induced DNA damage
inhibited DNA lesion repair, mononuclear leukocytes, 4619
- 2-Acetylaminofluorene**
benzo(a)pyrene and
activation of food-derived heterocyclic amine mutagens, cytochromes P-450, 3367
-mediated alteration
liver arylsulfotransferase IV, hepatocarcinogenesis, 5301
- Acetylation phenotype**
lack of association with breast cancer, 6649
- 9-O-Acetyl GD3**
natural
human melanoma, bovine buttermilk and chemically O-acetylated GD3, 1403
- N-Acetylneuraminosyl(α2-6)lactosamine**
accumulation of gangliosides
hepatoma, 1284
- ACHN cells**
blockage of autonomous growth
anti-renal cell carcinoma monoclonal antibody 5F4, 2968
- α1-Acid glycoprotein**
reversal of multidrug resistance by verapamil
modulation, Chinese hamster ovary cell lines, 2818
- Acticin**
concomitant infusion of amino acid mixture
prevention of central nervous system toxicity, 5475
- Aclarubicin**
antagonistic effect on cytotoxicity
etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidine, small cell lung cancer, 3311
- ACNU**
intrathecal perfusion
neurotoxicity, pharmacokinetics, 3119
- Acquired immunodeficiency syndrome: see AIDS**
- 4'-(9-Acridinylamino)methanesulfon-m-anisidine**
etoposide and
antagonistic effect of aclarubicin, small cell lung cancer, 3311
toxicity
long-term inhibition of DNA synthe-
- sis, trapped topoisomerase II complexes, 5813
- Acrolein**
-modified polydeoxyadenylic acid detection, 1,N⁶-propanodeoxyadenosine, 3005
- phosphoramido mustard-induced sister chromatid exchanges**
human lymphocytes, 4635
- F-Actin**
cellular levels as marker
cellular transformation, cell division, 2215
- α-Actinin**
expression in human hepatocellular carcinoma, 6291
- Actinomycin D**
antineoplastic activity
experimental and human malignancies, 3473
cytotoxicity of lonidamine
RIF-1 and HT1080 cells, 7867
induction of "reversible" translocation protein B23, cell growth inhibition, 5987
- reversal of multidrug resistance
lipophilic drugs, 3997
- Activin A**
hexamethylene bisacetamide and
synergistic action, murine erythroleukemia cells, 3182
- Adenine**
nucleotides
phospholipase C activity, small cell lung carcinoma, 5257
- Adenocarcinoma**
colon 26
cancer cachexia, 2290
liver metastases, slow delivery of IL-2, 7003
- colonic
anticachetic activity, 5'-deoxy-5-fluorouridine, 4528
chemoprevention, piroxicam and D,L-α-difluoromethylornithine, 2562
cytotoxicity, N-(5-indanyl)sulfonyl)-N'-(4-chlorophenyl)urea, 318
dose response to leucovorin, 3940
karyometric marker features, normal-appearing glands, 147
- leucovorin metabolism, 3493
- mitochondrial localization, N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl)urea, 664
- colorectal
properties of ornithine decarboxylase, 2088
- endometrial**
estrogen regulation, placental alkaline phosphatase gene expression, 3306
- gastric
ERBB2 expression, p185^{ERBB2}, 8002
- gastric and esophageal
chromosome 11p13-15 rearrangement, 6410
gene amplification, 6417
- Lewis^x-containing glycoproteins and gly-
- colipids
sera, 1375
- lung**
antitumor activity, L6-ricin immunotoxin, 3249
cigarette smoking, grade of differentiation and subtype, 444
immunohistochemical evidence, autocrine growth factors, 7077
p185^{ERBB2} expression, shortened survival, 5184
- mammary**
active specific immunotherapy, synthetic tumor-associated glycoconjugate, 4308
metastatic renal cell
recombinant interleukin 2, dose escalating regimen, 6723
- muco**
K-ras activation, 6139
- pancreatic**
detection of c-K-ras mutations, fine needle aspirates, 1279
novel ribonucleoprotein complex, monoclonal antibodies, 6015
- parotid gland**
phenotype, treatment with dibutyryl cyclic adenosine 3',5'-monophosphate, 6396
- prostatic, dorsolateral**
characterization, chemical induction, 700
chemical induction, cyproterone acetate and testosterone propionate, 691
- prostatic, Dunning**
androgen receptors, 735
differentiation, male genital tract mesenchymes, 4747
- renal**
ferric nitrilotriacetate-induced lipid peroxidation, sex hormone dependence, 5574
- thyroid**
type II, protein kinase C isozymes, 5515
- uterine**
developmental treatment with estrogens, 7677
- Adenoma**
carcinoma sequence
neoplastic transformation, colonic epithelial cell line, 4724
- genetic changes and histopathological types**
colorectal neoplasms, familial adenomatous polyposis, 7166
- thyroid**
cancer mortality in women, 2283
- Adenosine deaminase**
changes induced by phorbol esters
purine nucleoside phosphorylase, leukemic cell lines, 2891
- Adenosine kinase**
phosphorylation of tiazofurin
Chinese hamster ovary cells, 5269
- Adenosine cyclic 3':5'-monophosphate**

SUBJECT INDEX TO VOLUME 50

- dependent protein kinase
 - control by phorbol ester, 7145
- estrogen receptor mRNA
 - biphasic regulation, Leydig cells, 1528
- independent protein kinase
 - phosphorylation, pyruvate kinase type K, 4604
- modulation of intracellular levels
 - differentiation response, human neuroblastoma cells, 722
- receptor proteins
 - malignancy, new approaches to therapy, 7093
- Adenosine triphosphatase**
 - (sodium plus potassium)-activated inhibition by synthetic phospholipid analogues, 3025
- Adenosine triphosphate**
 - paradoxical metabolism of 6-mercaptopurine WEHI-3B murine leukemia cells, 108
- S-Adenosylhomocysteine**
 - S-adenosylmethionine biosynthesis inhibition of nucleic acid methylation, L1210 cells, 3838
- S-Adenosylmethionine**
 - biosynthesis and S-adenosylhomocysteine metabolism inhibition of nucleic acid methylation, L1210 cells, 3838
- Adhesion**
 - fibrosarcoma cell laminin peptides, 7612
 - molecular pathways spontaneous rosetting of T-cells, Hodgkin's cell line, 3131
 - neural cell adhesion molecule isoforms differential spectrum of expression, neuroectodermal tumors, 6364
 - ras-transformed tumor cells fibronectin proteolytic fragments, 4388
- Adhesion molecule 1**
 - differential expression primary and metastatic melanoma lesions, 1271
- Adjuvant**
 - therapy after surgical castration somatostatin analogue, prostate tumors, 2646
- Adrenal gland**
 - neuropeptide Y expression childhood neuroblastoma tumors, 6055
- Adriamycin**
 - biological monitoring screening, 3351
 - bolus arterial administration disposition, tissue-isolated tumor perfusion system, 1640
 - bound to microspheres induction of erythroid differentiation, K-562 cells, 1231
 - cyclophosphamide and 5-fluorouracil chemotherapy
 - sister chromatid exchanges, breast cancer, 4951
 - exposure of heart microsomes *dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane*, Fe³⁺ reduction, 2307
 - immunoconjugates hydrazone linker, compared to free
- Adriamycin**, 6608
 - synthesis, acid-sensitive hydrazone linker, 6600
- induced potentiation of invasion, 2018
 - interleukin 2 and dacarbazine antitumor efficacy, solid tumor systems, 5876
- micelle-forming polymeric anticancer drug, 1693
- murine tumor cell sensitivity drug presentation, phosphatidylcholine-phosphatidylserine liposomes, 3619
- resistance in MEL cells, 7895
- resistant small cell lung carcinoma reduced DNA topoisomerase II activity, 304
- systemic therapy site-dependent differences in response, fibrosarcoma, 7775
- transfer of resistance by fusion *M*, 170,000 P-glycoprotein, plasma membrane, 2191
- Aflatoxin B₁**
 - albumin adducts methods for quantitation, human exposure assessment, 245
 - carcinogenesis species susceptibility, 615
 - comparative action mammalian airway epithelium, 2493
 - DNA adducts formation and removal, mammalian tracheal epithelium, 4918
 - hepatitis B virus infection and induction of liver tumors, ducks, 2156
 - metabolic activation 2-amino-3-methylimidazo[4,5-f]quinoxoline, human adult and fetal livers, 2641
 - nonassociation with primary liver cancer cross-sectional ecological survey, China, 6882
 - treated DHBV-infected ducks hepatic neoplasms, 4072
- Aging**
 - DNA modifications diet and, rat liver and kidney, 3991
 - 3-methylcholanthrene binding mouse DNA, 4239
 - multistage hepatocarcinogenesis, 472
- Agriculture**
 - pesticide exposure and other risk factors leukemia, men in Iowa and Minnesota, 6585
- Ah genotype**
 - 3-methylcholanthrene binding mouse DNA, 4239
- AIDS**
 - immunopathogenesis of HIV infection, 5612s
- Airway**
 - mammalian epithelium comparative action, aflatoxin B₁, 2493
- Albumin**
 - aflatoxin adducts methods for quantitation, human exposure assessment, 245
- Alcohol**
 - consumption prospective study of stomach cancer, 627
- Allergy**
 - drug medical history and primary liver cancer, 6274
- Aluminum phthalocyanine**
 - cell and tissue distribution
- esophageal cancer in Uruguay**, 426
- precursor lesions of esophageal cancer**
 - young persons in high-risk population, China, 2268
- smoking and**
 - relation to cancers, northern Italy, 6502
- Aldehyde dehydrogenases**
 - importance in aldehydophosphamide detoxification, 4991
- Alkaline phosphatase**
 - asparagine-linked oligosaccharides Kasahara isozyme, FL amnion cells, 1079
 - bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody specific activation, mitomycin phosphate, 6944
- choriocarcinoma**, 3956
- gene expression regulated by estrogen**
 - human endometrial adenocarcinoma, 3306
- isoenzyme expression of hybrid form**
 - new cell line, gastric cancer, 3408
- molecular cloning of cDNAs**
 - human colon cancer cells, 1085
- Alkaloids**
 - Vinca**
 - increased sensitivity, cells overexpressing calmodulin, 6554
- Alkylation agents**
 - bifunctional *c-myc* and *c-fos* expression, 62
 - leukemia following chemotherapy breast cancer, 2741
 - quinone activity in quinone-resistant cells, 2872
 - resistance flow cytometric analysis, DNA damage and repair, 4453
 - role of glutathione S-transferase, modulation chemotherapy, 6449
- O⁶-Alkyguanine-DNA alkyltransferase**
 - chimeric P-enolpyruvate carboxykinase gene transgenic mice, 1701
 - immunoaffinity purification monoclonal antibodies, 58
 - mammalian response to alkylating carcinogenic and therapeutic agents, 6119
- Alkyl-lysophospholipid**
 - inhibition of estradiol uptake transforming growth factor- α secretion, breast cancer, 3172
 - selective killing of malignant cells leukemic patients, 4020
- Alleles**
 - allelotype of human malignant astrocytoma, 5784
 - common loss to subregion osteosarcoma, 2543
 - rare Harvey ras protooncogene locus, lung cancer, 1857
- Allergy**
 - drug medical history and primary liver cancer, 6274
- Aluminum phthalocyanine**
 - cell and tissue distribution

SUBJECT INDEX TO VOLUME 50

- effect of sulfonation, 4533
- Amine precursor uptake system**
mitochondrial glycerol phosphate dehydrogenase
insulinomas, carcinoid tumors, 7203
- Amines**
heterocyclic
metabolism of 2-acetylaminofluorene and benzo(a)pyrene, cytochromes P-450, 3367
- lysosomotropic
inhibition of catabolism, radiolabeled amines, 1243
- Amino acids**
 α -interferon structure
natural killer cell stimulatory activity, 5328
- mixture
acivicin and, prevention of CNS toxicity, 5475
- 3-Aminobenzamide**
6-mercaptopurine cytotoxicity
increased phosphoribosylpyrophosphate levels, Chinese hamster ovary cells, 1992
- 4-Aminobiphenyl**
hemoglobin adduct
withdrawal from smoking, 181
- 2-Amino-9- β -D-ribofuranosylpurine-6-sulfonamide**
chemotherapeutic characterization, 2625
- 4-Aminofolate analogues**
folylpolyglutamyl synthetase
tumors and proliferative intestinal epithelium, 4639
- Aminoglutethimide**
induction
decreased serum concentrations, tamoxifen and metabolites, 5851
- 5-Aminolevulinate synthase**
cytochrome P-450 and
induction of activity, rat hepatocytes, 5219
- 2-Amino-3-methylimidazo[4,5- β]quinoline**
metabolic activation of aflatoxin B₁
human adult and fetal livers, 2641
- mutagenic activation
cDNA-expressed human liver P-450, 2060
- γ -Amino-n-butryric acid**
baclofen and
inhibition of gastric carcinogenesis, 4931
- 7 α -(4'-Amino)phenylthio-1,4-androstadiene-3,17-dione**
aromatase inhibition
carcinoma cell cultures, 3652
- Aminopterin**
analogues
methotrexate and, growth inhibition studies, 1726
- monoclonal antibody conjugates
tumor necrosis factor, antitumor efficacy and toxicity, 6028
- Amnion cells**
sugar chains of alkaline phosphatase, 1079
- Amphotericin B**
lysis of promyelocytic HL-60 cells
combination with 2-chloroethyl-1-nitrosoureas, 3274
- Amplon**
- six-gene
DNA content, multidrug-resistant Chinese hamster cell line, 2803
- Amsacrine**
abrogation of cytotoxicity by novobiocin Chinese hamster cells, 2577
- CI-921 and
pharmacokinetic and toxicity scaling, 2692
- disposition in plasma
liver, Lewis lung tumor, 503
- potentiation of DNA strand breakage and cytotoxicity
tumor necrosis factor, 2636
- Androgen**
ablation
programmed cell death during regression, prostate cancer, 3748
- dependent renal microsomal cytochrome P-450
N-hydroxylation, 3-methoxy-4-aminoazobenzene, 2729
- effects of withdrawal
stem cell composition, Shionogi carcinoma, 2275
- induced autocrine heparin-binding growth factor
fibroblast growth factor receptor, Shionogi carcinoma, 2316
- induced growth inhibition
transforming growth factor- β , Shionogi carcinoma cells, 6179
- insensitive prostate tumors
somatostatin analogue, adjuvant therapy, 2646
- responsive Shionogi carcinoma 115 paracrine growth stimulation, 4979
- Androstenedione**
conversion to estrone
4-hydroxyandrostenedione, postmenopausal women with breast cancer, 193
- prospective population-based study
prostatic cancer, 169
- Anemia**
Fanconi's
mutagenic response, photoactivated bifunctional psoralens, 3289
- removal, psoralen-photoinduced DNA cross-links, 2443
- Angiogenesis**
immunohistochemical localization
basic fibroblast growth factor, astrotoma, 7393
- tumor
 α -difluoromethylornithine effect, 4131
- Animal models**
experimental
radioimmunotherapy, 962s
- murine
interleukin 1 as adjuvant, immunotherapy, 1212
- radioimmunotherapy
current status, 970s
- Anorexia**
elevated protein turnover and cachexia, hepatocellular carcinoma, 1226
- Anthracenedione**
antitumor agents
photosensitization, leukemic cells, 1936
- Anthracycline**
antibiotics
high liposome entrapment, 4260
- decreased uptake
Adriamycin resistance, erythroleukemia cells, 7895
- mechanisms of resistance
human and rat colon cancer cells, 6626
- Anthrapyrrazoles**
piroxanthrone
Phase I study and pharmacodynamics, 3284
- Antibiotics**
streptomycin
induction, mammalian DNA topoisomerase II-dependent DNA cleavage, 5841
- Antibodies**
 ^{212}Bi -labeled
radioimmunotherapy, peritoneal human colon cancer xenografts, 985s
- human anti-mouse
hazard recognition and prevention, monoclonal antibodies, 1049s
- monoclonal antibody treatment, immunoglobulin G subclass analysis, 1051s
- "instant" ^{99m}Tc -labeling kit for imaging preclinical evaluation, 794s
- rabbit and sheep
interstitial transport, normal and neoplastic tissues, 3487
- radiochemically pure development, 780s
- radioiodinated
targeting tumors, 857s
- tumor retention, aryl carbohydrate aducts, 783s
- radiolabeled
cancer targeting, whole-body autoradiography, 885s
- high dose, lymphoma, 1017s
- inhibition of catabolism, lysosomal amines and carboxylic ionophores, 1243
- results and potential, cancer therapy, 1011s
- targeting and therapy, glioma xenografts, 974s
- tissue uptake and metabolism, antigen:antibody complex formation, 840s
- targeted radionuclide therapy
dosimetric model, tumor cells in cerebrospinal fluid, 1043s
- Antibody-dependent cell-mediated cytotoxicity**
augmentation
interleukin 2, 5234
- Anticancer drugs**
changes in resistance
melphalan-induced glutathione content, stomach cancer, 3614
- high- and low-molecular-weight cytotoxic effects, multidrug-resistant Chinese hamster ovary cells, 1571
- disposition after bolus arterial administration
tissue-isolated tumor perfusion system, 1640
- micelle-forming polymeric, 1693

SUBJECT INDEX TO VOLUME 50

- Anticarcinoma agents**
 dequalinium
 inhibition, rodent protein kinase C, 677
- Anticonvulsants**
 barbiturate exposure *in utero* and childhood
 risk, intracranial and spinal cord tumors, 4600
- Antiestrogens**
 development
 use in breast cancer, 4177
 -resistant cell lines
 estrogen receptor characterization, 333
 steroid and nonsteroidal
 tamoxifen-stimulated endometrial carcinoma, 3189
- Antifolate**
 resistance in mammalian cells
 flow cytometric characterization,
 methotrexate and daunorubicin, 4946
- Antigens**
 patterns of distribution
 human carcinomas, 880s
- Antileukemic agents**
 methotrexate and teniposide
 continuous infusion, pediatric cancer patients, 4267
- Antinausea medications**
 gestational and familial risk factors
 childhood astrocytoma, 2608
- Antineoplastic agents**
 biological monitoring screening, 3351
 classification of treatments by differential toxicity
 oxygenated and hypoxic tumor subpopulations, fibrosarcoma, 3339
- interferon and cytotoxic agents
 experimental and human malignancies, 3473
- prolonged serum half-life
 incorporation, low density lipoprotein, 7476
- Antioxidants**
 xenobiotic-metabolizing enzyme gene expression
 doxorubicin-resistant breast cancer cells, 1397
- Anti-Tac-H**
 humanized antibody to interleukin 2 receptor
 immunotherapy, malignant and immune disorders, 1495
- Antitumor activity**
 Adriamycin (hydrazone-linked) immunoconjugates
 compared to free Adriamycin, tumor cell killing, 6608
 gemcitabine, 4417
 interaction with hyperthermia
 Co(III) mustard complex, 6971
 interleukin 1 α mediated effects
 ketoconazole, 4709
 irreversible inhibitors of ornithine decarboxylase
 macrophage-mediated tumoricidal activity, 4510
 mechanisms of immunotherapy
 monoclonal antibodies and interleukin 2, 5767
- Antitumor agents**
- amsacrine and CI-921
 pharmacokinetic and toxicity scaling, 2692
- anthracenedione
 photosensitization, leukemic cells, 1936
- nicotinamide and nicotinamide analogues
 mouse skin, 2470
- Vinca*
 use of small neurons, quantitative ultrastructural parameters, 1924
- A-particles**
 intracisternal
 mammary epithelium, 2404
- Aphidicolin**
 cytotoxic effects
 cell cycle phase-specific agents, 7307
- Apigenin**
 inhibitory effect on epidermal ornithine decarboxylase
 skin tumor promotion in mice, 499
- Apomucin**
 polypeptide core
 pancreatic tumor mucin antigen, 2997
- Appendectomy**
 appendicitis and large bowel cancer, 7549
- Arabinofuranosyl-5-azacytosine**
 Phase I and pharmacokinetic study, 1220
- 1- β -D-Arabinofuranosylcytosine**
 antineoplastic activity
 experimental and human malignancies, 3473
- conjugate of thioether phospholipid formulation, stability, and antitumor activity, 4401
- cis*-diamminedichloroplatinum and quantitation, drug synergism, 5318
- differentiation therapy, 3453
- DNA replication intermediates pH-step alkaline elution, 2658
- enhancement of toxicity
 DNA incorporation, 7279
- resistant leukemic cells
 substrate-specific deoxyctydine kinase deficiency, 6515
- 9- β -D-Arabinofuranosylguanine**
 transport and metabolism
 human T-lymphoblastoid cell line, 1817
- Arabinosyl-5-azacytosine**
 enhancement of toxicity
 DNA incorporation, 7279
- Arabinosyl nucleosides**
 phosphorylation and cytotoxicity
 modulatory activity, 2',2'-difluoro-deoxyctydine, 3675
- Arachidonic acid**
 12-O-tetradecanoylphorbol-13-acetate
 enhanced metabolism
 dog urothelial cells, 4650
- L-Arginine**
 -dependent reactive nitrogen intermediates
 tumor cell killing, activated macrophages, 1421
- Arginine deiminase**
 growth inhibition of tumor cells
Mycoplasma-infected cell line, 4522
- Aristolochic acid**
- activation of *ras* genes
 deoxyadenosine residues, rat tumors, 5464
- Aromatase**
 complementary DNA
 stable expression, mammalian cells, 6949
- inhibition by enzyme-activated irreversibly inhibitor
 carcinoma, 3652
- inhibitor CGS 16949A
 advanced breast cancer, postmenopausal women, 1381
- Arsenic**
 level in well water
 age-adjusted mortality, malignant neoplasms, 5470
- Artery**
 splenic
 induction of LAK cells, advanced malignancy, 4906
- Arylamine N-acetyltransferase**
 hepatic polymorphic
 purification, homozygous rapid acetylator inbred hamster, 7942
- Aryl hydrocarbon hydroxylase**
 acquisition of inducibility
 aromatic hydrocarbons, hepatocytes, 3226
- Arylmethylaminopropanediol**
 502U83
 Phase I and clinical pharmacology, 7496
 evaluation by pharmacodynamic assay
 antitumor activity, 3663
- Arylsulfotransferase IV**
 2-acetylaminofluorene-mediated alteration
 liver, hepatocarcinogenesis, 5301
- Asbestos**
 long and short crocidolite fibers
 cytotoxicity, 5153
- Ascites**
 hepatoma cells
 Adriamycin-induced potentiation, invasive capacity, 2018
- mammary tumor
 sialomucin, lytic susceptibility, 6800
 sialomucin susceptibility, tunicamycin effect, 5250
- multidrug-resistant
 photoreactive vinblastine derivative, Chinese hamster ovary cells, 403
- recurrent ovarian carcinoma
 intraperitoneal recombinant γ -interferon, 7318
- Ascitic fluid**
 anti-CD5 antibody-ricin A chain immunotoxins
 parameters, tumor-specific delivery, 2909
- induction in mice
 epidermal growth factor, transforming growth factor- α , 4915
- Ascorbate**
 free radical
 stimulation of growth, promyelocytic leukemia cell line, 5887
- Asialo-G_{M1}**
 positive liver cells
 suppression of hepatic metastases, 1834

SUBJECT INDEX TO VOLUME 50

- Aspartic acid**
 mutations of *c-ras*
 gastrointestinal cancer, 480
- Aspergillus versicolor**
 induction of pituitary tumors
 germ-free rats, 400
- Assays**
- DIB-1*
 mutagenesis, mouse intestine, 7992
 - DNA fingerprinting
 7,12-dimethylbenz[a]anthracene-induced and spontaneous liver tumors, 5245
 - enzyme-linked immunosorbent
 cancer procoagulant, new tumor marker, 6229
 - estradiol sensitivity test
 contact-sensitive plates, BALB/c 3T3 cell monolayers, 2113
 - evaluation of methods for quantitation
 aflatoxin-albumin adducts, human exposure assessment, 245
 - induction of cytochrome P-450 and 5-aminolevulinic synthase
 rat hepatocytes, 5219
 - inhibition of transformation
 chemotherapeutic agents, tracheal epithelial cells, 2068
 - in vivo* invasion
 low passage cultured cells, lung cancer, 7358
 - pharmacodynamic
 arylmethylenopropenediols, antitumor activity, 3663
 - ³²P-postlabeling
 combined with HPLC, N¹-methyldeoxyguanosine, 6580
 - quantitative cytochemical detection
 malignant and potentially malignant colon cells, 5112
 - tetrazolium
 tumor cell response, ionizing radiation, 1392
 - tetrazolium-based semiautomatic colorimetric
 evaluation, human antitumor cytotoxicity, 3681
 - use of screening phase data
 observer variation, sputum cytodiagnosis, 1216
 - use of small neurons
 quantitative ultrastructural parameters, *Vinca* antitumor agents, 1924
- Astatine-211**
 -labeled antibodies and fragments
 comparative tissue distribution, 3514
- Astatine-211 methylene blue**
 targeted radiotherapy
 micrometastases, human melanoma xenografts, 2963
- Astrocytes**
 fetal
 metalloproteinases, metalloproteinase inhibitors, 2322
- Astrocytoma**
 childhood
 gestational and familial risk factors, 2608
- differential expression of *ros* oncogene, 3032
- human malignant
 alleleotype, 5784
- immunohistochemical localization
 basic fibroblast growth factor, 7393
- malignant
 glutathione content, glutathione S-transferase expression, 6976
- Atomic bomb survivors**
 embryonic mutation
in utero carcinogenesis, 12-O-tetradecanoylphorbol-13-acetate treatment, 2135
- with and without breast cancer
 radiosensitivity, skin fibroblasts, 4050
- Autocrine growth factors**
 augmented *MYCN* expression
 malignant phenotype, neuroblastoma cells, 4411
- immunohistochemical evidence
 lung adenocarcinoma, 7077
- insulin-like growth factor I
 transforming growth factor- α , pancreatic cancer cell growth, 103
- Autoradiography**
 partial characterization of insulin-like growth factor I
 primary human lung cancer, 2481
- whole-body
 cancer targeting, radiolabeled antibodies, 8855
- Avian cells**
 transformed
 anchorage-independent phenotype, mitochondrial DNA modulation, 6675
- Azaserine**
 postinitiation phase of pancreatic carcinogenesis
 protective effect, voluntary exercise, 6811
- Azidothymidine**
 cytotoxicity
 5-fluorouracil enhancement, 4026
- Azoxymethane**
 -induced colon carcinogenesis
 different levels of calorie restriction, 5761
- B**
- Baclofen**
 γ -amino- η -butyric acid and
 inhibition of gastric carcinogenesis, 4931
- BALB/c/3T3 cells**
 effect of cellular density and viral oncogenes
 MHC class I antigen response, γ -interferon, 601
- Barbiturates**
 exposure *in utero* and during childhood
 risk, intracranial and spinal cord tumors, 4600
- Basal cell nevus syndrome**
 hypersensitivity of skin fibroblasts
 killing by ultraviolet B, 637
- Basement membrane**
 tumor promoter-stimulated *M*, 92,000 gelatinase
 normal and malignant human cells, 6162
- type IV collagen degradation
 proteolytic cascade independent of metalloproteinases, 5997
- B-cell neoplasms**
- antibody-dependent cell-mediated cytotoxicity
 anti-class II murine monoclonal antibody, interleukin 2 effects, 2991
- B-cells**
 differential growth-inhibitory effects
 gallium, iron concentrations, 5727
- growth factor-induced and α -interferon-inhibited proliferation
 hairy cells, cell surface antigen modulation, 4111
- Hodgkin's cells and
 characterization, cell surface molecule, 1650
- lymphomagenesis
 immunocompromised hosts, murine model, 7042, 7050
- malignancy
 fractionated radioimmunotherapy, ¹³¹I-Lym-1, 1014s
- pre-
 tumorigenic state, Abelson virus infection, 1917
- B16 cells:** see *Melanoma, B16*
- Benzene**
 metabolites
 induction of micronuclei, lymphocytes, 393
- Benzidine**
 congeners and dyes
ras gene activation, rat tumors, 266
- derivatives
 production of urothelial tumors, heterotopic bladder, 2868
- Benzo(a)pyrene**
 2-acetylaminofluorene and
 activation of food-derived heterocyclic amine mutagens, cytochromes P-450, 3367
- activity of NAD(P)H:quinone reductase
 forestomach and glandular stomach, 2064
- 7,12-dimethylbenz(a)anthracene and
 covalent DNA adducts, mouse epidermal subpopulations, 3048
- formation and persistence of adducts
 lung, liver, and peripheral blood lymphocyte DNA, 5088
- induced forestomach neoplasia
 conjugated dienoic derivatives, linoleic acid, 1097
- induced micronucleus formation
 gestation stage effect, covalent DNA modifications, 2146
- Benzo(a)pyrene diol-epoxide**
 binding to DNA
 inhibition of 6-mercaptopurine, CHO cells, 4355
- DNA adduct formation in mouse tissues
 relation to serum levels, 1189
- Bile acids**
 production of diacylglycerol
 intestinal microflora, 3595
- Biochemical field effect**
 quantitative measurements of protein thiol changes
 cervical intraepithelial neoplasia, uterine cervix carcinoma, 6663
- Bioluminescence**
 nuclear magnetic spectroscopy and
 cryospectrophotometry
 tumor energy, oxygenation status,

SUBJECT INDEX TO VOLUME 50

1681

Biopsy

- epitope mapping and use of anti-idiotype antibodies
- L6 monoclonal anticarcinoma antibody, 2449
- 1,2-Bis(3,5-dioxopiperazinyl-1-yl)propane**
modulation of free radical scavenging enzymes
- doxorubicin-induced cardiomyopathy, 5136
- d-1,2-Bis(3,5-dioxopiperazine-1-yl)propane**
inhibition of Fe^{3+} reduction
- CaATPase inactivation, heart microsomes exposed to Adriamycin, 2307
- 2,5-Bis(carboethoxyamino)-3,6-diaziridinyl-1,4-benzoquinone**
analogue
- structural and cytotoxic activity, 2003
- 1,3-Bis(2-chloroethyl)-1-nitrosourea**
amphotericin B with 2-chloroethyl-1-nitrosoureas
- lysis of promyelocytic HL-60 cells, 3274
- antineoplastic activity
- experimental and human malignancies, 3473
- cytotoxicity
- effect of hypoxia, 9L cells, 2719
- effect of α -difluoromethylornithine
- DNA interstrand cross-linking, brain tumor growth, 2769
- resistant malignant astrocytoma cell lines
- glutathione content, glutathione S-transferase expression, 6976
- N¹,N⁴-Bis(ethyl)homospermine**
growth of U-87 MG and SF-126 brain tumor cells, 3137
- Bismuth-212**
- labeled antibody
- radioimmunotherapy, peritoneal human colon cancer xenografts, 985s
- stability and tumor targeting, 4221
- cis-Bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II)**
liposome-entrapped
- Phase I clinical and pharmacological study, 4254
- Bisquinaldinium calmodulin antagonist**
phenothiazine and
- comparison of efficacy, P388 cell lines, 1165
- N,N'-Bis(trans-4-hydroxycyclohexyl)-N'-nitrosourea**
depletion of cellular glutathione
- sensitivity of K562 leukemia cells, 4-hydroperoxycyclophosphamide, 4067
- Blackfoot disease**
- age-adjusted mortality from malignant neoplasms
- arsenic level in well water, 5470
- Bladder**
- heterotopic
- production of urothelial tumors, benzidine derivatives, 2868
- two-stage carcinogenesis
- sodium L-ascorbate, sodium saccharin promotion, 4195
- Bladder neoplasms**
- allelic losses of chromosomes 9, 11, and

17, 44

- autochthonous rat model
- N*-methyl-*N*-nitrosourea induction, 6674
- clinical cancer progression
- multiparameter flow cytometry, monoclonal antibodies, 432
- collagen-mediated dispersion, 129
- correlation with tumor stage
- DNA *in situ* sensitivity to denaturation, 7912
- growth-regulated surface glycoproteins, 293
- hemoglobin adduct of 4-aminobiphenyl withdrawal from smoking, 181
- Blast cells**
- leukemic
- noncoordinated expression, ribosomal proteins, 5825
- myeloid leukemia
- receptor binding, granulocyte colony-stimulating factor, 1671
- Blastogenesis**
- inhibitory factor
- tumor growth inhibitory activity, lymphocytes, 345
- Blast progenitors**
- N*¹-behenoyl-1- β -D-arabinofuranosylcytosine effects
- acute myeloblastic leukemia, 7587
- Bleomycin**
- antineoplastic activity
- experimental and human malignancies, 3473
- calmodulin inhibitors and
- high grade gliomas, 6636
- cytotoxicity of lonidamine
- RIF-1 and HT1080 cells, 7867
- damage and repair**
- domain, human amplified *MYC* oncogenes, 2379
- induced DNA damage and repair
- lysophosphatidylcholine, permeabilized human cells, 1613
- intracellular DNA strand scission and growth inhibition
- Ehrlich ascites tumor cells, 5275
- iron complex
- plasma membrane perturbations, KB₃ cells, 385
- lung damage**
- cytostatic activity, reactive nitrogen intermediate production, 7863
- effect of erythrocytes, alveolar macrophage cytostatic activity, 2351
- Blood-brain barrier**
- morphological and electrophysiological study
- cisplatin and ORG-2766, rat spinal ganglion neurons, 2437
- Blood flow**
- tumor
- deuterium nuclear magnetic resonance imaging, mice, 363
- Blood group antigens**
- rare determinant Cad
- gangliosides and sialoglycoproteins, monoclonal antibodies, 5497
- Bloom's syndrome**
- abnormal profile of DNA replication intermediates, 3141
- B-lymphoblastoid cell lines

- malignant lymphoma antigen, nude mouse cells, 3106

Body mass

- association of change with breast cancer, 2152

Bombesin

- activation of inositol phospholipid signaling
- calcium efflux, breast cancer cells, 235
- related peptides
- binding and growth effects, colon cancer, 6772
- stimulated phospholipase C activity
- guanine and adenine nucleotides, small cell lung carcinoma, 5257
- stimulation of calcium mobilization
- tachykinin neuropeptides, small cell lung cancer, 240

Bone

- selective stimulation of cells
- mitogenic activity, prostatic cancer cells, 6902

Bone marrow

- antitumor activity of L6-ricin immunotoxin
- lung adenocarcinoma, 3249
- cloning of carcinoembryonic antigen gene family member
- leukocyte expression, chronic myeloid leukemia, 6534

Dosimetry

- ¹³¹I-labeled anti-carcinoembryonic antigen monoclonal antibody, 1039s
- elimination of small cell lung carcinoma monoclonal antibodies, immunomagnetic beads, 7216

- immunological detection of residual disease
- clinical remission, metastatic relapse in small cell lung cancer, 6545

- inhibition of tumor cell proliferation
- natural suppressor cells, 2582

- proliferative responsiveness
- granulocyte colony-stimulating factor, interleukin 2, 1847

Purging

- monoclonal antibody DF3, ricin conjugate, 1170
- mouse monoclonal antibody, M, 170, 000 glycoprotein and saporin-conjugated anti-mouse antibody, 4291

Replacement therapy

- target-specific immunoconjugates, 1538

- selective elimination of breast cancer cells

- antibody-*Pseudomonas exotoxin A* conjugate, 5992

Stroma

- chronic myelogenous leukemia, growth factors, 5801
- heparan sulfate-containing fraction, HL-60 cell maturation, 3781

Toxicity

- mechanism, diethyldithiocarbamate modulation, 6218

Transplantation

- neurotoxicity, high-dose busulfan in children, 6203

- ⁹⁰Y antibody therapy, colon cancer xenografts, 1008s

Boron

SUBJECT INDEX TO VOLUME 50

- neutron capture therapy, 1061**
selective delivery by *p*-boronophenylalanine
 tumors other than melanoma, 138
- Boronated compounds**
 neutron capture therapy, 4860
- Bowman-Birk protease inhibitor suppression**
 dimethylhydrazine-induced carcinogenesis, 580
- Brain**
bovine
 Ca^{2+} -dependent binding tamoxifen to calmodulin, 2753
- cerebral vasomotor responses**
 recombinant interleukin 2 infusion, 4377
- 5-[^{123}I]iodo-2'-deoxyuridine uptake therapeutic implications in humans, 5199**
- normal and 9L tumor**
 serpin inhibitors, urokinase and thrombin, 5039
- protein kinase C**
 phorbol ester mediation, phospholipid-free activation, 2081
- rate of buthionine entry**
 xenotransplanted human gliomas, 1251
- risk of intracranial and spinal cord tumors**
 barbiturate exposure, *in utero* and childhood, 4600
- tubulin**
 interaction of rhizoxin, 4277
- Brain neoplasms**
childhood astrocytoma
 gestational and familial risk factors, 2608
- effect of α -difluoromethylornithine 1,3-bis(2-chloroethyl)-1-nitrosourea and *cis*-diamminedichloroplatinum(II) cytotoxicity, 2769**
- growth of U-87 MG and SF-126 cells**
 N^1,N^4 -bis(ethyl)homospermine effect, 3137
- low density lipoprotein receptor activity**
 cholesterol requirement, 483
- pediatric**
 oncogene amplification, 2987
- Brazil**
 patterns of maté drinking, 7112
- Breast**
 benign proliferative disorders
 diet and, case-control study, 3176
- Breast neoplasms**
 acetylation phenotype, 6649
 activation of inositol phospholipid signaling
 calcium efflux, bombesin, 235
- advanced**
 cell kinetics, hormone receptors, 2958
 postmenopausal women, CGS 16949A, 1381
- allelotype**
 tumor progression, 7184
- association of change in body mass, 2152**
- atomic bomb survivors**
 radiosensitivity, skin fibroblasts, 4050
- automated quantitation**
 estrogen receptors, 3545
- binding of opioids to human MCF-7**
- cells**
 effects on growth, 2234
- biopsy samples**
 epidermal growth factor gene expression, 4204
- cancer mortality in women**
 thyroid disease, 2283
- candidate cancer chemopreventive agents**
 animal models, human clinical trials, 2 case-control study
- dietary and nondietary risk factors, Shanghai, 5017**
- cathepsin D**
 digestion of extracellular matrix, large acidic vesicles, 6045
- cell proliferation in tissue culture**
 pimozide and thioridazine, 5399
- cellular and molecular events**
 loss of estrogen sensitivity, 5868
- cloning and sequencing of complementary DNA**
M., 70,000 mucin-associated antigen, 5925
- cloning of estrogen-responsive mRNAs, 4098**
- cyclophosphamide/Adriamycin/5-fluorouracil chemotherapy**
 sister chromatid exchanges, 4951
- decreased serum concentrations**
 tamoxifen and metabolites, aminoglutethimide, 5851
- defects in tropomyosin expression**
 human mammary epithelial cells, 2105
- development and use of antiestrogens, 4177**
- distribution of glycoproteic antigen**
 definition by monoclonal antibody, 7333
- doxorubicin-resistant**
 antioxidant and xenobiotic-metabolizing enzyme gene expression, 1397
- effects of 2-deoxyglucose**
 magnetic resonance spectroscopy, 544
- elasticotic**
 elastin gene expression, epithelial cell lines, 2164
- estrogen-free conditions**
 receptor-negative, hormone-nonresponsive clone, 7285
- estrogen-induced breast cancer protein**
 monoclonal antibodies, *Escherichia coli*, 2390
- estrogen-positive and -negative**
 phorbol ester effects, epidermal growth factor receptors, 4849
- estrogen receptor gene methylation, 3974**
- four mammary epithelial cell lines**
 same patient, tumor progression, 7351
- growth in culture**
 eicosanoid synthesis, fatty acids and inhibitors, 7139
- hereditary**
 workshop on linkage studies, 4448
- hormonal modulation**
HER-2/neu protooncogene mRNA, p185 protein, 3947
- 4-hydroxyandrostenedione treatment**
 androstenedione conversion to estrone, postmenopause, 193
- immunocytochemical localization**
 estrogen and progesterone receptors, 7057
- immonscintigraphy with ^{99m}Tc -labeled monoclonal antibody**
 carcinoembryonic antigen reaction, 949s
- inhibition of estradiol uptake**
 transforming growth factor- α secretion, alkyl-lysophospholipid, 3172
- inhibition of estrogen-dependent growth reaction product, α -fetoprotein and estradiol, 415**
- insulin-like growth factor receptor expression, 48**
- interaction of methotrexate polyglutamates**
 dihydrofolate, leucovorin rescue, 3574
- irradiated**
 smoking and irradiated volume, inflammatory response, 2027
- isolation and characterization of MCF-10, 6075**
- leukemia following chemotherapy, 2741**
- molecular biochemical and cellular biology, 4446**
- molecular biology**
 Second Annual Pezcoller Symposium, 7402
- multiple stages**
 increased *erbB-2* gene copies, 6701
- node-positive**
HER-2/neu amplification, poor survival, 4332
- parathyroid hormone-related protein immunohistochemical localization, 7710**
- polypeptide core of pancreatic tumor mucin antigen, 2997**
- postmenopausal**
 dehydroepiandrosterone and dehydroepiandrosterone sulfate serum levels, 3859
- prediction of relapse and survival**
 PS_2 protein, 3832
- primary human**
 glutathione transferase activity, isoenzyme composition, 6848
- prognostic significance**
 insulin-like growth factor I receptors, 6931
- proliferation**
 estrogen-induced insulin-like growth factors, 7770
- purification from urine**
 epidermal growth factor-related protein, 642
- radioimmuno detection**
 ^{111}In -labeled monoclonal antibody, mucin-like antigen, 927s
- regulation of transforming growth factor- β species**
 estradiol, 299
- risk**
 dehydroepiandrosterone sulfate, 6571
 serum cholesterol and triglycerides, 2341
- seasonal change in concentration**
 progesterone receptor, 5883
- second passage**
in vitro chemosensitivity, clinical outcome, 2943
- selective elimination**
 antibody-*Pseudomonas* exotoxin A

SUBJECT INDEX TO VOLUME 50

- conjugate, human bone marrow, 5992
- survival**
prognostic value, laminin receptor expression, 1479
- T47D_{CO} cells as model for progression, 6208
- tumor characteristics and behavior
323/A3 surface glycoprotein, 3317
- ultrastructural and immunocytochemical characterization
MCF-10 line, 6087
- urokinase plasminogen activator as prognostic marker, 6827
- Brequin sodium**
inhibition of dihydroorotic acid dehydrogenase, 4644
- Phase I and pharmacokinetic study, 4595
- Bromocriptine**
attenuating effect on cysteamine anticarcinogenesis
N-methyl-*N'*-nitro-*N*-nitrosoguanidine, stomach cancer, 5308
- Bromodeoxyuridine**
c-myc down regulation
precommitment in HL-60 cells, 1411
- Bropirimine**
protection from carcinogen-induced bladder carcinoma
interferons, 1071
- Bryostatin**
differentiation and growth modulation
chronic myelogenous leukemia, 5520
- Bryostatins 1 and 2**
morphological and functional differentiation
SH-SY5Y human neuroblastoma cells, 3422
- Busulfan**
high-dose
dose-dependent neurotoxicity, children, 6203
- mechanisms of toxicity of hepsulfam
human tumor cell lines, 7555
- 1,3-Butadiene**
activation of mouse K-ras
codon 13 mutations, 4818
- carcinogenicity at low exposure concentrations, 6592
- Buthionine sulfoximine**
myelotoxicity
hematopoietic progenitor cells, 4038
- rate of entry into brain
xenotransplanted human gliomas, 1251
- Buttermilk**
bovine
human melanoma and, natural 9-*O*-acetyl GD3, 1403
- O⁶-Butylguanine**
determination in DNA
immunoaffinity extraction/gas chromatography-mass spectrometry, 6870
- Butyrate**
novobiocin and
alteration of differentiation state, human hepatocytes, 3101
- Butyrylcholinesterase**
mRNA
chromosome 3q26-ter, nervous system
- tumors, 1983**
- C**
- CA19-9 antigen**
potentiation of tumor lysis
bispecific antibody, large granular lymphocytes, 7122
- Cachexia**
anticachetic activity of 5'-deoxy-5-fluorouridine
colon 26 adenocarcinoma, 4528
- effects of tumor necrosis factor in rats, 4008
- elevated protein turnover and anorexia
hepatocellular carcinoma, 1226
- epithelial tight junctions
tumor necrosis factor, transepithelial permeability, 2172
- experimental model
inhibition of weight loss, ω -3 fatty acids, 5022
- induction by transplantable colon 26 adenocarcinoma, 2290
- prolonged survival of tumor-bearing rats
repetitive low-dose tumor necrosis factor, 3928
- Cadmium**
sulfide salts
 H_2O_2 formation, polymorphonuclear leukocytes, 7564
- Caerulein**
enhancement of gastric carcinogenesis
calcium channel blockers, 2095
- Cain Memorial Award Lecture, 4177**
- Calcium**
antagonism
newly synthesized dihydropyridines, P-glycoprotein photoaffinity labeling, 310
- antagonists
reversal of chemoresistance, renal cell carcinoma, 3670
- CaATPase inactivation in heart microsomes**
exposure to Adriamycin, ICRF-187, 2307
- calmodulin antagonist**
chemotherapy, experimental neuroendocrine lung tumors, 1645
- channel blocking activity
pyridine analogues, reversal of multidrug resistance, 3055
- dependent binding of tamoxifen to calmodulin
bovine brain, 2753
- efflux and inositol phospholipid signaling**
bombesin, breast neoplasms, 235
- enriched diet
colonic epithelial hyperproliferation, 1764
- growth factor-dependent signaling
inositol phosphate, antitumor ether lipid analogues, 4458
- intestinal absorption
structure-function studies, 1 α ,25-dihydroxyvitamin D₃ analogues, 6857
- intracellular
elevation by ether lipid, leukemic cells, 3327
- ionophores A23187 and ionomycin
- tumor-promoting effects, mouse epidermis, 5806**
- isolation and characterization of MCF-10, 6075**
- production of interleukin 1 and receptor expression**
adult T-cell leukemia, 4344
- stimulation of mobilization but not proliferation**
bombesin and tachykinin neuropeptides, small cell lung cancer, 240
- Calcium channel**
voltage-operated
small cell lung carcinoma, 3892
- Calcium channel blockers**
gastric carcinogenesis
caerulein enhancement, 2095
- Calcium phosphate**
-mediated transfer of DNA
spontaneous metastasis, 5581
- California**
Los Angeles County young men
life-style and workplace, stomach cancer by subsite, 2569
- Calmodulin**
bisquinaldinium calmodulin antagonist
phenothiazine efficacy, P388 cell lines, 1165
- Ca²⁺-dependent binding**
tamoxifen to calmodulin, bovine brain, 2753
- inhibitors**
bleomycin and, high grade gliomas, 6636
- overexpression**
increased sensitivity to *Vinca* alkaloids, gene transfection, 6554
- Calyculin A**
tumor promoter on CD-1 mouse skin, 3521
- Campototecin**
analogue CPT-11
metabolism and pharmacokinetics, mouse, 1715
- nonlinear pharmacokinetics, 1721
- analogue-resistant cell line establishment
non-small cell lung cancer, 5919
- diverse effects on cell cycle
lymphocytic and myelogenous leukemia cells, 5746
- involvement of nucleic acid synthesis
cell killing mechanisms, topoisomerase poisons, 6919
- potentiation of DNA strand breakage
and cytotoxicity
tumor necrosis factor, 2636
- resistant tumor cell lines
decreased expression, DNA topoisomerase I, 6925
- elevated expression, DNA topoisomerase II, 7962
- Carbohydrates**
analysis of immunoglobulin G myeloma proteins
lectin and HPLC, glycosyltransferases, 5345
- tumor cell surface**
inhibition of tumor growth, monoclonal IgM antibody, 7301
- Carcinoembryonic antigen**
anti-carcinoembryonic antigen
murine monoclonal antibodies, human

SUBJECT INDEX TO VOLUME 50

- immune response, 1055s
 anti-CEA antibody radiolabeled with In-111
 novel diethylenetriaminepentaacetic acid chelator, 7272
 cloning of gene family member
 leukocyte expression, chronic myeloid leukemia, 6534
 cloning of genes for T84.66
 myeloma, Chinese hamster ovary cells, 2128
 complementary DNA and genomic clones
 nonspecific cross-reacting antigen, Chinese hamster ovary and mouse fibroblast cells, 2397
 complementary reactivities
 anti-CEA and antitumor-associated glycoprotein 72 monoclonal antibodies, lung carcinoma, 6987
 α -fetoprotein expression
 monoclonal antibody targeting, human hepatoma/nude mouse model, 869s
 131 I-labeled anti-carcinoembryonic antigen monoclonal antibody
 tumor, red marrow and organ dosimetry, 1039s
 immunoscintigraphy with 99m Tc-labeled monoclonal antibody
 breast cancer, 949s
 Indium-labeled antigen
 presurgical imaging, colon cancer staging, 922s
 murine monoclonal antibodies
 targeting properties, pharmacokinetics, 2823
 regulation of expression
 γ -interferon, colorectal tumor cells, 6248
 serum level and tumor progression
 noncurative resection, gastric carcinoma, 3952
Carcinogenesis
 aflatoxin B₁
 species susceptibility, 615
 benzo(a)pyrene long term effects
 NAD(P)H:quinone reductase activity, forestomach and glandular stomach, 2064
 bioassay specimens
 occurrence, thymic lymphoma, 5675s
 bladder
 sodium saccharin promotion, sodium L-ascorbate, 4195
 chemotherapy and
 Third Charles Heidelberger Symposium, 7405
 colonic
 chemoprevention, piroxicam and D,L- α -difluoromethylornithine, 2562
 fat-fiber interrelationships, 1092
 induction by azoxymethane, levels of caloric restriction, 5761
 7,12-dimethylbenz[a]anthracene-induced changes in keratin expression, hamster, 4441
 dimethylhydrazine-induced suppression, Bowman-Birk protease inhibitor, 580
 epithelial cell evidence, multistep nature, 5653s
 esophageal
- dietary molybdenum, N-methyl-N-benzylnitrosamine, 2418
 from molecular mechanisms to molecular epidemiology, 2857
 gastric
 caerulein enhancement, calcium channel blockers, 2095
 inhibition, γ -amino-n-butyric acid and baclofen, 4931
 hamster buccal pouch model
 7,12-dimethylbenz(a)anthracene induction, 2505
 hormonal
 developmental treatment with estrogens, uterine adenocarcinoma, 7677
 increased cell division, 7415
 inhibition of streptozotocin-induced cell tumors
 insulin effects, pancreatic exocrine tumors, 1634
 intracisternal A-particles
 mammary epithelium, 2404
in utero
 embryonic mutation, 12-O-tetradecanoylphorbol-13-acetate treatment, 2135
 liver
 microsomal epoxide hydrolase gene expression, 6222
 nuclear DNA content, altered hepatic foci, 7571
 neoplastic transformation
 adenoma to carcinoma sequence, colonic epithelial cell line, 4724
 pancreatic
 protective effect, voluntary exercise, 6811
 phenotypic expression
 spontaneously transformed rat liver epithelial cells, 1941
 transfection of activated Ha-ras protooncogenes
 mouse mammary hyperplasia, 6010
 transplacental
 genetic damage by 4-nitroquinoline 1-oxide, 6192
 ultrastructural and immunocytochemical characterization
 MCF-10 cell line, 6087
Carcinogenicity
 1,3-butadiene at low exposure concentrations, 6592
 sulfide salts of nickel and cadmium
 H_2O_2 formation, polymorphonuclear leukocytes, 7564
Carcinogens
 aflatoxin B₁ and 2-amino-3-methylimidazo[4,5- β]quinoline
 metabolic activation, human adult and fetal livers, 2641
 exposure
 response of mouse skin tumors, doxorubicin, 6841
 -hemoglobin adducts
 acetylation phenotype, cigarette smoking, 3002
 hepatic neoplasms
 creosote-contaminated site, *Fundulus heteroclitus*, 5978
 -induced bladder carcinoma
 protection by interferons, bropirimine, 1071
 -induced methotrexate resistance
 dihydrofolate reductase gene amplification, inhibitors of poly(adenosine diphosphate-ribose) polymerase, 5756
 macromolecular adducts, 4611
 regulation of xenobiotic epoxide hydrolase messenger RNA
 hepatocyte nodules, hepatomas, 256
 transplacental
 4-(methylnitrosamo)-1-(3-pyridyl)-1-butanone, Syrian golden hamsters, 3435
 -treated Chinese hamster ovary cells
 DNA polymerase α -primase complexes, 6894
 -treated rats
 enzyme-altered foci in colons, 1911
Carcinoid neoplasms
 effects of interferon
 tumor tissue content, liver metastases, 3413
 islet cell carcinoma and
 somatostatin receptors, needle biopsy samples, 5969
 mitochondrial glycerol phosphate dehydrogenase
 amine precursor uptake system, 7203
 platelet-derived growth factor β -receptors, 748
Carcinoma
 -associated antigen
 biosynthesis and glycosylation, monoclonal antibody, 4656
 different types
 serous effusions, shed form of TAG-72, 4885
 enhanced tumor binding
 anti-TAG-72 monoclonal antibodies, 1291
 human
 patterns, antigen distribution, 880s
 keratin subtypes
 uterine cervix, histogenesis, 5143
 metastatic
 Phase I study, monoclonal antibody and interleukin 2, 7490
 neoplastic transformation of adenoma colonic epithelial cell line, 4724
 serological mapping of TAG-72, 4872
 uptake of Tc-99m MIBI, 2198
Carcinoma, adenoid cyst
 minor salivary gland origin
 biological characterization, pseudocyst-forming cell lines, 4139
Carcinoma, adrenocortical
 cell line establishment
 multiple pathways, steroid biosynthesis, 5488
Carcinoma, basal cell
 superficial
 photodynamic therapy, meso-tetraphenylporphinesulfonate tetrasodium salt, 4501
Carcinoma, bladder
 carcinogen-induced
 protection by interferons, bropirimine, 1071
 modulation of iododeoxyuridine-DNA incorporation
 radiosensitization, 4962
 oncogene-transfected rat cells

SUBJECT INDEX TO VOLUME 50

thermal response, 4515
Carcinoma, breast
 differential tumorigenicity of two cell lines
 establishment in serum-free medium, 1257
 estradiol-stimulated growth and protein synthesis
 modulation by retinoid, 1997
 increase in insulin receptor content
 insulin stimulation of growth, 7858
 inhibition of clonogenic growth
 use of immunotoxins in combination, 3231
 inhibition of proliferation by retinoic acid
 inhibition of *M*, 39,000 protein, 1977
int-1, int-2, c-myc, and *neu* oncogenes, 5911
 interaction of vasopressin and oxytocin, 7882
 preservation of steroid hormone receptors
 organ cultures, 78
 tumorigenicity and metastasis
 nude mice, 717
Carcinoma, bronchogenic
 estrogen and progesterone receptors, 6632
Carcinoma, cervical
 K-ras activation, 6139
 p52 messenger RNA, 1800
 resistance mechanism
 prevention of lysis by γ -interferon, 4923
Carcinoma, colonic
 acquired resistance
 cis-diamminedichloroplatinum(II), 72
 deficiency of low density lipoprotein receptor, 632
 growth adaptation to methotrexate, 6334
 induction of differentiation
 hexamethylene bisacetamide, transforming growth factor- β_1 , 261
 interaction of γ -interferon and 5-fluorouracil, 5834
 laminin-binding protein mRNA expression, 3888
 metabolism of diaziquone
 NAD(P)H:(quinone acceptor) oxidoreductase, 7293
 metabolism of mitomycin C by DT-diphosphatase, 7483
 modulation of interferon receptor expression, 26
 multidrug-resistant
 induction and selection by two methods, 3218
 quiescent, well-differentiated cells
 inhibited mitogenic response, transforming growth factor- β_1 , 7581
 soluble factor in normal tissues
 high-molecular-weight sialoglycoprotein production, 3331
 tumor localization
 combinations of monoclonal antibodies, 5225
 two distinct α -(1-3)-L-fucosyltransferase activities, 6787
 urokinase secretion
 induction by endogenous diglycerides, 2245

xenografts
 radioimmunotherapy, Y-90 monoclonal antibody, 4546
Carcinoma, colorectal
 alleleotype of human malignant astrocytoma, 5784
c-Ha-ras-1 oncogene-induced differentiation
 natural killer cell resistance, 2518
 evaluation of human antitumor cytotoxicity
 tetrazolium-based semiautomatic colorimetric assay, 3681
 pharmacokinetics of mouse monoclonal antibody 17-1A, 4866
Phase I trial
 5-fluorouracil, α_{2a} -interferon, 2056
 presence of villin
 diagnosis and follow-up, 438
 relationship of hepatic glucose production
 growth hormone, malnutrition severity, 2119
Carcinoma, endometrial
 expression of transforming growth factor- β_1
 inverse correlation, growth rate and morphology, 3394
 receptor characterization
 [α -Trp β]-luteinizing hormone-releasing hormone, epidermal growth factor, 1841
 tamoxifen-stimulated growth
 steroidal and nonsteroidal antiestrogens, 3189
Carcinoma, esophageal
 inhibitory effects of estrogen, 7212
Carcinoma, gastric
 cell line characteristics, 2773
 expression of ERBB2
 p185^{ERBB2} expression, amplification, 8002
 membrane vesicle formation
 acquired mitoxantrone resistance, 6100
 prognostic significance
 DNA ploidy patterns, S-phase fraction, 509
 serum carcinoembryonic antigen level
 tumor progression, noncurative resection, 3952
Carcinoma, hepatocellular
 accumulation
 highly acidic sulfated glycosphingolipids, 2917
 elevated protein turnover and anorexia
 cachexia, 1226
 enhanced ganglioside G_{D3} expression, 7697
 α -fetoprotein
 woodchuck model, hepadnavirus infection, 7843
 hepatocyte and oval cell antigens
 oncogene-transfected liver epithelial cells, 4809
 human α -actinin expression, 6291
 increase in active form of 3-hydroxy-3-methylglutaryl coenzyme A
 alteration of cholesterol biosynthesis, 3270
 3.0-kilobase DNA sequence
 rat liver cells and NIH3T3 fibroblasts,

p52 protein, 5658s
 medical history and primary liver cancer, 6274
 3-methylcholanthrene-inducible phenol uridine diphosphate-glucuronyl-transferase, 3569
 oncogene-transfected liver epithelial cells
 hepatocyte and oval cell antigens, 4809
ras gene mutations
 polymerase chain reaction, 1121
 rat hepatic oncofetal membrane glycoprotein
 identification and characterization, 4755
Carcinoma, lung
 anti-CEA and antitumor-associated glycoprotein 72 monoclonal antibodies
 complementary reactivities, 6987
 high molecular weight glycoprotein detection and characterization, 6738
 Lewis: see Lewis lung carcinoma tumor
 loss of heterozygosity genes on 11p, 2303
 Madison 109
 effects, cytochalasin B, 1431
primary giant cell
 c-myc joining with line 1 family member on chromosome 8, 3345
 small cell
 Adriamycin resistance, DNA topoisomerase II activity, 304
 voltage-operated calcium channels, 3892
 suppression of tumorigenicity nontumorigenic bronchial epithelial cells, somatic cell hybrids, 1890
 xenografted
 stability over time, myc family of oncogenes, 1566
Carcinoma, mammary
 activated *ras* oncogenes
 N-methyl-N-nitrosourea, prolactin, 4286
 aromatase inhibition
 enzyme-activated irreversible inhibitor, 3652
 growth factor synthesis
 insulin/insulin-like growth factor I independence, 5351
 ultrastructural differences in clones
 junctional intercellular communication, 358
 various photoradiation regimens
 antitumor efficacy, photodynamic therapy, 7236
Carcinoma, medullary thyroid
 establishment and characterization
 continuous cell line MTC-SK, 4160
Carcinoma, nasopharyngeal
 susceptibility in Malaysia
 relationship, immunoglobulin allotypes, 3186
Carcinoma, non-small cell lung
 monoclonal antibody and methotrexate immunoconjugate
 Phase I clinical comparative study, 4154
 specificity and tumor targeting monoclonal antibodies, 1330
Carcinoma, ovarian
 enhanced lysis

SUBJECT INDEX TO VOLUME 50

- activated peripheral blood lymphocytes, bifunctional immune heteroaggregates, 6508
- frequent loss of heterozygosity chromosomes 6q, 11, and 17, 2724
- prognostic indices for survival, 4626
- pS2 messenger RNA, 1800
- recurrent ascitic intraperitoneal recombinant γ -interferon, 7318
- reactivity to monoclonal antibody manganese superoxide dismutase, 2538
- reduced expression of c-erbB-2 γ -interferon, 7037
- resistance mechanism prevention of lysis by γ -interferon, 4923
- resistance to cyanocephaline doxorubicin DNA cross-linking, 4056
- targeting of human T-cells bispecific antibodies, 4227
- Carcinoma, pancreatic** sex and diet effects elastase 1-Simian virus mouse model, 7552
- Carcinoma, pancreatic islet cell** somatostatin receptors needle biopsy samples, 5969 somatostatin-secreting cell line release experiment, 3691
- Carcinoma, prostatic** androgen receptor gene expression, 5382 diethylstilbestrol-diphosphate cytotoxic action mitochondrial bc₁ complex, 5008 expression of IL-6 receptor and interleukin 6, 7786 high- and low-grade malignant variants ploidy level determinants, 4281
- Carcinoma, rectal** secretion extracellular matrix-degrading metalloproteinase matrix, 7758
- Carcinoma, renal cell** clonal analysis of lymphocytes, 5263 critical factors in biology human cancer metastasis, 6130 cytolytic activity of CD4⁺ and CD8⁺, 2363
- α -interferon effects expression, kidney-associated differentiation glycoprotein, 4190 inverse relationship epidermal growth factor receptor, HER2/neu, 4504 monoclonal antibody blockage of autonomous growth, ACHN cells, 2968
- pro-epidermal growth factor pro-transforming growth factor- α , EGF receptor gene expression, 3934 reversal of chemoresistance calcium antagonists, 3670 smoking and, 5231 xenografts antiproliferative and cytotoxic effects, tumor necrosis factor α and/or α -interferon, 6389
- Carcinoma, Shionogi** androgen-induced heparin-binding
- growth factor fibroblast growth factor receptor, 2316 androgen-responsive paracrine growth stimulation, autonomous subline, 4979 inhibition of androgen-induced growth transforming growth factor β , 6179 stem cell composition effects, androgen withdrawal, 2275
- Carcinoma, Signet-ring cell** stomach monoclonal antibody, tissue polypeptide antigen-related protein, 5192
- Carcinoma, small cell lung** bombesin-stimulated phospholipase C activity guanine and adenine nucleotides, 5257 elimination from human bone marrow monoclonal antibodies, immunomagnetic beads, 7216
- Carcinoma, squamous cell** evaluation of human antitumor cytotoxicity tetrazolium-based semiautomatic colorimetric assay, 3681
- head and neck adoptive immunotherapy, LAK cells and interleukin 2, 3113 C1q-binding macromolecules, 4349 libomycin-mediated DNA cleavage, 1732 production of parathyroid hormone-like protein fibroblast interaction, 3589 role of transforming growth factor- β proliferative effect, 2,3,7,8-tetrachlorodibenzo-p-dioxin, 7190
- Carcinoma, transitional cell** adherence to injured urothelial surfaces kinetics, F-344 rats, 2499 bladder allelic loss of chromosome 17p, distinction of high grade from low grade, 7081 clinical implications epidermal growth factor receptors, 2530 inhibitory effect of testosterone gap junctional intercellular communication, 2848
- Carcinoma, urinary bladder** low-grade malignant conversion, N-methyl-N-nitrosourea, 7062
- Carcinoma, uterine cervix** changes in protein thiols quantitative measurements, cervical intraepithelial neoplasia, 6663
- Carcinoma cells** human tumor associated Thomsen-Friedreich antigen, 4801 laser-irradiated rhodamine 123 phototoxicity, 4167 uptake of chemotherapeutic agents effect of osmotic pressure, 4704
- Carcinomatosis** peritoneal gastrointestinal cancer, early postoperative intraperitoneal chemotherapy, 5790
- Cardiomyopathy** doxorubicin-induced
- ICRF-187, free radical scavenging enzymes, 5136
- Casein** cooked promotion, colonic microadenoma growth, 6955
- Castanospermine** functional interaction of high mannose glycopeptides tumor necrosis factor and interleukin 1 interactions, 6285
- Castration** neonatal and adult testosterone substitution, enzyme-altered hepatic foci, 2679
- Catechol** oxidation and DNA binding 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, mouse epidermis, 1795
- Cathepsin B** cysteine proteinase inhibitor balance metastatic cell subpopulations, 6278
- Cathepsin D** breast cancer cells digestion of extracellular matrix, large acidic vesicles, 6045 tumor characteristics and behavior 323/A3 surface glycoprotein, breast cancer, 3317
- Cathepsin L** -like enzyme pancreatic cell line, 658
- CC-1065 analogue** U-71,184 resistance, B16 melanoma cells, 2485
- CCRF-CEM cells** cytotoxic effects of dihydroorotate inhibitors, 7793
- CD3** activation of tumor-infiltrating lymphocytes monoclonal antibodies, 1138
- CD4** anti-CD4 monoclonal antibody treatment tolerance induction, Moloney murine sarcoma virus, 5703
- CD8⁺** tumor-infiltrating lymphocytes renal cell carcinoma, 2363 immunopathogenesis of HIV infection, 5612s
- CD8⁺** T-cell-dependent surveillance MHC class I, unique antigen expression, 3851
- CD16** immunomodulatory properties and toxicity interleukin 2, cancer patients, 185
- CD30** bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody, 6944 ricin A chain-containing immunotoxins Hodgkin's disease, 84
- Cell culture** establishment of continuous cultures T-cell acute lymphoblastic leukemia, diagnosis, 10 normal and malignant populations cytological differences, 3390

SUBJECT INDEX TO VOLUME 50

- protein-free chemically defined medium characterization, pancreatic cancer cell lines, 7008
- serum-free medium differential tumorigenicity, breast carcinoma, 1257
- Cell cycle**
- abrogation by novobiocin of cytotoxicity amscrine, Chinese hamster cells, 2577
 - cytotoxicity of *N*-(5-indanyl sulfonyl)-*N'*-(4-chlorophenyl)urea nonproliferating colon adenocarcinoma, 318
 - diverse effects of camptothecin lymphocytic and myelogenous leukemia cells, 5746
 - inhibition of cell proliferation melanoma-inhibiting activity, 6981
 - inhibition of progression from G₂-phase to mitosis epidermal growth factor, various cells, 7932
 - kinetics of MCF-7 cells estrogen receptor concentration, α -interferon, 17 β -estradiol, and tamoxifen, 5387
 - long-term inhibition of DNA synthesis toxicity, mAMSA and mitoxantrone, 5813
 - mechanism of G₂ arrest p34^{cdc2} kinase activity inhibition, Chinese hamster ovary cells, 3761
 - mixed population of cycling and noncycling cells growth status, drug sensitivity, 3551
 - myths and realities, 6769
 - phase-specific agents cytotoxic effects, 7307
 - primary and metastatic spontaneous osteosarcoma DNA aneuploidy, 6176
 - S-phase fraction DNA ploidy patterns, gastric carcinoma, 509
- Cell death**
- epipodophyllotoxin-induced poly(adenosine diphosphate-ribose) synthesis-deficient V79 cells, 2713
- Cell membrane**
- cell signals and targets in cancer chemotherapy, 2203
- CEM cells**
- growth of human cell lines BALB/c mice, 5943
- Central nervous system**
- animal model to study toxicity of therapy childhood acute lymphoblastic leukemia, 6455, 6461
 - prevention of toxicity aciclovir, amino acid mixture, 5475
 - primitive neuroectodermal tumors reduction to homozygosity, childhood, 587
- Cerebrospinal fluid**
- concentrations of idarubicin and idarubicinol pediatric leukemia patients, 6525
 - dosimetric model antibody targeted radionuclide therapy, tumor cells, 1043s
- Cervical neoplasms**
- candidate cancer chemopreventive agents animal models, human clinical trials, 2 changes in protein thiols quantitative measurements, 6663 growth-regulating functions papillomavirus early gene products, 3730
 - human papillomavirus type 16 IgA and IgG antibodies to select peptides, 7815
 - immortalization of epithelial cells papillomavirus DNA, dysplastic differentiation, 3709
 - in situ* risk factors, case-control study, 3657 keratin subtypes in carcinomas histogenesis, differential diagnosis, 5143
- Cervix**
- risk of early cytological abnormalities oral contraceptive use, papillomavirus, 4670
- c-fos**
- cellular proliferation in macrophage cell line protein kinase C-induced stimulation or inhibition, 1828
 - TPA-resistant macrophage cell lines, 1510
- Chelates**
- bifunctional metals, radiotherapy, 7895
 - diaminedithiol bifunctional ^{99m}Tc labeling, proteins, 799s
- iron**
- gallium nitrate and fludarabine, HL-60 cell proliferation, 6466
- Y-90 monoclonal antibody**
- radioimmunotherapy, human colorectal carcinoma xenografts, 4546
- Chelators**
- diethylenetriaminepentaacetic acid In-111 anti-CEA antibody, pharmacokinetics, 7272
- Chemoprevention**
- colon carcinogenesis concurrent administration, piroxicam and D,L- α -difluoromethylornithine, 2562
 - differentiation therapy, 3453
 - evaluation by animal models human clinical trials, 2
 - 1,2-dimethylhydrazine-induced colon cancer organosulfur compounds, 5084
 - sputum cytodiagnosis use of screening phase data, observer variation, 1216
- Chemosensitivity**
- second passage human breast cancer cells preliminary correlations, clinical outcome, 2943
- Chemotherapeutic agents**
- cis*-diamminedichloroplatinum(II) DNA binding, cell survival, 3556
 - mixed population of cycling and noncycling cells drug sensitivity, growth status, 3551
 - uptake by carcinoma cells effect of osmotic pressure, 4704
- Chemotherapy**
- breast cancer leukemia, 2741
 - carcinogenesis and Third Charles Heidelberger Symposium, 7405
 - cell membrane and cell signals as targets, 2203
 - chromosome alterations in Hodgkin's disease, 558
 - cycle-specific cytotoxic tumor necrosis factor protection, hematopoiesis, 4216
 - differentiation therapy, 3453
 - early postoperative intraperitoneal peritoneal carcinomatosis, gastrointestinal cancer, 5790
 - experimental neuroendocrine lung tumors antagonist of Ca²⁺/calmodulin, 1645
 - heat radiosensitization human colony-forming unit-granulocyte-macrophage, 2044
 - inherent sensitivity and induced resistance irradiation, human cancer cell lines, 7513
 - inhibition of transformation tracheal epithelial cells, 2068
 - kinetics of formation and removal of cis-platin-DNA adducts blood cells and tumor tissues, 7887
 - mammalian O⁶-alkylguanine-DNA alkyltransferase response to alkylating carcinogenic and therapeutic agents, 6119
 - melanocytotoxicity and antimelanoma effects phenolic amine compounds, mice, 3743
 - modulators role of glutathione S-transferase, alkylating agent resistance, 6449
 - interleukin 6 perfusion, 5-fluorouracil treatment, 2885
 - reversal of multidrug resistance phenotype
 - cremophor EL, 4199
 - serum tumor marker half-life response and survival prediction, non-seminomatous germ cell tumors, 5904
 - toxicity of central nervous system therapy animal model, childhood acute lymphoblastic leukemia, 6455, 6461
 - tumor cell resistance cell-mediated cytotoxicity, natural killer or LAK cells, 5931
- China**
- case-control study in Shanghai dietary and nondietary risk factor, breast cancer, 5017
 - labeling index and labeling distribution cells in esophageal epithelium, esophageal cancer risk, 2651
 - nonassociation of aflatoxin primary liver cancer, 6882
 - tin miners

SUBJECT INDEX TO VOLUME 50

- radon, lung cancer association, 174
 young persons in high-risk population
 epidemiological study, precursor lesions of esophageal cancer, 2268
- Chinese hamster ovary cells**
 carcinogen-treated
 DNA polymerase α -primase complexes, 6894
 chimeric anti-CEA antibody, 2128
 chromosome 2 ornithine decarboxylase gene expression, 2239
 chronic glutathione elevation
 cis -diamminedichloroplatinum(II), radiation or hyperthermia, 5296
 complementary DNA and genomic clones
 carcinoembryonic antigen, nonspecific cross-reacting antigen, 2397
- DNA double-strand break repair pathways**
 cellular tolerance, topoisomerase II inhibitors, 5778
 etoposide-induced cell death
 role for p34^{cdc2} kinase, 3767
 hypoxic and aerobic exposure
 differential cytotoxicity, diaziquone, 1516
 inhibition of DNA excision repair
 methotrexate, 1786
 inhibition of 6-mercaptopurine binding of benzo(a)pyrene diol-epoxide to DNA, 4355
 inhibition of p34^{cdc2} kinase activity etoposide or irradiation, G₂ arrest, 3761
 6-mercaptopurine cytotoxicity
 increased phosphoribosylpyrophosphate levels, 1992
 N-methylnitrosourea-resistant tolerance, O⁶-methylguanine and 6-thioguanine cytotoxic effects, 4248
 multidrug-resistant
 cytotoxic effects, high- and low-molecular-weight anticancer agents, 1571
 multidrug-resistant ascites
 photoreactive vinblastine derivative, 403
 reversal of multidrug resistance by verapamil
 modulation, α_1 -acid glycoprotein, 2818
 tiazofurin
 phosphorylation by three enzymes, 5269
- Chitin**
 sulfated derivatives
 extracellular matrix and enzymatic degradation, metastatic melanoma cells, 3631
- Chloroaluminum phthalocyanine**
 cytotoxic interaction
 phototherapy and nigericin, 1620
- Chloroethylnitrosourea**
 efficacy
 polyamine depletion, human tumor cell lines, 521
- 2-Chloroethyl nitrosourea**
 induction of DNA damage
 malignant melanoma cells, 5898
- N-[4-Chlorophenyl]amino[carboxyl-2,3-dihydro-1H-indene-5-sulfonamide**
 kinetics in humans, 3910
- Cholesterol**
 alteration of biosynthesis
 active form of 3-hydroxy-3-methylglutaryl coenzyme A, hepatocellular carcinoma, 3270
 benign proliferative disorders of breast and diet
 case-control study, 3176
 low density lipoprotein receptor activity
 human intracranial tumors, 483
 triglycerides and risk of breast cancer, 2341
- Choline**
 -devoid diet
 reduction of I-compound levels, liver DNA, 7577
 ethanolamine and thiotepa cellular accumulation, L1210 cells, 4322
- Choriocarcinoma**
 alkaline phosphatase, 3956
 pathogenesis
 restriction fragment length polymorphisms, 488
 trophoblastic genetic origin, 6330
- CHO-UV-1 mutant**
 phenotypic characterization
 postreplication recovery of DNA, 2356
- Chromatography**
 high performance liquid carbohydrate analysis, immunoglobulin M myeloma proteins, 5345
 combined with ³²P-postlabeling assay, N¹-methyldeoxyguanosine, 6580
 immunoaffinity extraction/gas chromatography-mass spectrometry determination, O⁶-butylguanine, 6870
- Chromium compounds**
 role of valence state and solubility induction of cytotoxicity, diploid human fibroblasts, 7835
- Chromogranin**
 synaptophysin and i-dopa decarboxylase neuroendocrine differentiation markers, lung cancer, 6068
- Chromosome 1p35**
 high frequency of deletions human colorectal cancer, 7232
- Chromosome 2**
 ornithine decarboxylase gene expression ornithine decarboxylase-deficient Chinese hamster ovary cells, 2239
- Chromosome 3q26-ter**
 butyrylcholinesterase mRNA nervous system tumors, 1983
- Chromosome 8**
 joining of c-myc gene primary giant cell carcinoma of lung, 3345
- Chromosome 11**
 loss of heterozygosity of markers in tumors
 multiple endocrine neoplasia syndrome type 1, 6529
 suppressor regions
 loss of heterozygosity, Wilms' tumor, 3279
- Chromosome 11p**
 loss of heterozygosity for genes lung carcinoma, 2303
- Chromosome 11p13-15**
- rearrangement**
 gastric and esophageal adenocarcinomas, 6410
- Chromosome 12**
 methylation patterns of myxoid liposarcoma, 7902
- Chromosome 14q11**
 rearrangements in T-cell receptor α -chain locus adult T-cell leukemia, 6171
- Chromosome 17**
 reduction to homozygosity and gene amplification primitive neuroectodermal tumors, childhood, 587
 unrelated closely linked genes coregulation, O⁶-methylguanine-DNA methyltransferase, 1532
- Chromosome 17p**
 allelic loss
 high grade or low grade transitional cell carcinoma of bladder, 7081
- Chromosome 22**
 molecular genetic analysis meningioma, 5863
- Chromosomes**
 aberrations in uterine smooth muscle tumors, 4092
 abnormalities in malignant lymphoma Kurashiki, 2698
 allelic loss of 9, 11, and 17 human bladder cancer, 44
 analysis of thirty-one Wilms' tumors, 2786
 continuous cell line establishment human medullary thyroid carcinoma, 4160
 cytogenetic profile lung alveologenic carcinoma, 164
 etoposide-induced cell death p34^{cdc2} kinase activity, Chinese hamster ovary cells, 3767
 frequency and pattern of karyotypic abnormalities human prostate cancer, 3795
 gene rearrangements and HTLV-I infection, immortalized lymphocytes, 5697s
 karyotypic changes X-ray-induced transformants, 760
 malignant lymphoma antigen Bloom's syndrome B-lymphoblastoid cell lines, 3106
 mutations in germ cells doxorubicin-treated stem spermagonia, 370
 nonrandom alterations progression to immortality, tracheal epithelial cells, 740
 proteins HMG-14 and HMG-17 transformed human cells, 2022
 6q, 11, and 17 frequent loss of heterozygosity, ovarian carcinoma, 2724
 13q33-qter deletion linked to poly(ADP-ribose) polymerase gene, normal black population and multiple tumor DNA, 5406
 role of 1q trisomy tumor growth and metastasis, leukemic B-cell clones, 3737

SUBJECT INDEX TO VOLUME 50

- survey of exposure to genotoxic agents
primary myelodysplastic syndrome,
6876
- t(11;14)(q23\>2) translocation
B-cell lymphoma, 4856
- translocation
detection of minimal residual disease,
leukemic patients, 5240
- 14;18 translocation
amplified and rearranged *bcl-2* gene,
lymphoma cell lines, 2423
- two locations
human ornithine decarboxylase gene
sequences, colorectal neoplasms,
6146
- Cl-921**
amsacrine and
pharmacokinetic and toxicity scaling,
2692
- pharmacokinetics, 503
- Cigarette smoking**
carcinogen-hemoglobin adducts
acetylation phenotype, 3002
- drinking and
relation to cancers, northern Italy,
6502
- grade of differentiation and subtype
lung adenocarcinoma, 444
- irradiated volume and
inflammation response in lung, irradiated
breast cancer, 2027
- precursor lesions of esophageal cancer
young persons in high-risk population,
China, 2268
- prospective study of stomach cancer, 627
- renal cell carcinoma, 5231
- role of P450IIIE1
metabolism of 3-hydroxypyridine,
5333
- stomach cancer
U.S. Veterans, 3804
- stomach cancer and, 7084
- tobacco-specific nitrosamine hemoglobin
adducts
mass spectrometric analysis, 5438
- withdrawal
hemoglobin adduct, 4-aminobiphenyl,
181
- Cisplatin:** see *cis*-Diamminedichloroplatinum(II)
- Clara cells**
O⁶-methylguanine formation
pulmonary neoplasia, 4-(methylnitro-samino)-1-(3-pyridyl)-1-butane,
3772
- Clonality**
assessment in human tumors, 1355
- Clowes Memorial Award**
critical factors in biology
human cancer metastasis, 6130
- molecular cytogenetics, 3816
- c-myb**
down-regulation of expression
inhibition of DNA synthesis, T-leukemia cells, 7371
- c-myc**
amplification and rearrangement
radiation-induced osteosarcoma, 4146
- amplification during progression
radiation-induced rat skin tumors,
3073
- amplification of gene
- human medulloblastoma cell lines,
xenografts, 2347
- analysis of *int-1*, *int-2*, and *neu* oncogenes
breast carcinoma, 5911
- antisense inhibition of single copy N-*myc* expression
neuroepithelioma cell line, 6316
- c-fos* and
changes in expression, bifunctional alkylating agents, 62
- characterization of transforming N-*ras* gene
hepatocarcinogenesis, Hep G2 cell line, 1521
- differentiation of F9 cells into embryoid bodies
early growth-associated events, 3193
- down regulation
bromodeoxyuridine, precommitment in HL-60 cells, 1411
- family of oncogenes
stability over time, xenografted lung carcinoma, 1566
- human homologue
Moloney leukemia virus integration-4 locus, multiple myeloma, 6478
- importance of phenotypic and molecular characterization
neuroepithelioma tumor cell line, 2794
- inhibited mitogenic response
transforming growth factor- β 1, colon carcinoma cells, 7581
- joining with line 1 family member on chromosome 8
primary giant cell carcinoma of lung, 3345
- MDBP site in first intron, 6865
- morphological and functional differentiation
bryostatins 1 and 2, neuroblastoma, 3422
- murine model for B-cell lymphomagenesis
immunocompromised hosts, 7042
- nuclear matrix-associated region
recognition by nuclear protein, HL-60 cells, 3199
- suppression of malignant phenotype
somatic cell hybrids, 3095
- transfected rat cells
thermal response, 4515
- vimentin mRNA and
differing protein ratios, leukemic cells, 1988
- Codon 13**
mutations
activation of mouse K-*ras*, 1,3-butadiene, 4818
- mutations of *c-ras*
gastrointestinal cancer, 480
- Co(III) mustard complex**
cytotoxicity and radiosensitization
antitumor activity, interaction with hyperthermia, 6971
- Collagen**
basement membrane type IV degradation proteolytic cascade, metalloproteinases, 5997
- mediated dispersion
bladder carcinoma cells, 129
- migration through matrix
- tumor-infiltrating lymphocytes, 7153
- type IV
integrin receptors, metastatic B16 melanoma cells, 728
- Collagenase**
interstitial
cloning and characterization, human tumor cells, 5431
- localization at basal plasma membrane
human pancreatic cell line, 6995
- M*, 94,000 gelatin-degrading metalloprotease
differentiation, HL-60 cells, 1113
- type IV *M*, 72,000
cellular processing, interstitial collagenase in tumorigenic cell lines, 6184
- Colombia**
high risk population
gastric precancerous process, 4731, 4737
- Colon**
carcinogenesis
fat-fiber interrelationships, 1092
- enzyme-altered foci
carcinogen-treated rats, 1911
- epithelial hyperproliferation
calcium-enriched diet, 1764
- malignant and potentially malignant cells
quantitative cytochemical detection, 5112
- preneoplastic
protein kinase C activity, 1,2-dimethylhydrazine-induced alterations, 3915
- Colonic neoplasms**
azoxymethane-induced carcinogenesis
different levels of calorie restriction, 5761
- binding and growth effects
bombesin-related peptides, 6772
- candidate cancer chemopreventive agents
animal models, human clinical trials, 2
- chemically induced in the rat
tumor-associated antigens common to humans, 6358
- colon-specific antigen p
murine monoclonal antibodies, 6405
- colorectal adenocarcinoma
properties of ornithine decarboxylase, 2088
- comparative pharmacokinetics of murine monoclonal antibody
rat colon tumor in rats and nude mice, 873s
- cytotoxic and cytokinetic effects
fluorouracil and interferon, 5735
- 1,2-dimethylhydrazine-induced chemoprevention, organosulfur compounds, 5084
- human
hepatic metastases, radioimmuno-dection, 877s
- human and rat
resistance to anthracyclines, drug passive diffusion, 6626
- human colon carcinomatosis xenograft
radioimmunotherapy, ⁹⁰Y-ZCE025
monoclonal antibody, 989s
- inhibition of urokinase plasminogen activator

SUBJECT INDEX TO VOLUME 50

- extracellular matrix degradation, 4676
 metastatic
 cell surface sialoprotein, 1299
 microvascular architecture, 2411
 mitochondrial cytochrome *c* oxidase, 1596
 molecular cloning of cDNAs
 alkaline phosphatase, 1085
 neoplastic transformation
 adenoma to carcinoma sequence, colonic epithelial cell line, 4724
³¹P magnetic resonance spectroscopy, 527
 production of diacylglycerol
 intestinal microflora, 3595
 promotion of microadenoma growth
 mice and rats fed cooked sugar, cooked casein and fat, 6955
 radiolocalization of monoclonal antibodies
 hepatic metastases, 862s
 rectum and
 risks, source of fiber and fiber components, 3295
 reduced expression of HLA class I and II antigens, 8023
 risk
 rectal cell proliferation, ulcerative colitis, 1156
 selective immunosuppressive factor, 6158
 staging
 presurgical imaging, In-labeled anti-carcinoembryonic antigen, 922s
 tumor-bearing mice
 biodistribution, ¹⁸⁶Re labeled NR-LU-10 whole antibody, 7973
 xenografts
 bone marrow transplantation, ⁹⁰Y antibody therapy, 1008s
 monoclonal antibody uptake, irradiation, 159
 radioimmunotherapy, ²¹²Bi-labeled antibody, 985s
Colony-stimulating factor
 differentiation therapy, 3453
 granulocyte
 DNA topoisomerase II expression, human leukemia cells, 7198
 pharmacokinetics, renal and hepatic failure, 6615
 proliferative responsiveness, bone marrow cells, 1847
 receptor binding to blast cells, myeloid leukemia, 1671
 granulocyte and granulocyte-macrophage transferrin receptor gene expression, myeloid leukemia, 7955
 tumor necrosis factor- α , normal and leukemic hemopoietic progenitors, 5065
 granulocyte and macrophage
 receptor coexpression, novel myeloid leukemia cell line, 7703
 granulocyte-macrophage
 human tumors and derived lines, 6264
 immunoregulatory macrophages, murine mammary tumor, 227
 Phase I study, subcutaneous administration, 606
 tumor necrosis factor release, monocytic cells, 2673
 insulin family hormones and functional interactions, myeloid leukemic cells, 6471
Colorectal neoplasms
 cytokine gene expression, 4436
 genetic changes and histopathological types
 familial adenomatous polyposis, 7166
 high frequency of deletions
 chromosome 1p35, 7232
 human antigens
 tumor targeting in nude mice, monoclonal antibodies, 828s
 human ornithine decarboxylase gene sequences
 two chromosomal locations, 6146
 presence of villin
 diagnosis and follow-up, 438
 regulation of carcinoembryonic antigen expression
 γ -interferon, 6248
 remaining colorectal mucosa after surgery
 cancer of the large bowel, epithelial cell kinetics, 7937
 tumor radiation doses
 monoclonal antibody-associated ⁹⁰Y activity, 1029s
Complements
 C1q-binding macromolecules
 importance, head and neck cancer, 4349
Concomitant resistance
 correlation with seric antitumor activity
 mice bearing nonimmunogenic tumors, 7159
Confocal laser scanning microscopy
 rhodamine 123 phototoxicity
 laser-irradiated carcinoma cells, 4167
Contraceptives
 oral
 early cytological abnormalities, cervix, 4670
 steroid
 procabazine-induced sterility, genotoxicity, 1308
CPT-11
 metabolism and pharmacokinetics in mouse, 1715
 nonlinear pharmacokinetics, 1721
Cremophor EL
 reversal of multidrug resistance phenotype, 4199
Cresozote
 -contaminated site
 hepatocellular carcinomas, *Fundulus heteroclitus*, 5978
Cryospectrophotometry
 bioluminescence and nuclear magnetic spectroscopy
 tumor energy, oxygenation status, 1681
CSF-1
 receptor c-fms and
 Hodgkin's disease-derived cell line, 2049
Cyanomorpholino doxorubicin
 resistance in ovarian carcinoma cell line
 DNA cross-linking, 4056
Cyclopentenyl cytosine
 enhancement of toxicity and DNA incorporation
 arabinosyl-5-azacytosine, 1- β -D-arabinofuranosylcytosine, 7279
 pharmacokinetics and metabolism
 nonhuman primates, 7915
Cyclophosphamide
 ADCC with anti-melanoma monoclonal antibodies
 in vivo-activated LAK cells, 6311
 Adriamycin and 5-fluorouracil chemotherapy
 sister chromatid exchanges, breast cancer, 4951
Antineoplastic activity
 experimental and human malignancies, 3473
 biological monitoring screening, 3351
 identification of mouse aldehyde dehydrogenases
 importance, aldophosphamide detoxification, 4991
-induced toxicity
 glutathione protection, cardiac and skeletal muscle, 2455
Mechanisms of action
 hepatic P-450 expression, 5720
 melanoma cell vaccine and suppressor cell activity, active specific immunotherapy, 5358
 melphalan and VP-16 synergistic interactions, rhabdomyosarcoma xenograft, 284
 residual damage in mouse lungs long intervals, 2139
Cyclosporin A
 hexamethylene bisacetamide and recovery of herpes simplex virus type 2, latency in neuroblastoma, 7852
 verapamil and modulation of multidrug resistance, leukemia cell lines, 2953
Cyclosporine A
 Ig antigen expression
 N-nitroso-N-methylurea-induced rat mammary tumors, 3301
Cyproterone acetate
 chemical induction
 dorsolateral prostate adenocarcinoma, 691
 chemical induction of prostate carcinoma, 700
Cyst
 fluid of ovarian cancer
 high concentrations, trypsinogen-2, 2375
Cysteamine
 anticarcinogenesis
 bromocriptine attenuating effect, stomach cancer, 5308
Cysteine
 adduct formation in hemoglobin
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 5453
Cysteine proteinase inhibitor
 cathepsin B balance and metastatic cell subpopulations, 6278
Cytidine
 regulation of phospholipid pathways
 1- β -D-arabinofuranosylcytosine, 552
Cytidine 5'-monophosphate-N-acetylneurameric acid:Gal β 1-3GalNAc(2-3)sialyltransferase
 human leukemic myeloblasts and mye-

SUBJECT INDEX TO VOLUME 50

- I**
- loblastoid cells, 5003
 - Cytochalasin B**
 - effects on murine Madison 109 lung carcinoma
 - B16 melanoma, 1431
 - Cytochrome c oxidase**
 - mitochondrial
 - colon cancer, 1596
 - Cytochrome P-450**
 - activation of food-derived heterocyclic amine mutagens
 - 2-acetylaminofluorene and benzo(a)pyrene, 3367
 - 5-aminolevulinate synthase activities hepatocytes, 5219
 - androgen-dependent renal microsomal N-hydroxylation, 3-methoxy-4-amino-azobenzene, 2729
 - biotransformation of *N,N',N''*-triethyl-nethiophosphoramidate, 464
 - hepatic expression mechanisms of cyclophosphamide action, 5720
 - inactivation of mutagens human and rat liver microsomes, 2036
 - Cytochrome P450IA1**
 - messenger RNA expression
 - polymerase chain reaction, rat and human tissues, 4315
 - Cytochrome P450IIE1**
 - metabolism of 3-hydroxypyridine constituent of tobacco smoke, 5333
 - Cytokeratin 8**
 - tissue polypeptide antigen-related protein
 - monoclonal antibody, Signet-ring cell carcinoma of stomach, 5192
 - Cytokines**
 - cascade and monocyte activation interleukin 2 bolus treatment, human cancer, 5795
 - gene expression in human colorectal cancer, 4436
 - induction by flavone acetic acid, 1742
 - intraperitoneal recombinant γ -interferon recurrent ascitic ovarian carcinoma, 7318
 - production in T-cell lymphoma, 8028
 - regulation of tumor necrosis factor- α and β mRNA human peripheral blood mononuclear cells, 5072
 - systemic alkalinization flavone acetic acid, renal cancer, 7926
 - treatment of human myelomonocytic cell line neopterin and tryptophan formation, 2863
 - Cytology**
 - sputum cytodiagnosis use of screening phase data, observer variation, 1216
 - Cytolysis**
 - antibody-mediated redirected murine melanoma cells, 6034
 - anti-GD₃ monoclonal antibodies childhood T-cell acute lymphoblastic leukemia, 202
 - inverse correlation between MHC expression and LAK activity lined human gliosarcoma cells, 596
 - Cytoplasm**
- P**
- peripheral airway cell differentiation human lung cancer cell lines, 5481
 - Cytoskeleton**
 - cellular F-actin levels as marker cellular transformation, cell division, 2215
 - defects in tropomyosin expression human mammary epithelial cells, 2105
 - megakaryocytic differentiation of K562 cells phosphotyrosyl-specific protein phosphatases, 6323
 - tumor cell tumor cell-platelet-endothelial cell interactions, 7686
 - Cytosol**
 - folate-binding proteins compartmentation of tetrahydrofolates, 3262
 - Cytostatic drugs**
 - prevention of hematotoxic side effects synthetic hemoregulatory peptide, 328
 - Cytotoxic T-lymphocytes**
 - melanoma-specific HLA-A2-matched allogeneic melanoma, 492
- D**
- Dacarbazine**
 - interleukin 2 and Adriamycin antitumor efficacy, solid tumor systems, 5876
 - Daunorubicin**
 - characterization of antifolate resistance flow cytometry, mammalian cells, 4946
 - α -interferon and synergistic potential, anti-human T-leukemia immunotoxins, 32
 - resistant P388 cells elevated pentose cycle, glucuronyl-transferase, 3921
 - 3'-Deamino-3'-morpholino-13-deoxo-10-hydroxy-carboxymycin**
 - conquest of multidrug resistance, 4698
 - 5-Deazaacyclotetrahydrofolate**
 - metabolism, 3207
 - Deferoxamine**
 - single course neuroblastoma patients, 4929
 - Dehydroepiandrosterone sulfate**
 - breast cancer risk, 6571
 - dehydroepiandrosterone and serum levels, postmenopausal breast cancer, 3859
 - Deoxyadenosine**
 - 5-fluorodeoxyuridine or blockade of cytotoxic effects, 5-hexyl-2'-deoxyuridine, 4552
 - residues**
 - activation of ras genes, aristolochic acid, 5464
 - 2'-Deoxy-5-azacytidine**
 - cisplatin or 4-hydroperoxycyclophosphamide synergistic cytotoxicity, human tumor cells, 4572
 - Deoxycytidine kinase**
 - substrate-specific deficiency 1- β -D-arabinofuranosylcytosine-resistant leukemic cells, 6515
- 5'-Deoxy-5-fluorouridine**
 - anticachetic activity colon 26 adenocarcinoma, 4528
- 2-Deoxyglucose**
 - effects on breast cancer cells, 544
- 15-Deoxyspergualin**
 - inhibition of antibody response *Pseudomonas* exotoxin, mice, 7750
- Dequalinium**
 - inhibition of rodent protein kinase C, 677
- 4-Desacetylvinblastine**
 - immunoconjugate LY203725 antitumor activity, ovarian cancer, 3540
- 4-Desacetylvinblastine-3-carboxyhydrazide**
 - L1C2 immunoconjugate xenografts, antitumor activity, 1790
- 2-Desamino-2-methyl-N¹⁰-propargyl-5,8-dideazafolic acid**
 - multiple membrane transport systems, 7544
- 2-Desamino-N¹⁰-propargyl-5,8-dideazafolic acid**
 - activity in murine human systems, 5212
- Deuterium**
 - nuclear magnetic resonance imaging tracer distribution, tumor blood flow in mice, 363
- Dextrans**
 - low molecular weight covalent modification, immunoglobulins, 3638
- Diabetes**
 - medical history and primary liver cancer, 6274
- Diacetlyputrescine**
 - potentiation of natural killer cell activity tumor immunity, 5460
- Diacylglycerol**
 - production by human intestinal microflora, 3595
 - TPA and down-regulation, epidermal protein kinase C, 5748
- Diaminedithiol**
 - bifunctional chelating agent ^{99m}Tc labeling, proteins, 799s
- 2,5-Diamino-3-hexyne**
 - morphological evidence of lysosomal-tropic activity unsaturated putrescine analogues, 1929
- cis-Diamminedichloroplatinum(II)**
 - acquired resistance colon carcinoma cells, 72 addition of 2-nitroimidazole radiosensitizers hyperthermia, fibrosarcoma, 2734
- antineoplastic activity**
 - experimental and human malignancies, 3473
- 1- β -D-arabinofuranosylcytosine and quantitation, drug synergism, 5318**
 - chronic glutathione elevation cytotoxicity, 5296
- cross-linking of myeloid cell nuclear differentiation antigen to DNA**
 - 1,25-dihydroxy vitamin D₃, HL-60 cells, 1183
- cytotoxicity of lonidamine RIF-1 and HT1080 cells, 7867**

SUBJECT INDEX TO VOLUME 50

- decreased accumulation as mechanism of resistance**
non-small cell lung cancer cell lines, 2549
- 2'-deoxy-5-azacytidine and 4-hydroperoxycyclophosphamide**
synergistic cytotoxicity, human tumor cells, 4572
- DNA adducts**
formation and removal kinetics, chemotherapy, 7887
- DNA binding and cell survival,** 3556
- effect of α -difluoromethylornithine on cytotoxicity**
brain tumor growth, 2769
- nonuniform alteration of tissue distribution**
whole body hyperthermia, 2075
- ORG-2766 and electrophysiological study, rat spinal ganglion neurons,** 2437
- platinum-DNA adduct levels**
known prognostic variable, ovarian cancer, 2256
- resistance in ovarian cancer cell line**
increased removal, DNA-bound platinum, 1863
- selective reduction of nephrotoxicity**
ebselein, 7031
- Diaziquone**
differential cytotoxicity
hypoxic and aerobic exposure, Chinese hamster ovary cells, 1516
- metabolism by NAD(P)H:(quinone acceptor) oxidoreductase**
colon carcinoma cells, 7293
- Dibutyryl cyclic adenosine 3':5'-monophosphate**
granulocyte differentiation of U-937 cells, 20
- induction of cells with phenotypic features**
neuronal cells, parotid gland adenocarcinoma, 6396
- dl-N,N'-Dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane**
inhibition of Fe^{3+} reduction
lipid peroxidation, heart microsomes exposed to Adriamycin, 2307
- Diet**
activity of methylated forms of selenium
cancer prevention, 1206
- age-related DNA modifications**
rat liver and kidney, 3991
- association of change in body mass**
breast cancer, 2152
- benign proliferative disorders of breast and**
case-control study, 3176
- calcium-enriched**
colonic epithelial hyperproliferation, 1764
- chemoprevention of colon carcinogenesis**
concurrent administration, piroxicam and D,L- α -difluoromethylornithine, 2562
- cooked sucrose, casein and fat promotion, colonic microadenoma growth,** 6955
- dietary and nondietary risk factors**
case-control study, breast cancer, 5017
esophageal cancer in Uruguay, 426
- increased protein turnover**
normal energy metabolism, feeding, 1125
- malnutrition severity**
hepatic glucose production, colorectal carcinoma, 2119
- micronucleated erythrocytes**
index of cytogenetic damage in humans, 5049
- prospective study of stomach cancer,** 627
- sex and**
elastase 1-Simian virus mouse model, pancreatic carcinoma, 7552
- stomach cancer and**
case-cohort study, 7501
- tobacco use and**
fatal prostate cancer, Lutheran brotherhood cohort, 6836
- wheat bran and lard**
- N-methyl-N'-nitro-N-nitrosoguanidine-induced colon carcinogenesis,** 1092
- Dietary fat**
calories and body weight
mammary tumor development, rats and mice, 5710
- cooked**
promotion, colonic microadenoma growth, 6955
- Dietary fiber**
source and components
risks, cancer of colon and rectum, 3295
- Diethyldithiocarbamate**
mechanism of modulation
murine bone marrow toxicity, 6218
- Diethylenetriaminepentaacetic acid chelator**
In-111 anti-CEA antibody, pharmacokinetics, 7272
- DiethylNitrosamine**
-induced hepatic neoplasia
cytotoxicity phase, medaka, 5504
- Diethylstilbestrol**
-diphosphate cytotoxic action
mitochondrial bc₁ complex, prostatic carcinoma, 5008
- Differentiation**
cancer control and
Ninth Annual Sapporo Cancer Seminar, 1346
- therapy,** 3453
- 2',2'-Difluorodeoxycytidine**
antitumor activity, 4417
- dose rate and schedule**
administration in leukemia, 6823
- modulatory activity**
phosphorylation and cytotoxicity, arabinosyl nucleosides, 3675
- 2',2'-Difluoro-2'-deoxycytidine**
antitumor activity, 4417
- α -Difluoromethylornithine**
antineoplastic activity
experimental and human malignancies, 3473
- 1,3-bis(2-chloroethyl)-1-nitrosourea**
cis-diamminedichloroplatinum(II) cytotoxicity, brain tumor growth, 2769
- tumor angiogenesis,** 4131
- Digestive neoplasms**
patterns of mate drinking
Brazilian city, 7112
- Diglycerides**
endogenous
induction of urokinase secretion, colon carcinoma, 2245
- Dihydrofolate**
methotrexate polyglutamates and leucovorin rescue, breast cancer, 3574
- Dihydrofolate reductase**
gene amplification
poly(ADP-ribosylation), carcinogen-induced methotrexate resistance, 5756
- Dihydroorotate inhibitors**
cytotoxic effects
human CCRF-CEM leukemia, 7793
- Dihydroorotic acid dehydrogenase**
inhibition of Brequinar sodium, 4644
- Dihydropyridines**
newly synthesized
drug resistance, photoaffinity labeling of P-glycoprotein, 310
- Dihydropyrimidine dehydrogenase**
plasma 5-fluorouracil levels
circadian variation, drug levels, 197
- 7,8-Dihydroxy-7,8-dihydrobenzo(a)pyrene**
oxidation and DNA binding
catechol, mouse epidermis, 1795
- 2,5-Dihydroxypyridine**
role of P450IIE1
metabolism of 3-hydroxypyridine, 5333
- 1,25-Dihydroxyvitamin D₃**
-induced monocyte differentiation
cis-diamminedichloroplatinum(II) cross-linking, 1183
- 1 α ,25-Dihydroxyvitamin D₃**
effects on human chronic myelogenous leukemia, 3087
- structure-function studies on analogues**
leukemic cell growth, intestinal calcium absorption, 6857
- 3,2'-Dimethyl-4-aminobiphenyl**
chemical induction of prostate carcinoma, 700
- ciproterone acetate, testosterone propionate,** 691
- 7,12-Dimethylbenz(a)anthracene**
benzo(a)pyrene and
covalent DNA adducts, mouse epidermal subpopulations, 3048
- chemical induction of prostate carcinoma,** 700
- ciproterone acetate, testosterone propionate,** 691
- induced and spontaneous mouse liver tumors**
DNA fingerprinting, 5245
- induced hamster buccal pouch carcinogenesis model**
epidermal growth factor receptor, polyamine levels, 2505
- induced hamster cheek pouch carcinogenesis changes, keratin expression,** 4441
- 1,2-Dimethylhydrazine**
-induced alterations
protein kinase C activity, rat preneoplastic colon, 3915
- induced carcinogenesis**
suppression, Bowman-Birk protease inhibitor, 580
- induced colon cancer**
chemoprevention, organosulfur com-

SUBJECT INDEX TO VOLUME 50

- pounds, 5084
 mutagenesis of mouse intestine
Dlb-1 assay, 7992
- Dimethylnitrosamine**
 modulation of *O⁶*-methylguanine-DNA methyltransferase
 rat and hamster liver, 5426
 mutagenesis of mouse intestine
Dlb-1 assay, 7992
- 16,16-Dimethyl prostaglandin E₂**
 flurbiprofen and
 gastrointestinal tumorigenesis, 381
- Dimethyl sulfoxide**
 retinoic acid and
 HL-60 cell differentiation, 6258
- 2,4-Dinitrophenol**
 abrogation by novobiocin of cytotoxicity amssacrine, Chinese hamster cells, 2577
- 1,3-Dinitropyrene**
 inactivation by cytochrome P-450
 human and rat liver microsomes, 2036
- Diol epoxides**
 molecular dosimetry of polycyclic aromatic hydrocarbon epoxides and hemoglobin adducts, 4611
- Dipyridamole**
 5-fluorouracil and folic acid
 Phase I trial, 7206
 modulation of drug sensitivity
 multidrug-resistant tumor cells, 7537
 Phase I trial
 5-fluorouracil, concurrent continuous infusion, 2667
- Ditercalinium**
 inhibition of respiratory chain
 mammalian mitochondria, 7966
- DNA**
 age-related modifications
 diet and, rat liver and kidney, 3991
 aneuploidy
 primary and metastatic spontaneous osteosarcoma, 6176
 binding activity of human *c-ets-1* protooncogene, 5013
 binding and induction of unscheduled DNA synthesis
 activation of ethylene dibromide, glutathione S-transferases, 2747
 binding of 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene
 catechol, mouse epidermis, 1795
 binding of benzo(a)pyrene diol-epoxide
 inhibition of 6-mercaptopurine, CHO cells, 4355
 bleomycin-induced damage and repair
 lysophosphatidylcholine, permeabilized human cells, 1613
 -bound platinum
 resistance to *cis*-diamminedichloroplatinum(II), ovarian cancer cell line, 1863
 calcium phosphate-mediated transfer
 spontaneous metastasis, 5581
 content of six-gene amplicon
 multidrug-resistant Chinese hamster cell line, 2803
 covalent
 gestation stage effect, benzo(a)pyrene-induced micronucleus formation, 2146
 covalent adducts
- mouse epidermal subpopulations, 3048
 cross-linking
 resistance to cyanomorpholino doxorubicin, ovarian carcinoma, 4056
 damage and repair
 flow cytometric analysis, cells resistant to alkylating agents, 4453
 resistance to *cis*-diamminedichloroplatinum(II), non-small cell lung cancer, 2549
 damage and repair by bleomycin domain, human amplified *MYC* oncogenes, 2379
 defective postreplication repair
 xeroderma pigmentosum variant fibroblasts, 2593
 determination of *O⁶*-butylguanine immunoaffinity extraction/gas chromatography-mass spectrometry, 6870
 development of polypliodization
 taxol-resistant leukemia cells, 710
cis-diamminedichloroplatinum(II)
 binding and cell survival, 3556
 double-strand break repair pathways
 cellular tolerance, topoisomerase II inhibitors, 5778
 epoxide-induced cytogenetic damage
 glutathione S-transferase deficiency, marker of susceptibility, 1585
 fingerprinting
 7,12-dimethylbenz[a]anthracene-induced and spontaneous liver tumors, 5245
 flow and image cytometric analysis
 rhabdomyosarcoma, 6023
 genetic damage by 4-nitroquinoline 1-oxide
 pregnancy, 6192
 human
 endogenous retroviral elements, 5636s
 human blood leukocytes
O⁶-methylguanine accumulation, procarbazine exposure, 2759
 incorporation
 leucovorin effects, idoxuridine cytotoxicity, 6652
 incorporation of arabinosyl-5-azacytosine
 1-β-D-arabinofuranosylcytosine, cyclopentenyl cytosine, 7279
 induction of replicative competence
 normal liver, 7023
 inhibition of excision repair by methotrexate
 Chinese hamster ovary cells, 1786
in situ sensitivity to denaturation
 tumor stage, bladder cancer, 7912
 interspecific
 transfection and amplification, *M*, 100,000 melanoma-associated antigen, 1559
 interstrand cross-link and free radical formation
 Mitomycin C and analogues, multidrug resistant cell line, 648
 interstrand cross-linking
 α -difluoromethylornithine effect, 1,3-bis(2-chloroethyl)-1-nitrosourea and *cis*-diamminedichloroplatinum(II) cytotoxicity, 2769
- intracellular strand scission
 growth inhibition by bleomycin, Ehrlich ascites tumor cells, 5275
 iododeoxyuridine incorporation
 radiosensitization, bladder carcinoma cells, 4962
 3.0-kilobase sequence
 hepatocellular carcinoma, p52 protein, 5658s
 libomycin-mediated cleavage
 head and neck squamous carcinoma cells, 1732
 liver
 reduction of I-compound levels, choline-devoid diet, 7577
 low proliferative activity
 favorable prognosis, peripheral T-cell lymphoma, 4845
 MDBP site in first intron of human *c-myc* gene, 6865
 mechanism of hepsulfam action
 chronic myelogenous leukemia, 7559
 toxicity, human tumor cell lines, 7555
 methylation patterns of myxoid liposarcoma, 7902
 mitochondrial
 anchorage-independent phenotype, transformed avian cells, 6675
 mixed population of cycling and noncycling cells
 drug sensitivity, growth status, 3551
 molecular events in mutation and cancer, 2853
 mouse
 3-methylcholanthrene binding, 4239
 multiple tumor
 chromosome 13q33-qter deletion, normal black population, 5406
 nuclear
 content of altered hepatic foci, rat liver carcinogenesis model, 7571
 overreplication
 reoxygenation, hypoxic regions of solid tumors, 5031
 pancreatic adenocarcinoma
 novel ribonucleoprotein complex, monoclonal antibodies, 6015
 papillomavirus
 immortalization of cervical and foreskin epithelial cells, dysplastic differentiation, 3709
 papillomavirus 16 DNA
 immortalized keratinocyte lines, 1316
 platinum-adduct levels
 known prognostic variables, ovarian cancer, 2256
 ploidy analysis
 flow cytometry, feline mammary tumors, 4003
 ploidy and growth fraction
 Ki-67 monoclonal antibody, non-small cell lung neoplasms, 4382
 ploidy level determinations
 high- and low-grade malignant variants, prostatic carcinoma, 4281
 ploidy patterns
 S-phase fraction, gastric carcinoma, 509
 polymerase α -primase complexes
 carcinogen-treated Chinese hamster ovary cells, 6894
 postreplication recovery

SUBJECT INDEX TO VOLUME 50

phenotypic characterization, CHO-UV-1 mutant, 2356
³²P postlabeling
 1,N⁶-propanodeoxyadenosine, acrolein-modified polydeoxyadenylic acid, 3005
 psoralen-photoinduced cross-links
 removal of, normal and Fanconi's anemia fibroblasts, 2443
 repair synthesis and thymine dimer removal
 microinjected photoreactivating enzyme, xeroderma pigmentosum fibroblasts, 1905
 replication intermediates
 abnormal profile, Bloom's syndrome, 3141
 pH-step alkaline elution, 1-β-D-arabinofuranosylcytosine, 2658
 restriction fragment length polymorphisms
 pathogenesis, choriocarcinoma, 488
 role of P450IIIE1
 metabolism of 3-hydroxypyridine, tobacco smoke, 5333
 single strand breaks
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane, hepatocytes, 1810
 strand breakage
 genistein, HL-60 and K-562 leukemia cells, 2618
 synthesis
 abrogation by novobiocin of cytotoxicity, amsacrine, 2577
 L929 cells, doxorubicin exposure, 4776
 topoisomerase II gene expression
 phytohemagglutinin stimulation, human lymphocytes, 5649s
 topoisomerase II-mediated cleavage
 aclarubicin inhibition, VP-16 and mAMSA toxicity, 3311
 topoisomerase inhibitor-induced strand breakage
 cytotoxicity, tumor necrosis factor, 2636
 transcription factors
 steroid receptors, gene expression, 6430
 tumor
 ganglioside G_{D3} expression, hepatocellular carcinoma and NIH 3T3 cells, 7697
 DNA, complementary
 aromatase
 stable expression, mammalian cells, 6949
 butyrylcholinesterase mRNA
 chromosome 3q26-ter, nervous system tumors, 1983
 catalytic subunit of protein kinase A rat hepatomas, regenerating liver, 1675
 cloning and sequencing
M, 70,000 human breast epithelial mucin-associated antigen, 5925
 -expressed human liver P-450
 mutagenic activation, 2-amino-3-methylimidazo[4,5-*f*]quinoline, 2060
 gene *WDNM2* homology, 1667
 genomic clones for carnoembryonic antigen

nonspecific cross-reacting antigen, Chinese hamster ovary and mouse fibroblast cells, 2397
 human α-actinin expression
 hepatocellular carcinoma, 6291
mdr
 multidrug resistance phenotype, melanoma cells, 1779
 molecular cloning
 alkaline phosphatase, colon cancer cells, 1085
 tumor promoter-induced genes, 1626
 DNA adducts
 aflatoxin B₁
 formation and removal, mammalian tracheal epithelium, 4918
 aryl carbohydrate
 tumor retention, radioiodinated antibodies, 783s
 benzo(a)pyrene
 lung, liver, and peripheral blood lymphocytes, 5088
 -cisplatin
 formation and removal kinetics, chemotherapy, 7887
 formation in mouse tissues
 benzo(a)pyrene-diol-epoxide, relation to serum levels, 1189
 hemoglobin
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane, 5446
 molecular dosimetry, polycyclic aromatic hydrocarbon epoxides and diol epoxides, 4611
 tobacco-specific, mass spectrometric analysis, 5438
 platinum resistance
 role of carrier ligand, L1210 cells, 6497
 DNA damage
 induction by new 2-chloroethyl nitrosourea
 malignant melanoma cells, 5898
 metabolism of mitomycin C by DT-diaphorase
 colon carcinoma cells, 7483
 oxidative stress
 inhibited DNA lesion repair, N-acetoxy-2-acetylaminofluorene in leukocytes, 4619
 topoisomerase II-mediated episomes, tumor-bearing mice, 6154
 U.S.-Japan Seminar on molecular mechanisms, 7085
 DNA methylation
 cell lineage-specific hypomethylated sites major breakpoint cluster region, 4984
 DNA-methyltransferase inhibitors
 differentiation therapy, 3453
 DNA polymerases
 calf
 substrate specificity, exonuclease, 5340
 heat radiosensitization
 human colony-forming unit-granulocyte-macrophage, 2044
 inhibition by suramin
 DNA synthesis, HeLa cells, 7754
 DNA repair
 -deficient and -proficient mice
 differential effect, ionizing radiation on transcription, 5045
 double strand breaks
 radiation-resistant cells, transformed embryo cells, 6575
 DNA synthesis
 apoptosis and phenotypic expression
 growth determinants of altered foci, liver during phenobarbital promotion, 5127
 Ca²⁺ ionophores and ionomycin
 tumor-promoting effects, mouse epidermis, 5806
 dual mechanisms of inhibition by triciribine, 4891
 gastrin-stimulated
 inhibition by lorglumide and loxiglumide, tumoral acinar pancreatic cell line, 5829
 inhibition
 down-regulated c-myc expression, T-leukemia cells, 7371
 inhibition of DNA polymerases
 suramin, HeLa cells, 7754
 long-term inhibition
 trapped topoisomerase II complexes, MAMSA and mitoxantrone toxicity, 5813
 tamoxifen effect
 malignant glioma lines, 7134
 DNA topoisomerase I
 camptothecin analogue-resistant cell line establishment
 non-small cell lung cancer, 5919
 decreased expression
 camptothecin-resistant tumor cell lines, 6925
 diverse effects of camptothecin on cell cycle
 lymphocytic and myelogenous leukemia cells, 5746
 DNA topoisomerase II: *see also* Topoisomerase II
 elevated expression
 camptothecin-resistant tumor cell lines, 7962
 enhanced expression
 granulocyte colony-stimulating factor, human leukemia cells, 7198
 inhibitors
 cellular tolerance, DNA double-strand break repair pathways, 5778
 induction of differentiation, myelomonocytic leukemia, 6708
 long-term inhibition of DNA synthesis toxicity, mAMSA and mitoxantrone, 5813
 mammalian
 DNA cleavage induction, streptonigrin, 5841
 -mediated DNA damage of episomes tumor-bearing mice, 6154
 phorbol ester effects
 monocytoid differentiation, HL-60 cells, 7116
 poisons
 cell killing mechanisms, nucleic acid synthesis, 6919
 reduction of drug accumulation
 acquired teniposide-resistant KB cell lines, 5819
 L-Dopa decarboxylase
 synaptophysin and chromogranin neuroendocrine differentiation markers, lung cancer, 6068

SUBJECT INDEX TO VOLUME 50

- Dosimetry**
 antibody targeted radionuclide therapy
 tumor cells, cerebrospinal fluid, 1043s
¹³¹I- vs. ⁹⁰Y-IgG or fragments
 bidistribution, human colonic tumor
 xenografts, 2330
 tumor, organ, and red marrow
 ¹³¹I-labeled anti-carcinoembryonic antigen monoclonal antibody, 1039s
 tumor radiation doses
 monoclonal antibody-associated ⁹⁰Y
 activity, colorectal cancer, 1029s
- Doxorubicin**
 anthracycline antibiotics
 high liposome entrapment, 4260
 antineoplastic activity
 experimental and human malignancies, 3473
 cytotoxicity of ionidamine
 RIF-1 and HT1080 cells, 7867
 exposure
 DNA synthesis, L929 cells, 4776
 -induced automaticity
 chick heart cell aggregates, 4209
 -induced cardiomyopathy
 ICRF-187, free radical scavenging enzymes, 5136
 resistance in lung cancer cell line
 non-P-glycoprotein mediated mechanism, multidrug resistance, 5392
 -resistant breast cancer cells
 antioxidant and xenobiotic-metabolizing enzyme gene expression, 1397
 response of mouse skin tumors
 carcinogen exposure, 6841
 -treated stem spermatogonia
 chromosomal mutations, germ cells, 370
- Drug resistance**
 camptothecin-resistant tumor cell lines
 elevated expression, DNA topoisomerase II, 7962
 cell-mediated cytolysis
 natural killer or LAK cells, 5931
 gallium nitrate
 modulation of cellular iron uptake, 4468
 inherent sensitivity and induced resistance
 chemotherapy, human cancer cell lines, 7513
 mechanisms
 anthracyclines, human and rat colon cancer cells, 6626
- DT-diaphorase**
 metabolism of mitomycin C
 colon carcinoma cells, 7483
- Duodenum**
 gastrointestinal tumorigenesis
 flurbiprofen and 16,16-dimethyl prostaglandin E₂, 381
- Dyes**
 benzidine congeners
 ras gene activation, rat tumors, 266
 photosensitizing
 nontumorigenic revertants, human lung cancer cell lines, 5369
- Dysplasia**
 differentiation therapy, 3453
- E**
- Ebselen**
- selective reduction**
cis-diamminedichloroplatinum(II)
 nephrotoxicity, 7031
- Effector cells**
 antitumor
 heat treatment effect, tumor cells, 6199
- Ehrlich ascites tumor cells**
 intracellular DNA strand scission
 growth inhibition, bleomycins, 5275
- Eicosanoid**
 synthesis
 fatty acids and inhibitors, growth of breast cancer cells, 7139
- Elastase 1**
 -Simian virus mouse model
 sex and diet, pancreatic carcinoma, 7552
- Elastin**
 gene expression in elastotic human breast cancers
 epithelial cell lines, 2164
- Electron microscopy**
 removal of psoralen-photoinduced DNA cross-links
 normal and Fanconi's anemia fibroblasts, 2443
 rhodamine 123 phototoxicity
 laser-irradiated carcinoma cells, 4167
- Embryos**
 -derived tumors
 cytogenetic analysis, 3416
- Golden hamster**
 karyotypic changes, X-ray-induced transformants, 760
- Syrian hamster**
 modulation of gene expression, ionizing radiation, 339
 pH 6.70, neoplastic transformation, 3722
- transformed rat**
 M_r 92,000 gelatinase release, metastatic phenotype, 3872
- transformation with oncogenes H-ras and v-myc**
 induction and repair of DNA double strand breaks, radiation-resistant cells, 6575
- EMT6 cells**
 interaction with hyperthermia
 tetrachloroplatinum(II)(Nile blue)₂ and (neutral red)₂, 3826
- Encephalopathy**
 immunopathogenesis of HIV infection, 5612s
- Endocytosis**
 action of ether lipids
 WEHI-3B, HL-60 and FDCP-Mix A4 cells, 7505
- Endoderm**
 differentiation of F9 cells into embryoid bodies
 early growth-associated events, 3193
- Endometrium**
 normal and neoplastic
 insulin-like growth factor I receptors, 3019
- Endoplasmic reticulum**
 comparative action of aflatoxin B₁
 mammalian airway epithelium, 2493
- Endothelial cells**
 -tumor cell-platelet interactions
- tumor cell cytoskeleton, 7686**
- tumorigenic vascular establishment and characterization, 5526**
- vascular**
 tumor angiogenesis, α -difluoromethylornithine, 4131
- Endothelin**
 production in human cancer cell lines, 3257
- Enzymes**
 soluble and membrane-bound
 merocyanine 540-sensitized photoactivation, L1210 cells, 7765
- Epidemiology**
 basic science and prevention of cancer, 6441
- Epidermal cells**
 increased ornithine decarboxylase activity
 12-O-tetradecanoylphorbol-13-acetate, murine epidermis, 4741
- 12-O-tetradecanoylphorbol-13-acetate effect**
 intercellular communication, 1324
- Epidermal growth factor**
 autocrine growth factors
 immunohistochemical evidence, lung adenocarcinoma, 7077
- cellular proliferation and phenotype**
 neoplastic human salivary intercalated duct cell line, 7650
- effects of progesterone**
 human meningioma cells, 2604
- gene expression in breast cancer biopsy, 4204**
- glioma cell growth**
 migration and invasion, 6039
- inhibition of progression from G₂-phase to mitosis**
 receptor-mediated phenomenon, various cells, 7932
- receptor characterization**
 endometrial carcinoma, 1841
- receptor or HER2/neu gene product**
 murine monoclonal antibodies, 1550
- related protein**
 purification from urine, breast cancer patients, 642
- transforming growth factor- α and induction of ascitic fluid in mice, 4915**
- Epidermis**
 Ca²⁺ ionophores and ionomycin
 tumor-promoting effects, 5806
- differential down-regulation of protein kinase C**
 TPA and diacylglycerol, tumor promotion, 5740
- initiated mouse**
in vitro analogue, tumor promoters
 and antipromoters, 4794
- oxidation and DNA binding**
 7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene, catechol, 1795
- subpopulations**
 distribution, covalent DNA adducts, 3048
- tumor promoter-induced genes**
 cDNA clones, 1626
- Pineoplasms**
 T-cell lymphoma
 polyoma virus-induced salivary gland

SUBJECT INDEX TO VOLUME 50

- tumors, 5643s
Epipodophyllotoxin
 -induced cell death
 poly(adenosine diphosphate-ribose)
 synthesis-deficient V79 cells, 2713
Epirubicin
 high dose
 pharmacokinetics and toxicity, 5095
Episome
 topoisomerase II-mediated DNA damage
 tumor-bearing mice, 6154
Epithelial antigens
 Exo-1 and EPM-1
 epidermal keratinocyte maturation, benign and malignant neoplasia, 7668
Epithelial cells
 alveolar
 laminin adhesion and expression, clonally related transformed and control sublines, 3383
 bronchial
 suppression of tumorigenicity, lung carcinoma, 1890
 carcinogenesis
 evidence, multistep nature, 5653s
 cervical and foreskin
 immortalization by papillomavirus
 DNA, dysplastic differentiation, 3709
 colonic
 neoplastic transformation, adenoma to carcinoma, 4724
 elastin gene expression
 elastic human breast cancers, 2164
 growth of human cell lines
 BALB/c mice, 5943
 kinetics
 remaining colorectal mucosa after surgery, cancer of the large bowel, 7937
 liver
 resistance, transforming growth factor- β_1 , 3600
 responsiveness to transforming growth factor- β_1 , *vraf* transformation, 7468
 spontaneous transformation, phenotypic expression, 1941
 mammary
 defects, tropomyosin expression, 2105
 tumor progression, four cell lines from same patient, 7351
 oncogene-transfected liver
 hepatocyte and oval cell antigens, hepatocellular carcinoma, 4809
 papillomavirus type 16-positive
 nontumorigenic and tumorigenic cells, transforming growth factor β_1 response, 7324
 paracrine stimulation of prostate secretion, 1966
 tracheal
 inhibition of transformation, chemotherapeutic agents, 2068
 progression to immortality, nonrandom chromosome alterations, 740
vraf-transformed
 growth-related genes, tumor progression, 7460
Epithelium
 collagen-mediated dispersion
 bladder carcinoma cells, 129
 esophageal
 labeling index and labeling distribution, esophageal cancer risk, 2651
 gastrointestinal tumorigenesis
 flurbiprofen and 16,16-dimethyl prostaglandin E₂, 381
 mammalian airway
 comparative action, aflatoxin B₁, 2493
 mammary
 intracisternal A-particles, 2404
 oral
 proliferation pattern marker, intracellular H3 mRNA, 5107
 proliferative intestinal
 4-amino folate analogues of folylpolyglutamyl synthetase, 4639
 tracheal
 formation and removal, aflatoxin B₁-DNA adducts, 4918
Epitopes
 identification
 proliferation-associated nucleolar antigen P120, 2704
 mapping and use of anti-idiotypic antibodies
 L6 monoclonal anticarcinoma antibody, 2449
Epoxide
 -induced cytogenetic damage
 glutathione S-transferase deficiency, marker of susceptibility, 1585
Epoxide hydrolase
 gene expression
 liver carcinogenesis, 6222
 xenobiotic messenger RNA
 hepatocyte nodules, hepatomas, 256
Epstein-Barr virus
 -immortalized lymphoblastoid cells
 malignant phenotype suppression, Burkitt's lymphoma, 3095
Erythroblastosis virus
 -infected chickens
 immune abnormalities, 4764
Erythrocytes
 alveolar macrophage cytostatic activity
 bleomycin lung damage, 2351
 genetic damage by 4-nitroquinoline 1-oxide
 pregnancy, 6192
 micronucleated
 index of cytogenetic damage in humans, 5049
Erythroid cells
 induction of differentiation
 leukemic K-562 cells, Adriamycin bound to microspheres, 1231
Erythroleukemia cells
 Adriamycin resistance, 7895
 combination cytotoxic-differentiation therapy
 5-fluorouracil with hexamethylene bisacetamide, 3878
 differential expression of transglutaminase
 response to retinoic acid, 7830
Friend virus-induced
 immunotherapeutic approaches, leukemia, 5682s
 murine
 synergistic action, activin A and hexamethylene bisacetamide, 3182
Escherichia coli
 estrogen-induced breast cancer protein
 monoclonal antibodies, 2390
Esophageal neoplasms
 epidemiological study of precursor lesions
 young persons in high-risk population, China, 2268
epithelium
 labeling index and labeling distribution, China, 2651
mate drinking
 alcohol, tobacco and diet in Uruguay, 426
point mutations in codons of ras gene,
 4911
smoking and drinking
 northern Italy, 6502
Esophagus
 carcinogenesis
 dietary molybdenum, N-methyl-N-benzylnitrosamine, 2418
 N'-nitrosonornicotine and 4-(methylnitrosamo)-1-(3-pyridyl)-1-butanol
 comparative metabolism, 4685
papilloma
 mutational activation, H-ras oncogene, 1591
Estradiol
 estrogen responsiveness in pituitary tumors, 3786
 α -fetoprotein and
 inhibition, estrogen-dependent breast cancer growth, 415
 growth control of MCF-7 cells
 serum-containing medium, 7806
 inhibition of breast cancer cell proliferation
 pimozide and thiordiazine, 5399
 inhibition of uptake by alkyl-lysophospholipid
 transforming growth factor- α secretion, breast cancer, 3172
N-nitrosomethylurea-induced mammary tumors
 insulin-like growth factor-related peptides, 7179
 regulation of transforming growth factor- β species
 breast cancer, 299
 sensitivity test
 contact-sensitive plates, BALB/c 3T3 cell monolayers, 2113
 -stimulated growth
 modulation by retinoid, breast carcinoma, 1997
17 β -Estradiol
 α -interferon and tamoxifen
 estrogen receptor concentration, MCF-7 cell cycle kinetics, 5387
Estrogen
 cellular and molecular events in loss of sensitivity
 breast cancer cells, 5868
 -dependent breast cancer growth
 inhibition by reaction product, α -fetoprotein and estradiol, 415
 developmental treatment
 uterine adenocarcinoma, 7677
 development and use of antiestrogens
 breast cancer, 4177
 -free conditions
 receptor-negative, hormone-nonresponsive clone from breast cancer cell

SUBJECT INDEX TO VOLUME 50

- line, 7285
 -induced breast cancer protein
 monoclonal antibodies, *Escherichia coli*, 2390
 -induced cell growth
 leukotriene formation, Leydig cells, 3866
 -induced insulin-like growth factors
 proliferation, breast cancer cells, 7770
 -induced pituitary tumors
 genetic susceptibility, 7920
 inhibitory effects on growth
 esophageal carcinoma cell line, 7212
 preservation of steroid hormone receptors
 tors
 organ cultures, breast carcinoma, 78
 prospective, population-based study
 prostatic cancer, 169
 proximal tubule dysplasia
 localization, renal microplasmomas, 113
 receptor-positive and -negative breast cancer
 phorbol ester effects, epidermal growth factor receptors, 4849
 receptors in bronchogenic carcinoma, 6632
 receptor-specific ligand
 high specific activity, [$16\alpha\text{-}^{123}\text{I}$]iodoestradiol- 17β , 7799
 regulation of placental alkaline phosphatase gene expression
 human endometrial adenocarcinoma, 3306
 responsiveness in pituitary tumors, 3786
 -responsive transformed Leydig cells
 retinoic acid effect on proliferation, serum-free culture, 5060
 -sensitive progression
 gonadotropin-releasing hormone, polyoma virus-induced mammary tumors, 5892
 sex differences and estrogen
N-methyl-*N*-nitrosourea-induced rat thyroid tumors, 7662
- Estrone**
 treatment with 4-hydroxyandrostenedione
 postmenopausal women, breast cancer, 193
- Ethanolamine**
 choline and
 thioepa cellular accumulation, L1210 cells, 4322
- Ether**
 -linked phosphoglyceride
 content of human leukemia cells, 7174
- Ether lipids**
 analogues
 inhibition of Ca^{2+} signaling, 4458
 elevation of leukemic cell intracellular calcium, 3327
 role of endocytosis
 WEHI-3B, HL-60 and FDCP-Mix A4 cells, 7505
- Ethyl 5-amino-1,2-dihydro-2-methyl-3-phenyl-pyridol[3,4-*b*]pyrazin-7-yl carbamate**
 2-hydroxyethanesulfonate, hydrate
 selected tumor systems, cultures, and in mice, 3239
- Ethylene dibromide**
- selectivity of glutathione *S*-transferases
 activation, hepatocytes, 2747
- Ethylmethanesulfonate**
 inhibition of DNA excision repair
 methotrexate, Chinese hamster ovary cells, 1786
- Etoposide**
 4'-[9-acridinylamino)methanesulfon-m-aniside and
 antagonistic effect of aclarubicin, small cell lung cancer, 3311
 -induced cell death
 p34^{cdc2} kinase activity, Chinese hamster ovary cells, 3767
 inhibition of p34^{cdc2} kinase activity
 G_2 arrest, Chinese hamster ovary cells, 3761
 plasma protein binding
 prospective evaluation of model, cancer patients, 6854
- Etretrate**
 use of screening phase data
 observer variation, sputum cytodiagnosis, 1216
- Exercise**
 voluntary
 protective effect, pancreatic carcinogenesis, 6811
- Exonuclease**
 substrate specificity
 calf DNA polymerase, 5340
- Extracellular matrix**
 degradation
 inhibition, urokinase plasminogen activator, 4676
 -degrading metalloproteinase matrix secretion, human rectal carcinoma cell line, 7758
 diethylnitrosamine-induced hepatic neoplasia
 cytotoxicity phase, medaka, 5504
 differentiation therapy, 3453
 digestion large acidic vesicles
 cathepsin D, breast cancer cells, 6045
 inhibition of laminin- and thrombospondin-mediated melanoma cell adhesion
 migration and binding, adhesive proteins to sulfatide, 5937
 inhibition of sulfated chitin derivatives
 metastatic melanoma cells, 3631
 rapid degradation of proteins
 normal human uroepithelial cells, 1897
- Eye**
 nude mouse intraocular xenograft model
 heterotransplantation, lymphoid neoplasms, 3078
- F**
- Fab fragments**
 astatin-211-labeled antibodies and fragments
 comparative tissue distribution, 3514
 biodistribution of 791T/36 antibody and Fab/c fragment
 BALB/c and nude mice, human tumor xenografts, 2936
 enhanced delivery of monoclonal antibody F(ab')₂
 glioma xenografts, local hyperthermia,
- 1803
¹³¹I-labeled F(ab')₂ fragment of Mel-14 radioimmunotherapy, glioma xenografts, 1822
 intact antibodies and ricin A chain preparations, Hodgkin's disease, 2929
 monoclonal antibody and F(ab')₂ delivery to tumor glioma, 4105
- Fallopian tube neoplasms**
 immunolymphoscintigraphy
 F(ab')₂ fragments of monoclonal antibodies, 937s
- Familial adenomatous polyposis**
 genetic changes and histopathological types
 colorectal neoplasms, 7166
- Fatty acids**
 inhibitors and
 eicosanoid synthesis, growth of breast cancer cells, 7139
 mobilization
 reduced suppression by feeding, lymphoma-bearing mice, 2221
- ω-3 Fatty acids**
 inhibition of weight loss
 experimental cachexia model, 5022
- Fazarabine**
 Phase I and pharmacokinetic study, 1220
- F9 cells**
 differentiation into embryoid bodies
 early growth-associated events, 3193
- FDCP-mix A4 cells**
 role of endocytosis
 action of ether lipids, 7505
- Ferric nitrilotriacetate**
 -induced renal lipid peroxidation
 sex hormone dependence, 5574
- α-Fetoprotein**
 carcinoembryonic antigen expression
 monoclonal antibody targeting, human hepatoma/nude mouse model, 869s
 estradiol and
 inhibition, estrogen-dependent breast cancer growth, 415
 production of interleukin 6
 human liver cell lines, 7457
 woodchuck model of hepatitis C virus infection and disease, 7843
- Fibrin**
¹¹¹In-labeled anti-fibrin antibody detection, thrombophlebitis, 958s
- Fibrinogen**
 interaction with melanoma cells, 8010
- Fibroblast growth factor**
 basic
 immunohistochemical localization, astrocytoma, 7393
 receptors, glioma cell line, 2524
- receptor**
 androgen-induced heparin-binding growth factor, Shionogi carcinoma, 2316
- Fibroblasts**
 complementary DNA and genomic clones
 carcinoembryonic antigen, nonspecific cross-reacting antigen, 2397
 diploid human
 valence state and solubility, chromium

SUBJECT INDEX TO VOLUME 50

- compounds, 7835
Fanconi's anemia
 removal, psoralen-photoinduced DNA cross-links, 2443
 genetically manipulated
 implantation, antitumor α -interferon therapy, 5102
growth factor-triggered signal transduction
 role of *bcl-2*, 7399
malignant transformation
 hydroxyanthraquinones as tumor promoters, 6540
 transfected N-ras oncogene, 5587
modulation of parathyroid hormone-like protein
 squamous carcinoma, 3589
NIH3T3
 hepatocellular carcinoma 3.0-kilobase DNA sequence, 5658
normal
 spontaneous abnormalities, Li-Fraumeni cancer syndrome, 7979
skin
 basal cell nevus syndrome, killing by ultraviolet B, 637
 radiosensitivity, atomic bomb survivors with and without breast cancer, 4050
 β -subunit of platelet-derived growth factor
 neoplastic tissue and soft tissue tumors, 6344
10T½
 transient gene alterations, metastatic lung colonization, 4061
xeroderma pigmentosum variant
 defective postreplication repair, 2593
 thymine dimer removal, photoactivating enzyme, 1905
Fibronectin
 -binding ability
 antitumor efficacy, various mycobacteria, 3843
 oncofetal
 distribution, mammary tumors, 1608
 pre-messenger RNA
 alternative splicing in lung tissue, oncodysfunctional regulation, 1075
 proteolytic fragments
 adhesion, *ras*-transformed tumor cells, 4388
 receptor
 normal and transformed human cells, 1601
Fibrosarcoma
 addition of 2-nitroimidazole radiosensitizers
 cis-diamminedichloroplatinum(II), hyperthermia, 2734
 cell adhesion
 laminin peptides, 7612
 classification of antineoplastic treatments
 different toxicity, oxygenated and hypoxic tumor subpopulations, 3339
 interaction of SR-4233 with hyperthermia and radiation, 5055
 interaction with hyperthermia
 site-dependent differences
 response to systemic therapy with Adriamycin, 7775
Fish oil
 inhibition of weight loss by ω -3 fatty acids
 experimental cachexia model, 5022
Flavone acetic acid
 immunological effects, 6483
 -induced tumor vasculature shutdown
 role of tumor necrosis factor, 5537
 induction of cytokines, 1742
 inhibition of its ability to augment natural killer activity
 systemic alkalinization, renal cancer, 7926
Flavone-8-acetic acid
 production of nitric oxide
 activated macrophages, 6966
Flavonoids
 inhibitory effect of apigenin
 epidermal ornithine decarboxylase, skin tumor promotion, 499
Flavoproteins
 gene *WDNM2* homology, 1667
Flow cytometry
 analysis of DNA damage and repair cells resistant to alkylating agents, 4453
 characterization of antifolate resistance mammalian cells, methotrexate and daunorubicin, 4946
 clinical cancer progression
 monoclonal antibodies, urinary bladder tumors, 432
 DNA ploidy analysis
 mammary tumors, 4003
Flow karyotyping
 DNA content of six-gene amplicon multidrug-resistant Chinese hamster cell line, 2803
Flouxidine
 prolonged serum half-life
 incorporation, low density lipoproteins, 7476
Fludarabine
 iron chelates and gallium nitrate interaction, HL-60 cell proliferation, 6466
Fludarabine phosphate
 Phase I/II trial
 loading bolus and continuous infusion, pediatric patients, 7226
Fluorescein isothiocyanate
 rabbit and sheep antibodies
 interstitial transport, normal and neoplastic tissues, 3487
2-Fluoro-1- β -D-arabinofuranosyladenine 5'-monophosphate
 adenosine receptors
 natural killer cell activity, purine nucleosides, 4328
5-Fluorodeoxyuridine
 deoxyadenosine or blockade of cytotoxic effects, 5-hexyl-2'-deoxyuridine, 4552
5-Fluoro-2'-deoxyuridine
 enhancement of antitumor activity
 cytosolic folate-binding proteins, compartmentation of tetrahydrofolates, 3262
5-Fluorouracil
 antineoplastic activity
 experimental and human malignancies, 3473
 biological monitoring screening, 3351
 bolus arterial administration
 disposition, tissue-isolated tumor perfusion system, 1640
 cyclophosphamide and Adriamycin chemotherapy
 sister chromatid exchanges, breast cancer, 4951
 dipyridamole and folinic acid
 Phase I trial, 7206
 enhancement of azidothymidine cytotoxicity, 4026
 hexamethylene bisacetamide and cytotoxic-differentiation therapy, erythroleukemia cells, 3878
interferon
 cytotoxic and cytokinetic effects, colon cancer, 5735
 γ -interferon and
 colon carcinoma cell line, 5834
-mediated thymidylate synthase
 dose response to leucovorin, colon adenocarcinoma xenografts, 3940
Phase I trial
 dipyridamole, concurrent continuous infusion, 2667
 plasma levels and circadian variation dihydropyrimidine dehydrogenase activity, 197
 recombinant α_{2a} -interferon and
 Phase I trial, advanced colorectal carcinoma, 2056
 reconstitution of immune and hematopoietic systems
 interleukin 6 perfusion, 2885
 substitution
 self-splicing activity, *Tetrahymena* ribosomal RNA, 1757
Fluosol-DA
 changes in radiation sensitization
 ^{31}P nuclear magnetic resonance spectroscopy, 7252
Flurbiprofen
 16,16-dimethyl prostaglandin E₂ and gastrointestinal tumorigenesis, 381
Folate
 -based thymidylate synthase inhibitors, 5212
 uptake, multiple membrane transport systems, 7544
 -binding proteins
 compartmentation, endogenous tetrahydrofolates, 3262
 dose response to leucovorin
 colon adenocarcinoma xenografts, 3940
Folate compounds
 novel transport system
 wild-type and methotrexate-resistant L1210 cells, 1709
Folinic acid
 dipyridamole with 5-fluorouracil
 Phase I trial, 7206
Folylpolyglutamyl synthetase
 4-amino folate analogues
 tumors and proliferative intestinal epithelium, 4639
Forestomach neoplasia
 benzo(a)pyrene-induced conjugated dioenoic derivatives, linoleic acid, 1097
Foreskin

SUBJECT INDEX TO VOLUME 50

- immortalization of epithelial cells
papillomavirus DNA, dysplastic differentiation, 3709
- Framingham study
risk of large bowel cancer
physical activity, 3610
- France
HTLV-I-associated diseases, 5692s
- Friend erythroleukemia cells
 α/β -interferon-resistant
 α/β -interferon inhibition, mouse hepatocytes, 3533
- Friend virus
-induced erythroleukemia model
immunotherapeutic approaches, leukemia, 5682s
- α -L-Fucosidase
plasma
risk, borderline epithelial ovarian tumors, 4702
- α -(1-3)-L-Fucosyltransferase
two distinct activities
characterization, human colon carcinoma, 6787
- Fumaric acid derivatives
induction of glutathione transferases and NAD(P)H:quinone reductase
rodent cells and tissues, 7871
- Fundulus heteroclitus*
hepatic neoplasms
creosote-contaminated site, 5978
- G**
- β -Galactoside
-specific lectin from mistletoe extract
TNF- α , IL-1 and IL-6 increased secretion, mononuclear cells, 3322
- Galactosyltransferase
cancer-associated
new tumor marker, ovarian clear cell carcinoma, 754
- metastasis-associated murine melanoma cell, 7261
- Gallium
differential growth-inhibitory effects
B-cell lines, iron concentrations, 5727
- Gallium-67
uptake and retention in HL-60 cells
role of acidic receptosome, 1484
- Gallium nitrate
development of drug resistance
modulation of cellular iron uptake, 4468
- interaction with fludarabine and iron chelates
proliferation, HL-60 cells, 6466
- Ganglioside G₃_n
enhanced expression
human and rat hepatocellular carcinoma cells, NIH 3T3 cells, 7697
- Gangliosides
accumulation
N-acetylneuraminoxy(α 2-6)lactosamine, hepatoma, 1284
- 9-O-acetyl GD3
natural form, human melanoma and bovine buttermilk, 1403
- antiganglioside antibodies
increased lysis of melanoma, *in vivo*-elicited LAK cells, 6311
- sialoglycoproteins and
- rare blood group antigen determinant, monoclonal antibodies, 5497
- Gap junction**
intercellular communication and TPA
colony formation, coculture system in JB6 clones, 5567
- inhibitory effect of testosterone, transitional cell carcinoma, 2848
- 12-O-tetradecanoylphorbol-13-acetate effect, epidermal cells, 1324
- ultrastructural differences in intercellular communication
highly and weakly metastatic clones, mammary carcinoma, 358
- Gastric neoplasms**
diet and
case-cohort study, 7501
- heterogeneous protooncogene amplification
tumor progression and metastases, 7811
- meta-analysis of risk of stump cancer
remote partial gastrectomy, benign conditions, 6486
- newly established cell line
expression, hybrid form of alkaline phosphatase isoenzyme, 3408
- point mutations in codons of *ras* gene, 4911
- Gastrin**
-stimulated DNA synthesis
inhibition by lorglumide and loxiglumide, tumoral acinar pancreatic cell line, 5829
- Gastritis**
atrophic
stomach cancer and, comparative case-control analysis, 6559
- Gastrointestinal dysplasias**
activation of c-Ki-ras
polymerase chain reaction, 3627
- Gastrointestinal neoplasms**
mutations of *c-ras*, 480
peritoneal carcinomatosis
early postoperative intraperitoneal chemotherapy, 5790
- Gastrointestinal tract**
gastric precancerous process
high risk population, 4731, 4737
- Gelatinase**
M, 92,000
metastatic phenotype, transformed rat embryo cells, 3872
- tumor promoter-stimulated *M*, 92,000
normal and malignant human cells, 6162
- Gelonin**
pharmacokinetics of immunotoxins, 7519
- Gemcitabine: see 2',2'-Difluorodeoxycytidine**
- Genes**
AKR gene locus *AKv-1*
chemical induction, thymic lymphoma, 6235
- amplification
gastric and esophageal adenocarcinoma, 6417
- primitive neuroectodermal tumors, childhood, 587
- androgen receptor
prostate carcinoma, 5382
- bacterial *lacZ*
marker to detect micrometastasis formation, tumor progression, 2808
- bcl-2*
amplification and rearrangement, lymphoma cell lines, 2423
- chimeric P-enopyruvate carboxykinase-bacterial O^6 -alkylguanine-DNA alkyltransferase
transgenic mice, 1701
- c-Ki-ras
mutations, gastrointestinal cancer, 480
- cloning for T84.66
chimeric anti-CEA antibody, myeloma and Chinese hamster ovary cells, 2128
- erbB-2*
increased copies and expression, multiple stages of breast cancer, 6701
p185^{ERBB2}, gastric carcinoma, 8002
- expression
steroid receptors, transcription factors, 6430
- genetically manipulated fibroblasts
antitumor α -interferon therapy, 5102
- growth-related
tumor progression, *v-raf*-transformed liver epithelial cells, 7460
- HER/neu**
murine monoclonal antibodies, human epidermal growth factor receptor, 1550
- HSP-70**
expression in leukemic cells, 2877
- IFN α and IFN β**
absence from malignant glioma, interferon sensitivity, 278
- modulation of expression
ionizing radiation, Syrian hamster embryo cells, 339
- multidrug resistance
inverse correlation, *N-myc* in neuroblastoma, 3043
- myc family**
stability over time, xenografted lung carcinoma, 1566
- 11p**
loss of heterozygosity, lung carcinoma, 2303
- poly(ADP-ribose) polymerase**
chromosome 13q33-qter deletion, normal black population and multiple tumor DNA, 5406
- p53 rearrangements**
frequency and structure, human osteosarcoma, 7950
- progesterone receptor expression, 5291
- provincial gene *Mtv-3* endogenous expression
resistance to infection, 3754
- ras**
activation by aristolochic acid, deoxyadenosine residues, 5464
- benzidine congeners and dyes, rat tumors, 266
- neoplastic transformation, SV40-immortalized uroepithelial cells, 4779
- point mutation in codons, esophageal and gastric cancer, 4911
- ras mutations**
hepatocellular malignant tumors, polymerase chain reaction, 1121

SUBJECT INDEX TO VOLUME 50

- human prostate cancer, 6830
rearrangements
 HTLV-I infection, immortalized lymphocytes, 5697s
 S6, S11, and S14 ribosomal proteins
 noncoordinated expression, leukemic blast cells, 5825
six-gene amplicon
 DNA content, multidrug-resistant Chinese hamster cell line, 2803
smg p25A
 expression, neuroblastoma cell lines, 7242
transfection
 sensitivity to *Vinca* alkaloids, calmodulin overexpression, 6554
transforming N-ras
 hepatocarcinogenesis, hepatoma cell line, 1521
tumor promoter-induced
 cDNA clones, epidermis, 1626
tumor suppressor
 workshop, 6765
unrelated and closely linked
 coregulation, α -methylguanine-DNA methyltransferase, 1532
WDNM2 homology, 1667
- Genetics**
 analysis of malignant transformation, 3805
 changes and histopathological types
 colorectal neoplasms, familial adenomatous polyposis, 7166
 hereditary breast cancer
 workshop on linkage studies, 4448
 molecular cytogenetics, 3816
- Genistein**
 induction of differentiation and DNA strand breakage
 HL-60 and K-562 leukemia cells, 2618
- Genital neoplasms**
 immortalization of cervical and foreskin epithelial cells
 papillomavirus DNA, dysplastic differentiation, 3709
male
 mesenchymes, differentiation of Dunning prostatic adenocarcinoma, 4747
- Genotoxic agents**
 survey of exposure
 primary myelodysplastic syndrome, 6876
- Genotoxicity**
 procarbazine-induced sterility protection, steroid contraceptives, 1308
- Germ cell neoplasms**
 mutation frequencies in human tumor cell lines, 7513
 nonseminomatous
 serum tumor marker half-life during chemotherapy, 5904
- Germ cells**
 low levels of chromosomal mutations doxorubicin-treated stem spermatogonia, 370
- Gestation**
 differential effect of stage benzo(a)pyrene-induced micronucleus formation, 2146
- Glioblastoma**
- human
 purine metabolism, 1576
 rearrangement of human *ABL* oncogene, 3429
 release of interleukin 6, 6683
- Gloma**
 adoptive immunotherapy
 LAK cells and interleukin 2, 4338
 basic fibroblast growth factor-like activity
 receptors, 2524
 cell growth, migration, and invasion
 epidermal growth factor, 6039
 epidermal growth factor receptor, 8017
 expression of heterogeneous profiles
 plasminogen activators and inhibitors, 4957
 expression of metalloproteinases
 metalloproteinase inhibitors, 2322
 growth inhibition of transfected cells
 human interferon- β gene, 7826
 high grade
 calmodulin inhibitors with bleomycin, 6636
 human
 glycosphingolipids, 7444
 malignant
 absence of *IFNA* and *IFNB* genes, interferon sensitivity, 278
 tamoxifen effect, DNA synthesis, 7134
 monoclonal antibody and F(ab')₂ fragment
 delivery to tumor, 4105
 normal rat brain and 9L brain tumor
 serpin inhibitors, urokinase and thrombin, 5039
 phosphorylation of pyruvate kinase type K
 cyclic adenosine 5'-monophosphate-independent protein kinase, 4604
 potent cytotoxicity
 transferrin receptor-ricin A chain immunotoxin, 6696
- spheroid model**
 infiltrative and cytolytic activities, LAK cells, 2429
- transport**
 sarcosinamide and sarcosinamide chloroethylnitrosourea, 3062
- xenografts**
 radioimmunotherapy, ¹³¹I-labeled F(ab')₂ fragment, 1822
 targeting and therapy, radiolabeled antibodies, 974s
- xenotransplanted human**
 buthionine sulfoximine entry into brain, 1251
- Gliosarcoma cells**
 lined human
 inverse correlation, MHC expression and LAK activity, 596
- Glucocorticoid**
 effects on myeloma cells in culture, 1873
- Glucose**
 hepatic production
 growth hormone and malnutrition, colorectal carcinoma, 2119
- Glucose-6-phosphate dehydrogenase**
 modulation of NADPH pathways sex steroid hormone, MCF-7 cells, 1195
- Glucosylceramide synthase**
- inhibitor**
 inhibition of metastasis, Lewis lung carcinoma, 6731
- Glucuronyltransferase**
 elevated pentose cycle and daunorubicin-resistant P388 cells, 3921
- L-Glutamate**
¹³N-labeled
 short-term metabolic fate, Walker 256 carcinoma, 4839
- Glutamine**
 low concentrations
 growth adaptation and transformation suppression, NIH-3T3 cells, 2832
- Glutamine synthetase**
 altered acinar distribution
 growth response, hepatocytes after partial hepatectomy, 4407
- γ -Glutamyltranspeptidase**
 multistage hepatocarcinogenesis
 effects of age and sex, 472
- Glutathione**
 acquired resistance
 cis-diamminedichloroplatinum(II), colon carcinoma cells, 72
- chronic elevation
 cis-diamminedichloroplatinum(II), ionizing radiation or hyperthermia, 5296
- conjugation with prostaglandin D₂
 antiproliferative activity, glutathione depletion, 1879
- content and glutathione *S*-transferase expression
 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant malignant astrocytoma, 6976
- depletion by *N,N'*-bis(*trans*-4-hydroxy cyclohexyl)-*N'*-nitrosourea
 sensitivity of K562 leukemia cells, 4-hydroperoxycyclophosphamide, 4067
- melphalan treatment
 changes in resistance, stomach cancer, 3614
- protection of cardiac and skeletal muscle cyclophosphamide-induced toxicity, 2455
- Glutathione *S*-transferase**
 activation of ethylene dibromide by glutathione conjugation
 DNA binding, unscheduled DNA synthesis in hepatocytes, 2747
 alkylating agent resistance
 modulation chemotherapy, 6449
 deficiency as marker of susceptibility
 epoxide-induced cytogenetic damage, 1585
 expression in lymphocytes
 chronic lymphocytic leukemia, 3562
 transcriptional control of gene expression
 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, liver, 2251
- Glutathione transferases**
 activity and isoenzyme composition
 primary human breast cancers, 6848
 -mediated denitrosation
 nitrosoguanidinium compounds, rat, mouse, and hamster isozymes, 1440
 NAD(P)H:quinone reductase and
 induction by fumaric acid derivatives,

SUBJECT INDEX TO VOLUME 50

rodent cells and tissues, 7871
Glycerol phosphate dehydrogenase
 mitochondrial
 insulinomas, amine precursor uptake decarboxylation system, 7203
Glycine
 aspartic acid mutations at codon 13
 c-Ki-ras gene, gastrointestinal cancer, 480
Glycolipids
 liposome composition and other factors targeting of liposomes to tumors, biodistribution, 6371
Glycoproteins
 high mannose
 tumor necrosis factor and interleukin 1 interactions, 6285
Glycoprotein antigen
 characterization and distribution
 monoclonal antibody, breast cancer cell line, 7333
Glycoproteins
 anti-CEA and antitumor-associated glycoprotein 72 monoclonal antibodies complementary reactivities, lung carcinoma, 6987
 323/A3 surface
 tumor characteristics and behavior, breast cancer, 3317
EPM-1 and Exo-1 expression
 epidermal keratinocyte maturation, benign and malignant neoplasia, 7668
hepatocellular membrane
 identification and characterization, 4755
 high molecular weight human lung carcinoma-associated detection and characterization, 6738
 human melanoma adapted Newcastle disease virus mutant
 highly selective replication patterns, 5962
 human tumor associated Thomsen-Friedreich antigen, 4801
Lewis^x-containing
 glycolipids, adenocarcinoma, 1375
M_r, 41,000
 thrombin-independent platelet aggregation, melanoma metastatic variants, 6657
M_r, 100,000
 transfection and amplification, interspecific DNA, 1559
M_r, 170,000
 bone marrow purging, multidrug-resistant cells, 4291
 metastasis-associated melanoma cell surface galactosyltransferase, 7261
 surface growth regulation, human bladder cancer, 293
 transferrin receptor-related melanoma cells, 515
Glycosphingolipids
 acidic sulfated
 accumulation, hepatocellular carcinoma, 2917
 human glioma, 7444
Glycosyltransferases
 carbohydrate analysis
 immunoglobulin G myeloma proteins, 5345

Gonadectomy
 sex differences and estrogen
N-methyl-*N*-nitrosourea-induced rat thyroid tumors, 7662
Gonadotropin-releasing hormone agonist
 protection of testis, Zoladex, 568
 direct inhibiting effects
 estrogen-sensitive progression, polyoma virus-induced mammary tumors, 5892
Gossypol
 rhodamine 123 and
 MCF-7 cells, ³¹P nuclear magnetic resonance and toxicity studies, 6936
Grants
 funding, 3469
 traditional competing RO1, 3470
Granulocytes
 differentiation of U-937 cells
 dibutyryl cyclic adenosine 3':5'-monophosphate, 20
Growth factors
 autocrine
 insulin-like growth factor I, small cell lung cancer, 2511
 cell membrane and cell signals as targets
 cancer chemotherapy, 2203
 constitutive and induced expression
 chronic myelogenous leukemia Ph¹
 bone marrow stroma, 5801
 -dependent inositol phosphate Ca²⁺ signaling
 antitumor ether lipid analogues, 4458
 differentiation therapy, 3453
 effects of progesterone
 response to epidermal growth factor, human meningioma cells, 2604
 estradiol and
 growth control of MCF-7 cells, serum-containing medium, 7806
 heparin-binding
 androgen induction, fibroblast growth factor receptor, 2316
 paracrine growth stimulation
 androgen-responsive Shionogi carcinoma 115, 4979
 platelet-derived
 β-receptors, human carcinoid tumors, 748
 synthesis
 insulin/insulin-like growth factor I independence, mammary carcinoma, 5351
 -triggered signal transduction
 role of *bcl-2*, 7399
Growth hormone
 relationship of hepatic glucose production
 malnutrition severity, colorectal carcinoma, 2119
GTP-binding protein
 expression of *smg p25A*
 neuroblastoma cell lines, tumor tissues, 7242
Guanine
 nucleotides
 phospholipase C activity, small cell lung carcinoma, 5257
Gynecological neoplasms
 pS2 messenger RNA, 1800

H

H-2 complex
 potential lymphoma-inducing cells
 radiation leukemia virus variants, lymphomagenesis, 2554
Heart
 cell aggregates
 doxorubicin-induced automaticity, 4209
 microsomes exposed to Adriamycin
 inhibition of Fe³⁺ reduction, *dL-N,N'*-dicarboxyaminomethyl-*N,N'*-dicarboxymethyl-1,2-diaminopropane, 2307
Heat
 changes in intratumor pH by two heatings, 7108
 -resistant phenotype
 porphyrin photosensitivity, cell lines, 5365
 treatment effect on tumor cells
 antitumor effector cells, 6199
Heat shock
 HSP-70 expression in leukemic cells, 2877
HeLa cells
 induction of "reversible" translocation protein B23, exposure to actinomycin D, 5987
 inhibition of DNA polymerases by suramin
 DNA synthesis, 7754
Hematopoiesis
 normal
 thimerosal effect, leukemia and leukemic cell lines, 4429
 protective effect of tumor necrosis factor cycle-specific cytotoxic chemotherapy, 4216
Hematopoietic cells
 phosphorylation
 phosphoprotein NP33, nucleus-associated ribosomal S6 protein, 2895
 reconstitution after 5-fluorouracil treatment
 interleukin 6 perfusion, 2885
Hematopoietic growth factors
 control of myelosuppression
 radioimmunotherapy, 1003
Hematopoietic neoplasms
 oncogenes in fish, 5671s
Hematopoietic progenitor cells
 myelotoxicity
 l-phenylalanine mustard, l-butheione sulfoximine, 4038
 normal and leukemic interaction, tumor necrosis factor-α and colony-stimulating factor, 5065
Heme
 induction of cytochrome P-450
 5-aminolevulinate synthase activity, rat hepatocytes, 5219
 synthesis in normal mouse liver and tumors, 2337
Hemoglobin
 adduct formation
 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 5446
 adducts
 acetylation phenotype, cigarette smoking, 3002

SUBJECT INDEX TO VOLUME 50

- molecular dosimetry, polycyclic aromatic hydrocarbon epoxides and diol epoxides, 4611
- cysteine adduct formation
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 5453
- tobacco-specific adducts
mass spectrometric analysis, 5438
- Heparan sulfate**
-containing fraction of bone marrow stroma
maturation induction, HL-60 cells, 3781
- Heparin**
-binding growth factor
androgen induction, fibroblast growth factor receptor, 2316
- Hepatectomy**
partial
liver regeneration, transforming growth factor receptors, 1464
- Hepatitis**
medical history and primary liver cancer, 6274
- Hepatitis B virus**
aflatoxin B₁ and
induction of liver tumors, ducks, 2156
- aflatoxin B₁-treated DHBV-infected ducks
hepatic neoplasms, 4072
- chronic liver injury
hepatocarcinogenesis, transgenic mice, 3400
- Hepatitis virus**
woodchuck
hepatocellular carcinoma, α -fetoprotein, 7843
- Hepatocarcinogenesis**
2-acetylaminofluorene-mediated alteration
liver arylsulfotransferase IV, 5301
- chemical
early stages, cellular and molecular changes, 3439
- chronic liver injury in hepatitis B virus transgenic mice, 3400
- multistage
age and sex, 472
- transforming N-ras gene
hepatoma cell line, 1521
- Hepatocarcinogens**
genotoxic and nongenotoxic
H-ras mutational analysis, liver tumors, 4014
- Hepatocellular neoplasms**
microscopic
ovariectomy, acceleration of growth, 6779
- Hepatocytes**
acquisition of aryl hydrocarbon hydroxylase inducibility
nonresponsive mouse strains, 3226
- activation of ethylene dibromide
glutathione S-transferases, unscheduled DNA synthesis, 2747
- alteration of differentiation state
novobiocin and butyrate, 3101
- altered acinar distribution
glutamine synthetase, partial hepatectomy, 4407
- cytological study of vacuolated cells
winter flounder from Boston Harbor,
- 6744
- diethylnitrosamine-induced neoplasia
cytotoxicity phase, medaka, 5504
- enzyme-altered hepatic foci
testosterone substitution, neonatal and adult castration, 2679
- glucose production
growth hormone and malnutrition, colorectal carcinoma, 2119
- induction of replicative competence
normal liver, 7023
- α/β -interferon inhibition
IFN-resistant Friend erythroleukemia cells, 3533
- malignant transformation of C3H mouse fibroblasts
hydroxyanthraquinones as tumor promoters, 6540
- metabolism and DNA strand breaks
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, 1810
- 3-methylcholanthrene-inducible phenol uridine diphosphate-glucuronosyltransferase, 3569
- modification of plasma membrane proteins
peroxisome proliferator-induced alterations, 669
- nodules and hepatomas
regulation, xenobiotic epoxide hydrolase messenger RNA, 256
- oval cell antigens and
oncogene-transfected liver epithelial cells, hepatocellular carcinoma, 4809
- transformation
gene expression, clonally derived cell lines, 7593
- Hepatoma**
accumulation of gangliosides
N-acetyleneuraminosyl(α 2-6)lactosamine structure, 1284
- ascites
Adriamycin-induced potentiation, invasive capacity, 2018
- catalytic subunit of protein kinase A cDNA, 1675
- Hep G2 cell line
transforming N-ras gene, hepatocarcinogenesis, 1521
- human/nude mouse model
monoclonal antibody targeting, carcinogenembryonic antigen and α -fetoprotein expression, 869s
- inhibition of thymidylate biosynthesis
role of substrate depletion, trimetrexate, 3979
- regulation of succinyl coenzyme A:acetoacetyl coenzyme A transferase, 5858
- Hepsulfam**
mechanism of action
chronic myelogenous leukemia, 7559
- mechanisms of toxicity
human tumor cell lines, 7555
- Herpes simplex virus**
type 2
hexamethylene bisacetamide and cyclosporin A, latency in neuroblastoma, 7852
- Heteroaggregates**
enhanced lysis of ovarian carcinoma
- activated peripheral blood lymphocytes, 6508
- Hexakis(2-methoxyisobutylisonitrile)technetium-99m**
uptake by human carcinoma cell lines, 2198
- Hexamethylene bisacetamide**
activin A and
synergistic action, murine erythroleukemia cells, 3182
- cyclosporin A and
recovery of herpes simplex virus type 2, latency in neuroblastoma, 7852
- 5-fluorouracil and
cytotoxic-differentiation therapy, erythroleukemia cells, 3878
- induction of colon carcinoma differentiation
role, transforming growth factor- β , 261
- retinoic acid and
HL-60 cell differentiation, 6268
- Hexamethylmelamine**
parenteral formulation
Phase I and clinical pharmacological evaluation, 206
- 5-Hexyl-2'-deoxyuridine**
blockade of cytotoxic effects
5-fluorodeoxyuridine or deoxyadenosine, L1210 cells, 4552
- Histamine**
systemic toxicity
porphyrin photodynamic therapy, 539
- Histoculture**
native-state
distinction, small cell and non-small cell lung cancer, 6095
- Histone H3**
differentiation of F9 cells into embryoid bodies
early growth-associated events, 3193
- HLA complex**
A locus
molecular nature, *in vivo* mutations, 4584
- A2-matched allogeneic melanoma melanoma-specific cytotoxic T-lymphocytes, 492
- class I
N-myc relationship, human neuroblastoma cells, 7532
- class I and II antigens
reduced expression, colon cancer, 8023
- nasopharyngeal carcinoma susceptibility immunoglobulin allotypes, Malaysia, 3186
- HL-60 cells**
cis-diamminedichloroplatinum(II) cross-linking
myeloid cell nuclear differentiation antigen, 1183
- differentiation
M, 94,000 gelatin-degrading metalloprotease, 1113
- differentiation with retinoic acid
combined with sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide, 6268
- Ga-67 uptake and retention**
role of acidic receptosome, 1484
- induction of differentiation and DNA

SUBJECT INDEX TO VOLUME 50

- strand breakage
genistein, 2618
- induction of maturation
heparan sulfate-containing fraction,
bone marrow stroma, 3781
- lysis by amphotericin B
combination with 2-chloroethyl-1-nitrosoareas, 3274
- modulation of retinoic acid-induced differentiation
serum factors, sphinganine, 222
- monocytoid differentiation
phorbol ester effects, topoisomerase II activity, 7116
- multidrug resistance
synthetic peptides, P-glycoprotein, 1426
- nuclear matrix-associated region of c-myc
recognition by nuclear protein, 3199
- phorbol ester-induced macrophage-like differentiation
transferrin availability, 7221
- phospholipase A₂ activation
autoinduction, tumor necrosis factor gene expression, 7101
- proliferation
interaction of gallium nitrate, fludarabine and iron chelates, 6466
- proliferation and differentiation
homoharringtonine, 2031
- regulation of cell surface expression
nonspecific cross-reacting antigen, 7437
- regulation of differentiation
lipoxygenase pathway metabolites, 7257
- role of endocytosis
action of ether lipids, 7505
- stimulation of growth
ascorbate free radical, 5887
- variant cell resistant to induction to differentiation
type II protein kinase C, phorbol ester, 621
- Hodgkin's disease**
antitumor effects of ricin A chain immunotoxins
intact antibodies and Fab' fragments, 2929
- B-cells and
characterization, cell surface molecule, 1650
- chromosome alterations and chemotherapy, 558
- expression of CSF-1 and its receptor c-fms, 2049
- identification of M_r 70,000 antigen
Reed-Sternberg cells, interdigitating reticulum cells, 350
- molecular pathways of adhesion
spontaneous rosetting, T-cells, 3131
- ricin A chain-containing immunotoxins
CD30 antigen, 84
- Homoharringtonine**
proliferation and differentiation
human leukemic cells, 2031
- HT-29 cells**
inhibition of growth factor receptor binding
altered phosphoinositide synthesis, suramin, 6490
- HT29 factor**
production by colon cancer cells, 6158
- HTLV-I**
-associated diseases in France, 5692s
protection against STLV-I
vaccine subunit, 5687s
- transcriptional regulation by methylation, 4968
- HT1080 tumor cells**
tumor promoter-stimulated M, 92,000
gelatinase, 6162
- Human immunodeficiency virus**
growth of human cell lines
BALB/c mice, 5943
- immunopathogenesis, 5612s
-infected cells
tumor necrosis factor cytotoxic effect, stauroporine, 5287
- structural proteins
antibodies, canine sera, 5628s
- Human immunodeficiency virus-1**
evaluation of antiretroviral therapy
murine models, 5618s
- Hybridoma, T-cell**
revertants of LFA-1-deficient mutant
invasive and metastatic capacity, 3509
- Hydatidiform mole**
genetic origin of trophoblastic choriocarcinoma, 6330
- Hydralazine**
dose-dependent effects
microcirculatory function, murine
FSall tumors, 15
- Hydrocarbons, aromatic**
acquisition of aryl hydrocarbon hydroxylase inducibility
hepatocytes, nonresponsive mouse strains, 3226
- Hydrocarbons, polycyclic aromatic**
creosote-contaminated site
hepatic neoplasms, mummichog *Fundulus heteroclitus*, 5978
- molecular dosimetry of epoxides and diol epoxides
hemoglobin adducts, 4611
- Hydrogen peroxide**
formation by polymorphonuclear leukocytes
sulfide salts of nickel and cadmium, 7564
production by epidermal keratinocytes
TPA treatment, 6062
- Hydroperoxide**
Ca²⁺ ionophores and ionomycin
tumor-promoting effects, mouse epidermis, 5806
- 4-Hydroperoxycephalophosphamide**
2'-deoxy-5-azacytidine and cisplatin
synergistic cytotoxicity, human tumor cells, 4572
- intrathecal
nude rat model, human neoplastic meningitis, 1954
- purging of human rhabdomyosarcoma cells, 1455
- sensitivity of K562 leukemia cells
N,N'-bis(*trans*-4-hydroxycyclohexyl)-*N'*-nitrosoarene, 4067
- 4-Hydroxyandrostenedione**
peripheral conversion of androstenedione to estrone
tumor aromatase activity, postmeno-
- pausal women with breast cancer, 193
- Hydroxyanthraquinones**
tumor promoters
malignant transformation, C3H mouse fibroblasts, 6540
- N-Hydroxyarylamine O-acetyltransferase**
purification of hepatic polymorphic arylamine N-acetyltransferase
homozygous rapid acetylator inbred hamster, 7942
- 3-Hydroxy-3-methylglutaryl coenzyme A**
increase in active form
human hepatocellular carcinoma, cholesterol biosynthesis, 3270
- 3-Hydroxypyridine**
metabolism
role of P450IIIE1, tobacco smoke, 5333
- Hydroxyurea**
antineoplastic activity
experimental and human malignancies, 3473
- Hypercalcemia**
parathyroid hormone-related protein
immunohistochemical localization, breast cancer, 7710
- Hyperoxia**
pathobiology of lung tumors
induction, 4-(methylnitrosamo)-1-(3-pyridyl)-1-butane, 1960
- Hypertension**
interstitial pressure gradients
tissue-isolated and subcutaneous tumors, 4478
- Hyperthermia**
addition of 2-nitroimidazole radiosensitizers
cis-diamminedichloroplatinum(II), fibrosarcoma, 2734
- chronic glutathione elevation
cytotoxicity, 5296
- cytotoxicity and radiosensitization
antitumor activity, Co(III) mustard complex, 6971
- dose-dependent effect of hydralazine
microcirculatory function, murine
FSall tumors, 15
- effect on tumor cells and antitumor effector cells, 6199
- enhanced damage
M14 melanoma cells, liposome pre-treatment, 5119
- enhanced delivery of monoclonal antibody F(ab')₂
glioma xenografts, 1803
- enhancement of rhodamine 123 cytotoxicity
B16 melanoma cells, 2385
- heat-resistant phenotype
porphyrin photosensitivity, cell lines, 5365
- interleukin 2 and
Lewis lung carcinoma cells, 5027
- nicotinamide and
elimination, radioresistant hypoxic tumor cells, 7430
- radiation and
SR-4233 interaction, FSall murine fibrosarcoma tumor system, 5055
- radiosensitization
human colony-forming unit-granulo-

SUBJECT INDEX TO VOLUME 50

cyte-macrophage, 2044
rhodamine and
 cytotoxicity, 459
 tetrachloroplatinum(II)(Nile blue)₂ and
 tetrachloroplatinum(II)(neutral red)₂
 interaction, fibrosarcoma, 3826
 whole body
 nonuniform alteration, *cis*-diammine-dichloroplatinum(II) tissue distribution, 2075
Hyperthyroidism
 cancer mortality in women, 2283
Hypoxia
 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity
 9L cells, 2719
 effects of reoxygenation on cells
 solid tumors, 5031
 elimination of radioresistant hypoxic tumor cells
 nicotinamide and hyperthermia, 7430
 tumor subpopulations
 classification of antineoplastic treatments, differential toxicity, 3339

I

Ia complex
 cyclosporine A and antigen expression
N-nitroso-*N*-methylurea-induced rat mammary tumors, 3301

I-antigens
 sialyl I-antigens and
 differentiation-dependent expression, developing lung and lung cancer, 7603

ICAM-1
 differential expression
 primary and metastatic melanoma lesions, 1271

I-compounds
 diet and age-related DNA modifications
 rat liver and kidney, 3991
 reduction of levels in liver DNA
 choline-devoid diet, DNA of resulting neoplasms, 7577

ICRF-187
 inhibition of Fe³⁺ reduction, 2307
 modulation of free radical scavenging enzymes
 doxorubicin-induced cardiomyopathy, 5136

Idarubicin
 idarubicin and
 plasma pharmacokinetics, pediatric leukemia patients, 6525
 oral
 Phase II study, favorable histology non-Hodgkin's lymphoma, 6833

Idoxuridine
 cytotoxicity
 leucovorin effects, DNA incorporation, 6652

Ifosfamide
 enantiomers
 toxicity, pharmacokinetics, 252

[16 α -¹²⁵I]Iodoestradiol-17 β
 high specific activity
 estrogen receptor-specific radioligand, 7799

Immortalization
 progression to

nonrandom chromosome alterations, tracheal epithelial cells, 740

Immune response
 progressor variants derived from transfection
Ha-ras-induced tumor progression, 3159
 selective depletion of neutrophils
 abrogation of transplantation resistance, monoclonal antibody, 6243

Immunocompetence
 tumor host
 indomethacin-induced potentiation, radioresponse, 4473

Immunooncjugates
Adriamycin
 synthesis, acid-sensitive hydrazone linker, 6600
 immunohistochemical and pharmacokinetic characterization
 antiprostate monoclonal antibody 7E11-C5, 6423
 intraperitoneal, 1031s
 L/1C2-4-desacetylvinblastine-3-carboxyhydrazide
 xenografts, antitumor activity, 1790
 target-specific
 bone marrow replacement therapy, 1538

Immunofluorescence
 distribution of oncofetal fibronectin mammary tumors, 1608

Immunoglobulin A
 IgG antibodies to select peptides
 human papillomavirus type 16, cervical cancer, 7815

Immunoglobulin G
 chimeric 17-1A monoclonal antibody
 tumor localization and therapy, 993s
¹³¹I- vs. ⁹⁰Y-labeled
 radiation dose estimates, human colonic tumor xenografts, 2330
 mechanisms of antitumor activity
 interleukin 2 and monoclonal antibodies, 5767
 myeloma proteins
 carbohydrate analysis, glycosyltransferases, 5345
 rabbit and sheep antibodies
 interstitial transport, normal and neoplastic tissues, 3487
 subclass analysis
 human anti-mouse antibody response, monoclonal antibody treatment, 1051s

Immunoglobulin G3
 anti-G_{D3} monoclonal antibody
 light chain variants, avidity, 1503

Immunoglobulin M
 monoclonal antibody
 inhibition of tumor growth, tumor cell surface carbohydrates, 7301

Immunoglobulins
 allotypes
 nasopharyngeal carcinoma susceptibility, Malaysia, 3186
 covalent modification
 reduction of immunogenicity, low molecular weight dextrans, 3638
¹³¹I-labeled murine monoclonal antibody clearance from blood, anti-murine immunoglobulin antibody, 563

Immunohistochemistry
 partial characterization of insulin-like growth factor I
 primary human lung cancer, 2481

Immunolymphoscintigraphy
 immunoscintigraphy and
 F(ab')₂ fragments of monoclonal antibody, ovarian and fallopian tube cancer, 937s
^{99m}Tc-labeled monoclonal antibody carcinoembryonic antigen reaction, breast cancer, 949s

Immunomagnetic beads
 elimination of small cell lung carcinoma bone marrow, monoclonal antibodies, 7216

Immunoscintigraphy
 radiolabeled monoclonal antibodies
 multicenter studies, Italian National Research Council, 899s

Immunosuppression
 prevention of interleukin 2 binding cell surface receptor, suramin, 3036
 retroviral vector-mediated γ -interferon gene transfer
 antitumor immunity, 7820

Immunosuppressive factor
 production by colon cancer cells, 6158

Immunotherapy
 active specific
 suppressor cell activity, melanoma cell vaccine and cyclophosphamide, 5358
 synthetic tumor-associated glycoconjugate, mammary adenocarcinoma, 4308
 adoptive
 enhancement of LAK cell activity, retinoic acid, 3013
 head and neck cancer xenografts, LAK cells and interleukin 2, 3113
 interleukin 2 bolus treatment, human cancer, 5795
 LAK cells and interleukin 2, rat glioma, 4338
 adoptive transfer of tumor cytotoxic macrophages
 circulating blood monocytes, 7450
 anti-Tac-H antibody
 malignant and immune disorders, 1495
 cellular
 anti-CD3 and, hepatic metastases, 2476
 conditioning as a new approach, 4295
 heat treatment effect
 tumor cells, antitumor effector cells, 6199
 interleukin 1 as adjuvant
 murine tumor model, 1212
 mouse-human chimeric antibody
 multidrug transporter P-glycoprotein, 3167
 patterns of antigen distribution
 human carcinomas, 880s
 slow delivery of IL-2
 colon 26 adenocarcinoma liver metastases, 7003
 T-cell-mediated adoptive
 radiosensitive barrier, established tumors, 2228

Immunotoxins

SUBJECT INDEX TO VOLUME 50

- antibody-*Pseudomonas* exotoxin A conjugate**
elimination of breast cancer cells, bone marrow, 5992
- anti-human T-leukemia**
synergistic potential, α -interferon and daunorubicin, 32
- inhibition of antibody response to *Pseudomonas* exotoxin**
15-deoxyspergualin, mice, 7750
- α -interferon and**
enhanced therapeutic efficacy, ovarian tumor xenografts, 6379
- intraperitoneal**
inhibition of human tumor growth, nude mice, 288
- pharmacokinetics**
abrin A chain, ricin A chain, gelonin, and momordin, 7519
- purging of human bone marrow**
monoclonal antibody DF3, ricin conjugate, 1170
- ricin A chain**
CD30 antigen, Hodgkin's disease, 84
- use in combination**
inhibition of clonogenic growth, breast carcinoma, 3231
- N*-(5-Indanyl)sulfonyl)-*N'*-(4-chlorophenyl)urea**
cytotoxicity to human colon adenocarcinoma cells, 318
- Indium**
-labeled anti-carcinoembryonic antigen presurgical imaging, colon cancer staging, 922s
- Indium-111**
anti-carcinoembryonic antigen monoclonal antibody
mechanism, decreasing liver uptake, 846s
- anti-myosin monoclonal antibody complex
radioimmundetection, rhabdo- and leiomyosarcoma, 955s
- labeled anti-fibrin antibody detection, thrombophilia, 958s
- labeled bivalent hapten targeting to melanoma, monoclonal antibody conjugates, 3445
- labeled B72.3 monoclonal antibody human biodistribution, 932s
- labeled monoclonal antibody B6.2 uptake and metabolism, rat liver, 852s
- labeled monoclonal antibody breast tumor radioimmundetection, mucin-like antigen, 927s
- imaging and therapy, small cell lung cancer, 980s
- Indium-111 anti-CEA antibody**
pharmacokinetics
novel diethylenetriaminepentaacetic acid chelator, 7272
- Indole-3-carbinol**
lung tumorigenesis and DNA methylation
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone disposition, 2613
- Indomethacin**
-induced potentiation
- murine tumor radioresponse, tumor host immunocompetence**, 4473
- Infections**
fatal
prevention of, interleukin 1 α , 2099
- Inositol phosphate**
growth factor-dependent Ca²⁺ signaling
antitumor ether lipid analogues, 4458
- growth factor-triggered signal transduction
role of *bcl-2*, 7399
- Inositol phospholipid**
activation of signaling
bombezin, breast cancer cells, 235
- Insecticides**
survey of exposure to genotoxic agents
primary myelodysplastic syndrome, 6876
- Insulin**
effects on pancreatic exocrine tumors
inhibition, streptozotocin-induced islet cell tumors, 1634
- family hormones and colony-stimulating factors
functional interactions, myeloid leukemic cells, 6471
- insulin-like growth factor I independence
growth factor synthesis, mammary carcinoma cells, 5351
- stimulation of growth in breast carcinoma cells
progestins, increase in insulin receptor content, 7858
- Insulin-like growth factor I**
autocrine function
human small cell lung cancer, fresh tumor cells, 2511
- constitutive expression of *c-fos* protooncogene
keratinocytes, 6641
- partial characterization
primary human lung cancer, immunohistochemistry and receptor autoradiography, 2481
- prognostic significance of receptors
human breast cancer, 6931
- receptors in normal and neoplastic human endometrium, 3019
- transforming growth factor- α and autocrine growth factors, pancreatic cancer cell growth, 103
- Insulin-like growth factors**
estrogen-induced
proliferation, breast cancer cells, 7770
- gene expression
human smooth muscle tumors, 6689
- receptor expression in breast cancer, 48
- related peptides
hormonally stimulated *N*-nitrosomethylurea-induced mammary tumors, 7179
- Insulinoma**
amine precursor uptake decarboxylation system
mitochondrial glycerol phosphate dehydrogenase, 7203
- Integrin**
distribution in malignant melanoma
 β_3 subunit, tumor progression, 6757
- expression in human lung cancer
monoclonal antibodies, 6107
- β_1 Integrins
- monoclonal antibodies and synthetic peptide inhibitors**
human tumor cell migration, 4485
- Interferon**
cytotoxic agents and
antineoplastic activity, experimental and human malignancies, 3473
- differentiation therapy, 3453
- fluorouracil and
cytotoxic and cytokinetic effects, colon cancer, 5735
- human leukocyte, fibroblast, and immune
class I and II major histocompatibility complex, melanoma cells, 7422
- protection from carcinogen-induced bladder carcinoma
bropirimine, 1071
- sensitivity
absence of *IFNA* and *IFNB* genes, malignant glioma, 278
- tumor tissue content in liver metastases
human carcinoid tumors, 3413
- α -Interferon**
antitumor therapy
implantation, genetically manipulated fibroblasts, 5102
- daunorubicin and
synergistic potential, anti-human T-leukemia immunotoxins, 32
- down-regulation of α -interferon receptors
human lymphoblastoid cells, 2654
- 17 β -estradiol and tamoxifen
estrogen receptor concentration, MCF-7 cell cycle kinetics, 5387
- gene deletion in malignant cells
children with acute lymphocytic leukemia, 7781
- immunotoxins and
enhanced therapeutic efficacy, ovarian tumor xenografts, 6379
- inhibited proliferation of hairy cells
B-cell growth factor, cell surface antigen modulation, 4111
- γ -interferon and
antitumor effects, renal cancer, 5414
- interleukin 2 and
proliferation, lymphoid cells in organs, 5543
- [³⁵S]methionine-labeled
pharmacokinetics, tissue distribution, 4718
- renal cell carcinoma
expression, kidney-associated differentiation glycoprotein, 4190
- structure and natural killer cell stimulatory activity, 5328
- tumor necrosis factor and/or
antiproliferative and cytotoxic effects, renal cell carcinoma xenografts, 6389
- α -Interferon A/D**
interleukin 2 interactive effects
LAK activity, 1176
- α_2 -Interferon**
5-fluorouracil and
Phase I trial, advanced colorectal carcinoma, 2056
- α/β -Interferon**
inhibition of IFN-resistant Friend erythroleukemia cells

SUBJECT INDEX TO VOLUME 50

mouse hepatocytes, 3533
 β -Interferon
 gene deletion in malignant cells
 children with acute lymphocytic leukemia, 7781
 human gene
 transfection, growth inhibition of glioma cells, 7826
 γ -interferon and
 5-day continuous infusion, 4588
 γ -Interferon
 cytokine production in T-cell lymphoma, 8028
 effect of cellular density and viral oncogenes
 MHC class I antigen response, BALB/c/3T3 cells, 601
 5-fluorouracil and
 colon carcinoma cell line, 5834
 gene transfer
 retroviral vector, antitumor immunity, 7820
 α -interferon and
 antitumor effects, renal cancer, 5414
 β -interferon and
 5-day continuous infusion, 4588
 β_{nr} -interferon and
 receptor expression, colon carcinoma cells, 26
 intraperitoneal recombinant
 recurrent ascitic ovarian carcinoma, 7318
 inverse correlation between MHC expression and LAK activity
 lined human gliosarcoma cells, 596
 prevention of lysis
 resistance mechanism, ovarian and cervical carcinoma, 4923
 reduced expression of *c-erbB-2* ovarian carcinoma cells, 7037
 regulation of carcinoembryonic antigen expression
 colorectal tumor cells, 6248
 tumor necrosis factor and
 dependence of IL-2, tumor therapy, 1368
 ω -Interferon
 gene deletion in malignant cells
 children with acute lymphocytic leukemia, 7781
Interleukin 1
 adjuvant for active specific immunotherapy
 murine tumor model, 1212
 calcium dependency of production
 receptor expression, adult T-cell leukemia, 4344
 -induced augmentation of metastases
 human melanoma in nude mice, 4771
 interleukin 6 and tumor necrosis factor- α
 increased secretion
 β -galactoside-specific lectin, mononuclear cells, 3322
 tumor necrosis factor and
 coordinated induction, monocyte-mediated cytotoxicity, 3146
 high mannose glycopeptides, 6285
Interleukin 1 α
 mediated antitumor effects by ketoconazole, 4709
 prevention of fatal infections
 normal and anti-cancer drug-treated

mice, 2099
Interleukin 1 β
 clearance and tissue distribution in the rat, 5751
Interleukin 2
 activated killer cells
 susceptibility, multidrug-resistant leukemia cell lines, 6793
 activation of natural killer cells
 p75 receptor, p55 negative phenotype, 2683
 ADCC with anti-melanoma monoclonal antibodies
 in vivo-activated LAK cells, 6311
 Adriamycin and dacarbazine
 antitumor efficacy, solid tumor systems, 5876
 antibody-dependent cell-mediated cytotoxicity
 anti-class II murine monoclonal antibody, B-cell tumors, 2991
 augmentation
 antibody-dependent cell-mediated cytotoxicity, 5234
 bolus treatment
 adoptive treatment, human cancer, 5795
 cellular interactions
 liver lymphoid subsets, 1658
 dose escalating regimen
 metastatic renal cell adenocarcinoma, 6723
 high dose
 brief exposure, generation of LAK cells, 1686
 immunomodulatory properties and toxicity
 cancer patients, 185
 -induced activation of LAK cells and cytotoxic T-cells
 cervical lymph nodes, head and neck tumors, 5551
 -induced proliferation of lymphocytes
 enhancement by interleukin 4, interleukin 2-treated patients, 1160
 infusion
 cerebral vasomotor responses, 4377
 α -interferon A/D interactive effects
 LAK activity, 1176
 α -interferon and
 proliferation, lymphoid cells in organs, 5543
 interleukin 4 and
 tumor necrosis factor production, mononuclear phagocytes, 2949
 LAK cells and
 adoptive immunotherapy, rat glioma, 4338
 adoptive immunotherapy, head and neck cancer xenografts, 3113
 bolus and continuous infusion regimen, 7343
 Phase I trial, ovarian cancer, 6302
 LAK cells or
 monoclonal antibody therapy, murine lymphoma, 5421
 liposomes
 antitumor effects, MCA-106 sarcoma pulmonary metastases, 1853
 local hyperthermia and
 Lewis lung carcinoma cells, 5027
 maintenance and cure

L5178Y murine tumor-dormant state, 1361, 1368
 monoclonal antibodies and mechanisms of antitumor activity, 5767
 Phase I study, metastatic carcinoma, 7490
 prevention of binding to cell surface receptor
 suramin, immunosuppression, 3036
 proliferative responsiveness
 bone marrow cells, 1847
 prolongation of serum half-life
 LAK cell activity, pepstatin, 1107
 recombinant
 pharmacokinetics in humans, 2009
 slow delivery system
 immunotherapy, colon 26 adenocarcinoma liver metastases, 7003
 solid-phase anti-CD3 antibody activation
 murine tumor-infiltrating lymphocytes, 2587
 splenic artery perfusion
 induction of LAK cells, advanced malignancy, 4906
 susceptibility to lysis
 pulmonary alveolar macrophages, LAK cells, 1768
 systemic alkalization
 flavone acetic acid, renal cancer, 7926
 therapy
 sustained production, tumor necrosis factor, 2371
 tumor necrosis factor- α and
 OKT3-initiated lymphokine-activated effector, 3526
Interleukin 3
 induction by SSM
 Mycobacterium tuberculosis, 4032
Interleukin 4
 cytokine production in T-cell lymphoma, 8028
 effect on human monocyte activity, 3154
 interleukin 2 and
 tumor necrosis factor production, mononuclear phagocytes, 2949
 interleukin 2- or antibody-induced proliferation
 lymphocytes, interleukin 2-treated patients, 1160
 regulation of tumor necrosis factor- α and - β
 human peripheral blood mononuclear cells, 5072
Interleukin 6
 constitutive production by ovarian cancer cell lines
 primary ovarian tumor cultures, 6959
 expression of interleukin 6 receptor and prostate carcinoma cells, 7786
 interleukin 1 and tumor necrosis factor- α
 increased secretion
 β -galactoside-specific lectin, mononuclear cells, 3322
 mediators of lipogenic effects
 tumor necrosis factor, 4233
 perfusion
 reconstitution of immune and hematopoietic systems, 5-fluorouracil treatment, 2885
 production from human liver cell lines, 7457

SUBJECT INDEX TO VOLUME 50

- release by glioblastoma cells, 6683
Interstitial fluid
 pressure gradients
 tissue-isolated and subcutaneous tumors, 4478
Intestinal neoplasms
 risk of large bowel cancer
 physical activity, Framingham study, 3610
Intestine
 E1A-immortalized fetal epithelial cells altered expression, proteoglycans, 6716
 large bowel cancer
 appendectomy, appendicitis, 7549
 microflora
 production of diacylglycerol, 3595
 mouse
 mutagenesis, *D1b-1* assay, 7992
 proliferative epithelium
 4-aminofolate analogues of folylpolyglutamyl synthetase, 4639
Involucrin
 squamous differentiation
 cross-linked envelope-related markers, lung cancer, 120
Iodine
N-methyl-*N*-nitrosourea-induced thyroid tumors
 sex differences, gonadectomy, and estrogen, 7662
Iodine-123
 radioimmuno detection
 carcinoembryonic antigen monoclonal antibody fragments, 909s
Iodine-131
 astatin-211-labeled antibodies and fragments
 comparative tissue distribution, 3514
IgG or fragments
 radiation dose estimates, human colonic tumor xenografts, 2330
 -labeled anti-carcinoembryonic antigen monoclonal antibody
 tumor, red marrow and organ dosimetry, 1039s
 -labeled F(ab')₂ fragment of Mel-14 radioimmunotherapy, glioma xenografts, 1822
 -labeled monoclonal antibody
 clearance from blood, anti-murine immunoglobulin antibody, 563
Ly-1
 fractionated radioimmunotherapy, B-cell malignancies, 1014s
Iododeoxyuridine
 -DNA incorporation
 radiosensitization, bladder carcinoma cells, 4962
Iodo-2'-deoxyuridine
 specific uptake in rat brain tumors therapeutic implications in humans, 5199
Ionophores
 A23187 and ionomycin
 tumor-promoting effects, mouse epidermis, 5806
 carboxylic
 inhibition of catabolism, radiolabeled antibodies, 1243
 nigericin
 phototherapy cytotoxic interaction,
- V79 cells, 1620
Iowa men
 pesticide and agricultural risk factors, 6585
Iron
 bleomycin
 plasma membrane perturbations, KB₃ cells, 385
 cellular iron uptake
 development of drug resistance, gallium nitrate, 4468
 chelates
 gallium nitrate and fludarabine, HL-60 cell proliferation, 6466
 cytotoxicity
 long and short crocidolite asbestos fibers, 5153
 effect of erythrocytes
 alveolar macrophage cytostatic activity, bleomycin lung damage, 2351
 high vs. low concentrations differential growth-inhibitory effects, B-cell lines, 5727
 inhibition of Fe³⁺ reduction by ICRF-187, 2307
Irradiation
 fractionated
 SR 4233, potentiation of cell killing, 7745
 inhibition of p34^{cdc2} kinase activity G₂ arrest, Chinese hamster ovary cells, 3761
 monoclonal antibody uptake
 colon tumor xenografts, 159
Islet cell neoplasms
 streptozotocin-induced
 insulin effects, pancreatic exocrine tumors, 1634
Isothiocyanates
 inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butane metabolism mouse lung microsomes, 6817
Isozymes
 rat, mouse, and hamster
 glutathione transferase-mediated denitrosation, nitrosoquadinium compounds, 1440
J
Japan
 comparative case-control analysis stomach cancer and atrophic gastritis, 6559
K
KB cells
 teniposide-resistant reduction, drug accumulation and DNA topoisomerase II activity, 5819
KB₃ cells
 plasma membrane perturbations bleomycin-iron complex, 385
K-562 cells
 induction of differentiation and DNA strand breakage genistein, 2618
 induction of erythroid differentiation Adriamycin bound to microspheres, 1231
 megakaryocytic differentiation
- cytoskeletal organization, phosphotyrosyl-specific protein phosphatases, 6323
 sensitivity to 4-Hydroperoxycyclophosphamide *N,N'*-bis(*trans*-4-hydroxycyclohexyl)-*N'*-nitrosourea, 4067
Keratin
 changes in expression 7,12-dimethylbenz[a]anthracene-induced cheek pouch carcinogenesis, 4441
 four mammary epithelial cell lines same patient, tumor progression, 7351
 subtypes in carcinomas uterine cervix, histogenesis, 5143
Keratinocytes
 constitutive expression of *c-fos* protooncogene, 6641
 epidermal hydrogen peroxide production, TPA treatment, 6062
 maturation, Exo-1 and EPM-1 expression, 7668
human papillomavirus 16 DNA genomic rearrangements, 1316
 immortalization Simian virus 40 large T-antigen, keratin gene response to retinoids, 5947
 growth potential, c-Ha-ras oncogene, 2840
 induction of ornithine decarboxylase ultraviolet radiation, 2631
 initiated mouse epidermis *in vitro* analogue development, tumor promoters and antipromoters, 4794
Ketoconazole
 interleukin 1 α mediated antitumor effects, 4709
Ki-1 antigen
 establishment of Ki-1-positive T-cell line large cell lymphoma, 7682
Kidney
 androgen-dependent renal microsomal cytochrome P-450 N-hydroxylation, 3-methoxy-4-aminoazobenzene, 2729
 -associated differentiation glycoprotein α -interferon effects, renal cell carcinoma, 4190
 clearance and tissue distribution recombinant human interleukin 1 β , rats, 5751
 diet and age-related DNA modifications, 3991
 failure pharmacokinetics, recombinant human granulocyte colony-stimulating factor, 6615
 ferric nitrilotriacetate-induced lipid peroxidation sex hormone dependence, 5574
microneoplasms
 proximal tubule dysplasia, estrogen induction, 113
 normal cell lines and renal cancer establishment and characterization, 5531
Kidney neoplasms
 systemic alkalinization inhibition of flavone acetic acid, natural

SUBJECT INDEX TO VOLUME 50

- killer cell activity, 7926
Killer cells
 IL-2 activated
 susceptibility, multidrug-resistant leukemia cell lines, 6793
Kurashiki
 chromosome abnormalities in malignant lymphoma, 2698
- L**
- LAK cells**
 augmentation of activity by pepstatin
 prolongation, interleukin 2 serum half-life, 1107
 cell-mediated cytosis
 drug-resistant tumor cells, 5931
 enhancement of activity by retinoic acid, 3013
 generation
 brief exposure, high dose interleukin 2, 1686
 immunological effects
 flavone acetic acid, 6483
 induction by interleukin-2 splenic artery perfusion
 advanced malignancy, 4906
 infiltrative and cytolytic activities
 human glioma spheroid model, 2429
 interaction of fibrinogen with murine melanoma cells, 8010
 α -interferon A/D and interleukin 2
 interactive effects, 1176
 interleukin 2 and
 adoptive immunotherapy, head and neck cancer xenografts, 3113
 adoptive immunotherapy, rat glioma, 4338
 Phase I trial, ovarian cancer, 6302
 interleukin 2-induced activation
 tumor cytotoxic T-cells, cervical lymph nodes in head and neck tumors, 5551
 interleukin 2 or
 monoclonal antibody therapy, murine lymphoma, 5421
 interleukin 2 therapy and
 bolus and continuous infusion regimen, 7343
 inverse correlation with MHC expression
 lined human gliosarcoma cells, 596
in vivo-elicited
 increased lysis of melanoma, antigen-glioside antibodies, 6311
OKT3-initiated lymphokine-activated effector
 interleukin 2 and tumor necrosis factor- α , 3526
 susceptibility to lysis
 pulmonary alveolar macrophages, 1768
 synergistic action of plant rhamnogalacturonan
 antitumor cytotoxicity, target cell recognition, 3646
 tumor necrosis factor and
 resistance of ovarian cancer cells, HER2/neu oncogenes, 7364
Lambert-Eaton myasthenic syndrome
 voltage-operated calcium channels
 small cell lung carcinoma, 3892
Laminin
 adhesion and expression
 clonally related transformed and con-
- trol sublines, alveolar epithelial cell strain, 3383
 -binding protein mRNA expression
 colon carcinoma, 3888
 integrin receptors
 metastatic B16 melanoma cells, 728
 -mediated melanoma cell adhesion inhibition by suramin, thrombospondin, 5937
 peptide
 fibrosarcoma cell adhesion, 7612
 receptor expression
 prognostic value, breast cancer survival, 1479
Lard
 wheat bran and
 N-methyl-N'-nitro-N-nitrosoguanidine-induced colon carcinogenesis, 1092
Laryngeal neoplasms
 dietary indicators, 4497
Larynx neoplasms
 smoking and drinking
 northern Italy, 6502
Laser
 -irradiated carcinoma cells
 rhodamine 123 phototoxicity, 4167
L/IC2-4-desacetylvinblastine-3-carboxyhydrazide
 immunoconjugate in xenografts
 antitumor activity, 1790
9L cells
 effect of hypoxia
 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity, 2719
L929 cells
 DNA synthesis
 doxorubicin exposure, 4776
L1210 cells
 S-adenosylmethionine biosynthesis
 S-adenosylhomocysteine metabolism, inhibition of nucleic acid methylation, 3838
 blockade of cytotoxic effects
 5-fluorodeoxyuridine or deoxyadenosine, 5-hexyl-2'-deoxyuridine, 4552
 labeling of phosphatidylethanolamine thioptera, 4044
 liposomal vincristine preparations
 decreased drug toxicity, increased activity, 575
 role of carrier ligand
 platinum resistance, 6497
 thioptera accumulation and cytotoxicity
 ethanolamine and choline effects, 4322
 wild-type and methotrexate-resistant novel transport system, folate compounds, 1709
Le^v
 -related cell surface antigens
 mouse monoclonal antibodies, 2183
Lectin
 carbohydrate analysis
 immunoglobulin G myeloma proteins, 5345
 β -galactoside-specific
 TNF- α , IL-1 and IL-6 increased secretion, mononuclear cells, 3322
 pattern
 glycosylation alterations, U937 cell differentiation, 323
Leiomysoma
- human smooth muscle tumors
 insulin-like growth factor gene expression, 6689
Leiomyosarcoma
 ^{111}In -anti-myosin monoclonal antibody complex
 radioimmunodetection, 955s
 marital status and incidence of sarcomas of uterus, 1886
Leu-19
 immunomodulatory properties and toxicity
 interleukin 2, cancer patients, 185
Leucovorin
 dose response in colon tumors
 reduced folate pools, thymidylate synthase inhibition, 3940
 idoxuridine cytotoxicity
 DNA incorporation, 6652
 metabolism in colon adenocarcinoma xenografts, 3493
 rescue in breast cancer cell line
 methotrexate polyglutamates and dihydrofolate interaction, 3574
Leukemia
 Abelson virus-infected murine pre-B-cells
 tumorigenic state, 1917
 after chemotherapy for breast cancer, 2741
 antisense-mediated inhibition of *BCL2* protooncogene
 phosphodiester and phosphorothioate oligodeoxynucleotides, 6565
 cell-free extracts, 8034
 chromosome alterations in Hodgkin's disease
 chemotherapy, 558
 chronic myelogenous differentiation and growth modulation, bryostatin, 5520
 Ph⁺ bone marrow stroma, growth factors, 5801
 detection of minimal residual disease
 chromosomal location, 5240
 human leukemic myeloblasts and myeloblastoid cells
 cytidine 5'-monophosphate-N-acetylneurameric acid:Gal β 1-3GalNAc(2-3)sialyltransferase, 5003
 immunotherapeutic approaches
 Friend virus-induced erythroleukemia model system, 5682s
 melphalan-induced mutagenesis
 SV40-based shuttle vector, 7527
 multidrug-resistant
 susceptibility to IL-2 activated killer cells, 6793
 pediatric patients
 plasma pharmacokinetics, idarubicin and idarubicinol, 6525
 pesticide exposure and other agricultural risk factors
 men in Iowa and Minnesota, 6585
 pharmacologically directed design
 dose rate and schedule, 2',2'-difluoro-deoxyctidine, 6823
 plasmacytoid experimental transmission, Chinook salmon, 5679s
 promyelocytic stimulation of growth, ascorbate free radical, 5887

SUBJECT INDEX TO VOLUME 50

- selective killing of malignant cells**
 alkyl-lysophospholipid, 4020
taxol-resistant cells
 development of polyploidization, 710
thimerosal effect
 leukemic cell lines, normal hematopoiesis, 4429
- Leukemia, B-cell**
 role of 1q trisomy
 tumorigenicity, growth and metastasis, 3737
- Leukemia, CCRF-CEM**
 cytotoxic effects of dihydroorotate inhibitors, 7793
- Leukemia, chronic myeloid**
 cell lineage-specific hypomethylated sites
 major breakpoint cluster region, 4984
 interaction of tumor necrosis factor colony-stimulating factor, 5065
- Leukemia, hairy cell**
 B-cell growth factor-induced proliferation
 cell surface antigen modulation, α -interferon-inhibited proliferation, 4111
 epidemiology in Los Angeles County, 3605
- Leukemia, L1210**
 merocyanine 540-sensitized photoinactivation
 soluble and membrane-bound enzymes, 7765
 quantitation of drug synergism
cis-diamminedichloroplatinum, 1- β -D-arabinofuranosylcytosine, 5318
 sodium-dependent and equilibrative nucleoside transport, 6549
- Leukemia, lymphoblastic**
 childhood acute
 animal model to study toxicity, central nervous system therapy, 6455, 6461
- T-cell acute**
 anti-GD₁ monoclonal antibodies, 202
 continuous culture establishment, diagnosis, 10
- Leukemia, lymphocytic**
 acute
 deletion of α -, β -, and ω -interferon genes, malignant cells, 7781
 methotrexate and teniposide, pediatric cancer patients, 4267
- chronic
 glutathione S-transferase expression, lymphocytes, 3562
- Leukemia, lymphoid**
B and T
 morphologic, immunologic, and cytogenetic classification, 2212
- Leukemia, myeloblastic**
 acute
 N^4 -behenoyl-1- β -D-arabinofuranosylcytosine effects, blast progenitors, 7587
- Leukemia, myelogenous**
 chronic
 effects, 1 α ,25-dihydroxyvitamin D₃, 3087
 mechanism of hepsulfam action, 7559
- Leukemia, myeloid**
 chronic
 carcinoembryonic antigen gene cloning, leukocyte expression, 6534
 coexpression of receptors
 granulocyte- and macrophage-colony-stimulating factors, 7703
- heat radiosensitization**
 human colony-forming unit-granulocyte-macrophage, 2044
 receptor binding to blast cells
 granulocyte colony-stimulating factor, 1671
- Leukemia, myelomonocytic**
 induction of differentiation
 inhibitors of topoisomerase II, 6708
- Leukemia, T-cell**
 adult
 calcium dependency, interleukin 1 production, 4344
 HTLV-I-associated diseases, France, 5692s
 HTLV-I transcriptional regulation, methylation, 4968
 rearrangements, T-cell receptor α -chain locus, 6171
- Leukemia virus**
 radiation variants
 lymphoma-inducing cells, lymphogenesis, 2554
- Leukemic cells**
 1- β -D-arabinofuranosylcytosine-resistant substrate-specific deoxycytidine kinase deficiency, 6515
 blasts
 noncoordinated expression, ribosomal proteins, 5825
 elevation of intracellular calcium ether lipid SRI 62-834, 3327
 enhanced DNA topoisomerase II expression
 granulocyte colony-stimulating factor, 7198
 established and fresh
 ricin A chain immunotoxin, perhexilene, 5558
 ether-linked phosphoglyceride content, 7174
 growth
 structure-function studies, 1 α ,25-dihydroxyvitamin D₃ analogues, 6857
- HSP-70 expression**
 polymerase chain reaction, 2877
 induction of tumor necrosis factor
 human monocytes, 2708
 labeling of P-glycoprotein by verapamil, 1132
- lymphocytic and myelogenous**
 diverse effects of camptothecin, cell cycle, 5746
 modulation of multidrug resistance cyclosporin A and verapamil, 2953
- myeloid**
 functional interactions, colony-stimulating factors and insulin family hormones, 6471
 paradoxical metabolism of 6-mercaptopurine, 108
 photosensitization anthracenedione antitumor agents, 1936
 proliferation and differentiation homoharringtonine, 2031
 regulation of purine enzyme mRNA levels phorbol esters, 2891
 steroid-sensitive and -resistant glucocorticoid receptor, 1337
 vimentin and c-myc mRNA/protein ratios, 1988
- Leukemogenic virus**
 cell-free extracts, 8034
- Leukocytes**
 cloning of carcinoembryonic antigen gene family
 chronic myeloid leukemia, bone marrow, 6534
 human blood DNA
 O^2 -methylguanine accumulation, procarbazine exposure, 2759
 peripheral mononuclear oxidative stress and DNA repair, 4619
 polymorphonuclear H₂O₂ formation, sulfide salts of nickel and cadmium, 7564
- Leukotriene**
 formation
 estrogen-induced cell growth, Leydig cells, 3866
- Leukotriene D₄**
 lipoxygenase pathway metabolites regulation, HL-60 differentiation, 7257
- Lewis^x**
 -containing glycoproteins and glycolipids sera, adenocarcinoma, 1375
- Lewis lung carcinoma tumor**
 inhibition of experimental metastasis inhibitor of glycosylceramide synthase, 6731
 interleukin 2 treatment with local hyperthermia, 5027
 monoclonal antibody plasma membrane protein, lymph node adhesion and metastasis, 1948
 prostaglandin E₂-protein kinase A coupling tumor migration and metastasis, 2973
- Leydig cells**
 biphasic regulation
 estrogen receptor mRNA, adenosine cyclic 3':5'-monophosphate, 1528
 estrogen-induced cell growth leukotriene formation, 3866
 estrogen-responsive retinoic acid effect on proliferation, serum-free culture, 5060
- LFA-1**
 -deficient mutant T-cell hybridomas revertants, invasive and metastatic capacity, 3509
- Liblomycin**
 -mediated DNA cleavage head and neck squamous carcinoma cells, 1732
- Li-Fraumeni cancer syndrome**
 spontaneous abnormalities normal fibroblasts, 7979
- Ligands**
 carrier platinum resistance, L1210 cells, 6497
- Linoleic acid**
 conjugated dienoic derivatives benzo(a)pyrene-induced forestomach neoplasia, 1097
- Lipid**
 cell membrane and cell signals as targets cancer chemotherapy, 2203
 ferric nitrilotriacetate-induced renal peroxidation sex hormone dependence, 5574
 peroxidation *dl-N,N'*-dicarboxamidomethyl-*N,N'* -

SUBJECT INDEX TO VOLUME 50

- dicarboxymethyl-1,2-diaminopropane, heart microsomes exposed to Adriamycin, 2307
- Lipophilic drugs**
reversal of multidrug resistance, 3997
- Lipoproteins**
low density
prolonged serum half-life, antineoplastic drugs, 7476
- Liposarcoma**
myxoid
methylation patterns, 7902
- Liposomes**
composition and other factors
targeting to tumors, biodistribution, 6371
-encapsulated tumor necrosis factor α
immunomodulatory and toxic effects, 375
entrapment
anthracycline antibiotics, 4260
-entrapped *cis*-bis-neodecanoato-*trans*-R,
R-1,2-diaminocyclohexane platinum(II)
Phase I clinical and pharmacological study, 4254
growth inhibition of glioma cells
transfection, interferon- β gene, 7826
interleukin 2
antitumor effects, MCA-106 sarcoma
pulmonary metastases, 1853
phosphatidylcholine-phosphatidylserine
Adriamycin, murine tumor cell sensitivity, 3619
pretreatment
enhanced hyperthermic damage, M14
melanoma cells, 5119
sodium butyrate conjugated with anti-CD19
growth of malignant lymphoma, 3245
vincristine
increased activity, murine L1210 and P388 tumors, 575
- Lipoxygenase**
pathway metabolites
regulation, HL-60 differentiation, 7257
phospholipase A₂ activation
autoinduction, tumor necrosis factor gene expression, 7101
- Liver**
altered acinar distribution
glutamine synthetase, growth response, 4407
arylsulfotransferase IV
2-acetylaminofluorene-mediated alteration, hepatocarcinogenesis, 5301
asialo-G_{M1} positive cells
suppression of hepatic metastases, polyinosinic-polycytidine acid, 1834
biotransformation of *N,N',N'*-triethylethiophosphoramido, 464
carcinogenesis
microsomal epoxide hydrolase gene expression, 6222
carcinogenesis model
nuclear DNA content, altered hepatic foci, 7571
cDNA-expressed P-450
mutagenic activation, 2-amino-3-methylimidazo[4,5-*f*]quinoline, 2060
chronic injury
hepatocarcinogenesis, transgenic mice,
- 3400
cytological study of vacuolated cells
aberrant hepatocytes, fish, 6744
decreasing uptake
¹¹¹In-labeled anti-carcinoembryonic antigen monoclonal antibody, 8465
determinants of growth of altered foci
DNA synthesis, phenotypic expression, 5127
diet and age-related DNA modifications, 3991
diethylnitrosamine-induced hepatic neoplasia
cytotoxicity phase, medaka, 5504
disposition of amsacrine and its analogue, 503
DNA
reduction of I-compound levels, choline-devoid diet, 7577
early stages of chemical hepatocarcinogenesis
cellular and molecular changes, rat, 3439
enzyme-altered hepatic foci
testosterone substitution, neonatal and adult castration, 2679
epithelial cells
responsiveness to transforming growth factor- β 1, *v-raf* transformation, 7468
spontaneous transformation, phenotypic expression, 1941
TGF- β 1 resistance, 3600
failure
pharmacokinetics, recombinant human granulocyte colony-stimulating factor, 6615
formation and persistence of benzo(a)pyrene adducts, 5088
hepatic malignant tumors
ras gene mutations, polymerase chain reaction, 1121
hepatic P-450 expression
mechanisms of cyclophosphamide action, 5720
human adult and fetal
metabolic activation of aflatoxin B₁, 2-amino-3-methylimidazo[4,5-*f*]quinaline, 2641
In-111 monoclonal antibody B6.2
uptake and metabolism, 852s
lymphoid cell subsets
cellular interactions, interleukin 2, 1658
metastases
cellular immunotherapies, anti-CD3, 2476
effects of interferon, tumor tissue content, 3413
slow delivery of IL-2, colon 26 adenocarcinoma, 7003
metastases from human colon cancer in nude mice
radioimmuno detection, gamma-detecting probe, 877s
modulation of O⁶-methylguanine-DNA methyltransferase
dimethylnitrosamine treatment, 5426
neoplastic nodules
phenobarbital-enhanced formation, reactive oxygen, 7015
normal
induction of replicative competence,
- 7023
normal and tumors
heme synthesis, 2337
oncodevelopmental regulation of alternative splicing
fibronectin pre-messenger RNA, lung tissues, 1075
oncofetal membrane glycoprotein identification and characterization, 4755
oncogene-transfected epithelial cells
hepatocyte and oval cell antigens, hepatocellular carcinoma, 4809
production of interleukin 6 from cell lines, 7457
purification of hepatic polymorphic arylamine N-acetyltransferase
homozygous rapid acetylator inbred hamster, 7942
regenerating
catalytic subunit of protein kinase A cDNA, 1675
regeneration after partial hepatectomy
transforming growth factor receptors, 1464
-specific markers
gene expression in clonally derived cell lines, transformation of fetal hepatocytes, 7593
specific subtype of altered foci
tumor promotion, nafenopin, 3701
stem cell, 3811
transcriptional control
glutathione S-transferase gene expression, 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, 2251
v-raf-transformed epithelial cells
growth-related genes, tumor progression, 7460
Liver microsomes
human and rat
inactivation of mutagens, cytochrome P-450, 2036
Liver neoplasms
aflatoxin B₁-treated DHBV-infected ducks, 4072
7,12-dimethylbenz[a]anthracene-induced and spontaneous DNA fingerprinting, 5245
induction in ducks
aflatoxin B₁ and hepatitis B virus infection, 2156
microscopic
ovariectomy, acceleration of growth, 6779
mummichog *Fundulus heteroclitus*
creosote-contaminated site, 5978
mutational analysis of H-ras oncogene, 4014
oncogenes in fish, 5671s
primary
medical history, 6274
nonassociation of aflatoxin, China, 6882
Locus
hypoxanthine-guanine phosphoribosyl transferase
mutations, purine deoxyribonucleoside triphosphate pools, 4566
Lonidamine
cytotoxicity
combined with other drugs, RIF-1 and

SUBJECT INDEX TO VOLUME 50

- HT1080 cells, 7867
Lorglumide
 loxiglumide and
 inhibition of gastrin-stimulated DNA
 synthesis, tumoral acinar pancreatic
 cell line, 5829
Los Angeles County
 epidemiology of hairy cell leukemia, 3605
L3T4
 OK-432-specific T-cells
 mechanism, tumocidal activity, 4630
Lung
 alveolar epithelial cells
 clonally related transformed and con-
 trol sublines, laminin adhesion and
 expression, 3383
 bleomycin damage
 cytostatic activity, reactive nitrogen in-
 termediate production, 7863
 damage by bleomycin
 effect of erythrocytes, alveolar macro-
 phage cytostatic activity, 2351
 differentiation-dependent expression
 I-antigens and sialyl I-antigens, 7603
 fibronectin pre-messenger RNA
 alternative splicing, oncodelivery
 regulation, 1075
 formation and persistence of benzo-
 (a)pyrene adducts, 5088
 inflammatory response
 smoking and irradiated volume, irradi-
 ated breast cancer, 2027
 microsomes
 4-(methylnitrosamino)-1-(3-pyridyl)-1-
 butanone metabolism, inhibition by
 isothiocyanates, 6817
 pulmonary neoplasia
 O⁶-methylguanine formation in Clara
 cells, 4-(methylnitrosamino)-1-(3-
 pyridyl)-1-butanone, 3772
 residual damage at long intervals
 cyclophosphamide treatment, 2139
 tumorigenesis
 indole-3-carbinol effects, 4-(methylni-
 trosmo)-1-(3-pyridyl)-1-butanone
 disposition, 2613
Lung neoplasms
 alveogenic carcinoma
 cytogenetic profile, 164
 candidate cancer ch. preventive agents
 animal models, human clinical trials, 2
 clinical severity and stage migration, 4664
 differentiation-dependent expression
 I-antigens and sialyl I-antigens, 7603
 histologies
 sensitivity to photodynamic therapy,
 4272
 increased protein turnover
 normal energy metabolism, feeding,
 1125
 induction by 4-(methylnitrosamino)-1-(3-
 pyridyl)-1-butanone
 modulating effect of hyperoxia, patho-
 biology, 1960
 integrin expression
 monoclonal antibodies, 6107
Lewis
 disposition of amsacrine and its ana-
 logue, 503
 low passage cultured cells
in vivo invasion assay, 7358
 metastatic colonization
 protease and extracellular matrix genes,
 H-ras-transformed 10T½ fibroblasts,
 4061
neuroendocrine
 chemotherapy, Ca²⁺/calmodulin antag-
 onist, 1645
 neuroendocrine differentiation markers
 synaptophysin, chromogranin and L-
 dopa decarboxylase, 6068
non-small cell
 camptothecin analogue-resistant cell
 line establishment, 5919
 decreased accumulation, resistance to
 cis-diamminedichloroplatinum(II),
 2549
 expression, *neu* gene-encoded protein,
 421
 growth fraction and ploidy, Ki-67
 monoclonal antibody, 4382
 imaging with monoclonal antibody,
 milk fat globule antigen, 7068
 monoclonal antibody targeting, 866s
 nontumorigenic revertants
 photosensitizing dyes, 5369
 partial characterization of insulin-like
 growth factor I
 immunohistochemistry and receptor
 autoradiography, 2481
 peripheral airway cell differentiation,
 5481
 primary giant cell carcinoma
 c-myc joining with line 1 family mem-
 ber on chromosome 8, 3345
 production of human monocyte growth
 factor, 3863
 radon association
 case control study, Chinese tin miners,
 174
 rare alleles of H-ras protooncogene locus,
 1857
 residential radon
 case-control study, New Jersey women,
 6520
 small cell
 abnormal retinoblastoma gene expres-
 sion, xenografts, 5312
 altered structure, retinoblastoma sus-
 ceptibility gene, 3067
 antagonistic effect of actuarubicin, eto-
 poside and 4'-^(9-acridinylamino)methanesulfon-m-anisidine,
 3311
 autocrine function, insulin-like growth
 factor I, 2511
 calcium mobilization, bombesin and ta-
 chykinin neuropeptides, 240
 imaging and therapy of xenografts,
¹¹¹In-labeled monoclonal antibodies,
 980s
 immunological detection, residual mar-
 row disease, 6545
 inhibition of growth, neuropeptide an-
 tagonist, 3968
 neural cell adhesion molecule-related
 sialoglycoprotein, 1102
 radiolocalization, monoclonal anti-
 body, 3124
 xenografts, radiotherapy and magnetic
 resonance spectroscopy, 4880
 small cell and non-small cell
 growth in native-state histoculture,
 6095
 squamous differentiation
 cross-linked envelope-related markers,
 120
xenografts
 somatostatin analogue treatment, 4360
 [D-Trp]-Luteinizing hormone-releasing hor-
 mone
 receptor characterization
 endometrial carcinoma, 1841
Luteinizing hormone-releasing hormone
 antagonists or agonists
 regression, nitrosamine-induced pan-
 creatic cancers, 3716
Lymph nodes
 cervical
 locally activated lymphocytes, head and
 neck tumors, 5551
Lymphadenopathies
 immunopathogenesis of HIV infection,
 5612s
Lymphoblastoid cells
 down-regulation of α -interferon recep-
 tors, 2654
 Epstein-Barr virus-immortalized
 malignant phenotype suppression,
 Burkitt's lymphoma, 3095
Lymphocytes
 blastogenesis inhibitory factor
 tumor growth inhibitory activity, 345
 CD4⁺ and CD8⁺
 renal cell carcinoma, 2363
 clonal analysis
 primary renal cell carcinoma, 5263
 glutathione S-transferase expression
 chronic lymphocytic leukemia, 3562
 immortalized
 chromosome and gene rearrangements,
 immortalized lymphocytes, 5697s
 induction of micronuclei
 benzene metabolites, 393
 interleukin 2- or antibody-induced prolif-
 eration
 enhancement by interleukin 4, interleu-
 kin 2-treated patients, 1160
 large granular
 potentiation of tumor lysis, bispecific
 antibody, 7122
 locally activated
 cervical lymph nodes, head and neck
 tumors, 5551
 peripheral blood
 enhanced lysis of ovarian carcinoma,
 bifunctional immune heteroaggre-
 gates, 6508
 formation and persistence, benzo-
 (a)pyrene adducts, 5088
 phosphoramidate mustard-induced sister
 chromatid exchanges
 acrolein effect, 4635
 subset alterations
 nodes regional to human melanoma,
 3585
 tumor-infiltrating
 activation by monoclonal antibodies,
 CD3 complex, 1138
 migration through collagen matrix,
 7153
 solid-phase anti-CD3 antibody activa-
 tion, 2587
Lymphoid cells
 liver subsets
 cellular interactions, interleukin 2,

SUBJECT INDEX TO VOLUME 50

- 1658**
organs of mice
 proliferation, interferon α and interleukin 2, 5543
Lymphoid neoplasms
 heterotransplantation
 nude mouse intraocular xenograft model, 3078
Lymphoma
 amplification and rearrangement
bcl-2 gene, 2423
 -bearing mice
 reduced suppression, plasma saturated fatty acid mobilization, 2221
 Burkitt's
 malignant phenotype suppression, EBV-immortalized lymphoblastoid cells, 3095
 cutaneous T-cell
 clonotypic heterogeneity, 6620
 high dose radiolabeled antibody therapy, 1017s
 -inducing cells
 lymphomagenesis, radiation leukemia virus variants, 2554
 malignant
 chromosome abnormalities, Kurashiki, 2698
 liposomes containing sodium butyrate conjugated with anti-CD19, 3245
 malignant antigen
 Bloom's syndrome B-lymphoblastoid cell lines, 3106
 monoclonal antibody therapy
 interleukin 2 or LAK cells, 5421
 non-Hodgkin's
 Phase II study, oral idarubicin, 6833
 T-cell
 epineoplasms, polyoma virus-induced salivary gland tumors, 5643s
 thymic
 chemical induction, AKR gene locus *AKv-1*, 6235
 occurrence, carcinogenesis bioassay specimens, 5675s
 true histiocytic
 immunologic and ultrastructural characterization, Northern pike, 5668s
Lymphoma, B-cell
 determinants of antitumor effect
 radiolabeled monoclonal antibodies, 4935
 molecular characterization
 $t(11;14)(q23\sim 2)$ chromosome, 4856
 ^{90}Y -conjugated antiidiotype monoclonal antibody
 radioimmunotherapy, 1022s
Lymphoma, large cell
 establishment of Ki-1-positive T-cell line, 7682
Lymphoma, T-cell
 cytokine production, 8028
 peripheral
 favorable prognosis, low proliferative activity, 4845
Lymphoma cells
 L5178Y murine tumor-dormant state therapeutic effects, IL-2, 1361, 1368
Lymphomagenesis
B-cell
 immunocompromised hosts, murine model, 7042, 7050
radiation
 genetic analysis of resistance, mice, 3848
thymic
 mechanisms, retrovirus SL3-3, 5631s
Lymphoscintigraphy
melanoma
 low protein dose monoclonal antibody cocktail, 941s
Lysis
susceptibility
 sialomucin, rat mammary tumor ascites cells, 6800
Lysophosphatidylcholine
 bleomycin-induced DNA damage and repair
 permeabilized human cells, 1613

M
Macromolecules
C1q-binding
 importance, head and neck cancer, 4349
 normal and transformed human cells
 fibronectin receptor, 1601
 physiological barriers to delivery
 monoclonal antibodies in tumors, 814s
Macrophage growth factor
 CSF-1 and its receptor *c-fms*
 Hodgkin's disease-derived cell line, 2049
Macrophages
 activated
 nitric oxide production, flavone-8-acetic acid and xanthone-4-acetic acid, 6966
 tumor cell killing, l-arginine nitrogen intermediates, 1421
 alveolar
 cytostatic activity, bleomycin lung damage, 2351
 susceptibility to lysis, LAK cells, 1768
 cytostatic activity
 reactive nitrogen intermediate production, bleomycin lung damage, 7863
 cytotoxicity
 long and short crocidolite asbestos fibers, 5153
IC-21 cell line
 characterization of tumor binding, 4578
immunoregulatory
 granulocyte-macrophage colony-stimulating factor, murine mammary tumor, 227
-like differentiation
 phorbol ester-induced HL-60 cells, transferrin availability, 7221
-mediated tumorcidal activity
 ornithine decarboxylase inhibitors, 4510
nonspecific resistance to tumors
 neocarzinostatin derivative, 3897
 12-O-tetradecanoylphorbol-13-acetate-resistant cell line
 selection, variant lines, 1510
tumor cell line
 proliferation, protein kinase C-induced stimulation or inhibition, 1828
tumor cytotoxic
 adoptive transfer, circulating blood
monocytes, 7450
Magnetic resonance spectroscopy
 effects of 2-deoxyglucose
 breast cancer cells, 544
 ^{31}P
 human colon cancer, 527
 radiotherapy, small cell lung cancer xenografts, 4880
Major histocompatibility complex
 class I
 response to γ -interferon, cellular density and viral oncogenes, 601
 unique antigen expression, tumor progression, 3851
 class I and II
 human leukocyte, fibroblast, and immune interferences, melanoma cells, 7422
intraperitoneal recombinant γ -interferon
 recurrent ascitic ovarian carcinoma, 7318
inverse correlation with LAK activity
 lined human gliosarcoma cells, 596
Lyt-2⁺ T-cell proliferative response
 syngeneic tumor, absence of L3T4⁺ T-cells, 6256
Malaysia
 susceptibility to nasopharyngeal carcinoma
 relationship, immunoglobulin allotypes, 3186
Malignancy
 advanced
 induction of LAK cells, interleukin-2 splenic artery perfusion, 4906
 advancement of malignant phenotype
MYCN expression, neuroblastoma cells, 4411
 age-adjusted mortality
 arsenic level in well water, 5470
 cellular immunotherapies and anti-CD3 hepatic metastases, 2476
 c-Ha-ras oncogene expression
 immortalized human keratinocytes, growth potential, 2840
 colorectal tumorigenesis
 p53 gene mutations, 17p allelic deletions, 7717
cytotoxicity
 rhodamine 123 combined with hyperthermia, 459
 deletion of α -, β -, ω -interferon genes
 children with acute lymphocytic leukemia, 7781
embryo-derived tumors
 cytogenetic analysis, 3416
evidence for multistep nature
 human epithelial cell carcinogenesis, 5653s
experimental and human
 antineoplastic activity, interferon and cytotoxic agents, 3473
high- and low-grade malignant variants
 ploidy level determinants, prostatic carcinoma, 4281
malignant and potentially malignant colon cells
 quantitative cytochemical detection, 5112
mammary tumor growth
 methyl *p*-hydroxyphenyllactate, nuclear type II binding sites, 1470

SUBJECT INDEX TO VOLUME 50

- neoplasia**
 Exo-1 and EPM-1 expression, human epidermal keratinocyte maturation, 7668
 normal and malignant human cell populations in culture
 cytological differences, 3390
 parathyroid hormone-related protein immunohistochemical localization, breast cancer, 7710
 pro-epidermal growth factor transforming growth factor- α , renal carcinoma, 3934
 rearrangement of human *ABL* oncogene glioblastoma, 3429
 role of cAMP receptor proteins, 7093
 selective killing of cells
 alkyl-lysophospholipid, leukemic patients, 4020
 transformation
 molecular genetic approaches, 3805
 tumor necrosis factor
 children, 592
 uterine smooth muscle tumors
 chromosome aberrations, 4092
- Mammalian cells**
 Ω -alkylguanine-DNA alkyltransferase response to alkylating carcinogenic and therapeutic agents, 6119
 antifolate resistance
 flow cytometric characterization, methotrexate and daunorubicin, 4946
 decreased NADPH:cytochrome P-450 reductase activity
 impaired drug activation, 4692
 phenotypic characterization of CHO-UV-1 mutant
 postreplication recovery of DNA, 2356
 stable expression of aromatase complementary DNA, 6949
- Mammary gland**
 hyperplasia
 transfection, activated *Ha-ras* protooncogenes, 6010
 neoplastic progression in epithelium
 intracisternal A-particles, retrotransposons, 2404
- Mammary neoplasms**
 ascites cells
 sialomucin, lytic susceptibility, 6800
 sialomucin susceptibility, tunicamycin effect, 5250
 distribution of oncofetal fibronectin, 1608
 expansion of immunoregulatory macrophages
 granulocyte-macrophage colony-stimulating factor, 227
 fat, calories, and body weight, 5710
 flow cytometric DNA ploidy analysis, 4003
 genetic instability after v-H-ras transfection
 acquisition of metastatic ability, 6349
 growth control
 estradiol and growth factors, serum-containing medium, 7806
 metastatic ability
 H-ras oncogene expression, 1449
N-methyl-*N*-nitrosourea-induced inhibition by retinoic acid and ovariotomy, 5731
N-nitrosomethylurea-induced insulin-like growth factor-related peptides, 7179
N-nitroso-*N*-methylurea-induced effects of cyclosporine A, Ia antigen expression, 3301
 polyoma virus-induced gonadotropin-releasing hormone, estrogen-sensitive progression, 5892
 tumor growth
 methyl *p*-hydroxyphenyllactate, nuclear type II biding sites, 1470
 mAMSA: see 4'-(9-Acridinylamino)-methanesulfon-m-anisidine
 Manganese superoxide dismutase
 monoclonal antibody reactivity, human ovarian carcinoma, 2538
- Mannose** glycopeptides
 tumor necrosis factor and interleukin 1 interactions, 6285
- Marijuana** gestational and familial risk factors
 childhood astrocytoma, 2608
- Marriage** incidence of sarcomas of uterus, 1886
- Mass spectrometry** tobacco-specific nitrosamine hemoglobin adducts
 snuff dippers, smokers, and non-smokers, 5438
- Mate drinking** alcohol, tobacco, and diet
 esophageal cancer, Uruguay, 426
 patterns of
 Brazilian city, 7112
- Matrin** secretion from human rectal carcinoma cell line, 7758
- Maytansine** interaction of rhizoxin
 bovine brain tubulin, 4277
- MCF-7 cells** action of gossypol and rhodamine 123
 ³¹P nuclear magnetic resonance and toxicity studies, 6936
 cell cycle kinetics
 estrogen receptor concentration, α -interferon, 17 β -estradiol, and tamoxifen, 5387
 doxorubicin-resistant antioxidant and xenobiotic-metabolizing enzyme gene expression, 1397
 growth control
 estradiol and growth factors, serum-containing medium, 7806
 growth properties and tumorigenesis
 transfection, *ras* mutants, 67
 inhibition of estradiol uptake
 transforming growth factor- α secretion, alkyl-lysophospholipid, 3172
 modulation of NADPH pathways
 sex steroid hormone, 1195
 occupied nuclear estrogen receptor 2,3,7,8-tetrachlorodibenzo-*p*-dioxin effects, 3579
 opioid binding
 effects on growth, 2234
 opposite effects of tamoxifen
 protein kinase C activity, endogenous protein phosphorylation, 5845
- MCF-10 cells**
- immortalized breast epithelial cell line** ultrastructural and immunocytochemical characterization, 6087
 spontaneously immortalized human breast epithelial cell line isolation, characterization, 6075
- Meat, cured** gestational and familial risk factors
 childhood astrocytoma, 2608
- ME180 cells** modulation of epidermal growth factor receptors
 retinoic acid, 1201
- Medulloblastoma** amplification of *c-myc* gene
 xenografts, 2347
 oncogene amplification
 pediatric brain tumors, 2987
- Megakaryocytes** differentiation of K562 cells
 cytoskeletal organization, phosphotyrosyl-specific protein phosphatases, 6323
- Melanoma** adapted Newcastle disease virus mutant
 highly selective replication patterns, 5962
 antibody-mediated redirected cytolysis, 6034
 -associated antigen
 biosynthesis, neuroglandular antigen, 4557
 -associated glycoprotein *M*, 100,000
 transfection and amplification, interspecific DNA, 1559
 cell vaccine and cyclophosphamide
 suppressor cell activity, active specific immunotherapy, 5358
 cloning and characterization
 interstitial collagenase, 5431
 cytotoxicity
 rhodamine 123 combined with hyperthermia, 459
 enhanced hyperthermic damage
 liposome pretreatment, 5119
 evaluation of human antitumor cytotoxicity
 tetrazolium-based semiautomatic calorimetric assay, 3681
- human** bovine buttermilk and, natural 9-*O*-acetyl GD3, 1403
 human leukocyte, fibroblast, and immune interferons
 class I and II major histocompatibility complex, invariant chain, 7422
 increased lysis
 in vivo-elicited LAK cells, antiganglioside antibodies, 6311
 indium 111-labeled bivalent hapten bispecific monoclonal antibody conjugates, 3445
 -inhibiting activity
 inhibition of cell proliferation, cell cycle, 6981
 inhibition of cell invasion
 retinoic acid, reconstituted basement membrane, 4121
 interaction of fibrinogen, 8010
 interleukin 1-induced augmentation
 experimental metastases, 4771
in vitro properties of metastatic cells, 2296

SUBJECT INDEX TO VOLUME 50

- lymphoscintigraphy**
 low protein dose monoclonal antibody cocktail, 941s
- malignant**
 induction of DNA damage, new 2-chloroethyl nitrosourea, 5898
 integrin distribution, tumor progression, 6757
 melanocytotoxicity and antimelanoma effects
 phenolic amine compounds, mice, 3743
 melanotropin receptors, 1237
 metastasis-associated
 cell surface galactosyltransferase, 7261
 metastatic
 sulfated chitin derivatives, extracellular matrix and enzymatic degradation, 3631
 metastatic lesions
 differential expression, intercellular adhesion molecule 1, 1271
 metastatic variants
M, 41,000 glycoprotein, thrombin-independent platelet aggregation, 6657
 multidrug resistance phenotype
 transfection, *mdr1* cDNA, 1779
 poorly and highly metastatic
 differential effects, transforming growth factor- β_1 , 273
radioimaging
 99m Tc-labeled Fab fragment, 904s
regional nodes
 lymphocyte subset alterations, 3585
 selective delivery of boron
p-boronophenylalanine, 138
-specific cytotoxic T-lymphocytes
 HLA-A2-matched allogeneic melanoma, 492
 transferrin receptor-related glycoprotein, 515
tumor cell-platelet-endothelial cell interactions
 tumor cell cytoskeleton, 7686
tumor necrosis factor release from monocytic cells
 granulocyte-macrophage colony-stimulating factor, 2673
tumor xenografts
 growth inhibition, swainsonine, 1867
uveal
 ultraviolet light exposure, host factors, 5773
xenografts
 211 At-methylene blue, targeted radiotherapy, 2963
- Melanoma, B16**
 action of RU 38486
 glucocorticoid receptor monoclonal antibodies, 7985
 autocrine motility-like factor receptor, 409
 characterization of cells
 resistance to U-71,184, 2485
 effects of cytochalasin B, 1431
 hyperthermic enhancement, rhodamine 123 cytotoxicity, 2385
metastatic
 integrin receptors, laminin and type IV collagen, 728
 transfected with human urokinase gene and antisense gene
 secreted urokinase plasminogen activa-
- tor, metastatic potential, 7623
 tumor angiogenesis
 α -difluoromethylornithine effect, 4131
- Melphalan**
 antineoplastic activity
 experimental and human malignancies, 3473
 cyclophosphamide or VP-16
 synergistic interactions, rhabdomyosarcoma xenograft, 284
 eradication of MOPC-315 tumors
 tumor-specific cytotoxic CD8 $^+$ T-cells, 7641
 -induced glutathione content
 changes in resistance, stomach cancer, 3614
 -induced mutagenesis
 SV40-based shuttle vector, 7527
- Membrane**
 transport system
 uptake folate-based thymidylate synthase inhibitors, 7544
- Membrane antigen**
 hepatic oncofetal
 identification and characterization, 4755
- Membrane vesicles**
 formation due to acquired mitoxantrone resistance
 gastric carcinoma, 6100
- Meningioma**
 effects of progesterone
 response to epidermal growth factor, 2604
 molecular genetic analysis of chromosome 22, 5863
 schwannoma and
 clonal analysis, 6783
- Meningitis**
 neoplastic
 nude rat model, intrathecal 4-hydroperoxy-cyclophosphamide, 1954
- Mental retardation**
 gestational and familial risk factors
 childhood astrocytoma, 2608
- Merbarone**
 Phase I clinical and pharmacological study, 1151
- 6-Mercaptopurine**
 antineoplastic activity
 experimental and human malignancies, 3473
cytotoxicity
 phosphoribosylpyrophosphate levels, Chinese hamster ovary cells, 1992
 inhibition by benzo(a)pyrene diol-epoxide binding
 DNA, Chinese hamster ovary cells, 4355
 paradoxical metabolism
 WEHI-3b murine leukemia cells, 108
- MER cells**
 O' -methylguanine-DNA methyltransferase
 gene *MGMT* expression, 7908
- Merocyanine 540**
 -sensitized photoinactivation
 soluble and membrane-bound enzymes, L1210 cells, 7765
- Mesenchyma**
 male genital tract
 differentiation, Dunning prostatic ade-
- nocarcinoma, 4747
monoclonal antibody to human osteosarcoma, 152
 suppression of wound healing
 tumor-host interaction model, tumor-bearing animals, 7997
- Metalloprotease**
M, 94,000 gelatin-degrading
 differentiation, HL-60 cells, 1113
- Metalloproteinase**
 extracellular matrix-degrading
 secretion, human rectal carcinoma cell line, 7758
 inhibitors and
 fetal astrocytes, glioma cells, 2322
M, 72,000 type IV collagenase
 cellular processing, interstitial collagenase in tumorigenic cell lines, 6184
 proteolytic cascade
 basement membrane type IV collagen degradation, 5997
- Metallothionein**
 99m Tc B72.3 and its F(ab) 2 fragment
 pharmacokinetics, 835s
- Metals**
 occupations of parents
 children with retinoblastoma, 7129
 stable bifunctional chelates
 radiotherapy, 789s
- Metastasis**
 -associated melanoma cell surface galactosyltransferase, 7261
 cathepsin B to cysteine proteinase inhibitor balance, 6278
 cell membrane and cell signals as targets
 cancer chemotherapy, 2203
 critical factors in biology of human cancer, 6130
 differential spectrum of expression
 neural cell adhesion molecule isoforms,
 neuroectodermal tumors, 6364
 fibrosarcoma cell adhesion
 laminin peptides, 7612
hepatic
 asialo-G_{M1} positive liver cells, polyinosinic-polycytidine acid, 1834
 cellular immunotherapies, anti-CD3, 2476
 human colon cancer in nude mice, radioimmuno-detection, 877s
 radiolocalization of monoclonal antibodies, colon cancer, 862s
human melanoma cells
in vitro properties in nude mice, 2296
inhibition
 Lewis lung carcinoma, glucosylceramide synthase inhibitor, 6731
 interleukin 1-induced
 human melanoma in nude mice, 4771
 invasive capacity
 revertants, LFA-1-deficient mutant T-cell hybridomas, 3509
liver
 effects of interferon, tumor tissue content, 3413
 slow delivery of IL-2, colon 26 adenocarcinoma, 7003
lung colonization
 transient gene alterations, 10T½ fibroblasts, 4061
mammary carcinoma clones
 ultrastructural differences, intercellular

SUBJECT INDEX TO VOLUME 50

- communication, 358
 marker to detect micrometastasis formation
 bacterial *lacZ* gene, tumor progression, 2808
 melanoma cells
 sulfated chitin derivatives, extracellular matrix and enzymatic degradation, 3631
 melanoma lesions
 differential expression, intercellular adhesion molecule 1, 1271
 micrometastases
²¹¹At-methylene blue for targeted radiotherapy, human melanoma xenografts, 2963
 murine colon cancer
 cell surface sialoprotein, 1299
 nodes regional to human melanoma lymphocyte subset alterations, 3585
 plasma membrane protein identified by monoclonal antibody
 lymph node adhesion, Lewis lung carcinoma, 1948
 primary and metastatic spontaneous osteosarcoma
 DNA aneuploidy, 6176
 pulmonary
 interleukin 2 liposomes, MCA-106 sarcoma, 1853
 relapse in small cell lung cancer
 immunological detection, residual marrow disease, 6545
 relationship to H-ras oncogene expression
 rat mammary cancer cells, 1449
 renal cell adenocarcinoma
 recombinant interleukin 2, dose escalating regimen, 6723
 role of 1q trisomy
 tumorigenicity and growth, leukemic B-cell clones, 3737
 secreted urokinase plasminogen activator transfected murine B16 cells, 7623
 spontaneous
 calcium phosphate-mediated transfer of DNA, 5581
 transferrin receptor-related glycoprotein melanoma cells, 515
 transformed rat embryo cells
M, 92,000 gelatinase release, 3872
 tumor cell-platelet-endothelial cell interactions
 tumor cell cytoskeleton, 7686
 tumorigenicity and
 human breast carcinoma cell lines, nude mice, 717
 tumor migration and
 prostaglandin E₂-protein kinase A coupling, Lewis lung carcinoma variants, 2973
 tumor progression and
 heterogeneous protooncogene amplification, gastric cancer, 7811
Metastatic ability
 acquisition
 genetic instability after v-H-ras, mammary cancer cells, 6349
Metastatic potential
 secreted urokinase plasminogen activator transfected murine B16 cells, 7623
³⁵S|Methionine
-labeled human and murine α interferons
- pharmacokinetics, tissue distribution, 4718
Methotrexate
 aminopterin analogues and biochemical and growth inhibition studies, 1726
 antineoplastic activity experimental and human malignancies, 3473
 biological monitoring screening, 3351
 carcinogen-induced resistance
 dihydrofolate reductase gene amplification, inhibitors of poly(adenosine diphosphate-ribose) polymerase, 5756
 characterization of antifolate resistance flow cytometry, mammalian cells, 4946
 growth adaptation
 colon carcinoma cells, 6334
 immunoconjugate with monoclonal antibody
 Phase I trial, non-small cell lung carcinoma, 4154
 inhibition of DNA excision repair
 Chinese hamster ovary cells, 1786
 prolonged serum half-life
 incorporation, low density lipoproteins, 7476
 -resistant L1210 cells
 novel transport system, folate compounds, 1709
 teniposide and
 continuous infusion, pediatric cancer patients, 4267
 toxicity of central nervous system therapy animal model, childhood acute lymphoblastic leukemia, 6455, 6461
Methotrexate polyglutamates
 dihydrofolate and
 leucovorin rescue, breast cancer, 3574
3-Methoxy-4-aminoazobenzene
N-hydroxylation
 renal microsomal cytochrome P-450, 2729
Methylbenzylnitrosamine
 mutational activation of H-ras oncogene esophageal papilloma, 1591
3-Methylcholanthrene
 age-, tissue-, and *Ah* genotype-dependent binding differences
 mouse DNA, 4239
 -inducible phenol uridine diphosphate-glucuronosyltransferase
 hepatocyte nodules, hepatocellular carcinoma, 3569
N¹-Methyldeoxyguanosine
 combined HPLC/³²P-postlabeling assay, 6580
5,10-Methylenetetrahydrofolates
 colon adenocarcinoma xenografts
 leucovorin metabolism, 3493
O⁶-Methylguanine
 accumulation in blood leukocyte DNA procarbazine exposure, dose and repair, 2759
 formation in Clara cells
 pulmonary neoplasia, 4-(methylnitro-samo)-1-(3-pyridyl)-1-butane, 3772
6-thioguanine and
 tolerance to cytotoxic effects, CHO cells, 4248
- O⁶-Methylguanine-DNA methyltransferase**
 control of expression
 closely linked unrelated genes, 1532
 expression of gene *MGMT*
 MER⁻ and MER⁺ human tumor cells, 7908
 modulation in rat and hamster liver dimethylnitrosamine treatment, 5426
N-Methyl-N-benzylnitrosamine
 esophageal carcinogenesis
 dietary molybdenum, 2418
4-(Methylnitrosamo)-1-(3-pyridyl)-1-butane
 active transplacental carcinogen
 Syrian golden hamsters, 3435
 cysteine adduct formation in hemoglobin, 5453
 disposition and metabolism
 indole-3-carbinol effects, lung tumorigenesis, 2613
 dose-response study of DNA
 hemoglobin adduct formation, 5446
 metabolism and DNA strand breaks hepatocytes, 1810
O⁶-methylguanine formation in Clara cells
 pulmonary neoplasia, 3772
 mouse lung microsomes
 inhibition by isothiocyanates, 6817
N'-nitrosornornicotine and
 comparative metabolism, oral tissue and esophagus, 4685
 pathobiology of lung tumors
 modulating effect of hyperoxia, 1960
N-Methylnitrosourea
 -resistant Chinese hamster ovary cells
 tolerance, O⁶-methylguanine and 6-thioguanine cytotoxic effects, 4248
N-Methyl-N'-nitro-N-nitrosoguanidine
 attenuating effect of bromocriptine
 cysteamine anticarcinogenesis, stomach cancer, 5308
 calcium channel blockers
 caerulein, gastric carcinogenesis, 2095
 colonic epithelial hyperproliferation
 calcium-enriched diet, 1764
 gastrointestinal tumorigenesis
 flurbiprofen and 16,16-dimethyl prostaglandin E₂, 381
 -induced colon carcinogenesis
 wheat bran and lard, 1092
 inhibition of gastric carcinogenesis
 γ -amino-*n*-butyric acid and baclofen, 4931
 nonrandom chromosome alterations
 progression to immortality, tracheal epithelial cells, 740
N-Methyl-N-nitrosourea
 chemical induction of prostate carcinoma, 700
 cyproterone acetate, testosterone propionate, 691
 -induced autochthonous rat bladder cancer model, 6674
 -induced mammary cancer
 inhibition by retinoic acid and ovariectomy, 5731
 -induced rat thyroid tumors
 sex differences, gonadectomy, and estrogen, 7662
 induction of thymic lymphoma
 AKR gene locus *AKv-1*, 6235

SUBJECT INDEX TO VOLUME 50

- malignant conversion
low-grade rat urinary bladder carcinoma, 7062
prolactin or
activated *ras* oncogenes, mammary carcinoma, 4286
- N-(4-Methylphenylsulfonyl)-N'-(4-chlorophenyl)urea**
mitochondrial localization
colon adenocarcinoma cells, 664
- Methyl p-hydroxyphenyllactate**
nuclear type II binding sites
malignant cells, mammary tumor growth, 1470
- Micelle**
-forming polymeric anticancer drug, 1693
- Microcirculation**
microvascular architecture of colon tumors, 2411
- murine F3All tumors**
hydralazine effects, hyperthermia, 15
- β_2 -Microglobulin**
expression in human embryonal neuroblastoma
developmental regulation, 3694
- Micronuclei**
induction in human lymphocytes
benzene metabolites, 393
- Microsomes**
epoxide hydrolase gene expression
liver chemical carcinogenesis, 6222
- heart**
Adriamycin exposure, *dl-N,N'-dicarboxamidomethyl-N,N'-dicarboxymethyl-1,2-diaminopropane*, 2307
- lung**
4-(methylnitrosamo)-1-(3-pyridyl)-1-butanone metabolism, inhibition by isothiocyanates, 6817
- P-450**
mutagenic activation, 2-amino-3-methylimidazo[4,5-*f*]quinoline, 2060
- species susceptibility**
aflatoxin B₁ carcinogenesis, 615
- Microspheres**
binding of Adriamycin
induction of erythroid differentiation, K-562 cells, 1231
- Milk fat globule**
imaging of non-small cell lung cancers
monoclonal antibody KC-4G3, 7068
- membrane monoclonal antibodies**
synthetic peptides, 89
- Minnesota**
men
pesticide and agricultural risk factors, 6585
- Mitochondria**
bc₁-complex
diethylstilbestrol-diphosphate cytotoxic action, prostatic carcinoma, 5008
- cytochrome c oxidase**
colonic cancer, 1596
- DNA modulation**
anchorage-independent phenotype, transformed avian cells, 6675
- glycerol phosphate dehydrogenase**
insulinomas, amine precursor uptake decarboxylation system, 7203
- localization of *N*-(4-methylphenylsulfonyl)-*N'*-(4-chlorophenyl)urea
- colon adenocarcinoma cells, 664
- mammalian**
inhibition of respiratory chain, ditercalinium, 7966
- toxicity of cationic photosensitizers**
photochemotherapy, 7876
- Mitogenesis**
inhibitory effects of transforming growth factor- β 1
colon carcinoma cells, 7581
- Mitogens**
activity which selectively stimulated bone cells
prostatic cancer cells, 6902
- Mitomycin C**
activation by NADPH:cytochrome P-450 reductase, 7789
- antineoplastic activity**
experimental and human malignancies, 3473
- bolus arterial administration
disposition, tissue-isolated tumor perfusion system, 1640
- cytotoxicity of lidoniamine**
RIF-1 and HT1080 cells, 7867
- DNA interstrand cross-link and free radical formation**
multidrug resistant cell line, 648
- metabolism by DT-diaphorase**
colon carcinoma cells, 7483
- resistance and drug activation**
NADPH:cytochrome P-450 reductase activity, 4692
- Mitomycin phosphate**
specific activation
bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody, 6944
- Mitoxantrone**
acquired resistance
membrane vesicle formation, gastric carcinoma, 6100
- Moloney leukemia virus integration-4 locus**
human homologue
20 kilobases 3' of *myc* gene, rearrangement in multiple myeloma, 6478
- Molybdenum**
esophageal carcinogenesis
induction, *N*-methyl-*N*-benzylnitrosamine, 2418
- Momordina**
pharmacokinetics of immunotoxins, 7519
- Monensin**
carrier protein conjugates, 1385
- Mono-L-aspartyl chlorin e6**
tissue distribution and photosensitizing properties
mouse tumor model, 3>85
- Monoclonal antibodies**
17-1A
pharmacokinetics, various treatment schedules, 4866
- accumulation of highly acidic sulfated glycosphingolipids
hepatocellular carcinoma, 2917
- activation of tumor-infiltrating lymphocytes
- CD3 complex**, 1138
- Adriamycin immunoconjugates**
hydrazone linker, 6600, 6608
- aminopterin**
tumor necrosis factor effect, antitumor efficacy and toxicity, 6028
- anti-carcinoembryonic antigen**
¹¹¹In-labeled, decreasing liver uptake, 846s
- anticarcinoma**
epitope mapping, anti-idiotypic antibodies, 2449
- anti-CD3**
activation, tumor-infiltrating lymphocytes, 2587
- anti-CD4**
tolerance induction, Moloney murine sarcoma virus, 5703s
- anti-CD5 antibody-ricin A chain immunotoxins**
parameters, tumor-specific delivery, 2909
- anti-CD19 conjugate**
liposomes containing sodium butyrate, malignant lymphoma, 3245
- anti-CEA and antitumor-associated glycoprotein 72**
complementary reactivities, lung carcinoma, 6987
- anti-class II murine**
antibody-dependent cell-mediated cytotoxicity, interleukin 2 effects, 2991
- anti-GD₃**
childhood T-cell acute lymphoblastic leukemia, 202
- anti-human milk fat globule**
synthetic peptides, 89
- anti-TAG-72**
enhanced tumor binding, 1291
- anti-transferrin receptor**
inhibition of cell growth, 6295
- astatin-211-labeled antibodies and fragments, 3514
- 323/A3 surface glycoprotein
tumor characteristics and behavior, breast cancer, 3317
- augmentation of antibody-dependent cell-mediated cytotoxicity
interleukin 2, 5234
- biodistribution of ¹⁸⁶Re labeled NR-LU-10
colonic tumor-bearing mice, 7973
- biodistribution of KC-4G3
xenografted nude mice, 5954
- bismuth-labeled**
stability and tumor targeting, 4221
- bispecific**
potentiation of tumor lysis, large granular lymphocytes, 7122
targeting of human T-cells, ovarian carcinoma, 4227
- bispecific anti-CD30/anti-alkaline phosphatase**
specific activation, mitomycin phosphate, 6944
- bispecific conjugates**
indium 111-labeled bivalent hapten, melanoma, 3445
- carcinoembryonic antigen and α -fetoprotein expression**
human hepatoma/nude mouse model, 869s

SUBJECT INDEX TO VOLUME 50

- carcinoembryonic antigen
radioimmunodetection, ^{123}I or $^{99\text{m}}\text{Tc}$, 909s
- carcinoma-associated antigen
biosynthesis and glycosylation, 4656
- carrier protein-monensin conjugates, 1385
- cell binding characteristics
tumor localization properties, mice, 4423
- cell surface molecule characterization
B-cells and Hodgkin's cells, 1650
- chimeric 17-1A
tumor localization and therapy, 993s
- clinical cancer progression
flow cytometry, urinary bladder tumors, 432
- combinations
tumor localization, colon carcinoma, 5225
- decreased expression of DNA topoisomerase I
camptothecin-resistant tumor cell lines, 6925
- DF3 conjugated with ricin
purging, human bone marrow, 1170
- distribution of glycoproteic antigen
breast cancer celi line, 7333
- 7E11-C5
immunohistochemical and pharmacokinetic characterization, immunoconjugate CYT-356, 5423
- elimination of small cell lung carcinoma
bone marrow, immunomagnetic beads, 7216
- enhanced uptake
colon tumor xenografts, irradiation, 159
- estrogen-induced breast cancer protein
Escherichia coli, 2390
- 5F4
blockage of autonomous growth, ACHN cells, 2968
- F(ab')₂ fragment
delivery to tumor, glioma, 4105
- enhanced delivery to glioma xenografts, local hyperthermia, 1803
- immunolymphoscintigraphy, ovarian and fallopian tube cancer, 937s
- final common pathway of cancer, 4830
- gangliosides and sialoglycoproteins
rare blood group antigen determinant, 5497
- glucocorticoid receptors
RU 38486 action, B16 melanoma cells, 7985
- glycoprotein M, 170,000
saporin-conjugated anti-mouse antibody, multidrug-resistant cells, 4291
- growth inhibition of glioma cells
transfection, human interferon- β gene, 7826
- growth-regulated surface glycoproteins
human bladder cancer, 293
- hazard recognition and prevention
human anti-mouse antibodies, 1049s
- heteroaggregates
activated peripheral blood lymphocytes, lysis of ovarian carcinoma, 6508
- high molecular weight lung carcinoma-associated glycoprotein
detection and characterization, 6738
- human osteosarcoma, 152
- IgG3 anti-G_D₃
light chain variants, avidity, 1503
- IgM
inhibition of tumor growth, tumor cell surface carbohydrates, 7301
- ^{131}I -labeled
clearance from blood, anti-murine immunoglobulin antibody, 563
- ^{131}I -labeled anti-carcinoembryonic antigen
tumor, red marrow and organ dosimetry, 1039s
- ^{131}I -Lym-1
fractionated radioimmunotherapy, B-cell malignancies, 1014s
- imaging of non-small cell lung cancers
milk fat globule antigen, 7068
- immunoaffinity purification
 O^6 -alkylguanine-DNA alkyltransferase, 58
- immunoglobulin G subclass analysis
human anti-mouse antibody response, cancer patient treatment, 1051s
- ^{111}In -anti-myosin monoclonal antibody complex
radioimmunodetection, rhabdo- and leiomyosarcoma, 955s
- ^{111}In -labeled
imaging and therapy, small cell lung cancer, 980s
- uptake and metabolism, rat liver, 852s
- ^{111}In -labeled B72.3
human biodistribution, 932s
- intact antibodies and Fab' fragments
ricin A chain preparations, Hodgkin's disease, 2929
- integrin expression
human lung cancer, 6107
- interleukin 2 and
mechanisms of antitumor activity, 5767
- Phase I study, metastatic melanoma, 7490
- intracisternal A-particles
mammary epithelium, 2404
- ^{131}I - vs. ^{90}Y -IgG or fragments
biodistribution, dosimetry, 2330
- Ki-67
growth fraction and ploidy, non-small cell lung cancer, 4382
- L/IC2-4-desacetylvinblastine-3-carboxyhydrazide
xenografts, antitumor activity, 1790
- L ϵ -related cell surface antigens, 2183
- Lewis lung carcinoma variant
plasma membrane protein, lymph node adhesion and metastasis, 1948
- low protein dose cocktail
lymphoscintigraphy, melanoma, 941s
- L6-ricin immunotoxin
antitumor activity, lung adenocarcinoma, 3249
- methotrexate immunoconjugate
Phase I trial, non-small cell lung carcinoma, 4154
- mouse-human chimeric
multidrug transporter P-glycoprotein, 3167
- murine
carcinoembryonic antigen, targeting properties, 2823
- colon-specific antigen p, 6405
- comparative pharmacokinetics, rat colon tumor in rats and nude mice, 873s
- human epidermal growth factor receptor, HER2/neu gene product, 1550
- human immune response, anti-carcinoembryonic antigen, 1055s
- novel ribonucleoprotein complex
NIH 3T3 cells, pancreatic adenocarcinoma DNA, 6015
- patterns of antigen distribution
human carcinomas, 880s
- pharmacokinetics of immunotoxins
abrin A chain, ricin A chain, gelonin, and momordin, 7519
- physiological barriers to delivery in tumors
other macromolecules, 814s
- radioimmunodetection of cancer
experimental studies, overview, 809s
- radioiodinated
improved tumor retention, aryl carbohydrate adducts, 783s
- radiolabeled
determinants of antitumor effect, 4935
- inhibition of catabolism, lysosomal amines and carboxylic ionophores, 1243
- tumor immunoscintigraphy, multicenter studies, 899s
- radiolocalization
hepatic metastases, colon cancer, 862s
- pancreatic tumors, athymic mice, 7246
- small cell lung cancer, antigen-positive tissues, 3124
- reactivity to manganese superoxide dismutase
human ovarian carcinoma, 2538
- reduction of immunogenicity by covalent modification
immunoglobulins, low molecular weight dextrans, 3638
- regulation of carcinoembryonic antigen expression
 γ -interferon, colorectal tumor cells, 6248
- selective depletion of neutrophils
abrogation of transplantation resistance, syngeneic tumors, 6243
- serological mapping of TAG-72, 4872
- specificity and tumor targeting
non-small cell lung carcinoma, 1330
- streptavidin complex
disulfide bond-targeted radiolabeling, 804s
- synthetic peptide inhibitors and
human tumor cell migration, 4485
- targeting of non-small cell lung carcinoma, 866s
- 791T/36 biodistribution and Fab/c fragment
BALB/c and nude mice, human tumor xenografts, 2936
- technetium-99m-labeled
immunosciography, CEA in breast cancer, 949s
- therapy of murine lymphoma
interleukin 2 or LAK cells, 5421
- tissue polypeptide antigen-related protein
Signet-ring cell carcinoma, stomach, 5192
- tumor-associated antigens common to humans

SUBJECT INDEX TO VOLUME 50

- chemically induced colonic tumors of the rat, 6358
 tumor targeting
 innovations, pharmacology, 820s
 tumor targeting in nude mice
 human colorectal cancer antigens, 828s
Vinca alkaloid immunoconjugate
 antitumor activity, ovarian cancer, 3540
 resistance, human tumor cells, 7634
⁹⁰Y activity
 radioimmunotherapy, human colorectal carcinoma xenografts, 4546
 tumor radiation doses, colorectal cancer, 1029s
⁹⁰Y-ZCE025
 radioimmunotherapy, human colon carcinomatosis xenograft, 989s
- Monocytes**
 activation following high-dose interleukin 2 bolus treatment
 adoptive immunotherapy, human cancer, 579s
 activity
 effect of interleukin 4, 3154
 circulating blood
 adoptive transfer, tumor cytotoxic macrophages, 7450
 growth factor
 production by lung cancer cells, 3863
 induction of tumor necrosis factor leukemia cells, 2708
 -mediated cytotoxicity
 coordinated induction, tumor necrosis factor and interleukin 1, 3146
 tumor necrosis factor release
 granulocyte-macrophage colony-stimulating factor, melanoma, 2673
- Mononuclear cells**
 increased secretion of TNF- α , IL-1 and IL-6
 β -galactoside-specific lectin, mistletoe extract, 3322
 peripheral blood
 cytokine regulation, tumor necrosis factor- α and - β , 5072
- MOPC-315 neoplasms**
 eradication
 tumor-specific cytotoxic CD8 $^{+}$ T-cells, 7641
- Motility**
 -like factor receptor
 B16-F1 melanoma, 409
- Mouse mammary tumor virus**
 endogenous *Mtv* expression
 resistance to infection, 3754
- Mucin**
 -associated antigen *M*, 70,000
 cloning and sequencing, complementary DNA, 5925
 biodistribution of KC-4G3
 xenografted nude mice, 5954
 human pancreatic tumor
 polypeptide core, 2997
 -like antigen
 breast tumor radioimmunodetection,
 ¹¹¹In-labeled monoclonal antibody, 927s
 -secreting cells
 growth adaptation to methotrexate, colon carcinoma, 6334
- Mucomodulin**
- soluble factor in normal tissues
 high-molecular-weight sialoglycoprotein production, colon carcinoma, 3331
- Multidrug resistance**
 ascites
 photoreactive vinblastine derivative, Chinese hamster ovary cells, 403
 bone marrow purging
 mouse monoclonal antibody, *M*, 170, 000 glycoprotein and saporin-conjugated anti-mouse antibody, 4291
 Chinese hamster cell line
 DNA content, six-gene amplicon, 2803
 Chinese hamster ovary cells
 cytotoxic effects, high- and low-molecular-weight anticancer agents, 1571
 colon carcinoma
 induction and selection by two methods, 3218
 conquest of
 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarmomycin, 4698
 daunorubicin-resistant P388 cells
 elevated pentose cycle, glucuronosyltransferase, 3921
 DNA interstrand cross-link and free radical formation
 Mitomycin C and analogues, 648
 doxorubicin-resistant breast cancer cells
 antioxidant and xenobiotic-metabolizing enzyme gene expression, 1397
 gene
 inverse correlation, N-myc in neuroblastoma, 3043
 HL-60 cells
 synthetic peptides, P-glycoprotein, 1426
 human leukemia cell lines
 susceptibility to IL-2 activated killer cells, 6793
 labeling of P-glycoprotein by verapamil, 1132
 modulation by cyclosporin A and verapamil
 leukemia cell lines, 2953
 multidrug transporter P-glycoprotein
 mouse-human chimeric antibody, 3167
 newly synthesized dihydropyridines
 vincristine resistance, photoaffinity labeling of P-glycoprotein, 310
 non-P-glycoprotein mediated mechanism
 doxorubicin resistance, lung cancer cell line, 5392
 P388 cell lines
 efficacy, phenothiazine and bisquinaldinium calmodulin antagonist, 1165
 phenotype of melanoma cells
 transfection, *mdr1* complementary DNA, 1779
 reversal
 calcium antagonists, renal cell carcinoma, 3670
 lipophilic drugs, 3997
 phenotype, cremophor EL, 4199
 pyridine analogues, lower calcium channel blocking activity, 3055
 thioxanthenes, human and murine cell lines, 1748
 verapamil, modulation by α_1 -acid glycoprotein in Chinese hamster ovary cell lines, 2818
- transforming growth factor- β , resistance liver epithelial cells, 3600
 tumor cells
 modulation of drug sensitivity, dipyridamole, 7537
- Multiple endocrine neoplasia syndrome type I**
 loss of heterozygosity of markers chromosome 11 in tumors, 6529
- Mummichog**
Fundulus heteroclitus
 creosote-contaminated site, hepatic neoplasms, 5978
- Muramyl peptide**
 muramyl tripeptide and phosphatidylethanolamine
 Phase I and immunomodulatory study, 2979
- Muscle**
 cardiac and skeletal
 glutathione protection, cyclophosphamide-induced toxicity, 2455
 skeletal
 tumor necrosis factor- α , Walker 256 carcinosarcoma protein metabolism, 2765
- Muscle, smooth**
 cerebral vasomotor responses
 recombinant interleukin 2 infusion, 4377
 degradation of extracellular matrix proteins
 uroepithelial cells, 1897
 tumors
 insulin-like growth factor gene expression, 6689
 uterine
 chromosome aberrations, tumors, 4092
- Mutagenesis**
 Fanconi's anemia cells
 treatment, photoactivated bifunctional psoralens, 3289
 melphalan-induced
 SV40-based shuttle vector, 7527
- mouse intestine
D1b-1 assay, 7992
 valence state and solubility
 chromium compounds, diploid human fibroblasts, 7835
- Mutagens**
 heterocyclic amines
 metabolism of 2-acetylaminofluorene and benzo(a)pyrene, cytochrome P-450, 3367
 inactivation by cytochrome P-450
 human and rat liver microsomes, 2036
 2-naphthohydroxamic acid
 metabolic activation, *Salmonella typhimurium*, 4300
- Mutations**
 cancer and
 molecular events, 2853
 hypoxanthine-guanine phosphoribosyltransferase locus
 T-lymphoblasts, purine deoxyribonucleoside triphosphate pools, 4566
 inherent sensitivity and induced resistance chemotherapy, human cancer cell lines, 7513
 molecular nature
 autosomal HLA-A locus, 4584
 ras gene

SUBJECT INDEX TO VOLUME 50

- human prostatic cancer, 6830
MX2: see 3'-Deamino-3'-morpholino-13-deoxy-10-hydroxycarmomycin
- Mycobacteria**
 fibronectin-binding ability
 antitumor efficacy, 3843
- Mycobacterium tuberculosis**
 induction of interleukin 3 and tumor resistance
 SSM cancer immunotherapeutic agent, 4032
- Mycoplasma**
 -infected cell line
 growth inhibition of tumor cells, arginine deiminase, 4522
- Myeloblasts**
 leukemic
 cytidine 5'-monophosphate-N-acetyl-neurameric acid:Gal β 1-3GalNAc α (2-3)-sialyltransferase, 5003
- Myelodysplastic syndrome**
 primary
 survey of exposure, genotoxic agents, 6876
- Myeloid cells**
 nuclear differentiation antigen
cis-diamminedichloroplatinum(II)
 cross-linking, HL-60 cells, 1183
- Myeloma**
 chimeric anti-CEA antibody, 2128
 glucocorticoid effects, 1873
 immunoglobulin G
 carbohydrate analysis, glycosyltransferases, 5345
 multiple
 Moloney leukemia virus integration-4 locus, human homologue, 6478
- Myelomonocytic cells**
 cytokine treatment
 neopterin formation, tryptophan formation, 2863
- Myelopoiesis**
 interaction of tumor necrosis factor
 colony-stimulating factor, 5065
- Myelosuppression**
 control
 hematopoietic growth factors, radioimmunotherapy, 1003s
 granulocyte-macrophage colony-stimulating factor
 primary human tumors and derived lines, 6264
- Myosin**
 ^{111}In -anti-myosin monoclonal antibody complex
 radioimmuno detection, rhabdo- and leiomyosarcoma, 955s
- N**
- NADPH**
 modulation of pathways
 sex steroid hormone, MCF-7 cells, 1195
- NADPH:cytochrome P-450 reductase**
 activation of mitomycin C, 7789
 decreased activity
 impaired drug activation, mammalian cell line, 4692
- NAD(P)H:quinone acceptor oxidoreductase**
 metabolism of diaziquone
 colon carcinoma cells, 7293
- NAD(P)H:quinone reductase**
 benzo(a)pyrene long term effects
 forestomach and glandular stomach, 2064
- glutathione transferases and
 induction by fumaric acid derivatives, rodent cells and tissues, 7871
- Nafenopin**
 tumor promotion
 specific subtype of altered foci, rat liver, 3701
- 2-Naphthohydroxamic acid**
 metabolic activation
Salmonella typhimurium, 4300
- National Cancer Institute**
 funding, 3469
 traditional competing RO1 grants, 3470
- Natural killer cells**
 activation by interleukin 2
 p75 receptor, p55 negative phenotype, 2683
- cell-mediated cytosis**
 drug-resistant tumor cells, 5931
 flavone acetic acid modulation of activity
 systemic alkalization, renal cancer, 7926
- immunological effects**
 flavone acetic acid, 6483
 modulation of activity by purine nucleosides
 adenosine receptors, 4328
 murine model for B-cell lymphomagenesis
 immunocompromised hosts, 7042
- nonspecific resistance to tumors**
 neocarzinostatin derivative, 3897
 potentiation of activity
 tumor immunity, diacetylphtescine, 5460
- resistance**
c-Ha-ras-1 oncogene-induced differentiation, colorectal carcinoma, 2518
- stimulatory activity**
 α -interferon structure, 5328
- susceptibility of mammary tumor ascites cells**
 effect of tunicamycin on sialomucin, 5250
- synergistic action of plant rhamnogalacturonan**
 antitumor cytotoxicity, target cell recognition, 3646
- Natural suppressor cells**
 inhibition of tumor cell proliferation
 murine bone marrow, 2582
- N $^{\alpha}$ -Behenoyl-1- β -D-arabinofuranosylcysteine**
 blast progenitor effects
 acute myeloblastic leukemia, 7587
- Neocarzinostatin**
 antineoplastic activity
 experimental and human malignancies, 3473
- nonspecific resistance to tumors**
 natural killer cells and macrophages, 3897
- Neoplasia**
 experimental induction
 accessory sex organs, male rats, 142
- Neoplastic progression**
 intracisternal A-particles in mammary epithelium, 2404
- Neoplastic tissue**
 β -subunit of platelet-derived growth factor distribution, 6344
- Neoplastic transformation**
EJ/ras
 SV40-immortalized human uroepithelial cells, 4779
 hepatocellular carcinoma 3.0-kilobase DNA sequence
 rat liver cells, NIH3T3 fibroblasts, 5658s
- human colonic epithelial cell line**
 adenoma to carcinoma sequence, 4724
 increased cell division as a cause of human cancer, 7415
- multistage**
 pH 6.70, Syrian hamster embryo cells, 3722
- progressive state selection of cells**
 low serum, high density growth promotion, 5171
- radiation-induced**
 suppression at low extracellular pH, human cell hybrids, 2123
- v-ras**
 transforming growth factor- β 1 responsiveness, liver epithelial cells, 7468
- X-ray-induced transformants**
 karyotypic changes, 760
- Neopterin**
 formation and tryptophan degradation
 cytokine treatment, human myelomonocytic cell line, 2863
- Neovascularity**
 autochthonous tumor and transplanted normal tissue
 effects, recombinant human tumor necrosis factor, 2463
- Nephrotoxicity**
cis-diamminedichloroplatinum(II)
 selective reduction, ebselein, 7031
- Nervous system neoplasms**
 butyrylcholinesterase mRNA
 chromosome 3q26-ter, 1983
- Neural cell adhesion molecule**
 expression
 neural cell growth, suramin effect, 5164
 isoforms
 differential spectrum of expression, neuroectodermal tumors, 6364
 -related sialoglycoprotein
 small cell lung cancer, 1102
- Neuroblastoma**
 augmented *MYCN* expression
 advancement, malignant phenotype, 4411
 childhood tumors
 neuropeptide Y expression, developing adrenal gland, 6055
 embryonal
 β -microglobulin expression, developmental regulation, 3694
 expression of *smg* p25A, 7242
in vitro differentiation
 vasoactive intestinal peptide, 5177
 latency
 hexamethylene bisacetamide and cyclosporin A, herpes simplex virus type 2, 7852
- micrometastases**
 tumor spheroid model, biologically tar-

SUBJECT INDEX TO VOLUME 50

- geted radiotherapy, 1000s
 modulation of intracellular cyclic adenosine monophosphate
 differentiation response, 722
 morphological and functional differentiation
 bryostatins 1 and 2, 3422
 multidrug resistance gene
 N-myc oncogene, inverse correlation, 3043
 neuronal form of pp60^{c-src}
 clinical stage and prognosis, 6908
N-myc and HLA class I relationship, 7532
 primary human
 N-myc gene amplification, 1459
 single course of deferoxamine, 4929
- Neuroectodermal neoplasms**
 differential spectrum of expression
 neural cell adhesion molecule isoforms, 6364
 reduction to homozygosity
 gene amplification, childhood, 587
- Neuroendocrine neoplasms**
 experimental lung tumors
 chemotherapy, Ca^{2+} /calmodulin antagonist, 1645
- Neuroepithelioma**
 antisense inhibition of single copy *N-myc* expression, 6316
 tumor cell line NUB-20
 importance, phenotypic and molecular characterization, 2794
- Neurofibromatosis**
 molecular genetic analysis of chromosome 22
 meningioma, 5863
- Neuroglanular antigen**
 biosynthesis, 4557
- Neuroleptic agents**
 pimozide and thioridazine
 inhibition of breast cancer cell proliferation, 5399
- Neuronal cells**
 induction of cell with phenotypic features
 dibutyryl adenosine cyclic 3':5'-monophosphate, parotid gland adenocarcinoma, 6396
- Neurons**
 epidermal growth factor effect
 cellular proliferation, neoplastic salivary duct cell line, 7650
 small
 quantitative ultrastructural parameters, *Vinca* antitumor agents, 1924
 spinal ganglion
 electrophysiological study, cisplatin and ORG-2766, 2437
- Neuropeptide antagonist**
 inhibition of growth
 small cell lung cancer, 3968
- Neuropeptide Y**
 expression in developing adrenal gland
 childhood neuroblastoma tumors, 6055
- Neurotoxicity**
 dose-dependent
 high-dose busulfan, children, 6203
 pharmacokinetics and
 intrathecal perfusion of ACNU, 3119
Vinca antitumor agents
 quantitative ultrastructural parameters, use of small neurons, 1924
- Neutron capture therapy**
- boron, 1061**
 boronated compounds, 4860
 selective delivery of boron
 p-boronophenylalanine, tumors other than melanoma, 138
- Neutrophils**
 selective depletion using monoclonal antibody
 abrogation of transplantation resistance, syngeneic tumors, 6243
- Nickel**
 sulfide salts
 H_2O_2 formation, polymorphonuclear leukocytes, 7564
- Nicotinamide**
 analogues and
 antitumor promoters in mouse skin, 2470
 hyperthermia and
 elimination, radioresistant hypoxic tumor cells, 7430
- Nicotinamide ribonucleoside kinase**
 phosphorylation of tiazofurin
 Chinese hamster ovary cells, 5269
- Nigericin**
 cytotoxic interaction of phototherapy
 V79 cells, 1620
- NIH 3T3 cells**
 adaptation to low serum
 neoplastic transformation, 5171
 differences between normal and *ras*-transformed cells
 170kD and 180kD forms, topoisomerase II, 2901
 enhanced ganglioside G_{D_3} expression, 7697
 novel ribonucleoprotein complex
 monoclonal antibodies, pancreatic adenocarcinoma DNA, 6015
 suppression of transformation
 growth adaptation, low glutamine concentrations, 2832
- Nitrate**
 gastric precancerous process
 high risk population, 4731, 4737
- Nitric oxide**
 production by activated macrophages
 flavone-8-acetic acid, xanthone-4-acetic acid, 6966
- Nitrobenzylthioinosine**
 transport and metabolism in T-lymphoblastoid cells
 9- β -D-arabinofuranosylguanine, 1817
- Nitrogen**
 L-arginine-dependent reactive nitrogen intermediates
 tumor cell killing, activated macrophages, 1421
 reactive intermediate
 cytostatic activity, alveolar macrophage mediation, 7863
- Nitrogen-13**
 glutamate
 short-term metabolic fate, [^{13}N]glutamate, 4839
- Nitrogen mustard**
 antineoplastic activity
 experimental and human malignancies, 3473
 melphalan-induced mutagenesis
 SV40-based shuttle vector, 7527
- 2-Nitroimidazole**
- radiosensitizers**
cis-diamminedichloroplatinum(II), hyperthermia in fibrosarcoma, 2734
- 4-Nitroquinoline *N*-oxide**
 sensitivity of skin papillomas
 malignant conversion, 653
- 4-Nitroquinoline 1-oxide**
 genetic damage during pregnancy, 6192
- Nitrosamine**
 -induced pancreatic cancers
 regression, luteinizing hormone-releasing hormone antagonists or agonists, 3716
- tobacco-specific**
 active transplacental carcinogen, Syrian golden hamsters, 3435
 tobacco-specific hemoglobin adducts
 mass spectrometric analysis, 5438
- N-Nitrosobis(2-oxopropyl)amine**
 -induced pancreatic exocrine tumors
 insulin effects, 1634
- N-Nitrosodiethylamine**
 chemotherapy of experimental neuroendocrine lung tumors
 Ca^{2+} /calmodulin, 1645
- N-Nitrosodimethylamine**
 interspecies scaling of pharmacokinetics, 4366
 metabolic denitrosation, 1144
- Nitrosoguanidinium compounds**
 glutathione transferase-mediated denitrosation
 rat, mouse, and hamster isozymes, 1440
- N*-Nitrosomethylurea**
 -induced mammary tumors
 insulin-like growth factor-related peptides, 7179
- N*-Nitroso-*N*-methylurea**
 -induced rat mammary tumors
 effects of cyclosporine A, Ia antigen expression, 3301
- N*'-Nitrosornicotine**
 4-(methylnitrosamo)-1-(3-pyridyl)-1-butanol and
 comparative metabolism, oral tissue and esophagus, 4685
- Nitrosoureas**
 amphotericin B with 2-chloroethyl-1-nitrosoureas
 lysis of promyelocytic HL-60 cells, 3274
- N-myc***
 HLA class I relationship
 human neuroblastoma cells, 7532
 single copy
 antisense inhibition, neuroepithelioma cell line, 6316
- Nonspecific cross-reacting antigen**
 complementary DNA and genomic clones
 Chinese hamster ovary and mouse fibroblast cells, 2397
 regulation of cell surface expression
 differentiation, HL-60 cells, 7437
- Nonsteroidal antiinflammatory drugs**
 piroxicam
 chemoprevention of colon carcinogenesis, D,L- α -difluoromethylornithine, 2562
- Norway**
 total serum cholesterol and triglycerides
 risk of breast cancer, 2341
- Novobiocin**

SUBJECT INDEX TO VOLUME 50

- abrogation of cytotoxicity
 amsacrine, Chinese hamster cells, 2577
 butyrate and
 alteration of differentiation state, human hepatocytes, 3101
- N-ras**
 estrogen-induced pituitary tumors
 genetic susceptibility, 7920
- NSC 370147**
 antitumor activity in selected tumor systems
 culture and in mice, 3239
- Nuclear differentiation antigen**
 myeloid cell
cis-diamminedichloroplatinum(II)
 cross-linking, HL-60 cells, 1183
- Nuclear magnetic resonance**
 contrast-enhanced
 tumor necrosis factor- α , tumor-bearing mice, 7376
 cytidine phospholipid pathway regulation, 552
 deuterium
 tracer distribution, tumor blood flow in mice, 363
- ^{31}P**
 action of gossypol and rhodamine 123, 6936
- Nuclear magnetic resonance spectroscopy**
 bioluminescence and cryospectrophotometry
 tumor energy, oxygenation status, 1681
- ^{31}P**
 changes in radiation sensitization, fluo-sol-DA, 7252
- Nuclear markers**
 karyometric marker features
 normal-appearing glands, colonic adenocarcinoma, 147
- Nuclear matrix**
 -associated region of *c-myc*
 recognition by nuclear protein, HL-60 cells, 3199
- Nuclear proteins**
 final common pathway of cancer, 4830
- Nucleic acid**
 involvement of synthesis
 cell killing mechanisms, topoisomerase poisons, 6919
 methylation
S-adenosylmethionine biosynthesis, *S*-adenosylhomocysteine metabolism, 3838
- Nucleolar antigens**
P120
 final common pathway of cancer, 4830
 identification, epitope region, 2704
- Nucleosides**
 equilibrative transport
 sodium dependency, L1210 mouse leukemia cells, 6549
- purine**
 modulation of natural killer cell activity, adenosine receptors, 4328
- 5'-Nucleotidase**
 phosphorylation of tiazofurin
 Chinese hamster ovary cells, 5269
- Nucleotides**
 guanine and adenine
 phospholipase C activity, small cell lung carcinoma, 5257
- Nutrition**
- different levels of calorie restriction
 azoxymethane-induced colon carcinogenesis, 5761
- fat, calories, and body weight
 mammary tumor development, rats and mice, 5710
- O**
- Occupational risks**
 Chinese tin miners
 radon, lung cancer association, 174
- Los Angeles County young men
 life-style and workplace, stomach cancer by subsite, 2569
- occupations of parents
 children with retinoblastoma, 7129
- paternal
 Wilms' tumor, 3212
- Okadaic acid**
 calyculin A tumor promoter
 CD-1 mouse skin, 3521
- Okazaki fragment**
 dual mechanisms of inhibition of DNA synthesis
 triciribine, 4891
- OKT3**
 -initiated lymphokine-activated effectors
 interleukin 2 and tumor necrosis factor- α , 3526
- Oligodeoxynucleotides**
 phosphodiester and phosphorothioate antisense-mediated inhibition, *BCL2* protooncogenes, 6565
- Oligosaccharides**
 asparagine-linked
 alkaline phosphatase, FL amnion cells, 1079
- Oltipraz:** see 5-(2-Pyrazinyl)-4-methyl-1,2-dithiole-3-thione
- Oncogenes**
ABL
 rearrangement in glioblastoma, 3429
 amplification
 pediatric brain tumors, 2987
bcl-2
 growth factor-triggered signal transduction, 7399
 calcium phosphate-mediated transfer of DNA
 spontaneous metastasis, 5581
- c-ets-1**
 DNA-binding activity, localization and modulation, 5013
- c-Ha-ras**
 growth potential, human skin keratinocytes, 2840
- c-Ha-ras-I**
 differentiation and natural killer cell resistance, colorectal carcinoma, 2518
- c-myc and c-fos**
 changes in expression, bifunctional alkylating agents, 62
 differentiation therapy, 3453
- enhanced ganglioside G₃ expression
 human and rat hepatocellular carcinoma cells, NIH 3T3 cells, 7697
- erbB-2**
 increased gene copies, multiple stages of breast cancer, 6701
 evidence for multistep nature
 human epithelial cell carcinogenesis,
- 5653s**
 final common pathway of cancer, 4830
- Ha-ras-induced tumor progression**
 immune response, progressor variants, 3159
- hematopoietic and hepatic fish neoplasms, 5671s
- HER2/neu**
 epidermal growth factor receptor, renal cell carcinoma, 4504
 overexpression and poor survival, epithelial ovarian cancer, 4087
 resistant to tumor necrosis factor and LAK cells, ovarian cancer cells, 7364
- H-ras**
 metastatic ability, rat mammary cancer cells, 1449
 mutational activation, esophageal papilloma, 1591
 mutational analysis, mouse liver tumors, 4014
 protease and extracellular matrix expression, metastatic lung colonization, 4061
- H-ras and v-myc**
 induction and repair of DNA double strand breaks, rat embryo cells, 6575
- int-1, int-2, c-myc, and neu*
 breast carcinoma, 5911
- K-ras**
 activation by codon 13 mutations, 1,3-butadiene, 4818
 neoplasms, human female reproductive tract, 6139
 transformed tumor cells, adhesion on fibronectin proteolytic fragments, 4388
- MYC**
 damage and repair, bleomycin, 2379
- MYCN**
 malignant phenotype advancement, neuroblastoma cells, 4411
- N-myc**
 multidrug resistance gene, neuroblastoma, 3043
- N-ras**
 hepatocarcinogenesis, Hep G2 cell line, 1521
 malignant transformation, fibroblasts, 5587
- ras**
N-methyl-*N*-nitrosourea and prolactin, mammary carcinoma, 4286
- ras gene mutations**
 hepatic malignancy, tumors, polymerase chain reaction, 1121
- ras-transformed NIH-3T3 cells**
 normal NIH-3T3 cells or, 170kD and 180kD forms of topoisomerase II, 2901
- ros**
 differential expression, astrocytomas and cell lines, 3032
 spontaneous myogenic differentiation
 rhabdomyosarcoma, 6002
 steroid/thyroid receptor-like proteins, 451
- transfected liver epithelial cells
 hepatocyte and oval cell antigens, hepatocellular carcinoma, 4809
- transfected rat cells
 thermal response, 4515

SUBJECT INDEX TO VOLUME 50

- v-H-ras**
genetic instability and metastatic ability, mammary cancer cells, 6349
- viral**
cellular density, MHC antigen response to γ -interferon, 601
- v-myc**
H-ras and, radioresistance, 97
- v-ras**
growth properties and tumorigenesis, MCF-7 cells, 67
- Oncogenesis**
cellular F-actin levels as marker
cellular transformation, cell division, 2215
- loss of heterozygosity of markers
chromosome 11 in tumors, multiple endocrine neoplasia syndrome type 1, 6529
- Opioids**
binding to human MCF-7 cells
effects on growth, 2234
- Oral contraceptives**
human papillomavirus infection
risk of early cytological abnormalities, cervix, 4670
- Oral neoplasms**
smoking and drinking
northern Italy, 6502
- Oral tissue**
N'-nitrosornornicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
comparative metabolism, esophagus, 4685
- ORG-2766**
cisplatin and
electrophysiological study, rat spinal ganglion neurons, 2437
- Organ cultures**
preservation of steroid hormone receptors
breast carcinoma, 78
- Organosulfur compounds**
chemoprevention
1,2-dimethylhydrazine-induced colon cancer, 5084
- Ornithine decarboxylase**
 Ca^{2+} ionophores and ionomycin
tumor-promoting effects, mouse epidermis, 5806
- chromosome 2 gene expression
ornithine decarboxylase-deficient Chinese hamster ovary cells, 2239
- epidermal
inhibitory effect, apigenin, 499
- gene sequences
two chromosomal locations, colorectal neoplasms, 6146
- hamster buccal pouch carcinogenesis model
7,12-dimethylbenz(a)anthracene induction, 2505
- increased activity
12-O-tetradecanoylphorbol-13-acetate, murine epidermis, 4741
- induction by ultraviolet radiation
rat keratinocytes, 2631
- induction in hairless mice
acute and chronic ultraviolet radiation, 1580
- inhibitor
chemoprevention of colon carcinogenesis, piroxicam, 2562
- irreversible inhibitors
tumoricidal and antitumor activity, 4510
- properties in human colorectal adenocarcinoma, 2088
- Ornithine decarboxylase inhibitors**
differentiation therapy, 3453
- Osteosarcoma**
common allele loss to subregion, 2543
- frequency and structure of p53 rearrangements, 7950
- monoclonal antibody, 152
- pediatric
xenografts, development and characterization, 2781
- primary and metastatic spontaneous DNA aneuploidy, 6176
- radiation-induced
amplification and rearrangement, c-myc, 4146
- external beam or intraoperative radiation therapy, 54
- Oval cells**
antigens
oncogene-transfected liver epithelial cells, hepatocellular carcinoma, 4809
- early stages of chemical hepatocarcinogenesis
cellular and molecular changes, rat, 3439
- Ovarian neoplasms**
borderline epithelial
risk of, plasma α -L-fucosidase activity, 4702
- clear cell carcinoma
new tumor marker, cancer-associated galactosyltransferase, 754
- constitutive production of interleukin 6, 6959
- cyst fluid
high concentrations, trypsinogen-2, 2375
- cis*-diamminedichloroplatinum(II) resistance
increased removal, DNA-bound platinum, 1863
- epithelial
poor survival, *HER-2/neu* overexpression, 4087
- ^{131}I -labeled monoclonal antibody
clearance from blood, anti-murine immunoglobulin antibody, 563
- immunolymphoscintigraphy
 $\text{F}(\text{ab}')_2$ fragments of monoclonal antibodies, 937s
- interleukin 2 and LAK cells
Phase I trial, 6302
- K-ras** activation, 6139
- monoclonal antibody-*Vinca* alkaloid immunoconjugate
antitumor activity, 3540
- platinum-DNA adducts
known prognostic variables, 2256
- resistance to tumor necrosis factor and LAK cells
HER2/neu oncogenes, 7364
- xenografts
enhanced therapeutic efficacy, immunotoxins with α -interferon, 6379
- Ovariectomy**
acceleration of growth
microscopic hepatocellular neoplasms, mouse, 6779
- inhibition
N-methyl-*n*-nitrosourea-induced mammary cancer, 5731
- Oxantrazole:** see *Pirozantrone hydrochloride*
- Oxygen**
radical-scavenging capacity
tumor necrosis factor toxicity, mice, 3503
- reactive
phenobarbital-enhanced formation, neoplastic rat liver nodules, 7015
- stress-induced DNA damage
inhibited DNA lesion repair, peripheral mononuclear leukocytes, 4619
- Oxytocin**
vasopressin and
interaction with breast carcinoma cells, 7882

P

- p53**
differentiation of F9 cells into embryoid bodies
early growth-associated events, 3193
- frequency and structure of rearrangements
human osteosarcoma, 7950
- gene mutations
combination with 17p allelic deletions, colorectal tumorigenesis, 7717
- p185^{nm}**
expression in lung adenocarcinomas
shortened survival, 5184
- Pancreas**
cell line HPC-YP
characterization, cathepsin L-like enzyme, 658
- exocrine tumors
insulin effects, streptozotocin-induced cell tumors, 1634
- inhibition of gastrin-stimulated DNA synthesis
lorglumide and loxiglumide, 5829
- islet cell carcinoma
somatostatin-secreting cell line, release experiment, 3691
- Pancreatic neoplasms**
carcinogenesis
protective effect, voluntary exercise, 6811
- characterization of new cell line
propagation, protein-free chemically defined medium, 7008
- insulin-like growth factor I
transforming growth factor- α , autocrine growth factors, 103
- localization of collagenase
basal plasma membrane, 6995
- Meeting Report, 766**
- mucin antigen
polypeptide core, 2997
- nitrosamine-induced
regression, luteinizing hormone-releasing hormone antagonists or agonists, 3716
- radiolocalization by monoclonal antibody
athymic mice, 7246
- Papilloma**
esophageal
mutational activation, *H-ras* oncogene,

SUBJECT INDEX TO VOLUME 50

- 1591**
induction by transforming growth factor- β
pemphigus vulgaris antigen activity, 686
inhibitory effect of apigenin
 epidermal ornithine decarboxylase, skin tumor promotion, 499
sensitivity to malignant conversion
 urethane or 4-nitroquinoline *N*-oxide, 653
- Papillomavirus**
DNA
 immortalization of cervical and fore-skin epithelial cells, dysplastic differentiation, 3709
growth-regulating functions
 cervical cancer, 3730
oral contraceptive use
 risk of early cytological abnormalities, cervix, 4670
- Papillomavirus 16**
IgA and IgG antibodies to select peptides
 cervical cancer, 7815
-positive epithelial cells
 nontumorigenic and tumorigenic cells, transforming growth factor $\beta 1$ response, 7324
integration of DNA and genomic rearrangements
 immortalized keratinocyte lines, 1316
- Parathyroid hormone**
-like protein
 fibroblast interaction, squamous carcinoma, 3589
-related protein
 immunohistochemical localization, breast cancer, 7710
- Parotid gland**
adenocarcinoma
 phenotype, treatment with dibutyryl cyclic adenosine 3':5'-monophosphate, 6396
- P388 cells**
comparison of efficacy
 phenothiazine, bisquinaldinium calmodulin antagonist, 1165
daunorubicin-resistant
 elevated pentose cycle, glucuronyltransferase, 3921
- PD115934**
antitumor efficacy against solid tumors of mice, 4900
- Pemphigus vulgaris**
induction by transforming growth factor- β
 mouse papilloma cells, 686
- P-enolpyruvate carboxykinase**
-bacterial *O*⁶-alkylguanine-DNA alkyltransferase gene
 transgenic mice, 1701
- Pentose**
elevated cycle and glucuronyltransferase
daunorubicin-resistant P388 cells, 3921
- Pentoxifylline**
escalating dose
 constant dose of thiotapec, Phase I trial, 6806
- Peplomycin**
antineoplastic activity
 experimental and human malignancies, 3473
- Pepstatin**
augmentation of LAK activity
 prolongation, interleukin 2 serum half-life, 1107
- Peptides**
bombesin-related
 binding and growth effects, colon cancer, 6772
hemoregulatory
 prevention of side effects, cytostatic drugs, 328
insulin-like growth factor-related
N-nitrosomethylurea-induced mammary tumors, 7179
- laminin**
 fibrosarcoma cell adhesion, 7612
- synthetic**
 anti-human milk fat globule membrane monoclonal antibodies, 89
- P-glycoprotein, multidrug resistance in HL-60 cells, 1426**
- Perhexiline**
 enhancement of ricin A chain immuno-toxin
 established and fresh leukemic cells, 5558
- Peroxisome proliferators**
-induced alterations in expression
 hepatocyte plasma membrane proteins, 669
- Perspectives in Cancer Research**
cell cycle myths and realities, 6769
mammalian *O*⁶-alkylguanine-DNA alkyl-transferase
 response to alkylating carcinogenic and therapeutic agents, 6119
emerging biology of modern radiation oncology, 7735
epidemiology, basic science, and prevention of cancer
 implications for the future, 6441
increased cell division as a cause of human cancer, 7415
liver stem cell, 3811
role of cAMP receptor proteins
 malignancy, 7093
- Pesticides**
exposures and other agricultural risk factors
 leukemia, men in Iowa and Minnesota, 6585
survey of exposure to genotoxic agents
 primary myelodysplastic syndrome, 6876
- Pezzoller symposium**
therapeutic implications
 molecular biology of breast cancer, 7402
- P-glycoprotein**
 Adriamycin resistance in MEL cells, 7895
labeling
 verapamil, leukemic cell lines, 1132
- M_r 170,000**
transfer, Adriamycin resistance, 2191
- multidrug resistance in HL-60 cells, 1426**
multidrug transporter
 mouse-human chimeric antibody, 3167
- non-P-glycoprotein mediated mechanism**
multidrug resistance, doxorubicin resistance in lung cancer cell line, 5392
- photoaffinity labeling**
 newly synthesized dihydropyridines,
- vincristine resistance, 310**
- pH**
6.70
 neoplastic transformation, Syrian hamster embryo cells, 3722
- gastric precancerous process**
 high risk population, 4731, 4737
- intratumor**
 changes, two heatings, 7108
- low extracellular**
 suppression of radiation-induced neoplastic transformation, human cell hybrids, 2123
- Phagocytes**
mononuclear
 tumor necrosis factor production, interleukins 2 and 4, 2949
- Phenobarbital**
 biotransformation of *N,N',N''*-triethylethiophosphoramidate, 464
- determinants of growth of altered foci**
 DNA synthesis, phenotypic expression, 5127
- enhanced formation of reactive oxygen**
 neoplastic rat liver nodules, 7015
- Phenolic amine compounds**
 melanocytotoxicity and antimelanoma effects in mice, 3743
- Phenol uridine diphosphate-glucuronosyl-transferase**
 3-methylcholanthrene-inducible hepatocyte nodules, hepatocellular carcinoma, 3569
- Phenothiazine**
 bisquinaldinium calmodulin antagonist comparison of efficacy, P388 cell lines, 1165
- L-Phenylalanine mustard**
 melphalan-induced mutagenesis SV40-based shuttle vector, 7527
- myelotoxicity**
 hematopoietic progenitor cells, 4038
- Phorbol ester**
decreased expression of type II protein kinase C
 HL-60 variant cells, 621
- Phorbol ester**
antiproliferative effects
 macrophage cell line, 1510
- changes in adenosine deaminase**
 purine nucleoside phosphorylase, leukemic cell lines, 2891
- control of cAMP-dependent protein kinase, 7145**
- differential effects on epidermal growth factor receptors**
 ER-positive and -negative breast cancer cell lines, 4849
- effects on topoisomerase II activity**
 monocyte differentiation, HL-60 cells, 7116
- induced differentiation of U937 cells**
 glycosylation and lectin pattern, 323
- induced macrophage-like differentiation**
 HL-60 cells, transferrin availability, 7221
- mediation of phospholipid-free activation**
 rat brain protein kinase C, 2081
- Phosphatidylcholine**
-phosphatidylserine liposomes
 Adriamycin, murine tumor cell sensitivity, 3619

SUBJECT INDEX TO VOLUME 50

- Phosphatidylethanolamine**
labeling with thioteprin
L1210 cells, 4044
- muramyl peptide and muramyl tripeptide**
Phase I and immunomodulatory study, 2979
- Phosphatidylinositol**
-glycan anchored alkaline phosphatase
choriocarcinoma, 3956
- Phosphoglyceride**
ether-linked
content of human leukemia cells, 7174
- Phosphoinositide**
alteration of synthesis by suramin
inhibition of growth factor receptor
binding, HT-29 cells, 6490
- Phospholipase A₂**
activation
autoinduction of tumor necrosis factor
gene expression, 7101
- Phospholipase C**
bombesin-stimulated activity
guanine and adenine nucleotides, small
cell lung carcinoma, 5257
- Phospholipids**
-free activation of rat brain protein kinase
C
phorbol ester mediation, 2081
- pathways
cytidine, 1- β -D-arabinofuranosylcyto-
sine, 552
- synthetic analogues
inhibition, protein kinase C and sodium
pump, 3025
- thioether
1- β -D-arabinofuranosylcytosine, for-
mulation, 4401
- Phosphoprotein**
NP33 as nucleus-associated ribosomal S6
protein
phosphorylation in hematopoietic cells,
2895
- Phosphoramide mustard**
-induced sister chromatid exchanges
acrolein effect, human lymphocytes,
4635
- Phosphoribosylpyrophosphate**
increased levels
6-mercaptopurine cytotoxicity, Chinese
hamster ovary cells, 1992
- Phosphotryosyl**
-specific protein phosphatases
megakaryocytic differentiation, K562
cells, 6323
- Photochemotherapy**
mitochondrial toxicity
cathepsin photosensitizers, 7876
- Photodynamic therapy**
antitumor efficacy of various photoradiation
regimens
mammary carcinoma, 7236
- induced tumor destruction
role, thromboxane and prostacyclin re-
lease, 2599
- sensitivity of lung cancer histologies, 4272
- topical meso-tetraphenylporphinesulfon-
ate tetrasodium salt
superficial basal cell carcinoma, 4501
- Photoirradiation**
merocyanine 540-sensitized photoinactiva-
tion
soluble and membrane-bound enzymes,
- L1210 cells, 7765
- Photoreactivating enzyme**
thymine dimer removal and DNA repair
synthesis
xeroderma pigmentosum fibroblasts,
1905
- Photosensitizers**
aluminum phthalocyanine
cell and tissue distribution, effect of sul-
fonation, 4533
- dyes for selection of nontumorigenic rev-
ertants
human lung cancer cell lines, 5369
- leukemic cells
anthracenedione antitumor agents,
1936
- tissue distribution of mono-L-aspartyl
chlorin e6
mouse tumor model, 3985
- Phototherapy**
cytotoxic interaction with nigericin
V79 cells, 1620
- Phytohemagglutinin**
stimulation of human lymphocytes
induction, topoisomerase II gene
expression, 5649s
- Pimozide**
thioridazine and
inhibition of breast cancer cell prolif-
eration, 5399
- Piritrexim**
pediatric Phase I trial
pharmacokinetic study, 4464
- Piroxantrone**
Phase I study and pharmacodynamics,
3284
- Piroxicam**
D,L- α -difluoromethylornithine and
chemoprevention, colon carcinogene-
sis, 2562
- Pirozantrone hydrochloride**
Phase I and clinical pharmacological eval-
uation, 3905
- Pituitary neoplasms**
desensitization and resensitization
SMS 201-995, cell growth and prolac-
tin secretion, 6238
- estrogen-induced
genetic susceptibility, 7920
- estrogen responsiveness, 3786
- induction in germ-free rats
Aspergillus versicolor, 400
- p34^{cdc2} kinase
etoposide-induced cell death
Chinese hamster ovary cells, 3767
- inhibition of activity by etoposide or irra-
diation
G₂ arrest, Chinese hamster ovary cells,
3761
- Placenta**
stable expression of aromatase comple-
mentary DNA
mammalian cells, 6949
- Plasma**
biotransformation
tetrachloro(d,L-trans)-1,2-diaminocy-
clohexaneplatinum(IV), 4539
- disposition of amsacrine and its analogue,
503
- fatty acid mobilization and oxidation
reduced suppression by feeding, lym-
phoma-bearing mice, 2221
- kinetics**
immunotoxin uptake in solid tumors,
7382
- α -L-fucosidase activity
risk, borderline epithelial ovarian tu-
mors, 4702
- pharmacokinetics and cerebrospinal fluid**
concentrations
idarubicin and idarubicinol, pediatric
leukemia patients, 6525
- protein binding**
etoposide, prospective evaluation of
model, 6854
- Plasma membrane**
basal
localization of collagenase, human pan-
creatic cell line, 6995
- hepatocyte proteins**
peroxisome proliferator-induced alter-
ations, 669
- merocyanine 540-sensitized photoinacti-
vation
soluble and membrane-bound enzymes,
L1210 cells, 7765
- perturbations of KB₃ cells**
bleomycin-iron complex, 385
- protein identified by monoclonal antibody**
lymph node adhesion and metastasis,
Lewis lung carcinoma, 1948
- transfer of Adriamycin resistance
fusion of M, 170,000 P-glycoprotein,
2191
- Plasmin**
basement membrane type IV collagen
degradation
proteolytic cascade, metalloprotei-
nases, 5997
- Plasminogen activator**
inhibitors and
heterogeneous profiles, human glioma
lines, 4957
- protein and messenger RNA levels, tu-
mor cell lines, 1488
- urokinase**
inhibition by PAI-2, extracellular ma-
trix degradation, 4676
- Platelet-derived growth factor**
 β -receptors
stromal tissue cells, human carcinoid
tumors, 748
- neoplastic tissue and soft tissue tumors,
6344
- Platelets**
thrombin-independent aggregation
M, 41,000 glycoprotein, melanoma
metastatic variants, 6675
- tumor cell-endothelial cell interactions
tumor cell cytoskeleton, 7686
- Platinum**
-DNA adducts
known prognostic variable, ovarian can-
cer, 2256
- DNA-bound**
cis-diamminedichloroplatinum(II) re-
sistance, ovarian cancer cell line,
1863
- resistance**
role of carrier ligand, L1210 cells, 6497
- Platinum compounds**
liposome-entrapped *cis*-bis-neodeca-
noato-*trans*-R,R-1,2-diaminocyclo-
hexane platinum(II)

SUBJECT INDEX TO VOLUME 50

- Phase I clinical and pharmacological study, 4254**
- P388 neoplasms**
- liposomal vincristine preparations
 - decreased drug toxicity, increased activity, 575
- Poly(adenosine diphosphate-ribose)**
- synthesis-deficient V79 cells
 - epipodophyllotoxin-induced cell death, 2713
- Poly(adenosine diphosphate-ribose) polymerase**
- dihydrofolate reductase gene amplification
 - carcinogen-induced methotrexate resistance, 5756
 - deletion on chromosome 13q33-qter
 - normal black population, multiple tumor DNA, 5406
 - gene expression
 - Ewing's sarcoma cells, 38
- Polyamines**
- depletion
 - chloroethylnitrosourea efficacy, human tumor cell lines, 521
 - α -difluoromethylornithine effect
 - tumor angiogenesis, 4131
 - endogenous and exogenous support of tumor growth, 5077
 - hamster buccal pouch carcinogenesis model
 - 7,12-dimethylbenz(a)anthracene induction, 2505
 - human ornithine decarboxylase gene sequences
 - two chromosomal locations, colorectal neoplasia, 6146
- Polydeoxyadenylic acid**
- acrolein-modified
 - detection, 1,N⁶-propanodeoxyadenosine, 3005
- Polyinosinic-polycytidine acid**
- asialo-G_{M1} positive liver cells
 - suppression of hepatic metastases, 1834
- Polymerase chain reaction**
- activation of c-Ki-ras
 - gastrointestinal dysplasias, 3627
 - cytochrome P450IA1 mRNA expression rat and human tissues, 4315
 - HSP-70 expression in leukemic cells, 2877
 - ras* gene mutations
 - hepatocellular malignant tumors, 1121
- Polymorphisms**
- restriction fragment length
 - pathogenesis, choriocarcinoma, 488
- Polyoma virus**
- induced mammary tumors
 - gonadotropin-releasing hormone, estrogen-sensitive progression, 5892
 - induced salivary gland tumors
 - T-cell lymphoma, epineoplasms, 5643s
 - regulatory region
 - ultraviolet-inducible proteins, 5374
- Polyps**
- malignant and potentially malignant colon cells
 - quantitative cytochemical detection, 5112
- Porphyria**
- boronated compounds for neutron capture therapy, 4860
- photodynamic therapy**
- systemic toxicity in mice, 539
- photosensitivity**
- heat-resistant phenotype, cell lines, 5365
- pp60^{c-sar}**
- neuronal form
 - expression in neuroblastoma, clinical stage and prognosis, 6908
- p52 protein**
- hepatocellular carcinoma 3.0-kilobase DNA sequence
 - rat liver cells, NIH3T3 fibroblasts, 5658s
- p185 protein**
- hormonal modulation of HER-2/neu protooncogene mRNA
 - breast cancer, 3947
- Prednisolone**
- toxicity of central nervous system therapy animal model, childhood acute lymphoblastic leukemia, 6455, 6461
- Prednisone**
- antineoplastic activity
 - experimental and human malignancies, 3473
- Pregnancy**
- barbiturate exposure *in utero* and childhood risk, intracranial and spinal cord tumors, 4600
 - genetic damage by 4-nitroquinoline 1-oxide, 6192
 - genetic origin of trophoblastic choriocarcinoma, 6330
 - gestational and familial risk factors
 - childhood astrocytoma, 2608
- Pressure**
- osmotic
 - uptake of chemotherapeutic agents, carcinoma cells, 4704
- Probe**
- gamma-detecting
 - radioimmunodetection, hepatic metastases, 877s
- Procarbazine**
- cytotoxic
 - protection of testis, Zoladex, 568
 - exposure
 - O⁶-methylguanine accumulation, human blood leukocyte DNA, 2759
 - induced sterility and genotoxicity
 - protection, steroid contraceptives, male rats, 1308
- Procoagulant**
- new tumor marker
 - enzyme-linked immunosorbent assay, 6229
- Progesterone**
- N-nitrosomethylurea-induced mammary tumors
 - insulin-like growth factor-related peptides, 7179
 - receptors in bronchogenic carcinoma, 6632
 - response to epidermal growth factor
 - human meningioma cells, 2604
- Progesterins**
- insulin receptor content
 - insulin stimulation growth, breast carcinoma, 7858
- Prolactin**
- estrogen-induced pituitary tumors
 - genetic susceptibility, 7920
 - N-methyl-N-nitrosourea or activated ras oncogenes, mammary carcinoma, 4286
 - N-nitrosomethylurea-induced mammary tumors
 - insulin-like growth factor-related peptides, 7179
 - secretion and cell growth
 - SMS 201-995, pituitary tumor cells, 6238
- Prolactinoma**
- spontaneous prolactin transplantable tumor
 - Wistar/Furth rat, 4081
- Promutagens**
- mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline
 - cDNA-expressed human liver P-450, 2060
- 1,N⁶-Propanodeoxyadenosine**
- acrolein-modified polydeoxyadenylic acid DNA, ³²P postlabeling, 3005
- N¹⁰-Propargyl-5,8-dideazafolic acid**
- multiple membrane transport systems, 7544
- Prostacyclin**
- release
 - thromboxane, photodynamic therapy-induced tumor destruction, 2599
- Prostaglandin D₂**
- conjugation with intracellular glutathione
 - antiproliferative activity, glutathione depletion, 1879
- Prostaglandin E₂**
- protein kinase A coupling
 - tumor migration and metastasis, Lewis lung carcinoma variants, 2973
- Prostaglandins**
- systemic toxicity
 - porphyrin photodynamic therapy, 539
- Prostate**
- paracrine stimulation of secretion, 1966
- Prostatic neoplasms**
- antiprostate monoclonal antibody 7E11-C5
 - immunohistochemical and pharmacokinetic characterization, immunoconjugate CYT-356, 5423
 - development
 - serum vitamin A, epidemiological study, 2311
- Dunning**
- expression of androgen receptor, 735
- fatal**
- diet and tobacco use, Lutheran brotherhood cohort study, 6836
- frequency and pattern of karyotypic abnormalities**
- normalities, 3795
- mitogenic activity**
- selective stimulation, human bone cells, 6902
- programmed cell death during regression**
- androgen ablation, 3748
- prospective, population-based study**
- androstenedione, estrogens, 169
- ras gene mutations**
- 6830
- somatostatin analogue**
- adjuvant therapy after surgical castration, 2646
- Protease**

SUBJECT INDEX TO VOLUME 50

- extracellular matrix gene expression**
 metastatic lung colonization, *H-ras*-transformed 10T½ fibroblasts, 4061
- Protein**
 binding in plasma
 etoposide, prospective evaluation of model, 6854
- cAMP receptor
 malignancy, new approaches to therapy, 7093
- carrier protein-monensin conjugates, 1385
- chromosomal
HMG-14 and *HMG-17*, transformed human cells, 2022
- cytosolic
 folate-binding, compartmentation of tetrahydrofolates, 3262
- elevated turnover and anorexia
 cachexia, hepatocellular carcinoma, 1226
- increased turnover
 normal energy metabolism, normal energy metabolism, 1125
- M*, 39,000
 retinoic acid inhibition, breast carcinoma proliferation, 1977
- retinoid modulation
 estradiol-stimulated growth, breast carcinoma cells, 1997
- ^{99m}Tc labeling
 diaminedithiol bifunctional chelating agent, 799s
- ultraviolet-inducible
 polyoma virus regulatory region, 5374
- Protein B23**
 induction of "reversible" translocation exposure to actinomycin D, cell growth inhibition, 5987
- Protein kinase**
 cAMP-dependent
 control by phorbol ester, 7145
- cell membrane and cell signals as targets cancer chemotherapy, 2203
- cyclic adenosine 5'-monophosphate-independent
 phosphorylation of pyruvate kinase type K, glioma, 4604
- regulation of epidermal growth factor receptor
 growth-modulating agents, 533
- tumor-promoting activity of staurosporine
 mouse skin, 4974
- Protein kinase A**
 catalytic subunit
 cDNA, hepatomas and regenerating liver, 1675
- prostaglandin E₂ coupling
 tumor migration and metastasis, Lewis lung carcinoma variants, 2973
- Protein kinase C**
 activity in rat preneoplastic colon
 1,2-dimethylhydrazine-induced alterations, 3915
- assessment of isozymes
 enzyme immunoassay and overexpression of type II, thyroid adenocarcinoma, 5515
- augmentation of tumor necrosis factor cytotoxic effect
 staurosporine, HIV-infected cells, 5287
- decreased expression of type II
 HL-60 variant cells, 621
- epidermal
 down-regulation by TPA and diacylglycerol, tumor promotion, 5740
- ether-linked phosphoglyceride content human leukemia cells, 7174
- induced stimulation or inhibition
 cellular proliferation, macrophage tumor cell line, 1828
- inhibition by synthetic phospholipid analogues, 3025
- inhibition in rodent by dequalinium, 677
- modulation of retinoic acid-induced differentiation
 serum factors and sphinganine, HL-60 cells, 222
- morphological and functional differentiation
 bryostatins 1 and 2, neuroblastoma, 3422
- opposite effects of tamoxifen
 endogenous protein phosphorylation, MCF-7 cells, 5845
- production of diacylglycerol
 intestinal microflora, 3595
- rat brain
 phorbol ester mediation, phospholipid-free activation, 2081
- regulation by ionizing radiation, 3963
- TPA-resistant macrophage cell lines, 1510
- Protein phosphatases**
 phosphotyrosyl-specific
 megakaryocytic differentiation, K562 cells, 6323
- Protein thiols**
 quantitative measurements of changes cervical intraepithelial neoplasia, uterine cervix carcinoma, 6663
- Proteoglycans**
 altered expression
 E1A-immortalized fetal intestinal epithelial cells, 6716
- Protooncogenes**
BCL2
 antisense-mediated inhibition, phosphodiester and phosphorothioate oligodeoxynucleotides, 6565
- c-erbB-2*
 γ-interferon, ovarian carcinoma cells, 7037
- c-ets-1*
 DNA-binding activity, localization and modulation, 5013
- c-fms*
 expression of CSF-1, Hodgkin's disease-derived cell line, 2049
- c-fos*
 constitutive expression, keratinocytes, 6641
- c-Ki-ras* activation
 gastrointestinal dysplasias, polymerase chain reaction, 3627
- detection of *c-K-ras* mutations
 fine needle aspirates, pancreatic adenocarcinoma, 1279
- HER-2/neu*
 amplification predicts poor survival, node-positive breast cancer, 4332
- hormonal modulation, breast cancer, 3947
- heterogeneous amplification
 tumor progression and metastases, gastric cancer, 7811
- H-ras*
 rare alleles, lung cancer, 1857
- transfection, mouse mammary hyperplasia, 6010
- neu*
 protein expression, non-small cell lung carcinoma, 421
- N-myc*
 gene amplification, primary human neuroblastoma, 1459
- ras*
 no evidence for point mutations in codons, esophageal and gastric cancers, 4911
- rearrangement of human *ABL* oncogene glioblastoma, 3429
- Pseudocyst**
 -forming cell lines
 biological characterization, adenoid cystic carcinoma, 4139
- Pseudomonas**
 exotoxin A conjugate
 antibody, inhibition of breast cancer cells, 5992
- Pseudomonas exotoxin**
 inhibition of antibody response
 15-deoxyergualin, mice, 7750
- Psoraleen**
 photoactivated bifunctional mutagenic response, Fanconi's anemia cells, 3289
- photoinduced DNA cross-links removal of, normal and Fanconi's anemia fibroblasts, 2443
- pS2 protein**
 prediction of relapse and survival breast cancer, 3832
- Public issues**
 funding, 3469
- traditional competing RO1 grants, 3470
- Purine**
 metabolism of human glioblastoma, 1576
- Purine deoxyribonucleoside triphosphate pool perturbations**
 T-lymphoblasts, 4566
- Purine nucleoside phosphorylase**
 changes induced by phorbol esters adenosine deaminase, leukemic cell lines, 2891
- Putrescine analogues**
 unsaturated morphological evidence, lysosomal activity, 1929
- 5-(2-Pyrazinyl)-4-methyl-1,2-dithiole-3-thione transcriptional control glutathione S-transferase gene expression, liver, 2251
- Pyridine**
 analogues reversal of multidrug resistance, lower calcium channel blocking activity, 3055
- Pyrimidine**
de novo enzyme dihydroorotic acid dehydrogenase inhibition by Brequinar sodium, 4644
- Pyrimidinone**
 bropirimine

SUBJECT INDEX TO VOLUME 50

- protection, carcinogen-induced bladder carcinoma, 1071
- Pyruvate kinase**
type K
phosphorylation, glioma, 4604
- Q**
- Quinone**
activity of alkylating agents
quinone-resistant cells, 2872
- R**
- Radiation**
addition of 2-nitroimidazole radiosensitizers
cis-diamminedichloroplatinum(II), fibrosarcoma, 2734
hyperthermia and
SR-4233 interaction, FSaIIC murine fibrosarcoma tumor system, 5055
hyperthermia/PtCl₄(dye)₂ complexes, 3826
-induced neoplastic transformation suppression at low extracellular pH, human cell hybrids, 2123
-induced osteosarcoma amplification and rearrangement, *c-myc*, 4146
external beam or intraoperative radiation therapy, 54
-induced rat skin tumors *c-myc* amplification during progression, 3073
ionizing chronic glutathione elevation, cytotoxicity, 5296
modulation of gene expression, Syrian hamster embryo cells, 339
regulation of protein kinase C, 3963
transcription, repair-deficient and repair-proficient mice, 5045
tumor cell response, tetrazolium assay, 1392
leukemia virus variants potential lymphoma-inducing cells, lymphomagenesis, 2554
lymphomagenesis genetic analysis of resistance, mice, 3848
oncology emerging biology, 7735
residual damage in mouse lungs at long intervals cyclophosphamide treatment, 2139
-resistant cells induction and repair of DNA double strand breaks, transformed embryo cells, 6575
sensitization induced by flusol-DA ³¹P nuclear magnetic resonance spectroscopy, 7252
ultraviolet induction of ornithine decarboxylase, rat keratinocytes, 2631
- Radioantibodies**
intraperitoneal immunoconjugates, 1031s
- Radioimaging**
^{99m}Tc-labeled Fab fragment melanoma antigen, melanoma, 904s
- Radioimmunoconjugates**
radiolabeled antigen:antibody complex formation, 840s
- Radioimmundetection**
breast tumor
¹¹¹In-labeled monoclonal antibody, mucin-like antigen, 927s
- cancer**
experimental studies, overview, 809s
carcinoembryonic antigen monoclonal antibody fragments
¹²³I or ^{99m}Tc, 909s
- hepatic metastases from human colon cancer
nude mice, gamma-detecting probe, 877s
overview of 1978-1988
standardization, clinical trials, 892s
- radioimmunotherapy** and introduction of Second Conference, 778s
rhabdo- and leiomyosarcoma
¹¹¹In-anti-myosin monoclonal antibody complex, 955s
- Radioimmunotherapy**
animal current status, 970s
biological considerations, 964s
experimental animal models, 962s
fractionated
B-cell malignancies, ¹³¹I-Lym-1, 1014s
hematopoietic growth factors control of myelosuppression, 1003s
human colon carcinomatosis xenograft monoclonal antibody ⁹⁰Y-ZCE025, 989s
human colorectal carcinoma xenografts Y-90 monoclonal antibody, 4546
intracerebral human glioma xenografts ¹³¹I-labeled F(ab')₂ fragments, monoclonal antibody Mel-14, 1822
peritoneal human colon cancer xenografts ²¹²Bi-labeled antibody, 985s
- radiolabeled antibodies**
inhibition of catabolism, lysosomal-trophic amines and carboxylic ionophores, 1243
tumor localization and therapy chimeric 17-1A monoclonal antibody, 993s
⁹⁰Y-conjugated antiidiotype monoclonal antibody human B-cell lymphoma, 1022s
- Radioiodination**
antibody for targeting tumors, 857s
- Radiolabeling**
disulfide bond-targeted streptavidin-biotinylated monoclonal antibody complex, 804s
- Radionuclides**
antibody targeted dosimetric model, tumor cells in cerebrospinal fluid, 1043s
- Radioresistance**
synergistic effect *v-myc* oncogene with *H-ras*, 97
- Radioresponse**
indomethacin-induced potentiation tumor host immunocompetence, 4473
- Radiosensitization**
heat human colony-forming unit-granulocyte-macrophage, 2044
interaction with hyperthermia
- Co(III) mustard complex, 6971
iododeoxyuridine-DNA incorporation bladder carcinoma cells, 4962
skin fibroblasts atomic bomb survivors with and without breast cancer, 4050
- Radiotherapy**
biologically targeted tumor spheroid model, neuroblastoma micrometastases, 1000s
differentiation therapy, 3453
fractionated irradiation SR 4233, potentiation of cell killing, 7745
small cell lung cancer xenografts ³¹P magnetic resonance spectroscopy, biochemical analysis, 4880
stable bifunctional chelates of metals, 789s
targeted ²¹¹At-methylene blue, human melanoma xenografts, 2963
- Radon**
lung cancer association case control study, Chinese tin miners, 174
residential lung cancer in New Jersey women, case-control study, 6520
- Receptors**
 β -platelet-derived growth factor, human carcinoid tumors, 748
adenosine natural killer cell modulation, purine nucleosides, 4328
androgen expression in Dunning tumors, 735
gene expression, prostate carcinoma, 5382
antigen clonotypic heterogeneity, cutaneous T-cell lymphoma, 6620
anti-transferrin monoclonal antibodies, inhibition of cell growth, 6295
autocrine motility-like factor B16-F1 melanoma, 409
autoradiography insulin-like growth factor I, primary human lung cancer, 2481
basic fibroblast growth factor-like activity glioma cell line, 2524
cholecystokinins inhibition of gastrin-stimulated DNA synthesis, antagonists, 5829
CSF-1
c-fms, Hodgkin's disease-derived cell line, 2049
endothelin human cancer cell lines, 3257
epidermal growth factor clinical implications, transitional cell carcinoma, 2530
 G_2 -phase progression to mitosis, various cells, 7932
glioma, 8017
glioma cell growth, migration and invasion, 6039
growth-regulating functions of HPV, cervical cancer, 3730
hamster buccal pouch carcinogenesis

SUBJECT INDEX TO VOLUME 50

- model, 2505
HER2/neu gene expression, renal cell carcinoma, 4504
 immunohistochemical evidence, lung adenocarcinoma, 7077
 modulation by retinoic acid, ME180 cells, 1201
 murine monoclonal antibodies, HER2/neu gene product, 1550
 phorbol ester effects, ER-positive and -negative breast cancer, 4849
 pro-transforming growth factor- α , renal cancer, 3934
 regulation, growth-modulating agents, 533
estrogen
 antiestrogen-resistant cell lines, 333
 automated quantitation, breast neoplasms, 3545
 cell kinetics, advanced breast cancer, 2958
 high specific activity, [16α - ^{123}I]iodoestradiol- 17β , 7799
 messenger ribonucleic acid, adenosine cyclic 3'-5'-monophosphate, 1528
 methylation, breast tumors, 3974
 $\text{T}47\text{D}_{\text{co}}$ cells as model for progression, breast cancer, 6208
estrogen and progesterone
 bronchogenic carcinoma, 6632
 epidermal growth factor, breast cancer biopsy, 4204
 immunocytochemical localization, primary breast cancer, 7057
Fc γ
 potentiation of tumor lysis, large granular lymphocytes, 7122
fibroblast growth factor
 androgen-induced heparin-binding growth factor, Shionogi carcinoma, 2316
fibronectin
 normal and transformed human cells, 1601
glucocorticoid
 effects on myeloma cells in culture, 1873
 monoclonal antibodies, RU 38486 action in B16 melanoma cells, 7985
 steroid-sensitive and -resistant leukemic cells, 1337
granulocyte- and macrophage-colony-stimulating factors
 coexpression, novel myeloid leukemia cell line, 7703
growth factor
 inhibition of binding by suramin, HT-29 cells, 6490
insulin
 progestins and insulin-stimulated growth, breast carcinoma, 7858
insulin-like growth factor
 breast cancer, 48
insulin-like growth factor I
 normal and neoplastic human endometrium, 3019
 prognostic significance, human breast cancer, 6931
integrin
 laminin and type IV collagen, B16 melanoma cells, 728
interferon
 modulation, colon carcinoma cells, 26
 α -interferon
 down-regulation, human lymphoblastoid cells, 2654
interleukin 1
 calcium dependency, adult T-cell leukemia, 4344
interleukin 2
 anti-Tac-H antibody, malignant and immune disorders, 1495
interleukin 6
 expression in prostate carcinoma cells, 7786
laminin
 prognostic value, breast cancer survival, 1479
low density lipoprotein
 cholesterol requirement, intracranial tumors, 483
 deficiency, colonic carcinoma cell lines, 632
[D-Trp β]-luteinizing hormone-releasing hormone
 epidermal growth factor, endometrial carcinoma, 1841
melanotropin
 experimental tumors, melanoma, 1237
motility factor
 inhibition of melanoma cell invasion, retinoic acid, 4121
nuclear estrogen
 2,3,7,8-tetrachlorodibenzo-*p*-dioxin effects, MCF-7 cells, 3579
nuclear type II binding sites
 methyl *p*-hydroxyphenyllactate, mammary tumor growth, 1470
p75
 natural killer cell activation, interleukin 2 treatment, 2683
platelet-derived growth factor
 β -subunit distribution, neoplastic tissue and soft tissue tumors, 6344
progesterone
 cell kinetics, advanced breast cancer, 2958
 regulation of gene expression, 5291
 seasonal change in concentration, breast cancer, 5883
somatostatin
 needle biopsy samples, carcinoids and islet cell carcinoma, 5969
steroid
 transcription factors, gene expression, 6430
steroid hormone
 preservation in organ cultures, breast carcinoma, 78
steroid/thyroid
 -like proteins, oncogenic potential, 451
T cell α -chain
 locus rearrangements, adult T-cell leukemia, 6171
transferrin
 B-cell growth, inhibition by gallium, 5727
 glycoprotein, melanoma cells, 515
 ricin A chain immunotoxin conjugate, glioma, 6696
transforming growth factor
 liver regeneration, partial hepatectomy, 1464
Receptosome
 acidic
 uptake and retention of Ga-67, HL-60 cells, 1484
Rectal cells
 proliferation and colon cancer risk
 ulcerative colitis, 1156
Rectum
 colon cancer and
 risks, source of fiber and fiber components, 3295
Reed-Sternberg cells
 B-cells and Hodgkin's cells
 characterization, cell surface molecule, 1650
 identification of *M*, 70,000 antigen
 interdigitating reticulum cells, 350
Renal neoplasms
 antitumor effects
 α -interferon and γ -interferon, 5414
 cytokine induction by flavone acetic acid, 1742
 normal kidney cell lines and establishment and characterization, 5531
Reproductive tract neoplasms
 female
K-ras activation, 6139
Reticulum cells
 interdigitating
 M , 70,000 antigen, Reed-Sternberg cells, 350
Retinoblastoma
 abnormalities in gene structure and expression
 small cell lung cancer, xenografts, 5312
 altered structure and expression
 susceptibility gene, small cell lung cancer, 3067
 children with
 occupations of parents, 7129
 estrogen-induced pituitary tumors
 genetic susceptibility, 7920
 homozygous deficiency at autosomal locus *aprt*
 human somatic cells, 1738
Retinoic acid
 combined with sodium butyrate
 dimethyl sulfoxide or hexamethylene bisacetamide, HL-60 cell differentiation, 6268
 differential expression of transglutaminase
 erythroleukemia cells, 7830
 enhancement of LAK cell activity, 3013
 -induced differentiation
 serum factors and sphinganine, HL-60 cells, 222
Inhibition
 N -methyl-*N*-nitrosourea-induced mammary cancer, 5731
Inhibition of breast carcinoma proliferation
 inhibition of *M*, 39,000 protein, 1977
 inhibition of melanoma cell invasion
 reconstituted basement membrane, 4121
 modulation of epidermal growth factor receptors
 ME180 cells, 1201
 modulation of intracellular cyclic adenosine monophosphate differentiation response, neuro-

SUBJECT INDEX TO VOLUME 50

- blastoma cells, 722
proliferation of estrogen-responsive Leydig cells
serum-free culture, 5060
steroid/thyroid receptor-like proteins
oncogenic potential, 451
- Retinoids**
differentiation therapy, 3453
immortalization of human keratinocytes
Simian virus large T-antigen, 5947
modulation of estradiol-stimulated growth
protein synthesis and secretion, breast carcinoma, 1997
- Retrotransposons**
intracisternal A-particles
mammary epithelium, 2404
- Retrovirus**
avian erythroblastosis virus-infected chickens
immune abnormalities, 4764
endogenous elements in human DNA, 5636
evaluation of antiretroviral therapy
murine models, 5618s
multifocal vascular tumors in fowl, 4787
SL3-3
mechanisms, thymic lymphomagenesis, 5631s
vector-mediated γ -interferon gene transfer
antitumor immunity, 7820
- Rhabdoid neoplasm**
extrarenal
establishment of cell line, 2177
- Rhabdomyosarcoma**
flow and image cytometric DNA analysis, 6023
human cells
purging, 4-hydroperoxycyclophosphamide, 1455
 ^{111}In -anti-myosin monoclonal antibody complex
radioimmunodetection, 955s
morphological and molecular characterization
spontaneous myogenic differentiation, 6002
12-O-tetradecanoylphorbol-13-acetate-induced differentiation, 3377
xenograft
cyclophosphamide, melphalan and VP-16, 284
- Rhamnogalacturonan**
synergistic action
antitumor cytotoxicity, NK and LAK cells, 3646
- $^{116}\text{Rhenium NR-LU-10 whole antibody}$**
biodistribution-pharmacokinetic and imaging studies
colonic tumor-bearing mice, 7973
- Rhizoxin**
interaction with bovine brain tubulin, 4277
- Rhodamine 123**
combined with hyperthermia
cytotoxicity, 459
gossypol and
MCF-7 cells, ^{31}P nuclear magnetic resonance and toxicity studies, 6936
hyperthermic enhancement of cytotoxicity
- B16 mouse melanoma cells, 2385
phototoxicity in laser-irradiated carcinoma cells
electron microscopy, confocal laser scanning microscopy, 4167
- Ribonuclease**
novel complex defined by monoclonal antibodies
NIH 3T3 cells, pancreatic adenocarcinoma DNA, 6015
- Ribosomal proteins**
S6, S11, and S14
noncoordinated expression, leukemic blast cells, 5825
- Ricin**
conjugated with monoclonal antibody DF3
purging, human bone marrow, 1170
- Ricin A chain**
anti-CD5 antibody conjugate
parameters, tumor-specific delivery, 2909
antitumor effects of immunotoxins
intact antibodies and Fab' fragments, Hodgkin's disease, 2929
carrier protein-monensin conjugates, 1385
-containing immunotoxins
CD30 antigen, Hodgkin's disease, 84
immunotoxin activity
perhexilene, established and leukemic cells, 5558
pharmacokinetics of immunotoxins, 7519
-transferrin receptor immunotoxin conjugate
cytotoxicity, glioma, 6696
- RNA**
induction of "reversible" translocation protein B23, exposure to actinomycin D, 5987
noncoordinated expression of ribosomal proteins
leukemic blast cells, 5825
- RNA, messenger**
butyrylcholinesterase
chromosome 3q26-ter, nervous system tumors, 1983
cellular and molecular events
loss of estrogen sensitivity, breast cancer cells, 5868
cytochrome P450IA1 expression
polymerase chain reaction, rat and human tissues, 4315
cytokine regulation
tumor necrosis factor- α and - β , peripheral blood mononuclear cells, 5072
estrogen receptor
adenosine cyclic 3':5'-monophosphate, Leydig cells, 1528
- estrogen-responsive**
cloning, breast cancer cell line, 4098
fibronectin
alternative splicing in lung tissue, oncodevelopmental regulation, 1075
final common pathway of cancer, 4830
glucocorticoid effects
myeloma cells in culture, 1873
- HER-2/neu protooncogene**
hormonal modulation, breast cancer, 3947
- intracellular H3**
proliferation pattern marker, hamster oral epithelium, 5107
laminin-binding protein
colon carcinoma, 3888
 O^6 -methylguanine-DNA methyltransferase
gene MGMT expression, 7908
plasminogen activators and inhibitors
twenty-two human tumor cell lines, 1488
- pS2**
gynecological cancers, 1800
regulation of progesterone receptor gene expression, 5291
retinoblastoma gene structure and expression
small cell lung cancer, xenografts, 5312
terminal deoxynucleotidyl transferase phorbol ester induction, leukemic cell lines, 2891
- transfection and amplification of gene M**, 100,000 melanoma-associated glycoprotein, 1559
- transferrin receptor gene expression**
granulocyte colony-stimulating factor, myeloid leukemia, 7955
- vimentin and c-myc**
differing protein ratios, leukemic cells, 1988
- xenobiotic epoxide hydroxylase**
regulation, hepatocyte nodules and hepatomas, 256
- RNA, ribosomal**
self-splicing activity of *Tetrahymena* effect, 5-fluorouracil substitution, 1757
- RU 38486**
glucocorticoid receptor monoclonal antibodies
B16 melanoma cells, 7985

S

- Saccharin**
promotion
sodium L-ascorbate, two-stage bladder carcinogenesis, 4195
- Salivary duct cell neoplasms**
epidermal growth factor effect
cellular proliferation, 7650
- Salivary gland**
human adenoid cystic carcinoma
biological characterization, pseudocyst-forming cell lines, 4139
- Salivary gland neoplasms**
polyoma virus-induced
T-cell lymphoma, epineoplasms, 5643s
- Salmonella typhimurium**
metabolic activation of 2-naphthohydroxamic acid, 4300
- Saporin**
-conjugated anti-mouse antibody
bone marrow purging, multidrug-resistant cells, 4291
- Sapporo Cancer Seminar**
Ninth Annual, 1346
- Sarcoma**
Ewing's
poly(adenosine diphosphate ribose) polymerase activity, 38
incidence in uterus
marital status, 1886
- Li-Fraumeni cancer syndrome**
normal fibroblasts, spontaneous abnor-

SUBJECT INDEX TO VOLUME 50

- malities, 7979
 oxygen radical-scavenging capacity
 tumor necrosis factor toxicity, mice, 3503
 progressive syngeneic murine
 phenotype analyses and cellular mechanisms, pre-effector T-cell response, 4371
 pulmonary metastases
 antitumor effects, interleukin 2 liposomes, 1853
 tumor energy and oxygenation status
 bioluminescence, nuclear magnetic spectroscopy and cryospectrophotometry, 1681
- Sarcoma virus**
 Moloney murine
 tolerance induction, anti-CD4 monoclonal antibody, 5703s
- Sarcosinamide**
 sarcosinamide chloroethylnitrosourea and
 transport, glioma cells, 3062
- Schwannoma**
 meningioma and
 clonal analysis, 6783
- Selenium**
 activity of methylated forms
 cancer prevention, 1206
- Serpin**
 inhibitors of urokinase and thrombin
 normal rat brain and 9L brain tumor, 5039
- Serum**
 antitumor activity
 concomitant resistance, mice bearing nonimmunogenic tumors, 7159
 canine
 antibodies that recognize human HIV structural proteins, 5628s
 factors and sphinganine
 retinoic acid-induced differentiation, HL-60 cells, 222
 vitamin A
 prostatic cancer development, epidemiological study, 2311
- Sex differences**
 age and
 multistage hepatocarcinogenesis, 472
 diet and
 elastase 1-Simian virus mouse model, pancreatic carcinoma, 7552
 gonadectomy and estrogen
 N-methyl-N-nitrosourea-induced rat thyroid tumors, 7662
- Sex hormone dependence**
 ferric nitrilotriacetate-induced renal lipid peroxidation, 5574
- Sex organs**
 accessory
 experimental induction, neoplasia, 142
- Sialoglycoprotein**
 gangliosides and
 rare blood group antigen determinant, monoclonal antibodies, 5497
 high-molecular-weight production
 soluble factor in normal tissues, colon carcinoma, 3331
 neural cell adhesion molecule-related small cell lung cancer, 1102
- Sialomucin**
- effect of tunicamycin
 natural killer susceptibility, mammary tumor ascites cells, 5250
 lytic susceptibility
 rat mammary tumor ascites cells, 6800
- Sialoprotein**
 cell surface
 metastatic murine colon cancer, 1299
- Sialyltransferases**
 human leukemic myeloblasts and myeloblastoid cells, 5003
- Simian T-cell lymphotropic virus type I**
 protection, vaccine subunit, 5687s
- Simian virus**
 elastase 1 mouse model
 sex and diet, pancreatic carcinoma, 7552
- Simian virus 40**
 -based shuttle vector
 melphalan-induced mutagenesis, 7527
 -immortalized human uroepithelial cells EJ/ras neoplastic transformation, 4779
 large T-antigen
 immortalization, human keratinocytes, 5947
- Sister chromatid exchange**
 cyclophosphamide/Adriamycin/5-fluorouracil chemotherapy
 women with breast cancer, 4951
 phosphoramido mustard-induced acrolein effect, human lymphocytes, 4635
- Skin**
 antitumor promoters
 nicotinamide and nicotinamide analogues, 2470
 calyculin A tumor promoter, 3521
 epidermal ornithine decarboxylase induction
 acute and chronic ultraviolet radiation, hairless mice, 1580
 fibroblasts
 radiosensitivity, atomic bomb survivors with and without breast cancer, 4050
 hypersensitivity of fibroblasts
 basal cell nevus syndrome, killing by ultraviolet B, 637
 immortalized keratinocytes
 growth potential, c-Ha-ras oncogene, 2840
 papilloma sensitivity to malignant conversion
 urethane or 4-nitroquinoline N-oxide, 653
 tissue distribution and photosensitizing properties
 mono-L-aspartyl chlorin e6, mouse tumor model, 3985
 tumor-promoting activity of staurosporine, 4974
- Skin neoplasms**
 candidate cancer chemopreventive agents
 animal models, human clinical trials, 2
 distribution of covalent DNA adducts
 mouse epidermal subpopulations, 3048
 inhibitory effect of apigenin
 epidermal ornithine decarboxylase, 499
 radiation-induced
 c-myc amplification during progression, 3073
 response to doxorubicin
- carcinogen exposure, 6241
SMS 201-995
 cell growth and prolactin secretion
 desensitization and resensitization, pituitary tumor cells, 6238
- Sodium**
 -dependent and equilibrative nucleoside transport
 L1210 mouse leukemia cells, 6549
- pump
 inhibition of activated adenosine triphosphatase, synthetic phospholipid analogues, 3025
- Sodium butyrate**
 conjugated with anti-CD19
 effect of liposomes, growth of malignant lymphoma, 3245
 retinoic acid and
 HL-60 cell differentiation, 6268
- Sodium dodecyl sulfate**
 -activated tumor antithrombin serpin inhibitors, urokinase and thrombin, 5039
- Sodium L-ascorbate**
 sodium saccharin promotion
 two-stage bladder carcinogenesis, 4195
- Soft tissue neoplasms**
 β -subunit of platelet-derived growth factor distribution, 6344
- Solvents**
 survey of exposure to genotoxic agents primary myelodysplastic syndrome, 6876
- Somatic cells**
 homozygous deficiency
 autosomal locus *aprt*, 1738
 hybrids
 suppression of malignant phenotype, 3095
 immune response of syngeneic hybrids, 1544
 tumor suppression
 nonmalignant bronchial epithelial cells, 1890
- Somatostatin**
 -secreting cell line
 release experiment, 3691
- Somatostatin analogue**
 prostate tumors
 adjuvant therapy after surgical castration, 2646
 response of human lung tumor xenografts, 4360
- Species differences**
 susceptibility to aflatoxin B₁, carcinogenesis, 615
- Spermatogenesis**
 protection from cytotoxic procarbazine Zoladex, 568
- Spermatogonia**
 doxorubicin-treated
 chromosomal mutations, germ cells, 370
- Spheroids**
 glioma model
 infiltrative and cytolytic activities, LAK cells, 2429
- Sphinganine**
 serum factors and
 retinoic acid-induced differentiation, HL-60 cells, 222

SUBJECT INDEX TO VOLUME 50

- Spinal cord**
 rat ganglion neurons
 electrophysiological study, cisplatin and ORG-2766, 2437
- Spinal cord neoplasms**
 risk of
 barbiturate exposure, *in utero* and childhood, 4600
- Splenectomy**
 micronucleated erythrocytes
 index of cytogenetic damage in humans, 5049
- Sputum**
 cytodiagnosis
 use of screening phase data, observer variation, 1216
- SR-4233**
 interaction with hyperthermia and radiation
 FSALLC murine fibrosarcoma tumor system, 5055
- potentiation of cell killing**
 fractionated irradiation, mouse tumors, 7745
- SSM**
 induction of interleukin 3 and tumor resistance
Mycobacterium tuberculosis, 4032
- Staging**
 colon cancer
 presurgical imaging, In-labeled anti-carcinoembryonic antigen, 922s
- Staurosporine**
 augmentation of cytotoxic effect
 tumor necrosis factor, HIV-infected cells, 5287
- regulation of epidermal growth factor receptor
 growth-modulating agents, 533
- tumor-promoting activity
 mouse skin, 4974
- Stem cells**
 composition of Shionogi carcinoma effects, androgen withdrawal, 2275
- liver, 3811
- ras* gene activation in rat tumors
 benzidine congeners and derived dyes, 266
- Stereology**
 multistage hepatocarcinogenesis effects of age and sex, 472
- Steroids**
 biosynthesis
 multiple pathways, adrenocortical carcinoma cell line, 5488
- hormone receptors
 preservation in organ cultures, breast carcinoma, 78
- modulation of NADPH pathways
 MCF-7 cells, 1195
- sensitive and -resistant leukemic cells
 glucocorticoid receptor, 1337
- thyroid receptor-like proteins
 oncogenic potential, 451
- Stomach**
 benzo(a)pyrene long term effects
 NAD(P)H:quinone reductase activity, 2064
- gastrointestinal tumorigenesis
 flurbiprofen and 16,16-dimethyl prostaglandin E₂, 381
- Signet-ring cell carcinoma
- monoclonal antibody, tissue polypeptide antigen-related protein, 5192
- Stomach neoplasms**
 atrophic gastritis and
 comparative case-control analysis, 6559
- attenuating effect of bromocriptine
 cysteamine anticarcinogenesis, 5308
- cigarette smoking among U.S. Veterans, 3804
- cigarette smoking and, 7084
- diet and
 case-cohort study, 7501
- human gastric carcinoma
 cell line characteristics, 2773
- life-style and workplace
 young men of Los Angeles County, 2569
- melphalan-induced glutathione content changes in resistance, 3614
- relation to diet, cigarettes, and alcohol consumption
 prospective study, 627
- Streptavidin**
 -biotinylated monoclonal antibody complex
 disulfide bond-targeted radiolabeling, 804s
- Streptonigrin**
 induction
 mammalian DNA topoisomerase II-dependent DNA cleavage, 5841
- Streptozotocin**
 -induced islet cell tumors
 insulin effects, pancreatic exocrine tumors, 1634
- Stroma**
 bone marrow
 heparan sulfate-containing fraction, HL-60 cell maturation, 3781
- diethylnitrosamine-induced hepatic neoplasia
 cytotoxicity phase, medaka, 5504
- Stromal cells**
 paracrine stimulation of prostate secretion, 1966
- production of endothelin in human cancer cell lines, 3257
- Stromal tissue cells**
 human carcinoid tumors
 platelet-derived growth β -receptors, 748
- Substrate**
 depletion
 inhibition of thymidylate biosynthesis by trimetrexate, hepatoma cells, 3979
- Succinyl coenzyme A:acetoxacetyl coenzyme A transferase**
 regulation in rat hepatoma cell lines, 5858
- Sucrose**
 cooked
 promotion, colonic microadenoma growth, 6955
- Sulfatide**
 migration and binding of adhesive proteins
 laminin- and thrombospondin-mediated melanoma cell adhesion, suramin, 5937
- Sulphydryl boron hydrides**
 boronated compounds for neutron capture therapy, 4860
- Sulfide salts**
- nickel and cadmium
 H₂O₂ formation, polymorphonuclear leukocytes, 7564
- Sulfinosine**
 chemotherapeutic characterization, 2625
- Superoxide dismutase**
 manganese
 monoclonal antibody reactivity, human ovarian carcinoma, 2538
- oxygen radical-scavenging capacity
 tumor necrosis factor toxicity, mice, 3503
- Suppressor cells**
 active specific immunotherapy
 melanoma cell vaccine, cyclophosphamide, 5358
- Suramin**
 inhibition of DNA polymerases
 DNA synthesis, HeLa cells, 7754
- inhibition of laminin- and thrombospondin-mediated melanoma cell adhesion
 migration and binding, adhesive proteins to sulfatide, 5937
- neural cell growth
 N-CAM expression, 5164
- phosphoinositide synthesis**
 inhibition of growth factor receptor binding, HT-29 cells, 6490
- prevention of interleukin 2 binding to cell surface receptor
 mechanism, immunosuppression, 3036
- Swainsonine**
 growth inhibition of human melanoma tumor, 1867
- Synaptophysin**
 chromogranin and L-dopa decarboxylase neuroendocrine differentiation markers, lung cancer, 6068

T

- Tachykinin neuropeptides**
 stimulation of calcium mobilization
 bombesin, small cell lung cancer, 240
- TAG-72**
 anti-CEA and
 complementary reactivities, lung carcinoma, 6987
- characterization of shed form
 serous effusions, different types of carcinomas, 4835
- serological mapping
 use of nineteen distinct monoclonal antibodies, 4872
- Tamoxifen**
 Ca²⁺-dependent binding to calmodulin
 bovine brain, 2753
- decreased serum concentrations
 induction by aminoglutethimide, 5851
- development and use of antiestrogens
 breast cancer, 4177
- DNA synthesis**
 proliferation, malignant glioma lines, 7134
- α -interferon and 17 β -estradiol
 estrogen receptor concentration, MCF-7 cell cycle kinetics, 5387
- protein kinase C activity
 endogenous protein phosphorylation, MCF-7 cells, 5845
- stimulated endometrial carcinoma

SUBJECT INDEX TO VOLUME 50

- steroidal and nonsteroidal antiestrogens, 3189
- Taxol**
-resistant leukemia cells
development of polyploidization, 710
- T-cells**
anti-Tac-H antibody
interleukin 2 receptor, malignant and human disorders, 1495
- bone marrow replacement therapy
target-specific immunoconjugates, 1538
- cellular immunotherapies and anti-CD3
hepatitis metastases, 2476
- cytotoxic
locally activated lymphocytes, head-neck tumors, 5551
- establishment of Ki-1-positive cell line
large cell lymphoma, 7682
- immune abnormalities
avian erythroblastosis virus-infected chickens, 4764
- Lyt-2⁺ proliferative response
syngeneic tumor, absence of L3T4⁺ T-cells, 6256
- mediated adoptive immunotherapy
radiosensitive barrier, established tumors, 2228
- OK-432-specific L3T4⁺ Lyt⁻
mechanism, tumocidal activity, 4630
- pre-effector
phenotype analyses and cellular mechanisms, progressive syngeneic murine sarcoma, 4371
- spontaneous rosetting
molecular pathways of adhesion, Hodgkin's cell line, 3131
- targeting with bispecific antibodies
ovarian carcinoma, 4227
- therapeutic effects of IL-2
tumor-dormant state, 1361, 1368
- tumor-specific cytotoxic CD8⁺
eradicating, MOPC-315 tumor, 7641
- 10T½ cells**
protease and extracellular matrix expression
metastatic lung colonization, H-ras transformation, 4061
- 3T3 cells**
bombesin-stimulated phospholipase C activity
guanine and adenine nucleotides, 5257
- control of cAMP-dependent protein kinase
phorbol ester, 7145
- Kirsten-ras⁺ tumor-progressing and K-ras⁺ revertant
adhesion, fibronectin proteolytic fragments, 4388
- Technetium-99m**
"instant" labeling kit
antibody imaging, preclinical evaluation, 794s
- labeled Fab fragment reactive with melanoma antigen
radioimaging, melanoma, 904s
- labeled monoclonal antibody
immunoscintigraphy, CEA in breast cancer, 949s
- labeling of proteins
diaminedithiol bifunctional chelating agent, 799s
- meta'llothionein-B72.3
F(ab')₂ fragment, pharmacokinetics, 835s
- radioimmuno detection
carcinoembryonic antigen monoclonal antibody fragments, 909s
- Telegocidin**
tumor-promoting activity of staurosporine
mouse skin, 4974
- Teniposide**
methotrexate and
continuous infusion, pediatric cancer patients, 4267
- potentiation of DNA strand breakage and cytotoxicity
tumor necrosis factor, 2636
- resistant KB cells
reduction, drug accumulation and DNA topoisomerase II activity, 5819
- Teratocarcinoma**
differentiation of F9 cells into embryoid bodies
early growth-associated events, 3193
- embryo-derived tumors
cytogenetic analysis, 3416
- Terminal deoxynucleotidyl transferase**
changes in adenosine deaminase
phorbol esters, leukemic cell lines, 2891
- Testis**
protection by Zoladex
cytotoxic procarbazine, 568
- Testosterone**
inhibitory effect
gap junctional intercellular communication, transitional cell carcinoma, 2848
- substitution
enzyme-altered hepatic foci, neonatal and adult castration, 2679
- Testosterone propionate**
chemical induction
dorsolateral prostate adenocarcinoma, 691
- prostate carcinoma, 700
- Tetrachloro(D,L-trans)-1,2-diaminocyclohexaneplatinum(IV)**
biotransformation in rat plasma, 4539
- 2,3,7,8-Tetrachlorodibenzo-p-dioxin**
occupied nuclear estrogen receptor
MCF-7 cells, 3579
- proliferative effect
role of transforming growth factor- β , squamous carcinoma cells, 7190
- Tetrachloroplatinum(II)**
(Nile blue), and (neutral red)₂
hyperthermia interaction, fibrosarcoma, 3826
- 12-O-Tetradecanoylphorbol-13-acetate**
colony formation and intercellular communication
coculture system, JB6 clones, 5567
- decreased expression of type II protein kinase C
HL-60 variant cells, 621
- diacylglycerol and
down-regulation, epidermal protein kinase C, 5740
- effects on epidermal growth factor receptors
ER-positive and -negative breast cancer, 4849
- embryonic mutation
in utero carcinogenesis, 2135
- enhanced metabolism of arachidonic acid
dog urothelial cells, 4650
- hydrogen peroxide production
epidermal keratinocytes, 6062
- increased ornithine decarboxylase activity
epidermal cell subpopulations, murine epidermis, 4741
- induced differentiation
human rhabdomyosarcoma cell line, 3377
- intercellular communication in various clones
mouse epidermal JB6 cells, 1324
- tumor-promoting effects
Ca²⁺ ionophores and ionomycin, mouse epidermis, 5806
- Tetrahydrofolates**
analogue
metabolism of 5-deazaacyclotetrahydrololate, 3207
- colon adenocarcinoma xenografts
leucovorin metabolism, 3493
- endogenous
compartmentation, cytosolic folate-binding proteins, 3262
- Tetrahymena**
ribosomal RNA
self-splicing activity, 5-fluorouracil substitution, 1757
- meso-Tetraphenylporphinesulfonate tetrasodium salt**
photodynamic therapy
superficial basal cell carcinoma, 4501
- Tetrazolium**
-based semiautomatic colorimetric assay
evaluation, human antitumor cytotoxicity, 3681
- Thermal sensitivity**
oncogene-transfected rat cells, 4515
- Thermotolerance**
changes in intratumor pH by two heatings, 7108
- Thimerosal**
leukemia effect
leukemic cell lines, normal hematopoiesis, 4429
- Thioether**
phospholipid
1- β -D-arabinofuranosylcytosine, formulation, 4401
- Thioguanine**
antineoplastic activity
experimental and human malignancies, 3473
- 6-Thioguanine**
 δ -methylguanine and
tolerance to cytotoxic effects, CHO cells, 4248
- Thioridazine**
pimozide and
inhibition of breast cancer cell proliferation, 5399
- Thiotepa**
antineoplastic activity
experimental and human malignancies, 3473
- cellular accumulation and cytotoxicity
ethanolamine and choline, L1210 cells, 4322
- constant dose

SUBJECT INDEX TO VOLUME 50

- escalating dose of pentoxifylline, Phase I trial, 6806
- labeling of phosphatidylethanolamine L1210 cells, 4044
- Thioxanthenes**
cellular and biochemical characterization multidrug resistance reversal, human and murine cell lines, 1748
- Thomsen-Friedenreich antigen**
human tumor associated, 4801
- Thrombin**
-independent platelet aggregation *M*, 41,000 glycoprotein, melanoma metastatic variants, 6657
- urokinase and
serpin inhibitors, normal rat brain and 9L brain tumor, 5039
- Thrombophlebitis**
detection with ^{111}In -labeled anti-fibrin antibody, 9585
- Thrombospondin**
-mediated melanoma cell adhesion inhibition by suramin, laminin, 5937
- Thromboxane**
prostacyclin release and
role, photodynamic therapy-induced tumor destruction, 2599
- systemic toxicity
porphyrin photodynamic therapy, 539
- Thymidine**
analogue uptake
rat brain tumors, therapeutic implications in humans, 5199
- Thymidylate**
inhibition of biosynthesis
substrate depletion by trimetrexate, hepatoma cells, 3979
- Thymidylate synthase**
dose response to leucovorin
colon adenocarcinoma, 3940
- inhibitor 2-desamino- N^{10} -propargyl-5,8-dideazafolic acid
murine and human systems, 5212
- Thymidylate synthase inhibitors**
folate-based
multiple membrane transport systems, 7544
- Thymine**
dimer removal and DNA repair synthesis
microinjected photoreactivating enzyme, xeroderma pigmentosum fibroblasts, 1905
- Thymus**
lymphomagenesis
retrovirus SL3-3, 5631s
- Thyroid**
adenocarcinoma
type II, protein kinase C isozymes, 5515
- disease
cancer mortality in women, 2283
- receptor-like proteins
oncogenic potential, 451
- Thyroid neoplasms**
 N -methyl- N -nitrosourea-induced sex differences, gonadectomy, and estrogen, 7662
- Tiazofurin**
phosphorylation by three enzymes Chinese hamster ovary cells, 5269
- Tight junctions**
epithelial
tumor necrosis factor, transepithelial permeability, 2172
- T-leukemia cells**
down-regulated *c-myb* expression
inhibition of DNA synthesis, 7371
- T-lymphoblastoid cells**
transport and metabolism
 9β -D-arabinofuranosylguanine, 1817
- T-lymphoblasts**
purine deoxyribonucleoside triphosphate pools mutations, 4566
- Tobacco**
active transplacental carcinogen, Syrian golden hamsters, 3435
esophageal cancer in Uruguay, 426
- N' -nitrosornornicotine and 4-(methylnitrosamo)-1-(3-pyridyl)-1-butane
comparative metabolism, oral tissue and esophagus, 4685
- smoke constituent 3-hydroxypyridine metabolism, role of P450IIIE1, 5333
- specific nitrosamine 4-(methylnitrosamo)-1-(3-pyridyl)-1-butane
-specific nitrosamine hemoglobin adducts mass spectrometric analysis, 5438
- use
diet and fatal prostate cancer, Lutheran brotherhood cohort, 6836
- Topoisomerase II:** *see also* DNA topoisomerase II
induction of gene expression
phytohemagglutinin stimulation, human lymphocytes, 5649s
- 170kD and 180kD forms
differences, normal and *ras*-transformed NIH-3T3 cells, 2901
- mediated DNA cleavage
aclacinycin inhibition, VP-16 and m-AMSA toxicity, 3311
- reduced DNA activity
Adriamycin resistance, small cell lung carcinoma, 304
- VP-16-induced cell death mechanism, 2713
- Trachea**
low passage cultured cells from lung cancer
in vivo invasion assay, 7358
- Transferrin**
carrier protein-monensin conjugates, 1385
- independence
phorbol ester-induced macrophage-like differentiation, HL-60 cells, 7221
- Transformation**
suppression
growth adaptation to low glutamine concentrations, NIH-3T3 cells, 2832
- Transforming growth factor**
receptors
liver regeneration, partial hepatectomy, 1464
- Transforming growth factor- α**
autocrine growth factors
immunohistochemical evidence, lung adenocarcinoma, 7077
- epidermal growth factor and
induction of ascitic fluid in mice, 4915
- inhibition of estradiol uptake
alkyl-lysophospholipid, breast cancer, 3172
- inhibitory effects of transforming growth factor- β 1
mitogenic response, colon carcinoma cells, 7581
- insulin-like growth factor I and
autocrine growth factors, pancreatic cancer cell growth, 103
- pro-EGF receptor gene expression, renal carcinoma, 3934
- Transforming growth factor- β**
induction of pemphigus vulgaris antigen activity
mouse papilloma cells, 686
- inhibition of androgen-induced growth Shionogi carcinoma cells, serum-free medium, 6179
- proliferative effect
2,3,7,8-tetrachlorodibenzo-*p*-dioxin, squamous carcinoma cells, 7190
- three species
regulation by estradiol, breast cancer, 299
- Transforming growth factor- β 1**
differential effects
poorly and highly metastatic melanoma cells, 273
- expression by human endometrial carcinoma
inverse correlation, growth rate and morphology, 3394
- induction of colon carcinoma differentiation
hexamethylene bisacetamide, 261
- inhibitory effect on mitogenic response quiescent, well-differentiated colon carcinoma cells, 7581
- normal and chronic phase chronic myelogenous leukemia
 Ph^1 bone marrow stroma, 5801
- resistance
liver epithelial cells, 3600
- response of tumorigenic and nontumorigenic cells
papillomavirus type 16-positive epithelial cells, 7324
- responsiveness of liver epithelial cells v-raf/transformation, 7468
- Transglutaminase**
differential regulation
response to retinoic acid, erythroleukemia cells, 7830
- Transglutaminase I**
hamster buccal pouch carcinogenesis model
7,12-dimethylbenz(*a*)anthracene induction, 2505
- Transplantation**
abrogation of resistance in syngeneic tumors
selective depletion of neutrophils, monoclonal antibody, 6243
- Bone marrow**
neurotoxicity, high-dose busulfan in children, 6203
- ^{90}Y antibody therapy, colon cancer xenografts, 1008s
- bone marrow purging
immunotoxin, multidrug-resistant cells, 4291
- cell-free extracts, 8034
- growth of human cell lines
BALB/c mice, 5943

SUBJECT INDEX TO VOLUME 50

- heterotransplantation of human lymphoid neoplasms
nude mouse intraocular xenograft model, 3078
immune response to syngeneic tumor cell hybrids, 1544
low passage cultured cells from lung cancer
in vivo invasion assay, 7358
normal tissue and autochthonous tumor effects, recombinant human tumor necrosis factor, 2463
- Triciribine**
dual mechanisms
inhibition of DNA synthesis, 4891
- N,N',N''-Triethylenethiophosphoramido biotransformation**, 464
- Trimetrexate**
role of substrate depletion
inhibition of thymidylate biosynthesis, hepatoma cells, 3979
- Tropomyosins**
defects in expression
human mammary epithelial cells, 2105
- Trypsinogen-2**
high concentrations
cyst fluid of ovarian cancer, 2375
- Tryptophan**
degradation and neopterin formation
cytokine treatment, human myelomonocytic cell line, 2863
- Tubercidin**
adenosine receptors
natural killer cell activity, purine nucleosides, 4328
- Tubulin**
bovine brain
interaction of rhizoxin, 4277
- Tumor-associated antigens**
anti-Tac-H antibody
interleukin 2 receptor, malignant and human disorders, 1495
common to humans
chemically induced colonic tumors of the rat, 6358
synthetic tumor-associated glycoconjugate
active specific immunotherapy, mammary adenocarcinoma, 4308
- Tumor cells**
antitumor efficacy
vaccinia virus-modified tumor cell vaccine, 6915
cloning and characterization
interstitial collagenase, 5431
dosimetric model for antibody treated radionuclide therapy
cerebrospinal fluid, 1043
growth inhibition
arginine deiminase, *Mycoplasma*-infected cell line, 4522
heat treatment effect
antitumor effector cells, 6199
inhibition of proliferation
natural suppressor cells, murine bone marrow, 2582
killing by activated macrophages
L-arginine, reactive nitrogen intermediates, 1421
migration
monoclonal antibodies, synthetic peptide inhibitors, 4485
- multifocal vascular
newly isolated retrovirus, fowl, 4787
platelet-endothelial cell interactions
tumor cell cytoskeleton, 7686
response to ionizing radiation
tetrazolium assay, 1392
selection for resistance
monoclonal antibody-*Vinca* alkaloid immunoconjugates, 7634
transitional
adherence to injured urothelial surfaces, kinetics, 2499
twenty-two cell lines
protein and messenger RNA levels, plasminogen activators and inhibitors, 1488
- Tumor growth**
inhibition by intraperitoneal immunotoxins
nude mice, 288
inhibitory activity
lymphocyte blastogenesis inhibitory factor, 345
support
endogenous and exogenous polyamines, 5077
- Tumorigenesis**
colorectal
p53 gene mutations, 17p allelic deletions, 7717
differentiation therapy, 3453
endogenous *Mtv* expression
resistance to infection, 3754
gastrointestinal
flurbiprofen and 16,16-dimethyl prostaglandin E₂, 381
growth properties and
ras mutants, MCF-7 cells, 67
inhibitory effect of apigenin
epidermal ornithine decarboxylase, skin tumor promotion, 499
lung
indole-3-carbinol effects, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanolone disposition, 2613
- Tumorigenicity**
metastasis and
human breast carcinoma cell lines, nude mice, 717
role of 1q trisomy
growth and metastasis, leukemic B-cell clones, 3737
suppression of lung carcinoma
nontumorigenic bronchial epithelial cells, somatic cell hybrids, 1890
two breast carcinoma cell lines
establishment in serum-free medium, 1257
- Tumor necrosis factor**
antitumor efficacy and toxicity
aminopterin-monoclonal antibody conjugates, 6028
augmentation of cytotoxic effect
staurosporine, HIV-infected cells, 5287
autochthonous tumor and transplanted normal tissue, 2463
cachectic effects, 4008
children with malignancies, 592
endogenous
protective protein against cytotoxicity, exogenous TNF, 4941
epithelial tight junctions
- transepithelial permeability, 2172
flavone acetic acid-induced tumor vasoconstriction shutdown, 5537
- gene expression**
autoinduction, phospholipase A₂ activation, 7101
host sensitivity to toxicity
oxygen radical-scavenging capacity, mice, 3503
impact of tolerance on antitumor efficacy, 2261
induction by leukemia cell
human monocytes, 2708
interferon- γ
dependence of IL-2, tumor therapy, 1368
interleukin 1
and
coordinated induction, monocyte-mediated cytotoxicity, 3146
interleukin 1 interactions and high mannose glycopeptides, 6285
LAK cells and
resistance of ovarian cancer cells, HER2/neu oncogenes, 7364
mediators of lipogenic effects
interleukin 6, 4233
potentiation
topoisomerase inhibitor-induced DNA strand breakage, 2636
production by mononuclear phagocytes interleukins 2 and 4, 2949
protective effect
hematopoiesis, cycle-specific cytotoxic chemotherapy, 4216
release from monocytic cells by melanoma granulocyte-macrophage colony-stimulating factor, 2673
repetitive low-dose recombinant prolonged survival, tumor-bearing rats, 3928
reversal of multidrug resistance
lipophilic drugs, 3997
sustained production
correlation, response to interleukin 2 therapy, 2371
- Tumor necrosis factor- α**
contrast-enhanced magnetic resonance imaging
tumor-bearing mice, 7376
cytokine regulation of messenger RNA
human peripheral blood mononuclear cells, 5072
effects on skeletal muscle
Walker 256 carcinosarcoma protein metabolism, 2765
free and liposome-encapsulated immunomodulatory and toxic effects, 375
granulocyte colony-stimulating factor
GM-CSF-dependent growth, normal and leukemic hemopoietic progenitors, 5065
interleukin 2 and
OKT3-initiated lymphokine-activated effectors, 3526
 α -interferon and/or
antiproliferative and cytotoxic effects, renal cell carcinoma xenografts, 6389
interleukin 1 and interleukin 6 increased secretion
 β -galactoside-specific lectin, mononuclear cells, 3322

SUBJECT INDEX TO VOLUME 50

Tumor necrosis factor- β
 cytokine regulation of messenger RNA
 human peripheral blood mononuclear
 cells, 5072

Tumor progression
 allelotype of breast cancer, 7184
 c-myc amplification
 radiation-induced rat skin tumors, 3073
 four mammary epithelial cell lines
 same patient, 7351
 growth-related genes
 v-ras-transformed liver epithelial cells,
 7460

Ha-ras-induced
 immune response, progressor variants,
 3159

integrin distribution
 malignant melanoma, 6757

laminin-binding protein mRNA expression
 colon carcinoma, 3888

marker to detect micrometastasis formation
 bacterial lacZ gene, 2808

metastases and
 heterogeneous protooncogene amplification, gastric cancer, 7811

serum carcinoembryonic antigen level
 gastric carcinoma, noncurative resection, 3952

steroid/thyroid receptor-like proteins
 oncogenic potential, 451

T47D_{co} cells as model
 hormone resistance, breast cancer, 6208

unique tumor antigens
 MHC class I, murine tumors, 3851

Tumor promoters
 antipromoters and
 in vitro analogue development, initiated
 mouse epidermis, 4794

hydroxyanthraquinones
 malignant transformation, C3H mouse fibroblasts, 6540

-induced genes
 cDNA clones, epidermis, 1626

12-O-tetradecanoylphorbol-13-acetate
 colony formation and intercellular communication, JB6 clones, 5567

Tumor promotion
 Ca²⁺ ionophores and ionomycin
 mouse epidermis, 5806

down-regulation of epidermal protein kinase C
 TPA and diacylglycerol, 5748

U.S.-Japan Seminar on molecular mechanisms, 7085

Tumors
 energy and oxygenation status
 bioluminescence, nuclear magnetic spectroscopy and cryospectrophotometry, 1681

human
 assessment of clonality, 1355

nonimmunogenic
 seric antitumor activity, concomitant resistance, 7159

other than melanoma
 boron delivery, p-boronophenylalanine,, 138

physiological barriers to monoclonal antibody delivery

other macromolecules, 814s
 -secreted vascular permeability factor, 1774

solid
 antitumor efficacy, PD115934, 4900
 granulocyte-macrophage colony-stimulating factor effects, 6264
 immunotoxin uptake, plasma kinetics, 7382

interleukin 2, Adriamycin and dacarbazine, 5876

reoxygenation of cells from hypoxic regions, 5031

spheroid model
 biologically targeted radiotherapy, neuroblastoma micrometastases, 1000s

suppressor genes workshop, 6765

targeting
 site-specifically radioiodinated antibody, 857s

targeting by monoclonal antibodies
 innovations, pharmacology, 820s

tissue-isolated and subcutaneous
 interstitial pressure gradients, 4478

Tunicamycin
 effect on sialomucin and natural killer susceptibility
 mammary tumor ascites cells, 5250

U

502U83
 Phase I and clinical pharmacology monthly single dose schedule, 7496

U-937 cells
 granulocyte differentiation
 dibutyryl adenosine cyclic 3',5'-monophosphate, 20

growth of human cell lines
 BALB/c mice, 5943

phorbol ester-induced differentiation
 alterations in glycosylation, lectin pattern, 323

U-71,184
 resistance
 characterization of B16 melanoma cells, 2485

Ulcer
 meta-analysis of risk
 gastric stump cancer, remote partial gastrectomy, 6486

Ulcerative colitis
 rectal cell proliferation
 colon cancer risk, 1156

Ultraviolet B
 hypersensitivity of skin fibroblasts to killing
 basal cell nevus syndrome, 637

Ultraviolet irradiation
 acute and chronic
 induction of epidermal ornithine decarboxylase activity, hairless mice, 1580

immune response to progressor variants
 Ha-ras-induced tumor progression, 3159

immune response to syngeneic tumor cell hybrids, 1544

-inducible proteins
 polyoma virus regulatory region, 5374

inhibition of DNA excision repair
 methotrexate, Chinese hamster ovary cells, 1786

microinjected photoreactivating enzyme thymine dimer removal, xeroderma pigmentosum fibroblasts, 1905

Ultraviolet light
 uveal melanoma
 host factors, 5773

Universal response surface approach
 quantitation of drug synergism
 cis-diamminedichloroplatinum, 1- β -D-arabinofuranosylcytosine, 5318

Urethane
 sensitivity of skin papillomas
 malignant conversion, 653

Urinary bladder
 clinical cancer progression in tumors
 flow cytometry, monoclonal antibodies, 432

Urine
 purification of epidermal growth factor-related protein
 breast cancer patients, 642

Uroepithelial cells
 rapid degradation of extracellular matrix proteins, 1897

SV40-immortalized
 EJ/ras neoplastic transformation, 4779

Urokinase
 secretion from human colon carcinomas
 induction by endogenous diglycerides, 2245

thrombin and
 serpin inhibitors, normal rat brain and 9L brain tumor, 5039

Urokinase plasminogen activator
 prognostic marker in breast cancer, 6827

secreted
 metastatic potential, murine B16 cells, 7623

Urothelial neoplasms
 production in heterotopic bladder benzidine derivatives, 2868

Urothelium
 adherence to injured surfaces
 transitional tumor cells, kinetics, 2499

12-O-tetradecanoylphorbol-13-acetate
 enhanced arachidonic acid metabolism, 4650

Uruguay
 mate drinking
 alcohol, tobacco and diet, 426

Uterine cervix
 keratin subtypes in carcinomas
 histogenesis, differential diagnosis, 5143

Uterus
 human smooth muscle tumors
 insulin-like growth factor gene expression, 6689

incidence of sarcomas
 marital status, 1886

smooth muscle tumors
 chromosome aberrations, 4092

V

Vaccine
 interleukin 1 as adjuvant
 active specific immunotherapy, murine tumor model, 1212


subunit
 STLV-I challenge, *Macaca nemestrina*,

SUBJECT INDEX TO VOLUME 50

- 5687s**
- Vaccinia virus**
-modified tumor cell vaccine
 antitumor efficacy, 6915
- Vacuoles**
cytological study
 aberrant hepatocytes, fish, 6744
- Vascular permeability factor**
tumor-secreted, 1774
- Vascular tissues**
establishment and characterization
 tumorigenic murine vascular endothelial cell line, 5526
- Vasculature**
microvascular architecture of colon tumors, 2411
- Vasoactive intestinal peptide**
in vitro differentiation of neuroblastoma cells, 5177
- Vasomotor function**
recombinant interleukin 2 infusion, 4377
- Vasopressin**
oxytocin and
 interaction with breast carcinoma cells, 7882
- V79 cells**
abrogation of cytotoxicity by novobiocin amsscarine, 2577
- cytotoxic interaction
 phototherapy and nigericin, 1620
- poly(adenosine diphosphate-ribose) synthesis-deficient
epipodophyllotoxin-induced cell death, 2713
- Verapamil**
cyclosporin A and
 modulation of multidrug resistance, leukemic cell lines, 2953
- labeling of P-glycoprotein, 1132
- reversal of multidrug resistance
 modulation by α_1 -acid glycoprotein, Chinese hamster ovary cell lines, 2818
- Villin**
diagnosis and follow-up
 colorectal cancer, 438
- Vimentin**
c-myc mRNA and
 differing protein ratios, leukemic cells, 1988
- Vinblastine**
antineoplastic activity
 experimental and human malignancies, 3473
- photoreactive derivative
 multidrug-resistant ascites, Chinese hamster ovary cells, 403
- Vinca alkaloids**
antitumor agents
 use of small neurons, quantitative ultrastructural parameters, 1924
- immunoconjugate LY203725
 antitumor activity, ovarian cancer, 3540
- increased sensitivity
 cells overexpressing calmodulin, 6554
- monoclonal antibody immunoconjugates
 resistance, human tumor cells, 7634
- Vincristine**
antineoplastic activity
 experimental and human malignancies, 3473
- biological monitoring screening, 3351
- cytotoxic effects
 cell cycle phase-specific agents, 7307
- liposomal preparations
 increased activity, murine L1210 and P388 tumors, 575
- reversal of resistance
 newly synthesized dihydropyridines, P-glycoprotein photoaffinity labeling, 310
- Vitamin A**
benign proliferative disorders of breast and diet
case-control study, 3176
- serum
 prostate cancer development, epidemiological study, 2311
- Vitamin D₃**
differentiation therapy, 3453
- VP-16**
cyclophosphamide or melphalan
 synergistic interactions, rhabdomyosarcoma xenograft, 284
- W**
- Walker 256 carcinoma**
short-term metabolic fate
L-[¹⁴N]glutamic acid, 4839
- Walker 256 carcinosarcoma**
protein metabolism
 tumor necrosis factor- α effects, skeletal muscle, 2765
- WEHI-3B cells**
role of endocytosis
action of ether lipids, 7505
- Welding**
occupations of parents
 children with retinoblastoma, 7129
- Wheat bran**
lard and
N-methyl-N'-nitro-N-nitrosoguanidine-induced colon carcinogenesis, 1092
- Wilms' tumor**
chromosome analysis of thirty-one tumors, 2786
- loss of heterozygosity
 suppressor regions limited to chromosome 11, 3279
- paternal occupation and, 3212
- Wound healing**
suppression in tumor-bearing animals
tumor-host interaction model, 7997
- X**
- Xanthone-4-acetic acid**
production of nitric oxide
 activated macrophages, 6966
- Xenografts**
amplification of c-myc gene
medulloblastoma, 2347
- colon adenocarcinoma
dose response to leucovorin, 3940
- leucovorin metabolism, 3493
- colon cancer
bone marrow transplantation, ⁹⁰Y antibody therapy, 1008s
- colon carcinomatosis
radioimmunotherapy, monoclonal antibody, 989s
- colon tumor
- monoclonal antibody uptake, irradiation, 159
- colorectal carcinoma**
radioimmunotherapy, Y-90 monoclonal antibody, 4546
- epidermal growth factor receptor
glioma, 8017
- glioma
monoclonal antibody F(ab')₂ delivery, hyperthermia, 1803
- radioimmunotherapy, ¹³¹I-labeled F(ab')₂ fragment, 1822
- targeting and therapy, radiolabeled antibodies, 974s
- head and neck cancer**
adoptive immunotherapy, LAK cells and interleukin 2, 3113
- human colonic tumor**
biodistribution, ¹³¹I- vs. ⁹⁰Y-IgG or fragments, 2330
- human melanoma**
²¹At-methylene blue, targeted radiotherapy, 2963
- human tumor**
biodistribution of 791T/36 antibody, Fab/c fragment, 2936
- lung carcinoma**
stability over time, myc family of oncogenes, 1566
- lung tumor**
somatostatin analogue treatment, 4360
- melanoma**
growth inhibition, swainsonine, 1867
- nude mice**
biodistribution of KC-4G3, 5954
- nude mouse intraocular model**
heterotransplantation, lymphoid neoplasms, 3078
- ovarian tumor**
enhanced therapeutic efficacy, immunotoxins with α -interferon, 6379
- pediatric osteosarcoma**
development and characterization, 2781
- peritoneal human colon cancer**
radioimmunotherapy, ²¹²Bi-labeled antibody, 985s
- renal cell carcinoma**
antiproliferative and cytotoxic effects, tumor necrosis factor α and/or α -interferon, 6389
- rhabdomyosarcoma**
cyclophosphamide, melphalan and VP-16, 284
- small cell lung cancer**
abnormalities, retinoblastoma gene structure and expression, 5312
- imaging and therapy, ¹¹¹In-labeled monoclonal antibodies, 980s
- radiotherapy, magnetic resonance spectroscopy, 4880
- Xeroderma pigmentosum**
fibroblasts
DNA repair synthesis, photoreactivating enzyme, 1905
- variant fibroblasts
defective postreplication repair, 2593
- X-rays**
evidence for multistep nature
 human epithelial cell carcinogenesis, 5653s
- induced transformants

SUBJECT INDEX TO VOLUME 50

- karyotypic changes, 760
- Y**
- Yttrium-90
antibody therapy
bone marrow transplantation, colon
cancer xenografts, 1008s
- conjugated antiidiotype monoclonal antibody
radioimmunotherapy, B-cell lymphoma, 1022a
- IgG or fragments
radiation dose estimates, human colonic tumor xenografts, 2330
- monoclonal antibody
- radioimmunotherapy, human colorectal carcinoma xenografts, 4546
- monoclonal antibody-associated activity
tumor radiation doses, colorectal cancer, 1029s
- ZCE025 monoclonal antibody
radioimmunotherapy, human colon carcinomatosis xenograft, 989s



OL
0

90

MI

Contents of Volume 50

January 1, Number 1

- Editorial**
1 Message from the New Editor-in-Chief, Carlo M. Croce.
Review
2 Identification of Candidate Cancer Chemopreventive Agents and Their Evaluation in Animal Models and Human Clinical Trials: A Review, Charles W. Boone, Gary J. Kelloff, and Winifred E. Malone.

BASIC SCIENCES

- *10 Establishment of Continuous Cultures of T-Cell Acute Lymphoblastic Leukemia Cells at Diagnosis. Ruth Gjerst, Alice Yu, and Martin Haas.
15 Dose-dependent Effect of Hydralazine on Microcirculatory Function and Hyperthermic Response of Murine F9Tall Tumors. Joachim Kalinus, Paul Okunieff, and Peter Vaupel.
*20 Differentiation of U-937 Histiocytic Lymphoma Cells towards Mature Neutrophil Granulocytes by Dilutyryl Cyclic Adenosine-3',5'-monophosphate. Debra L. Laskin, Andrew J. Beavis, Andrea A. Sirak, Sean M. O'Connell, and Jeffrey D. Laskin.
*26 Modulation of Interferon Receptor Expression during Combination α -Interferon and γ -Interferon Treatment of Human Colon Carcinoma Cells. Joan H. Schiller, Sarah M. Bushmeyer, Frank J. Ruzicka, Gerald P. Principe, Connie R. Falynck, and Ernest C. Borden.
*32 Synergistic Potentiation of *In Vitro* Antitumor Activity of Anti-Human T-Lymphokine Immunotoxins by Recombinant α -Interferon and Dauromurine. Soichiro Yokota, Hideki Hara, Yi Luo, and Ben K. Seon.
*38 Enhanced Poly(adenylyl diphosphate ribose) Polymerase Activity and Gene Expression in Ewing's Sarcoma Cells. Sarada C. Prasad, Peter J. Thraves, Kishor G. Bhata, Mark E. Smulson, and Anatoly Dritschko.
*44 Allelic Losses of Chromosomes 9, 11, and 17 in Human Bladder Cancer. Yvonne C. Tsui, Peter W. Nichols, Alan L. Hitt, Zippora Williams, Donald G. Skinner, and James A. Jones.
*48 Insulin-like Growth Factor Receptor Expression and Function in Human Breast Cancer. Kevin J. Cullen, Douglas Yee, William S. Sly, James Perdue, Brian Hampton, Marc E. Lipman, and Neal Rosen.
54 Radiation-induced Osteosarcoma in Dogs after External Beam or Intraperitoneal Radiation Therapy. Sharon McChesney Gillette, Edward L. Gillette, Barbara E. Powers, and Stephen J. Withrow.
*58 Immunotherapy Purification of Human O^6 -Aalkylguanine-DNA Alkylytransferase Using Newly Developed Monoclonal Antibodies. Thomas P. Brent, Mathew von Wronski, Charles N. Pezzani, and Darel D. Bigner.
*62 Changes in $c-myc$ and $c-fos$ Expression in a Human Tumor Cell Line following Exposure to Bifunctional Alkylating Agents. Bernard W. Futscher and Leonard C. Erickson.
*67 Growth Properties and Tumorigenesis of MCF-7 Cells Transfected with Isogenic Mutants of ras^{H} . Connie L. Sommers, Alex Papageorge, George Wilding, and Edward P. Gelmann.
*72 Characterization of Acquired Resistance to *cis*-Diamminedichloroplatinum(II) in Human Colon Carcinoma Cells. R. J. Fram, B. A. Woda, J. M. Wilson, and N. Robichaud.

Editorial

- 221 Message from the New Editor-in-Chief, Carlo M. Croce.

BASIC SCIENCES

- *222 Modulation of Retinoic Acid-induced Differentiation of Human Leskin (HL-60) Cells by Serum Factors and Sphinganine. Victoria L. Stevens, Nancy E. Owens, Elliott F. Winton, Joseph M. Kinkade, Jr., and Alfred H. Merrill, Jr.
227 Expansion of Immunoregulatory Macrophages by Granulocyte-Macrophage Colony-stimulating Factor Derived from a Murine Mammary Tumor. Yanping Fu, Gordon Watson, Joaquin J. Jimenez, Yang Wang, and Diana M. Lopez.
*235 Activation of Inositol Phospholipid Signaling and Ca^{2+} Efflux in Human Breast Cancer Cells by Bombesin. K. V. Patel and M. P. Schrey.
*240 Stimulation of Calcium Mobilization but not Proliferation by Bombesin and Tachykinin Neuropeptides in Human Small Cell Lung Cancer Cells. Noriko Takuwa, Yoh Takuwa, Yasuhiro Ohue, Hidehito Mukai, Kazuyuki Endoh, Kenjiro Yamashita, Mamoru Kumada, and Etsuko Munekata.
*245 Evaluation of Methods for Quantitation of Aflatoxin-Albumin Adducts and Their Application to Human Exposure Assessment. Christopher P. Wild, Yuan-Zhou Jiang, Gabriele Sabbioni, Brigitte Chapot, and Ruggero Montesano.

Asterisks * preceding page numbers refer to studies using human-derived material.

January 15, Number 2

- *78 Preservation of Steroid Hormone Receptors in Organ Cultures of Human Breast Carcinomas. Rafael Mira-y-Lopez and Liliana Osowski.

- *84 Evaluation of Ricin A Chain-containing Immunotoxins Directed against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease. Andreas Engert, Francis Burrows, Wolfram Jung, Pier Luigi Tazzari, Harald Stein, Michael Pfreundschuh, Volker Diehl, and Philip Thorpe.

- *89 Synthetic Peptides Reactive with Anti-Human Milk Fat Globule Membrane Monoclonal Antibodies. Pei-Xiang Xing, Kerry Reynolds, Joe J. Tjandra, Xi-Lin Tang, and Ian F. C. McKenzie.

- *97 Synergistic Effect of the ν -myc Oncogene with $H-ras$ on Radioresistance. W. Gillies McKenna, Marisa C. Weiss, Brian Endlich, C. Clifton Lin, Vincent J. Bakanus, Martin L. Kelsten, and Ruth J. Muschel.

- *103 Insulin-like Growth Factor I and Transforming Growth Factor α Autocrine Growth Factors in Human Pancreatic Cancer Cell Growth. Eiji Ohmura, Masaki Otada, Noritaka Onoda, Yoshinobu Kamiya, Hiromi Murakami, Toshio Tsuchima, and Kazuo Shirane.

- *106 On the Paradoxically Concentration-dependent Metabolism of 6-Mercaptopurine in WEHI-3b Murine Leukemia Cells. Jan Lillemark, Birgitta Peterson, Britt Engberg, Pierre Lafolie, Michel Masquelier, and Curt Petersen.

- 113 Morphology and Anatomic Localization of Renal Microangiomas and Proximal Tubule Dysplasias Induced by Four Different Estrogens in the Hamster. Stanley Goldfarb and Thomas D. Pugh.

- *120 Cross-Linked Envelope-related Markers for Squamous Differentiation in Human Lung Cancer Cell Lines. Mark L. Levitt, Adri F. Gazdar, Herbert K. Oie, Hildegard Schuller, and Scott M. Thacher.

- 129 Collagen-mediated Dispersion of NBT-II Rat Bladder Carcinoma Cells. Gordon C. Tucker, Brigitte Boyer, Jelena Gavrilovic, Hervé Emond, and Jean Paul Thiriet.

- *138 Selective Delivery of Boron by the Melanin Precursor Analogue p -Boronophenylalanine to Tumors Other Than Melanoma. Jeffrey A. Codere, John D. Glass, Ralph G. Fairchild, Peggy L. Micca, Irwin Fand, and Darren D. Joel.

- 142 Experimental Induction of Neoplasia in the Accessory Sex Organs of Male Lobund-Wistar Rats. Dennis M. Hoover, Kevin L. Best, Brian K. McMenamin, Roy N. Tamura, and Blake L. Neuhauser.

- *147 Karyometric Marker Features in Normal-appearing Glands Adjacent to Human Colonic Adenocarcinoma. Mariluce Bibbo, Fabrizio Michelassi, Peter H. Bartels, Harvey Ditch, Christopher Bania, Enrique Lerma, and Anthony G. Montag.

- *152 Monoclonal Antibody to Human Osteosarcoma: A Novel M_1 , 26,000 Protein Recognized by Murine Hybridoma TMMR-2. Cheng C. Tsai, Michael H. McGuire, Richard J. Mellitt, R. August Ritter III, Jianzhang Xu, Daniel J. Litwack, and Stanford T. Roodman.

- *159 Enhancement of Monoclonal Antibody Uptake in Human Colon Tumor Xenographs following Irradiation. H. Kalofonos, G. Rowlinson, and A. A. Petatos.

January 15, Number 2

- *252 Efficacy, Toxicity, Pharmacokinetics, and *In Vitro* Metabolism of the Enantiomers of Hosfnamide in Mice. Dominique Masurel, Peter J. Houghton, Connie L. Young, and Irving W. Wainer.

- 256 Regulation of Microsomal Xenobiotic Epoxide Hydrolase Messenger RNA in Persistent Hepatocyte Nodules and Hepatomas Induced by Chemical Carcinogens. Victor D-H. Ding, Ross Cameron, and Cecily Bickett.

- *261 Role of Transforming Growth Factor β_1 in Induction of Colon Carcinoma Differentiation by Hexamethylene Bisacetamide. Paul Schroy, Jeff Riffkin, Robert J. Coffey, Sidney Winograd, and Eileen Friedman.

- 266 α -Gene Activation in Rat Tumors Induced by Benzidine Generators and Derived Dyes. Steven H. Reynolds, Rachel M. Patterson, John H. Menear, Robert R. Maronpot, and Marshall W. Anderson.

- 273 Differential Effects of Transforming Growth Factor β_1 on the Growth of Poorly and Highly Metastatic Murine Melanoma Cells. Daniel L. Mooradian, Anthony F. Purchio, and Leo T. Furcht.

- *278 Absence of *IFNA* and *IFNB* Genes from Human Malignant Gloma Cell Lines and Lack of Correlation with Cellular Sensitivity to Interferons. Junji Miyakoshi, Kelly D. Dobler, Joan Allalunis-Turner, John D. S. McLean, Kenneth Petru, Peter B. R. Allen, Keith N. Aronky, Bryce Weir, Debbie Huyser-Wierenga, Dorcas Fulton, Raul C. Urtasun, and Rufus S. Day III.

- *284 Cytogenetic Profile of *In Vitro* Spontaneously Transformed and Chemical Tumor-derived Cell Lines Related to the Mouse Lung Alveologenic Carcinoma. Irit Markus and Garry J. Smith.

CLINICAL AND EPIDEMIOLOGICAL INVESTIGATIONS

- 169 A Prospective, Population-based Study of Androstenolone, Estradiol, and Prostatic Cancer. Elizabeth Barrett-Connor, Cedric Garland, Janice B. McPhillips, Kay-Tee Khaw, and Deborah L. Wingard.

- 174 Quantitative Evaluation of the Radon and Lung Cancer Association in a Case Control Study of Chinese Tea Makers. Jay H. Luom, You-lin Qiao, Philip R. Taylor, Shu-Xiang Yan, Arthur Schatzkin, Bao-Lin Mao, Jian-Yu Rao, Xiang-Zhen Xuan, and Jun-Yao Li.

- 181 Decline of the Hemoglobin Adduct of 4-Aminobiphenyl during Withdrawal from Smoking. Malcolm MacLennan, Matthew S. Bryant, Paul L. Skipper, and Steven C. Tannenbaum.

- 185 Immunomodulatory Properties and Toxicity of Interleukin 2 in Patients with Cancer. Walter J. Urba, Ronald G. Steis, Dan L. Longo, William C. Kopp, Annette E. Malush, Luisa Marcon, David L. Nelson, Henry C. Stevenson, and Jeffrey W. Clark.

- 193 Effect of Treatment with 4-Hydroxyandrostenolone on the Peripheral Conversion of Androstenolone to Estrone and *In Vitro* Tumor Aromatase Activity in Postmenopausal Women with Breast Cancer. M. J. Reed, L. C. Lai, A. M. Owen, A. Singh, N. G. Colsham, A. Puthoff, M. W. Ghochik, N. A. Shaikh, and V. H. T. James.

- 197 Relationship between Dihydropyrimidine Dehydrogenase Activity and Plasma 5-Fluorouracil Levels with Evidence for Circadian Variation of Enzyme Activity and Plasma Drug Levels in Cancer Patients Receiving 5-Fluorouracil by Protracted Continuous Infusion. Barry E. Harris, Ruiling Song, Sung-jaw Soong, and Robert B. Dioso.

- 202 Anti-GD₁ Monoclonal Antibody Analysis of Childhood Cell-line Acute Lymphoblastic Leukemia: Detection of a Target Antigen for Antibody-mediated Cytotoxicity. Gregory H. Reaman, Barbara J. Taylor, and William D. Merritt.

- 206 Phase I and Clinical Pharmacological Evaluation of a Parenteral Hexamethylmelamine Formulation. Matthew M. Ames, Ronald L. Richardson, John S. Kovach, Charles G. Moertel, and Michael J. O'Connell.

* * *

- 211 Announcements
Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Collected Perspectives in Cancer Research
Recent Deaths
Calendar of Events

- 212 Errata
K. A. Foon, *JGIM* 49: 1621-1639, 1989.
R. Larson and P. Cerutti, *JGIM* 49: 5627-5632, 1989.

- 213 Instructions for Authors

- 219 Author Index

- *284 Synergistic Interactions between Cyclophosphamide or Melphalan and VP-16 in a Human Rhabdomyosarcoma Xenograft. Eileen R. Liley, Mindy C. Rosenberg, Gertrude B. Elion, O. Michael Colvin, Darel D. Bigner, and Henry S. Friedman.

- *288 Inhibition of Human Tumor Growth by Intraperitoneal Immunotoxin in Nude Mice. Alexander Marks, David Etteman, Michael J. Bjorn, Melanie Lei, and Reuben Baumal.

- *293 Growth-regulated Surface Glycoprotein of Human Bladder Cancer. Johanne Gauthier and Yves Fradet.

- *299 Differential Regulation of Expression of Three Transforming Growth Factor β Species in Human Breast Cancer Cell Lines by Estradiol. Bradley A. Arnick, Murray Kotz, and Rik Deryck.

- *304 Reduced DNA Topoisomerase II Activity and Drug-induced DNA Cleavage Activity in an Adriamycin-resistant Human Small Cell Lung Carcinoma Cell Line. Steven de Jong, Jan G. Zijlstra, Elisabeth G. de Vries, and Nanno H. Mulder.

- 310 Activities of Newly Synthesized Dihydropyrimidines in Overcoming of Vinristine Resistance, Calcein Antagonism, and Inhibition of Photoaffinity Labeling of P-Glycoprotein in Rodents. Akira Kiuchi, Tetsuro Sano, Ken-ichi Suzuki, Haruki Inada, Masaya Okumura, Junko Kikuchi, Shin-ichi Sato, Kimitoshi Kohno, and Michio Kubano.

- *310 N-(4-Indanoyl)-N'-4-chlorophenylurea, a Novel Agent Equally Cytotoxic to Nonproliferating Human Colon Adenocarcinoma Cells. Peter J. Houghton, Frank C. Bailey, Glen S. Germain, Gerald B. Grindey, Bryant C. Witt, and Janet A. Houghton.

CONTENTS OF VOLUME 50

- *323 Alterations in Glycosylation and Lectin Pattern during Phorbol Ester-induced Differentiation of U937 Cells. R. Hass, L. Kohler, W. Rehfeldt, V. Leibmann, W. Muller, K. Resch, and M. Goppelt-Strube.
- 328 Prevention of Hematotoxic Side Effects of Cytostatic Drugs in Mice by a Synthetic Hemopoietic Peptide. W. R. Paukovits, M. Guigon, K. A. Binder, A. Hergl, O. D. Laerum, and R. Schulte-Hermann.
- *333 Characterization of the Estrogen Receptor in Two Antiestrogen-resistant Cell Lines, LY2 and T47D. Alaka Mullick and Pierre Chamberon.
- 339 Modulation of Gene Expression following Ionizing Radiation. Gayle E. Woloschak, Chin-Mei Chang-Liu, Pocahontas Shearin Jones, and Carol A. Jones.
- *345 Tumor Growth Inhibitory Activity of a Lymphocyte Blastogenesis Inhibitory Factor. Kazuhisa Sugimura, Takeshi Ohno, Shigebaru Fukuda, Yumiko Wada, Tatsuki Kimura, and Ichiro Azuma.
- *350 Identification of an *M*, 70,000 Antigen Associated with Reed-Sternberg Cells and Interdigitating Reticulum Cells. Pei-Ling Hu and Su-Ming Hsu.
- 358 Ultrastructural Differences in Junctional Intercellular Communication between Highly and Weakly Metastatic Clones Derived from Rat Mammary Carcinoma. Jin Ren, Jun-ichi Hamada, Noritoshi Takeichi, Seizo Fujikawa, and Hiroshi Kobayashi.
- 363 Deuterium Nuclear Magnetic Resonance Imaging of Tracer Distribution in D_2O Clearance Measurements of Tumor Blood Flow in Mice. Jacqueline B. Larcombe McDouall and Jeffrey L. Evelhoch.
- 370 Low Levels of Chromosomal Mutations in Germ Cells Derived from Doxorubicin-treated Stem Spermatogonia in the Mouse. Marvin L. Meistrich, Maria E. A. van Beek, Jan C. Liang, Susan L. Johnson, and John L. Johnson.
- *375 Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats. Robert J. Debs, Henry J. Fuchs, Ramila Philip, Elsa N. Brunetti, Nejat Duzgunes, Judd E. Shelloo, Denny Liggitt, and John R. Panton.
- Review**
- 451 Steroid/Thyroid Receptor-like Proteins with Oncogenic Potential: A Review. Mels Sluyser.
- *459 *In Vitro* and *In Vivo* Cytotoxicity of Rhodamine 123 Combined with Hyperthermia. Willie H. Goffney, Jian H. Wong, David H. Kern, David Chase, David N. Krag, and F. Kristian Storn.
- 464 Biotransformation of *N,N,N'*-Triethylbenzophenonephosphamide: Oxidative Desulfurization to Yield *N,N,N'*-Triethylbenzene-phosphamide Associated with Suicide Inactivation of a Phenoxbarbital-inducible Hepatic P-450 Monooxygenase. Sze-fong Ng and David J. Waxman.
- 472 Quantitative Stereological Analysis of the Effects of Age and Sex on Multistage Hepatocarcinogenesis in the Rat by Use of Four Cytochemical Marker. Yi-hua Xu, Harold A. Campbell, Gerald L. Sandler, Suzanne Hendrick, Robert Maronpot, Kiyoma Sato, and Henry C. Piot.
- *480 Glycine to Aspartic Acid Mutations at Codon 13 of the *c-Ki-ras* Gene in Human Gastrointestinal Cancers. Yasuhiro Nagata, Masumi Abe, Kohmei Kobayashi, Kuniko Yoshida, Tsunehisa Ishibashi, Tomoki Naoe, Eiichi Nakayama, and Hiroshi Shitai.
- *483 Low Density Lipoprotein Receptor Activity in Human Intracranial Tumors and Its Relation to the Cholesterol Requirement. Mats J. Rudling, Bo Angelin, Curt O. Peterson, and V. Peter Collins.
- *488 Studies on the Pathogenesis of Choriocarcinoma by Analysis of Restriction Fragment Length Polymorphisms. Chiharu Azuma, Fumitaka Saji, Toshiatsu Nobunaga, Shiro Kamura, Tadashi Kimura, Yoshihiro Tokugawa, Masayasu Koizumi, and Osamu Tanizawa.
- *492 Generation of Human Autologous Melanoma-specific Cytotoxic T-Cells Using HLA-B2-matched Allogeneic Melanomas. Nancy J. Crowley, Craig L. Slingsby, Jr., Timothy L. Darrouzet, and Hilliard F. Siegler.
- 499 Inhibitory Effect of Apigenin, a Plant Flavonoid, on Epidermal Ornithine Decarboxylase and Skin Tumor Promotion in Mice. Huachen Wei, Laura Tye, Edward Bresnick, and Diane F. Birt.
- 503 Disposition of Amsacrine and Its Analogue 9-(2-Methoxy-4-(methylsulfonyl)phenyl)amino)-N,5-dimethyl-4-acridinecarboxamide (C1921) in Plasma, Liver, and Lewis Lung Tumors in Mice. Philip Kestell, James W. Paxton, Pandora C. Evans, Deborah Young, Jeffrey L. Jurina, Ian G. C. Roberson, and Bruce C. Baguley.
- *509 Retrospective Analysis of the Prognostic Significance of DNA Ploidy Patterns and S-Phase Fraction in Gastric Carcinoma. Yutaka Yonemura, Shigekazu Oyama, Kanzo Sugiyama, Toru Kamata, Xabier De Arribalza, Hironobu Kimura, Takeo Kosaka, Akio Yamaguchi, Kouichi Miwa, and Isuo Miyazaki.
- 381 Effect of Flurbiprofen and 16,16-Dimethyl Prostaglandin E₂ on Gastrointestinal Tumorigenesis Induced by *N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine in Rats. Colorectal Epithelium of Stomach and Duodenum. Thomas Lehner, Eleanor E. Deschner, Kasimati A. Karmani, and Jerome J. DeCosse.
- *385 Plasma Membrane Perturbation of KB Cells Induced by the Bleomycin-In Complex. C. Baully, J. C. Beauvillain, J. L. Bernier, and J. P. Hénichart.
- *393 Characterization of Micronuclei Induced in Human Lymphocytes by Benzene Metabolites. Janice W. Yager, David A. Eastmond, More L. Robertson, William M. Paradise, and Martyn T. Smith.
- 400 Induction of Pituitary Tumors in Germ-free Rats Exposed to *Aspergillus versicolor*. Yukiko Sumi, Hiroshi Nagura, and Masasumi Miyakawa.
- *403 Sensitization of Multidrug-resistant Mouse Ascites HD33 and Chinese Hamster Ovary CHPCS3 Cells by a Photoreactive Vinblastine Derivative, NAPAVIN. Georgios Nikolaus, Christof Granzow, Michael Stohr, and Herwig Ponstingl.
- 409 Identification of B16-F1 Melanoma Autocrine Motility-like Factor Receptor. Ivan R. Nabu, Hideomi Watanabe, and Avraham Raz.
- *415 Inhibition of Estrogen-dependent Breast Cancer Growth by a Reaction Product of α -Fetoprotein and Estradiol. Herbert I. Jacobson, James A. Bennett, and Gerald J. Mizejewski.
- *421 Expression of the *aer* Gene-encoded Protein (P185^{wt}) in Human Non-Small Cell Carcinomas of the Lung. David B. Weiner, Joanne Nordberg, Robert Robinson, Peter C. Nowell, Adi Gardner, Mark I. Greene, William V. Williams, Jeffrey A. Cohen, and Jeffrey A. Kern.
- CLINICAL AND EPIDEMIOLOGICAL INVESTIGATIONS**
- 426 *Meat* Drinking, Alcohol, Tobacco, Diet, and Esophageal Cancer in Uruguay. Eduardo De Stefani, Nubia Muñoz, Jacques Esteve, Alberto Vassallo, Cesar G. Victoria, and Silviane Teuchmann.
- Cancer Progression in Urinary Bladder Tumors Evaluated by Multiparameter Flow Cytometry with Monoclonal Antibodies. Yves Fradet, Marc Tardif, Lucie Bourget, Jean Robert, and the Laval University Urology Group.**
- *438 Presence of Villin, a Tissue-specific Cytoskeletal Protein, in Sera of Patients and an Initial Clinical Evaluation of Its Value for the Diagnosis and Follow-up of Colorectal Cancers. B. Didouet, L. Jacob, P. Beuzeboc, H. Magdelenat, S. Robine, Y. Chapuis, B. Christoforov, G. A. Cremer, P. Pouillard, P. Bonnichon, F. Pinon, R. J. Salmon, A. Pointreau-Bellanger, J. Bellanger, M. T. Maunoury, and D. Louvard.
- 444 Association of Adenocarcinoma of the Lung with Cigarette Smoking by Grade of Differentiation and Subtype. Takaiichiro Suzuki, Tomotaka Sobue, Isaburo Fujimoto, Otsuru Doi, and Ryueki Tateishi.
- * * *
- 448 Special Announcement
New Deadline for Submission of Applications for Active and Corresponding Membership in the American Association for Cancer Research
- 449 Announcements
Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Collected Perspectives in Cancer Research
- 450 Author Index

February 1, Number 3

- 515 Differential Expression of a *M*, ~90,000 Cell Surface Transferrin Receptor-related Glycoprotein on Murine B16 Metastatic Melanoma Sublines Selected for Enhanced Brain or Ovary Colonization. Garth L. Nicolson, Tatsuhito Inoue, Carolyn S. Van Pelt, and Philip G. Cavanaugh.
- *521 Comparisons between Sensitive and Resistant Human Tumor Cell Lines Regarding Effects of Polyamine Depletion on Chloroethynitrosoureas Efficacy. Jerome Steinfeld and Wendy S. Sprague.
- *527 ³¹P Magnetic Resonance Spectroscopy of Human Colon Cancer. John N. Kaszas, Thomas E. Merchant, Louis W. Gierke, and Thomas Glonek.
- *533 Regulation of the Epidermal Growth Factor Receptor by Growth-modulating Agents: Effects of Staurosporine, a Protein Kinase Inhibitor. Bethann Friedman, Hirota Fujiki, and Martha Rich Rosner.
- 539 Systemic Toxicity in Mice Induced by Localized Porphyrotherapy. Angela Ferraro and Charles J. Gomer.
- *544 Effects of 2-Diazoxycine on Drug-sensitive and Drug-resistant Human Breast Cancer Cell Toxicity and Magnetic Resonance Spectroscopy Studies of Metabolism. Ofer Kaplan, Gil Navon, Robbie C. Lyon, Patrick J. Faustino, Eric J. Straka, and Jack S. Cohen.
- *552 Regulation of the Cytidine Phospholipid Pathways in Human Cancer Cells and Effects of 1,3-D-Arabinofuranosylcytosine: A Noninvasive ³¹P Nuclear Magnetic Resonance Study. Peter F. Daly, Gerhard Zugmaier, David Sandier, Mary Carter, C. E. Myers, and J. S. Cohen.
- *558 Induction of Chromosome Breaks and Sister Chromatid Exchanges in Patients with Hodgkin's Disease by Two Combination Chemotherapy Regimens of Different Leukemogenetic Potential. Pramila Sen, Nell M. Bailey, Fredrick B. Hagemeyer, and Jan C. Liang.
- *563 Clearance of ¹³¹I-labeled Marine Monoclonal Antibody from Patients' Blood by Intravenous Human Anti-Murine Immunoglobulin Antibody. J. Simon W. Stewart, Gregory B. Sivolepenko, Victoria Hird, Kevin A. Davies, Mark Walport, Mary A. Ritter, and Agamemnon A. Epenoter.
- 568 Protection of Spermatogenesis in Rats from the Cytotoxic Procarbazine by the Depot Formulation of Zoledar, a Gonadotropin-releasing Hormone Agonist. Jerry Ann Ward, Janet Robinson, Barrington J. A. Furr, Stephen M. Shalet, and Ian D. Morris.
- 575 Liposomal Vinristine Preparations Which Exhibit Decreased Drug Toxicity and Increased Activity against Marine L1210 and P388 Tumors. Lawrence D. Mayer, Marcel B. Bally, Helen Lougheed, Dana Mason, and Pieter R. Cullis.
- 580 Suppression of Dimethylhydrazine-induced Carcinogenesis in Mice by Dietary Addition of the Bowman-Birk Protease Inhibitor. William H. St. Clair, Paul C. Billings, Josephine A. Carew, Christine Keller-McGandy, Paul Newberne, and Ann R. Kennedy.
- *587 Reduction to Homozygosity and Gene Amplification in Central Nervous System Primitive Neuroectodermal Tumors of Childhood. Corey Raffel, Floyd E. Giles, and Kenneth I. Weinberg.
- *592 Tumor Necrosis Factor in Children with Malignancies. Ulta M. Saarinen, Eeva-Kaarina Koekko, Anna-Maja Teppo, and Martti A. Simes.
- *596 Decreased Susceptibility of Lined Human Glososarcoma Cells to Lymphokine-activated Killer Cell Cytotoxicity by γ -Interferon Treatment. Shin-ichi Miyatake, Haruhiko Kikuchi, Yoshihumi Oda, Tatsuya Nishioka, Jun Takahashi, Seiji Kondoh, Masato Matsumoto, Toshiki Yamasaki, Koh-ichi Iwasaki, Tomokazu Aoki, Shinpei Kasakura, and Yuzuru Nambu.
- 601 Effect of Cellular Density and Viral Oncogenes on the Major Histocompatibility Complex Class I Antigen Response to γ -Interferon in BALB/c/3T3 Cells. Margaret K. Offermann and Douglas V. Falter.
- *606 Phase I Study of Intravenously Administered Bacterially Synthesized Granulocyte-Macrophage Colony-stimulating Factor and Comparison with Subcutaneous Administration. Graham J. Lipschitz, Darryl Maher, Marian O'Connor, Michael Green, William Sheridan, Michael Rallings, Eric Bonnen, Antony W. Burgess, Katherine McGrath, Richard M. Fox, and George Myerson.
- *615 Species Susceptibility to Aflatoxin B₁ Carcinogenesis: Comparative Kinetics of Microsomal Biotransformation. Howard S. Ramsdell and David L. Eaton.
- *621 Decreased Expression of Type II Protein Kinase C in HL-60 Variant Cells Resistant to Induction of Cell Differentiation by Phorbol Diester. Masakatsu Nishikawa, Fumihiko Komada, Yasuhiro Uemura, Hiroyoshi Hida, and Shigenobu Shirakawa.
- *627 A Prospective Study of Stomach Cancer and Its Relation to Diet, Cigarettes, and Alcohol Consumption. Abraham Nomura, John S. Grove, Grant N. Stemmermann, and Richard K. Severson.
- *632 Evidence for Deficiency of Low Density Lipoprotein Receptor on Human Colonic Carcinoma Cell Lines. Michele Fabriant and Selwyn A. Broitman.
- *637 Hypersensitivity of Skin Fibroblasts from Basal Cell Nevus Syndrome Patients to Killing by Ultraviolet B but not by Ultraviolet C Radiation. Lee A. Applegate, Leonard H. Goldberg, Ronald D. Ley, and Honnavara N. Ananthaswamy.
- *642 A *M*, 43,000 Epidermal Growth Factor-related Protein Purified from the Urine of Breast Cancer Patients. Klaus Eckert, Andreas Granetzny, Joerg Fischer, Ebba Nexo, and Richard Grossé.
- *648 DNA Interstrand Cross-Link and Free Radical Formation in a Human Multidrug-resistant Cell Line from Mitoxantrone C and Its Analogs. Lata Dusre, Sankaran Rajagopalan, Helen M. Eliot, Joseph M. Covey, and Bindra K. Sinha.

CONTENTS OF VOLUME 50

- #653 Sensitivity of Subpopulations of Mouse Skin Papillomas to Malignant Conversion by Urethane or 4-Nitroquinoline N-Oxide.** Henry Hennings, Robert Shores, Michael Balashak, and Stuart H. Yuspa.
- #658 Characterization of a Cathepsin L-like Enzyme Secreted from Human Pancreatic Cancer Cell Line HPC-XP.** Nozomi Yamaguchi, Sung min Chung, Osumi Shirane, Kunihiko Koyama, and Jiro Imanishi.
- #664 Evidence for Mitochondrial Localization of *N*-*(4-Methylphenylsulfonyl)-N'*-*(4-chlorophenyl)urea* in Human Colon Adenocarcinoma Cells.** Peter J. Houghton, Frank C. Bailey, Janet A. Houghton, K. Gopal Murti, J. Jeffry Howbert, and Gerald B. Grindley.
- #669 Prenostane Proliferator-induced Alterations in the Expression and Modification of Rat Hepatocyte Plasma Membrane Proteins.** James R. Barnes, Satya Khurana, Xunhui Lin, Lijun Zhang, Jansardan K. Reddy, M. Sambasiva Rao, Steven T. Isay, Cheryl L. Nehme, and Barbara E. Fayos.
- #677 Inhibition of Rodent Protein Kinase C by the Anticarcinoma Agent Dequalinium.** Susan A. Rotenberg, Stephen Smiley, Marius Ueffing, Robert S. Krauss, Lan Bo Chen, and I. Bernard Weinstein.
- *#686 Induction by Transforming Growth Factor β of Pemphigus Vulgaris Antigen Activity in Mouse Papilloma Cells.** Molly Kulesz-Martin, Ingrid Glurich, Barbara Lisfeld, and Paul Kozlowski.
- #691 Induction of Dorsal-epididymal Prostate Adenocarcinomas and Other Adenocarcinomas in Sprague-Dawley Rats by Chronic Administration of *N*-Methyl-*N*-nitrosamine, 7,12-Dimethylbenz(a)anthracene, and 3,2'-Dimethyl-4-aminobiphenyl after Sequential Treatment with Cyproterone Acetate and Testosterone Propionate.** Maarten C. Boland and Menk K. Prinsen.
- 700 Characterization of Adenocarcinomas of the Dorsal-epididymal Prostate Induced in Wistar Rats by *N*-Methyl-*N*-nitrosamine, 7,12-Dimethylbenz(a)anthracene, and 3,2'-Dimethyl-4-aminobiphenyl, following Sequential Treatment with Cyproterone Acetate and Testosterone Propionate.** Maarten C. Boland, Menk K. Prinsen, Theo J. M. Dirksen, and Ben J. Spit.
- *710 Development of Polyplodization in Taxol-resistant Human Leukemia Cells *In Vitro*.** John R. Roberts, David C. Allison, Ross C. Donchow, and Eric Rowinsky.
- *717 Tumorigenicity and Metastasis of Human Breast Carcinoma Cell Lines in Nude Mice.** Jane E. Price, Aristidis Polyzos, Ruofan Zhang, and Lisa M. Daniels.
- *722 Modulation of Intracellular Cyclic Adenosine Monophosphate Levels and the Differentiation Response of Human Neuroblastoma Cells.** Matthew Lando, Elliot Abramson, M. Anthony Verity, and Neil Sidell.
- 728 Analysis of Integrin Receptors for Laminin and Type IV Collagen on Metastatic B16 Melanoma Cells.** Daniel M. Ramos, Emanuel D. Berston, and Randall H. Kramer.
- 735 Expression and Localization of Androgen Receptor in the P-3327 Dunning Rat Prostatic Adenocarcinoma.** Valerie E. Quarmby, William C. Beckman, Jr., David B. Cooke, Dennis B. Lubahn, David R. Joseph, Elizabeth M. Wilson, and Frank S. French.
- 740 Nonrandom Chromosome Alterations That Correlate with Progression to Immortality in Rat Tracheal Epithelial Cells Transformed with *N*-Methyl-*N*-nitro-*N*-nitrosoguanidine.** Sumiyoshi Endo, Paul Netesheim, Mitsuo Oshimura, and Cheryl Walker.
- *748 Expression of Platelet-derived Growth Factor β -Receptors on Stromal Tissue Cells in Human Carcinoid Tumors.** Keiko Funa, Vasili Papapoulos, Claes Juhlin, Jonas Rastad, Goran Åkerblom, Carl-Henrik Heldin, and Kjell Oberg.
- *754 Cancer-associated Galactosyltransferase as a New Tumor Marker for Ovarian Clear Cell Carcinoma.** Shiro Nozawa, Masazumi Yajima, Tatsuji Sakuma, Yasuhiro Udagawa, Kazuhisa Kiguchi, Motoko Sakayori, Sonoko Narisawa, Rihachi Iizuka, and Morio Uemura.
- 760 Karyotypic Changes with Neoplastic Conversion in Morphologically Transformed Golden Hamster Embryo Cells Induced by X-Rays.** Masugi Watanabe, Keiji Suzuki, and Seiji Kodama.
-
- Meeting Report**
- 766 U. S.-Japan Cooperative Cancer Research Program Conference: Fundamental and Clinical Aspects of Pancreatic Cancer.** Dante G. Scarpelli and Yoichi Konishi.
- 770 Special Announcement**
- New Deadlines for Submission of Applications for Active and Corresponding Membership in the American Association for Cancer Research
- 770 Announcements**
- Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Collected Perspectives in Cancer Research
Calendar of Events
- 772 Author Index**

February 1, Number 3, Supplement

PROGRAM PLANNING COMMITTEE

William C. Eckelman
David M. Goldenberg (*Chairman*)
Edgar Haber
Thomas Hoffman
Steven M. Larson
Stanley E. Order
Howard Sands
Mette Strand

PROGRAM

Introduction to the Second Conference on Radioimmunodetection and Radioimmunotherapy of Cancer.
David M. Goldenberg

778s

SESSION I

Radiochemistry of Antibodies

Chairperson: William C. Eckelman

Development of Radiochemically Pure Antibodies.	780s
<i>W. C. Eckelman</i>	
Improving the Tumor Retention of Radioiodinated Antibody: Aryl Carbohydrate Adducts.	783s
<i>Seham A. Ali, Stephen D. Warren, Karen Y. Richter, Christopher C. Badger, Janet F. Eary, Oliver W. Press, Kenneth A. Krohn, Irwin D. Bernstein, and Wil B. Nelp</i>	
Stable Bifunctional Chelates of Metals Used in Radiotherapy.	789s
<i>Min K. Moi, Sally J. DeNardo, and Claude F. Meares</i>	
Preliminary Evaluation of an "Instant" 99m Tc-labeling Kit for Antibody Imaging.	794s
<i>Hans J. Hansen, Anastasia L. Jones, Robert M. Sharkey, Ruth Grebenau, Nancy Blazejewski, Arthur Kunz, Michael J. Buckley, Edward S. Newman, Frank Ostella, and David M. Goldenberg</i>	
99m Tc Labeling of Proteins: Initial Evaluation of a Novel Diaminedothiol Bifunctional Chelating Agent.	799s
<i>Kwamena E. Baidoo, Ursula Scheffel, and Susan Z. Lever</i>	
Disulfide Bond-targeted Radiolabeling: Tumor Specificity of a Streptavidin-biotinylated Monoclonal Antibody Complex.	804s
<i>Renato B. del Rosario and Richard L. Wahl</i>	

SESSION II

Experimental Studies of Radioimmunodetection

Chairpersons: Howard Sands and Jeffrey Schlom

Experimental Studies of Radioimmunodetection of Cancer: An Overview.	809s
<i>Howard Sands</i>	
Physiological Barriers to Delivery of Monoclonal Antibodies and Other Macromolecules in Tumors.	814s
<i>Rakesh K. Jain</i>	
Innovations That Influence the Pharmacology of Monoclonal Antibody Guided Tumor Targeting.	820s
<i>Jeffrey Schlom, Patricia Horan Hand, John W. Greiner, David Colcher, Shashi Shrivastav, Jorge A. Carrasquillo, James C. Reynolds, Steven M. Larson, and Andrew Burditschek</i>	
Comparison of Tumor Targeting in Nude Mice by Murine Monoclonal Antibodies Directed against Different Human Colorectal Cancer Antigens.	828s
<i>Robert M. Sharkey, David V. Gold, Rosario Annipoti, Rae Vagg, Cathy Ballance, Edward S. Newman, Frank Ostella, Hans J. Hansen, and David M. Goldenberg</i>	
Pharmacokinetics of 99m Tc-Metallothionein-B7.2 and its F(ab') ₂ Fragment.	835s
<i>Beverly A. Brown, Cynthia B. Dearborn, Cynthia A. Drozynski, and Howard Sands</i>	
Mechanisms of Tissue Uptake and Metabolism of Radiolabeled Antibody—Role of Antigen:Antibody Complex Formation.	840s
<i>J. David Beatty, Barbara G. Beatty, Margaret O'Conor-Tressel, Tulan Do, and Raymond J. Paxton</i>	

CONTENTS OF VOLUME 50

Mechanism of Decreasing Liver Uptake of ^{111}In -labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody by Specific Antibody Pretreatment in Tumor Bearing Mice <i>Barbara G. Beatty, Margaret O'Conor-Tressel, Tulan Do, Raymond J. Paxton, and J. David Beatty</i>	846s
Uptake and Metabolism of ^{111}In -labeled Monoclonal Antibody B6.2 by the Rat Liver <i>Peter L. Jones, Beverly A. Brown, and Howard Sands</i>	852s
Site-specifically Radioiodinated Antibody for Targeting Tumors. <i>Douglas W. Rea, Michael E. Ultee, Benjamin A. Belinku, Jr., Daniel J. Coughlin, and Vernon L. Alvarez</i>	857s
Radiolocalization of Monoclonal Antibodies in Hepatic Metastases from Human Colon Cancer in Congenitally Athymic Mice. <i>Kazuhiko Yoshida, Michel Rivoire, Chaitanya Diggi, Sydney Welt, Alfred M. Cohen, and Elin R. Sigurdson</i>	862s
Monoclonal Antibody Targeting of Human Non-Small Cell Carcinoma of the Lung. <i>Rhona Stein, Robert M. Sharkey, and David M. Goldenberg</i>	866s
Carcinoembryonic Antigen and α -Fetoprotein Expression and Monoclonal Antibody Targeting in a Human Hepatoma/Nude Mouse Model. <i>Zhifa F. Wang, Rhona Stein, Robert M. Sharkey, and David M. Goldenberg</i>	869s
Comparative Pharmacokinetics of a Murine Monoclonal Antibody to a Rat Colon Tumor in Rats and Nude Mice. <i>Jorge Laborda, Jean-Yves Douillard, Elaine F. Lizzio, and Thomas Hoffman</i>	873s
Radioimmunodetection of Hepatic Metastases from Human Colon Cancer in Nude Mice with a Gamma-detecting Probe. <i>Michel Rivoire, Kazuhiko Yoshida, Chaitanya Diggi, Sydney Welt, Alfred Cohen, and Elin R. Sigurdson</i>	877s
Patterns of Antigen Distribution in Human Carcinomas. <i>M. Jules Matthes, Pierre P. Major, David M. Goldenberg, Arnold S. Dion, Robert V. P. Hutter, and Kenneth M. Klein</i>	880s
Use of Whole-Body Autoradiography in Cancer Targeting with Radiolabeled Antibodies. <i>Irwin Fand, Robert M. Sharkey, and David M. Goldenberg</i>	885s

SESSION III

Clinical Studies of Radioimmunodetection

Chairpersons: Steven M. Larson and Abass Alavi

Clinical Radioimmunodetection, 1978-1988: Overview and Suggestions for Standardization of Clinical Trials. <i>Steven M. Larson</i>	892s
Tumor Immunoscintigraphy by Means of Radiolabeled Monoclonal Antibodies: Multicenter Studies of the Italian National Research Council—Special Project “Biomedical Engineering”. <i>Antonio G. Siccaldi</i>	899s
Radioimaging of Melanoma Using ^{99m}Tc -labeled Fab Fragment Reactive with a High Molecular Weight Melanoma Antigen. <i>Lamk M. Lamki, Alexander A. Zukowski, L. Joy Shranken, Sawa S. Legha, Robert S. Benjamin, Carl E. Plager, Darrell F. Salk, Robert W. Schroff, and James L. Murray</i>	904s
Clinical Studies of Cancer Radioimmunodetection with Carcinoembryonic Antigen Monoclonal Antibody Fragments Labeled with ^{131}I or ^{99m}Tc . <i>David M. Goldenberg, Hildegard Goldenberg, Robert M. Sharkey, Edith Higginbotham-Ford, Robert E. Lee, Lawrence C. Swaine, Karen A. Burger, Diane Tsai, Jo Ann Horowitz, Thomas C. Hall, Carl M. Pinsky, and Hans J. Hansen</i>	909s
Presurgical Imaging with Indium-labeled Anti-Carcinoembryonic Antigen for Colon Cancer Staging. <i>J. David Beatty, Lawrence E. Williams, David Yamauchi, Blaine A. Morton, L. Robert Hill, Barbara G. Beatty, Raymond J. Paxton, Bruce Merchant, and John E. Shively</i>	922s
Breast Tumor Radioimmunodetection with a ^{111}In -labeled Monoclonal Antibody (MAS) against a Mucin-like Antigen. <i>Pierre P. Major, Arnold S. Dion, Charlene J. Williams, M. Jules Matthes, Taqui Wang, and Leonard Rosenthal</i>	927s
Human Biodistribution of ^{111}In -labeled BT2.3 Monoclonal Antibody. <i>Steven J. Harwood, Robert G. Carroll, William B. Webster, Linda M. Zangara, David L. Laven, Michele A. Morrissey, and Barbara J. Sinner</i>	932s
Immunophosphoscopy and Immunoscintigraphy of Ovarian and Fallopian Tube Cancer Using Fab'_2 Fragments of Monoclonal Antibody OC 125. <i>Pentti Lehtovirta, Kalevi J. A. Kairemo, Kristian Liewendahl, and Markku Seppälä</i>	937s
Lymphoscintigraphy in Melanoma: Initial Evaluation of a Low Protein Dose Monoclonal Antibody Cocktail. <i>Richard L. Wahl, Monica Liebert, John Headington, Barry S. Wilson, Barry L. Shulkin, Jon L. Johnson, Shirley Mallette, Ronald B. Natale, William Coon, Mary East, Robertson V. Venable, M. B. Brown, John T. Niederhuber, and Neil A. Swanson</i>	941s
Immunophosphoscopy and Immunoscintigraphy of Ovarian and Fallopian Tube Cancer Using Fab'_2 Fragments of Monoclonal Antibody OC 125. <i>Kalevi J. A. Kairemo</i>	949s
Radioimmunodetection in Rhabdo- and Leiomyosarcoma with ^{111}In -Anti-Myosin Monoclonal Antibody Complex. <i>André Planting, Jaap Verweij, Peter Cox, Mike Pillay, and Gerrit Stoter</i>	955s
Detection of Thrombophlebitis with ^{111}In -labeled Anti-Fibrin Antibody: Preliminary Results. <i>Abass Alavi, Naresh Gupta, Harold I. Palevsky, Mark A. Kelley, Allison D. Jallow, Ann A. Byar, and Harvey J. Berger</i>	958s

SESSION IV

Prospects for Therapy, I: Experimental

Chairperson: Mette Strand

Radioimmunotherapy in Experimental Animal Models: Principles Derived from Models. <i>David A. Scheinberg and Mette Strand</i>	962s
Biological Considerations for Radioimmunotherapy. <i>Robert M. Sharkey, Rosalyn D. Blumenthal, Hans J. Hansen, and David M. Goldenberg</i>	964s
Current Status of Animal Radioimmunotherapy. <i>Barry W. Wessels</i>	970s
Targeting and Therapy of Human Glioma Xenografts <i>In Vivo</i> Utilizing Radiolabeled Antibodies. <i>Jeffery A. Williams, Barry W. Wessels, James A. Edwards, Kenneth A. Kopfer, Philip M. Wanek, Moody D. Wharam, Stanley E. Order, and Jerry L. Klein</i>	974s
Imaging and Therapy of Small Cell Carcinoma Xenografts Using ^{111}In -labeled Monoclonal Antibody SWA11. <i>Alan Smith, Peter Groscurth, Robert Waisel, Gerrit Westera, and Rolf A. Stahel</i>	980s
Radioimmunotherapy of Peritoneal Human Colon Cancer Xenografts with Site-specifically Modified ^{212}Bi -labeled Antibody. <i>R. Bruce Simonson, Michael E. Ultee, Jo A. Hauer, and Vernon L. Alvarez</i>	985s
Radioimmunotherapy of Human Colon Carcinomatosis Xenograft with ^{90}Y -ZCE025 Monoclonal Antibody: Toxicity and Tumor Phenotype Studies. <i>Jose M. Esteban, David M. Hyams, Barbara G. Beatty, Bruce Merchant, and J. David Beatty</i>	989s
Comparative Binding and Preclinical Localization and Therapy Studies with Radiolabeled Human Chimeric and Murine 17-IA Monoclonal Antibodies. <i>Donald J. Buchsbaum, Pamela G. Brubaker, David E. Hanna, Arthur A. Glafelter, Valeri H. Terry, Dianne M. Guillebaud, and Zenon Stepienski</i>	993s
Tumor Spheroid Model for the Biologically Targeted Radiotherapy of Neuroblastoma Micrometastases. <i>K. A. Walker, R. Mairs, T. Murray, T. E. Hilditch, T. E. Wheldon, A. Gregor, and I. M. Hann</i>	1000s
Use of Hematopoietic Growth Factors to Control Myelosuppression Caused by Radioimmunotherapy. <i>R. D. Blumenthal, R. M. Sharkey, L. M. Quinn, and D. M. Goldenberg</i>	1003s
Role of Bone Marrow Transplantation in ^{90}Y Antibody Therapy of Colon Cancer Xenografts in Nude Mice. <i>Blaine A. Morton, Barbara G. Beatty, Angeles P. Mison, Philip M. Wanek, and J. David Beatty</i>	1008s

CONTENTS OF VOLUME 50

SESSION V

Prospects for Therapy, II: Clinical

Chairperson: Stanley E. Order

Radiolabeled Antibodies: Results and Potential in Cancer Therapy. <i>S. E. Order, A. M. Sleper, G. B. Stillwagon, J. L. Klein, and P. K. Leichner</i>	1011s
Fractionated Radioimmunotherapy of B-Cell Malignancies with ^{111}I -Lym-1. <i>Gerald L. DeNardo, Sally J. DeNardo, Lois F. O'Grady, Norman B. Levy, Gregory P. Adams, and Stanley E. Mills</i>	1014s
High Dose Radiolabeled Antibody Therapy of Lymphoma. <i>Irvin D. Bernstein, Janet E. Earp, Christopher C. Badger, Oliver W. Press, Frederick R. Appelbaum, Paul J. Martin, Kenneth A. Krohn, William B. Neip, Bruce Porter, Darrell Fisher, Richard Miller, Sherrie Brown, Ronald Levy, and E. Donnall Thomas</i>	1017s
Radioimmunotherapy of Human B-Cell Lymphoma with ^{90}Y -conjugated Antidiotype Monoclonal Antibody. <i>Barbara A. Parker, Artenisio B. Vassos, Samuel E. Haiper, Richard A. Miller, Homer Huf, Diane G. Amos, Joseph I. Simoni, Robin J. Starr, Mark R. Green, and Ivor Royston</i>	1022s
Estimation of Monoclonal Antibody-associated ^{90}Y Activity Needed to Achieve Certain Tumor Radiation Doses in Colorectal Cancer Patients. <i>Lawrence E. Williams, Barbara G. Beatty, J. David Beatty, Jeffrey Y. C. Wong, Raymond J. Paxton, and John E. Shively</i>	1029s
Intrapерitoneal Immunoconjugates. <i>Thomas W. Griffin, Jeffrey Collins, Faran Bokhari, Mark Stochi, A. Bertrand Brill, Tsunao Ito, George E. Emond, and Howard Sands</i>	1031s
Tumor, Red Marrow, and Organ Dosimetry for ^{111}In -labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody. <i>Jeffry A. Siegel, David A. Pawlyk, Robert E. Lee, Norma L. Sasso, Jo Ann Horowitz, Robert M. Sharkey, and David M. Goldenberg</i>	1039s
Dosimetric Model for Antibody Targeted Radionuclide Therapy of Tumor Cells in Cerebrospinal Fluid. <i>W. T. Millar and A. Barrett</i>	1043s

SESSION VI

Host Responses and Complications

Chairperson: Thomas Hoffman

Anticipating, Recognizing, and Preventing Hazards Associated with <i>in Vivo</i> Use of Monoclonal Antibodies: Special Considerations Related to Human Anti-Mouse Antibodies. <i>Thomas Hoffman</i>	1049s
Immunoglobulin Class and Immunoglobulin G Subclass Analysis of Human Anti-Mouse Antibody Response during Monoclonal Antibody Treatment of Cancer Patients. <i>Heiner M. Blotiere, J. Y. Dell'Orto, H. Koprowski, and Z. Steplewski</i>	1051s
Human Immune Response to Anti-Carcinoembryonic Antigen Murine Monoclonal Antibodies. <i>Michele J. Losman, Robert L. DeJager, Marc Monesier, Robert M. Sharkey, and David M. Goldenberg</i>	1055s
Author Index	1059s

February 15, Number 4

Perspectives in Cancer Research

- 1061 Boron Neutron Capture Therapy of Cancer. Rolf F. Barth, Albert H. Soloway, and Ralph G. Fairchild.

- *1071 Protection from Carcinogen-induced Murine Bladder Carcinoma by Interferons and an Oral Interferon-inducing Pyrimidine, BrOpirimine. Ernest C. Borden, Younan A. Sidky, Erdogan Erulkur, Wendell Wierenga, and George T. Bryan.

- *1075 Oncodevelopmental Regulation of the Alternative Splicing of Fibronectin Pre-Messenger RNA in Human Lung Tissues. Fumitaka Oyama, Susumu Hirohashi, Yukio Shimamoto, Koiti Titani, and Kyoshiro Sekiguchi.

- *1079 Structure of the Asparagine-linked Oligosaccharide of an Alkaline Phosphatase, Eukaryotic Isozyme, Purified from FL Amnion Cells. Tamio Endo, Kazuhi Higashino, Toshihiko Hada, Hiroyasu Imanishi, Koji Muratani, Naohisa Kochiue, and Akira Kobata.

- *1085 Molecular Cloning of Complementary DNAs Encoding Alkaline Phosphatase in Human Colon Cancer Cells. James R. Gum, James W. Hicks, Todd L. Fock, and Young S. Kim.

- 1092 Interactive Effects of Dietary Wheat Bran and Lard on N-Methyl-N'-nitro-N-nitrosoguanidine-induced Colon Carcinogenesis in Rats. E. J. Sinkeldean, C. F. Kuper, M. C. Bosland, V. M. H. Hollander, and Rob J. A. M. Veldker.

- 1097 Inhibition of Benz(a)pyrene-induced Murine Forestomach Neoplasia by Conjugated Diene Derivatives of Linoleic Acid. Yeong L. Ha, Jayne Starkson, and Michael W. Pritch.

- *1102 Expression of Neural Cell Adhesion Molecule-related Sialoglycoprotein in Small Cell Lung Cancer and Neuroblastoma Cell Lines. H69 and CHP-212. C. E. Kity Moolenaar, Egbert J. Muller, Dick J. Schol, Carl G. Figdor, Elizabeth Bock, Dieter Bitter-Suermann, and Rob J. A. M. Michalides.

- *1107 Prolongation of Serum Half-Life of Interleukin 2 and Augmentation of Lymphokine-activated Killer Cell Activity by Peptostatin in Mice. Hiroaki Ohmishi, Kent M. Lin, and T. Ming Chu.

- *1113 A Latent M, 94,000 Gelatin-degrading Metalloprotease Induced during Differentiation of HL-60 Promyelocytic Leukemia Cells: A Member of the Collagenase Family of Enzymes. George E. Davis and Brian M. Martin.

- *1121 Analysis of ras Gene Mutations in Human Hepatic Malignant Tumors by Polymerase Chain Reaction and Direct Sequencing. Minoru Tada, Masao Omata, and Masao Otto.

- *1125 Increased Protein Turnover despite Normal Energy Metabolism and Responses to Feeding in Patients with Lung Cancer. Sheila Melville, Margaret A. McVernon, A. Graham Calder, and Peter J. Garlick.

- *1132 Binding of an Optically Pure Photoaffinity Analogue of Verapamil, LU-49888, to P-Glycoprotein from Multidrug-resistant Human Leukemic Cell Lines. Xiao-dong Qian and William T. Beck.

- *1138 Activation of Human Tumor-infiltrating Lymphocytes by Monoclonal Antibodies Directed to the CT43 Complex. Deric D. School, Carolyn M. Selbeck, Anthony F. Massaro, Sung-Eun Jung, and Timothy J. Eberlein.

- 1144 Metabolic Denitration of N-Nitrodimethylamine *in Vivo* in the Rat. Anthony J. Streeter, Raymond W. Nims, Pamela R. Sheffles, Young-Hun Heur, Chung S. Yang, Bruce A. Mico, Charles T. Gombart, and Larry K. Keefer.

- *1151 Phase I Clinical and Pharmacological Study of Mercurothane. R. P. Warrell Jr., J. Muindi, Y.-W. Stevens, S. J. Lee, D. A. Lowenthal, I. Haines, T. D. Walsh, L. Baltzer, S. Yalcin, and C. W. Young.

- *1156 Rectal Cell Proliferation and Colon Cancer Risk in Ulcerative Colitis. Guido Bianco, Gian Maria Paganelli, Mario Miglioli, Stefano Brilli, Giulio Di Febo, Giuseppe Gizzii, Maurizio Pomì de Leon, Massimo Campieri, and Luigi Barberi.

- *1160 Enhancement by Interleukin 4 of Interleukin 2- or Antibody-induced Proliferation of Lymphocytes from Interleukin 2-treated Cancer Patients. Jonathan Treisman, Carl M. Higuchi, John A. Thompson, Steven Gillis, Catherine G. Lindgren, Donald E. Kern, Stanley R. Ridell, Philip D. Greenberg, and Alexander Feger.

- 1165 Comparison of the Efficacy of a Phenothiazine and a Bioquinolinium Calmodulin Antagonist against Multidrug-resistant P388 Cell Lines. William N. Hait and Noah R. Pierson.

- *1170 Evaluation of Monoclonal Antibody DF3 Conjugated with Ricin as a Specific Immunotoxin for *In Vitro* Purging of Human Bone Marrow. Carlo Tondini, Stephen A. Pap, Daniel F. Hayes, Anthony D. Elias, and Donald W. Kufe.

- *1176 Interactive Effects of α -Interferon A/D and Interleukin 2 on Murine Lymphokine-activated Killer Cell Activity: Analysis at the Effector and Precursor Level. Nathaniel P. Chiklada, Isabel Lewis, James Ulchake, Jill Stanley, Raymond Tubbs, and James H. Finke.

- *1183 *cis*-Diamminedichloroplatinum(II) Cross-Linking of the Human Myeloid Cell Nuclear Differentiation Antigen to DNA in HL-60 Cells following 1,2,5-Dihydroxy Vitamin D₃-induced Monocyte Differentiation. Marek Gaczynski, Judith A. Briggs, Andrzej Wiedrowski, Ryszard Olinski, Milan Uzunkovic, Jane B. Lian, Gary S. Stein, and Robert C. Briggs.

- *1189 DNA Adduct Formation in Murine Tissues in Relation to Serum Levels of Benzo(a)pyrene-diol-epoxide after Injection of Benzo(a)pyrene or the Diol-epoxide. Gary L. Ginsberg and Thomas B. Atherton.

- *1195 Sex Steroid Hormone Modulation of NADPH Pathways in MCF-7 Cells. Michael Thomas, Cyril Bader, and Jean-Dominique Monet.

- *1201 Modulation of Epidermal Growth Factor Receptors by Retinoic Acid in ME180 Cells. Zai-Sheng Zheng and Lowell A. Goldsmith.

- 1206 Activity of Methylated Forms of Selenium in Cancer Prevention. Clement Ip and Howard E. Ganther.

- *1212 Interleukin 1 as an Adjuvant for Active Specific Immunotherapy in a Murine Tumor Model. Craig S. McCune and Diana M. Marquie.

- *1216 Use of Screening Phase Data to Evaluate Observer Variation of Sputum Cytodiagnosis as an Outcome Measure in a Chemoprevention Trial. George P. Brownian, Andrew Arnold, Mark N. Levine, Terry D'Souza, Linda M. Turner-Smith, Romy Cayo, Brenda Johnson, and Rhonda Birse.

- *1220 Phase I and Pharmacokinetic Study of Arabinofuranosyl-5-azacytosine (Fazarabine, NSC 281272). Antonella Surbone, Harry Ford, Jr., James A. Kelley, Non Ben-Baruch, Rose V. Thomas, Robert Fine, and Kenneth H. Cowan.

- *1226 Contribution of Elevated Protein Turnover and Anoxia to Cachexia in Patients with Hepatocellular Carcinoma. Stephen J. D'Onofrio, Janice Ogden, Rita Ramjee, and Joy Rund.

- *1231 Induction of Erythroid Differentiation in Human Leukemic K-562 Cells by Membrane-directed Action of Adriamycin Covalently Bound to Microspheres. Pierre Jeannesson, Chantal Treisman, Brigitte Gérard, Jean-Claude Jandillier, Kevin L. Ross, and Zoltán A. Tókai.

- 1237 Melanotropin Receptors of Murine Melanoma Characterized in Cultured Cells and Demonstrated in Experimental Tumors *In Situ*. Jeffrey B. Tatro, Margaret L. Entwistle, Bruce R. Lester, and Seymour Reichlin.

- *1243 Inhibition of Catabolism of Radiolabeled Antibodies by Tumor Cells Using Lysozymotropic Amines and Carboxylic Ionophores. Oliver W. Pres, Kenneth DeSantes, Susan K. Anderson, and Francis Geisler.

- *1251 Rate of Butathione Sulfoxime Entry into Brain and Xenotransplanted Human Gliomas. Istvan Felczi, Owen W. Griffith, Eric S. Schlager, Durrell D. Bigner, Henry S. Friedman, and Dennis R. Groothuis.

CONTENTS OF VOLUME 50

- *1257 Differential Tumorigenicity of Two Autologous Human Breast Carcinoma Cell Lines, HMT-390PS1 and HMT-390PS2. Established in Serum-free Medium. Ole William Petersen, Bo van Deurs, Kirsten Vanq Nielsen, Mogens Winkel Madsen, Inga Laursen, Ingegerd Balvè, and Per Bränd.
- *1271 Differential Expression of Intercellular Adhesion Molecule 1 in Primary and Metastatic Melanoma Lesions. Piergiorgio Natali, Maria R. Nicotra, Renato Cavallaro, Aldo Bigotti, Gaetano Romano, Massimo Tempini, and Sandomè Ferrone.
- *1279 Detection of c-K-ras Mutations in Fine Needle Aspirates from Human Pancreatic Adenocarcinomas. Darryl Shiba, Concepcion Almoguera, Kathleen Forrester, Jordan Duniz, Sue Ellen Martin, Michele M. Cosgrove, Manuel Prutchi, and Norman Arheim.
- *1284 Accumulation of Gangliosides with N-Acetylneuraminoacyl- β -Glucosamine Structure in Primary Human Hepatoma. Takao Taki, Kaname Yamamoto, Mikio Takamatsu, Kazuo Ishii, Akio Miyagi, Kiyoshi Sekiguchi, Isao Ikeda, Kunio Kurata, Jun Nakayama, Shirou Hama, and Makoto Matsumoto.
- *1291 Enhanced Tumor Binding Using Immunohistochemical Analyses Sees Generation Anti-Tissue-associated Glycoprotein 72 Monoclonal Antibodies versus Monoclonal Antibody B72.3 in Human Tissue. Alfredo Molinolo, Jean F. Simpson, Ann Thor, and Jeffrey Schlom.
- 1299 Cell Surface Sialoprotein Alterations in Metastatic Murine Colon Cancer Cell Lines Selected in an Animal Model for Colon Cancer Metastasis. Robert S. Breslau, Richard W. Rockwell, Rajiv Dahya, Quan-Yang Duh, and Young S. Kim.
- 1306 Protection by Steroid Contraceptives against Procarbazine-induced Sterility and Genotoxicity in Male Rats. Juan Felipe Velez de la Calle and Bernard Jégou.
- *1316 Integration of Human Papillomavirus 16 DNA and Genomic Rearrangements in Immortalized Human Keratinocyte Lines. Nicholas C. Popescu and Joseph A. DiPietro.
- 1324 Effect of 12-O-Tetradecanoylphorbol-13-acetate on Intercellular Communication in Various Clones of Mouse Epidermal JB6 Cells. Hiroshi Miki, Ichiro Yamada, Ursula I. Heinze, Susan Kenney, Charles W. Riggs, and Jerry M. Rice.
- *1330 Murine Monoclonal Antibodies Raised against Human Non-Normal Cell Carcinoma of the Lung: Specificity and Tumor Targeting. Rhona Stein, Susan Chen, Robert M. Sharkey, and David M. Goldenberg.
- *1337 Immunocytochemical Localization of the Glucocorticoid Receptor in Steroid-sensitive and -resistant Human Leukemic Cells. Tony Antaki, Dajan O'Donnell, and E. Brad Thompson.
- Meeting Report**
- 1346 Ninth Annual Sapporo Cancer Seminar: Cell Differentiation and Cancer Control. A. Bloch, H. P. Koeffler, G. B. Pierce, and M. Hozumi.
- Special Announcement**
- New Deadlines for Submission of Applications for Active and Corresponding Membership in the American Association for Cancer Research
- Announcements**
- Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Death
Calendar of Events
- Errata**
- J. L. Bos, *Cancer Res.*, 49: 4682-4689, 1989.
F. H. Deal *et al.*, *Cancer Res.*, 49: 6985-6988, 1989.
- Author Index**

March 1, Number 5

- Review**
- 1355 Assessment of Clonality in Human Tumors: A Review. J. S. Wainscoat and M. F. Fey.
-
- 1361 Maintenance and Cure of the L5178Y Murine Tumor-dormant State by Interleukin 2: *In Vivo* and *In Vitro* Effects. Cheng-Ming Liu, Yasuhiro Suzuki, Lieping Chen, Takeshi Okuyasu, Catherine E. Calkins, and E. Frederick Wheelock.
- 1368 Maintenance and Cure of the L5178Y Murine Tumor-dormant State by Interleukin 2: Dependence of Interleukin 2 on Infused Interleukin- γ and on Tumor Necrosis Factor for Its Antitumor Effects. Lieping Chen, Yasuhiro Suzuki, Cheng-Ming Liu, and E. Frederick Wheelock.
- *1375 Profile of Lewis^x-containing Glycoproteins and Glycolipids in Sera of Patients with Adenocarcinoma. A. K. Singhal, T. F. Ørnstoft, E. Nudelman, S. Nance, L. Schibig, M. R. Stroud, H. Clausen, and S. Hakomori.
- *1381 Preliminary Study of the Treatment of Advanced Breast Cancer in Postmenopausal Women with the Aromatase Inhibitor CGS 16949A. Robert C. Stein, Mitchell Desai, Joanna Davoren, Andrea Hedley, Hubert T. Ford, Jean-Claude Gatz, and R. Charles Coombes.
- *1385 Carrier Protein-Mannosidase Conjugates: Enhanced Immuno-toxin Cytotoxicity and Potential in Tumor Treatment. Marco Colombatti, Lorena Dell'Arciprete, Roberto Chignola, and Giuseppe Tridente.
- *1392 Use of the Tetrazolium Assay in Measuring the Response of Human Tumor Cells to Ionizing Radiation. Patricia Price and Trevor J. McMillan.
- *1397 Antioxidant and Xenobiotic-metabolizing Enzyme Gene Expression in Doxorubicin-resistant MCF-7 Breast Cancer Cells. Steven A. Akman, Gerald Forrest, Fong-Fong Chu, R. Steven Esworthy, and James H. Doroshow.
- *1403 Biochemical and Serological Characteristics of Natural 9-O-Acetyl GD3 from Human Melanoma and Bovine Buttermilk and Chemically O-Acetylated GD3. Gerd Ritter, Erika Boosfeld, Ellen Marksteiner, Robert K. Yu, Shunlin Ren, William B. Stallcup, Herbert F. Oettgen, Lloyd J. Old, and Philip O. Livingston.
- *1411 c-myc Down Regulation and Precommitment in HL-60 Cells Due to Bromodeoxyuridine. Andrew Yen and Mary E. Forbes.
- 1421 L-Arginine-dependent Reactive Nitrogen Intermediates as Mediators of Tumor Cell Killing by Activated Macrophages. Robert Keller, Michael Guiges, and Ruth Keist.
- *1426 Mechanisms of Multidrug Resistance in HL60 Cells: Detection of Resistance-associated Proteins with Antibodies against Synthetic Peptides That Correspond to the Deduced Sequence of P-Glycoprotein. David Marquardt, Sue McCrone, and Melvin S. Carter.
- 1431 Effects of Cytokinin B in Culture and *In Vivo* on Murine Madin-Darby Lung Carcinoma and on B16 Melanoma. Peter F. Bousquet, Lesa A. Paulton, Christopher Fondy, Karen M. Lipkis, Karen J. Loucy, and Thomas P. Fondy.
- 1440 Rat, Mouse and Hamster Insulinase Specificity in the Glutathione Transferase-mediated Detoxification of Nitrosoureas and Compounds. David E. Jensen and Robert L. Mackay.
- 1449 Relationship between Metastatic Ability and H-ras Oncogene Expression in Rat Mammary Cancer Cells Transfected with the v-H-ras Oncogene. Natasha Kyriandou and John T. Isaacs.
- *1455 *In Vitro* Purging of Human Rhabdomyosarcoma Cells Using 4-Hydroperoxyclorophenamide. M. Fevzi Ozkaynak, Jan Nolta, and Robertson Parkman.
- *1459 *c-myc* Gene Amplification and Expression in Primary Human Neuroblastoma. Irene Slavc, Richard Ellenberg, Woo-Hee Jung, Gordon F. Sawtell, Cynthia Kretschmar, Holcombe Grier, and Bruce R. Korf.
- 1464 Transforming Growth Factor Receptors in Liver Regeneration following Partial Hepatectomy in the Rat. Philip A. Gruppuso, Janet E. Mead, and Nelson Fausto.
- *1470 Methyl ρ -Hydroxyphenylacetate and Nuclear Type II Binding Sites in Malignant Cells: Measured Fate and Mammary Tumor Growth. Barry M. Mukaverich, Rebecca R. Gregory, MaryAnn Alejandro, Francis S. Kittrell, Daniel Medina, James H. Clark, Manju Varma, and Rajender S. Varma.
- *1479 Independent Prognostic Value of Laminin Receptor Expression in Breast Cancer Survival. Lourdes A. Marques, Eduardo L. F. Franco, Humberto Torloni, M. Mizzi Brentani, J. Baptista da Silva-Neto, and Ricardo R. Brentani.
- *1484 Role of the Acidic Receptome in the Uptake and Retention of 35 Ca by Human Leukemic HL60 Cells. Christopher R. Chimbari and Zorica Zivkovic-Bjelac.
- *1488 Protein and Messenger RNA Levels of Plasminogen Activators and Inhibitors Analyzed in 22 Human Tumor Cell Lines. Paul H. A. Quax, René T. J. van Leeuwen, Hein W. Verspaget, and Jan H. Verheijen.
- *1495 Anti-Tac-H1 Humanized Antibody to the Interleukin 2 Receptor with New Features for Immunotherapy in Malignant and Immune Disorders. R. P. Junghans, T. A. Waldmann, N. F. Landolfi, N. M. Avdalovic, W. P. Schneider, and C. Queen.
- *1503 Light Chain Variants of an IgE Anti-G_{DP} Monoclonal Antibody and the Relationship among Avidity, Effector Functions, Tumor Targeting, and Antitumor Activity. Paul B. Chapman, Mathew Loberberg, and Alan N. Houston.
- 1510 Selection and Preliminary Characterization of Variant Lines of a Murine Macrophage Tumor Resistant to the Antiproliferative Effects of Phorbol Esters. Nigel T. Goode, John P. Moore, and Ian R. Hart.
- 1516 Differential Cytotoxicity of Diaziquone toward Chinese Hamster Ovary Cells under Hypoxic and Aerobic Exposure Conditions. Peter J. O'Brien, Hari K. Kaul, and Andrew M. Rauth.
- *1521 Characterization of a Transforming *N-ras* Gene in the Human Hepatoma Cell Line Hep G2: Additional Evidence for the Importance of c-myc and *N-ras* Cooperation in Hepatocarcinogenesis. Cynthia A. Richards, Steven A. Short, Snorri S. Thorsteinsson, and Brian E. Huber.
- *1528 Biphasic Regulation of the Messenger Ribonucleic Acid Coding for the Estrogen Receptor by Cyclic Adenosine 3':5'-Monophosphate in Tumor Leydig Cells. Anne Hansen, Annette Frøyse, Winnie Eskild, Tore Jahnson, and Vidar Hansson.
- *1532 Coregulation of the Human α -Methylglutamine-DNA Methyltransferase with Two Unrelated Genes That Are Closely Linked. Peter Karran, Anne Hansen, Peter Macpherson, Sarah Cairns-Smith, and Anne Priestley.
- *1538 Application of Target-specific Drug Immunomimetics to Experimental Bone Marrow Replacement Therapy in Mice. Lei Ding, Li-zhang Yu, Shusheng Xie, Donger Gong, Ruci Vergidis, and Erwin Diener.
- 1544 Immune Response to Somatic Cell Hybrids between Ultraviolet Radiation-induced Regressor and Spontaneous Progressor C3H Mouse Tumor Cells. Peter W. Chen, David S. Kaba, and Honnava N. Ananthaswamy.
- *1550 Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product. Brian M. Fendly, Marcy Wingert, Robert M. Hudziak, Michael T. Lipari, Mary Anna Napier, and Axel Ullrich.
- *1576 Inter-specific DNA-mediated Transfer and Amplification of a Gene Specifying a M, 100,000 Human Melanoma-associated Cell Surface Glycoprotein. Charles D. Rosenberg, Soldano Ferrone, Carl V. Hamby, Valeria Mancino, and Lloyd H. Graf Jr.
- *1586 Analysis of the Activation of the *c-myc* Family Oncogene and of Its Stability over Time in Xenografted Human Lung Carcinomas. Sylvie Gazzera, Elisabeth Brambilla, Christiane Chauvin, Michele Jacrot, Alim Louis Benabid, and Christian Brambilla.
- 1571 Comparison of the Cytotoxic Effects of the High- and Low-Molecular-Weight Anticancer Agents on Multidrug-resistant Chinese Hamster Ovary Cells *In Vitro*. Yoichi Miyamoto, Tatsuya Oda, and Hiroshi Maeda.
- *1576 Purine Metabolism of Human Glioblastoma *In Vivo*. Konrad Pilwens, Peter Chiba, Andreas Knollbach, Benedict Czernak, Katharina Stenzel, Elisabeth Gersdorf, Bernhard Ausserer, Christian Murr, Rainier Goebi, Gunther Stochammer, Hans Maier, and Herwig Koschnig.
- 1580 Acute and Chronic Ultraviolet Radiation Induction of Epidermal Ornithine Decarboxylase Activity in Hairless Mice. Greg D. Hillebrand, Marcia S. Winslow, Mark J. Benzinger, David A. Heitmeier, and Donald L. Bissett.
- *1585 Human Glutathione-S-Transferase Deficiency as a Marker of Susceptibility to Epoxide-induced Cytogenetic Damage. John K. Wiencie, Karl T. Kelsey, Rosita A. Lamela, and William A. Toscano, Jr.
- 1591 Mutational Activation of the Cellular Harvey *nor* Oncogene in Rat Esophageal Papillomas Induced by Methylbenzyl-nitrosamine. Yian Wang, Ming You, Steven H. Reynolds, Gary D. Stoer, and Marshall W. Anderson.
- *1596 Expression of Mitochondrial Cytochrome *c* Oxidase in Human Colonic Cell Differentiation, Transformation, and Risk for Colonic Cancer. Barbara G. Heordt, Heidi K. Haley, Martin Lipkin, and Leonard H. Augenlicht.
- *1601 Differences in the Biosynthesis and Localization of the Fibronectin Receptor in Normal and Transformed Cultured Human Cells. Steven K. Akiyama, Hanne Larjava, and Kenneth M. Yamada.
- *1606 Distribution of Oncofetal Fibronectin in Human Mammary Tumors: Immunofluorescent Study on Histological Sections. Brigitte London-Rosa, Philippe Vieil, Hidemasa Matsura, Henrik Claessen, Corinne Quadrato, and Pierre Burdin.
- *1613 Bleomycin-induced DNA Damage and Repair in Human Cells Permeabilized with Lysoleosphatidylcholine. Khalilah Sidik and Michael J. Smerdon.
- 1620 Enhancement of Photodynamic Cell Killing (*with Chloraluminium Phthalocyanine*) by Treatment of V79 Cells with the Iono-phore Nigericin. Marie E. Barnes, Marian E. Clay, Keith Freeman, Antonio R. Antunes, and Nancy L. Oleinick.
- 1626 Isolation and Characterization of Complementary DNA Clones Corresponding to Genes Induced in Mice Epidermis *In Vivo* by Tumor Promoter. Staffan Bohm, Anna Bergstrand, Carl Persson-Morath, and Rune Tögföld.
- 1634 Inhibition of Streptozotocin-induced Islet Cell Tumors and N-Nitrosodiethylpropylamine-induced Pancreatic Exocrine Tumors in Syrian Hamsters by Exogenous Insulin. Parviz M. Pour, Katherine Kazakoff, and Kim Carlson.
- 1640 Disposition of Anticancer Drugs after Bolus Arterial Administration in a Tissue-isolated Tumor Perfusion System. Kazuhiko Ohkouchi, Hirofumi Imoto, Yoshimbu Takakura, Mitsu Hashida, and Hitoshi Sezaki.
- 1645 Successful Chemotherapy of Experimental Neuroendocrine Lung Tumors in Hamsters with an Antagonist of Ca²⁺/Calmodulin. H. M. Schulter, E. Correa, M. Orloff, and G. K. Reznik.
- *1650 Characterization of a Cell Surface Molecule Expressed on B-Lymphocytes and Hodgkin's Cells. Ashraf Imam, Efstathis Stathopoulos, Suzan L. Holland, Alan L. Epstein, and Clive R. Taylor.

CONTENTS OF VOLUME 50

*1658 Analysis of Liver Lymphoid Cell Subsets Pre- and Post-*In Vivo* Administration of Human Recombinant Interleukin 2 in a C57BL/6 Murine System. Rene Lafreniere, Knut Borckenhagen, Laurette D. Bryant, Andrew R. Anton, Andrew Chung, and Man-Chu Poon.

Letter to the Editor

1667 Note re: T. Neil Dear *et al.*, Transcriptional Down-regulation of a Rat Gene, *WDN/M2*, in Metastatic DMBA-8 Cells. *Cancer Res.*, 49: 5323-5328, 1989. T. N. Dear.

Special Announcement

New Deadlines for Submission of Applications for Active and Corresponding Membership in the American Association for Cancer Research

1668 Announcements

Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Deaths
Calendar of Events

1670 Author Index

March 15, Number 6

*1671 Receptor Binding of Human Granulocyte Colony-stimulating Factor to the Blast Cells of Myeloid Leukemia. Yun-Feng Piao and Tetsuro Okabe.

1675 Isolation of a Complementary DNA Encoding the Catalytic Subunit of Protein Kinase A and Studies on the Expression of This Sequence in Rat Hepatomas and Regenerating Liver. Jeffrey S. Roth, Ling-Ling Hsieh, Carl Peraino, and I. Bernard Weinstein.

*1681 Assessment of Tumor Energy and Oxygenation Status by Bioluminescence, Nuclear Magnetic Resonance Spectroscopy, and Cytospectrophotometry. W. Mueller-Klieser, C. Schaefer, S. Walenta, E. K. Roßblad, B. M. Fenton, and R. M. Sutherland.

*1686 Generation of Human Lymphokine-activated Killer Cells following Brief Exposure to High Dose Interleukin-2. Sharon A. Horton, Robert K. Oldham, and John R. Yannelli.

1693 Characterization of Anticancer Activity of the Mice-forming Polymyxin Drug Adriamycin-conjugated Poly(ethylene glycol)-Poly(aspartic acid) Block Copolymer. Masayuki Yokoyama, Mizue Miyashita, Norio Yamada, Teruo Okano, Yasuhisa Sakurai, Kazunori Kataoka, and Shouhei Inoue.

1701 High Level, Regulated Expression of the Chimeric P-Epoxyphosphate Carboxykinase (GEP)-Bacterial P-Alkylation-DNA Alkytransferase (*ada*) Gene in Transgenic Mice. In Kyung Lim, Luba I. Dumenco, Jeung Yun, Cheryl Donovan, Berta Warman, Naomi Gondotzky, Thomas E. Wagner, D. Wade Clapp, Richard W. Hanson, and Stanton L. Gerson.

1709 Characteristics of a Novel Transport System for Folate Compounds in Wild-Type and Methotrexate-resistant L1210 Cells. Gary B. Henderson and Brian P. Strauss.

1715 Metabolism and Pharmacokinetics of the Camptothecin Analogue CPT-11 in the Mouse. Norimasa Kaneda, Hiroshi Nagata, Tomio Furuta, and Teruo Yokokura.

1721 Nonlinear Pharmacokinetics of CPT-11 in Rats. Norimasa Kaneda and Teruo Yokokura.

1726 Biochemical and Growth Inhibition Studies of Methotrexate and Aminopterin Analogues Containing a Tetrazole Ring in Place of the γ -Carboxyl Group. John J. McGuire, Cynthia A. Russell, Wanda E. Bolanowska, Cheryl M. Freitag, Christopher S. Jones, and Thomas I. Kalman.

*1732 Libomycin-mediated DNA Cleavage in Human Head and Neck Squamous Carcinoma Cells and Purified RNA. Karsten Wassermann, Leonard A. Zwilling, J. William Lowen, John A. Hartley, Kiyohiro Nishikawa, Juan-Ru Lin, and Robert A. Newman.

*1738 Honozyme Deficiency at Autosomal Locus *aprl* in Human Somatic Cells *In Vivo* Induced by Two Different Mechanisms. Masayuki Hakoda, Kusuji Nishikawa, and Naoya Kamatani.

1742 Correlation between *In Vitro* Induction of Cytokine Gene Expression by Flavone Acetic Acid and Strict Dose Dependency and Therapeutic Efficacy against Murine Renal Cancer. Kenneth F. Mace, Ronald L. Hornung, Robert H. Wiltrout, and Howard A. Young.

*1748 Cellular and Biochemical Characterization of Thioxanthenes for Removal of Multidrug Resistance in Human and Murine Cell Lines. James M. Ford, Edward P. Bruggeman, Ira Pastan, Michael M. Gottsman, and William N. Hall.

1757 Effect of 5-Fluorouracil Substitution on the Self-Splicing Activity of *Tetrahymena* Ribosomal RNA. Peter V. Danenberg, Luke C. C. Shea, and Kathleen Danenberg.

1764 Effect of a Calcium-enriched Diet on the Colonic Epithelial Hyperproliferation Induced by N-Methyl-N'-nitro-N-nitrosoguanidine in Rats on a Low Calcium and Fat Diet. Ron Reshef, Paul Rozen, Zvi Fireman, Nachum Fine, Miriam Barzilai, Shaul M. Shasha, and Tamar Shkolnik.

*1768 Susceptibility to Lysis of Palmonary Alveolar Macrophages by Human Lymphokine-activated Killer Cells. Renato Zambello, Livio Trentin, Cristina Feruglio, Pietro Buiatti, Maria Masciarelli, Angelo Cipriani, Carlo Agostoni, and Giampietro S. Menegato.

1774 Purification and NH₂-Terminal Amino Acid Sequence of Guinea Pig Tumor-secreted Vascular Permeability Factor. Donald R. Senger, Daniel T. Connolly, Livingston Van De Water, Joseph Feder, and Harold F. Dvorak.

*1779 Multidrug Resistance Phenotype of Human BRO Melanoma Cells Transfected with a Wild-Type Human *mdr1* Complementary DNA. Carsten R. Lincke, Alexander M. van der Bliek, Gerrit J. Schuurhuis, Trintje van der Velde-Koerts, Jaap J. M. Smits, and Piet Borst.

1786 Inhibition of DNA Excision Repair by Methotrexate in Chinese Hamster Ovary Cells following Exposure to Ultraviolet Irradiation or Ethylmethanesulfonate. Alexander H. Borchers, Katherine A. Kennedy, and James A. Straw.

*1790 Antitumor Activity of 4-(α -D-Glucosaminyl)-2,4-Diacetyl-β-D-glucoside Immunoconjugate in Xenografts. David A. Johnson, A. Leroy Baker, Bennett C. Laguzza, Daniel V. Fia, and Magda C. Gutowski.

1795 Oxidation and DNA Binding of (+)-7,8-Dihydroxy-7,8-dihydrodibenzo[*p*]phenanthrene in Mice Epidermis *In Vivo* and Effects of Coadministration of Catechol. Asieh A. Melikian, Kourosh Bagheri, and Dietrich Hoffman.

*1800 Detection of *g32* Messenger RNA in Gynecological Cancers. Stanislaw J. Wysocki, Erika Hahné, Anne Masters, Victoria Smith, Anthony J. McCartney, and Roland Hahné.

*1803 Enhanced Delivery of a Monoclonal Antibody *F(ab')2 Fragment to Subcutaneous Human Glomus Xeognathops Using Local Hyperthermia. Darren A. Cope, Mark W. Dewhurst, Henry S. Friedman, Darren D. Bigner, and Michael R. Zalusky.*

1810 Metabolism and DNA Single Strand Breaks Induced by 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanone and Its Analogs in Primary Culture of Rat Hepatocytes. Lili Liu, Moulay A. Alaoui-Jamali, Najat El Alami, and Andre Castangouy.

*1817 Transport and Metabolism of 9-(β -D-Arabinofuranosyl)guanine in Human T-Lymphoblastoid Cell Line: Nitrobenzylthiobiosine-sensitive and -insensitive Influx. Karen L. Prus, Devon R. Averett, and Thomas P. Zimmerman.

*1822 Radioimmunoassay of Intracellular Human Gloma Xenographs with ¹²⁵I-labeled *F(ab')2 Fragments of Monoclonal Antibody MeI-14. Edward V. Capolino, Michael R. Zalusky, Karen E. Archer, Michael A. Nonska, Henry S. Friedman, Stefan Carrel, and Darren D. Bigner.*

1828 Protein Kinase C-induced Stimulation or Inhibition of Cellular Proliferation in a Mammalian Macrophage Tumor Cell Line. Nigel T. Goode, John P. Moore, and Ian R. Hart.

1834 Role of Asialo-GM₁ Positive Liver Cells from Atypical Nude or Polyomavirus-Polyclonal Acid-treated Mice in Supporting Co-derived Experimental Hepatic Metastasis. Stefan A. Cohen, Shee-pon Tsung, Ralph J. Doerr, and Martin H. Goldstein.

*1841 Detection and Partial Characterization of Receptors for [α -D-Tryptophyl]Lantana-Hypercalcinizing Hormone and Epidermal Growth Factor in Human Endometrial Carcinoma. Gordan Skralovic, James L. Wittif, and Andrew V. Schally.

*1847 Differences in *In Vitro* Proliferative Responsiveness to Granulocyte Colony-stimulating Factor and Interleukin 2 of Bone Marrow Cells from Mice Treated with Chemotherapeutic Drugs. Uta Mizushima, Toshihiko Morikage, and Saburo Yano.

*1853 Increased Local Antitumor Effects of Interleukin 2 Liposomes in Mice with MCA-106 Sarcoma Pulmonary Metastases. Peter M. Anderson, Emmanuel Katsanis, Arnold S. Leonard, Douglas Schow, Cynthia M. Loefler, Mitchell B. Goldstein, and Augusto C. Ochoa.

*1857 Association of Rare Alleles of the Harvey rat Protooncogene with Lung Cancer. Haruhiko Sugimura, Neil E. Caporaso, Rama V. Modali, Robert N. Hoover, James H. Resau, Benjamin F. Trump, Joyce A. Lonergan, Theodore G. Krontiris, Dean L. Manis, Ansley Weston, and Curtis C. Harris.

*1863 Increased Removal of DNA-bound Platinum in a Human Ovarian Cancer Cell Line Resistant to *cis*-Diamminedichloroplatinum(II). Hidetaka Matsuda, Toshio Tanaka, Hiroyuki Matsuda, and Izuo Kusaka.

*1867 Growth Inhibition of Human Melanoma Tumor Xenografts in Atypical Nude Mice by Swainsonine. James W. Dennis, Kay Koch, Shida Yousefi, and Ingrid VanderEist.

*1873 Glucocorticoid Effects on Myeloma Cells in Culture: Growth Inhibition with Induction of Glucocorticoid Receptor Messenger RNA. Masahiro Gomi, Kaname Moriwaki, Shuichi Katajiri, Yoshiaki Kurata, and E. Brad Thompson.

*1879 Conjugation of 9-Deoxy- $\Delta^5,\Delta^{12}(\text{E})$ -prostaglandin D₂ with Intracellular Glutathione and Enhancement of Its Antiproliferative Activity by Glutathione Depletion. Jacob Atsmon, Michael L. Freeman, Michael J. Meredith, Brian J. Sweetman, and L. Jackson Roberts II.

*1886 Marital Status and the Incidence of Sarcomas of the Uterus. Stephen M. Schwartz and Noel S. Weiss.

*1890 Suppression of Tumorigenicity of a Human Lung Carcinoma Line by Nontransforming Bronchial Epithelial Cells in Somatic Cell Hybrids. M. Edward Kaighn, Edward W. Gabriele, Deborah S. Iman, Elisa A. Pauli, and Curtis C. Harris.

*1897 Rapid Degradation of Extracellular Matrix Protein by Normal Human Esophageal Cells. Lynn E. Allen, Louis Dubuce, Ofelia Alvarez, and Peter A. Jones.

*1905 Effects of Microinjector Photoreactivating Enzyme on Thymine Dimer Removal and DNA Repair Synthesis in Normal Human and Xeroderma Pigmentosum Fibroblasts. Len Roza, Wim Vermeulen, Jacqueline B. A. Bergen, Henkogen, Andries P. M. Eker, Nicolaas G. J. Jaspers, Paul H. M. Lohman, and Jan H. J. Hoeijmakers.

1911 Enzyme-altered Fats in Colonies of Carcinogen-treated Rats. Betty J. Barlow, Mary Ann O'Riordan, Thomas A. Stellato, Beverly M. Calkins, and Theresa P. Prelow.

1917 Multistage Progression of Aboleson Virus-infected Murine Pro-B-Cells to the Tumorigenic State. Gregory J. Palumbo, Brad W. Ozanne, and John R. Kettman.

1924 Use of Small Neurons in Developing Quantitative Ultrastructural Parameters for Nematicide Side Effects of *Vinc* Antitumor Agents. Linda J. Müller, Carry M. Moeren-van Delft, Rokus Zijl, and Eric W. Roubos.

1929 Morphological Evidence for an Apparent Lysosomotropic Activity by Unsaturated Putrescine Analogs. Carl W. Porter, J. Stanek, J. Black, M. Vaughan, B. Ganis, and A. Pleshkewych.

*1936 Photooxidation of Human Lekemek Cells by Anthracenedione Antitumor Agents. John A. Hartley, Stephen M. Farrow, Robert L. Souhami, Krzysztof Reska, and J. William Low.

1941 Phenoxy Expression in Spontaneously Transformed Cultured Rat Liver Epithelial Cells. Ming-Sound Tsao, Jessica Shepherd, and Gerald Batis.

1948 A Monoclonal Antibody to Lewis Lung Carcinoma Variant II-59 Identifies a Plasma Membrane Protein with Apparent Relevance to Lymph Node Adhesion and Metastasis. William Shestowsky, Lucia Fallavollita, and Prina Brodt.

*1954 Activity of Intracellular 4-Hydroxy-*p*-cyclophosphamide in a Nude Rat Model of Human Nonseminomatous Meningitis. Herbert E. Fuks, Gerald E. Archer, O. Michael Cohen, Sandra H. Bigler, James M. Schuster, Gregory N. Fuller, Lawrence H. Mullanier, S. Clifford Schold, Jr., Henry S. Friedman, and Darren D. Bigner.

1960 Pathobiology of Lung Tumors Induced in Hamsters by 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanone and the Modulating Effect of Hyperoxia. Hildegarde M. Schuller, Hans-Peter Witschi, Eric Nemer, Priyavadan A. Joshi, Enrique Correa, and Kenneth L. Becker.

*1966 Paracrine Stimulation of Polarized Secretion from Monolayers of a Neoplastic Prostatic Epithelial Cell Line by Prostatic Stromal Cell Proteins. Daniel Djakic, Mary A. Tarkington, and John H. Lynch.

1975 Announcements

Eighty-first Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Deaths

1976 Author Index

CONTENTS OF VOLUME 50

April 1, Number 7

*1977 Retinoic Acid Inhibition of Human Breast Carcinoma Proliferation Is Accompanied by Inhibition of the Synthesis of a M_r 39,000 Protein. Joseph A. Fontana, Dante Miranda, and Alicia Burrows Mezu.

*1983 Expression of Alternatively Terminated Unusual Human Butyrylcholinesterase Messenger RNA Transcripts, Mapping to Chromosome 3q26-ter, in Nervous System Tumors. Averell Gatt, Catherine A. Prody, Ronit Zamir, Judith Lieman-Hurwitz, Haim Zukut, and Hermoni Sorci.

*1988 Relation between the Abundance of Messenger RNA and the Corresponding Protein of Two Growth-related Genes, c-jun and c-myc, in Leukemic Blasts. Cefalo, Sergio Ferrari, Enrico Tagliafico, Marco D'Onici, Giovanni Ceccherelli, Rossella Manfredini, Licia Selleri, Amelia Donelli, Stefano Sacchi, Giuseppe Torelli, and Umberto Torelli.

1992 Correlation of Enhanced 6-Mercaptopurine Cytotoxicity with Increased Phosphoribosylpyrophosphate Levels in Chinese Hamster Ovary Cells Treated with 3-Aminobenzoic Acid. Kevin Moses, Elaine Willmore, Adrian L. Harris, and Barbara W. Durkacz.

*1997 Retinoid Modulation of Estradiol-stimulated Growth and Protein Synthesis and Secretion in Human Breast Carcinoma Cells. Joseph A. Fontana, Alicia Burrows Mezu, Brenda N. Cooper, and Dante Miranda.

*2003 Comparison of the Structural and Cytotoxic Activity of Novel 2,6-Bis(carboethoxyamino)-3,6-diaridinyl-1,4-benzoquinone Analogues. A. Dzieleñska, J. Butler, B. M. Hoey, J. S. Lea, and T. H. Ward.

*2009 Pharmacokinetics of Recombinant Interleukin 2 in Humans. Michael W. Kozak, George Henssner, Evan M. Herst, Peter W. A. Mansell, Roland Meretzman, Jonathan E. Kolitz, and Edward C. Bradley.

2018 Potentiation of Invasive Capacity of Rat Ascites Hepatoma Cells by Adriamycin. Fumiyo Immamura, Takeshi Horai, Mutsuko Mukai, Kiyoko Shinkai, and Hitoshi Akedo.

*2022 Expression of Chromosomal Proteins HMG-14 and HMG-17 in Transformed Human Cells. Massimo P. Crippa, James M. Pash, Brenda I. Gewin, Thomas E. Smithgall, Robert J. Glazer, and Michael Bustin.

*2027 Effects of Smoking and Irradiated Volume on Inflammatory Response in the Lung of Irradiated Breast Cancer Patients Evaluated with Bronchoalveolar Lavage. Leif Bjerner, Lars Franzen, Bo Litstrand, Kenneth Nilsson, Tord Ångström, and Roger Henriksson.

*2031 Effect of Homeostatin on Proliferation and Differentiation of Human Leukemic Cells *In Vitro*. Jian-Yuan Zhou, Dan-Lin Chen, Ze-Shuang Shen, and Hui-Peter Koelliker.

*2036 Incubation of 1,3-, 1,6-, and 1,8-Dinitropurine by Cytochrome P-450 Enzymes in Human and Rat Liver Microsomes. Tsutomu Shimada and F. Peter Guengerich.

*2044 Host Radiosensitization and the Level of DNA Polymerases α and β of Human Colony-forming Unit-Granulocyte-Macrophage and Myeloid Leukemias Sensitive and Resistant to Chemo-therapeutic Agents. Nahid F. Mivechi, Hayato Miyachi, and Kevin J. Scanlon.

*2049 Expression of the Macrophage Growth Factor CSF-1 and Its Receptor c-fms by a Hodgkin's Disease-derived Cell Line and Its Variants. Elisabeth Pajetta, Janis Racavskis, E. Richard Stanley, Michael Andreoff, Peter Papenhausen, and Peter H. Wiernik.

*2056 Phase I Trial of 5-Fluorouracil and Recombinant α_2 -Interferon in Patients with Advanced Colorectal Carcinoma. Scott Wadler, Mark Goldman, Anne Lyer, and Peter H. Wiernik.

*2060 Mutagenic Activation of 2-Amino-3-methylimidazo[4,5-f]quinoxaline by Complementary DNA-expressed Human Liver P-450. Toshifumi Oyama, Harry V. Geibor, and Frank J. Gonzalez.

2064 Long Term Effects of Benzo(a)pyrene on the Activity of NAD(P)H:Quinone Reductase in the Forestomach and Glandular Stomach of ICR/Ha Mice. Ali D. Jasim, Velta L. Sparmins, and Lee W. Wattenberg.

2068 Inhibition of Transformation in Cultured Rat Tracheal Epithelial Cells by Potential Chemopreventive Agents. Vernon E. Steele, Gary J. Kelloff, Betty P. Wilkinson, and Julia T. Arnold.

2075 Nonuniform Alteration of c-fos-Diaminodichloroplatinum(II) Tissue Distribution in Dogs with Whole Body Hyperthermia. J. E. Riviere, R. L. Page, R. A. Rogers, S. K. Chang, M. W. Dewhirst, and D. E. Thrall.

2081 Phorbol Esters Mediate Phospholipid-free Activation of Rat Brain Protein Kinase C. Corinne Da Silva, Xiangtan Fan, Isabelle Marchely, and Monique Castagna.

*2088 Properties of Ornidithine Decarboxylase in Human Colorectal Adenocarcinomas. Olli A. Hictala, Keuk Y. Yun, Janine Pilon, Kevin O'Donnell, Christopher P. Holroyde, Irwin Kline George A. Reichard, Samuel Litwin, Susan K. Gilmour, and Thomas G. O'Brien.

2095 Effect of Calcium Channel Blockers on Gastric Carcinogenesis and Caerulein Enhancement of Gastric Carcinogenesis Induced by N-Methyl-N'-nitro-N-nitrosoguanidine in Wistar Rats. Masaharu Tatsuta, Hiroyasu Ishii, Miyako Babu, Akihiko Nakazumi, Hiroyuki Uehara, and Haruo Taniguchi.

*2099 Prevention of Fatal Infection by Recombinant Human Interleukin 1 α in Normal and Anticancer Drug-treated Mice. Toshihiko Morikage, Yutaka Mizushima, Ken-ichi Sakamoto, and Saburo Yano.

*2105 Tropomyosin of Human Mammary Epithelial Cells: Consistent Defects of Expression in Mammary Carcinoma Cell Lines. Basudev Bhattacharya, Gaddamangalur L. Prasad, Eva M. Valerius, David S. Salomon, and Herbert L. Cooper.

*2113 Estradiol Sensitivity Test Using Contact-sensitive Plates of Confluent BALB/c 3T3 Cell Monolayers. Hideo Matsuka, Hiroaki Ueo, Kazuhiko Yano, Yuichiro Kido, Ken Shirabe, Tetsuya Mitadomi, and Keizo Sugimachi.

*2119 Relationship of Relative Glucose Production to Growth Hormone and Severity of Malnutrition in a Population with Colorectal Carcinoma. John A. Tayek, Linda Bulcavage, and Rowan T. Chleboski.

*2123 Suppression of Radiation-induced Neoplastic Transformation of Human Cell Hybrids by Long Term Incubation at Low Extracellular pH. Marc S. Mendonca, Chi-Sun, and J. Leslie Redpath.

*2128 Cloning of the Genes for TRA46, an Antibody That Has a High Specificity and Affinity for Carcinoembryonic Antigen, and Expression of Chimeric Human/Mouse TRA46 Genes in Myeloma and Chinese Hamster Ovary Cells. Michael Neuimair, Louise Shively, Fan-Shun Chen, Franz-Josef Gaida, Christine Iglen, Raymond J. Paxton, John E. Shively, and Arthur D. Riggs.

*2135 Embryonic Mutation as a Possible Cause of *in Utero* Carcinogenesis in Mice Revealed by Postnatal Treatment with 12-O-Tetradecanoylphorbol-13-acetate. Taisie Nomura, Hiroo Nakajima, Toshihiro Hatanaka, Masakatsu Kinuta, and Tadashi Honjo.

*2139 Residual Damage in Mouse Lungs at Long Intervals after Cyclophosphamide Treatment. Elizabeth L. Travis, Luc Bucci, and Mao-Zheng Fang.

*2146 Differential Effect of Gestation Stage on Benzo(a)pyrene-induced Micronucleus Formation and/or Covalent DNA Modifications in Mice. Mian-Ying Wang and Lee-Jane W. Lu.

*2152 Association of Change in Body Mass with Breast Cancer. Rachel Ballard-Barabas, Arthur Schatzkin, Philip R. Taylor, and Lisa Lictria Kahle.

*2156 Contribution of Aflatoxin B₁ and Hepatitis B Virus Infection in the Induction of Liver Tumors in Ducks. Lucyna Cova, Christopher P. Wild, Raj Mehrotra, Vladimir Turusov, Tomoyuki Shirai, Véronique Lambert, Chantal Jaquet, Lorenzo Tomatis, Christian Trépo, and Ruggero Montesano.

*2164 Elastin Gene Expression in Elastotic Human Breast Cancers and Epithelial Cell Lines. Ravi Krishnan and Edward G. Cleary.

*2172 Effect of Tumor Necrosis Factor on Epithelial Tight Junctions and Transepithelial Permeability. James M. Mullin and Kathleen V. Snock.

*2177 Establishment and Characterization of a Cell Line (Wa-2) Derived from an Extranodal Rhabdoid Tumor. R. Handgretinger, A. Kimmig, E. Koscielniak, D. Schmidt, G. Rudolph, H. Wolbold, P. Paulus, K. Schilbach-Stueckle, C. Oettlinger, A. Menrad, M. Sproll, G. Bruchelt, R. Dopfer, J. Treuner, and D. Niethammer.

*2181 Highly Tumor-reactive, Internalizing, Mouse Monoclonal Antibodies to Le⁺-related Cell Surface Antigen. Ingegerd Hellstrom, H. Jacques Garrigue, Ursula Garrigue, and Karl Erik Hellstrom.

*2191 Transfer of Adriamycin Resistance by Fusion of M, 17,000 P-Glycoprotein to the Plasma Membrane of Sensible Cells. James A. Belli, Yin Zhang, and Pamela Fritz.

*2198 Uptake of the Cation Hexakis[2-methoxyethyl]bis(aziridinyl)-Tetraether-99m in Human Carcinoma Cell Lines *In Vitro*. Laurence I. Delmont-Moingeon, David Fornica-Worms, Annick D. Van den Abeele, B. Leonard Holman, Alan Davison, and Alun G. Jones.

Meeting Reports

2203 The Cell Membrane and Cell Signals as Targets in Cancer Chemotherapy: AACR, EORTC, and BACR Special Conference in Cancer Research. Garth Powis, John Hickman, Paul Workman, Thomas R. Tritton, Jean-Pierre Abita, Wolfgang E. Berdel, Andreas Gescher, Harold L. Moses, and Garth L. Nicolson.

2212 Morphologic, Immunologic, and Cytogenetic Classification of the Chronic (Mature) B and T Lymphoid Leukemias: Fourth Meeting of the MHC Cooperative Study Group. J. M. Bennett, G. Juliusson, and C. Mecucci.

2213 Eighth Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events

2214 Author Index

April 15, Number 8

*2215 Cellular F-Actin Levels as a Marker for Cellular Transformation: Relationship to Cell Division and Differentiation. Jian Yu Rao, Eddie R. Hurst, Wesley Dale Bates, Philip L. Jones, Rebecca A. Bass, Linda T. Archer, Paul B. Bell, and George P. Hemstreet III.

2216 Reduced Suppression of Plasma Saturated Fatty Acid Mobilization and Oxidation by Feeding in Lymphoma-bearing Mice. Ram Kannan, Minerva Gan-Espano, and Noma Baker.

2218 Radiosensitive Barrier to T-Cell-mediated Adoptive Immunotherapy of Established Tumors. Michel Awad and Robert J. North.

*2234 Binding of Opiooids to Human MCF-7 Breast Cancer Cells and Their Effects on Growth. Rhoda Maneckjee, Ratna Biswas, and Barbara K. Von derhaar.

*2239 Expression of Human Chromosome 2 Ornithine Decarboxylase Gene in Ornithine Decarboxylase-deficient Chinese Hamster Ovary Cells. Jen-Tseng Hsieh, Mitchell E. Denning, Shawn M. Heidel, and Ajit K. Verma.

*2245 Urokinase Secretion from Human Colon Carcinomas Induced by Endogenous Dipeptides. Brigitte Marian, Shahshankar Harvey, Diogenes Infante, Gabor Markus, Sidney Winaver, and Eileen Friedman.

2251 Transcriptional Control of Glutathione S-Transferase Gene Expression by the Chemoprotective Agent 5-(2-Pyrazinyl)-4-methyl-1,2-dithiole-3-thione (Oltipraz) in Rat Liver. Nancy E. Davidson, Patricia A. Egner, and Thomas W. Kensler.

*2256 Evaluation of Platinum-DNA Adduct Levels Relative to Known Prognostic Variables in a Cohort of Ovarian Cancer Patients. Eddie Reed, Yechiam Osthege, Seth M. Steinberg, Stuart H. Yuspa, Robert C. Young, Robert F. Ozols, and Miriam C. Poirier.

*2261 Impact of Tolerance on Antitumor Efficacy of Tumor Necrosis Factor in Mice. Douglas L. Fraker, Brett C. Sheppard, and Jeffrey A. Norton.

*2268 An Epidemiological Study of Precursor Lesions of Esophageal Cancer among Young Persons in a High-Risk Population in Hualian, China. Jenny C. Chang-Claude, Jürgen Wahrendorf, Qiu Song Liang, Yang Guan Rei, Nubia Muñoz, Massimo Crespi, Richard Raedsch, David I. Thurnham, and Pelayo Correa.

2275 Effects of Androgen Withdrawal on the Stem Cell Composition of the Shionogi Carcinoma. Nicholas Bruchovsky, Paul S. Remond, Andrew J. Coldman, S. Larry Goldenberg, Mary To, and Dona Lawson.

*2283 Cancer Mortality in Women with Thyroid Disease. Marlene B. Goldman, Richard R. Monson, and Farahale Maloof.

2290 Experimental Cancer Cachexia Induced by Transplantable Colon 26 Adenocarcinoma in Mice. Yutaka Tanaka, Hiroyuki Eda, Takashi Tanaka, Toshiaki Udagawa, Tohru Ishikawa, Ikuo Horii, Hideo Ishitsuka, Tatsushi Kataoka, and Tetsuo Taguchi.

*2296 *In Vitro* Properties of Human Melanoma Cells Metastatic in Nude Mice. Dorothee Herlyn, Dimitrios Iliopoulos, Pamela J. Jensen, Amnette Parmiter, Janet Baird, Haliotta Hotta, Koji Adachi, Alonso H. Ross, Jadranka Jambrosic, Hilary Koprowski, and Meenhard Herlyn.

*2303 Loss of Heterozygosity for Genes on 11p and the Clinical Course of Patients with Lung Carcinoma. Michael A. Skinner, Robin Vollmer, Gudrun Hüper, Patricia Abbott, and J. Dirk Igglehart.

2307 *d*-N,N'-Dicarbonylmethoxy-N,N'-disubstituted-1,2-diaminopropane (ICRF-198) and *d*-L-1,2-Bis(4-oxazoline)-3,4-dioxapentane (ICRF-187) Inhibition of Fe²⁺ Reduction, Lipid Peroxidation, and Ca/ATPase Inactivation in Heart Microsomes Exposed to Adriamycin. Glenn F. Vile and Christine C. Winterbottom.

*2311 Serum Vitamin A and Subclinical Development of Prostate Cancer in the First National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Michael E. Reichman, Richard B. Hayes, Regina G. Ziegler, Arthur Schatzkin, Philip R. Taylor, Lisa L. Kable, and Joseph F. Fraumeni, Jr.

2316 Interaction of Androgen-induced Autocrine Heparin-binding Growth Factor with Prostaglandin E2 Receptor on Androgen-dependent Shionogi Carcinoma 115 Cells. Norio Nonomura, Juan Lu, Akira Tanaka, Hiroshi Yamashita, Bunzo Sato, Takao Sonoda, and Keishi Matsumoto.

*2322 Expression of Metalloproteinases and Metalloproteinase Inhibitors in Fibroblasts and Glialoma Cells. Gerard Apodaca, James T. Rutka, Karen Bouhana, Michael E. Berens, Jane R. Giblin, Mark L. Rosenblum, James H. McKerron, and Michael J. Bands.

*2323 Biodistribution and Radiation Dose Estimates for Yttrium- and Iodine-labeled Monoclonal Antibody IgG and Fragments in Nude Mice Bearing Human Colonic Tumor Xenografts. Robert M. Sharkey, Cecilia Motta-Hennessy, David Pawlik, Jeffry A. Siegel, and David M. Goldenberg.

2327 Heme Synthesis in Normal Mouse Liver and Mouse Liver Tumors. Daniel L. Stout and Frederick F. Becker.

CONTENTS OF VOLUME 50

- *2341 Total Serum Cholesterol and Triglycerides and Risk of Breast Cancer: A Prospective Study of 24,529 Norwegian Women. Lars J. Vatten and Olav P. Foss.
- *2347 Amplification of the *c-myc* Gene in Human Medulloblastoma Cell Lines and Xenografts. Sandra H. Bigner, Henry S. Friedman, Bert Vogelstein, W. Jerry Oakes, and Darelle D. Bigner.
- 2351 Effect of Erythrocytes on Alveolar Macrophage Cytolytic Activity Induced by Bleomycin Lung Damage in Rats. Anne E. Huot, R. Mary Gundel, and Miles P. Hacker.
- 2356 Genetic and Biochemical Characterization of the CHO-UV-1 Mutant Defective in Postreplication Recovery of DNA. Patricia Henito, Andrew R. S. Collins, Laura Correll, Albert J. Fornace, Jr., Amato Giaccia, and Charles A. Waldren.
- *2363 Characterization of the Cytolytic Activity of CD4⁺ and CD8⁺ Tumor-infiltrating Lymphocytes in Human Renal Cell Carcinoma. James H. Finke, Patricia Rayman, Jeannie Alexander, Mark Edinger, Raymond R. Tubbs, Robert Connely, Edson Pontes, and Ronald Bukowski.
- *2371 Correlation between Clinical Response to Interleukin-2 Therapy and Sustained Production of Tumor Necrosis Factor. Jean-Yves Blay, Marie C. Favrot, Sylvie Negrier, Valérie Combaret, Salem Chouah, Alain Mercadier, Pierre Kaemmerlen, Chris R. Franks, and Thierry Philip.
- *2375 Cyst Fluid of Ovarian Cancer Patients Contains High Concentrations of Trypsinogen-2. Erkki Koivunen, Outi Nikula, Hannu Hallila, and Ulf-Håkan Stennan.
- *2379 Damage and Repair Induced by Bleomycin in the Domain of Human Amplified myc Oncogenes. N. O. Bianchi, M. S. Bianchi, D. López-Larraza, K. Alitalo, and A. de la Chapelle.
- 2385 Hyperthermic Enrichment of Rhodamine 123 Cytoxicity in B16 Mouse Melanoma Cells *In Vitro*. David N. Kring, Alain P. Theon, and Lydia Gan.
- *2390 Monoclonal Antibodies against Native and Denatured Forms of Estrogen-induced Breast Cancer Protein (BCE1/S9) Obtained by Expression in *Escherichia coli*. Jean-François Prud'homme, André Jolivet, Marie-France Pichon, Jean-François Savoüret, and Edwin Milgrom.
- 2397 Expression of Complementary DNA and Genomic Clones for Carcinoembryonic Antigen and Nonspecific Cross-Reacting Antigen in Chinese Hamster Ovary and Mouse Fibroblast Cells and Characterization of the Membrane-expressed Products. Laura J. F. Heba, Heinrich Schrewe, John A. Thompson, Shinzo Okawa, Hiroshi Nakazato, and John E. Shively.
- 2404 Expression of the Retroribosomes, Intracisternal A-Particles, during Neoplastic Progression of Mouse Mammary Epithelium Analyzed with a Monoclonal Antibody. Bonnie B. Ach and Harold L. Asch.
- 2411 Microvascular Architecture of Experimental Colon Tumors in the Rat. Stewart A. Skinner, Peter J. M. Tutton, and Paul E. O'Brien.
- 2418 Effect of Dietary Molybdenum on Esophageal Carcinogenesis in Rats Induced by N-Methyl-N-benzylnitrosamine. Hisanao Komada, Yoshimura Kise, Manabu Nakagawa, Manabu Yamamura, Koshiro Hoiki, and Masakatsu Yamamoto.
- *2549 Decreased Accumulation as a Mechanism of Resistance to *cis*-Diamminedichloroplatinum(II) in Human Non-Small Cell Lung Cancer Cell Lines: Relation to DNA Double-Strand Breaks. Masaaki Bungo, Yutaka Fujita, Kazuo Kasai, Kazuhiko Nakagawa, Yuichiro Ohe, Yasutomo Sasaki, Shozo Iriko, and Nagahiro Sujo.
- 2554 Characteristics of Potential Lymphoma-inducing Cells in Mice Sensitive or Resistant to Lymphomagenesis by Radiation Leukemia Virus Variants. Irina Gokhman, Alpha Peled, and Nechama Hanan-Ghera.
- 2562 Chemoprevention of Colon Carcinogenesis by Concurrent Administration of Piroxicam, a Nonsteroidal Antiinflammatory Drug with D,L-*Difluoromethylornithine*, an Ornithine Decarboxylase Inhibitor, in Dla^b Bandar Sh. Reddy, Jayashree Nayini, Kenji Tokuno, Jeff Rigott, Edith Zang, and Gary Kelloff.
- *2569 Life-Style, Workplace, and Stomach Cancer by Subsite in Young Men of Los Angeles County. Anna H. Wu-Williams, Mimi C. Yu, and Thomas M. Mack.
- 2577 Abrogation by Novobiocin of Cytotoxicity Due to the Topoisomerase II Inhibitor Anisomycin in Chinese Hamster Cells. H. Utsumi, M. L. Shibuya, T. Konaka, W. E. Buddenbaum, and M. M. Elkina.
- 2582 Inhibition of Tumor Cell Proliferation by Natural Suppressor Cells Present in Marine Bone Marrow. Kihaya Sugiyama, Muneyuki Inaba, Hajime Ogata, Ryoko Yasumura, Evelio E. Sardina, Kayo Inaba, Sho-ichi Kuma, Robert A. Good, and Susumu Ichihara.
- 2587 Solid-Phase Anti-CD4 Antibody Activation of Murine Tumor-infiltrating Lymphocytes. Anthony F. Massaro, Deric D. Schoof, Amy Rubinstein, Markus Zuber, Frank J. Leonard-Vidal, and Timothy J. Eberlein.
- *2593 Defective Postreplication Repair in Xeroderma Pigmentosum Variant Fibroblasts. Jayne C. Boyer, William K. Kaufmann, Bruna P. Brylawski, and Maria Cordeiro-Stone.
- 2599 Role of Thromboxane and Prostaglandin Release on Photodynamic Therapy-induced Tumor Destruction. Victor H. Figari, T. Jeffrey Wierman, and Karola Weber Doak.
- *2604 Effects of Progesterone on the Response to Epidermal Growth Factor and Other Growth Factors in Cultured Human Meningioma Cells. Jan W. Koper, John A. Foekens, R. Braakman, and Steven W. J. Lamberts.
- *2423 Amplified and Rearranged *ker-2* Genes in Two Lymphoma Cell Lines, FL-218 and FL-318, Carrying a 1418 Translocation. Ryuichi Amakawa, Shirou Fukuhara, Hitoshi Ohno, Satoko Tadaka, Mitsuru Horii, Fumiyo Matsuyama, Isamu Kato, Tokio Kakita, and Osamu Nagasuchi.
- *2429 Infiltrative and Cytolytic Activities of Lymphokine-activated Killer Cells against a Human Gloma Spheroid Model. Kouichi Iwasaki, Haruhiko Kituchi, Shin-ichi Miyatake, Tomokazu Arai, Toshiki Yamasaki, and Yoshihumi Oda.
- 2437 Morphological and Electrophysiological Study of the Effects of Cisplatin and ORC-2766 on Rat Spinal Ganglion Neurons. Linda J. Müller, Roland Gerritsen van Hoop, Carry M. Moorer-van Det, Willem H. Gispert, and Eric W. Roubos.
- *2443 Molecular Analysis by Electron Microscopy of the Removal of Psoralen-photodinitro DNA Cross-links in Normal and Fanconi's Anemia Fibroblasts. S. Rousset, S. Nocentini, B. Revet, and E. Mousacchi.
- *2449 Epitope Mapping and Use of Anti-Idiotype Antibodies to the L6 Monoclonal Anticarcinoma Utebie. Karl Erik Hellström, Dale E. Yelton, H. Perry Fell, Donna Beaton, Margit Gayle, Michael MacLean, Maria Kahn, and Ingegerd Hellström.
- 2455 Glutathione Protects Cardiac and Skeletal Muscle from Cyclophosphamide-induced Toxicity. Henry S. Friedman, O. Michael Colvin, Kazuo Aizaki, Jim Popp, Edward H. Bossen, Keith A. Reimer, James B. Powell, John Histon, Steve S. Gross, Roberto Levi, Darelle D. Bigner, and Owen W. Griffith.
- *2463 Studies of Effects of Recombinant Human Tumor Necrosis Factor on Antechorionic Tumor and Transplanted Normal Tissue in Mice. Joe K. McIntosh, James J. Muñiz, William D. Travis, and Steven A. Rosenberg.
- 2470 Nicotinamide and Nicotinamide Analogs as Antitumor Promoters in Mouse Skin. Andreas Ludwig, Manfred Dietl, Gity Schäfer, Karin Müller, and Helmuth Hilz.
- 2476 Comparison of Cellular Immunotherapies and Anti-CD3 in the Treatment of MCA-38-LD Experimental Hepatic Metastases in C57BL/6 Mice. Steven Gallinger, David W. Hoskin, J. Brendan M. Mullin, Albert H. C. Wong, and John C. Rodger.
- *2481 Partial Characterization of Insulin-like Growth Factor I in Primary Human Lung Cancers Using Immunohistochemical and Receptor Autoradiographic Techniques. Kazuto Shigematsu, Yasumitsu Kataoka, Takahiro Kamio, Masaki Kuribara, Masami Niwa, and Hideo Tsuchiya.
- 2485 Characterization of B16 Melanoma Cells Resistant to the CC-1065 Analogue U-71,184. B. C. Moy, G. L. Petzold, G. J. Badiner, R. C. Kelly, P. A. Aristoff, E. G. Adams, L. H. Li, and B. K. Bhuyan.
- 2493 Comparative Action of Aflatoxin B₁ in Mammalian Airway Epithelium. Dennis W. Wilson, R. Wayne Ball, and Roger A. Coulombe, Jr.
- May 1, Number 9**
- *2608 Gestational and Familial Risk Factors for Childhood Astrocytoma: Results of a Case-Control Study. René R. Kujitus, Greta R. Bunin, Catharine C. Nass, and Anna T. Meadows.
- 2613 Effects of Indole-3-carbinol on Lung Tumorigenesis and DNA Methylation Induced by 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanoine (NNK) and on the Metabolism and Disposition of NNK in A/J Mice. Mark A. Morse, Susan D. LaGreca, Shantu G. Amin, and Fung-Lung Chung.
- *2618 Induction of Differentiation and DNA Strand Breakage in Human HL-60 and K-562 Leukemia Cells by Genistein. Andreas Constantinos, Kaoru Kiguchi, and Eliezer Huberman.
- 2625 Chemotherapeutic Characterization in Mice of 2-Amino-9,9-difluorofuran-2-yl-6-sulfonamide (Sulfamazine), a Novel Purine Nucleoside with Unique Antitumor Properties. Thomas L. Avery, Rick A. Finch, Karen M. Vasquez, Saeed Radparvar, Nacem B. Hanna, Ganapathy R. Revankar, and Roland K. Robins.
- 2631 Ultraviolet Radiation Induction of Ornithine Decarboxylase in Rat Keratinocytes. Cheryl F. Rosen, Dragan Gajic, and Daniel J. Drucker.
- *2636 Potentiation of Topoisomerase Inhibitor-induced DNA Strand Breakage and Cytotoxicity by Tumor Necrosis Factor: Enhancement of Topoisomerase Activity as a Mechanism of Potentiation. Teruhiko Utsumi, Michael R. Mattern, Christopher K. Mirabelli, and Nabil Hanna.
- *2641 Metabolic Activation of Aflatoxin B₁ and 2-Amino-3-methylimidazo-4,5-furanone by Tamoxifen. Adult and Fetal Livers. Mitsuaki Honda, Masaki Tamada, Kiyohide Ohta, Kazuo Nagashima, Koshiro Hoiki, and Tetsuya Kamatani.
- 2646 Treatment of R-3327 Prostate Tumors with a Somatostatin Analog (Somatuline) as Adjunctive Therapy following Surgical Castration. Arthur E. Bogden, John E. Taylor, Jacques-Pierre Moreau, and David H. Coyle.
- *2651 Labeling Index and Labeling Distribution of Cells in Esophageal Epithelium of Individuals at Increased Risk for Esophageal Carcinoma in Huiyan, China. Li Dong Wang, Martin Lipkin, Song Liang Qui, Guan Rui Yang, Chung S. Yang, and Harold L. Newmark.
- *2654 The Down-Regulation of α -Interferon Receptors in Human Lymphoblastoid Cells: Relation to Cellular Responsiveness to the Antiproliferative Action of α -Interferon. Lawrence M. Pfeiffer and David B. Donner.
- *2499 Kinetics of Transitional Tumor Cell Line 4909 Adherence to Injured Urothelial Surfaces in F-344 Rats. William A. See, Phillip H. Chapman, and Richard D. Williams.
- 2505 Expression of Epidermal Growth Factor Receptor, Polyamines Levels, Ornithine Decarboxylase Activity, Micrometastasis, and Transglutaminase II in a 7,12-Dimethylbenz(a)anthracene-induced Hamster Buccal Pouch Carcinogenesis Model. Dong M. Shin, Irma B. Gimenez, Jin S. Lee, Kenji Nishioka, Michael J. Wangovich, Scott Thacher, Reuben Lotan, Thomas J. Slaga, and Waun Ki Hong.
- *2511 Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells. Valentine M. Macaulay, Michele J. Everard, J. Derrick Teale, Peter A. Trout, Judson J. Van Wyk, Ian E. Smith, and John L. Miller.
- *2518 c-Ha-ras-1 Oncogene-induced Differentiation and Natural Killer Cell Resistance in a Human Colorectal Carcinoma Cell Line. Darius J. Bagh, John C. D'Emilia, Ian C. Summerhayes, Glenn D. Steele, and Teresa Barozzi.
- *2524 Basic Fibroblast Growth Factor-like Activity and Receptors Are Expressed in a Human Gloma Cell Line. Richard S. Morrison, Janet L. Gross, William F. Herblin, Thomas M. Reilly, Pat A. LaSala, Ronnie L. Alterman, Joseph R. Moskal, Paul L. Kornblith, and Daniel L. Dester.
- *2530 Clinical Implications of the Expression of Epidermal Growth Factor Receptors in Human Transitional Cell Carcinoma. Edward M. Messing.
- 2538 Reactivity of a Monoclonal Antibody to Manganese Superoxide Dismutase with Human Ovarian Carcinoma. Mutsumi Ishikawa, Yuji Yaginuma, Hiroaki Hayashi, Tetsuya Shimizu, Yasuo Endo, and Naoyuki Taniguchi.
-
- Letter to the Editor
- 2543 Correspondence re: Junya Toguchida et al., Assignment of Common Allele Loss in Osteosarcoma to Subregions 17p13. Cancer Res., 49: 6247-6251, 1989. Burton Zbar.
- 2544 Announcement
- Eighteenth Annual Meeting of the AACR
Employment Register at the AACR Annual Meeting
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events
- 2546 Erratum
- R. Parker et al., 49: 4791-4795, 1989.
- 2547 Author Index

CONTENTS OF VOLUME 50

- *2713 Mechanism of Epipodophyllotoxin-induced Cell Death in Poly(Adenosine Diphosphate-Ribose) Synthesis-deficient V79 Chinese Hamster Cell Lines. Sandu Chatterjee, Divyang Trivedi, Shirley J. Petzold, and Nathan A. Berger.
- *2719 Effect of Hyponix on 1,3-Bis(2-chloroethyl)-1-nitrosoureas Cytotoxicity. 9L Cells. Aparajita Sarkar, Jih-Tsun Ho, Laurence J. Marton, and Dennis F. Deen.
- *2724 Frequent Loss of Heterozygosity on Chromosomes 6q, 11, and 17 in Human Ovarian Carcinomas. Je H. Lee, John J. Kavanagh, David M. Wildrick, J. Taylor Wharton, and Mark Black.
- *2729 Androgen-dependent Real Microsatellite Cytochrome P-450 Enzyme Responsible for N-Hydroxylation and Metabolic Activation of 3-Methoxy-4-aminobenzoene in the BALB/c Mouse. Masakuni Degawa, Shin-ichi Miura, and Yoshiyuki Hashimoto.
- *2734 Addition of 2-Nitroimidazole Radiosensitizers to *cis*-Diamminedichloroplatinum with Radiation and with or without Hyperthermia in the Mice FSaIIc Fibrosarcoma. Terence S. Herman, Beverly A. Teicher, Sylvia A. Holden, M. Raphael Pfeffer, and Steven M. Jones.
- *2741 Leukemia following Chemotherapy for Breast Cancer. Rochelle E. Curtis, John D. Boice, Jr., William C. Moloney, Lynn Gieseker Roës, and John T. Flannery.
- *2747 Selectivity of Rat and Human Glutathione S-Transferases in Activation of Ethylene Dibromide by Glutathione Conjugation and DNA Binding and Induction of Unscheduled DNA Synthesis in Human Hepatocytes. Jon L. Cmarik, Philip B. Inskip, Michael J. Meredith, David J. Meyer, Brian Ketterer, and F. Peter Guengerich.
- *2753 Ca²⁺-dependent Binding of Tamoxifen to Calmodulin Isolated from Bovine Brain. M. Celeste F. Lopes, M. Graça P. Vale, and António P. Carvalho.
- *2759 Accumulation of O⁶-Methylguanine in Human Blood Leukocyte DNA during Exposure to Procarbazine and Its Relationships with Dose and Response. Vassilis L. Souloukos, Stella Kaita, Viki A. Boussioutis, Gerasimos A. Pangalis, and Soterios A. Kyriopoulos.
- *2765 Neopterin Formation and Tryptophan Degradation by a Human Myelomonocytic Cell Line (THP-1) upon Cytokine Treatment. Gabriele Werner-Felmayer, Ernst Robert Werner, Dietmar Fuchs, Arno Hauser, Gilbert Reibniger, and Helmut Wachter.
- *2768 Production of Urothelial Tumors in the Heterotopic Bladder of Rat by Benzidine Derivatives. Ching Y. Wang, Kim Zukowski, Hideyuki Yamada, Katsumi Imaida, and Mei-Sie Lee.
- 2872 Activity of Quinone Alkylating Agents in Quinone-resistant Cells. Ascher Begler and Marsha K. Leith.
- *2877 Use of Polymerase Chain Reaction to Detect the Expression of the *M*, 70,000 Heat Shock Genes in Control or Heat Shock Leukemic Cells Correlated to Their Heat Response. Nahid F. Michevi and John J. Rossi.
- *2885 Interleukin 6 Perfusion Stimulates Reconstitution of the Immune and Hematopoietic Systems after 5-Fluorouracil Treatment. Fumihiro Takatsuki, Akira Okano, Cheiko Suzuki, Yuko Miyasaka, Toshio Hirano, Tadamitsu Kishimoto, Daisuke Ejima, and Yukio Akiyama.
- *2891 Phorbol Esters Induce Changes in Adenosine Deaminase, Purine Nucleoside Phosphorylase, and Terminal Deoxynucleotidyl Transferase Messenger RNA Levels in Human Leukemic Cell Lines. Vicente Madrid-Marín, Hector Martínez-Valdez, and Amos Cohen.
- *2895 Identification of Phosphoprotein NP33 as a Nucleus-associated Ribosomal S6 Protein and Its Phosphorylation in Hematopoietic Cells. Donald E. Macfarlane and David Gallani.
- 2901 Differences between Normal and *ras*-transformed NIH-3T3 Cells in Expression of the 170KD and 180KD Forms of Topoisomerase II. Richard D. White, Thomas D. Y. Chung, Glenn H. Hofmann, Michael R. Mattern, Christopher K. Mirabelli, Fred H. Drake, and Randall K. Johnson.
- *2909 Parameters Affecting Tumor-specific Delivery of Anti-CD5 Antibody-Rituximab in *In Vivo*. Odile Rostaing-Capillon and Pierre Casellas.
- *2917 Accumulation of Highly Acidic Sulfated Glycosphingolipids in Human Hepatocellular Carcinoma Defined by a Series of Monoclonal Antibodies. Nozomu Hiraiwa, Yoshihiro Fukuda, Hiroo Imura, Keishi Tadano-Arimoto, Ken-ichi Nagai, Inoko Ishizuka, and Reiji Kannagi.
- *2929 Antitumor Effects of Ricin A Chain Immunotoxins Prepared from Instant Antibodies and Fab Fragments on Solid Human Hodgkin's Disease Tumors in Mice. Andreas Engert, Gary Martin, Michael Pfreundschuh, Peter Amiot, Su-Ming Hsu, Peter Diehl, and Philip Thorpe.
- *2936 Comparison of Biodistribution of 791T/36 Monoclonal Antibody and its Fab₂ Fragment in BALB/c Mice and Nude Mice Bearing Human Tumor Xenografts. Sylvie Demignot, Malcolm W. Fimmo, and Robert W. Baldwin.
- *2943 Preliminary Correlations of Clinical Outcome with *In Vitro* Cytosensitivity of Second Passage Human Breast Cancer Cells. Helene S. Smith, Wainer Zoli, Annalisa Volpi, Alan Hiller, Marc Lipman, Sandra Swain, Brian Mayall, Charles Dollbaum, Adeline J. Hackett, and Dino Amadori.
- *2949 Influences of Interleukins 2 and 4 on Tumor Necrosis Factor Production by Murine Mononuclear Phagocytes. William H. McBride, James S. Economou, Ramin Nayersina, Sian Comora, and Richard Essner.
- *2766 Effects of Tumor Necrosis Factor α on Skeletal Muscle and Walker 256 Carcinoma Protein Metabolism Studied *In Vivo*. John A. Tayek and Jo Anne Brasel.
- *2769 Effect of α -Difluoromethylorotate on 1,3-Bis(2-chloroethyl)-1-nitrosoureas and *cis*-Platinum-Dichloroplatinum(II) Cytotoxicity, DNA Interstrand Cross-Linking, and Growth in Human Brain Tumor Cell Lines *In Vitro*. Karl J. Hunter, Dennis F. Deen, Małgorzata Pellarin, and Laurence J. Marton.
- *2773 Characteristics of Cell Lines Established from Human Gastric Carcinomas. Joe-Gab Hall, Harold Frucht, Renato V. LaRocca, David P. Bliss, Jr., Yule Kuritz, Terence Chen, Jerry G. Henslee, David B. Trepel, Robert T. Jensen, Bruce E. Johnson, Henry-Jung Bang, Jin-Pok Kim, and Adri F. Gazdar.
- *2781 Development and Characterization of Pediatric Osteosarcoma Xenographs. William H. Meyer, Janet A. Houghton, Peter J. Houghton, Bruce L. Webber, Edwin C. Douglass, and A. Thomas Look.
- *2786 Chromosome Analysis of 31 Wilms' Tumors. Sheng Wang-Wuu, Shirley Soukup, Kevin Bove, Betsy Gotvald, and Beatrice Lampkin.
- *2794 Importance of Phenotypic and Molecular Characterization for Identification of a Neuroepithelioma Tumor Cell Line, NUB-20. Herman Yeger, Orna Mor, Gladys Pawlin, Chaim Kaplinsky, and Yosef Shiloh.
- 2803 Determination of the DNA Content of a Site-Gene Amplicon in the Multidrug-resistant Chinese Hamster Cell Line CHPB3 by Flow Karyotyping. A. P. M. Jongma, J. Rietveld, and J. A. Atieno.
- *2808 Bacterial *lacZ* Gene as a Highly Sensitive Marker to Detect Micrometastasis Formation during Tumor Progression. Wen-chang Lin, Theresa P. Pretlow, Thomas G. Pretlow II, and Lloyd A. Culp.

*2818 Reversal of Multidrug Resistance by Verapamil and Modulation by α_1 -Acid Glycoprotein in Wild-type and Multidrug-resistant Chinese Hamster Ovary Cell Lines. Mitali Chatterjee, Craig N. Robson, and Adrian L. Harris.

*2823 Marine Mollusc Toxins: Antibodies against Carcinoembryonic Antigen, Human, Immunological, Pharmacologic, and Targeting Properties in Humans. Robert M. Sharkey, David M. Goldenberg, Hildegard Goldenberg, Robert E. Lee, Cathy Ballance, David Pawlik, Donald Varga, and Hans J. Hansen.

*2832 Suppression of Transformation by and Growth Adaptation to Low Concentrations of Glutamine in NIH-3T3 Cells. Andrew L. Rubin.

*2840 c-Ha-ras Oncogene Expression in Immortalized Human Keratinocytes (HaCaT) Alters Growth Potential in Bok Lacks Correlation with Malignancy. Petra Boukamp, Eric J. Stanbridge, Debra Yin Foo, Peter A. Cerutti, and Norbert E. Fusenig.

*2848 Inhibitory Effect of Testosterone on Gap Junctional Intercellular Communication of Human Transitional Cell Carcinoma Cell Lines. Kazunori Kihara, Iwao Fukui, Yotsubo Higashii, and Hiroyuki Oshima.

Meeting Report

2853 Molecular Events in Mutation and Cancer: AACR Special Conference in Cancer Research. Dinshaw Patel, Bea Singer, and Bernard S. Strauss.

2857 Fourth Aspen Cancer Conference: Carcinogenesis—From Molecular Mechanisms to Molecular Epidemiology. Raymond W. Tennant.

2859 Annual Meeting: Eighth Annual Meeting of the AACR Employment Register at the Annual Meeting AACR Special Conferences in Cancer Research Future Annual Meetings of the AACR Calendar of Events

2862 Author Index

May 15, Number 10

- *2953 Combined Use of Cyclosporin A and Verapamil in Modulating Multidrug Resistance in Human Leukemia Cell Lines. Xiu F. Hu, T. J. Martin, David R. Bell, Mario de Luise, and John R. Zaiberg.
- *2958 Tumor-proliferative Activity, Progesterone Receptor Status, Estrogen Receptor Level, and Clinical Outcome of Estrogen Receptor-positive Advanced Breast Cancer. Angelo Paradiso, Stefania Tommasi, Anita Mangia, Vito Lorusso, Gianni Simone, and Mario De Lena.
- *2963 21st-Amino Methyle Blue for Targeted Radiotherapy of Human Melanoma Xenographs: Treatment of Micrometastases. Eva M. Link and Robert N. Carpenter.
- *2968 Blockage of Autonomous Growth of ACHN Cells by Anti-Renal Cell Carcinoma Monoclonal Antibody 5F4. John Kochevar.
- 2973 Association of a Functional Prostaglandin E₂-Protein Kinase A Coupling with Responsiveness of Metastatic Lewis Lung Carcinoma Variants to Prostaglandin E₂ and to Prostaglandin E₂-producing Nonmetastatic Lewis Lung Carcinoma Variants. M. Rita I. Young, Patrick Duffie, Yvonne Lozano, Melvin E. Young, and Mark A. Wright.
- *2979 Phase I and Immunobiological Study of a Muramyl Peptide, Muramyl Tripeptide Phosphatidylethanolamine. Walter J. Urba, Lynn D. Morrison, Dan L. Longo, Ronald G. Steis, John W. Smith II, Igol Cedar, Stephen Creekmore, Mario Szeto, Kevin Conlon, William C. Kopp, Christoph Huber, Manfred Herold, Gregory Alvoid, Sandra Snow, and Jeffrey W. Clark.
- *2987 Oncogene Amplification in Pediatric Brain Tumors. Jonathan C. Watson, Robert L. Saylor III, Paul Zeltzer, Henry S. Friedman, Sandra H. Bigner, Peter C. Burger, Darel D. Bigner, A. Thomas Look, Edwin C. Douglass, and Garrett M. Brodeur.
- *2991 Antibody-dependent, Cell-mediated Cytotoxicity by an Anti-Class II Murine Monoclonal Antibody: Effects of Recombinant Interleukin 2 on Human Effector Cell Lysis of Human B-Cell Tumors. William C. Biddle, James Pancok, Martin Goldrosen, Tim Han, Kenneth A. Foon, and Louis Vaikus.
- *2997 Polypeptide Core of a Human Pancreatic Tumor Mucin Antigen. Michael S. Lan, Michael A. Hollingsworth, and Richard S. Metzgar.
- *3002 Acetylation Phenotype, Carcinogen-Hemoglobin Adducts, and Cigarette Smoking. Paolo Vinchci, Neil Caporaso, Steven R. Tannenbaum, Paul L. Skipper, Joseph Glogowski, Helmut Barsch, Maria Coda, Glenn Talaska, and Fred Kadlubar.
- 3005 Detection of 1,N⁶-Propanodeoxyadenosine in Acrolein-modified Polydeoxyadenic Acid DNA by ³²P Postlabeling. Raymond A. Smith, Daniel S. Williamson, Ronald L. Cerny, and Samuel M. Cohen.
- *3013 Enhancement of Murine Lymphokine-activated Killer Cell Activity by Retinoic Acid. Tsung-Ising Lin and T. Ming Chi.
- *3019 Insulin-like Growth Factor 1 Receptors in Normal and Neoplastic Human Endometrium. Francisco Talavera, R. Kevin Reynolds, James A. Roberts, and K. M. J. Menon.
- *3025 Inhibition of Protein Kinase C (Sodium plus Potassium)-activated Adenosine Triphosphatase, and Sodium Pump by Synthetic Phospholipid Analogs. Bin Zheng, Kazuhiko Oishi, Mamoru Shoji, Hansjörg Elb, Wolfgang E. Beigel, Joseph Hajdu, William R. Vogler, and J. F. Kuo.
- *3032 Differential Expression of *ras* Oncogene in Primary Human Astrocytomas and Astrocytoma Cell Lines. Julian K. Wu and Donna M. Chikarishi.
- *3036 Suramin Prevents Binding of Interleukin 2 to Its Cell Surface Receptor: A Possible Mechanism for Immunosuppression. Gordon B. Mills, Nan Zhang, Christopher May, Mary Hill, and Andrew Chung.
- *3043 Inverse Correlation between Expression of Multidrug Resistance Gene and N-myc Oncogene in Human Neuroblastomas. Akira Nakagawa, Kenji Kadomatsu, Shin-ichi Sato, Kimitoshi Kohno, Hiroshi Takano, Kohei Akazawa, Yoshiaki Nose, and Michihiko Kuwano.
- 3048 Distribution of Covalent DNA Adducts in Mouse Epidermal Subpopulations after Topical Application of Benzo(a)pyrene and 7,12-Dimethylbenz(a)anthracene. Wanda Baer-Dubow, Rebecca J. Morris, Rosalynn D. Gill, and John Di Giovanni.
- *3055 Two Pyridine Analogues with Micro Effective Ability to Reverse Multidrug Resistance and with Lower Calcium Channel Blocking Activity Than Their Dihydropyridine Counterparts. Norimasa Shudo, Tetsuro Mizoguchi, Tatsuo Kiyosue, Makoto Arita, Akihiko Yoshimura, Kiyotomo Seto, Ryozo Sakada, and Shin-ichi Akiyama.
- *3062 Transport of Amino Acid Amide Sarcoinamide and Sarcoinamide Chlorothiptyrosine in Human Gloma SK-MG-1 Cells. Violetta Skalski, William Feindel, and Lawrence C. Panacci.
- *3067 Altered Structure and Expression of the Human Retinoblastoma Susceptibility Gene in Small Cell Lung Cancer. Charles H. Heidel, Chih-Lin Hsieh, Adri F. Gazdar, Bruce E. Johnson, Alan Y. Sakaguchi, Susan L. Naylor, Wen-Hwa Lee, and Eva Y.-H. P. Lee.
- 3073 Amplification of the c-myc Oncogene during Progression of Radiation-induced Rat Skin Tumors. Seymour J. Garte, Frederic J. Burns, Tracy Ashkenazi-Kimmel, Mary Feibis, and Mary Jean Sawey.
- *3078 Heterotransplantation of Human Lymphoid Neoplasms Using a Nude Mouse Intracranial Xenograft Model. Les White, Annette Trickett, Murray D. Norris, Vivienne Tobias, Lea Sosula, Glenn M. Marshall, and Bernard W. Stewart.
- *3087 Effects of 1,25-Dihydroxyvitamin D₃ on the Human Chronic Myelogenous Leukemia Cell Line RW-Len-4. Stephen R. Lasky, William Bell, Richard D. Huhn, Marshall R. Posner, Michael Wiemann, Paul Calabresi, and Charles Eli.
- *3095 Suppression of the Malignant Phenotype in Somatic Cell Hybrids between Burkitt's Lymphoma Cells and Epstein-Barr Virus-immortalized Lymphoblastoid Cells despite Derepressed c-myc Expression. Jürgen Wolf, Michael Pawlita, Jörn Bullerdiek, and Harald zur Hausen.
- *3101 Alteration of Differentiation State of Human Hepatocytes Cultured with Novobiocin and Butyrate. Yoshiyuki Kaneko, Toshihumi Nakayama, Ayumi Tsukamoto, and Kiyoshi Kuroki.
- *3106 Malignant Lymphoma Antigen Expressed in Nude Mouse Tumor Cells Derived from Carcinogen-transformed Bloom's Syndrome Cell Lines. Yukimasa Shiraiishi, Toshiaki Monki, Hiroshi Hara, Kyojiro Araki, Mitsuo Kozuru, and Avery A. Sandberg.

CONTENTS OF VOLUME 50

- *3113 Local Adoptive Immunotherapy of Human Head and Neck Cancer Xenografts in Nude Mice with Lymphokine-activated Killer Cells and Interleukin-2. Manuela Sacchi, Carl H. Snyderman, Dae Seog Heo, Jonas T. Johnson, Frank d'Amico, Ronald B. Herberman, and Theresa L. Whiteside.

3119 Neurotoxicity and Pharmacokinetics of Intrathecal Perfusion of ACNU in Dogs. Masato Kochi, Jun-ichi Kuratsu, Yosuke Miura, Shu-ichi Takaki, Nobuhiko Inoue, Nobuyuki Sueyoshi, Shozaburo Uemura, and Yukitaka Ushio.

*3137 Effect of N,N'-Bis(ethyl)homospermine on the Growth of U-87 MG and SF-126 Human Brain Tumor Cells. Hirak S. Basu, Malgorzata Pellarin, Burr G. Feuerstein, Dennis F. Deen, Raymond J. Bergeron, and Laurence J. Marton.

*3141 An Abnormal Profile of DNA Replication Intermediates in Bloom's Syndrome. Ulf Lönn, Sigrid Lönn, Urban Nylen, Gerard Winblad, and James German.

*3146 Coordinated Induction of Autocrine Tumor Necrosis Factor and Interleukin 1 in Normal Human Monocytes and the Implications for Monocyte-mediated Cytotoxicity. Diana M. Smith, Gregory A. Lackides, and Lois B. Epstein.

*3154 Effect of Recombinant Human Interleukin-4 on Human Monocyte Activity. Melissa M. Hudson, Avi B. Markowitz, Jordan U. Gutierrez, Rebecca D. Knowles, John S. Snyder, and Eugene S. Kleinerman.

3159 Immune Response to Progeria Variants Derived from Transfection of an Ultraviolet Radiation-induced C3H Mouse Regressor Tumor Cell Line with Activated Harvey-ras Oncogenes. David S. Kabe, William E. Pierciell, Jane E. Price, and Honnava R. N. Ananthanath.

*3167 Mouse-Human Chimeric Antibody against the Multidrug Transporter P-Glycoprotein. Hirofumi Hamada, Keiji Miura, Keiko Ariyoshi, Yuki Higuchi, Shigeo Sato, Kohzo Kameyama, Yoshihiko Kurosawa, and Tatsushi Tsuneto.

*3172 Inhibition of Estradiol Uptake and Transforming Growth Factor α Secretion in Human Breast Cancer Cell Line MCF-7 by an Alkyl-lysophosphatidyl. Hiroshi Kosano, Youros Yasutomo, Nobu Kuga, Naoko Nagata, Hiromi Inagaki, Shigaki Tanaka, and Osamu Takatani.

*3176 A Case-Control Study of Diet and Benign Proliferative Epithelial Disorders of the Breast. Thomas E. Rohan, Martin G. Cook, John D. Potter, and Anthony J. McMichael.

3182 Synergistic Action of Actin A and Hexamethylene Bisacetamide in Differentiation of Murine Erythroleukemia Cells. Takeyuki Yamashita, Yuzuru Eto, Hiroshi Shibusi, and Etsuro Ogata.

*3186 Relationship between Immunoglobulin Allotypes and Susceptibility to Nasopharyngeal Carcinoma in Malaysians. Robert E. Tarone, Paul R. Levine, Mamnoon Yadav, and Janardan P. Pandey.

*3189 Effect of Steroidal and Nonsteroidal Antiestrogens on the Growth of a Tamoxifen-stimulated Human Endometrial Carcinoma (EnCa01) in Athyric Mice. Marco M. Gottardi, Michelle E. Ricchio, Pendicherry G. Satyasaroop, and V. Craig Jordan.

3193 Molecular Analysis of Early Growth-associated Events during the Differentiation of F9 Cells into Embryoid Bodies. Mary Maureen Whitman, Yu-Min Shen, Dianne Soprano, and Kenneth J. Soprano.

*3199 Identification of a Nuclear Matrix-associated Region of the c-wye Protooncogene and Its Recognition by a Nuclear Protein in the Human Leukemia HL-60 Cell Line. Robin H. Chou, Judy R. Churchill, Marcella M. Flubacker, Diane E. Mapstone, and JoLynda Jones.

*3207 *In Vivo* and *In Vitro* Metabolism of 5-Doxazocysterahydrofolate, an Acyclic Tetrahydrofolate Analogue. Mary H. Hanlon, Robert Feroni, Robert J. Mullin, and Barry R. Keifei.

*3212 Wilms' Tumor and Paternal Occupation. Andrew F. Olshan, Norman E. Breslow, Janet R. Daniel, John M. Falletta, Seymour Grufferman, Leslie L. Robinson, Mary Waskierwitz, and G. Denman Hammond.

*3218 Biological Characterization of Multidrug-resistant Human Colon Carcinoma Sublines Induced/Selected by Two Methods. Li-Ying Yang and Jose M. Trujillo.

3226 Acquisition of Aryl Hydrocarbon Hydroxylase Inducibility by Aromatic Hydrocarbons in Monolayer-cultured Hepatocytes from Nonresponsive Mouse Strains. Nobuo Nemoto, Junko Sakurai, Ayumi Tazawa, and Takatoshi Ishikawa.

*3231 Use of Immunotoxins in Combination to Inhibit Clonogenic Growth of Human Breast Carcinoma Cells. Y. H. Yu, J. R. Crews, K. Cooper, S. Ramakrishnan, L. L. Houston, D. S. Leslie, S. L. George, Y. Lidor, C. M. Boyer, D. B. King, and R. C. Bassi, Jr.

*3239 Antitumor Activity of Ethyl 5-Anilino-1,2-dihydro-2-methyl-3-phenylproline-3,5-bis(2-phenyl-7-phenoxyl)-2-Hydroxyethanethiofuranate, Hydrate (NSC 370147) against Selected Tumor Systems in Culture and in Mice. William R. Waud, Wilbur R. Leopold, William L. Elliott, Donald J. Wykes, W. Russell Laster, Jr., Carroll G. Temple, Jr., Steadman D. Harrison, Jr., and Daniel P. Griswold, Jr.

*3124 Redlocalization of Human Small Cell Lung Cancer and Anti-gem-positive Normal Tissues Using Monoclonal Antibody LS2D0617. Barry S. Wilson, Ezio Petrella, Steven R. Lowe, Kristine Lien, Daniel G. Mackensen, Dalia S. Gridley, and Dwight R. Stickney.

3131 Correspondence re: Martin E. Sanders *et al.*, Molecular Pathways of Adhesion in Spontaneous Rosetting of T-Lymphocytes to the Hodgkin's Cell Line L428. *Cancer Res.*, 48: 37-40, 1988. D. J. Flavell and D. H. Wright. Reply by Martin E. Sanders.

Letter to the Editor

3136 Author Index

June 1, Number 11

*3245 Effect of Liposomes Containing Sodium Butyrate Conjugated with Anti-CD19 Monoclonal Antibody on *In Vitro* and *In Vivo* Growth of Malignant Lymphoma. Masahiko Watanabe, John M. Pesando, and Sen-Itaru Nakamura.

*3249 Antitumor Activity of IgG-Ricin Immunoconjugate against the H2981-T3 Lung Adenocarcinoma Cell Line *In Vitro* and *In Vivo*. Heinrich Schmidberger, Laurel King, Larry C. Lasky, and Daniel A. Valera.

*3257 Production of Endothelin in Human Cancer Cell Lines. Masatoshi Kubushita, Ken Yamaguchi, Koichi Nagasaki, Chiaki Hayashi, Ai Suzuki, Shingo Hori, Shunnozumi Honda, Youshiro Nakamura, and Kaoru Abe.

*3262 Role for Cytosolic Folate-binding Proteins in the Compartmentation of Endogenous Tetrahydrofolate and the 5,5'-Dithiobis-Tetrahydrofolate-mediated Enzyme of 5-Fluoro-2'-deoxyuridine Antimicrobial Activity *In Vitro*. Larry H. Matherly, Catherine A. Czajkowski, Stephen R. Muench, and John T. Paikai.

*3270 Increase in the Active Form of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase in Human Hepatocellular Carcinoma: Possible Mechanism for Alteration of Cholesterol Biosynthesis. Sumio Kawata, Kenji Takaiishi, Tohru Nagae, Nobuyuki Ito, Yoshihiko Matsuda, Shinji Tamura, Yuji Matsuzawa, and Seiichiro Tarui.

*3274 Lysis of Human Pronyltely-HL-60 Cells by Amphotericin B in Combination with 2-C₁₈-O-2-hydroxy-3-nitrosoresins: Role of the Carbonylating Activity of Nitroresins. Janina Bräutigam, Svetlana Elberg, Kenneth B. Schechtman, and Gerald Medoff.

*3279 Loss of Heterozygosity in Wilms' Tumors, Studied for Six Putative Tumor Suppressor Regions. Is Limited to Chromosome 11. M. Mannens, P. Deville, J. Blick, I. Mandjes, J. de Kraker, C. Heyting, R. M. Slater, and A. Westerveld.

*3284 Phase I Study and Pharmacodynamics of Pivansertamide (NSC 39174), a New Anthracycline. Alexander Hantel, Ross C. Donehower, Eric K. Rofoss, Estil Vance, Barbara V. Clarke, William P. McGuire, David S. Ettinger, Dennis A. Notz, and Louise B. Grochow.

*3289 Mutagenic Response of Fanconi's Anemia Cells from a Defined Complementation Group after Treatment with Photoactivated Bi-functional Psoralens. Dora Papadopoulou, Berardino Porfirio, and Ethel Moustachchi.

*3295 Risks Associated with Sources of Fiber and Fiber Components in Cancer of the Colon and Rectum. Jo L. Frishenfeld, Sonja Granom, Peter J. Horwath, James R. Marshall, Brenda P. Haughey, and Gregg Wilkinson.

*3301 Effect of Cyclosporine A on An Antigen Expression in N-Nitroso-N-methylurethane-induced Rat Mammary Tumors. Dominique J. Bernard, Jean-Claude Maurizis, Jacques Chassagne, Bernard Sauvage, Yvette Fonc, Philippe Chollet, and Robert Plagne.

*3306 Estrogen Regulation of Plasmid Alkaline Phosphatase Gene Expression in a Human Endometrial Adenocarcinoma Cell Line. Judith L. Albert, Susan A. Sundstrom, and C. Richard Lytle.

*3311 Antagonistic Effect of Aspirin on the Cytotoxicity of Etoposide and 4'-[6-Aminohexamethyl]methanesulfon-m-anisidine in Human Small Cell Lung Cancer Cell Lines and on Topoisomerase II-mediated DNA Cleavage. Peter Buhl Jensen, Boe Sandahl Serenius, Erland J. F. Demant, Maxwell Schedsel, Palle Scheild Jensen, Lars Vindelev, and Henie Høi Hansen.

*3317 Association of the 323/343 Surface Glycoprotein with Tumor Characteristics and Behavior in Human Breast Cancer. Atul K. Tandon, Gary M. Clark, Gary C. Chamness, and William L. McGuire.

*3322 Inverse Secretion of Tumor Necrosis Factor α , Interleukin 1, and Interleukin 6 by Human Monocytic Cells Exposed to β -Galactosidase-specific Lectin from Clinically Applied Mytilus Extract. Tibor Hajto, Katarina Hostankova, Kari Frei, Christiane Rordorf, and Hans-Joachim Gabius.

*3327 Elevation of Leukemic Cell Intracellular Calcium by the Ether Lipid SRB 62-834. Charles M. Lazebny, Michael G. Thompson, and John A. Hickman.

*3331 Soluble Factor in Normal Tissues That Stimulates High-Molecular-Weight Sialoglycoprotein Production by Human Colon Carcinoma Cells. Tatsumi Irimura, Andrew M. McLasciac, Deborah A. Carlson, Masato Iriyagi, Elizabeth A. Grimm, David G. Menter, David M. Ota, and Karen R. Cleary.

3339 Classification of Anticancer Treatments by Their Differential Toxicity toward Putative Oxygenated and Hypoxic Tumor Subpopulations *In Vivo* in the NSCLC Murine Fibrosarcoma. Beverly A. Teicher, Sylvia A. Holden, Antoine Al-Achchi, and Terese S. Herman.

*3345 Joining of the c-wye Gene and a L1 Family Member on Chromosome 8 in a Human Primary Giant Cell Carcinoma of the Lung. Masayoshi Iizuka, Masahiko Shiraiishi, Michihiro C. Yoshida, Kenichi Hayashi, and Takuji Sekiya.

*3351 Biological Monitoring Screening of Patients Provided Antineoplastic Drugs including Adriamycin, Cyclophosphamide, 5-Fluorouracil, Methotrexate, and Vinca-alkaloids. Mary A. Newman, Shane Que Hee, Rita Schoeny, and Robert Lowry.

*3367 Metabolism of 2-Acetylaminofluorene and Benz(a)pyrene and Activation of ω -Cell-derived Heterocyclic Amine Mutagens by Human Cytochrome P-450. Michael E. McManus, Wendy M. Burgess, Maurice E. Verones, Anthony Hugget, Linda C. Quattrochi, and Robert H. Takei.

*3377 12-O-Tetradecanoylphorbol-13-Cateate-Induced Differentiation of a Human Rhinoblastomaclone. Linel Salvatore Aguzzino, Maria Bouche, Sergio Adamo, and Mario Molinari.

3383 Adhesion to Laminin and Expression of Laminin in Clonally Re-derived Transformed and Control Sublines from an Avian Epithelial Cell Strain. John G. Steele, Tarja A. Savolainen, B. Ann Dalton, Leon Smith, and Gary J. Smith.

*3390 Cytological Differences between Normal and Malignant Human Cell Populations in Culture. Una Gilvary, Denise Farrell, Vincent Lynch, Michael Moriarty, Margaret Dooley, Elizabeth Law, and Martin Clynes.

*3394 Expression of Transforming Growth Factor β , by Human Endometrial Carcinoma Cell Lines: Inverse Correlation with β Effects on Growth Rate and Morphology. Jeff A. Boyd and David G. Kaufman.

3400 Hepatocarcinogenesis Due to Chronic Liver Cell Injury in Hepatitis C Virus Transgenic Mice. Harold A. Dunsford, Stewart Seal, and Francis V. Chisari.

*3408 Expression of a Hybrid Form of Alkaline Phosphatase Isoenzyme in a Newly Established Cell Line (HUG-1) from a Gastric Cancer Patient. Hirokazu Imanishi, Tohru Hada, Koji Murazaki, Kazuyuki Hirano, and Kazuya Higashino.

*3413 Effects of Interferon on Tissue Content in Liver Metastases of Human Carcinoid Tumors. Torbjörn Andersson, Erik Wihander, Barbro Eriksson, P. G. Lindgren, and Kjell Öberg.

3416 Cytogenetic Analysis of Marine Embryo-derived Tumors. R. J. van Berlo, B. de Jong, J. W. Oosterhof, T. Dijkhuizen, J. Buit, and A. Dam.

*3427 Effects of Brystostatin 1 and 2 on Morphological and Functional Differentiation of SH-SY5Y Human Neuroblastoma Cells. Annika M. Jalava, Jari Heikkilä, Göran Åkerblad, George R. Pettitt, and Karl E. Åkerblad.

*3429 Rearrangement of the Human *ABE* Oncogene in a Glioblastoma. Noe Heisterkamp, Christine Morris, Lenay Sender, Eva Knoppel, Luis Uribe, Mei-Ying Cui, and John Groffen.

3435 The Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-butanone is an Active Transplacental Carcinogen in Syrian Golden Hamsters. Enrique Correa, Pravadan A. Johli, André Castonguay, and Hildegard M. Schüller.

3439 Cellular and Molecular Changes in the Early Stages of Chemical Hepatocarcinogenesis in the Rat. Ritesh P. Evans, Harusige Nakatsuksa, Elizabeth R. Marsden, Chu-Chieh Hsu, Harold A. Dunsford, and Snorre S. Thorberg.

*3445 Targeting of Indium-111-labeled Biotinylated Hapten to Human Melanoma Cells by Biotinylated Monoclonal Antibody Conjugates: Imaging of Tumors Injected in Nude Mice. Jean-Marie Le Douarin, Alain Gruaz-Guyon, Marie Martin, Emmanuel Gauthier, Michel Delaigle, and Jacques Barber.

Meeting Report

3453 Differential Therapy. Reuben Lotan, Gillian E. Francis, Colette S. Freeman, and Samuel Waxman.

3465 Announcements

AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
New NCI Document: "Models of Metastasis"
Recent Deaths
Calendar of Events

3466 Erratum

G. Powis *et al.*, 2203-2211, 1990.
T. Nomura *et al.*, 2135-2138, 1990.

3467 Author Index

xi

CONTENTS OF VOLUME 50

June 15, Number 12

- 3469 Editorial.** Carlo M. Croce, Editor-in-Chief.
- Public Issues**
- 3470 Where Have Traditional Competing ROI Grants Gone?** Samuel Broder and John Hartinger.
- Reviews**
- 3473 Antineoplastic Activity of the Combination of Interferon and Cytotoxic Agents against Experimental and Human Malignancies: A Review.** Scott Wadler and Edward L. Schwartz.
-
- 3487 Intestinal Transport of Rabbit and Sheep Antibodies in Normal and Neoplastic Tissues.** Michelle A. Clauss and Rakesh K. Jain.
- *3493 Relationship between Dose Rate of [6⁵¹Cr]Leucovorin Administration, Plasma Concentrations of Reduced Folates, and Pools of 5,10-Methylenetetrahydrofolates and Tetrahydrofolates in Human Colon Adenocarcinoma Xenografts.** Janet A. Houghton, Larry G. Williams, Siebold S. N. de Graaf, Pamela J. Cheshire, John H. Rodman, Dan C. Maneval, Irving W. Wainer, Philippe Jadoul, and Peter J. Houghton.
- *3503 Manipulation of Oxygen Radical-scavenging Capacity in Mice Alters Host Sensitivity to Tumor Necrosis Factor Toxicity but Does Not Interfere with Its Antitumor Efficacy.** Gabriel J. Hauser, Joe K. McIntosh, William D. Travis, and Steven A. Rosenberg.
- 3509 Invasive and Metastatic Capacity of Revertants of LFA-1-deficient Mutant T-Cell Hybrids.** Folkert F. Roosien, Patricia E. de Kuiper, Diana de Rijk, and Ed Roos.
- 3514 Comparative Tissue Distribution in Mice of the α -Emitter ²¹⁴At and ²¹⁰Pb as Labels of a Monoclonal Antibody and F(ab')₂ Fragment.** Pradeep K. Gang, Cary L. Harrison, and Michael R. Zalutsky.
- *3521 Calyculin A, an Inhibitor of Protein Phosphatases, is a Potent Tumor Promoter on CD-1 Mouse Skin.** Masami Suganuma, Hirota Fujiki, Hiroko Furuya-Sugano, Shigeru Yoshizawa, Shigeru Yamamoto, Yuko Kata, Nobuhiko Fusani, and Takashi Sugimura.
- *3526 Characterization of OKT3-initiated Lymphokine-activated Effectors Expanded with Interleukin 2 and Tumor Necrosis Factor α .** Stephen C. Yang, Laura B. Owen-Schaub, Jack A. Roth, and Elizabeth A. Grimm.
- 3533 Inhibition by α / β -Interferon of the Multiplication of α / β -Interferon-resistant Friend Erythroleukemia Cells Cocultured with Mouse Hepatocytes.** Hiroaki Yasu, Enrico Proietti, Françoise Vignau, Pierre Eid, and Jon Gresser.
- *3540 Antitumor Activity of the Monoclonal Antibody-Vice Alkaloid Immunocomplex LY203725 (KS1/4-Desserrylvinblastine-3-carboxyazide) in a Nude Mouse Model of Human Ovarian Cancer.** Lynn D. Apelein, Dianna L. Zimmerman, Stephen L. Briggs, and Thomas F. Bumol.
- *3545 Automated Quantitation of Immunocytochemically Localized Estrogen Receptors in Human Breast Cancer.** Richard A. McClelland, Pauline Finlay, Kerry J. Walker, Denise Nicholson, John F. R. Robertson, Roger W. Blamey, and Robert L. Nicholson.
- 3551 Differential Drug Sensitivity Confered by Growth Status in a Mixed Population of Cyclins and Noncyclins.** M. H. Barcellos-Hoff, L. J. Marton, and Dennis F. Deen.
- *3556 Correlation between Cell Killing by *cis*-Diamminedichloroplatinum(II) in Six Mammalian Cell Lines and Binding of a *cis*-Diamminedichloroplatinum(II)-DNA Anticancer.** Philippe M. A. B. Terheggen, Joke Y. Emont, Ben G. J. Floot, Robert Dijkman, Peter I. Schrier, Leo den Engelse, and Adriana C. Beggs.
- *3562 Characterization of Glutathione S-Transferase Expression in Lymphocytes from Chronic Lymphocytic Leukemia Patients.** John C. Schisselbauer, Robert Silber, Esperanza Papadopoulos, Kevin Abrams, Frank P. LaCreta, and Kenneth D. Tew.
- 3569 Persistently Increased Expression of a 3-Methylcholanthrene-inducible Phenyl Uridine Diphosphate-Glucuronosyltransferase in Rat Hepatocyte Nodules and Hepatocellular Carcinomas.** Karl Walter Bock, Peter A. Munzel, Elke Rohrdanz, Dieter Schenck, and Lennart C. Eriksson.
- *3574 Interaction of Methotrexate Polyglutamates and Dihydrofolate during Leucovorin Rescue in a Human Breast Cancer Cell Line (MCF-7).** Carmen J. Allegra and Donna Boarman.
- *3579 Effects of 2,3,7,8-Tetrachlorobenz-p-dioxin and Related Compounds on the Occupied Nuclear Estrogen Receptor in MCF-7 Human Breast Cancer Cells.** M. Harris, T. Zacharewski, and S. Safe.
-
- *3585 Lymphocyte Subset Alterations in Nodes Regional to Human Melanoma.** Zohreh Farzad, Alisair J. Cochran, William H. McBride, J. Dixon Gray, Victoria Wong, and Donald L. Morton.
- *3589 Modulation of the Production of a Parathyroid Hormone-like Protein in Human Squamous Carcinoma Cell Lines by Interaction with Fibroblasts.** Klaas Hoekman, Clemens W. G. M. Löwik, Marjan v. d. Ruit, Johanna Kempenaer, Olaf L. M. Bijvoet, and Maria Poncet.
- *3595 Production of Diacylglycerol, an Activator of Protein Kinase C, by Human Intestinal Microflora.** Masami Morotomi, Jose G. Guillen, Paul LoGerfo, and I. Bernard Weinstein.
- *3600 Isolation and Characterization of a Rat Liver Epithelial Cell Line Resistant to the Antiproliferative Effects of Transforming Growth Factor β (Type I).** Munral S. Chapekar, Anthony C. Hugget, Caroline C. Cheng, Lori L. Hampton, K-H. Lin, and Snorre S. Thorgerisson.
- *3605 Epidemiology of Hairy Cell Leukemia in Los Angeles County.** Leslie Bernstein, Patricia Newton, and Ronald K. Ross.
- *3610 Physical Activity and Risk of Large Bowel Cancer in the Framingham Study.** Rachel Ballard-Barbash, Arthur Schatzkin, Demetrios Albanes, Mark H. Schiffman, Bernard E. Kreiger, William B. Kannel, Keaver M. Anderson, and William H. Ekelund.
- *3614 Changes in Glutathione Content and Resistance to Anticancer Agents in Human Stomach Cancer Cells Induced by Treatments with Melphalan *In Vitro*.** S. C. Barranco, C. M. Townsend, Jr., B. Weintraub, E. G. Beasley, K. K. MacLean, J. Shaefter, N. H. Liu, and K. Schellering.
- 3619 Enhancement of Murine Tumor Cell Sensitivity to Adriamycin by Presentation of the Drug in Phosphatidylcholine-Phosphatidylinositol Liposomes.** Dominic Fan, Corazon D. Bucana, Catherine A. O'Brian, Leonard A. Zwelling, Christopher Seid, and Isaiah J. Fidler.
- *3627 Activation of c-Ki-ras in Human Gastrointestinal Dysplasias Determined by Direct Sequencing of Polymerase Chain Reaction Products.** Stephen J. Meltzer, Shrikant M. Mane, Patrick K. Wood, James H. Resau, Carmel Newkirk, John A. Terzakis, Burton J. Korleitz, Wilfred M. Weinstein, and Samuel W. Neeman.
- 3631 Inhibition by Sulfated Chitin Derivatives of Invasion through Extracellular Matrix and Enzymatic Degradation by Metastatic Melanoma Cells.** Ikuo Saiki, Jun Murata, Motoyo Nakajima, Seishi Tokura, and Ichiro Azuma.
- *3638 Reduction of Immunogenicity by Covalent Modification of Murine and Rabbit Immunoglobulins with Oxidized Dextrans of Low Molecular Weight.** Roberto Fagnani, Michael S. Hagan, and Richard Bartholomew.
- *3640 Synergistic Action of a Plant Rhamnoglycan Enhancing Antitumor Cytotoxicity of Human Natural Killer and Lymphokine-activated Killer Cells: Chemical Specificity of Target Cell Recognition.** Edgar A. Mueller and F. Alfred Anders.
- *3652 Aromatase Inhibition by an Enzyme-activated Irreversible Inhibitor in Human Carcinoma Cell Cultures.** Robert W. Brueggemeier and Nancy E. Katic.
- *3657 Risk Factors for *In Situ* Cervical Cancer: Results from a Case-Control Study.** Carol J. Jones, Louise A. Brinton, Richard F. Hamman, Paul D. Stolley, Herman F. Lehman, Robert S. Levine, and Katherine Mallin.
- *3663 Evaluation of Arylmethylaminopropiobenzoil as a Novel *In Vitro* Pharmacodynamic Assay: Comparison with Mitogen Activity *In Vitro*.** David J. Adams, Pamela J. Watkins, Vincent C. Knick, Richard L. Tuttle, and Kenneth W. Baird.
- *3670 Effects of Calcium Antagonists in Multistage Resistant Primary Human Renal Cell Carcinomas.** Gerald H. Mikisch, Jutta Kosig, Gerhard Keilhauer, Erich Schlick, Reinhold K. Tschadka, and Peter M. Alken.
- *3675 Modulatory Activity of 2',2'-Difluorobenzoylcyclidine on the Phosphorylation and Cytotoxicity of Arabinosyl Nucleosides.** Varsha Gandhi and William Plunkett.
- *3681 Evaluation of Tetrazium-based Semiautomated Colorimetric Assay for Measurement of Human Antitumor Cytotoxicity.** Daeg Seog Heo, Jae-Gahb Park, Kensiuk Hata, Roger Day, Ronald B. Herberman, and Theresa L. Whitehead.
- *3691 A Somatosatin-secreting Cell Line Established from a Human Pancreatic Islet Cell Carcinoma (Somatostatinoma): Release Experiment and Immunohistochemical Study.** Haruo Iguchi, Itsuro Hayashi, and Akira Kohno.
- *3694 β -Microglobulin Expression in Human Embryonal Neuroblastoma Reflects Its Developmental Regulation.** Mark J. Cooper, Grover M. Hutchins, Robert J. Mennic, and Mark A. Israel.
-
- 3701 Tumor Promotion by the Peroxisome Proliferator Naftnopin Involving a Specific Subtype of Altered Fao in Rat Liver.** Bettina Kraupp-Gratz, Wolfgang Huber, Barbara Putz, Ulrich Gerbracht, and Rolf Schulte-Hermann.
- *3709 Human Cervical and Fallopian Epithelial Cells Immortalized by Human Papillomavirus DNA Exhibit Dysplastic Differentiation *In Vitro*.** C. D. Woodward, S. Waggoner, W. Barnes, M. H. Stoler, and J. A. DiPaolo.
- 3716 Repression of Nitrosamine-induced Pancreatic Cancer in Hamsters Treated with Luteinizing Hormone-releasing Hormone Agonists or Agonists.** Bela Szende, Goran Skralovic, Kate Groot, Karoly Lapis, and Andrew V. Schally.
- 3722 Multistage Neoplastic Transformation of Syrian Hamster Embryo Cells Cultured at pH 6.70.** R. A. LeBeouf, G. A. Kerckaert, M. J. Aardema, and D. P. Gibson.
- *3730 Growth-regulating Functions of Human Papillomavirus Early Gene Products in Cervical Cancer Cells Acting Dominant over Enhanced Epidermal Growth Factor Receptor Expression.** Magnus von Knebel Doeberitz, Lutz Gissmann, and Harald zur Hausen.
- *3737 Human Ig Trisomy in Tumorigenicity, Growth, and Metastasis of Human Leukemic B-Cell Clones in Nude Mice.** Tarunendu Ghose, Christine L. Y. Lee, Louis A. Fernandez, Spencer H. S. Lee, Raja Raman, and Patricia Colp.
- 3743 Melanocytotoxicity and Antimetastatic Effects of Phenolic Amine Compounds in Mice *In Vivo*.** Frank Alena, Kowichi Jimbow, and Shozo Ito.
- *3748 Programmed Cell Death during Regression of PC-82 Human Prostate Cancer following Androgen Ablation.** Natasha Kyrianiou, Hugh F. English, and John T. Isaacs.
- 3754 A Congenic Line of the BALB/c Mouse Strain with the Endogenous Mouse Mammary Tumor Virus Prevalent Gene *Mtr-3*: Tissue-specific Expression and Correlation with Resistance to Mouse Mammary Tumor Virus Infection and Tumorigenesis.** Pierre Hainaut, Marc Castellazzi, Dominique Gonzales, Nathalie Clause, Jo Hilgers, and Michel Crepin.
- 3761 Inhibition of p34 cdc2 Kinase Activity by Etoposide or Irradiation as a Mechanism of G₂ Arrest in Chinese Hamster Ovary Cells.** Richard B. Lock and Warren E. Ross.
- 3767 Possible Role for p34 cdc2 Kinase in Etoposide-induced Cell Death of Chinese Hamster Ovary Cells.** Richard B. Lock and Warren E. Ross.
- 3772 Dose-Response Relationship between O 6 -Methylguanine Formation in Clara Cells and Induction of Pulmonary Neoplasia in the Rat by 4-(Methyl)nitrosamo-1-(S-Prvidyl)-1-butamine.** Steven A. Belinsky, Julie F. Foley, Catherine M. White, Marshall W. Anderson, and Robert R. Maronpot.
- *3781 A Heparan Sulfate-containing Fraction of Bone Marrow Stromal Induces Maturation of HL-60 Cells *In Vitro*.** Sharon D. Lukhart, Charles A. Mangilia, Leo T. Furcht, James B. McCarthy, and Theodore R. Osgeme.
- 3786 Estradiol Stimulation and Inhibition of Cell Growth in New Estrogen-sensitive Cell Lines and Tumors Established from the MMTV Tumor.** Marie-Odile Joly-Pharaboz, Fei Zhou-Li, Bruno Boulard, and Jean Andre.
- *3795 Frequency and Pattern of Karyotypic Abnormalities in Human Prostate Cancer.** Arthur R. Brothman, Donna M. Peehl, Ankita M. Patel, and John E. McNeal.
-
- Letter to the Editor**
- 3804 Stomach Cancer and Cigarette Smoking among U. S. Veterans, 1954-1980.** Joseph K. McLaughlin, Zdenek Hrubec, William J. Blot, and Joseph F. Fraumeni, Jr.
- Meeting Report**
- 3805 Workshop Report from the Division of Research Grants, National Institutes of Health: Molecular Genetic Approaches to the Analysis of Malignant Transformation—A Pathology B Study Section Workshop.** Philip Furmanski, Frank Chisari, Angel Pellicer, Nelson Fausto, and Martin Padarathsingh.
- 3807 Announcements**
- AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
American Cancer Society Research Grants in Primary Prevention and Detection
Calendar of Events
- 3808 Errata**
- G. Skralovic *et al.*, 50: 1841-1846, 1990.
S. H. Bigner *et al.*, 50: 2347-2350, 1990.
- 3810 Author Index**

CONTENTS OF VOLUME 50

July 1, Number 13

Perspectives in Cancer Research
Special Lecture

3816 Molecular Cytogenetics: Rosetta Stone for Understanding Cancer—Twenty-ninth G. H. A. Clowes Memorial Award Lecture. Janet D. Rowley.

3826 Interaction with Hyperthermia of Tetrachloroplatinum(II)(Nile Blue) and Tetrachloroplatinum(II)(Neutral Red) in EMT6 Murine Cells and the Murine F344 Fibrosarcoma. Terence S. Herman, Beverly A. Teicher, M. Raphael Pfeiffer, Vrinda S. Khandekar, and Timothy T. Korbut.

3832 Prediction of Relapse and Survival in Breast Cancer Patients by p52 Protein Status. John A. Foekens, Marie-Christine Rio, Patrick Seguin, Wim L. J. van Putten, Joël Faquin, Martin Nap, Jan G. M. Klijn, and Pierre Chamont.

3838 Combined Inhibition of S-Adenosylmethionine Biosynthesis and S-Adenosylhomocysteine Metabolism Enhances Inhibition of Nucleic Acid Methylation and LI210 Cell Growth. Debora L. Kramer, Carl W. Porter, Ronald T. Borchardt, and Janice R. Sufrin.

3843 Comparison of the Fibronectin-binding Ability and Antitumor Efficacy of Various Mycoactin. M'Lise A. Hudson, Julie K. Ritchey, William J. Catalona, Eric J. Brown, and Timothy L. Ratliff.

3848 Genetic Analysis of Resistance to Radiation-Induced Lymphomagenesis with Recombinant Inbred Strains of Mice. Masaaki Okumoto, Ryosuke Nishikawa, Syunsuke Imai, and Jo Higlers.

3851 Major Histocompatibility Complex Class I and Unique Antigen Expression by Murine Tumors That Escaped from CD8⁺ T-Cell-dependent Surveillance. Patricia L. Ward, Hartmut K. Koeppen, Teresa Hureau, Donald A. Rawle, and Hans Schreiber.

3859 Relationship of Serum Levels of Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate to the Risk of Developing Postmenopausal Breast Cancer. Gary B. Gordon, Tracy L. Bush, Kathy J. Heltsouer, Susan R. Miller, and George W. Comstock.

3863 A Human Monocyte Growth Factor Produced by Lung Cancer Cells. Tetsuro Okabe and Kaoru Yasukawa.

3866 Effects of Estrogen on Cell Proliferation and Leukotriene Formation in Transformed Mouse Leydig Cells Cultured under Serum-free Conditions. Yasuko Nishizawa, Kazumasa Nishii, Yoshio Nishizawa, Masafumi Koga, Susumu Kishimoto, Keishi Matsusomo, and Bunzo Sato.

3872 M₉ 92,000 Gelatinase Release Correlates with the Metastatic Phenotype in Transformed Rat Embryo Cells. Eric J. Bernhard, Ruth J. Muschel, and Edward N. Hughes.

3878 Combination Cytotoxic-Differentiation Therapy of Mouse Erythroleukemic Cells with S-Fuorouracil and Hexamethylene Biacetamide. Samuel Waxman, Barbara M. Scher, Nella Hellinger, and William Scher.

3888 Expression of a M_{32,000} Lamina-binding Protein Messenger RNA in Human Colon Carcinoma Correlates with Disease Progression. Ken-ichi Mafune, T. S. Ravikumar, Jau Min Wong, Hsiukang Yow, Lan Bo Chen, and Glenn D. Steele, Jr.

3892 Volume-operated Calcium Channels in Small Cell Lung Carcinoma Cell Lines: Pharmacological, Functional, and Immunological Properties. Emanuele Sher, Atanasio Pandolfi, and Francesco Clementi.

3897 Role of Natural Killer Cells and Macrophages in the Nonspecific Resistance to Tumors in Mice Stimulated with SMANCS, a Polymer-conjugated Derivative of Necoxazostatin. Fujio Suzuki, Richard B. Pollard, Satomi Uchimura, Tetsuo Munakata, and Hiroshi Maeda.

3905 Phase I and Clinical Pharmacological Evaluation of Pirazoxantone Hydrochloride (Oxantrazole). Matthew M. Ames, Charles L. Loprinzi, Jerry M. Collins, Carol van Haelst-Pisan, Ronald L. Richardson, Joseph Rubin, and Charles G. Moertel.

3910 Kinetics of N-(4-Chlorophenyl)amino[carboxy]L-2,3-dihydro-1H-indene-5-sulfonamide (LY18661) in Humans. Kenneth R. Hande, John Kutsch, Martha Hamilton, Winston Satterlee, Linda Jackson, Gerald Grindley, and John D. Hainsworth.

3915 1,2-Dimethylhydrazine-induced Alterations in Protein Kinase C Activity in the Rat Preneoplastic Colon. Charles L. Baum, Ramesh K. Wali, Michael D. Styrn, Merry J. G. Bolt, and Thomas A. Brasitus.

3921 Elevated Pentose Cycle and Glucuronidyltransferase in Dammourin-resistant P388 Cells. Teresa Gessner, Lurine A. Vaughan, Blake C. Beehler, Christopher J. Berrels, and Raymond M. Baker.

3928 Prolonged Survival of Tumor-bearing Rats with Repetitive Low-Dose Recombinant Tumor Necrosis Factor. Brett C. Shepard, David Venzon, Douglas L. Fraker, Howard N. Langstein, J. Christian Jensen, and Jeffrey A. Norton.

- *3934 Modulation of Pro-Epidermal Growth Factor, Pro-Transforming Growth Factor α and Epidermal Growth Factor Receptor Gene Expression in Human Renal Carcinomas. Petro E. Petrides, Susanne Bock, Jutta Bovens, Rainer Hofmann, and Gerhard Jakse.
- *3940 Influence of Dose of 16 β -RS11-Leucovisor on Reduced Folate Pools and 5-Fluorouracil-mediated Thymidine Synthase Inhibition in Human Colon Adenocarcinoma Xenographs. Janet A. Houghton, Larry G. Williams, Pamela J. Cheshire, Irving W. Wagner, Philippe Jadaud, and Peter J. Houghton.
- *3947 Hormonal Modulation of HER-2/neu Protooncogene Messenger Ribonucleic Acid and p185 Protein Expression in Human Breast Cancer Cell Lines. Linnea D. Read, Duane Keith, Jr., Dennis J. Slamon, and Benita S. Katenstein-Lobenberg.
- *3952 Serum Carcinoembryonic Antigen Level Increases Correlate with Tumor Progression in Patients with Differentiated Gastric Carcinoma following Noncurative Resection. Yoshihiko Machara, Keizo Sugimura, Masanobu Akagi, Teruo Kagegawa, Hisaka Shimazu, and Masao Tomita.
- *3956 Expression of a Nago-type, Phosphatidylinositol-Glycan Anchored Alkaline Phosphatase in Human Choriocarcinoma. Mark E. Lowe and Arnold W. Strauss.
- *3963 Regulation of Protein Kinase C by Ionizing Radiation. Gayle E. Woloschak, Chin-Mei Chang-Liu, and Pochahonts Shearin-Jones.
- *3968 A Neuropeptide Antagonist That Inhibits the Growth of Small Cell Lung Cancer *in Vitro*. Penelli J. Woll and Enrique Rozenburg.
- *3974 Estrogen Receptor Gene Methylation in Human Breast Tumors. Nicole S. LaFlette, Suzanne A. W. Fuqua, Gary C. Chamberlain, Marc S. Cheah, Geoffrey L. Greene, and William L. McGuire.
- *3979 Role of Substrate Depletion in the Inhibition of Thymidylate Biosynthesis by Dihydrofolate Reductase Inhibitor Trimetrexate in Cultured Hepatoma Cells. Myung S. Rhee, Małgorzata Balinska, Małgorzata Bunn, David G. Priess, Gladys F. Maley, Frank Maley, and John Galvin.
- *3985 Tissue Distribution and Photosensitizing Properties of Mono-l-aspartyl Chlorin ϵ in a Mouse Tumor Model. Charles J. Gomer and Angela Ferraro.
- *3991 Association between Diet and Age-related DNA Modifications (I-Compounds) in Rat Liver and Kidney. Donghui Li and Kurt Randerath.
- *3997 Reversal of Lipophilic Resistance by Lipophilic Drugs. Eva Hofsäß and Jon Nissen-Meyer.
- *4003 Flow Cytometric DNA Ploidy Analysis of Feline Mammary Tumors. Jules M. H. M. Minke, Cees J. Cornelisse, John A. M. Stolwijk, Nel J. Kuipers-Dijkshoorn, Gerard R. Rutteman, and Wim Misrauw.
- *4008 Cachectic Effects of Recombinant Human Tumor Necrosis Factor in Rats. Gail Hunting, Douglas L. Fraker, J. Christian Jensen, Catherine M. Gorschlüter, and Jeffrey A. Norton.
- *4014 Mutational Analysis of the H-ras Oncogene in Spontaneous C57BL/6 x C3H/He Mice Liver Tumors and Tumors Induced by Genotoxic and Nongenotoxic Hepatocarcinogens. Tony R. Fox, Alan M. Schiuma, Philip G. Watanabe, Barry L. Yano, Veronika M. Maher, and J. Justin McCormick.
- *4020 Selective Killing of Malignant Cells from Leukemic Patients by Alkyl-Lysophosphatidyl-Leo P. Verdronck, Els O. Witteveen, Hans G. van Heugten, Erik Rozemuller, and Gert Rijken.
- *4026 5-Fluorouracil Enhances Azidothymidine Cytotoxicity: *In Vitro*, *In Vivo*, and Biochemical Studies. Isa Brunetti, Alfredo Falcone, Paul Calabresi, Frederick A. Goulette, and James W. Dawson.
- *4032 Induction of Interleukin 3 and Tumor Resistance by SSM, a Cancer Immunotherapeutic Agent Extracted from *Mycoctonus terebrans*. Hidetaka Sasaki, David Schmitt, Yoshiro Hayashi, Richard B. Pollard, and Fujio Suzuki.
- *4038 Effects of 1-Phenylalanine Mustard and L-Buthionine Sulfoximine on Murine and Human Hematopoietic Progenitor Cells *in Vitro*. De-Lin Du, Donna A. Volpe, Charles K. Griehaber, and Martin J. Murphy, Jr.
- *4044 Characterization of Nonexchangeable Radioactivity in LI210 Cells Incubated with [³H]-Thioguanine. Merrill J. Eggers and Stuart W. Snyder.
- *4050 Radiosensitivity of Skin Fibroblasts from Atomic Bomb Survivors with and without Breast Cancer. Sadayuki Ban, Richard B. Setlow, Michael A. Bender, Haruo Ezaki, Toshiro Hiraoaka, Motoi Yamane, Masayuki Nishiki, Kiyohiko Dohi, Akio A. Awa, Richard C. Miller, Dilys M. Parry, John J. Mulvihill, and Gilbert W. Beebe.
- *4056 Paradoxical Increase in DNA Cross-Linking in a Human Ovarian Carcinoma Cell Line Resistant to Cytomorpholino Doxorubicin. Derick H. M. Lau, Kevin L. Ross, and Branimir I. Sikic.
- *4061 Transient Alterations in the Expression of Protease and Extracellular Matrix Genes during Metastatic Lung Colonization by H-ras-transformed 10T_{1/2} Fibroblasts. M. C. Gingras, L. Jarolim, J. Finch, G. T. Bowden, J. A. Wright, and A. H. Greenberg.
- *4067 Depletion of Cellular Glutathione by N,N'-Bis(triazin-4-yl)-N-nitrosourea as a Determinant of Sensitivity of K562 Human Leukemia Cells to 4-Hydroperoxycyclphosphamide. Christine M. Chresta, Tim R. Crook, and Robert L. Souhami.
- *4072 Hepatic Neoplasms in Aflatoxin B₁-treated, Congenital Duck Hepatitis B Virus-infected, and Virus-free Pekin Ducks. John M. Cullen, Patricia L. Marion, Glenn J. Sherman, Xin Hong, and John E. Newbold.
- *4081 Spontaneous Prostatic Transplantable Tumor in the Wistar/Furth Rat (SM/WF): A New Animal Model of Human Prostate Cancer. Jacqueline Trouiller, Christian Girod, Bruno Claustre, Marie-Odile Joly-Paraboz, and Pascale Chevallier.
- *4087 Overexpression of HER-2/neu Is Associated with Poor Survival in Advanced epithelial Ovarian Cancer. A. Berchuck, A. Kamel, R. Walker, B. Kortes, J. Orr, R. Lawrence, J. T. Soper, D. Dodge, D. L. Clarke-Pearson, P. Marks, S. McKenzie, S. Yin, and R. C. Bast, Jr.
- *4092 Chromosomal Aberrations in Uterine Smooth Muscle Tumors: Potential Diagnostic Relevance of Cytogenetic Instability. Jonathan A. Fletcher, Cynthia C. Morton, Karen Pavilia, and Janice M. Lage.
- *4098 Cloning of Estrogen-responsive Messenger RNAs in the T-47D Human Breast Cancer Cell Line. David L. Manning, Leslie H. Archibald, and Kim T. Ow.
- *4105 Monoclonal Antibody and F(ab)₂ Fragment Delivery to Tumor in Patients with Glioma: Comparison of Intracarotid and Intravenous Administration. Michael R. Zalutsky, Robin P. Morely, Jonathan C. Benjamin, Edward V. Colapinto, Gregory N. Fuller, Hugh P. Coakham, and Darrell D. Bigner.
- *4111 B-Cell Growth Factor-induced and α -Interferon-inhibited Proliferation of Hairy Cell Leukemia Coincides with Modulation of Cell Surface Antigen. Haim Gamliel, Bernard H. Brownstein, Dorit Gurfil, Shai-Hua Wu, Michael C. Rosner, and Harvey M. Golomb.
- *4121 Retinoic Acid Inhibition of Human Melanoma Cell Invasion through a Receptor-mediated Mechanism and Its Relation to Decreases in the Expression of Prostaglandin Endoperoxide Synthase-2. Mary J. C. Hendrix, W. Rebecca Wood, Elisabeth A. Seifert, Dafna Lotan, Motoyo Nakajima, Ronald L. Misiroglu, Richard E. B. Seifert, William G. Steiner-Stevenson, Sandra J. Beauvais, Lance A. Liotta, Mark E. Sobet, Abraham Raz, and Reuben Lotan.
- *4131 Tumor Angiogenesis and Polyaniline: α -Difluoromethylhydrazine, an Irreversible Inhibitor of Ornithine Decarboxylase, Inhibits B16 Melanoma-induced Angiogenesis *In Vivo* and the Proliferation of Vascular Endothelial Cells *In Vitro*. Masaharu Takigawa, Motomu Enomoto, Yukimitsu Nishida, Hau-Ou Pan, Akhiro Kinoshita, and Fujio Suzuki.
- *4139 Biological Characterization of Permeabilizing-forming Cell Lines from Human Adenoid Cystic Carcinomas of Minor Salivary Gland Origin. Kanemitsu Shirasuna, Kazuya Watanabe, Hideyuki Furusawa, Munehisa Saka, Shigejuki Morioka, Hideo Yoshikawa, and Tokuzo Matsuya.
- *4146 Amplification and Rearrangement of c-myc in Radiation-induced Murine Osteosarcomas. Silvia A. Sturm, P. Gunter Strauss, Sabine Adolph, Horst Hamseuer, and Volker Erffle.
- *4154 Phase I Clinical Comparative Study of Monoclonal Antibody KS1/4 and KS1/4 Merlotretase Immunoconjugate in Patients with Non-Small Cell Lung Carcinoma. Darlene J. Elias, Lynn Hirschowitz, Lawrence E. Klein, Joan F. Kroemer, Robert O. Dillman, Leslie E. Walker, James A. Robb, and Richard M. Timms.
- *4160 Establishment and Characterization of Continuous Cell Line MTC-SK Derived from a Human Medullary Thyroid Carcinoma. Roswith Prager, Heinz Höller, Annemarie Behmel, Elisabeth Ingolic, and Veronika Walser.
- *4167 Rhodamine 123 Cytotoxicity in Laser-irradiated MGH-U1 Human Carcinoma Cells Studied *In Vitro* by Electron Microscopy and Confocal Laser Scanning Microscopy. Christopher R. Shea, Margaret E. Sherwood, Thomas J. Flotte, Norah Chen, Manfred Scholtz, and Tayyaba Hasan.

- 4173 Announcements
AACR Special Conference in Cancer Research
Future Annual Meetings of the AACR
American Cancer Society Research Grants in Primary Prevention and Detection
Calendar of Events

- 4174 Erratum
J.-T. Hsieh *et al.*, 50: 2239-2244, 1990.
4175 Author Index

CONTENTS OF VOLUME 50

July 15, Number 14

- Special Lecture**
- 4177 Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture. Leonard J. Lerner and V. Craig Jordan.
- *4190 Antiproliferative and Antitumor Effects of *c*-Interferon in Renal Cell Carcinomas: Correlation with the Expression of a Kidney-associated Differentiation Glycoprotein. David M. Nanus, Lawrence M. Pfeiffer, Neil H. Bander, Sanjeev Bahri, and Anthony P. Albino.
- 4195 Synergism by Sodium L-Ascorbate but Inhibition by L-Ascorbic Acid for Human Saccharomyces Pombe of Rat Two-Stage Bladder Carcinogenesis. Shigeki Fukushima, Satoshi Uwagawa, Tomoyuki Shirai, Ryohel Hasagawa, and Kumiko Ogawa.
- *4199 Reversal of the Multidrug Resistance Phenotype with Cremophor EL, a Common Vehicle for Water-insoluble Vitamins and Drugs. David M. Woodcock, Sara Jefferson, Martha E. Linsenmeyer, Penelope J. Crowther, Grace M. Chojnowski, Brenda Williams, and Ivan Bertoncello.
- *4204 Epidermal Growth Factor Gene Expression in Human Breast Cancer Biopsy Samples: Relationship to Estrogen and Progesterone Receptor Gene Expression. Helmut Dotzlaw, Teresa Miller, John Karvelas, and Leigh C. Murphy.
- 4209 Dexorubicin-induced Autotoxicity in Chick Heart Cell Aggregates. Joann C. Mitridis and Stephen M. Vogel.
- 4216 Protective Effects of Tumor Necrosis Factor on Murine Hematopoiesis during Cyclo-specific Cytotoxic Chemotherapy. Lars Sjöstrand, David J. Warren, and Malcolm A. S. Moore.
- 4221 Improved *In Vivo* Stability and Tumor Targeting of Bismuth-labeled Antibody. Curtis L. Rugg, Wendie T. Anderson-Berg, Martin W. Brechbill, Saed Mirzaee, Otto A. Gansow, and Mette Strand.
- *4227 Targeting Human T-Lymphocytes with Bispecific Antibodies to React against Human Ovarian Carcinoma Cells Growing in *su/su* Mice. Maria A. Garrido, María J. Valdado, David F. Winkler, Julie A. Titus, Toby T. Hecht, Pilar Perez, David M. Segal, and John R. Wunderlich.
- 4233 Search for Mediators of the Lipogenic Effects of Tumor Necrosis Factor: Potential Role for Interleukin 6. Carl Grunfeld, Salih Adi, Mounir Soued, Arthur Moser, Walter Fiers, and Kenneth R. Feingold.
- 4239 Age-, Tissue-, and *Ah* Genotype-dependent Differences in the Binding of 3-Methylcholanthrene and Its Metabolite(s) to Mouse DNA. Lee-Jane W. Lu, Ronald G. Harvey, Hongmee Lee, Jennifer R. Baxter, and Lucy M. Anderson.
- 4248 Tolerance to *O*-Methylguanine and 6-Thioguanine Cytotoxic Effects: A Cross-resistant Phenotype in N-Methyltrifluoromethyl-resistant Chinese Hamster Ovary Cells. Gabriele Aquilina, Anna Maria Giannarini, Andrea Zijno, Alfonso Di Muccio, Eugenia Dogliotti, and Margherita Bignami.
- *4254 Phase I Clinical and Pharmacological Study of Liposome-entrapped *cis*-Bis-neocodostearin-*R,R*-1,2-diaminocyclohexane Platinum(II). Roman Perez-Soler, Gabriel Lopez-Berestein, Julio Lautenberger, Samia Al-Baker, Karen Francis, Dede Macias-Kiger, Martin R. Raber, and Abdul R. Khokhar.
- 4260 Anthracycline Antibiotics with High Liposome Entrapment: Structural Features and Biological Activity. Roman Perez-Soler and Waldemar Prębeck.
- *4267 Pharmacokinetics of Continuous Infusion of Methotrexate and Teniposide in Pediatric Cancer Patients. John H. Rodman, Marc Sunderland, Ronald L. Kavanagh, Judith Ochs, Jack Yalowich, William E. Evans, and Gaston K. Rivera.
- *4272 Sensitivity of Different Human Lung Cancer Histologies to Photodynamic Therapy. Roger R. Perry, Wilbert Matthews, James B. Mitchell, Angelo Russo, Steven Evans, and Harvey I. Pass.
- 4277 Interaction of Rhizoxin with Bovine Brain Tubulin. Angelique S. Sullivan, Veena Prasad, Mary Carmen Roach, Masaki Takahashi, Shigeo Iwasaki, and Richard F. Ludueña.
- *4281 Ploidy Level Determinations in High-Grade and Low-Grade Malignant Variants of Prostatic Carcinoma. Gun Forslund and Anders Zetterberg.
- 4286 Reduction in the Frequency of Activated *r-sar* Oncogenes in Rat Mammary Carcinomas with Increasing N-Methyl-N-nitrosourea Doses or Increasing Prolatin Levels. Rong Zhang, Jill D. Haag, and Michael N. Gould.
- *4291 *In Vitro* Bone Marrow Purging of Multidrug-resistant Cells with a Mouse Monoclonal Antibody Directed against M, 170,000 Glycoprotein and a Saporin-conjugated Anti-Mouse Antibody. Angelo Distefano, Pier Luigi Tazzari, Mariangrazia Micheli, Giuseppe Visani, Marco Gobbi, Andrea Bonadini, Cristina Tassi, Renato Fanini, Daniela Damiani, Maria Grandi, Stefano Pileri, Andrea Bolognesi, Firenze Stirpe, Michele Bacchiani, and Tatsuki Tsuji, and Santa Turelli.
- 4295 Conditioning: A New Approach to Immunotherapy. Vithal K. Ghanta, Nancy S. Hiramoto, H. Brent Solvason, Seng-Jaw Soong, and Raymond N. Hiramoto.
- 4300 Metabolic Activation of the Potent Mutagen, 2-Naphthylhydroxamic Acid, in *Salmonella typhimurium* TA98. Mei-Sie Lee and Masakazu Isobe.
- 4308 Active Specific Immunotherapy of a Murine Mammary Adenocarcinoma Using a Synthetic Tumor-associated Glycoconjugate. Peter Y. S. Fung, Marian Madej, R. Rao Kangany, and B. Michael Longenecker.
- *4315 Induction and Developmental Expression of Cytochrome P4501A1 Messenger RNA in Rat and Human Tissues: Detection by the Polymerase Chain Reaction. Curtis J. Oemicinski, Carrie A. Redlich, and Paolo Costa.
- 4322 Effects of Anthracycline and Choline on Thiotepa Cellular Accumulation and Cytotoxicity in L1210 Cells. Merrill J. Egon, Stuart W. Snyder, and Bruce E. Wiethearn.
- *4328 Adenosine Receptors and Modulation of Natural Killer Cell Activity by Purine Nucleotides. Teresa Priebe, Chris D. Platoucas, and J. Arly Nelson.
- *4332 HER-2/neu Amplification Predicts Poor Survival in Node-positive Breast Cancer. Åke Borg, Åke Tandon, Helgi Sigurdsson, Gary M. Clark, Märten Fernö, Suzanne A. W. Fouqa, Dick Kilander, and William L. McGuire.
- 4338 Adoptive Immunotherapy of a Rat Glioma Using Lymphokine-activated Killer Cells and Interleukin 2. Jone-Jün Tseng, Rolf F. Barth, Nancy R. Cletonen, and Wanda A. Gordon.
- *4344 Calcium Deficiency of the Production of Interleukin 1 and the Expression of Interleukin 1 Receptors of Human Adult T-Cell Leukemia Cells. Yoshio Tanaka, Uki Yamashita, Kenichi Watanabe, Kazuhiko Nagata, Naoki Mori, Susumu Oda, and Sumiya Eto.
- *4349 Significance of Clq-binding Macromolecules within the Head and Neck Cancer Patient. Stimson P. Schantz, Howard E. Savage, Barry W. Brown, Gregory Young, Frank J. Liu, Gregg Reger, and Robert A. Newman.
- 4355 Inhibition by 6-Mercaptopurine of the Binding of a Benzopyran-Diol-Epoxye to DNA in Chinese Hamster Ovary Cells. Michael C. MacLeod, Ronald M. Humphrey, Tim Bickerstaff, and Anne Daylong.
- *4360 Response of Human Lung Tumor Xenographs to Treatment with a Somatostatin Analogue (Somatostatin). Arthur E. Boggs, John E. Taylor, Jacques-Pierre Moreau, Da H. Hoy, and Doreen J. LePage.
- 4366 Interpecies Scaling of the Pharmacokinetics of *N*-Nitrosodimethylamine. Charles T. Gombar, George W. Harrington, Harry M. Pylypiv, Jr., Lucy M. Anderson, Amos E. Palmer, Jerry M. Rice, Peter N. Magee, and Eric S. Burak.
- Meeting Reports**
- 4446 UCLA Colloquium—New Insights into Breast Cancer: The Molecular Biochemical and Cellular Biology of Breast Cancer. Robert B. Dickson, Marc E. Lippman, and Denis Stanion.
- 4448 Workshop on Linkage Studies of Hereditary Breast Cancer. G. M. Lenoir, S. A. Narod, and B. A. J. Fonder.
- 4450 Announcements
- AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
American Cancer Society Research Grants in Primary Prevention and Detection
Calendar of Events
- 4451 Errata
- A. W. Tong et al., 49: 4829-4834, 1989.
N. Kaneda et al., 50: 1713-1720, 1990.
N. Kaneda and T. Yokokura, 50: 1721-1725, 1990.
- 4452 Author Index

August 1, Number 15

- *4453 Flow Cytometric Analysis of DNA Damage and Repair in the Cells Resistant to Alkylating Agents. Stefan S. Frankfurt, Daniel Seckinger, and Everett V. Sugarbaker.
- 4458 Inhibition of Growth Factor-dependent Inositol Phosphate Ca^{2+} Signaling by Antitumor Ether Lipid Analogues. Markus J. Seewald, Richard A. Olsen, Inder Sehgal, Deborah C. Meider, Edward J. Modest, and Garth Powis.
- *4464 Pediatric Phase I Trial and Pharmacokinetic Study of Plituximab Administered Orally on a Five-Day Schedule. Peter C. Adamson, Frank M. Balis, James Miser, Robert J. Wells, W. Archie Bleyer, Thomas E. Williams, Andrew Gillespie, John S. Penta, Neil J. Clendenning, and David G. Poplack.
- *4468 Development of Drug Resistance to Gallium Nitrate through Modulation of Cellular Iron Uptake. Christopher R. Chittambar, Zora Zivkovic-Gilgenbach, Jana Narasimhan, and William E. Anholme.
- 4473 Dependence of Indomethacin-induced Potentiation of Murine Tumor Radioresponse on Tumor Host Immunocompetence. Lukas Milas, Yuichi Furuta, Nancy Hunter, Iku Nishiguchi, and Sanyukta Runkel.
- 4478 Interstitial Pressure Gradients in Tissue-isolated and Subcutaneous Tumors: Implications for Therapy. Yves Boucher, Laurence T. Baxter, and Rakesh K. Jain.
- *4485 Monoclonal Antibody and Synthetic Peptide Inhibitors of Human Tumor Cell Migration. Kenneth M. Yamada, Dorothy W. Kennedy, Susan Y. Yamada, Harvey Gralnick, Wen-Tien Chen, and Steven K. Akyama.
- *4497 Dietary Indicators of Laryngeal Cancer Risk. Carlo La Vecchia, Eva Negri, Barbara D'Avanzo, Silvia Franceschi, Adriano Decarli, and Peter Boyle.
- *4501 Photodynamic Therapy by Topical meso-Tetraphenylporphyrin-sulfonate Tetrasodium Salt Administration in Superficial Basal Cell Carcinomas. Olivia Santoro, Gaetano Bandiera Monte, Elsa Melloni, Renato Marchesini, Franco Zunino, Paolo Lepera, and Giuseppe De Palo.
- *4504 Inverse Relationship of Epidermal Growth Factor Receptor and HER2/neu Gene Expression in Human Renal Cell Carcinoma. Uwe Weindner, Stephan Peter, Torsten Strehmel, Rolf Hussmann, and Helmut Sies.
- 4510 Effects of Three Irreversible Inhibitors of Ornithine Decarboxylase on Macrophage-mediated Tumoricidal Activity and Antitumor Activity in B16F1 Tumor-bearing Mice. Terry L. Bowlin, Brenda J. Hooper, Andrea L. Rosenberger, Gregory F. Davis, and Prasad S. Sunkara.
- *4515 Thermal Response of Oncogene-transfected Rat Cells. Gloria C. Li, Clifton Ling, Brian Endlich, and Johnson Y. Mak.
- *4522 Potent Growth Inhibition of Human Tumor Cells in Culture by Arginine Deiminase Purified from a Culture Medium of a *Mycoplasm*-infected Cell Line. Kaoru Miyazaki, Haruo Takaku, Makoto Umeda, Tuyosi Fujita, Weida Huang, Takashi Kimura, Jinpei Yamashita, and Takekazu Horii.
- 4528 Anticancer Activity of 5'-Deoxy-5-fluorouridine in a Murine Tumor Cascade Model: Colon 26 Adenocarcinoma. Yutaka Tanaka, Hiroyuki Eda, Kaori Fujimoto, Takashi Tanaka, Tohru Ishikawa, and Hideo Ishitsuka.
- 4533 Effect of Sulfonation on the Cell and Tissue Distribution of the Photosensitizer Aluminol Phthalocyanine. Wai-Shun Chan, John F. Marshall, Russel Svensen, Joanne Bedwell, and Ian R. Hart.

CONTENTS OF VOLUME 50

- 4539** *In Vitro* Biotransformations of Tetrachloro(d,L-trans)-1,2-diaminocyclohexanephtalimide (Tetraplatin) in Rat Plasma. Stephen G. Chaney, Steven Wyrick, and Gail Kaun Till.
- *4546** Radioimmunotheapy of Human Colorectal Carcinoma Xenografts Using ^{3}H -labeled Monoclonal Antibody CO17-1A Prepared by Two Bifunctional Chelate Techniques. Yu-Chen C. Lee, Lee C. Washburn, Tan Han H., Sue Bill L. Byrd, James E. Crook, E. C. Holloway, and Zenon Steplewski.
- 4552** 5-Hexyl-2'-deoxyuridine Blocks the Cytotoxic Effects of 5-Fluorodeoxyuridine or Deoxycytidine in Leukemia L1210 Cells in Culture. Joseph G. Cory, Mary C. Halley, Andras Jeney, and Karoly Lapis.
- *4557** Biosynthesis, Glycosylation and Intracellular Processing of the Neoglycoprotein Antigen, a Human Melanoma-associated Antigen. Walter T. Dixon, Douglas J. Demetrick, Kunio Ohshima, Lydia K. J. Sikora, and L. Martin Jerry.
- *4566** Mutations Induced at the Hypoxanthine-Guanine Phosphoribosyltransferase Locus of Human T-lymphoblasts by Perturbations of Purine Deoxyribonucleoside Triphosphate Pools. Susan S. Mattano, Thomas D. Paletta, and Beverly S. Mitchell.
- *4572** Synergistic Cytotoxicity of 2'-Deoxy- β -D-xyloside and Cisplatin or 4-Hydroperoxy-cyclophosphamide with Human Tumor Cells. Philip Frost, James L. Abbuzzese, Barbara Hunt, Dorothy Lee, and Martha Ellis.
- 4578** Characterization of Target Binding by the IC-21 Macrophage Cell Line. Eric K. Crawford, Patricia S. Latham, Eliza M. Shah, and Jeffrey D. Hasday.
- *4584** Molecular Nature of *In Vivo* Mutations in Human Cells at the Autosomal HLA-A Locus. Alexander A. Morley, Scott A. Grist, David R. Turner, Alexander Kuttula, and Greg Bennett.
- *4588** Biological and Clinical Effects of the Combination of β - and γ -Interferons Administered as a 5-Day Continuous Infusion. Jean H. Schiffer, Barry Storer, Patricia L. Witt, Beth Nelson, Raymond R. Brown, Michel Horisberger, Sidney Grossberg, and Ernest C. Bordignon.
- *4595** Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 648390). Dennis A. Noe, Eric K. Rowinsky, Huay-Shin L. Shen, Barbara V. Clarke, Louis B. Grochow, William B. McGuire, Alexander Hanel, David B. Adams, Martin D. Abeloff, David S. Ettinger, and Ross C. Donehower.
- *4600** Exposure to Barbiturates *In Utero* and during Childhood and Risk of Intracranial and Spinal Cord Tumors. Marilyn K. Goldhaber, Joseph V. Setzer, Robert A. Hant, and Charles P. Quesenberry.
- *4604** Phosphorylation of Pyruvate Kinase Type K in Human Glomas by a Cyclic Adenosine 5'-Monophosphate-Independent Protein Kinase. Paschal A. Oude Weernink, Gert Rijksen, Margreet C. M. van der Heijden, and Gerard E. J. Stuurman.
- *4611** Molecular Dosimetry of Poly(cyclic Aromatic Hydrocarbon Epoxides and Diol Epoxides via Hemoglobin Adducts. Billy W. Day, Stephen Naylor, Liang-Shang Gan, Yusufi Sabah, Thanh T. Nguyen, Paul L. Skipper, John S. Wishnok, and Steven R. Tannenbaum.
- *4619** Oxidative Stress Induces DNA Damage and Inhibits the Repair of DNA Lesions Induced by N-Acetoxy-2-acetylaminofluorene in Human Peripheral Monuclear Leukocytes. Ronald W. Pero, Marshall W. Anderson, Geraldine A. Doyle, Colleen H. Anna, Felix Romigk, Melvin Markowitz, and Carl Bryngelson.
- *4626** Comparison of the Predictive Power of Different Prognostic Indices for Overall Survival in Patients with Advanced Ovarian Carcinoma. Birth Lund, Paul Williamson, Hans C. van Houwelingen, and Jean P. Nejt.
- 4630** Mechanism of Tumorigenic Activity of OK-432-specific L3T4⁺ Lyt2⁻ T-Cells. Shiochi Ozaki, Toshihiko Saginomita, Takeshi Watanabe, and Hiroshi Obaya.
- *4635** Effect of Acrolein on Phosphoramid Mustard-induced Sister Chromatid Exchanges in Cultured Human Lymphocytes. James L. Wilmer, Gregory L. Exeson, and Andrew D. Kligerman.
- 4639** Differing Specificities for 4-/minofolate Analogs of Folatepolyglutamyl Synthetase from Tumors and Proliferative Intestinal Epithelium of the Mouse with Significance for Selective Antitumor Action. B. G. Rumberger, J. R. Barrueco, and F. M. Sironiak.
- *4644** *In Vitro* Inhibition of the Pyrimidine de Novo Enzyme Dihydropyrimidyl Acid Dehydrogenase by Bregman Sodium (DUP-785; NSC 368390) in Mice and Patients. G. J. Peters, G. Schwartzmann, J. C. Nadal, E. J. Laurence, C. J. van Groeningen, W. J. F. der Vigh, and H. M. Pinedo.
- 4650** Mechanism of 12-O-Tetradecanoylphorbol-13-acetate Enhanced Metabolism of Anthracycline Acid in Dog Urothelial Cells. Terry V. Zenser, Thomas E. Eling, Zofia M. Duniec, Yun-Hua Huang Wong, and Bernard B. Davis.
- *4656** Biosynthesis and Glycosylation of the Carcinoma-associated Antigen Recognized by Monoclonal Antibody KS1/4. Philip D. Fernsten, Katherine W. Pekey, Ralph A. Reisfeld, and Leslie E. Walker.
- *4664** Classifying Clinical Severity to Help Solve Problems of Stage Migration in Nonconcurrent Comparisons of Lung Cancer Therapy. David G. Pfister, Carolyn K. Wells, Charles K. Chan, and Alvin R. Feinstein.
- *4670** Oral Contraceptive Use, Human Papillomavirus Infection, and Risk of Early Cytological Abnormalities of the Cervix. Bryan P. Negrini, Mark H. Schiffman, Robert J. Kurman, Willard Barnes, Linda Lannom, Karen Malley, Louise A. Branton, Gregorio Delgado, Sidney Jones, Jean-Gilles Tchabti, and Wayne D. Lancaster.
- *4676** Inhibition of Cancer Cell Urokinase Plasminogen Activator by Its Specific Inhibitor PAI-2 and Subsequent Effects on Extracellular Matrix Degradation. Mark S. Baker, Pamela Bleakley, Graeme C. Woodward, and Julian P. Doe.
- 4685** Comparative Metabolism of 1'-Nitrosonornicotine and 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone by Cultured F344 Rat Oral Tissue and Esophagus. Sharon E. Murphy, Rachel Heilman, and Neil Trushin.
- 4692** Decreased NADPH:Cytchrome P-450 Reductase Activity and Impaired Drug Activation in a Mammalian Cell Line Resistant to Mitomycin C under Aerobic but not Hypoxic Conditions. Paul R. Hoban, Michael I. Walton, Craig N. Robson, Judith Godden, Ian J. Stratford, Paul Workman, Adriana L. Harris, and Ian D. Hickson.
- *4698** 3'-Desmino-3'-morpholinol-13-deoxy-10-hydroxycamptothecin Confers Multiple Resistance by Rapid Infusion, following Higher Frequency of DNA Single and Double-Strand Breaks. Naoya Horichi, Haim Tapiero, Yohsaku Sugimoto, Masami Bungo, Masahiko Nishiyama, Alain Fourcade, Theodore J. Lampidis, Kazuo Kasahara, Yasuyasu Sasaki, Terumi Takahashi, and Nagahiro Saito.
- *4702** Plasma α -Fucosidase Activity and the Risk of Borderline Epithelial Ovarian Tumors. Bernard L. Harlow, Noel S. Weiss, and Eric H. Holmes.
- *4704** Effect of Osmotic Pressure on Uptake of Chemotherapeutic Agents by Carcinoma Cells. Robert L. Stephen, Jeanne M. Novak, Elizabeth M. Jensen, Carl Kabitz, and Saundra S. Buys.
- *4709** Potentiation of Interleukin-1 Mediated Antitumor Effects by Ketocazole. Paul G. Braunschweiger, Nirmal Kumar, Ioannis Constantinidis, Janina P. Wehrle, Jerry D. Glickson, Candace S. Johnson, and Philip Furmanek.
- *4718** Pharmacokinetics, Tissue Distribution, and Cell Localization of [^{35}S]Methionine-labeled Recombinant Human and Murine α -Interferon in Mice. Terrance G. Johns, Julie A. Kerr, Barry J. A. Veitch, Ian R. Mackay, Peter J. Tutton, Martin J. Tymms, Brian F. Cheetham, Paul J. Hertzog, and Anthony W. Linnane.
- *4724** Neoplastic Transformation of a Human Colon Epithelial Cell Line: *In Vitro* Evidence for the Adenoma to Carcinoma Sequence. Ann C. Williams, Sara J. Harper, and Christos Paraskeva.
- 4829** Editorial. Carlo M. Croce, Editor-in-Chief.
Special Lecture
- 4830** The Final Common Pathway of Cancer: Presidential Address. Harris Busch.
- 4839** Short-Term Metabolic Fate of L-[^{3}H]Glutamate in the Walker 256 Carcinosarcoma *In Vivo*. Sabina Filo-DeRico, Alan S. Gelbard, Arthur J. L. Cooper, Karen C. Rosenspire, and Edward Nieves.
- *4845** Low Proliferative Activity Is Associated with a Favorable Prognosis in Peripheral T-Cell Lymphoma. Helen L. Gronlund, Terry N. Woodbridge, David T. Purtilo, Irene Pieroni, Martin Best, Leslie Woodbridge, James O. Armitage, and Dennis D. Weisenburger.
- *4849** Differential Effects of Phorbol Ester on Epidermal Growth Factor Receptor in Estrogen Receptor-positive and -negative Breast Cancer Cell Lines. Masafumi Koga, Elizabeth A. Musgrave, and Robert L. Sutherland.
- *4856** Molecular Characterization of a ((11;14)(q23;q22)) Chromosome Translocation in a B-Cell Lymphoma. Yukihiko Akao, Yoshihide Tsujimoto, Janet Finan, Peter C. Nowell, and Carlo M. Croce.
- 4860** *In Vitro* Determination of Uptake, Retention, Distribution, Biological Efficacy, and Toxicity of Boronated Compounds for Neutron Capture Therapy: A Comparison of Porphyrins with Self-hydryl Boro Hydrides. R. G. Fairchild, S. Bahl, B. H. Laster, J. Kafe-Ezra, and E. A. Popescu.
- *4866** Pharmacokinetics of the Mouse Monoclonal Antibody 17-1A in Cancer Patients Receiving Various Treatment Schedules. Jan-Erik Frödin, Ann-Kari Lefvert, and Håkan Mellstedt.
- *4872** Serological Mapping of the TAG-72 Tumor-associated Antigen Using 19 Distinct Monoclonal Antibodies. Masahide Kuroki, Philip D. Fernsten, David Wunderlich, David Colcher, Jean F. Simpson, Diane J. Poole, and Jeffrey Schlom.
- *4880** Early Effects of Radiotherapy in Small Cell Lung Cancer Xeno-grafts Monitored by ^{31}P Magnetic Resonance Spectroscopy and Biochemical Analysis. Paul E. G. Kristoffersen, Erik J. Pedersen, Bjørn Quistorff, Folmer Elling, and Mogens Spang-Thomsen.
- *4885** Characterization of the Sheet Form of the Human Tumor-associated Glycoprotein (TAG-72) from Serum Effusions of Patients with Different Types of Carcinomas. Raju S. Katari, Philip D. Fernsten, and Jeffrey Schlom.
- 4891** Dual Mechanism of Inhibition of DNA Synthesis by Triciribine. Linda L. Worring, Lynn B. Townsend, Linda M. Jones, Katherine Z. Borysko, David L. Gildersleeve, and William B. Parker.
- *4900** Antitumor Efficacy of PD15934 (NSC 366140) against Solid Tumors of Mice. Patricia LoRusso, Antoinette J. Wozniak, Lisa Polin, David Cappa, Wilbur R. Leopold, Lester M. Werbel, Laura Biernat, Maria E. Dan, and Thomas H. Corbett.
- *4906** *In Vitro* Induction of Lymphokine-activated Killer Cells by Interleukin-2: Splenic Artery Perfusion in Advanced Malignancy. Richard J. Klasa, Hubert K. B. Silver, and Spencer Kong.
- *4731** Gastric Precancerous Process in a High Risk Population: Cross-sectional Studies. Pelayo Correa, William Haenzel, Carlos Cueto, Diego Zavala, Elizabeth Fontan, Guillermo Zarama, Steven Tannenbaum, Tito Collazos, and Bernardo Ruiz.
- *4737** Gastric Precancerous Process in a High Risk Population: Cohort Follow-up. Pelayo Correa, William Haenzel, Carlos Cueto, Diego Zavala, Elizabeth Fontan, Guillermo Zarama, Steven Tannenbaum, Tito Collazos, and Bernardo Ruiz.
- 4741** Identification of Epidermal Cell Subpopulations with Increased Ornithine Decarboxylase Activity following Treatment of Murine Epidermis with 12-O-Tetradecanoylphorbol-13-acetate. Fredrik M. Robertson, Susan K. Gilman, Alan H. Conney, Mon-Tuan Huang, Andrew J. Beavis, Jeffrey D. Latkin, Ohi A. Hietala, and Thomas G. O'Brien.
- 4747** Influence of Male Genital Tract Mesenchymes on Differentiation of Dunning Prostatic Adenocarcinoma. Norio Hayashi, Gerald R. Cunha, and Y. C. Wong.
- 4755** Identification and Characterization of a Rat Hepatic Oncostat Membrane Glycoprotein. Ronald A. Faro, Kerry D. McEntire, Nancy L. Thompson, and Douglas C. Nixon.
- 4764** Immune Abnormalities in Avian Erythroblastosis Virus-infected Chickens. Arundhati Rao, Kimberly Kline, and Bob G. Sanders.
- *4771** Interleukin 1-induced Augmentation of Experimental Metastases from a Human Melanoma in Nude Mice. Raffaella Giavazzi, Angela Garofalo, Maria Rosa Bani, Mauro Abbate, Pietro Ghelli, Diana Bonacchi, Alberto Mantovani, and Elisa Bettati Deiana.
- 4776** DNA Synthesis by L929 Cells following Doxorubicin Exposure. Karl W. Lanks and John M. Lehman.
- *4779** EJ/ras Neoplastic Transformation of Simian Virus 40-immortalized Human Ureter epithelial Cells: A Rare Event. Brian J. Christian, Chinghai Kao, Shi-Qi Wu, Lorraine F. Messner, and Catherine A. Reznikoff.
- 4787** Malignant Vascular Tumors in Fowl Induced by a Newly Isolated Retrovirus. Dov Sofer, Nitza Resnick-Roguel, Amiram Eldor, and Moshe Kotler.
- 4794** Development of an *In Vitro* Analogue of Initiated Mouse Epidermis to Study Tumor Promoters and Antipromoters. Henry Hennings, Victor A. Robinson, Delores M. Michael, George R. Pettit, Reinhard Jung, and Stuart H. Yuspa.
- *4801** Analysis of Human Tumor Associated Thomsen-Friedreich Antigen. John Samuel, Antoine A. Noujaim, Grant D. MacLean, Mansoor R. Suresh, and B. Michael Longenecker.
- 4809** Expression of Hepatocyte and Oval Cell Antigens in Hepatocellular Carcinomas Produced by Oncogene-transfected Liver Epithelial Cells. Michele Goyette, Ronald Farb, Randy Braun, Douglas Hixon, and Nelson Fausto.
- 4818** Activation of K-ras by Codon 13 Mutations in CS7BL/6 \times C3H F1 Mouse Tumors Induced by Exposure to 1,3-Dinitropropane. Tamra Goodrow, Steven Reynolds, Robert Maronpot, and Marshall Anderson.
-
- 4824** Announcements
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
American Cancer Society Research Grants in Primary Prevention and Detection
Calendar of Events
- 4825** Erratum
R. S. Morrison *et al.*, 50: 2524-2529, 1990.
- 4826** Author Index

August 15, Number 16

- 4829** Editorial. Carlo M. Croce, Editor-in-Chief.
Special Lecture
- 4830** The Final Common Pathway of Cancer: Presidential Address. Harris Busch.
- 4839** Short-Term Metabolic Fate of L-[^{3}H]Glutamate in the Walker 256 Carcinosarcoma *In Vivo*. Sabina Filo-DeRico, Alan S. Gelbard, Arthur J. L. Cooper, Karen C. Rosenspire, and Edward Nieves.
- *4845** Low Proliferative Activity Is Associated with a Favorable Prognosis in Peripheral T-Cell Lymphoma. Helen L. Gronlund, Terry N. Woodbridge, David T. Purtilo, Irene Pieroni, Martin Best, Leslie Woodbridge, James O. Armitage, and Dennis D. Weisenburger.
- *4849** Differential Effects of Phorbol Ester on Epidermal Growth Factor Receptor in Estrogen Receptor-positive and -negative Breast Cancer Cell Lines. Masafumi Koga, Elizabeth A. Musgrave, and Robert L. Sutherland.
- *4856** Molecular Characterization of a ((11;14)(q23;q22)) Chromosome Translocation in a B-Cell Lymphoma. Yukihiko Akao, Yoshihide Tsujimoto, Janet Finan, Peter C. Nowell, and Carlo M. Croce.
- 4860** *In Vitro* Determination of Uptake, Retention, Distribution, Biological Efficacy, and Toxicity of Boronated Compounds for Neutron Capture Therapy: A Comparison of Porphyrins with Self-hydryl Boro Hydrides. R. G. Fairchild, S. Bahl, B. H. Laster, J. Kafe-Ezra, and E. A. Popescu.
- *4866** Pharmacokinetics of the Mouse Monoclonal Antibody 17-1A in Cancer Patients Receiving Various Treatment Schedules. Jan-Erik Frödin, Ann-Kari Lefvert, and Håkan Mellstedt.
- *4872** Serological Mapping of the TAG-72 Tumor-associated Antigen Using 19 Distinct Monoclonal Antibodies. Masahide Kuroki, Philip D. Fernsten, David Wunderlich, David Colcher, Jean F. Simpson, Diane J. Poole, and Jeffrey Schlom.
- *4880** Early Effects of Radiotherapy in Small Cell Lung Cancer Xeno-grafts Monitored by ^{31}P Magnetic Resonance Spectroscopy and Biochemical Analysis. Paul E. G. Kristoffersen, Erik J. Pedersen, Bjørn Quistorff, Folmer Elling, and Mogens Spang-Thomsen.
- *4885** Characterization of the Sheet Form of the Human Tumor-associated Glycoprotein (TAG-72) from Serum Effusions of Patients with Different Types of Carcinomas. Raju S. Katari, Philip D. Fernsten, and Jeffrey Schlom.
- 4891** Dual Mechanism of Inhibition of DNA Synthesis by Triciribine. Linda L. Worring, Lynn B. Townsend, Linda M. Jones, Katherine Z. Borysko, David L. Gildersleeve, and William B. Parker.
- *4900** Antitumor Efficacy of PD15934 (NSC 366140) against Solid Tumors of Mice. Patricia LoRusso, Antoinette J. Wozniak, Lisa Polin, David Cappa, Wilbur R. Leopold, Lester M. Werbel, Laura Biernat, Maria E. Dan, and Thomas H. Corbett.
- *4906** *In Vitro* Induction of Lymphokine-activated Killer Cells by Interleukin-2: Splenic Artery Perfusion in Advanced Malignancy. Richard J. Klasa, Hubert K. B. Silver, and Spencer Kong.
- *4911** No Evidence for Point Mutations in Codons 12, 13, and 61 of the *K-ras* Gene in a High-Incidence Area for Esophageal and Gastric Cancers. T. Victor, R. Du Toit, A. M. Jordaan, A. J. Bestier, and D. P. van Helden.
- *4915** Epidermal Growth Factor and Transforming Growth Factor α Induces Acute Fluid in Mice. Eiji Ohmura, Tohru Tsuchiya, Yoshihiko Kamiya, Masaki Okada, Noriaki Onoda, Kazuo Shirane, and Hiroshi Demura.
- 4918** Comparative Formation and Removal of Aflatoxin B₁-DNA Adducts in Cultured Mammalian Tracheal Epithelium. R. Wayne Ball, Dennis W. Wilson, and Roger A. Coulombe, Jr.
- *4923** Expression of a Resistance Mechanism in Ovarian and Cervical Carcinoma Cells Prevents Their Lysis by γ -Interferon. L. Stewart Massad, David G. Mutch, C. Bethan Powell, Ming-Shian Kao, and John Leslie Collins.
- *4929** Effects of a Single Course of Deferoxamine in Neuroblastoma Patients. Alberto Donfrancesco, Giovanni Debi, Carlo Dominici, Domenico Pileggi, Marianti A. Castello, and Lawrence Helson.
- 4931** Inhibition by γ -Aminobutyric Acid and Baclofen of Gastric Carcinogenesis Induced by N-Methyl-N-nitroso-N-nitrosoguanidine in Wistar Rats. Masaharu Tatsumi, Hiroyasu Ishii, Miyako Baba, Akihiko Nakazawa, Makoto Ichii, and Haruo Taniguchi.
- 4935** Determinants of the Antitumor Effect of Radiolabeled Monoclonal Antibodies. S. J. Knox, R. Levy, R. A. Miller, W. Uhland, J. Schiele, W. Ruehl, R. Finston, P. Day-Lollini, and M. L. Goris.

CONTENTS OF VOLUME 50

- *4941 Expression of Endogenous Tumor Necrosis Factor as a Protective Protein against the Cytotoxicity of Exogenous Tumor Necrosis Factor. Takeshi Himeko, Naoki Watanabe, Naofumi Yamauchi, Masahiro Maeda, Yasushi Tsuji, Tetsuro Okamoto, Hiroshi Neda, and Yoshiro Niitsu.
- *4946 Flow Cytometric Characterization of Antitumor Resistance in Cultured Mammalian Cells Using Fluorescently Labelled Methotrexate and Diamorubicin. Steven W. Sherwood, Yehuda G. Ansari, Arturo Molina, and Robert T. Schimke.
- *4951 Induction, Accumulation, and Persistence of Sister Chromatid Exchanges in Women with Breast Cancer Receiving Cyclophosphamide, Adriamycin, and 5-Fluorouracil Chemotherapy. James D. Tucker, Andrew J. Wyrobek, Linda K. Ashworth, Mari L. Christensen, Gary V. Burton, Anthony V. Carano, and Richard B. Evered.
- *4957 Expression of Heterogeneous Profiles of Plasminogen Activators and Plasminogen Activator Inhibitors by Human Glioma Lines. Robert G. Stiritz, Margaret R. Gyeky, Kerry L. Cole, Paul McKeever, and James Varani.
- *4962 Modulation of dUTdR-DNA Incorporation and Radiosensitization in Human Bladder Carcinoma Cells. Keith A. Kunagi, Miguel A. Vasquez-Padua, Elizabeth M. Miller, and Timothy J. Kinsella.
- *4968 Human T-Lymphotropic Virus Type I Transcriptional Regulation by Methylation. Daniela Saggioro, Maria Ponzozzo, and Luigi Chieco-Bianchi.
- *4974 Tumor-promoting Activity of Staphylococcus, a Protein Kinase Inhibitor on Murine Skin. Shigeki Yohizawa, Hiroko Fujiki, Hiroko Suguri, Masami Suganuma, Michie Nakayasu, Ric Matsushima, and Takashi Sugimura.
- 4979 Paracrine Growth Stimulation of Androgen-responsive Shionogi Carcinoma 115 by Its Autonomous Subline (Shionogi Subline 2). Yuu Furuya, Naohide Sato, Koichiro Akakura, Tomohiko Ichikawa, Noriaki Suzuki, Ryoko Sato, and Jun Shimazaki.
- *4984 Presence of Cell Lineage-specific Hypomethylated Sites in the Major Breakpoint Cluster Region. Craig E. Litz, Adam N. Goldfarb, John G. Strickler, and Richard D. Bruning.
- 4991 Identification of the Meme Aldehyde Dehydrogenases Important in Aldehydefume Detoxification. Carl L. Manthey, Gregory J. Landkamer, and Norman E. Sladek.
- *5003 Human Leukemic Myeloblasts and Myeloblastoid Cells Contain the Enzyme Cytidine-5'-Monophosphate-N-acetylneuraminate Acid-α/β(1-3)GalNAc(2-3)-Sialyltransferase. Amita Kanan, D. Robert Sutherland, Ethan Fibach, Kushi L. Matta, Alex Hindenlang, Inka Brochhausen, William Kuhns, Robert N. Taub, Dirk H. van den Eijnden, and Michael A. Baker.
- *5008 Role of the Mitochondrial K_c -Complex in the Cytotoxic Action of Dihydrofumaryl-Diphosphate toward Prostatic Carcinoma Cells. Peter Schulz, Thomas A. Link, Laura Chaudhuri, and Friedrich Fritter.
- *5013 Localization and Modulation of the DNA-binding Activity of the Human c-e α -1 Protooncogene. E. Shyam P. Reddy and Veena N. Rao.
- *5017 A Case-Control Study of Dietary and Nonlifestyle Risk Factors for Breast Cancer in Shanghai. Yu Shan-Zhang, Lu Rui-Fang, Xu Da-Dao, and Geoffrey R. Howe.
- 5022 Inhibition of Weight Loss by ω -3 Fatty Acids in an Experimental Cachexia Model. Michael J. Tisdale and Jasmin K. Dhesi.
- *5027 Effects of Interleukin 2 Treatment Combined with Local Hyperthermia in Mice Infected with Lewis Lung Carcinoma Cells. Kong-Nian Shen, Li Lu, Bo Wu, Homayoon Shadmehr, Ned B. Hornbeck, and Hal E. Broxmeyer.
- 5031 Effects of Reoxygenation on Cells from Hypoxic Regions of Solid Tumors: Analysis of Transplanted Murine Tumors for Evidence of DNA Overreplication. S. D. Young and R. P. Hill.
- 5039 Serpin Inhibitors of Urokinase and Thrombin in Normal Rat Brain and the M1 Brain Tumor: Evidence for Elevated Expression of Protease Nexin I-like Inhibitor and a Novel Sodium Dodecyl Sulfate-activated Tumor Antithrombin. J. S. Ran, J. B. Baker, R. A. Morantz, B. Kimler, R. Evans, and B. W. Festoff.
- 5045 Differential Effect of Ionizing Radiation on Transcription in Repair-deficient and Repair-proficient Mice. George P. Munson and Gayle E. Woloschak.
- *5049 Micronucleated Erythrocytes as an Index of Cytogenetic Damage in Humans: Demographic and Dietary Factors Associated with Micronucleated Erythrocytes in Splenectomized Subjects. Daniel F. Smith, James MacGregor, Robert A. Hitt, Kim Hooper, Carol M. Wehr, Beverly Peters, Lynn R. Goldman, Leslie A. Yuan, Philip A. Smith, and Charles E. Becker.
- 5055 Interaction of SR-4233 with Hyperthermia and Radiation in the F344C Murine Fibrosarcoma Tumor System *In Vitro* and *In Vivo*. Terence S. Herman, Beverly A. Teicher, and Norman Coleman.
- *5060 Effect of Retinoic Acid on Proliferation of Estrogen-responsive Transformed Murine Leydig Cells in Serum-free Culture. Takahisa Hirase, Masaharu Koga, Haruhiko Kouhara, Susumu Kishimoto, Keishi Matsumoto, and Bunzo Sato.
- *5065 Opposite Effect of Tumor Necrosis Factor α on Granulocyte Colony-stimulating Factor and Granulocyte-Macrophage Colony-stimulating Factor-dependent Growth of Normal and Leukemic Hemopoietic Progenitors. Wanda Piachello, Fiorella Sanvisio, Antonella Severino, Silvia Morelli, Anna Maria Vaira, Alessandra Sciacchiti, and Massimo Aglietta.
- *5072 Cytokine Regulation of Tumor Necrosis Factor- α and β (Lymphotoxin)-Messenger RNA Expression in Human Peripheral Blood Monocytic Cells. Atan Kaid, Elaine P. Director, Mark C. Stoveroff, Michael T. Lotze, and Steven A. Rosenberg.
- 5077 Endogenous and Exogenous Polyamines in Support of Tumor Growth. Nikolaus Seiter, Shakir Sarhan, Christine Graeffel, R. Jones, Bernd Knödlein, and J.-P. Moulinous.
- 5084 Chemoprevention of 1,2-Dimethylhydrazine-induced Colon Cancer in Mice by Naturally Occurring Organosulfur Compounds. Hiromichi Sumiyoshi and Michael J. Wangovich.
- 5088 Formation and Persistence of Novel Benz(a)pyrene Adducts in Rat Lung, Liver, and Peripheral Blood Lymphocyte DNA. Jeffrey Ross, Garret Nelson, Andrew Kligerman, Gregory Erexson, Miriam Bryant, Karen Earley, Ramesh Gupta, and Stephen Nesnow.
- *5095 Pharmacokinetics and Toxicity of Two Schedules of High Dose Epirubicin. Sergei Alexei Tujlajland, Rowan Grant Doig, Mordechai Moty Sobol, Douglas MacGregor Watson, William Peter Sheridan, George Morstyn, George Mihaly, and Michael David Green.
- *5102 Implantation of Genetically Manipulated Fibroblasts into Mice as Antitumor α -Interferon Therapy. Hiromi Ogura, Kenzaburo Tani, Keiya Ozawa, Shigezaku Nagata, Shigeo Asano, and Fumimaro Takaku.
- 5107 Use of Intracellular H3 Messenger RNA as a Marker to Determine the Proliferation Pattern of Normal and 7,12-Dimethylbenz(a)anthracene-transformed Hamster Oral Epithelium. David T. W. Wong, Ming Ying Chou, Long-Chang Chang, and George T. Gallagher.
- *5112 Quantitative Cytochemical Detection of Malignant and Potentially Malignant Cells in the Colon. Alastair James Best, Pranab K. Das, Hindra R. H. Patzi, and Cornelis J. F. Van Noorden.
- Letter to the Editor**
- 5204 Correspondence re: David L. Beaton and Barbara Roberts. Antileukemic Effects of Diferloxamine on Human Myeloid Leukemia Cell Lines. *Cancer Res.*, 49: 4809-4812, 1989. Martin Poot and Horger Hoehn. Reply by David L. Beaton.
- Announcements**
- 85-second Annual Meeting of the AACR
Call for Nominations for the Scientific Awards of the AACR
AACR Special Conference in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events
- 5207 Author Index

September 1, Number 17

- Editorial**
- 5211 Advances in Brief. Carlo M. Croce, Editor-in-Chief.
- *5212 Activity of the Thymidylate Synthase Inhibitor 2-Desamin-N⁸-propargyl-5,8-dihydrofolic Acid and Related Compounds in Murine (L1210) and Human (W12) Systems *In Vitro* and in L1210 *In Vivo*. Ann L. Jackson, Gordon A. Taylor, Bruce M. O'Connor, Joel A. Bishop, Richard G. Moran, and A. Hilary Calvert.
- 5219 Induction of Cytochrome P-450 and 5-Aminolevulinic Synthase Activities in Cultured Rat Hepatocytes. Peter R. Sinclair, William J. Bement, Sally A. Haugen, Jacqueline F. Sinclair, and Philip S. Guelman.
- *5225 Tumor Localization by Combinations of Monoclonal Antibodies in a New Human Colon Carcinoma Cell Line (LIM1899). Sarah M. Andrew, Jin Ghee Teh, Ricky W. Johnstone, Sarah M. Russell, Robert H. Whitehead, Ian F. C. McKenzie, and Geoffrey A. Pietersz.
- *5231 Smoking and Renal Cell Carcinoma. Carlo L. Vecchia, Eva Negri, Barbara D'Avanzo, and Silvia Franceschi.
- *5234 Augmentation of Antibody Dependent Cell Mediated Cytotoxicity Following *In Vitro* Therapy with Recombinant Interleukin 2. Jacqueline A. Hank, Randy R. Robinson, Jean Surjus, Barbara M. Mueller, Ralph A. Resfeld, and Randi K. Sondel.
- *5240 Detection of Minimal Residual Disease in Leukemic Patients with the t(10;14)(q24;q11) Chromosomal Translocation. Jacob Kagan, Lawrence R. Finger, Emanuel Besa, and Carlo M. Croce.
- 5245 DNA Fingerprinting of 7,12-Dimethylbenz(a)anthracene-induced and Spontaneous CD-1 Mouse Liver Tumors. Brian J. Ledwith, Richard D. Storer, Srinivasa Prahalada, Sujata Manam, Karen R. Leander, Matthew J. van Zwieten, Warren W. Nichols, and Matthews O. Bradley.
- 5250 Effect of Tunicamycin on Sialomucin and Natural Killer Susceptibility of Rat Mammary Tumor Ascites Cells. Seema Bharathan, John Moriarity, Charles E. Moody, and Anne P. Sherblom.
- *5257 Effect of Guanine and Adenosine Nucleosides on Boneless-stimulated Phospholipase C Activity in Membranes from Swiss 3T3 and Small Cell Lung Carcinoma Cells. Youv Sharont, Jean Viatte, Jane B. Trepel, and Edward A. Sausville.
- 5263 Clonal Analysis of Lymphocytes from Tumor, Peripheral Blood, and Nontumorous Kidney in Primary Renal Cell Carcinoma. Tae-Yoon Kim, Andrew C. von Eschenbach, Marylynn D. Filaccio, Kazuhiro Hayakawa, David R. Parkinson, Charles M. Bach, and Kyogo Itoh.
- 5269 Tiazofurin Is Phosphorylated by Three Enzymes from Chinese Hamster Ovary Cells. Priscilla P. Saunders, Christy D. Spindler, Mei-Tao Tan, Esperanza Alvarez, and Roland K. Robins.
- 5275 Intracellular DNA Strand Scission and Growth Inhibition of Ehrlich Ascites Tumor Cells by Bleomycin. Robert W. Byrnes, Jeffrey Temple, Daniel Sem, Suzanne Lyman, and David H. Petering.
- *5287 Augmentation of Cytotoxic Effect of Tumor Necrosis Factor α in Human Immunodeficiency Virus-infected Cells by Sitosleptin, a Potent Protein Kinase C Inhibitor. Yoshiaki Hamamoto, Toshifumi Matsuyama, Naoki Yamamoto, and Nobuyuki Kobayashi.
- *5291 Regulation of Progesterone Receptor Gene Expression. E. Veglio, M. G. Coccia, F. Raspagliosi, A. Piffanelli, R. Fontanelli, and A. Maggi.
- 5296 Failure of Chronic Glutathione Elevation to Reduce Cytotoxicity Produced by Exposure to *cis*-Diamminedichloroplatinum(II), Ionizing Radiation, or Hyperthermia. Michael L. Freeman, Michael J. Meredit, and Donald R. Eisert.
- 5301 2-Acetylaminofluorene-mediated Alteration in the Level of Liver Arylalkylamine-N-acetyltransferase IV during Rat Hepatocarcinogenesis. David P. Ringer, Tom R. Norton, and Boyd A. Howell.
- 5306 Attenuating Effect of Bromocriptine on Cysteamine Anticarcinogenesis of Stomach Cancers Induced by N-Methyl-N-nitro-N-nitrosoguanidine. Masaharu Tatuta, Hiroshi Iishi, Miyako Baba, Makoto Ichi, Akihiko Nakazumi, Hiroyuki Usuda, and Haruo Taniguchi.
- *5312 Abnormalities in Structure and Expression of the Retinoblastoma Gene in Small Cell Lung Cancer Cell Lines and Xenografts in Nude Mice. Kären Rygaard, George D. Sorenson, Olve S. Petengill, Charles C. Cate, and Mogens Spang-Thomsen.
- 5318 Application of a New Approach for the Quantitation of Drug Synergism to the Combination of *cis*-Diamminedichloroplatinum and 1,3-D-Aminobifuranosylcytosine. William R. Greco, Hyung Sook Park, and Youcef M. Rustum.
- *5328 α -Interferon Structure and Natural Killer Cell Stimulatory Activity. Bo-Jiang Li, Xiao-Xia Zhao, Xin-Yan Liu, Hyun Suk Kim, Karel Raska, Jr., John R. Ortaldo, Barbara Schwartz, and Sidney Pestka.
- 5333 Role of P4501E1 in the Metabolism of 3-Hydroxyxypyridine, a Constituent of Tobacco Smoke. Redox Cycling and DNA Strand Scission by the Metabolite 2,5-Dihydroxypyridine. Sang Geon Kim and Raymond F. Novak.

CONTENTS OF VOLUME 50

- *5340 Substrate Specificity of the Exonuclease Associated with Calf DNA Polymerase *c*. Ralph D. Sabatino, Thomas W. Myers, and Robert A. Bambara.**
- *5345 Carbohydrate Analysis of Immunoglobulin G Myeloma Proteins by Lectin and High Performance Liquid Chromatography: Role of Glycosyltransferases in the Structures. Tetsuo Nishizuka, Shigeru Fujii, Yoshio Kanayama, Atsushi Nishikawa, Yoshiaki Tomiyama, Masao Iida, Takahiro Karasuno, Hiroshi Nakao, Takeshi Yonezawa, Naoyuki Taniguchi, and Seiichiro Tanu.**
- 5351 Role of Growth Factor Synthesis in the Acquisition of Insulin/Insulin-like Growth Factor 1 Independence in Rat Mammary Carcinoma Cells. Stephen P. Ether, Caterina Chiodino, and Richard F. Jones.**
- *5358 Suppressor Cell Activity in a Randomized Trial of Patients Receiving Active Specific Immunotherapy with Melanoma Cell Vaccine and Low Doses of Cyclophosphamide. Dave S. B. Hoorn, Leland J. Fosher, Anne S. Nitze, Roger Bohman, and Donald L. Morton.**
- 5365 Porphyry Photosensitivity in Cell Lines Expressing a Hemoplasmin Phenotype. Charles J. Gomer, Natalie Rucker, and Sam Wong.**
- *5369 Photosensitizing Dyes for the Selection of Nontransforming Revertants from Human Lung Cancer Cell Lines. Josh W. McDonald, Douglas E. Brash, Allan R. Osteroff, and Curtis C. Harris.**
- 5374 Identification of Ultraviolet-inducible Proteins That Bind to a TGAACAA Sequence in the Polyoma Virus Regulatory Region. Zeev A. Ronai and I. Bernard Weinstein.**
- *5382 Androgen Receptor Gene Expression in Human Prostate Carcinoma Cell Lines. W. D. Tilley, C. M. Wilson, M. Marcelli, and M. J. McPhaul.**
- *5387 Effect of α -Interferon, 17 β -Estradiol, and Tamoxifen on Estrogen Receptor Concentration and Cell Cycle Kinetics of MCF-7 Cells. W. R. Bezvoda and K. Meyer.**
- *5392 Non-P-Glycoprotein Mediated Multidrug Resistance Precedes P-Glycoprotein Expression during *In Vitro* Selection for Doxorubicin Resistance in a Human Lung Cancer Cell Line. F. Baas, A. P. M. Jongma, H. J. Broxterman, R. J. Arcesi, D. Housman, G. L. Scheffer, A. Riethorst, M. van Groenigen, A. W. M. Nieuwland, and H. Joenje.**
- *5399 Inhibition of Human Breast Cancer Cell Proliferation in Tissue Culture by the Neuroleptic Agents Pimozide and Thioridazine. Jeannine S. Strobl, Keila L. Kirkwood, Tracy K. Lantz, Michael A. Lewine, Virginia A. Peterson, and Jennings F. Worley III.**
- *5406 A Deletion Linked to a Poly(ADP-ribose) Polymerase Gene on Chromosome 13q33-qter Occurs Frequently in the Normal Black Population as Well as in Multiple Tumor DNA. Kishor G. Bhattacharya, Barry W. Cherneny, Konrad Huppel, Ian T. Magrath, Jeffrey Cosman, Edward Sausville, Francisco Barriga, Bruce Johnson, Barry Gause, George Bonney, Janet Neequisti, Maria DeBernardi, and Mark Smulson.**
- *5414 Antitumor Effects of α -Interferon and γ -Interferon on a Murine Renal Cancer (Renca) *In Vitro* and *In Vivo*. T. J. Sayers, T. A. Wiltrout, K. McCormick, C. Husted, and R. A. Wiltrout.**
- 5421 Monoclonal Antibody Therapy of Murine Lymphoma: Enhanced Efficacy by Concurrent Administration of Interleukin 2 or Lymphotoxin-activated Killer Cells. Kirk R. Schultz, Jay P. Klarinet, David J. Peace, Martin A. Cheever, Christopher C. Badger, Irwin D. Bernstein, and Philip D. Greenberg.**
- 5426 Modulation of O⁶-Methylguanine-DNA Methyltransferase in Rat and Hamster Liver after Treatment with Dimethylnitrosamine. Janet Hall, Henriette Bresl, Mireille Serres, Ghislaine Martel-Planche, Christopher P. Wild, and Ruggero Montesano.**
- *5431 Cloning and Characterization of Human Tumor Cell Interstitial Collagenase. Nancy Smyth Templeton, Peter D. Brown, Anna T. Levy, Inger M. K. Margulies, Lance A. Liotta, and William G. Steiner-Stevenson.**
- *5436 Mass Spectrometric Analysis of Tobacco-specific Nitrosamine Hemoglobin Adducts in Snuff Dipper Smokers, and Non-smokers. Steven G. Carmella, Shashi S. Kagan, Mark Kagan, Peter G. Follett, George Palladino, Arthur M. Quari, Elaine Quart, and Stephen S. Hecht.**
- 5441 Dose-Response Study of DNA and Hemoglobin Adduct Formation by 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanol in F344 Rats. Sharon E. Murphy, Adrienne Palomino, Stephen S. Hecht, and Dietrich Hoffmann.**
- 5453 Evaluation of Cysteine Adduct Formation in Rat Hemoglobin by 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanol and Related Compounds. Steven G. Carmella, Shashi S. Kagan, Thomas E. Pratt, and Stephen S. Hecht.**
- 5460 Potentiation of Natural Killer Cell Activity and Tumor Immunity by Diacetyleptenacine. Terry L. Bowlin, Andrea Rosenberger, David Stemmerk, and Michael L. Edwaris.**
- 5464 Aristolochic Acid Activates *nus* Genes in Rat Tumors at Deoxyadenosine Residues. Heinz H. Schmeiser, Johannes W. G. Janssen, John Lyons, Hans R. Scherf, Wolfgang Plau, Albrecht Buchmann, Claus R. Bartram, and Manfred Wiesler.**
- *5470 Ecological Correlation between Arsenic Level in Well Water and Age-adjusted Mortality from Malignant Neoplasms. Chen-jen Chen and Chih-jen Wang.**
- 5475 Prevention of Central Nervous System Toxicity of the Antitumor Antibiotic Actinomycin by Concomitant Infusion of an Amino Mixture. Marta G. Williams, Robert H. Earhart, Howard Bailey, and J. Patrick McGovern.**
- *5481 Peripheral Airway Cell Differentiation in Human Lung Cancer Cell Lines. Adi F. Gazdar, R. Ilona Linnoila, Yukio Kurita, Herbert K. Oie, James L. Mulshine, Jean C. Clark, and Jeffrey A. Whitsett.**
- *5488 Establishment and Characterization of a Human Adrenocortical Carcinoma Cell Line That Expresses Multiple Pathways of Steroid Biosynthesis. Adi F. Gazdar, Herbert K. Oie, Cedric H. Shackleton, T. R. Chen, Timothy J. Triche, Charles E. Myers, George P. Chrousos, Murray F. Brennan, C. A. Stein, and Renato V. La Rocca.**
- *5497 Gangliosides and Sialoglycoproteins Carrying a Rare Blood Group Antigen Determinant, Cad, Associated with Human Cadherins as Detected by Specific Monoclonal Antibodies. Nozomu Hiraiwa, Kiyotaka Tsuysuka, Yu-Teh Li, Mitsuhiro Tanaka, Taiko Seno, Yasuo Okubo, Yoshihiro Fukuda, Hiroo Imura, and Reiji Kannagi.**
- 5504 Cytotoxicity Phase of Diethylnitrosamine-induced Hepatic Neoplasia in Medaka. Durrell J. Lauren, Swee J. Teh, and David E. Hinton.**
- 5515 Assessment of Protein Kinase C Isozymes by Enzyme Immunoassay and Overexpression of Type II in Thyroid Adenocarcinoma. Masatoshi Hagiwara, Takahisa Hachiya, Masao Watanabe, Nobuteru Usuda, Futoshi Iida, Katsuyski Tama, and Hiroyoshi Hidaka.**
- *5520 Differentiation and Growth Modulation of Chronic Myelogenous Leukemic Cells by Bryostatin. Michael Lilly, Chris Tompkins, Chris Brown, George Pettit, and Andrew Kraft.**
- 5526 Establishment and Characterization of a Tumorigenic Marine Vasculor Endothelial Cell Line (F-2). Ken-ichi Toda, Kaoru Tsujika, Yukiya Maruguchi, Kazuhiko Ishii, Yoshiaki Miyachi, Kagemasa Kubiyashi, and Sadao Imaamura.**
- *5531 Establishment and Characterization of Human Renal Cancer and Normal Kidney Cell Lines. T. Ebert, N. H. Bandier, C. L. Finsland, R. D. Ramsawak, and L. J. Old.**
- 5537 Role of Tumor Necrosis Factor in Flavone Acetic Acid-induced Tumor Vasculature Shutdown. Viswanathan Mahadevan, Saleem T. A. Malik, Anthony Meager, Walter Fiers, Graham P. Lewis, and Ian R. Hart.**
- 5543 *In Vivo* Administration of Interferon α and Interleukin 2 Induces Proliferation of Lymphoid Cells in the Organs of Mice. Raj K. Patel, William D. Travis, and Steven A. Rosenberg.**
- *5551 *In Vivo* Interleukin-2-induced Activation of Lymphokine-activated Killer Cells and Tumor Cytotoxic T-Cells in Cervical Lymph Nodes of Patients with Head and Neck Tumors. Licia Rivoltini, Carlo Gambacorti-Passerini, Massimo Squarrellini-Saraceni, Maria Iaria Grossi, Giulio Cantù, Roberto Molinari, Attilio Orazi, and Giorgio Parmiani.**
- *5558 Enhancement of Ricin A Chain Immunotoxin Activity by Perhexilane on Established and Fresh Leukemic Cells. Jean-Pierre Jaffrézou, Thierry Levade, Emiliene Kuhlein, Olivier Thureyman, Marie Chiron, Hélène Grandjean, Dominique Carnier, and Guy Laurent.**
- 5567 Effect of 12-O-Tetradecanoylphorbol-13-acetate on Colony Formation and Intercellular Communication in a Coculture System of JB6 Clones. Ichiro Yamamoto, Ursula I. Heine, Susan Kenney, Charles W. Rugg, and Jerry M. Rice.**
- 5574 Combined Histological and Biochemical Analysis of Sex Hormone Dependence of Ferric Nitroferricyanate-induced Renal Lipid Peroxidation in ddY Mice. Shinji Toyokuni, Shigenori Okada, Shuji Hamazaki, Yukiko Minamiyama, Yoshihiro Yamada, Ping Liang, Yasutomo Fukunaga, and Osamu Midorikawa.**
- 5581 Selection for Spontaneous Metastasis after Calcium Phosphate-mediated Transfer of DNA. Ruth J. Muschel.**
- *5587 Malignant Transformation of Human Fibroblasts by a Transfected N-ras Oncogene. Daniel M. Wilson, Dajan Yang, John E. Dillberger, Stephen E. Dietrich, Veronica M. Maher, and J. Justin McCormick.**
-
- 5594 Announcements**
Eighty-second Annual Meeting of the AACR
Call for Nominations for the Scientific Awards of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Death
Calendar of Events
- 5596 Employment Register of the AACR**
- 5604 Author Index**

September 1, Number 17, Supplement

PROGRAM

List of Members of the World Committee 1988–1989.....	5609s
Acknowledgments	5610s
Foreword. <i>David S. Yohn</i>	5611s

I. Control of AIDS: From the Laboratory to the Clinic to the Community

Immunopathogenesis of Human Immunodeficiency Virus Infection. <i>Harry L. Joachim</i>	5612s
Murine Models for Evaluating Antiretroviral Therapy. <i>Ruth M. Ruprecht, Lisa D. Bernard, Ting-Chao Chou, Miguel A. Gama Sosa, Fatemeh Fazely, John Koch, Prem L. Sharma, and Steve Mullaney</i>	5618s
Studies with Canine Sera That Contain Antibodies Which Recognize Human Immunodeficiency Virus Structural Proteins. <i>Helena V. Strandstrom, Joanne R. Higgins, Kevin Mossie, and Gordon H. Theilen</i>	5628s

II. Comparative Aspects of Leukemia and Related Diseases of Mammals

Mechanisms of Thymic Lymphomagenesis by the Retrovirus SL3-3. <i>Esther F. Hays, Gregory Bristol, and Skye McDougall</i>	5631s
Endogenous Retroviral Elements in Human DNA. <i>C. Leib-Mösch, R. Brack-Werner, T. Werner, M. Bachmann, O. Faff, V. Erflie, and R. Hehlmann</i>	5636s
T-Cell Lymphomas Emerging as Epineplasmas in Mice Bearing Transplanted Polyoma Virus-induced Sarcoma Gland Tumors. <i>C. J. Dave, R. Freund, S. R. Abramson-Leeman, T. W. Dubensky, J. Carroll, M. E. Dorf, and T. L. Benjamin</i>	5643s
Induction of Topoisomerase II Gene Expression in Human Lymphocytes upon Phytohemagglutinin Stimulation. <i>Ching-Long Hwang, Cheng-Hsu Wang, Yi-Jen Chen, Jacqueline Whang-Peng, and Jaulang Hwang</i>	5649s

CONTENTS OF VOLUME 50

Evidence for the Multistep Nature of <i>in Vitro</i> Human Epithelial Cell Carcinogenesis. <i>John S. Rhin, Jae Hyung Yoo, Jang Hyeon Park, Peter Thraves, Zahra Salehi, and Anatoly Driscoll</i>	5653s
A Human Hepatocellular Carcinoma 3.0-Kilobase DNA Sequence Transforms Both Rat Liver Cells and NIH3T3 Fibroblasts and Encodes a 52-Kilodalton Protein. <i>Stringer Sue Yang, Ke Zhang, Wilfred Vieira, Janet V. Taub, Jill H. Zielstra-Rylals, and Ronald L. Somerville</i>	5658s

III. Comparative Biology of Hematopoietic and Related Neoplasms of Lower Animals in the Human Food Chain

Immunological and Ultrastructural Characterization of True Histiocytic Lymphoma in the Northern Pike, <i>Esox lucius</i> L. <i>James S. Thompson and Anja I. Kostial</i>	5668s
Oncogenes in Hematopoietic and Hepatic Fish Neoplasms. <i>Rebecca J. Van Beneden, Kelly W. Henderson, Donald G. Blair, Takis S. Papas, and Henry S. Gardner</i>	5671s
Occurrence of Thymic Lymphoma in Carcinogenesis Bioassay Specimens of the Japanese Medaka (<i>Oryzias latipes</i>). <i>Michael St. J. Battalora, William E. Hawkins, William W. Walker, and Robin M. Overstreet</i>	5675s
Experimental Transmission of a Plasmacytoid Leukemia of Chinook Salmon, <i>Oncorhynchus tshawytscha</i> . <i>Michael L. Kent and Sheila C. Dawe</i>	5679s

IV. Immunobiology and Control of Leukemia

Immunotherapeutic Approaches to Leukemia: The Use of the Friend Virus-induced Erythroleukemia Model System. <i>Candace S. Johnson, Ming-Jei Chang, Sally M. Thurlow, S. Camilla Pourbohloul, and Philip Furmanski</i>	5682s
Subunit Vaccine Protects <i>Macaca nemestrina</i> (Pig-tailed Macaque) against Simian T-Cell Lymphotropic Virus Type I Challenge. <i>Charlene S. D'ezzuti, Donald E. Frazier, Laura Y. Huff, Paul C. Stromberg, and Richard G. Olsen</i>	5687s
Epidemiologic and Immunobiology of Human T-Cell Leukemia/Lymphoma Virus Type I-associated Adult T-Cell Leukemia and Chronic Myeloproliferative Diseases as Seen in France. <i>A. Gessain, O. Gout, F. Saal, M. T. Daniel, B. Rio, G. Fladring, F. Sigaux, O. Lyon-Caen, J. Peries, and G. de Thé</i>	5692s
Chromosome and Gene Rearrangements in Immortalized Human Lymphocytes Infected with Human T-Lymphotropic Virus Type I. <i>Koshi Maruyama, Tokunori Fukushima, Kiyoko Kawamura, and Shigenobu Mochizuki</i>	5697s
Induction of Moloney Murine Sarcoma Virus Tolerance in Adult Mice by Anti-CD4 Monoclonal Antibody Treatment. <i>Giovanni Biasi, Maria Mazzocchi, Antonella Facchinetto, Marina Panozzo, Paola Zanovello, Dino Collavo, and Luigi Chicco-Bianchi</i>	5703s
Author Index	5707s

September 15, Number 18

Editorial 5709 Advances in Brief. Carlo M. Croce, Editor-in-Chief. Review 5710 Analysis of Dietary Fat, Calories, Body Weight, and the Development of Mammary Tumors in Rats and Mice: A Review. Laurence S. Freedman, Carolyn Clifford, and Mark Messina.	*5773 Uveal Melanoma in Relation to Ultraviolet Light Exposure and Host Factors. Elizabeth A. Holly, Diana A. Aston, Devon H. Char, Jennifer J. Kristiansen, and David K. Ahn.
	5778 DNA Double-Strand Break Repair Pathways and Cellular Tolerance to Inhibitors of Topoisomerase II. Keith Caldecott, Geoffrey Banks, and Penny Jeggo.
	*5784 Allelotype of Human Malignant Astrocytoma. Dan Fults, Carolyn A. Pedone, Gregory A. Thomas, and Ray White.
	*5790 Early Postoperative Intraperitoneal Chemotherapy as an Adjuvant Therapy to Surgery for Peritoneal Carcinomatosis from Gastrointestinal Cancer: Pharmacological Studies. Paul H. Sugarbaker, T. Graves, A. DeBruijn, W. J. Cunningham, R. E. Mullins, W. E. Hull, L. Oliff, and P. Schlegel.
	*5795 Adoptive Immunotherapy of Human Cancer: The Cytokine Cascade and Monocyte Activation following High-Dose Interleukin 2 Bolus Treatment. G. Boccelli, R. Mascilli, E. M. Ruggeri, P. Carlini, G. Giannelli, E. Montesoro, G. Mastrobardino, G. Isacchi, U. Testa, F. Calabresi, and C. Peschle.
	*5800 Constitutive and Induced Expression of Growth Factors in Normal and Chronic Phase Chronic Myelogenous Leukemia Ph ¹ Bone Marrow Stromal Cells: Meir Wetzel, Raziel Kurzrock, Kerry Taylor, Gary Spitzer, Hagop Kantarjian, Gabrielle Baiocchi, Stella Kiu, Jordan U. Gutierrez, and Moshe Talpaz.
	5806 Ability of the Ca ²⁺ -Ionophores A23187 and Ionomycin to Mimic Some of the Effects of the Tumor Promoter 12-O-Tetradecanoylphorbol-13-acetate on Hydroperoxide Production, Ornithine Decarboxylase Activity, and DNA Synthesis in Mouse Epidermis <i>In Vitro</i> . Elisabeth M. Perchetti, Denalisa Jones, and Jean-Pierre Perchetti.
	*5813 Long-Term Inhibition of DNA Synthesis and the Persistence of Trapped Topoisomerase II Complexes in Determining the Toxicity of the Antitumor DNA Intercalators mAMSA and Mitoxantrone. Mary E. Fox and Paul J. Smith.
	*5819 Reduction of Drug Accumulation and DNA Topoisomerase II Activity in Acquired Teniposide-resistant Human Cancer KB Cell Lines. Ken-ichi Matsuo, Kimiochi Kohno, Hiroshi Takano, Shin-ichi Sato, Akira Kue, and Michihiko Kuwano.
	*5825 Noncoordinated Expression of S6, S11, and S14 Ribosomal Protein Genes in Lysogenic Blatt Cell Lines. Sergio Ferrari, Rossella Manfredini, Enrico Tagliafico, Elena Rossi, Amadea Donelli, Giuseppe Toselli, and Umberto Toselli.
	*5829 Lorglumide and Lovastatin Inhibit Gastrin-stimulated DNA Synthesis in a Rat Tumoral Acinar Pancreatic Cell Line (AR42J). Catherine Seva, Jean Luc Scemama, Marie José Bastie, Lucien Pradayrol, and Nicole Vaysse.
	*5883 Seasonal Change in the Concentration of Progesterone Receptor in Breast Cancer. Ian M. Holdaway, Barbara H. Mason, Roger J. Marshall, Lorraine M. Neave, and Ronald G. Kay.
	*5887 Ascorbate Free Radical Stimulates the Growth of a Human Pronelymphocytic Leukemia Cell Line. Francisco J. Alcaín, M. Isabel Burón, Juan Carlos Rodríguez-Aguilar, José M. Vilalba, and Plácido Navas.
	5892 Direct Inhibiting Effects of [D-Trp] ¹ Gonadotropin-releasing Hormone on the Estrogen-sensitive Progression of Polyoma Virus-induced Malignant Tumors in Athymic Mice. Christian Neri, Daniel Blangy, Bernard Schatz, Katy Dion, Monique Bérebi, and Pierre-Marie Martin.
	*5898 DNA Damage Induced by a New 2-Chloroethyl Nitrosourea on Malignant Melanoma Cells. Denise Godenec, Maryse Rapp, Alain Thierry, Françoise Laval, Jean-Claude Madelmont, Philippe Chole, and Annie Vevey.

CONTENTS OF VOLUME 50

- *5904 Serum Tumor Marker Half-life during Chemotherapy Allows Early Prediction of Complete Response and Survival in Non-seminomatous Germ Cell Tumors. Guy C. Toner, Nancy L. Geller, Claire Tan, Jerome Nisenbaum, and George J. Bodl.
- *5911 Analysis of the *Int-1*, *Int-2*, *c-myc*, and *new* Oncogenes in Human Breast Carcinomas. Shari L. Meyers, Michael T. O'Brien, Terry Smith, and Jaquelin P. Dudley.
- *5919 Establishment of a Camptothecin Analog (CPT-11)-resistant Cell Line of Human Non-Small Cell Lung Cancer: Characterization and Mechanism of Resistance. Fumihiro Kanazawa, Yoshikazu Sugimoto, Koichi Minato, Kazuo Kasahara, Masami Bungo, Kazuhiko Nakagawa, Yasuhiro Fujiwara, Leroy F. Liu, and Nagahiro Saito.
- *5925 Cloning and Sequencing of a Complementary DNA Encoding a *M. tuberculosis* Human Breast Epithelial Mucin-associated Antigen. David Larocca, Jerry A. Peterson, Gary Walkup, Ramon Urrea, and Roberto L. Ceriani.
- *5931 Human Tumor Cell Line Resistance to Chemotherapeutic Agents Does Not Predict Resistance to Natural Killer or Lymphokine-activated Killer Cell-mediated Cytolysis. W. Grayson Harter, Coryenne Tom, John R. McGregor, Lynn Slade, and Wolford E. Samlowski.
- *5937 Suramin Inhibits Laminin- and Thrombospondin-mediated Melanoma Cell Adhesion and Migration and Binding of These Adhesive Proteins to Sulafide. Vivian S. Zabrenetsky, Elise C. Kohn, and David D. Roberts.
- *5943 Growth of Human Cell Lines in BALB/c Mice. Barney S. Graham and Neal T. Wertheimer.
- *5947 Immunotherapy of Human Keratinocytes by Simian Virus 40 Large T-Antigen Alters Keratin Gene Response to Retinoids. Chapita Agarwal and Richard L. Eckert.
- *5954 Pharmacokinetics, Biodistribution, and Gamma Camera Imaging of ¹¹¹In-KC-4G3 Murine Monoclonal Antibody in Athymic Nude Mice with or without Human Tumor Xenografts. Clifford Longley, Philip Furmanek, David G. Dinhart, James Lear, Duane Bloedow, Ravindra Kadlwal, and Paul A. Bunn, Jr.
- *5962 Isolation of a Human Melanoma Adapted Newcastle Disease Virus Mutant with Highly Selective Recognition Patterns. T. Ahert and V. Schirrmacher.
- *5969 Detection of Somatostatin Receptors in surgical and Peritoneal Biopsy Samples of Carcinoids and Islet Cell Carcinomas. J. C. Reubi, L. K. Krois, B. Waser, D. M. Nagorey, P. U. Heitz, J. W. Charboneau, C. C. Reading, and C. Moorel.
- 5978 Hepatic Neoplasms in the Mimicking *Fundulus heteroclitus* from a Crescent-contaminated Site. Wolfgang K. Vogelstein, John W. Fournier, Peter A. Van Veld, and Robert J. Huggett.
- *5987 Short Exposure to Actinomycin D Induces "Reversible" Translocation of Protein B23 as Well as "Reversible" Inhibition of Cell Growth and RNA Synthesis in HeLa Cells. Benjamin Yat-Ming Yang, Amy Mei-Shiu Bor, and Pui-Kwong Chan.
- *5992 Selective Elimination of Breast Cancer Cells from Human Bone Marrow Using an Antibody-Pseudomonas Exotoxin A Conjugate. Michael J. Bjorn, Ronald Manger, Gowalia Sivam, Alton C. Morgan, Jr., and Beverly Torok-Storb.
- *5997 Basement Membrane Type IV Collagen Degradation: Evidence for the Involvement of a Proteolytic Cascade Independent of Metalloproteinases. A. R. Mackay, R. H. Corbett, J. L. Hartzler, and P. O. Thorbergsson.
- *6002 Morphological and Molecular Characterization of Spontaneous Malignant Differentiation in a Human Rhabdomyosarcoma Cell Line. David N. Shapiro, Peter J. Houghton, Bonnie J. Hazelton, Glen S. Germain, Kurangutti G. Munir, Atiqur Rahaman, and Janet A. Houghton.
- *6010 Transfection of Activated *Hoxa-10* Protooncogenes Causes Mouse Mammary Hyperplasia. Shigeaki Miyamoto, Raphael C. Guzman, Robert A. Shurter, Gary L. Firestone, and Satyabrata Nandi.
- *6015 A Novel Ribonucleoprotein Complex Defined by Monoclonal Antibodies to NIH 3T3 Cells Transfected with Human Pancreatic Adenocarcinoma DNA. Michael A. Hollingsworth, Michael J. Borowitz, Mary Lou Everett, and Richard S. Metzger.
- *6023 Flow and Image Cytometric DNA Analysis in Rhabdomyosarcoma. Aretz Kowal-Vern, Frank Gonzalez-Crusi, Joyce Turner, Yolanda P. Trujillo, Pauline Chou, Chester Herman, Melanie Castelli, and Jamie Waclawchuk.
- *6028 Effect of Tumor Necrosis Factor on the Antitumor Efficacy and Toxicity of Aminopterin-Monoclonal Antibody Conjugates: Parameters for Optimization of Therapy. S. M. Russell, K. G. Krauer, I. F. C. McKenzie, and G. A. Pietersz.
- *6034 Antibody-mediated Redirected Cytolysis against Murine Melanoma Cells *in Vitro*. Osumu Usuda, Masafumi Ito, Constantin A. Bona, and Thomas M. Moran.
- *6039 Effect of Epidermal Growth Factor on Gloma Cell Growth, Migration, and Invasion *in Vitro*. Morten Lund-Johansen, Rolf Bjerkvig, Peter A. Humphrey, Sandra H. Bigner, Darell D. Bigner, and Ole-Dirk Laerum.
- *6045 Cathepsin D in Breast Cancer Cells Can Digest Extracellular Matrix in Large Acidic Vesicles. Philippe Montcouquer, Paul H. Mangat, Guillermo Salazar, Muriel Morisset, Alain Sahquet, and Henri Rochelet.
- *6055 Neuropeptide Y Expression in the Developing Adrenal Gland and in Childhood Neuroblastoma Tumors. Pamela S. Cohen, Mark J. Cooper, Lee J. Helman, Carol J. Thiele, Robert C. Seeger, and Mark A. Israel.
- 6113 Announcements**
Eighty-second Annual Meeting of the AACR
Call for Nominations for the Scientific Awards of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Death
Calendar of Events
- 6115 Errata**
E. A. Mueller and F. A. Anderer, p. 3646-3651, 1990.
J.-M. Le Doussal et al., p. 3445-3452, 1990.
August 15, 1990 *Cancer Research* cover legend.
- 6116 Author Index**
- 6243 Modulation of the Immune Response to Transplanted Tumors in Rats by Selective Depletion of Neutrophils *in Vivo* Using a Monoclonal Antibody: Abrogation of Specific Transplantation Resistance to Chemical Carcinogen-induced Syngeneic Tumors by Selective Depletion of Neutrophils *in Vivo*. Yasuhiko Midorikawa, Takao Yamashita, and Fujio Sendo.**
- *6248 Regulation of Carcinoembryonic Antigen Expression in Different Human Colorectal Tumor Cells by Interferon- γ . Fiorella Guadagni, Patricia L. Witt, Paul F. Robbins, Jeffrey Schlom, and John W. Greene.
- *6256 Requirements for the Generation of a Lyt-2⁺ T-Cell Proliferative Response to a Syngeneic Tumor in the Absence of L3T4⁺ T-Cells. Donald E. Kern, Jay P. Klamet, Martin A. Cheever, and Philip D. Greenberg.
- *6264 *In Vitro* Assessment of the Effects of Granulocyte-Macrophage Colony-stimulating Factor on Primary Human Tumors and Derived Lines. Richard S. Fouk, Martha H. Marshall, Paul P. Trotta, and Daniel D. Von Hoff.
- *6268 Combinations of Retinoid Acid with Either Sodium Butyrate, Dimethyl Sulfone, or Hexamethylene Bisacetamide Synergistically Induce Differentiation of the Human Myeloid Leukemia Cell Line HL60. Theodore R. Berman and Ruyi He.
- *6274 Medical History and Primary Liver Cancer. Carlo La Vecchia, Eva Negri, Barbara D'Avanzo, Peter Boyle, and Silvia Franceschi.
- 6278 Cathepsin B to Cysteine Proteinase Inhibitor Balance in Metastatic Cell Subpopulations Isolated from Marine Tumors. Jurij Rozhin, Angel P. Perez-Gil, Irene H. Ziegler, Kevin K. Nelson, Young Sook Chang, Dunnie Fong, James M. Onoda, Kenneth V. Horn, and Bonnie F. Sloane.
- *6285 Evidence That High Mannose Glycoproteins Are Able to Functionally Interact with Recombinant Tumor Necrosis Factor and Recombinant Interleukin 1. Andrej Muchmore, Jean Decker, Alan Shaw, and Paul Wingfield.
- *6291 Expression of Human α -Actinin in Human Hepatocellular Carcinoma. Masaki Nishiyama, Mehmet Ozkurt, Mark Fröhlich, Ken-ichi Mafune, Glenn Steele, Jr., and Jack R. Wands.
- *6295 Combinations of Anti-Transferrin Receptor Monoclonal Antibodies Inhibit Human Tumor Cell Growth *In Vitro* and *In Vivo*: Evidence for Synergistic Antiproliferative Effects. Suhaila White, Raymond Taetle, Paul A. Seligman, Mary Rutherford, and Ian S. Trowbridge.

October 1, Number 19

Perspectives in Cancer Research

6119 Mammalian O^6 -Aalkylguanine-DNA Alkylytransferase: Regulation and Importance in Response to Alkylating Carcinogenic and Therapeutic Agents. Anthony E. Pegg.

Special Lecture

6130 Critical Factors in the Biology of Human Cancer Metastasis: Twenty-eighth G. H. A. Clowes Memorial Award Lecture. Isaiah J. Edler.

*6139 K-ras Activation in Neoplasms of the Human Female Reproductive Tract. Takayuki Endo, Masaki Inoue, Alan D. Perantonis, Naoki Terakawa, Osamu Tanizawa, and Jerry M. Rice.

*6146 Two Chromosomal Locations for Human Ornithine Decarboxylase Gene Sequences and Elevated Expression in Colorectal Neoplasia. Diane M. Radford, Hiroshi Nakao, Roger L. Eddy, Linda L. Haley, Mary G. Byers, W. Michael Henry, David D. Lawrence, Carl W. Porter, and Thomas B. Shows.

*6154 Topoisomerase II-mediated DNA Damage of Episomes in Tumor-bearing Mice. Emily B. Cullinan, Loreetta S. Grawton, Youcef M. Rustum, and Terry A. Beerman.

*6158 Selective Immunoprecipitation of a Factor Produced by Colon Cancer Cells. Ellen C. Eber, Arthur L. Roberts, Dennis Devereux, and Hideaki Nagase.

*6162 Tumor Promoter-stimulated *Myc* 92,000 Gelatinase Secreted by Normal and Malignant Human Cells: Isolation and Characterization of the Enzyme from HT1080 Tumor Cells. Ute M. Möll, Gary L. Youngblom, Karen B. Rosinski, and James P. Quigley.

*6171 Retinoblastoma in the Human *T*-Cell-Retinoblastoma Cluster occurs in Patients with Adult T-Cell Leukemia Carrying Translocations Involving Chromosome 14q1. Masaharu Isobe, Naoki Sadamori, Giandomenico Russo, Shoichi Shimizu, Shunji Yamamori, Takahiro Royama, Yasuaki Yamada, Shuichi Ikeda, Michio Ichimaru, Jacob Kagan, and Carlo M. Croce.

6176 Comparison of DNA Amplification of Primary and Metastatic Spontaneous canine Osteosarcomas. Michael H. Fox, Leslie W. Armstrong, Steven J. Withrow, Barbara E. Powers, Susan M. LaRue, Rodney C. Straw, and Edward L. Gillette.

*6179 Roles of Transforming Growth Factor β in Inhibition of Androgen-induced Growth of Shionogi Carcinoma Cells in Serum-free Medium. Hiroshi Yamamoto, Norio Nonomura, Akira Tanaka, Toshiyuki Yasui, Yasuhiro Nishizawa, Keishi Matsumoto, and Bunzo Sato.

*6184 Independent Expression and Cellular Processing of *M*, 72,000 Type IV Collagenase and Intersitial Collagenase in Human Tumorigenic Cell Lines. Peter D. Brown, Anna T. Levy, Inger M. K. Margulies, Lance A. Liotta, and William G. Muller.

6192 Induction of Covalent DNA Modifications and Micronucleated Erythrocytes by 4-Nitroquinoline 1-Oxide in Adult and Fetal Mice. Lee-Jane Y. Lu, Jennifer R. Baxter, Mian-Ying Wang, Barbara L. Harper, Fumiyo Tasaka, and Kohfuku Kohda.

6199 Effect of Heat Treatment on Tumor Cells and Antitumor Effector Cells. Kenichi Misé, Norimichi Kan, Takeshi Okino, Masaki Nakamishi, Kohji Saito, Yasufumi Teramura, Seiji Yamasaki, Kazuhisa Ohgaki, and Takeyoshi Tobe.

*6203 Dose-dependent Neovascularity of High-Dose Busulfan in Children: A Clinical and Pharmacological Study. Gilles Vassal, Alain Derafshian, Olivier Hartmann, Dominique Challine, Ellen Benhamou, Dominique Valente-Couanet, Laurence Brugères, Chantal Kalifa, Alain Gruyer, and Jean Lemire.

*6208 T47D_{TC}, genetically Unstable and Containing Estrogen Receptor Mutations, Are a Model for the Progression of Breast Cancers to Hormone Resistance. Mark L. Graham II, Nancy L. Krett, Louise A. Miller, Kimberly K. Leslie, David F. Gordon, William M. Wood, Lisa L. Wei, and Kathryn B. Horwitz.

6218 Mechanism of Diethylstilbestrol Modulation of Murine Bone Marrow Toxicity. Therese K. Schmalbach and Richard F. Borch.

6222 Expression of Rat Microsomal Epoxide Hydrolase Gene during Liver Chemical Carcinogenesis. Shinichi Kondo, Brian I. Carr, Kenkichi Takagi, Ting H. Huang, Yun-Mei Chou, Kazushige Yokoyama, and Keiichi Itakura.

*6229 An Enzyme-linked Immunosorbent Assay for Cancer Procoagulant and Its Potential as a New Tumor Marker. Stuart G. Gordon and Barbara A. Cross.

6235 Role of the AKR Gene Locus *Akr-1* in Susceptibility to Chemical Induction of Thymic Lymphomas. Frederick B. Becker.

6238 Desensitization and Re-sensitization of Rat Pituitary Tumor Cells in Long-Term Culture to the Effects of the Somatostatin Analogue SMS 201-995 on Cell Growth and Prolactin Secretion. Jan W. Koper, Leo J. Hofland, Peter M. van Koetsveld, Fred den Holder, and Steven W. J. Lamberts.

CONTENTS OF VOLUME 50

- *6302 Phase I Trial of Intraperitoneal Recombinant Interleukin-2/Lymphotoxin-activated Killer Cells in Patients with Ovarian Cancer. James A. Stewart, Jerome L. Belinson, Ann L. Moore, John A. Dorohi, Barbara W. Grant, Larry D. Haugh, John D. Roberts, Richard J. Alberini, and Richard F. Branda.
- *6311 Increased lysis of Melanoma by *in Vitro*-elicited Human Lymphokine-activated Killer Cells after Addition of Antiangiogenesis Antibodies *In Vitro*. W. Harel, H. Shau, C. G. Hadley, A. C. Morgan, Jr., R. A. Reisfeld, D. A. Chereb, and M. S. Mitchell.
- *6316 Antisense Inhibition of Single Copy N-myc Expression Results in Decreased Cell Growth without Reduction of c-myc Protein in a Neuroepithelioma Cell Line. Angelo Rosolen, Luke Whittlesey, Naohiko Ikegaki, Roger H. Kennett, and Leonard M. Neckers.
- *6323 Megakaryocytic Differentiation of K562 Cells Is Associated with Changes in the Cytoskeletal Organization and Pattern of Chromatographically Distinct Forms of Phosphotyrosyl-specific Protein Phosphatases. T. Martin Butler, Andrew Ziemiczki, and Robert R. Fries.
- *6330 Genetic Origin of a Trophoblastic Choriocarcinoma. R. S. K. Chaganti, Prasad R. K. Koduri, Ranjita Chakraborty, and Walter B. Jones.
- *6334 Growth Adaptation to Methotrexate of HT-29 Human Colon Carcinoma Cells Is Associated with Their Ability to Differentiate into Columnar Absorptive and Mucus-secreting Cells. Thécla Lesseluer, Alain Barbat, Elisabeth Dusault, and Alain Zweibaum.
- *6344 *In Situ* Distribution of the β -Subunit of Platelet-derived Growth Factor Receptor in Nonneoplastic Tissue and in Soft Tissue Tumors. Wilbur A. Franklin, William H. Christison, Margo Coley, Anthony G. Montag, Janet K. Stephens, and Charles E. Hart.
- 6349 Genetic Instability and the Acquisition of Metastatic Ability by Rat Mammary Cancer Cells following *H-ras* Oncogene Transformation. Tomohiko Ichikawa, Natasha Kyprianou, and John T. Isaacs.
- *6358 Tumor-associated Antigens Common to Humans and Chemically Induced Colon Tumors of the Rat. Jayant D. Shetye, Carlos A. Rubio, Ulrich Harnenberg, James Ware, Annika Duvander, and Håkan T. Mellstedt.
- *6364 Differential Spectrum of Expression of Neural Cell Adhesion Molecule Isoforms and LI Adhesion Molecules on Human Neuroectodermal Tumors. Dominique F. Figarella-Branger, Pascale L. Durber, and Geneviève Renouf.
- *6371 Effect of Liposomes Composition and Ocular Factors on the Targeting of Liposomes to Experimental Tumors: Biostabilization and Imaging Studies. Alberto Gabizone, David C. Price, John Huberty, Robert S. Breslau, and Demetrios Papadopoulos.
- *6379 Enhanced Therapeutic Efficacy against an Ovarian Tumor Xenograft of Immunotoxins Used in Conjunction with Recombinant α -Interferon. F. Pearson, E. Hedrick, W. E. Fogler, R. L. Bull, D. K. Ferris, C. W. Riggs, R. H. Wiltrout, G. Sivam, A. C. Morgan, D. Kerster, P. M. Kiet, and R. Willemsen.
- *6389 Antiproliferative and Cytotoxic Effects of Single and Combined Treatment with Tumor Necrosis Factor α and/or α -Interferon on a Human Renal Cell Carcinoma Xenotransplanted into *nu/nu* Mice: Cell Kinetic Studies. Heinz Baisch, Ulrich Otto, and Gunter Kloppel.
- *6396 Induction of Cells with Phenotypic Features of Neuronal Cells by Treatment with Dibutyryl Cyclic Adenosine 3',5'-Monophosphate in a Human Parotid Gland Adenocarcinoma Cell Line in Culture. Shinichi Nagamine, Tetsuo Yanagawa, Takashi Bando, Yoshiaki Yura, Hideo Yoshida, and Mitsunobu Sato.
- *6405 Murine Monoclonal Antibodies to Colon-specific Antigen p.** David V. Gold, Mary Ann Noceca, Richard Stephens, and David M. Goldenberg.
- *6410 *Lip13-15* Is a Specific Region of Chromosomal Rearrangement in Gastric and Esophageal Adenocarcinomas. Eduardo Rodriguez, Palivaruthi H. Rao, Marc Ladanyi, Naser Altorki, Anthony P. Albino, David P. Kelsen, Suresh C. Jhanwar, and R. S. K. Chaganti.
- *6417 Gene Amplification in Gastric and Esophageal Adenocarcinomas. Jane Houldsworth, Carlos Cordon-Cardo, Marc Ladanyi, David M. Kelsen, and R. S. K. Chaganti.
- *6423 Immunohistochemical and Pharmacokinetic Characterization of the Site-specific Immunoconjugate CYT-356 Derived from Anti-prostate Monoclonal Antibody 7E11-C5. A. Dwight Lopes, Wendy L. Davis, Maurice J. Rosenblatt, Albert J. Uveges, and Steven C. Gilman.

Meeting Report

- 6430 Steroid Receptors, Transcription Factors, and Gene Expression: AACR Special Conference in Cancer Research. Larry Denner, Hongqian Ji, Russell D. Owen, Gregory J. Kato, Christine L. Clarke, Hae-Young Lee, and Utam K. Pati.
- 6436 Announcements
- Eighty-second Annual Meeting of the AACR
Call for Nominations for the Scientific Awards of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
American Cancer Society Call for Grant Applications—
Nutrition and Cancer
Recent Death
Calendar of Events
- 6439 Author Index

October 15, Number 20

- Perspectives in Cancer Research
- 6441 Epidemiology, Basic Science, and the Prevention of Cancer: Implications for the Future. C. S. Muir.
- Review
- 6449 Glutathione-S-Transferases: Role of Alkylating Agent Resistance and Possible Target for Modulation Chemotherapy—A Review. David J. Waxman.
-
- 6455 An Animal Model to Study Toxicity of Central Nervous System Therapy for Childhood Acute Lymphoblastic Leukemia: Effects on Growth and Craniofacial Proportion. Ann Schumion, Anna E. Zengel, Phyllis J. Mulliken, Nancy J. Tarbell, Anthony Howes, and Melissa S. Tassinari.
- 6461 An Animal Model to Study Toxicity of Central Nervous System Therapy for Childhood Acute Lymphoblastic Leukemia: Effects on Behavior. Phyllis J. Mulliken, William J. Kerman, Melissa S. Tassinari, Ann Schumion, Deborah P. Waber, Anthony Howes, and Nancy J. Tarbell.
- *6466 Interaction of Gallium Nitrate with Fludarabine and Iron Chelators: Effects on the Proliferation of Human Leukemic HL60 Cells. Joel H. Lundberg and Christopher R. Chittambar.
- *6471 Functional Interactions between Colony-stimulating Factors and the Insulin Family Hormones for Human Myeloid Leukemic Cells. Donna Okkenberg, Barbara S. Dieckmann, and Peter L. Greenberg.
- *6478 Human Homologue of Moloney Leukemia Virus Integration-4 Locus (*MLV-I-4*). Located 20 Kilobases 3' of the *myc* Gene, Is Rearranged in Multiple Mammals. Antonio J. Palumbo, Mario Boccadoro, Silvano Battaglio, Paolo Corradini, Philip N. Tsichlis, Kay Huehner, Alessandro Pilieri, and Carlo M. Croce.
- *6483 Immunological Effects of Flavone Aescic Acid. Pierre L. Triozzi, John J. Rinehart, Louis Malpeis, Donn C. Young, and Michael R. Grever.
- *6486 Meta-Analysis of the Risk of Gastric Stump Cancer: Detection of High-Dose Pancreatic Enzyme for Stomach Cancer—Remote Protection? G. John A. Offerhaus, Kasper W. F. Terسمitt, Francis M. Giardello, G. William Moore, Guido N. J. Tytgat, and Jan P. Vandenhoecke.
- *6490 Suramin Alters Phosphoinositide Synthesis and Inhibits Growth Factor Receptor Binding in HT-29 Cells. Reinhard Kopp and Andreas Pleijer.
- 6497 Role of Carrier Ligand in Platinum Resistance in L1210 Cells. Gregory R. Gibbons, Jimmy D. Page, Stanley K. Mauldin, Intisar Husain, and Stephen G. Chaney.
- *6502 Smoking and Drinking in Relation to Cancers of the Oral Cavity, Pharynx, Larynx, and Esophagus in Northern Italy. Silvia Franceschi, Renata Talamini, Salvatore Barra, Anna F. Barón, Eva Negri, Ettore Bidoli, Diego Serraino, and Carlo La Vecchia.
- *6508 Enhanced *In Vitro* Lysis of Human Ovarian Carcinomas with Activated Peripheral Blood Lymphocytes and Bifunctional Immune Heteroaggregates. John H. Donohue, Patrick S. Ramsey, Lindsey A. Kerr, David M. Segal, and David J. McKean.
- 6515 Substrate-specific Deoxycytidine kinase Deficiency in 1- β -D-Arabinofuranosylcytosine-resistant Leukemic Cells. D. J. Richel, L. P. Colly, G. J. A. Arkesteijn, M. W. Arentsen-Honders, M. D. G. Kerster, P. M. ter Kiet, and R. Willemsen.
- *6520 Case-Control Study of Residential Radon and Lung Cancer among New Jersey Women. Janet B. Schoenberg, Judith B. Klotz, Homer B. Wilcox, Gerald P. Nichols, Maria T. Gil-del Real, Annette Stehmann, and Thomas J. Mason.
- *6525 Plasma Pharmacokinetics and Cerebral Fluid Concentrations of Irinotecan and Irinotecan in Pediatric Leukemia Patients: A Children's Cancer Study Group Report. Joe M. Reid, Thomas W. Pendergrass, Mark D. Krailo, G. Denman Hammond, and Matthew M. Ames.
- *6529 Loss of Heterozygosity of Markers on Chromosome 11 in Tumors from Patients with Multiple Endocrine Neoplasia Syndrome Type I. D. M. Radford, S. W. Ashley, S. A. Wells, Jr., and D. S. Gerhard.
- *6534 Cloning of a Carcinoembryonic Antigen Gene Family Member Expressed in Leukocytes of Chronic Myeloid Leukemia Patients and Bone Marrow. Barbara Berling, Frank Kolbinger, Fritz Grunert, John A. Thompson, Frank Brummayer, Franz Buchegger, Sabine von Kleist, and Wolfgang Zimmermann.
- 6540 Hydroxyanthraquinones as Tumor Promoters: Enhancement of Malignant Transformation of C3H Mouse Fibroblasts and Growth Stimulation of Primary Rat Hepatocytes. Detlef Wölfe, Christoph Schmitte, Johannes Westendorf, and Hans Marquardt.
- *6545 Immunological Detection of Residual Marrow Disease at Clinical Revision Predicts Metastatic Relapse in Small Cell Lung Cancer. R. C. F. Leonard, L. W. Duncan, and F. G. Hay.
- 6549 Sodium-dependent and Equilibrative Nucleoside Transport Systems in L1210 Mouse Leukemia Cells: Effect of Inhibitors of Equilibrative Systems on the Content and Retention of Nucleosides. Lina Dagnino and Alan R. P. Patterson.
- 6554 Increased Sensitivity to *Vinca* Alkaloids in Cells Overexpressing Calmodulin by Gene Transfection. Masaru Ido, Lisette Lagace, and James G. Chaffoules.
- *6559 A Comparative Case-Control Analysis of Stomach Cancer and Atrophic Gastritis. Ikuo Kato, Sukeumi Tomimaga, Yoshiaki Ito, Seiki Kobayashi, Yuki Yoshii, Akira Matsunaga, Akira Kameya, and Tomoyuki Kano.
- *6565 Antisense-mediated Inhibition of *BCL2* Protooncogene Expression and Leukemic Cell Growth and Survival: Comparisons of Phosphodiester and Phosphorothioate Oligodeoxynucleotides. John C. Reed, Cy Stein, C. Subashige, Subrata Haldar, Carlo M. Croce, Samuel Yum, and Jack Cohen.
- *6571 Dehydroepiandrosterone Sulfate and Breast Cancer Risk. Elizabeth Barrett-Connor, Nancy Lee J. Friedlander, and Kay-Tee Khaw.
- 6575 Induction and Repair of DNA Double Strand Breaks in Radiation-resistant Cells Obtained by Transformation of Primary Rat Embryo Cells with the Oncogenes *H-ras* and *v-myc*. George Iliakis, Lorenz Metzger, Ruth J. Muschel, and W. Gillies McKenna.
- *6580 Combined High-Performance Liquid Chromatography 32 P-Post-labeling Assay of *N*¹-Methyldeoxyguanosine. P. G. Shields, A. C. Povey, V. L. Wilson, A. Weston, and C. C. Harris.
- *6585 Pesticide Exposures and Other Agricultural Risk Factors for Leukemia among Men in Iowa and Minnesota. Linda Morris Brown, Aaron Blair, Robert Gibson, George D. Everett, Kenneth P. Carter, Leonard M. Schuman, Leon F. Burmeister, Stephanie F. Van Lier, and Fred Dick.
- 6592 Carcinogenicity of 1,3-Butadiene in C57BL/6 x C3H F₁ Mice at Low Exposure Concentrations. Ronald L. Melnick, James Huff, Billy J. Chou, and Rodney A. Miller.
- *6600 Evaluation *In Vitro* of Adriamycin Immunocomplexes Synthesized Using an Acid-sensitive Hydrazide Linker. Robert S. Greenfield, Takushi Kaneko, Ann Dues, Mary A. Edson, Kathleen A. Fitzgerald, Lee J. Olech, James A. Grattan, George L. Spitalny, and Gary R. Braslavsky.
- *6608 Antitumor Activity of Adriamycin (Hydrazino-link) Immunocomplexes Compared with Free Adriamycin and Specificity of Tumor Cell Killing. Gary R. Braslavsky, Mary A. Edson, Walter Pearce, Takushi Kaneko, and Robert S. Greenfield.
- *6615 Influence of Renal and Hepatic Failure on the Pharmacokinetics of Recombinant Human Granulocyte Colony-stimulating Factor (KRN6001) in the Rat. Hideji Tanaka and Tomonobu Tokuda.
- *6620 Clonotypic Heterogeneity in Cutaneous T-Cell Lymphomas. Yves-Jean Bignon, Pierre Souleyrand, Hughes Roger, Yvette Foncet, Dominique Bernard, Jacques Chassagne, François Ramos, Michel D'Incan, Philippe Chollet, Bernard Dutagué, and Robert Plagne.
- *6626 Mechanism of Resistance of Confluent Human and Rat Colon Cancer Cells to Anthracyclines: Alteration of Drug Passive Diffusion. Hélène Pelletier, Jean-Marc Milutin, Bruno Chaffert, Michel Manfait, Philippe Genet, and François Martin.
- *6632 Estrogen and Progesterone Receptors in Bronchogenic Carcinoma. Philip T. Cagle, Dina R. Mody, and Mary R. Schwartz.
- *6636 The Effect of Calmodulin Inhibitors with Bleomycin on the Treatment of Patients with High Grade Gliomas. William N. Hait, Thomas N. Byrne, Joseph Piepmeyer, Henry J. Durivage, Supra Choudhury, Carol A. Davis, and Jay A. Gates.
- *6641 Constitutive Expression of the *c-fos* Protooncogene in Murine Keratinocytes: Potentiation of the Mitogenic Response to Insulin-like Growth Factor. Michael Reich, Arthur I. Radin, and Tracey F. Weinstock.
- *6649 Acetylation Phenotype Is Not Associated with Breast Cancer. Peter F. Ilett, Peter Dettoni, David M. Ingram, and William M. Castleden.
- *6652 Effects of Leucorin on Idoxuridine Cytotoxicity and DNA Incorporation. Raymond F. Greene and Jerry M. Collins.
- 6657 Expression of a *M*, 41,000 Glycoprotein Associated with Thrombin-independent Platelet Aggregation in High Metastatic Variants of Murine B16 Melanoma. Masahiko Watanabe, Yoshikazu Sugimoto, and Takashi Tsuruo.
- *6663 Quantitative Measurements of Changes in Protein Thiols in Cervical Intraporphelia Neoplasia and in Carcinoma of the Human Uterine Cervix Provide Evidence for the Existence of a Biochemical Field Effect. C. Benedetto, F. Bajardi, B. Ghiringhelli, L. Marzocci, G. Nohammer, P. Phitakkraiwan, W. Rojanapo, E. Schausstein, and T. F. Slater.
- *6668 Characterization of an *N*-Methyl-*N*-nitrosourea-induced Autochthonous Rat Bladder Cancer Model. Gary D. Steinberg, Charles B. Brendler, Tomohiko Ichikawa, Robert A. Squire, and John T. Isaacs.

CONTENTS OF VOLUME 50

- *6675 Mitochondrial DNA Modulation of the Anchorage-independent Phenotype of Transformed Avian Cells.** Karen Zinkiewich-Péroti, Manon Parent, and Réjean Morais.
- *6683 Human Glioblastoma Cells Release Interleukin 6 *in Vivo* and *in Vitro*.** Erwin Van Meir, Yutaka Sawamura, Annie-Claire Diserens, Marie-France Hanoué, and Nicolas de Tribolet.
- *6689 Insulin-like Growth Factor Gene Expression in Human Smooth Muscle Tumors.** Ton Gijselmans, Irma Prinsen, Jan A. M. Van Unnik, Cornelis J. M. Lips, Willem Den Otter, and John S. Sussenbach.
- *6696 Potent Cytotoxicity of an Antibius Transferin Receptor-Biota A-Chain Immunotoxin on Human Glioma Cells *In Vitro*.** Lawrence D. Recht, Thomas W. Griffin, Vic Raso, and Ali R. Salimi.
- *6701 Increased erbB-2 Gene Copies and Expression in Multiple Stages of Breast Cancer.** J. Dirk Igelsberg, Matthias H. Kraus, Beatrice C. Langton, Gudrun Huper, Bille Jo Kems, and Jeffrey R. Marks.
- 6708 Induction of the Differentiation of WEHI-3B D⁺ myelomonocytic Leukemia Cells by Inhibitors of Topoisomerase II.** Germana Rappa, Aurelio Lorigo, and Alan C. Sartorelli.
- *6716 Altered Expression of Proteoglycans in E1A-immortalized Rat Fetal Intestinal Epithelial Cells in Culture.** Peggy Lévy, Shahin Emami, Gisèle Cherqui, Eric Chastre, Christian Gispach, and Jacques Picard.
- *6723 Subcutaneous Recombinant Interleukin 2 in a Dose Escalating Regimen in Patients with Metastatic Renal Cell Adenocarcinoma.** Robert P. Whitehead, Dave Ward, Lucy Hemmingway, George P. Hemstreet III, Edward Bradley, and Michael Konrad.
- *6731 Inhibition of Experimental Metastasis of Murine Lewis Lung Carcinoma by an Inhibitor of Glycosidase Synthase and Its Possible Mechanism of Action.** Jin-ichi Inokuchi, Masayuki Jimbo, Keiko Momosaki, Hiroshi Shimono, Atsuo Nagamatsu, and Norman S. Radin.
- *6738 Detection and Characterization of a High Molecular Weight Human Lung Carcinoma-associated Glycoprotein.** Peter Maimonis, Daniel F. Hayes, Carl O'Hara, and Donald Kufe.
- 6744 Cytological Study of Vacuolated Cells and Other Aberrant Hepatocytes in Winter Flounder from Boston Harbor.** Joel E. Bodammer and Robert A. Murchelano.
- *6757 Integrin Distribution in Malignant Melanoma: Association of the β_1 Subunit with Tumor Progression.** Steven M. Albeda, Stephen A. Mette, David E. Elder, Rosemary Stewart, Laszlo Damjanovich, Meenhard Herlyn, and Clayton A. Buck.

Meeting Report

- 6765 Tumor Suppressor Genes Workshop.** Alfred G. Knudson and Arthur C. Upton.

- 6766 Annual Meeting.** Eighty-second Annual Meeting of the AACR. AACR Special Conferences in Cancer Research. Future Annual Meetings of the AACR. American Cancer Society Call for Grant Applications—Nutrition and Cancer. Recent Death. Calendar of Events.

- 6768 Author Index**

November 1, Number 21

- Perspectives in Cancer Research**
6769 The Cell Cycle: Myths and Realities. Renato Baserga.

- *6772 Specific Binding and Growth Effects of Bombesin-related Peptides on Mouse Colon Cancer Cells *In Vitro*.** Satya Narayan, Yan-Shi Guo, Courtney M. Townsend, Jr., and Pomila Singh.

- 6779 Oxytropin Accelerates the Growth of Microscopic Hepatocellular Neoplasms in the Mouse: Possible Association with Whole Body Growth and Fat Deposition.** Stanley Goldfarb and Thomas D. Pugh.

- *6783 Clonal Analysis of Human Meningiomas and Schwannomas.** Lee B. Jacoby, Karen Pulaski, Guy A. Rouleau, and Robert L. Martuza.

- *6787 Identification and Characterization of Two Distinct α -(1-3)- β -Fucosyltransferase Activities in Human Colon Carcinoma.** George B. Stroup, Kalyan R. Anumula, Thomas F. Kline, and Madelyn M. Calabiano.

- *6793 Susceptibility of Multidrug-resistant Human Leukemia Cell Lines to Human Interleukin 2-activated Killer Cells.** Astrid Kimmig, Volker Geckeler, Manfred Neumann, Gerhard Frese, Rüpert Handgretinger, Gabriele Kardos, Heyke Dödzens, and Dietrich Niethammer.

- 6800 Sialomucin and Lytic Susceptibility of Rat Mammary Tumor Asclines Cells.** John Moriarity, Colleen K. Seely, Seema Bharathan, Charles E. Moody, and Anne P. Sherblom.

- *6806 Phase I Trial of Escalating Pentoxifylline Dose with Constant Dose Thiotepa.** Bruce J. Dezube, J. Paul Eder, and Arthur B. Pardee.

- 6811 Protective Effects of Voluntary Exercise during the Postinitiation Phase of Pancreatic Carcinogenesis in the Rat.** B. D. Roebuck, Jennifer McCaffrey, and Karen Baumgarner.

- 6817 Metabolism of 4-(Methylnitrosamo)-1-(3-pyridyl)-1-butanone in Mouse Lung Microsomes and Its Inhibition by Isothiocyanates.** Theresa J. Smith, Zuyu Guo, Paul E. Thomas, Fung-Lung Chung, Mark A. Morse, Karen Ellind, and Chung S. Yang.

- *6823 Pharmacologically Directed Design of the Dose and Schedule of 2',2'-Difluorodeoxycytidine (Gemcitabine) Administration in Leukemia.** Ralf Grunewald, Hagop Kantarjian, Michael J. Keating, James Abbuzzese, Peter Tarassoff, and William Plunkett.

- *6827 Urokinase-Plasminogen Activator, a New and Independent Prognostic Marker in Breast Cancer.** Michael J. Duffy, David Reilly, Cathriona O'Sullivan, Niall O'Higgins, James J. Fennelly, and Peter Andreassen.

- *6830 ras Gene Mutations in Human Prostate Cancer.** Bob S. Carter, Jonathan I. Epstein, and William B. Isaacs.

- *6833 Phase II Study of Oral Irinotecan in Favorable Histology Non-Hodgkin's Lymphoma.** Dehyn C. Case, Jr., Daniel M. Hayes, Marjoram Gerber, Richard Gams, Thomas J. Ervin, and Brian M. Dorst.

- *6836 Diet, Tobacco Use, and Fatal Prostate Cancer: Results from the Lethman Brotherhood Cohort Study.** Ann W. Hsing, Joseph K. McLaughlin, Leonard M. Schuman, Erik Birkle, Gloria Gridley, Sholom Wacholder, Harvey T. Co Chien, and William J. Blot.

- 6841 Response of Mouse Skin Tumors to Doxorubicin Is Dependent on Carcinogen Exposure.** W. Nicoll Keith, P. Joseph Mee, and Robert Brown.

- *6848 Glutathione Transferase Activity and Isoenzyme Composition in Primary Human Breast Cancers.** Thomas C. Shea, Ginger Cialio, Kenneth E. Comstock, Barbara J. S. Sanderson, Nelson A. Burstein, Edward J. Keenan, Bengt Mannervik, and W. David Henner.

- *6854 Prospective Evaluation of a Model for Predicting Epoxide Plasma Protein Binding in Cancer Patients.** Clinton F. Stewart, Ronald A. Fleming, Susan G. Arbuck, and William E. Evans.

- *6857 Structure-Function Studies on Analogs of 10,25-Dihydroxyvitamin D₃: Differential Effects on Leukemic Cell Growth, Differentiation, and Intestinal Calcium Absorption.** Anthony W. Norman, J. Y. Zhou, Helen L. Henry, Milan R. Uskokovic, and H. Philip Koefoed.

- *6865 An MDPB Site in the First Intron of the Human c-myc Gene.** Xian-Yang Zhang, Prakash C. Upadhyak, Kezuo Wu, Kenneth C. Ehrlich, and Melanie Birnbaum.

- 6870 Determination of α -D-Glutamine in DNA by Immunoaffinity Extraction/Gas Chromatography-Mass Spectrometry.** Marina Bonfanti, Cinzia Magagnotti, Alessandra Galli, Renzo Bagatti, Massimo Moretti, Pierluigi Gariboldi, Roberto Fanelli, and Luisa Airola.

- *6876 Survey of Exposure to Genotoxic Agents in Primary Malignant Mesothelioma: Correlation with Chromosome Patterns and Data on Patients without Hematological Disease.** Helen Goldberg, Ed Lust, Jonni Moore, Peter C. Nowell, and Emmanuel C. Bea.

- *6882 Nonoccurrence of Atavistin with Primary Liver Cancer in a Cross-Sectional Ecological Survey in the People's Republic of China.** T. Colin Campbell, Junshi Chen, Chongbo Liu, Junyao Li, and Banoo Parhami.

- 6894 DNA Polymerase α -Primase Complexes from Carcinogen-treated Chinese Hamster Ovary Cells.** Angelika Brucker, Lawrence A. Loeff, and Heinz Walter Thielmann.

- *6902 Human Prostatic Cancer Cells, PC3, Elaborate Mitogenic Activity Which Selectively Stimulates Human Bone Cells.** Victor S. Perletti, Subbaraman Mohan, Sandra J. Herring, David J. Baylink, and Thomas A. Linkhart.

- *6906 Expression of the Neuronal Form of p69⁰⁻⁶ in Neuroblastomas in Relation to Clinical Stage and Prognosis.** Catarina Björnfors, Fredrik Hedborg, Irena Johansson, Magnus Nordenskjöld, and Sven Pihlman.

- 6915 Antitumor Efficacy of Vaccinia Virus-modified Tumor Cell Vaccine.** Tetsuya Ito, Da-Qing Wang, Morimasa Maru, Kazuhiro Nakajima, Shiro Kato, Takashi Kurimura, and Nobutaka Wakamaya.

- 6919 Involvement of Nucleic Acid Synthesis in Cell Killing Mechanisms of Topoisomerase Poisons.** Peter D'Arpa, Christopher Beardmore, and Leroy F. Liu.

- *6925 Decreased Expression of DNA Topoisomerase I in Camptothecin-resistant Tumor Cell Lines as Determined by a Monoclonal Antibody.** Yoshihiko Sugimoto, Satomi Tsukahara, Tomoko Oh-hara, Toshiyuki Ito, and Takashi Tsuruo.

- *6931 Prognostic Significance of Insulin-like Growth Factor 1 Receptors in Human Breast Cancer.** J. Bonnerie, J. P. Peyrat, R. Beaucet, and A. Demalie.

- *6936 Action of Gossypol and Rhodamine 123 on Wild Type and Multi-drug-resistant MCF-7 Human Breast Cancer Cells:** ³¹P Nuclear Magnetic Resonance and Toxicity Studies.

- Beverly J. Jaroszewski, Ofer Kaplan, and Jack S. Cohen.

- 6944 Specific Activation of the Prodrug Mitomycin Phosphate by a Bispecific Anti-CD30/Anti-Alkaline Phosphatase Monoclonal Antibody.** Ugo Salmon, Frank Hartmann, Peter Senter, Christoph Pohl, Andreas Engert, Volker Diehl, and Michael Pfreundschuh.

- *6949 Stable Expression of Human Aromatase Complementary DNA in Mammalian Cells: A Useful System for Aromatase Inhibitor Screening.** Dujin Zhou, Dennis Ponpon, and Shiuhan Chen.

- 6955 Promotion of Colonic Micronodules Growth in Mice and Rats Fed Cooked Sugar or Cooked Caselin and Fat.** Denis E. Corpet, Dennis Stamp, Alan Medina, Salmon Minikit, Michael C. Archer, and W. Robert Bruce.

- *6959 Constitutive Production of Interleukin 6 by Ovarian Cancer Cell Lines and by Primary Ovarian Tumor Cultures.** Joanna M. Watson, John L. Sennatoff, Jonathan S. Berch, and Otoniel Martinez-Maza.

- 6966 Evidence for the Production of Nitric Oxide by Activated Macrophages Treated with the Antitumor Agents Flavone-8-acetic Acid and Xanthone-4-Acid.** Lindy L. Thomsen, Lai-Ming Ching, and Bruce C. Baguley.

- *6971 Cytotoxicity, Radioresistant, Antitumor Activity, and Interaction with Hyperthermia of a Col(II) Mustard Complex.** Beverly A. Teicher, Michael J. Abrams, Kristina W. Rose, and Terence S. Herman.

- *6976 Glutathione Content and Glutathione-S-transferase Expression in 1,3-Bis(2-chlorovinyl)-1-nitrosourea-resistant Human Malignant Astrocytoma Cell Lines.** Francis Ali-Osman, Donna E. Stein, and Alexander Renwick.

- *6981 Melanoma-inhibiting Activity Inhibits Cell Proliferation by Prolongation of the S Phase and Arrest of Cells in the G₁ Compartment.** F. X. Weilbach, U. Bogdahn, M. Poot, R. Apfel, C. Behl, D. Drenkard, R. Martin, and H. Hoech.

- *6987 Complementary Reactivities of Anti-Carcinoembryonic Antigen and Antitumor-associated Glycoprotein 72 Monoclonal Antibodies in Lung Carcinomas.** P. Battista, R. Murray, S. Mammarella, M. C. Curia, A. Colasante, S. Rosini, G. Letti, R. Sacco, D. French, L. Frati, and R. Mariani Costantini.

- *6995 Localization of Collagenase at the Basal Plasma Membrane of a Human Pancreatic Carcinoma Cell Line.** Ute M. Moll, Bernard Lane, Stanley Zucker, Ko Suzuki, and Hideaki Nagase.

- *7003 Application of an Interleukin 2 Slow Delivery System to the Immunotherapy of Established Murine Colorectal Carcinoma Liver Metastases.** Toshiyuki Furukawa, Kenichi Sakagami, Junji Matsuda, Shigehiro Shiozaki, Sosumi Uchida, Keiji Fujio, Yoshihiro Tadaka, Tadao Ochiai, and Kunio Orita.

- *7006 Characterization of New Human Pancreatic Cancer Cell Lines Which Propagate in a Protein-free Chemically Defined Medium.** Nozomi Yamaguchi, Yoshiro Yamamura, Kunihiko Koyama, Eigo Otsuji, Jiro Imanishi, and Tsukasa Ashihara.

- 7015 Phenobarbital Enhances the Formation of Reactive Oxygen in Neoplastic Rat Liver Nodules.** Werner Scholtz, Karin Schütze, Werner Kunz, and Michael Schwarz.

- 7023 Induction of Replicative Competence ("Priming") in Normal Liver.** Janet E. Mead, Lundy Braun, Deborah A. Marin, and Nelson Fausto.

- 7031 Selective Reduction of *cis*-Diamminedichloroplatinum(II) Nephrotoxicity by Ebselen.** Glenn S. Baldwin, J. Gordon McVie, Marin A. van der Valk, Gerrit Los, Jeroen J. M. de Goede, and Nico P. E. Vermeulen.

- *7037 γ -Interferon Reduces Expression of the Protooncogene *c-erbB-2* in Human Ovarian Carcinoma Cells.** Christian Matz, Elisabeth Müller-Holzen, Evi Greizer, Marcus V. Cronauer, Alain G. Zeimet, Wolfgang Doppler, Brigitte Eibl, Nancy E. Hynes, and Günter Dosenbichler.

- 7042 A Murine Model for B-cell Lymphomagenesis in Immunocompetent Hosts: c-myc-neoarranged B-cell Lines with a Preneoplastic Phenotype.** Dean W. Felsher, Kathleen A. Dents, Diane Weiss, Dale T. Ando, and Jonathan Braun.

- 7050 A Murine Model for B-Cell Lymphomagenesis in Immunocompetent Hosts: Natural Killer Cells Are an Important Component of Host Resistance to Premalignant B-cell Lines.** Dean W. Felsher, Sung-Hee Rhim, and Jonathan Braun.

- *7057 Immunocytochemical Localization of Estrogen and Progesterone Receptors and Prognosis in Human Primary Breast Cancer.** Angelika Reiner, Birgit Neumeister, Jürgen Spohn, Georg Anger, Michael Schepmer, and Raimund Jakob.

- 7062 *In Vitro* Malignant Conversion of Low-Grade Rat Urinary Bladder Carcinoma Cells by Exposure to N-Methyl-N-nitrosourea.** Masayuki Azuma, Hitoshi Momose, and Ryōichi Oyusa.

- *7068 Imaging of Non-Small Cell Lung Cancers with a Monoclonal Antibody, KC-402, Which Recognizes a Human Milk Fat Globule Antigen Found in Dismant, Rayon, and F. Schmetter.** James L. Less, Gary J. Miller, Stephan D. Ghosh, Duane C. Bloodworth, Ravinder Kalish, Patrick Moran, Paul Seligman, James R. Murphy, Kenneth Korright, and Paul A. Bunn, Jr.

- *7077 Immunohistochemical Evidence of Autocrine Growth Factors in Adenocarcinoma of the Human Lung.** Masahiro Tateshi, Teruyoshi Ishida, Tetsuya Mitsudomi, Satoshi Kaneko, and Keizo Sugimachi.

CONTENTS OF VOLUME 50

Advances in Brief

- *7081 Allelic Loss of Chromosome 17p Distinguishes High Grade from Low Grade Transitional Cell Carcinomas of the Bladder. Aria F. Olumi, Yvonne C. Tsai, Peter W. Nichols, Donald G. Skinner, Delver R. Cain, Leon I. Bender, and Peter A. Jones.

Letter to the Editor

- 7084 Cigarette Smoking and Stomach Cancer. Abraham Nomura.

John S. Grove, Grant N. Stemmermann, and Richard K. Severson.

Meeting Report

- 7085 U.S.-Japan Seminar on Molecular Mechanisms of Initiation, Promotion and Progression. William F. Benedict, Curtis C. Harris, Hirota Fujiki, and Kumao Toyoshima.

Announcements

Eighty-second Annual Meeting of the AACR

AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Recent Death
Calendar of Events

7084 Author Index

Perspectives in Cancer Research

- 7093 Role of Cyclic AMP Receptor Proteins in Growth, Differentiation, and Suppression of Malignancy: New Approaches to Therapy. Yoon S. Cho-Chung.

- *7101 Phospholipase A₂ Activation and Autoinduction of Tumor Necrosis Factor Gene Expression by Tumor Necrosis Factor. David R. Springs, Matthew L. Sherman, Kyoko Imamura, Misunobu Mohri, Christina Rodriguez, Gregory Robbins, and Donald W. Kufe.

- 7108 Changes in Intramural pH by Two Heating. Jyh-Cherng Lin and Chang W. Song.

- *7112 Patterns of Mate Linking in a Brazilian City. Cesar G. Victoria, Nubia Muñoz, Bernardo L. Horta, and Everton O. Ramos.

- *7116 Phorbol Ester Effects on Topoisomerase II Activity and Gene Expression in HL-60 Human Leukemia Cells with Different Proliferatives toward Monocytoid Differentiation. Leonard A. Zavellin, Michael Hinds, Diana Chan, Elizabeth Altschuler, Janice Mayes, and Theodore F. Zippel.

- *7123 Potentiation of Tumor Lysis by a Bispecific Antibody that Binds to CA19-9 Antigen and the Fc_Y-Receptor Expressed by Human Large Granular Lymphocytes. Irma García de Palazón, Cecilia Gerecel-Taylor, Joanne Kitson, and Louis M. Weiner.

- *7129 Occupations of Parents of Children with Retinoblastoma: A Report from the Children's Study Group. Greta R. Bonin, Alena Petrukhina, Anna T. Meadows, Beverly S. Emanuel, Jonathan D. Buckley, William G. Woods, and G. Denman Hammond.

- *7134 Effect of Tamoxifen on DNA Synthesis and Proliferation of Human Malignant Glioma Lines *In Vitro*. Ian F. Pollack, Margaret S. Randall, Matthew P. Kristofik, Robert H. Kelly, Robert G. Selker and Frank T. Verostek, Jr.

- *7139 Effects of Fatty Acids and Inhibitors of Eicosanoid Synthesis on the Growth of a Human Breast Cancer Cell Line in Culture. David P. Rose and Jeanne M. Connolly.

- 7145 Posttranslational Control of Cyclic AMP-Dependent Protein Kinase by Phorbol Ester in Normal but not in Chemically Transformed JET3 Cells. Hee-Youn Park and Judith Campisi.

- *7153 *In Vitro* Migration of Lymphocytes through Collagen Matrix: Arrested Locomotion in Tumor-Infiltrating Lymphocytes. Keili G. Applegate, Charles M. Balch, and Neal P. Pasquini.

- *7159 Correlation between Serum Antitumor Activity and Concomitant Resistance in Mice Bearing Nonimmunogenic Tumors. Raúl A. Ruggiero, Oscar D. Bustamante, Paula Kramer, R. Daniel Bonfil, and Christiane Dosse-Pasqualini.

- *7166 Genetic Changes and Histopathological Types in Colorectal Tumors from Patients with Familial Adenomatous Polyposis. Michiko Miyaki, Madoka Seki, Mieko Okamoto, Akyoshi Yamamoto, Yoshio Maeda, Kyoko Tanaka, Rei Kikuchi, Takeo Iwami, Tatsuro Ueda, Akihi Tomonaga, Yusuke Nakamura, Ray White, Yoshio Miki, Jiji Utsunomiya, and Moto Koike.

- *7174 Ether-linked Phosphoglyceride Content of Human Leukemia Cells. Marie C. Chabot, Diane G. Greene, Joni K. Brockschmidt, Robert L. Capizzi, and Robert L. Wykle.

- *7179 Role of Insulin-like Growth Factor-receptor Peptides in the Estradiol-, Prostaglandin-, and Progesterone-stimulated Growth of N-Tri-nosomethylsilyl-induced Rat Mammary Tumors in Soft Agar. Andrew Manni, Carol Wright, Betty Badger, James Lynch, and Laurence Demers.

- *7184 Allelotype of Breast Cancer: Cumulative Allele Losses Promote Tumor Progression in Primary Breast Cancer. Takaaki Sato, Akira Tanigami, Kazuhiko Yamakawa, Futoshi Akiyama, Fujio Kasumi, Goi Sakamoto, and Yusuke Nakamura.

- *7190 Role of Transforming Growth Factor β in the Proliferative Effect of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Human Squamous Carcinoma Cells. Charles D. Hébert, Qun-Li Cao, and Linda S. Birnbaum.

- *7198 Enhanced Expression of DNA Topoisomerase II by Recombinant Human Granulocyte Colony-stimulating Factor in Human Leukemia Cells. Masayuki Towatari, Yoshihisa Ito, Yoshihisa Morishita, Mitune Tanimoto, Kohei Kawashima, Yasuo Morishima, Toshiro Andoh, and Hidehiko Saito.

November 15, Number 22

- *7203 High Activity of Mitochondrial Glycerol Phosphate Dehydrogenase in Insulinomas and Carcinoid and Other Tumors of the Amine Precursor Uptake Decarboxylation System. Michael J. MacDonald, Thomas F. Warner, and Robert J. Mertz.

- *7206 Phase I Trial of Dipyridamole with 5-Fluorouracil and Folinic Acid. G. T. Budd, A. Jayaraj, D. Grabowski, D. Adelstein, L. Bauer, J. Boyett, R. Bukowski, S. Murthy, and J. Weick.

- *7212 Inhibitory Effects of Estrogen on the Growth of a Human Esophageal Carcinoma Cell Line. Hiroshi Ueo, Hideo Matsukura, Keizo Sugimachi, Hiroyuki Kuwano, Masaki Mori, and Tsuyoshi Akiyoshi.

- *7216 Elimination of Small Cell Carcinoma of the Lung from Human Bone Marrow by Monoclonal Antibodies and Immunomagnetic Beads. James J. Vredenburgh and Edward D. Ball.

- *7221 Phorbol Ester-induced Macrophage-like Differentiation of Human Prolymphocytic Leukemia (HL-60) Cells Occurs Independently of Transferrin Availability. Ian D. Traynor and Michael J. Clements.

- *7226 Pharmacology of Fludarabine Phosphate after a Phase I/II Trial by a Loading Bolus and Continuous Infusion in Pediatric Patients. Vassilios I. Avramis, Josette Champagne, Judith Sato, Mark Kraife, Lawrence J. Ettinger, David G. Poplack, Jerry Finkelman, Gregory Reaman, G. Dennis Hammond, and John S. Holcenberg.

- *7232 Human Colorectal Cancer: High Frequency of Deletions at Chromosome 1p35. Ilona Leister, András Weith, Silke Brüderlein, Christiane Dosse-Pasqualini, and Carsten Schubert.

- 7236 Effects of Various Photooxidation Regimens on the Antitumor Efficacy of Photodynamic Therapy for 3R29AC Mammary Carcinomas. Scott L. Gibson, Karl R. VanDerMeid, Richard S. Murari, Richard R. Raberbaum, and Russell H. Wolford.

- *7242 Expression of the smg p25A (a rat p21-like GTP-binding Protein) Gene in Human Neuroblastoma Cell Lines and Tumor Tissues. Kimihiko Sano, Hajime Nakamura, Satoshi Mabuchi, Takeo Tanaka, Akira Nagakawara, and Yoshimi Taki.

- *7246 Radiolocalization of Human Pancreatic Tumors in Athymic Mice by Monoclonal Antibody DU-PAN 1. Andrew J. Worlock, Michael R. Zalutsky, and Richard S. Metzgar.

- 7252 Changes in Radiation Sensitivity Induced by Fludarabine as Measured by ³¹P Nuclear Magnetic Resonance Spectroscopy. Jason A. Koutcher, Alan A. Alfieri, Alice B. Kornblith, Mary L. Devitt, David Cowburn, Douglas Ballou, and Jac H. Kim.

- *7257 Regulation of HL-60 Differentiation by Lipoxigenase Pathway Metabolites *In Vitro*. Alan M. Miller, Steven M. Cobb, and Raquel McTiernan.

- 7261 Metastasis-associated Murine Melanoma Cell Surface Galactosyltransferase: Characterization of Enzyme Activity and Identification of the Major Surface Substrates. Antonino Passaniti and Gerald W. Hart.

- *7272 Pharmacokinetics in Patients of an Anti-Carcinoembryonic Antigen Antibody Radiolabeled with Iodine-111 Using a Novel Diethylenetriamine Pentacetic Acid Chelator. D. J. Hnatowich, M. Ruskowski, A. B. Brill, D. A. Sieberer, H. Misra, G. Mandriossi, H. Bushe, A. Resigno, S. Stevens, D. K. Johnson, and T. W. Griffin.

- *7279 Enhancement of the Toxicity and DNA Incorporation of A-Vinylbenzyl-5-acetoxy- and 1- β -D-Arabinofuranosylcytosine by Cyclopentenyl Cytosine. Jean L. Green and Carmen J. Allegre.

- *7285 Characterization of a Receptor-negative, Hormone-naïve Resistant Clone Derived from a T47D Human Breast Cancer Cell Line kept under Estrogen-free Conditions. Catherine S. Murphy, John J. Pink, and V. Craig Jordan.

- *7293 Metabolism of Diaziquone by NAD(P)H:Quinone Reductase (DT-Diaphorase): Role in Diaziquone-induced DNA Damage and Cytotoxicity in Human Colon Carcinoma Cells. David Siegel, Neil W. Gibson, Peter C. Preusch, and David Ross.

- 7301 Inhibition of *In Vitro* Tumor Growth by a Monoclonal IgM Antibody Recognizing Tumor Cell Surface Carbohydrates. Juana Gil, Rita Alvarez, Juan E. Viñuela, José G. Ruiz de Morales, Ana Bustos, Emilio G. De la Concha, and José L. Subiza.

- *7307 Cytotoxic Effects of Cell Cycle Phase Specific Agents: Results of Cell Cycle Perturbation. Andrew L. Kung, Anders Zetterberg, Steven W. Sherwood, and Robert T. Schimke.

- *7318 Intraperitoneal Recombinant γ -Interferon in Patients with Recurrent Asciitic Ovarian Cancer: Modulation of Cytotoxicity and Cytokine Production in Tumor-associated Effector and of Major Histocompatibility Antigen Expression on Tumor Cells. P. Allavena, F. Pecatori, D. Maggioli, A. Erroi, M. Sironi, N. Colombo, A. Lissoni, A. Galazka, W. Meiers, C. Mangioni, and A. Mantovani.

- *7324 Differential Response of Nontumorigenic and Tumorigenic Human Papillomavirus Type 16-positive Epithelial Cells to Transforming Growth Factor β . L. Braun, M. Durst, R. Mikumo, and P. Gruppuzzi.

- *7333 Characterization and Distribution in Human Tissues of a Glycoprotein Antigen Defined by Monoclonal Antibody 1ME₉, Raised against the Human Breast Cancer Cell Line T47D. Gianfranco Pancino, Colette Chaplin, Eduardo Osinaga, Beatrice Bettaille, Martine Le Roy, Fabien Calvo, and Alberto Ricetti.

- *7343 Interleukin 2 and Lymphokine-activated Killer Cell Therapy: Analysis of a Bolus Interleukin 2 and Continuous Infusion Interleukin 2 Regimen. Jeffrey W. Clark, John W. Smith II, Ronald G. Stess, Walter J. Urba, Edward Crum, Robin Miller, John McKnight, JoAnn Berman, Henry C. Stevenson, Stephen Creekmore, Michael Stewart, Kevin Conlon, Mario Szolnoki, Peter Kremers, Paul Cohen, and Dan L. Longo.

- *7351 Tumor Progression in Four Mammary Epithelial Cell Lines Derived from the Same Patient. Vimla Band, Deborah Zajchowski, Karen Swisher, Douglas Trask, Victoria Kulesa, Craig Cohen, James Connolly, and Ruth Sager.

- *7358 *In Vivo* Invasion Assay of Low Passage Cultured Cells Derived from Human Lung Cancer Using Deepithelialized Rat Tracheas Xenotransplanted into Nude Mice. Hisami Yamakawa, Masayuki Baba, and Yutaka Yamaguchi.

- *7364 Resistance of Human Ovarian Cancer Cells to Tumor Necrosis Factor and Lymphokine-activated Killer Cells: Correlation with Expression of HER2/neu Oncogenes. Alan Lichtenstein, James Berenson, Joseph F. Gera, Kristine Waldburger, Otoniel Martinez-Maza, and Jonathan S. Berek.

- *7371 Down-Regulated c-myc Expression Inhibits DNA Synthesis of T-Lymphoma Cells in Most Patients. Donatella Venturelli, Maria Teresa Mariano, Cezary Szczepiorkowski, Mauro Valitorto, Beverley Lange, William Cristi, Michael Link, and Bruno Calabretta.

- *7376 Contrast-enhanced Magnetic Resonance Imaging of Tumor-bearing Mice Treated with Human Recombinant Tumor Necrosis Factor α . Klaus P. Aicher, Jean W. Dupon, David L. White, Sharon L. Iukerman, Michael E. Moseley, Richard Juster, Werner Rosenau, Jeffrey L. Winkelske, and Robert C. Brasch.

- *7382 Pharmacokinetic Analysis of Immunoconjugate Uptake in Solid Tumors: Role of Plasma Kinetics, Capillary Permeability, and Binding. Cynthia Sung, Richard J. Youle, and Robert L. Dedrick.

- *7393 Immunohistochemical Localization of Basic Fibroblast Growth Factor in Astrocytomas. David Zagzag, Douglas C. Miller, Yasufumi Sato, Daniel B. Rifkin, and David E. Burstein.

Advances in Brief

- 7394 Role of α -2B in Growth Factor Triggered Signal Transduction. Subrahmanyam Haldar, John C. Reed, Christine Beatty, and Carlo M. Croce.

Meeting Reports

- 7402 Second Annual Perezceller Symposium: Therapeutic Implications of the Molecular Biology of Breast Cancer. Marc Lippman and Enrico Mihich.

- 7405 Carcinogenesis and Chemotherapy—Cancer's Continuing Core Challenges: Third Charles H. Hood Symposium. Toshio Kuroki.

7410 Announcements

- Eighth Annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events

- 7411 Erratum
S. S. Yang *et al.*, 50 (Suppl.) 565s-567s, 1990.

7412 Author Index

7413 Statement of Ownership, Management and Circulation

CONTENTS OF VOLUME 50

December 1, Number 23

Perspectives in Cancer Research

- *7415 Increased Cell Division as a Cause of Human Cancer. Susan Preston-Martin, Malcolm C. Pike, Ronald K. Ross, Peter A. Jones, and Brian E. Henderson.

- *7422 Effect of Recombinant Human Leukocyte, Fibroblast, and Immune Interferons on Expression of Class I and II Major Histocompatibility Complex and Invariant Chain in Early Passage Human Melanoma Cells. Paola Nistico, Raffaele Tecco, Patrizio Giacomini, Andrea Cavallari, Igna D'Agnano, Paul B. Fisher, and Pier Giorgio Natali.

- *7430 Combination of Nicotinamide and Hyperthermia to Eliminate Radiosensitive Chronically and Acutely Hypoxic Tumor Cells. Michael R. Horsman, David J. Chaplin, and Jens Overgaard.

- *7437 Regulation of the Cell Surface Expression of a Nonconspecific Cross-Reacting Antigen Variant during Differentiation of HL-60 Cells. Ilse Novak-Hofer, Peter Blaustein, and P. August Schubiger.

- *7444 Glycosphingolipids of Human Glialomas. Richard Jennewein, Appletree Rodden, Bernhard L. Bauer, Hans-Dieter Menzel, and Heribert Wiegandt.

- *7450 Adoptive Transfer of Tumor Cytotoxic Macrophages Generated *in Vitro* from Circulating Blood Monocytes: A New Approach to Cancer Immunotherapy. Reinhard Andreesen, Carmen Scheibenbogen, Wolfgang Brügger, Stefan Krause, Hans-Gerd Meierohrt, Hans-Georg Leser, Hans Engler, and Georg W. Löhr.

- *7457 Production of Interleukin 6 from Human Liver Cell Lines: Production of Interleukin 6 Is Not Concordant with the Production of α -Fetoprotein. Tetsuya Matsuguchi, Seiichi Okamura, Chiyuki Kawasaki, and Yoshiyuki Niho.

- *7460 Expression of Growth-related Genes during Tumor Progression in *v-maf*-transformed Rat Liver Epithelial Cells. Lori L. Hampton, Peter J. Warland, Betty Yu, Snorri S. Thorgeirsson, and Anthony C. Hugget.

- *7468 Altered Responsiveness of Rat Liver Epithelial Cells to Transforming Growth Factor β , following Their Transformation with *v-maf*. Anthony C. Hugget, Lori L. Hampton, Caroline P. Ford, Peter J. Warland, and Snorri S. Thorgeirsson.

- *7476 Prolonged Serum Half-life of Antineoplastic Drugs by Incorporation into the Low Density Lipoprotein. P. Chris de Smidt and Theo J. C. van Berkel.

- *7483 Metabolism of Mitomycin C-induced Role in Mitomycin C-induced DNA Damage and Cytotoxicity in Human Colon Carcinoma Cells. David Siegel, Neil W. Gibson, Peter C. Preusch, and David Ross.

- *7490 Phase I and Clinical Pharmacology Trial of 502U83 Using a Monthly Single Dose Schedule. Daniel D. Von Hoff, John G. Kuhn, Kathleen A. Havlik, Anne-Marie Langevin, Thomas D. Brown, Geoffrey R. Weiss, Judy N. Turner, Joseph Purvis, V. Sol Lucas, Kenneth W. Bain, William Wargin, James Hubbell, Richard L. Tuttle, Jim M. Koehler, and Gregory L. Freeman.

- *7501 A Case-Cohort Study of Diet and Stomach Cancer. Po-Huang Chyou, Abraham M. Y. Nomura, Jean H. Hankin, and Grant N. Stemmermann.

- *7505 Role of Endocytosis in the Action of Ether Lipids WEHI-3B, HL40, and FDCP-Mix A4 Cells. G. W. Bazil and T. M. Dester.

- *7513 Inherent Sensitivity and Induced Resistance to Chemotherapeutic Drugs and Irradiation in Human Cancer Cell Lines: Relationship to Mutation Frequencies. Christopher N. Parris, M. Claire Walker, John R. W. Masters, and Colin F. Arlett.

- *7519 Pharmacokinetics in the Rat of a Panel of Immunotoxins Made with Abin A Chain, Ricin A Chain, Gelonin, and Monomeric. Edward J. Wawrzynczak, Alan J. Cumber, Raymond V. Henry, Julie May, David R. Newell, Geoffrey D. Parnell, Nan R. Worrell, and J. Anthony Forrester.

- *7527 Melphalan-induced Mutagenesis in an SV40-based Shuttle Vector: Predilection of A-T-T-A Transversions. Peng Wang, Richard A. O. Bennett, and Lawrence F. Povirk.

- *7532 *In Vitro* Modulation and Relationship between N-myco and HLA Class I RNA Steady-State Levels in Human Neuroblastoma Cells. Nicole Gross, Daniel Beck, and Simone Favre.

- *7537 Modulation of Drug Sensitivity by Dipyridamole in Multidrug Resistant Tumor Cells *In Vitro*. David R. Shalinsky, Michael Andreff, and Stephen B. Howell.

- *7544 Multiple Membrane Transport Systems for the Uptake of Folate-labeled Thymidine Synthesis Inhibitors. Gerrit Janzen, Jan H. Schornagel, G. Robbin Westerhof, Gert Rijksen, David R. Newell, and Ann L. Jackman.

- *7549 Appendectomy, Appendicitis, and Large Bowel Cancer. Gary D. Friedman and Bruce H. Fireman.

- *7552 Characterization of the Elastase 1-Simian Virus 40 T-Antigen Mouse Model of Pancreatic Carcinoma: Effects of Sex and Diet. Daniel S. Longnecker, Elina T. Kuhlmann, and Daniel H. Freeman, Jr.

- *7555 Mechanisms of Toxicity of Hepasulfam in Human Tumor Cell Lines. Diane Y. Pacheco, Cheryl Cook, Jeffrey R. Hincks, and Neil W. Gibson.

- *7559 *In Vitro* Studies on the Mechanism of Action of Hepasulfam in Chronic Myelogenous Leukemia Patients. Jeffrey R. Hincks, Arun Adlakha, Cheryl A. Cook, Candace S. Johnson, Philip Furmanski, and Neil W. Gibson.

- *7564 Carcinogenic Sulfate Salts of Nickel and Cadmium Induce H_2O_2 Formation by Human Polymorphonuclear Leukocytes. Zhaojing Zhang, Walter Trull, Karen L. Koenig, and Kristyna Freinkel.

- *7571 Nuclear DNA Content of Altered Hepatic Foci in a Rat Liver Carcinogenesis Model. Jian H. Wang, Lucia I. Hinrichsen, Cecilia M. Whitaite, Ronald L. Cechner, and Oscar Sudilovsky.

- *7577 Persistent Reduction of Indigenous DNA Modification (L-Coumarate) Levels in Liver DNA from a Fischer 344 Rat Fed Choline-deficient Diet and in DNA of Radiation Neoplasias. Dongui Li, Richard C. Deering, Xu Nalin Chandar, Benito Lombard, and Kurt Randerath.

- *7581 Inhibitory Effects of Transforming Growth Factor β_1 on Mitogenic Response, Transforming Growth Factor α , and c-myc in Quiescent, Well-Differentiated Colorectal Carcinoma Cells. Kathleen M. Mulder, Qing Zhong, Hoong Ghee Choi, Lisa E. Humphrey, and Michael G. Brattain.

- *7587 Effects of N'-Behenyl-1- β -D-Arabinofuranosylcytosine on Blast Progenitors of Acute Myeloblastic Leukemia. Nobuo Nara, Shoji Tohda, Toshiya Suzuki, Kaoru Nagata, Yoko Yamashita, Yasufumi Imai, Yasuo Maruyama, and Junji Tomiyama.

- *7593 Gene Expression in Clonally Derived Cell Lines Produced by *in Vitro* Transformation of Rat Fetal Hepatocytes: Isolation of Cell Lines Which Retain Liver-specific Markers. G. C. T. Yeoh, C. Hillard, S. Fletcher, and A. Douglas.

- *7603 Differential-expression of *I* and *Sialyl I* Antigens in the Developing Lung of Human Embryos and in Lung Cancers. Shigeaki Itai, Junko Nishikata, Naoyumi Takahashi, Osamu Tanaka, Yoshio Matsubara, Shizuo Hasegawa, Noboru Yanai, Kazuo Takaoka, Shigeaki Arii, Takayoshi Tobe, and Reiji Kanagai.

- *7612 Definition of a Sequence, RVVVLPR, within Laminin Peptide F-9 That Mediates Metastatic Fibrosarcoma Cell Adhesion and Spreading. Amy P. N. Skubitz, James B. McCarthy, Qi Zhao, Xiangyan Yi, and Leo T. Furcht.

- *7623 Relationship between Secreted Urokinase Plasminogen Activator Activity and Metastatic Potential in Murine B16 Cells Transfected with Human Urokinase Sense and Antisense Genes. Heron Yu and Richard M. Schultz.

- *7634 *In Vivo* Selection of Human Tumor Cells Resistant to Monoclonal Antibody 7.1a. Akasoid Immunoconjugates. James J. Starling, Ronald S. Macaulay, Ann Hinson, Joann Hoskins, Bennett C. Laguzza, Robert A. Gadski, Joann Strnad, Lana Rittmann-Grauer, Sonia V. DeHerdt, Thomas F. Bumol, and Robert E. Moore.

- *7641 Importance of Tumor-specific Cytotoxic CD8+ T-Cells in Eradication of a Large Subcutaneous MOPC-315 Tumor following Low-Dose Melphalan Therapy. Blaine Y. Takekue, Joseph M. Pyk, and Margalit B. Mokyr.

- *7650 Effect of Epidermal Growth Factor on the Cellular Proliferation and Phenotype of a Neoplastic Human Salivary Interdigitated Cell Line or Its Derivatives. Wald Aladit, Hideo Yoshida, and Mitsutomo Sato.

- *7662 Effect of Sex Difference, Gonadectomy, and Estrogen on N-Methyl-N-nitrosourea Induced Rat Thyroid Tumors. Kyoko Mori, Masashi Naito, Hiromitsu Watanabe, Nobuo Takeichi, Kiyohiko Dohi, and Akifiro Ito.

- *7668 Expression of Epithelial Antigen Esx-1 and EPN-1 in Human Epidermal Keratinocyte Maturation and Benign and Malignant Neoplasia. Reinhard Klingel, Petra Boukamp, Roland Möll, Wolfgang Tilgen, Norbert E. Fueglin, Karl-Hermann Meyer zum Buschenfelde, and Wolfgang Dippold.

- *7677 Uterine Adenocarcinoma in Mice following Developmental Treatment with Estrogens: A Model for Hormonal Carcinogenesis. Reitha R. Newbold, Bill C. Bullock, and John A. McLachlan.

- *7682 A Ki-1 (CD90)-positive T (E \times CD4+) Intra-Cell Line, DL-40, Established from Aggressive Large Cell Lymphoma. Ichiro Kubonishi, Hiroshi Sonobe, Tatsuhi Miyagi, Yoshihito Iwahara, Junio H. Ohbayashi, Kazuma Ohbayashi, Kenkai Toyama, Yuji Ohtsuki, and Iao Miyoshi.

- *7686 An *In Vivo* Study of the Role of the Tumor Cell Cytoskeleton in Tumor Cell-Platelet-Endothelial Cell Interactions. Hemangi Suzanne E. G. Pigiel, James S. Hatfield, Kevin K. Nelson, Clement A. Diglio, John D. Taylor, and Kenneth V. Honn.

- *7697 Enhanced Expression of Ganglioside G_{M1} in Human and Rat Hepatocellular Carcinoma Cells and NIH 3T3 Cells Transfected with Human Tumor DNAs. Jian Yan Yu, Yang-guo Gu, Liang Xia, Martin J. Murphy, Jr., Way Lee, Neng-hau Gao, Jian-ren Gu, and J. Peter Fuhrer.

- *7701 A Novel Human Myeloid Leukemia Cell Line, NKN-L1, Co-expressing Granulocyte Colony-stimulating Factor Receptors and Macrophage Colony-stimulating Factor Receptors. Takeo Kataoka, Yoshitsugu Morishita, Michinori Ogura, Yasuo Morishita, Masayuki Towatari, Yukio Kato, Hideo Inoue, and Hidehiko Sato.

- *7710 Immunohistochemical Localization of Parathyroid Hormone Protein in Human Breast Cancer. Justine Southby, Mark W. Kissin, Janine A. Danks, John A. Hayman, Jane M. Moseley, Michael A. Henderson, Richard C. Bennett, and John T. Martin.

Advances in Brief

- *7717 p53 Gene Mutations Occur in Combination with 17p Allelic Deletions as Late Events in Colorectal Tumorigenesis. Suzanne J. Baker, Anton, Jr., C. Presinger, J. Milburn Jesup, Christos Paraskevas, Sanford Markowitz, J. K. V. Wilson, Stanley Hamilton, and Bert Vogelstein.

Announcements

- Eighth-annual Meeting of the AACR
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events

- *7725 Employment Register of the AACR

- *7733 Author Index

December 15, Number 24

Perspectives in Cancer Research

- 7735 The Emerging Biology of Modern Radiation Oncology. Thomas E. Goffman, Andrew Raubitschek, James B. Mitchell, and Eli Glasztien.

- 7745 Potentiation by the Hypoxic Cytotoxin SR 4233 of Cell Killing Produced by Fractionated Irradiation of Mouse Tumors. J. Martin Brown and Marilyn J. Lehman.

- *7750 Inhibition of Antibody Response to *Passalus* Exotoxin and an Immunotoxin Containing *Passalus* Exotoxin by 15-Deoxyspergualin in Mice. Lee H. Pai, David J. FitzGerald, Mark Tepper, Bernice Schacter, George Spinelli, and Ira Pastan.

- *7754 Suramin Affects DNA Synthesis in HeLa Cells by Inhibition of DNA Polymerases. Hitesh K. Jindal, Christopher W. Anderson, Randall G. Davis, and Jamboor K. Vishwanatha.

- *7758 Purification and Characterization of Extracellular Matrix-degrading Metalloproteinase, Matrix (Pump-1), Secreted from Human Rectal Carcinoma Cell Line. Kaoru Miyazaki, Yasuhisa Hatori, Fuminori Uematsu, Hidekazu Yasumura, and Makoto Ueda.

- 7765 Mercaptopurine 540-sensitized Photoinactivation of Soluble and Membrane-bound Enzymes in L1210 Leukemia Cells. David K. Gaffey and Fritz Sieber.

- *7770 Role of Extragonadal Insulin-like Growth Factors in the Proliferation of Human Breast Cancer Cells. Bart van der Burg, Linda Inderbitze, Adri J. P. van Selten-Millenburg, Siegfried W. de Laat, and Everardus J. J. van Zoelen.

- *7775 Site-dependent Differences in Response of the UV-2327 Murine Fibrosarcoma to Systemic Therapy with Adriamycin. Alexander N. Starostinsky, Dominic Fan, Catherine A. O'Brien, Corazon D. Buscana, Krishna P. Gupta, and Isaiah J. Fidler.

- *7781 Deletion of α_1 , β_1 , and ω -Interferon Genes in Malignant Cells from Children with Acute Lymphocytic Leukemia. Stefan Einhorn, Dan Grander, Olle Björk, Karen Bröndum-Nielsen, and Stefan Söderhäll.

- *7786 Expression of the Interleukin-6 Receptor and Interleukin-6 in Prostate Carcinoma Cells. Clay B. Sigall, Gina Schwab, Richard P. Norden, David J. FitzGerald, and Ira Pastan.

- *7789 Activation of Mitomycin C by NAD(P)H-Cytchrome P-450 Reductase. H. Frances J. Bligh, Agnieszka Bartoszek, Craig N. Robson, Ian D. Hickson, Charles B. Kapoor, Jean D. Beppi, and C. Roland Wolf.

- *7793 Cytotoxic Effects of Diphosphonate Inhibitors upon Human CCRF-CEM Leukemia. Julie Brooke, Eve Szabolcs, Stephen D. Lyons, Richard J. Goodridge, Michael C. Haranayi, Anthony Poirier, and Richard I. Christopherson.

CONTENTS OF VOLUME 50

- *7799 Characterization of High Specific Activity [^{113}In]-Jade-17 β -estradiol as an Estrone Receptor-specific Radioligand Capable of Labeling Human Breast-tissue Tumors.** Edward J. Pavlik, Katherine Nelson, Holly H. Galloway, John R. van Nagell Jr., Elvis S. Donaldson, W. J. Shih, Jay A. Spicer, David F. Preston, Richard J. Barancuk, and Michael E. Kennedy.
- *7800 Growth Control of Human Mammary Cancer Cells (MCF-7 Cells) in Culture: Effect of Estradiol and Growth Factors in Serum-containing Medium.** Ashbjorn Askgard, Edie Utsaker, Thor Thoren, Oscar A. Lea, and Hooshang Lahooti.
- *7801 Heterogeneous Protrusionate Amplification Correlates with Tumor Progression and Presence of Metastases in Gastric Cancer Patients.** Giorgelina M. Ranazzo, Natalia S. Pellegrini, Carlo Previati, Ariete Sangalli, Antonio Vian, Marco Meltoni, and Dino Amadori.
- *7802 Occurrence of IgA and IgG Antibodies to Select Peptides Representing Human Papilloma Virus Type 16 among Cervical Cancer Cases.** Constance Valérie M. Marin, Suzanne Loo de Lao, Maria Brenes, Louise A. Branton, J. Alan Rawls, Maurice Green, William C. Reeves, and William E. Rawls.
- *7803 Retroviral Vector-mediated γ -Interferon Gene Transfer into Tumor Cells Generates Potent and Long Lasting Antitumor Immunity.** Bernd Gansbacher, Rajat Banerji, Brian Daniels, Karen Zier, Kathy Crotin, and Eli Gilboa.
- *7804 Growth Inhibition of Gloma Cells Transfected with the Human β -Interferon Gene by Liposomes Coupled with a Monoclonal Antibody.** Masaki Mizuno, Jun Yoshida, Kenichiro Sugita, Itaru Inoue, Hisao Seo, Yukata Hayashi, Takuji Kubozuka, and Kuniyo Yagi.
- *7805 Differential Expression of Transglutaminase in Human Erythroleukemia Cells in Response to Retinoid Acid.** T. Sudhoff, P. J. Birckbichler, K. N. Lee, E. Conway, and M. K. Patterson, Jr.
- *7806 Role of Valence State and Solubility of Chromium Compounds on Induction of Cytotoxicity, Mutagenicity, and Anchorage Independence in Diploid Human Fibroblasts.** Kim A. Biedermann and Joseph R. Randolph.
- *7807 α -Fetoprotein in the Woodchuck Model of Hepadnavirus Infection and Disease: Normal Physiological Patterns and Responses to Woodchuck Hepatitis Virus Infection and Hepatocellular Carcinoma.** Paul J. Cox, John L. Gerin, and Bud C. Tennant.
- *7808 Effect of Hexamethyl Biacetamide and Cyclohexane on a Recombinant Human Simian Virus Type 2 from the *In Vitro* Model of Latency in a Human Neuroblastoma Cell Line.** Yasuo Kondo, Yoshiaki Yura, Hiroki Iga, Tetsuo Yanagawa, Hideo Yoshida, Nanayo Furumoto, and Mitsunobu Sato.
- *7809 Progression Increase Insulin Receptor Content and Insulin Stimulation of Growth in Human Breast Carcinoma Cells.** Vincenzo Papa, Costanzo C. Reese, Antonio Brunetti, Riccardo Vigneri, Pentti K. Sitteri, and Ira D. Goldfine.
- *7810 Role of Reactive Nitrogen Intermediate Production in Alveolar Macrophage-mediated Cytotoxicity Induced by Bleomycin Lung Damage in Rats.** Anne E. Huot and Miles P. Hacker.
- *7811 Cytotoxicity of Loundaine Alone and in Combination with Other Drugs against Murine RIF-1 and Human HT1080 Cells *In Vitro*.** Shoucheng Ning and George M. Hahn.
- *7812 Induction of Glutathione Transferases and NAD(P)H:Quinone Reductase by Fumaric Acid Derivatives in Rodent Cells and Tissues.** Sharon R. Spencer, Cynthia A. Wilczak, and Paul Talalay.
- *7813 Mitochondrial Toxicity of Cationic Photosensitizers for Phototherapy.** Joseph S. Modica-Napolitano, John L. Joyal, Gulshan Ara, Alan R. Oeroff, and June R. Aprilte.
- *7814 Interaction of Vasopressin and Octoxin with Human Breast Carcinoma Cells.** A. H. Taylor, V. T. Y. Ang, J. S. Jenkins, J. J. Silverlight, R. C. Coombes, and Y. A. Lugani.
- *7815 Mutation of the Formation and Removal of Cephalosporin-DNA Adducts in Blood Cells and Tumor Tissue of Cancer Patients Receiving Chemotherapy: Comparison with *In Vitro* Adduct Formation.** Anne Marie J. Fichtinger-Schepman, Saskia D. van der Velde-Van Der Velden, Helma C. M. van Dijk-Knijnenburg, Allan T. van Oosterom, Robert A. Baan, and Frits Berends.
- *7816 Sequential Emergence of Distinct Resistance Phenotypes in Murine Erythroleukemia Cells under Adriamycin Selection: Decreased Anthracycline Uptake Precedes Increased P-Glycoprotein Expression.** Christopher A. Slapak, Janice C. Daniel, and Stuart B. Levy.
- *7817 Myxomatous Liposomes with (12/16)(q3Xp11) Contains Site-Specific Insertions in Methyltransferase Genes, Including a Zinc Finger Gene Mapped to the Breakpoint Region on Chromosome 12.** Sylvie Paulin, Claude Turc-Carel, Paola Da Cn, Scheila Jani-Sait, Chandrika Sreenakantaiah, Stanton P. L. Long, Bert Vogelstein, Kenneth W. Kinzler, Avery A. Sandberg, and Robert M. Germuth.
- *7818 Expression of the O^6 -Methylguanine-DNA Methyltransferase Gene (*MGMT*) in MEF and MEF-Human Tumor Cells.** Albert J. Forstmeier, Jr., Mathilda A. Papatheou, Michele Christine Hollander, and Daniel B. Yarosh.
- *7819 DNA *In Situ* Sensitivity to Denaturation in Bladder Cancer and Its Correlation with Tumor Stage.** P. R. Bretton, Z. Darzykiewicz, E. Henry, M. Kimmel, W. R. Fair, and M. R. Melamed.
- *7820 Pharmacokinetics and Metabolism of Cyclopentenyl Cytosine in Nonhuman Primates.** Susan M. Blaney, Frank M. Balis, Lajos Hegedus, Richard L. Heideman, Cynthia McCully, Robert F. Murphy, James A. Kelley, and David G. Poplack.
- *7821 Relationship of Polymorphisms near the Rat Prokrta, Nras, and Retinoblastoma Genes with Susceptibility to Estrogen-induced Pituitary Tumor.** Laurie A. Shepel and Jack Gorski.
- *7822 Systemic Alkalinization Inhibits the Ability of Flavone Acetone to Act as a Normal Killer Acetone.** Activation of Cytokine Gene Expression and Synergies with Herceptin 2 for the Treatment of Murine Renal Cancer.
- *7823 Epidermal Growth Factor Inhibits Transiently the Progression from G₀ to G₁ in Normal Killers.** Activation of Cytokine Gene Expression and Synergies with Herceptin 2 for the Treatment of Murine Renal Cancer.
- *7824 Interaction of Fliringenin with Murine Melanoma Cells: Covalent Association with Cell Membranes and Protection against Recognition by Lymphokine-activated Killer Cells.** Massimo Cardinali, Ryosuke Uchino, and Soo Il Chung.
- *7825 Characterization of the Epidermal Growth Factor Receptor in Human Gloma Cell Lines and Xenographs.** Sandra H. Bigner, Peter A. Humphrey, Albert J. Wong, Bert Vogelstein, Joachim Mark, Henry S. Friedman, and Durrell D. Bigner.
- *7826 Reduced Expression of HLA Class I and II Antigens in Colon Cancer.** Carl J. McDougall, Sing Sang Ngai, Im S. Goldman, Thomas Godwin, Juan Felix, Jerome J. DeCosse, and Basil Rires.
- *7827 Interleukin 4 and γ -Interferon May Play a Role in the Histopathogenesis of Peripheral T-Cell Lymphoma.** Kazunori Ohnishi, Atsushi Ichikawa, Yoshiyuki Kagami, Tetsuro Nagasaki, Tamizuku Niwa, Tomonosu Hotta, and Hidehiko Saito.

Letter to the Editor

- 8034 **Response to: July 1, 1990 Cover of *Cancer Research*.** Ludwik Gross
- 8035 **Announcements**

Eighty-second Annual Meeting of the AACR
Travel Grants for the AACR and ASCO Annual Meetings for Young Minority Scientists
AACR Special Conferences in Cancer Research
Future Annual Meetings of the AACR
Calendar of Events

- 8037 **Acknowledgment to Reviewers**

- 8047 **Author Index**

Cover Illustrations for Volume 50

January 1: Alfred G. Knudson, Jr., Henry C. Pitot, and Ernst L. Wynder, recipients of American Cancer Society awards for their contributions to cancer research.

January 15: J. Michael Bishop and Harold E. Varmus, winners of the 1989 Nobel Prize for Physiology or Medicine.

February 1: Raunes C. Gupta, Erika Randerath, Kurt Randerath, and M. V. Reddy, and a diagram of the ^{32}P postlabeling technique.

February 15: Janardan K. Reddy, M. Sambasiva Rao, and electron micrographs of normal rat liver and hepatocyte showing peroxisome proliferation.

March 1: William Weiss, W. G. Figueroa, Benjamin L. Van Duuren, H. Sakabe, Alfred M. Thiess, Sidney Laskin, Marvin Kuschner, and Robert T. Drew, investigators of bis(chloromethyl) ether (BCME).

March 15: James A. Miller, Elizabeth C. Miller, Allan H. Conney, Herbert K. Remmer, and Ryuchi Kato, and illustrations of 3-methylcholanthrene-induced azo dye N -demethylase and reductase and of the substrate-induced benzo(a)pyrene metabolism.

April 1: Jan Waldenstrom, a pioneer investigator in neoplasia of the immune system and discoverer of Waldenstrom's macroglobulinemia.

April 15: St. Jude Children's Research Hospital, Danny Thomas, and a hospital patient.

May 1: Carlo Croce, Ronald M. Evans, Erkki Ruoslahti, Hartmann Stahelin, and Anthony von Warburg, winners of the 1990 awards of the American Association for Cancer Research.

May 15: Ross McIntyre, Edwin Mirand, Albert Owens, and Sydney Salmon, officers of the American Association of Cancer Institutes.

June 1: Margaret Foti, Executive Director of the American Association for Cancer Research and Managing Editor of its official publication, *Cancer Research*.

June 15: Joseph G. Fortner, President of the General Motors Cancer Research Foundation, and Roger B. Smith, Chief Executive Officer and Chairman of the Board of General Motors.

July 1: Arnold Graffi, founder of the Cancer Institute in Berlin-Buch, Germany.

July 15: Annerose Anders, Fritz Anders, Myron Gordon, and Curt Kosswig, and photos of the swordfish and platyfish and hybrids with melanomas and of genetically controlled features in backcross fishes.

August 1: Bert Vogelstein, winner of the 1990 Bristol-Myers Squibb Award.

CONTENTS OF VOLUME 50

- August 15: Eleanor Deschner, Charles Philippe Leblond, Martin Lipkin, and Henry Quastler, and a graph depicting biomarkers in studies of cancer prevention.
- September 1: Webster K. Cavenee, Sir David Cox, Mark S. Ptashne, Raymond L. White, winners of the 1990 General Motors Cancer Research Foundation awards.
- September 15: Children's Hospital of Philadelphia, Giulio D'Angio, a hospital patient, and Audrey Evans.
- October 1: Charles R. Ebersol, Sandor Eckhardt, G. P. Murphy, and C. G. Schmidt, officers of the International Union Against Cancer (UICC).
- October 15: McArdle Laboratory, Michael McArdle, and Harold P. Rusch.
- November 1: Sandor Eckhardt and the National Institute of Oncology, Budapest, Hungary.
- November 15: Vincent T. DeVita, Jr., and Emili Frei III, winners of the 1989 Armand Hammer Foundation award.
- December 1: Paul Kleihues, Tomas Lindahl, Anthony E. Pegg, and Manfred F. Rajewsky, researchers in *O⁶-methyltransferase*.
- December 15: Harris Busch, 1989-1990 President of the American Association for Cancer Research.

0

